PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BAETEN, CGMI; GEERDES, BP; ADANG, EMM; HEINEMAN, E; KONSTEN, J; ENGEL, GL; KESTER, ADM; SPAANS, F; SOETERS, PB				BAETEN, CGMI; GEERDES, BP; ADANG, EMM; HEINEMAN, E; KONSTEN, J; ENGEL, GL; KESTER, ADM; SPAANS, F; SOETERS, PB			ANAL DYNAMIC GRACILOPLASTY IN THE TREATMENT OF INTRACTABLE FECAL INCONTINENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRACILIS MUSCLE TRANSPOSITION; QUALITY-OF-LIFE; TERM FOLLOW-UP; NEOANAL SPHINCTER; CONTINENCE; NEOSPHINCTER	Background. In patients with intractable fecal incontinence, conventional treatment is not always successful. Dynamic graciloplasty (transposition of the gracilis muscle to the anus with the implantation of stimulating electrodes) was developed to provide such patients with functional neosphincters. We evaluated the clinical results of this new surgical approach and the effects on quality of life. Methods. We treated 52 patients with dynamic graciloplasty. The clinical results of treatment were evaluated in an interview, by anal manometry, and by enema testing. The degree of continence was scored. To assess quality of life, four questionnaires were administered (parts 1 and 2 of the Nottingham Health Profile, the State-Trait Anxiety Inventory, and the Self-rating Depression scale). Results. Among the 52 patients, 38 (73 percent) were continent after a median follow-up of 2.1 years. At 52 weeks the patients' condition had improved with respect to the median frequency of defecation (from five to two times per 24 hours, P<0.001), the median time defecation could be postponed (from 9 seconds to 19 minutes, P=0.012), and the median time an enema could be retained (from 0 to 180 seconds, P=0.005). Patients in whom the technique was successful became less anxious than those in whom it failed (P=0.002) and improved with regard to effectiveness in their occupations, ability to perform tasks around the home, personal relationships, sexual function, and social life (P=0.01). They also became less isolated socially (P=0.05). Conclusions. Dynamic graciloplasty is a safe and reliable technique in patients with severe incontinence and may result in a better quality of life.	UNIV LIMBURG HOSP,DEPT GEN SURG,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT PLANNING,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT METHODOL & STAT,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT CLIN NEUROPHYSIOL,MAASTRICHT,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)			Adang, E.M.M./L-4169-2015; Heineman, Erik/ABG-9592-2021					ADANG EMM, 1993, THEOR SURG, V8, P122; BAETEN C, 1988, DIS COLON RECTUM, V31, P134, DOI 10.1007/BF02562646; BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; CAVINA E, 1990, INT J COLORECTAL DIS, V5, P6, DOI 10.1007/BF00496141; CHACHQUES JC, 1986, BIOMECHANICAL CARDIA, P59; CHRISTIANSEN J, 1990, BRIT J SURG, V77, P1039, DOI 10.1002/bjs.1800770928; CORMAN ML, 1980, DIS COLON RECTUM, V23, P552; DICKSON JAS, 1968, J PEDIATR SURG, V3, P696; DIJKSTRA PM, 1974, STEMMING ONTSTEMMING, P56; Dixon W. J., 1990, BMDP STATISTICAL SOF; GEORGE BD, 1993, BRIT J SURG, V80, P1342, DOI 10.1002/bjs.1800801042; GOEI R, 1990, RADIOLOGY, V174, P121, DOI 10.1148/radiology.174.1.2294537; HALLAN RI, 1990, BRIT J SURG, V77, P208, DOI 10.1002/bjs.1800770226; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KONSTEN J, 1993, WORLD J SURG, V17, P404, DOI 10.1007/BF01658712; KONSTEN J, 1993, DIS COLON RECTUM, V36, P559, DOI 10.1007/BF02049862; LEGUIT P, 1985, DIS COLON RECTUM, V28, P1, DOI 10.1007/BF02553893; LITTLE RJA, 1987, STATISTICAN ANAL MIS, P174; MADOFF RD, 1992, NEW ENGL J MED, V326, P1002; MANDELSTAM DA, 1985, COLOPROCTOLOGY PELVI, P217; MEUNIER PD, 1993, DIGEST DIS, V11, P252, DOI 10.1159/000171417; NELSON R, 1994, DIS COLON RECTUM S, V37, pP9; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; RAFFENSPERGER J, 1979, J PEDIATR SURG, V14, P794, DOI 10.1016/S0022-3468(79)80267-5; RINTALA R, 1992, J PEDIATR SURG, V27, P902, DOI 10.1016/0022-3468(92)90394-M; SALMONS S, 1969, J PHYSIOL-LONDON, V201, P535, DOI 10.1113/jphysiol.1969.sp008771; SONNINO RE, 1991, J PEDIATR SURG, V26, P1219, DOI 10.1016/0022-3468(91)90338-T; Spielberger C., 1983, STAI MANUAL; Swash M, 1992, COLOPROCTOLOGY PELVI, P196; Van der Ploeg HM, 1980, PSYCHOLOOG, V15, P460; WILLIAMS NS, 1991, LANCET, V338, P1166; YOSHIOKA K, 1988, DIS COLON RECTUM, V31, P767, DOI 10.1007/BF02560102; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	35	203	208	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1600	1605		10.1056/NEJM199506153322403	http://dx.doi.org/10.1056/NEJM199506153322403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753138				2022-12-28	WOS:A1995RC19200003
J	GILL, TM; TINETTI, ME				GILL, TM; TINETTI, ME			GERIATRIC-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											GILL, TM (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.			Gill, Thomas/0000-0002-6450-0368	NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER; NIA NIH HHS [AG10469] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; HAYNES RB, 1994, JAMA-J AM MED ASSOC, V271, P1256, DOI 10.1001/jama.271.16.1256; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V271, P992, DOI 10.1001/jama.271.13.992; 1991, NEW ENGL J MED, V325, P445	16	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1684	1686						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752416				2022-12-28	WOS:A1995RB09700024
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-FATTY-ACIDS; WOMEN				RUSSELL, RM (corresponding author), TUFTS UNIV,JEAN MAYER HUMAN NUTR RES CTR AGING,BOSTON,MA 02111, USA.							ALOIA JF, 1994, ANN INTERN MED, V120, P97, DOI 10.7326/0003-4819-120-2-199401150-00001; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; GOLDSTEIN DJ, 1994, AM J CLIN NUTR, V60, P647, DOI 10.1093/ajcn/60.5.647; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; GREENBERG RE, 1994, NEW ENGL J MED, V331, P141; KUCAMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; 1994, DIABETES CARE, V17, P519; 1994, STATEMENT T FATTY AC, P1; 1994, JAMA-J AM MED ASSOC, V272, P1942; 1994, NEW ENGL J MED, V330, P1029	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1699	1700						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752424				2022-12-28	WOS:A1995RB09700032
J	STOECKLE, R; DOUGLAS, RG				STOECKLE, R; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,WHITE HOUSE STN,NJ	Merck & Company	STOECKLE, R (corresponding author), CORNELL UNIV,COLL MED,NEW YORK,NY 10021, USA.							ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JACOBSON MA, 1994, J INFECT DIS, V169, P384, DOI 10.1093/infdis/169.2.384; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SONNABEND JA, 1994, 34TH INT C ANT AG CH; 1994, TUBERCULOSIS NEW YOR; 1994, MMWR-MORBID MORTAL W, V43, P740; 1993, NEW ENGL J MED, V329, P898; 1994, MMWR-MORBID MORTAL W, V43, P661	16	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1686	1688		10.1001/jama.273.21.1686	http://dx.doi.org/10.1001/jama.273.21.1686			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752417				2022-12-28	WOS:A1995RB09700025
J	RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK				RADY, PL; YEN, A; ROLLEFSON, JL; ORENGO, I; BRUCE, S; HUGHES, TK; TYRING, SK			HERPESVIRUS-LIKE DNA-SEQUENCES IN NON-KAPOSIS SARCOMA SKIN-LESIONS OF TRANSPLANT PATIENTS	LANCET			English	Note								Herpesvirus-like DNA sequences (KSHV) have been reported to be associated with various forms of Kaposi's sarcoma (KS). To determine if KSHV was associated with other proliferative skin lesions from non-AIDS immunocompromised patients, 33 shin lesions (basal cell carcinomas, squamous cell carcinomas, actinic keratoses, verruca vulgaris, atypical squamous proliferations, and seborrhoeic keratosis) from 4 organ-transplant patients receiving immunosuppressive therapy were tested for KSHV by PCR. KSHV sequences were detected in 82% of these skin lesions. Our results suggest that KSHV is associated with lesions other than KS in non-AIDS immunocompromised patients, and may also be involved in the pathogenesis of the various forms of proliferative skin lesions from organ-transplant patients.	UNIV TEXAS,MED BRANCH,DEPT IMMUNOL MICROBIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT DERMATOL,GALVESTON,TX 77550; BAYLOR COLL MED,DEPT DERMATOL,HOUSTON,TX 77030	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine			RADY, PETER/AAA-4481-2021					Brash DE, 1991, P NATL ACAD SCI USA, V101, P24; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; HUANG YQ, 1995, LANCET, V45, P759; MCGREGOR JM, 1994, J AM ACAD DERMATOL, V30, P701, DOI 10.1016/S0190-9622(08)81498-3; RADY P, 1992, CANCER RES, V52, P3804; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	9	201	206	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1339	1340						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752756				2022-12-28	WOS:A1995RA14800009
J	CRENSHAW, CA; SHAW, JG				CRENSHAW, CA; SHAW, JG			COMMENTARY ON JFK AUTOPSY ARTICLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note																		1992, JFK CONSPIRACY SILEN	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1632	1632		10.1001/jama.273.20.1632	http://dx.doi.org/10.1001/jama.273.20.1632			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745780				2022-12-28	WOS:A1995QY54100034
J	WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH				WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH			VARIATION IN OFFICE-BASED QUALITY - A CLAIMS-BASED PROFILE OF CARE PROVIDED TO MEDICARE PATIENTS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE; FAMILY PHYSICIANS; SPECIALTIES; POPULATION; INTERNISTS; ASSURANCE; OUTCOMES; SYSTEMS; MIX	Objectives.-To demonstrate that claims data ''profiling'' can be used as an ongoing method to support ambulatory care quality improvement; to measure the quality of office-based care provided to elderly patients with diabetes in three states; and to identify factors associated with better attainment of quality standards. Study Design.-A cross-sectional study based on a 100% sample of the Medicare claims (Part B and Part A) submitted between July 1, 1990, and June 30, 1991. Setting.-All primary care practices (both solo and group) actively seeing Medicare patients with diabetes in Alabama, Iowa, and Maryland (n=2980). Patients.-All elderly (greater than or equal to 65 years) Medicare patients seen by the study physicians and assigned a diagnosis of diabetes (n=97 388) by any office-based physician during the year. Main Outcome Measures.-The proportion of patients with diabetes receiving the following procedures (from any provider) at least once during the study period: hemoglobin A(1C) measurement, ophthalmologic examination, total cholesterol measurement, and blood glucose measurement. We considered the first three services to be optimally recommended and blood glucose measurement to be of limited use. Results.-Based on analyses of services provided in the ambulatory setting, we found that 84% of diabetics did not appear to receive the recommended hemoglobin A(1C) measurement, 54% did not see an ophthalmologist, and 45% received no cholesterol screening. Practice patterns varied considerably across the three states (up to 2.38-fold), even after adjusting for patient case mix and physician characteristics. Patients of general practitioners were less likely to meet recommended quality criteria than patients of internists or family practitioners. Patients receiving care from rural practitioners were less likely to receive services, either recommended or not, than those in urban locations. Conclusions.-Elderly patients with diabetes do not appear to be receiving optimal care. This study underscores the value of practice guideline development and dissemination in the ambulatory arena. This study provides substantial evidence that existing administrative claims data can be used to support ambulatory quality improvement activities.	BRANDEIS UNIV,HELLER GRAD SCH,INST HLTH POLICY,WALTHAM,MA 02254; PK NICOLLET MED FDN,MINNEAPOLIS,MN; HARVARD UNIV,SCH PUBL HLTH,CTR QUAL CARE RES & EDUC,BOSTON,MA 02115	Brandeis University; Harvard University; Harvard T.H. Chan School of Public Health	WEINER, JP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS HLTH SERV RES & DEV CTR,BALTIMORE,MD 21205, USA.		Garnick, Deborah w/I-9009-2012					ALLERHEILIGEN DA, 1990, DIABETES MELLITUS RE; BRANCH WT, 1987, OFFICE PRACTICE MED; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; Garnick D W, 1994, J Ambul Care Manage, V17, P44; Garnick D W, 1994, Int J Qual Health Care, V6, P163; GARNICK DW, 1994, JOINT COMM J QUAL IM, V20, P679, DOI 10.1016/S1070-3241(16)30117-1; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; LATHERS A, 1995, J AMB CARE MANAGE, V18, P56; Lawthers A G, 1993, Jt Comm J Qual Improv, V19, P552; Leatherman S, 1991, QRB Qual Rev Bull, V17, P349; LINN LS, 1984, INQUIRY-J HEALTH CAR, V21, P266; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; PALMER RH, 1994, FINAL REPORT EXTERNA; PALSEY B, 1987, AM J PUBLIC HEALTH, V77, P659; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STARFIELD B, 1993, PRACTICE VARIATION O; TOBIN T, 1959, ECONOMETRICA, V26, P24; Weiner J P, 1990, QRB Qual Rev Bull, V16, P424; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; 1994, HLTH 1993; 1993, DEV EVALUATING METHO; 1988, DIABETES CARE, V11, P745; 1994, REPORT C 1994; 1989, DIABETES CARE, V12, P365	38	291	292	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1503	1508		10.1001/jama.273.19.1503	http://dx.doi.org/10.1001/jama.273.19.1503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739076				2022-12-28	WOS:A1995QX41800032
J	HILDEBRANDT, ER; COZZARELLI, NR				HILDEBRANDT, ER; COZZARELLI, NR			COMPARISON OF RECOMBINATION IN-VITRO AND IN ESCHERICHIA-COLI-CELLS - MEASURE OF THE EFFECTIVE CONCENTRATION OF DNA IN-VIVO	CELL			English	Article							SITE-SPECIFIC RECOMBINATION; DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; BACTERIAL REPLICONS; EXCLUDED VOLUME; INVIVO; CONDENSATION; REPLICATION; CHROMATIN; CYTOPLASM	Despite the extremely high concentration of DNA in nucleoid/nuclear regions, chromosomal dimerization and entanglement are avoided. To help understand this, we measured the effective concentration of DNA in E. coli, a value that reflects the functional impact of the cellular milieu on DNA site reactivity. We used as probes plasm id fusion reactions by two site-specific recombinases. The normalized extents and rates of fusion in these systems were much lower in vivo than in analogous in vitro reactions. We calculate that the effective concentration of plasmid DNA is about one order of magnitude lower than the chemical concentration. We suggest that in bacterial cells DNA accessibility is highly restricted and that this dominates the forces that increase DNA activity, such as macromolecular crowding.			HILDEBRANDT, ER (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM31655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1983, CELL, V32, P1301, DOI 10.1016/0092-8674(83)90311-2; ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; ADAMS DE, 1992, J MOL BIOL, V226, P661, DOI 10.1016/0022-2836(92)90623-R; ALATOSSAVA T, 1985, J BACTERIOL, V162, P413, DOI 10.1128/JB.162.1.413-419.1985; AUSTIN S, 1981, CELL, V25, P729, DOI 10.1016/0092-8674(81)90180-X; BERG OG, 1990, BIOPOLYMERS, V30, P1027, DOI 10.1002/bip.360301104; BLAKELY G, 1993, CELL, V75, P351, DOI 10.1016/0092-8674(93)80076-Q; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BLISKA JB, 1988, THESIS U CALIFORNIA; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOHRMANN B, 1993, ULTRAMICROSCOPY, V49, P235, DOI 10.1016/0304-3991(93)90230-U; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Croston GE, 1993, CURR OPIN CELL BIOL, V5, P417, DOI 10.1016/0955-0674(93)90006-C; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; FULTON AB, 1982, CELL, V30, P345, DOI 10.1016/0092-8674(82)90231-8; GIAEVER GN, 1988, BIOPHYS CHEM, V29, P7, DOI 10.1016/0301-4622(88)87020-0; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GOODSELL DS, 1991, TRENDS BIOCHEM SCI, V16, P203, DOI 10.1016/0968-0004(91)90083-8; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; GUARNEROS G, 1972, J MOL BIOL, V52, P30; HOESS RH, 1990, NUCLEIC ACIDS MOL BI, V4, P99; JAWORSKI A, 1991, J BIOL CHEM, V266, P2576; KELLENBERGER E, 1987, TRENDS BIOCHEM SCI, V12, P105, DOI 10.1016/0968-0004(87)90049-1; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; LLOYD RS, 1978, BIOCHEMISTRY-US, V17, P1890, DOI 10.1021/bi00603a014; MANIATIS T, 1974, J MOL BIOL, V84, P37, DOI 10.1016/0022-2836(74)90211-3; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARKO JF, 1994, SCIENCE, V265, P506, DOI 10.1126/science.8036491; MINTON AP, 1981, BIOPOLYMERS, V20, P2093, DOI 10.1002/bip.1981.360201006; NASH HA, 1981, J BIOL CHEM, V256, P9246; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P3; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; PAL SK, 1986, J MOL BIOL, V192, P275, DOI 10.1016/0022-2836(86)90364-5; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PETTIJOHN DE, 1982, CELL, V30, P667, DOI 10.1016/0092-8674(82)90269-0; PETTIJOHN DE, 1980, P NATL ACAD SCI-BIOL, V77, P1331, DOI 10.1073/pnas.77.3.1331; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SIKORAV JL, 1991, J MOL BIOL, V222, P1085, DOI 10.1016/0022-2836(91)90595-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSE Y, 1980, CELL, V22, P269, DOI 10.1016/0092-8674(80)90174-9; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P175, DOI 10.1016/0167-4781(93)90142-Z; ZIMMERMAN SB, 1985, NUCLEIC ACIDS RES, V13, P2241, DOI 10.1093/nar/13.7.2241; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	62	47	47	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					331	340		10.1016/0092-8674(95)90386-0	http://dx.doi.org/10.1016/0092-8674(95)90386-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736586	Bronze			2022-12-28	WOS:A1995QW89400005
J	ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC				ICHTCHENKO, K; HATA, Y; NGUYEN, T; ULLRICH, B; MISSLER, M; MOOMAW, C; SUDHOF, TC			NEUROLIGIN-1 - A SPLICE SITE-SPECIFIC LIGAND FOR BETA-NEUREXINS	CELL			English	Article							BINDING PROTEIN; AGRIN; SEQUENCE; MEMBRANE; LAMININ	Neurexins are neuronal cell surface proteins with hundreds of isoforms generated by alternative splicing. Here we describe neuroligin 1, a neuronal cell surface protein that is enriched in synaptic plasma membranes and acts as a splice site-specific ligand for beta-neurexins. Neuroligin 1 binds to beta-neurexins only if they lack an insert in the alternatively spliced sequence of the G domain, but not if they contain an insert, The extracellular sequence of neuroligin 1 is composed of a catalytically inactive esterase domain homologous to acetylcholinesterase. In situ hybridization reveals that alternative splicing of neurexins at the site recognized by neuroligin 1 is highly regulated. These findings support a model whereby alternative splicing of neurexins creates a family of cell surface receptors that confers Interactive specificity onto their resident neurons.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ICHTCHENKO, K (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Missler, Markus/0000-0001-8008-984X	NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; DELAESCALERA S, 1990, EMBO J, V11, P3593; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; GEHLSEN KR, 1992, J CELL BIOL, V117, P449, DOI 10.1083/jcb.117.2.449; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SIKORAV JL, 1987, EMBO J, V7, P1865; Summers MD, 1987, MANUAL METHODS BACUL; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAKAGI Y, 1988, FEBS LETT, V282, P17; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V11, P4683; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	25	540	557	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					435	443		10.1016/0092-8674(95)90396-8	http://dx.doi.org/10.1016/0092-8674(95)90396-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736595	Bronze			2022-12-28	WOS:A1995QW89400015
J	GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE				GULY, UM; MITCHELL, RG; COOK, R; STEEDMAN, DJ; ROBERTSON, CE			PARAMEDICS AND TECHNICIANS ARE EQUALLY SUCCESSFUL AT MANAGING CARDIAC-ARREST OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR-FIBRILLATION; CARDIOPULMONARY-RESUSCITATION; HEARTSTART-SCOTLAND; FLYING SQUAD; DEFIBRILLATION; SURVIVAL; EMERGENCY; EXPERIENCE; EPINEPHRINE; STATEMENT	Objective-To examine the effect on survival of treatment by ambulance paramedics and ambulance technicians after cardiac arrest outside hospital. Design-Prospective study over two years from 1 April 1992 to 31 March 1994. Setting-Accident and emergency department of university teaching hospital. Subjects-502 consecutive adult patients with out of hospital cardiopulmonary arrest of cardiac origin. Interventions-Treatment by ambulance technicians or paramedics both equipped with semiautomatic defibrillators. Main outcome measures-Rate of return of spontaneous circulation, hospital admission, and survival to hospital discharge. Results-Rates of return of spontaneous circulation, hospital admission, and survival to hospital discharge were not significantly different for patients treated by paramedics as opposed to ambulance technicians. Paramedics spent significantly longer at the scene of the arrest than technicians (P<0.0001). Conclusions-The response of ambulance paramedics to patients with cardiopulmonary arrest outside hospital does not provide improved outcome when compared with ambulance technicians using basic techniques and equipped with semi-automatic defibrillators.	ROYAL EDINBURGH INFIRM,DEPT ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh								ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BOSSAERT L, 1989, RESUSCITATION, V17, pS55, DOI 10.1016/0300-9572(89)90091-9; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; CUMMINS RO, 1991, RESUSCITATION, V21, P960; CUMMINS RO, 1995, JAMA-J AM MED ASSOC, V253, P2408; CUSACK S, 1992, ARCH EMERG MED, V9, P203; DARK PM, 1990, SCOT MED J, V35, P73, DOI 10.1177/003693309003500304; DELUNA AB, 1989, AM HEART J, V117, P151, DOI 10.1016/0002-8703(89)90670-4; DICKEY W, 1991, Q J MED, V80, P729; DYBVIK T, 1995, IN PRESS RESUSCITATI; HAMER DW, 1993, RESUSCITATION, V26, P31, DOI 10.1016/0300-9572(93)90160-R; HARRISON EE, 1981, ANN EMERG MED, V10, P420, DOI 10.1016/S0196-0644(81)80309-5; JAKOBSSON J, 1987, ACTA MED SCAND, V222, P117; KERN KB, 1990, RESUSCITATION, V20, P221, DOI 10.1016/0300-9572(90)90005-Y; KOSTER R, 1992, RESUSCITATION, V24, P143, DOI 10.1016/0300-9572(92)90020-D; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; MARTIN DR, 1993, RESUSCITATION, V26, P63, DOI 10.1016/0300-9572(93)90164-L; MYERBURG RJ, 1980, AM J MED, V68, P568, DOI 10.1016/0002-9343(80)90307-1; OLSON DW, 1989, ANN EMERG MED, V18, P806, DOI 10.1016/S0196-0644(89)80200-8; PANTRIDG.JF, 1967, LANCET, V2, P271; ROWLEY JM, 1987, BRIT MED J, V295, P1387, DOI 10.1136/bmj.295.6610.1387; SCHUTTLER J, 1991, ANAESTHESIST, V40, P172; SEDGWICK ML, 1994, RESUSCITATION, V27, P55, DOI 10.1016/0300-9572(94)90022-1; SEDGWICK ML, 1992, RESUSCITATION, V24, P73, DOI 10.1016/0300-9572(92)90175-C; SMITH JP, 1986, CAN J PREHOSP MED, V1, P5; STIELL IG, 1992, NEW ENGL J MED, V327, P1047; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; STULTS KR, 1986, AM J EMERG MED, V4, P491, DOI 10.1016/S0735-6757(86)80001-8; VONPLANTA M, 1992, RESUSCITATION, V24, P227, DOI 10.1016/0300-9572(92)90182-C; WEAVER WD, 1990, CIRCULATION, V82, P2027, DOI 10.1161/01.CIR.82.6.2027; 1991, NATIONAL HLTH SERVIC; 1993, HLTH NATION KEY AREA	36	59	59	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1091	1094		10.1136/bmj.310.6987.1091	http://dx.doi.org/10.1136/bmj.310.6987.1091			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742673	Green Published			2022-12-28	WOS:A1995QW61800012
J	LUMB, KJ; KIM, PS				LUMB, KJ; KIM, PS			MEASUREMENT OF INTERHELICAL ELECTROSTATIC INTERACTIONS IN THE GCN4 LEUCINE-ZIPPER	SCIENCE			English	Article							X-RAY STRUCTURE; COILED-COIL; PROTEINS; STABILITY; DIMERIZATION; REGION; DNA; SPECTROSCOPY; TROPOMYOSIN; CONTRIBUTE	The dimerization specificity of the bZIP transcription factors resides in the leucine zipper region. It is commonly assumed that electrostatic interactions between oppositely charged amino acid residues on different helices of the leucine zipper contribute favorably to dimerization specificity. Crystal structures of the GCN4 leucine zipper contain interhelical salt bridges between Glu(20) and Lys(15') and between Glu(22) and Lys(27'). C-13-nuclear magnetic resonance measurements of the glutamic acid pK(a) values at physiological ionic strength indicate that the salt bridge involving Glu(22) does not contribute to stability and that the salt bridge involving Glu(20) is unfavorable, relative to the corresponding situation with a neutral (protonated) Glu residue, Moreover, the substitution of Glu(20) by glutamine is stabilizing. Thus, salt bridges will not necessarily contribute favorably to bZIP dimerization specificity and may indeed be unfavorable, relative to alternative neutral-charge interactions.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute				Lumb, Kevin/0000-0003-2778-9956	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044162] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44162] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BERGER B, IN PRESS P NATL ACAD; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN JS, 1970, NATURE, V228, P642, DOI 10.1038/228642a0; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ELLENBERGER T, 1994, CURR OPIN STRUC BIOL, V4, P12, DOI 10.1016/S0959-440X(94)90054-X; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; Fersht A R, 1972, Cold Spring Harb Symp Quant Biol, V36, P71; GOODMAN EM, 1991, BIOCHEMISTRY-US, V30, P11615, DOI 10.1021/bi00114a002; GRADDIS TJ, 1993, BIOCHEMISTRY-US, V32, P12664, DOI 10.1021/bi00210a015; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; Honig B., 1992, CURR OPIN STRUC BIOL, V2, P40; JOHN M, 1994, J BIOL CHEM, V269, P16247; Kirkwood JG, 1938, J CHEM PHYS, V6, P506, DOI 10.1063/1.1750302; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LETAI A, 1995, P NATL ACAD SCI USA, V92, P92, DOI 10.1073/pnas.92.1.92; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; LUMB KJ, UNPUB; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; OAS TG, 1990, BIOCHEMISTRY-US, V29, P2891, DOI 10.1021/bi00464a001; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; OSHEA EK, 1992, CELL, V66, P699; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SHAKA AJ, 1983, J MAGN RESON, V53, P313, DOI 10.1016/0022-2364(83)90035-5; STONE D, 1975, PROTEINS CONTRACTILE, P125; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; THOMPSON KS, 1993, BIOCHEMISTRY-US, V32, P5491, DOI 10.1021/bi00072a001; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	49	180	184	2	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					436	439		10.1126/science.7716550	http://dx.doi.org/10.1126/science.7716550			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716550				2022-12-28	WOS:A1995QU57200046
J	SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT				SANGUINETTI, MC; JIANG, CG; CURRAN, ME; KEATING, MT			A MECHANISTIC LINK BETWEEN AN INHERITED AND AN ACQUIRED CARDIAC-ARRHYTHMIA - HERG ENCODES THE I-KR POTASSIUM CHANNEL	CELL			English	Article							PIG VENTRICULAR MYOCYTES; III ANTIARRHYTHMIC AGENT; RECTIFIER K+-CURRENT; DELAYED RECTIFIER; CELLS; KINETICS; BLOCK; PROLONGATION; MODULATION; DOFETILIDE	Mutations in HERG cause an inherited cardiac arrhythmia, long QT syndrome (LQT), To define the function of HERG, we expressed the protein in Xenopus oocytes. The biophysical properties of expressed HERG are nearly identical to the rapidly activating delayed rectifier K+ current (I-Kr) in cardiac myocytes. HERG current is K+ selective, declines with depolarizations above 0 mV, is activated by extracellular K+, and is blocked by lanthanum. Interestingly, HERG current is not blocked by drugs that specifically block I-Kr in cardiac myocytes, These data indicate that HERG proteins form I-Kr channels, but that an additional subunit may be required for drug sensitivity. Since block of I-Kr is a known mechanism for drug-induced cardiac;arrhythmias, the finding that HERG encodes I-Kr channels provides a mechanistic link between certain forms of inherited and acquired LQT.	UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	SANGUINETTI, MC (corresponding author), UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112, USA.		Sanguinetti, Michael/AAN-2615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052338] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL 52338-01, R01-HL48074] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BALSER JR, 1990, J GEN PHYSIOL, V96, P835, DOI 10.1085/jgp.96.4.835; BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CHINN K, 1993, J PHARMACOL EXP THER, V264, P553; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRY P, 1976, LANCET, V2, P231; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FOLLMER CH, 1992, AM J PHYSIOL, V262, pC75, DOI 10.1152/ajpcell.1992.262.1.C75; GINTANT GA, 1992, HEART CARDIOVASCULAR, P1121; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; LYNCH JJ, 1994, J PHARMACOL EXP THER, V269, P541; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; ROSEN DM, 1988, CONTROL CARDIAC ARRH, P559; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; SANGUINETTI MC, 1992, PFLUG ARCH EUR J PHY, V420, P180, DOI 10.1007/BF00374988; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; SANGUINETTI MC, 1990, AM J PHYSIOL, V259, pH1881, DOI 10.1152/ajpheart.1990.259.6.H1881; SCAMPS F, 1989, AM J PHYSIOL, V257, pC1086, DOI 10.1152/ajpcell.1989.257.6.C1086; SHIBASAKI T, 1987, J PHYSIOL-LONDON, V387, P227, DOI 10.1113/jphysiol.1987.sp016571; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; YANG T, 1994, CIRC RES, V75, P870, DOI 10.1161/01.RES.75.5.870	32	2002	2090	4	115	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					299	307		10.1016/0092-8674(95)90340-2	http://dx.doi.org/10.1016/0092-8674(95)90340-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736582	Bronze			2022-12-28	WOS:A1995QV41000019
J	DAS, G; HINKLEY, CS; HERR, W				DAS, G; HINKLEY, CS; HERR, W			BASAL PROMOTER ELEMENTS AS A SELECTIVE DETERMINANT OF TRANSCRIPTIONAL ACTIVATOR FUNCTION	NATURE			English	Article							RNA POLYMERASE-II; TRANS-ACTIVATOR; SNRNA PROMOTER; BINDING; DOMAINS; OCT-1; SPECIFICITY; EXPRESSION; ENHANCER; DISTINCT	IN eukaryotes, activation of transcription involves an interplay between activators bound to cis-regulatory elements and factors bound to basal elements near the start site of transcription. The basal elements, for example the TATA box or proximal sequence element (PSE) of small nuclear RNA (snRNA) promoters, nucleate the assembly of basal transcription complexes, components of which interact with activators(1,2). Although one basal transcription complex can interact with many activators, it is unclear whether different basal transcription complexes can direct different responses to particular activators. We show here that changing the arrangement of basal elements can alter the response to transcriptional activation domains. Indeed, in the human U6 snRNA promoter, point mutation of either a TATA box or PSE results in diametrically opposed responses to VP16- and Sp1-derived activation domains. These basal elements can even discriminate small changes in an activation domain. Thus the arrangement of basal promoter elements provides a mechanism for differential regulation of transcription.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Herr, Winship/E-6491-2012	Herr, Winship/0000-0002-3606-4546				BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAS G, 1993, J BIOL CHEM, V268, P25026; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; HERNANDEZ N, 1988, EMBO J, V7, P3125, DOI 10.1002/j.1460-2075.1988.tb03179.x; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TANAKA M, 1994, MOL CELL BIOL, V14, P6056, DOI 10.1128/MCB.14.9.6056; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1988, GENE DEV, V2, P1764, DOI 10.1101/gad.2.12b.1764; TANAKA M, 1994, MOL CELL BIOL, V16, P6046; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	30	105	111	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					657	660		10.1038/374657a0	http://dx.doi.org/10.1038/374657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715708				2022-12-28	WOS:A1995QT18900064
J	RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS				RICHARD, I; BROUX, O; ALLAMAND, V; FOUGEROUSSE, F; CHIANNILKULCHAI, N; BOURG, N; BRENGUIER, L; DEVAUD, C; PASTURAUD, P; ROUDAUT, C; HILLAIRE, D; PASSOSBUENO, MR; ZATZ, M; TISCHFIELD, JA; FARDEAU, M; JACKSON, CE; COHEN, D; BECKMANN, JS			MUTATIONS IN THE PROTEOLYTIC-ENZYME CALPAIN-3 CAUSE LIMB-GIRDLE MUSCULAR-DYSTROPHY TYPE-2A	CELL			English	Article							ACTIVATED NEUTRAL PROTEASE; CALCIUM-DEPENDENT PROTEASE; FUNCTIONAL IMPLICATIONS; BINDING PROTEINS; SEQUENCES; MUSCLE; GENE; TRANSCRIPTION; EXPRESSION; LINKAGE	Limb-girdle muscular dystrophies (LGMDs) are a group of inherited diseases whose genetic etiology has yet to be elucidated, The autosomal recessive forms (LGMD2) constitute a genetically heterogeneous group with LGMD2A mapping to chromosome 15q15.1-q21.1, The gene encoding the muscle-specific calcium-activated neutral protease 3 (CANP3) large subunit is located in this region. This cysteine protease belongs to the family of intracellular calpains, Fifteen nonsense, splice site, frameshift, or missense calpain mutations cosegregate with the disease in LGMD2A families, six of which were found within La Reunion island patients, A digenic inheritance model is proposed to account for the unexpected presence of multiple independent mutations in this small inbred population. Finally, these results demonstrate an enzymatic rather than a structural protein defect causing a muscular dystrophy, a defect that may have regulatory consequences, perhaps in signal transduction.	UNIV SAO PAULO, INST BIOCIENCIAS, DEPT BIOL, BR-05508900 SAO PAULO, BRAZIL; INDIANA UNIV, SCH MED, DEPT MED & MOLEC GENET, INDIANAPOLIS, IN 46202 USA; CNRS, UNITE A614, INSERM, F-75005 PARIS, FRANCE; HENRY FORD HOSP, DETROIT, MI 48202 USA; CTR ETUD POLYMORPHISME HUMAIN, FDN JEAN DAUSSET, F-75010 PARIS, FRANCE	Universidade de Sao Paulo; Indiana University System; Indiana University-Purdue University Indianapolis; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Henry Ford Health System; Henry Ford Hospital; Foundation Jean Dausset-CEPH	RICHARD, I (corresponding author), GENETHON, 1 RUE INT, F-91000 EVRY, FRANCE.		Richard, isabelle/J-8298-2013; Beckmann, Jacques S/A-9772-2008; Passos-Bueno, Maria Rita/I-6796-2016; Allamand, Valérie/AAH-6272-2021; Zatz, Mayana/M-5338-2015; Allamand, Valerie/M-4333-2017	Beckmann, Jacques S/0000-0002-9741-1900; Passos-Bueno, Maria Rita/0000-0002-9248-3008; Allamand, Valérie/0000-0001-8997-9742; Zatz, Mayana/0000-0003-3970-8025; Tischfield, Jay/0000-0003-3217-8287				ALLAMAND V, 1995, HUM MOL GENET, V4, P459, DOI 10.1093/hmg/4.3.459; ALLAMAND V, 1995, IN PRES AM J HUM GEN; BACH G, 1993, AM J HUM GENET, V53, P330; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BONILLA E, 1988, CELL, V54, P447, DOI 10.1016/0092-8674(88)90065-7; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Bushby K.M.D., 1994, DIAGNOSTIC CRITERIA, P25; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHIANNILKULCHAI N, 1995, IN PRESS HUM MOL GEN, V4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; EMORI Y, 1986, FEBS LETT, V194, P249, DOI 10.1016/0014-5793(86)80094-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HEINISCH U, 1995, AM J HUM GENET, V56, P51; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; IMAJOH S, 1986, J BIOCHEM-TOKYO, V100, P633, DOI 10.1093/oxfordjournals.jbchem.a121755; JACKSON CE, 1961, PEDIATRICS, V28, P77; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KEEN J, 1991, TRENDS GENET, V7, P5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MATSUMURA K, 1993, LANCET, V341, P521, DOI 10.1016/0140-6736(93)90279-P; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIYAMOTO S, 1994, NATL ACAD SCI US, V94, P12740; MURACHI T, 1989, BIOCHEM INT, V18, P263; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; OHNO S, 1989, CYTOGENET CELL GENET, V51, P1054; OPPENHEIM A, 1990, HUM GENET, V86, P175; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; RICHARD I, 1994, GENOMICS, V23, P619, DOI 10.1006/geno.1994.1550; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; RODIUS F, 1994, AM J HUM GENET, V54, P1050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sambrook J, 1989, MOL CLONING LABORATO; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; SORIMACHI H, 1993, J BIOL CHEM, V268, P10593; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P2951, DOI 10.1093/nar/10.9.2951; SUZUKI K, 1990, CELL STRUCT FUNCT, V15, P1, DOI 10.1247/csf.15.1; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WALTON JN, 1954, BRAIN, V77, P169, DOI 10.1093/brain/77.2.169; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YOUNG K, 1992, GENOMICS, V13, P1370, DOI 10.1016/0888-7543(92)90074-3	54	794	822	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 7	1995	81	1					27	40		10.1016/0092-8674(95)90368-2	http://dx.doi.org/10.1016/0092-8674(95)90368-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720071	Bronze			2022-12-28	WOS:A1995QR97000005
J	SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF				SHER, GD; GINDER, GD; LITTLE, J; YANG, SY; DOVER, GJ; OLIVIERI, NF			EXTENDED THERAPY WITH INTRAVENOUS ARGININE BUTYRATE IN PATIENTS WITH BETA-HEMOGLOBINOPATHIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICKLE-CELL-ANEMIA; GLOBIN GENE-EXPRESSION; INCREASED FETAL HEMOGLOBIN; ADULT ERYTHROID-CELLS; HYDROXYUREA INDUCTION; DIABETIC MOTHERS; SODIUM-BUTYRATE; F PRODUCTION; DISEASE; 5-AZACYTIDINE	Background. Enhanced production of fetal hemoglobin lessens the severity of beta-thalassemia and sickle cell disease, Intravenous infusion of arginine butyrate can increase the number of reticulocytes containing fetal_hemoglobin in patients with these disorders, and it has induced a substantial increase in hemoglobin in one patient with thalassemia. We therefore tested the efficacy of this agent in patients with beta-hemoglobinopathies. Methods. We treated 10 patients with severe beta-thalassemia or sickle cell disease with arginine butyrate at an initial dose of 500 mg per kilogram of body weight per day (final dose, 2000 mg per kilogram per day), 6 days per week, for a mean (+/-SD) of 10+/-1.2 weeks (range, 9 to 13). A hematologic response was defined as an increase in the hemoglobin concentration of at least 2 g per deciliter in patients with thalassemia and as a twofold increase in fetal hemoglobin in patients with sickle cell disease. Results. There were increases in gamma-globin messenger RNA and in reticulocytes containing fetal hemoglobin, but no increases in hemoglobin, in the patients with thalassemia, A small, unsustained increase in fetal hemoglobin was observed in two patients with sickle cell disease, Drug toxicity was minimal at standard doses. One patient had a grand mat seizure after inadvertently receiving 2000 mg of arginine butyrate per kilogram over a period of six hours. Conclusions. Ten weeks of intravenous arginine butyrate did not produce a hematologic response in 10 patients with either severe beta-thalassemia or sickle cell disease.	HOSP SICK CHILDREN,HAEMOGLOBINOPATHY PROGRAM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON,CANADA; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University			Olivieri, Nancy/AAI-2250-2020		NIDDK NIH HHS [DK 29902] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK029902, R01DK029902] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARD H, 1985, PEDIATRICS, V75, P1143; BRITTENHAM GM, 1985, BLOOD, V65, P183; CAO A, 1994, BLOOD REV, V8, P1, DOI 10.1016/0268-960X(94)90002-7; CHARACHE S, 1992, BLOOD, V79, P2555; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; COLLINS AF, 1995, BLOOD, V85, P43, DOI 10.1182/blood.V85.1.43.bloodjournal85143; Constantoulakis P, 1989, Prog Clin Biol Res, V316B, P351; CONSTANTOULAKIS P, 1991, BLOOD, V77, P1326; DESFORGES JF, 1993, NEW ENGL J MED, V329, P1038, DOI 10.1056/NEJM199309303291413; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; DOVER GJ, 1986, BLOOD, V67, P735; DOVER GJ, 1992, NEW ENGL J MED, V327, P569; DOVER GJ, 1994, BLOOD, V84, P339; DOVER GJ, 1978, BLOOD, V52, P664; DOVER GJ, 1992, SEMIN ONCOL, V19, P61; DOVER GJ, 1985, BLOOD, V66, P527; FIBACH E, 1993, BLOOD, V82, P2203, DOI 10.1182/blood.V82.7.2203.bloodjournal8272203; GINDER GD, 1984, P NATL ACAD SCI-BIOL, V81, P3954, DOI 10.1073/pnas.81.13.3954; GLAUBER JG, 1991, MOL CELL BIOL, V11, P4690, DOI 10.1128/MCB.11.9.4690; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; LETVIN NL, 1984, NEW ENGL J MED, V310, P869, DOI 10.1056/NEJM198404053101401; LEY TJ, 1983, BLOOD, V62, P370; LITTLE J, 1994, CLIN RES, V42, pA238; LITTLE JA, 1995, BLOOD, V85, P1712, DOI 10.1182/blood.V85.7.1712.bloodjournal8571712; MILLER BA, 1987, NEW ENGL J MED, V316, P244, DOI 10.1056/NEJM198701293160504; MILLER BA, 1986, BLOOD, V67, P104; NATHAN DG, 1990, ANN NY ACAD SCI, V612, P179; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; PACE B, 1994, BLOOD, V84, P4344, DOI 10.1182/blood.V84.12.4344.bloodjournal84124344; PAPAYANNOPOULOU T, 1984, SCIENCE, V224, P617, DOI 10.1126/science.6200940; PEMBREY ME, 1978, BRIT J HAEMATOL, V40, P415, DOI 10.1111/j.1365-2141.1978.tb05813.x; PERRINE RP, 1972, LANCET, V2, P1163; PERRINE SP, 1989, BLOOD, V74, P454; PERRINE SP, 1988, P NATL ACAD SCI USA, V85, P8540, DOI 10.1073/pnas.85.22.8540; PERRINE SP, 1987, BIOCHEM BIOPH RES CO, V148, P694, DOI 10.1016/0006-291X(87)90932-6; PERRINE SP, 1985, NEW ENGL J MED, V312, P334, DOI 10.1056/NEJM198502073120602; PERRINE SP, 1993, NEW ENGL J MED, V328, P81, DOI 10.1056/NEJM199301143280202; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; RODGERS GP, 1992, SEMIN ONCOL, V19, P67; RODGERS GP, 1990, NEW ENGL J MED, V322, P1037, DOI 10.1056/NEJM199004123221504; VEITH R, 1985, NEW ENGL J MED, V313, P1571, DOI 10.1056/NEJM198512193132503; VICHINSKY EP, 1994, BLOOD, V83, P1124; WAYE JS, 1991, BLOOD, V77, P1100; WEATHERALL DJ, 1981, THALASSEMIA SYNDROME, P148; WOOD WG, 1980, BRIT J HAEMATOL, V45, P431, DOI 10.1111/j.1365-2141.1980.tb07163.x	47	133	143	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1606	1610		10.1056/NEJM199506153322404	http://dx.doi.org/10.1056/NEJM199506153322404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753139				2022-12-28	WOS:A1995RC19200004
J	GOLDFRANK, LR				GOLDFRANK, LR			EMERGENCY-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEDIATRIC EMERGENCY				GOLDFRANK, LR (corresponding author), NYU,BELLEVUE HOSP CTR,NEW YORK,NY 10016, USA.							BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; Bernstein E, 1994, Acad Emerg Med, V1, P277; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Birnbaum A, 1994, Acad Emerg Med, V1, P213; BREWER RD, 1994, NEW ENGL J MED, V331, P513, DOI 10.1056/NEJM199408253310806; BROOKOFF D, 1994, NEW ENGL J MED, V331, P518, DOI 10.1056/NEJM199408253310807; FRIEDMAN E, 1994, JAMA-J AM MED ASSOC, V271, P1535, DOI 10.1001/jama.271.19.1535; GOLDSTEIN KP, 1993, JAMA-J AM MED ASSOC, V270, P2190, DOI 10.1001/jama.270.18.2190; KELLERMANN AL, 1994, JAMA-J AM MED ASSOC, V271, P1953, DOI 10.1001/jama.271.24.1953; LINDEGREN ML, 1993, JAMA-J AM MED ASSOC, V270, P2185, DOI 10.1001/jama.270.18.2185; LOWE RA, 1994, ANN EMERG MED, V23, P286, DOI 10.1016/S0196-0644(94)70042-7; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; STERN SA, 1995, ACAD EMERG MED, V2, P89, DOI 10.1111/j.1553-2712.1995.tb03167.x; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; 1994, NEW ENGL J MED, V330, P1426	15	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1673	1674		10.1001/jama.273.21.1673	http://dx.doi.org/10.1001/jama.273.21.1673			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752410				2022-12-28	WOS:A1995RB09700018
J	WELLS, PS; HIRSH, J; ANDERSON, DR; LENSING, AWA; FOSTER, G; KEARON, C; WEITZ, J; DOVIDIO, R; COGO, A; PRANDONI, P; GIROLAMI, A; GINSBERG, JS				WELLS, PS; HIRSH, J; ANDERSON, DR; LENSING, AWA; FOSTER, G; KEARON, C; WEITZ, J; DOVIDIO, R; COGO, A; PRANDONI, P; GIROLAMI, A; GINSBERG, JS			ACCURACY OF CLINICAL-ASSESSMENT OF DEEP-VEIN THROMBOSIS	LANCET			English	Article							B-MODE ULTRASONOGRAPHY; VENOUS THROMBOSIS; IMPEDANCE PLETHYSMOGRAPHY; SYMPTOMATIC OUTPATIENTS; CONTRAST VENOGRAPHY; DIAGNOSIS; ULTRASOUND; EFFICACY; LEG	The clinical diagnosis of deep-vein thrombosis is generally thought to be unreliable, From experience, we hypothesised that this widely held view might be incorrect. We developed a clinical model and prospectively tested its ability in three tertiary care centres to stratify symptomatic outpatients with suspected deep-vein thrombosis into groups with high, moderate, or low probability groups of deep-vein thrombosis. We evaluated our clinical model in combination with venous ultrasonography to determine the potential for an improved and simplified diagnostic approach in patients with suspected deep-vein thrombosis. All patients were clinically assessed to determine the probability for deep-vein thrombosis before they had ultrasonography and venography. All tests were performed and interpreted by independent observers, In 529 patients, the clinical model predicted prevalence of deep-vein thrombosis in the three categories: 85% in the high pretest probability category, 33% in the moderate, and 5% in the low category. There was no statistical difference in the performance of the model in the three centres. The model demonstrated excellent interobserver reliability (Kappa=0.85), There were important differences with ultrasonography between the high and low pretest probability groups for both positive predictive values (100% (95% CI, 94-100%) vs(63% [35-85%], respectively). Thus, use of the clinical model combined with ultrasonography would decrease the number of false positive and negative diagnosis if venography were done when the ultrasound result and pretest probability were discordant. The diagnostic process could be simplified by excluding those patients with low pretest probability and normal ultrasound results from serial testing.	HAMILTON CIV HOSP,RES CTR,HAMILTON,ON,CANADA; HENDERSON GEN HOSP,HAMILTON,ON L8V 1C3,CANADA; IST SEMEIOT MED,PADUA,ITALY; VICTORIA GEN HOSP,HALIFAX,NS B3H 2Y9,CANADA; UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & I,1105 AZ AMSTERDAM,NETHERLANDS; MCMASTER UNIV,MED CTR,HAMILTON,ON,CANADA	McMaster University; McMaster University; Dalhousie University; University of Victoria; University of Amsterdam; Academic Medical Center Amsterdam; McMaster University	WELLS, PS (corresponding author), OTTAWA CIVIC HOSP,OTTAWA,ON K1A 1J8,CANADA.		ginsberg, jeffrey s/ABC-1065-2020; Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550; Anderson, David/0000-0003-0845-1722				ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; BETTMANN MA, 1987, RADIOLOGY, V165, P113, DOI 10.1148/radiology.165.1.3306781; COGO A, 1993, THROMB HAEMOSTASIS, V70, P404; COLTON T, 1974, STAT MED, P174; CRANLEY JJ, 1976, ARCH SURG-CHICAGO, V111, P34; DAUZAT MM, 1986, J ULTRAS MED, V5, P625; GINSBERG JS, 1991, RADIOLOGY, V181, P651, DOI 10.1148/radiology.181.3.1947076; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HEIJBOER H, 1992, THROMB HAEMOSTASIS, V67, P510; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; MCLACHLIN J, 1962, ARCH SURG-CHICAGO, V85, P738; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P30; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P52; SANDLER DA, 1984, LANCET, V2, P716; SLEZEWSKI M, 1991, EUR RAD, V13, P1747; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008; WELLS PS, 1992, BLOOD S, V80, P316	23	522	561	1	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1326	1330		10.1016/S0140-6736(95)92535-X	http://dx.doi.org/10.1016/S0140-6736(95)92535-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752753				2022-12-28	WOS:A1995RA14800006
J	PEDERSEN, TR; KJEKSHUS, J; BERG, K; HAGHFELT, T; FAERGEMAN, O; THORGEIRSSON, G; PYORALA, K; MIETTINEN, T; WILHELMSEN, L; OLSSON, AG; WEDEL, H				PEDERSEN, TR; KJEKSHUS, J; BERG, K; HAGHFELT, T; FAERGEMAN, O; THORGEIRSSON, G; PYORALA, K; MIETTINEN, T; WILHELMSEN, L; OLSSON, AG; WEDEL, H			BASE-LINE SERUM-CHOLESTEROL AND TREATMENT EFFECT IN THE SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY (4S)	LANCET			English	Note							MYOCARDIAL-INFARCTION; MORTALITY; DISEASE	We examined the relation between the risk of major coronary events (coronary death and non-fatal myocardial infarction) and baseline cholesterol revels in patients with coronary heart disease, randomised to placebo or simvastatin therapy in the Scandinavian Simvastatin Survival Study (4S). The relative risk reduction in the simvastatin group was 35% (95% CI 15-50) in the lowest quartile of baseline low-density-lipoprotein cholesterol and 36% (19-49) in the highest. Simvastatin significantly reduced the risk of major coronary events in all quartiles of baseline total, high-density-lipoprotein, and low-density-lipoprotein cholesterol, by a similar amount in each quartile.			PEDERSEN, TR (corresponding author), AKER HOSP,DEPT MED,CARDIOL SECT,N-0514 OSLO,NORWAY.							ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1994, LANCET, p[344, 1383]; FROST PH, 1987, AM HEART J, V113, P1356, DOI 10.1016/0002-8703(87)90648-X; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; ULVENSTAM G, 1984, PREV MED, V13, P355, DOI 10.1016/0091-7435(84)90027-6; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; 1978, AM J CARDIOL, V42, P489; 1989, LANCET, V1, P473; 1993, AM J CARDIOL, V71, P393	10	262	266	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1274	1275						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746058				2022-12-28	WOS:A1995QY93300010
J	LANDEFELD, CS; PALMER, RM; KRESEVIC, DM; FORTINSKY, RH; KOWAL, J				LANDEFELD, CS; PALMER, RM; KRESEVIC, DM; FORTINSKY, RH; KOWAL, J			A RANDOMIZED TRIAL OF CARE IN A HOSPITAL MEDICAL UNIT ESPECIALLY DESIGNED TO IMPROVE THE FUNCTIONAL OUTCOMES OF ACUTELY ILL OLDER PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GERIATRIC CONSULTATION TEAM; PRACTICE GUIDELINES; CLINICAL-TRIAL; PHYSICIANS; MORBIDITY; RECOMMENDATIONS; PLACEMENT; PROGRAM; SERVICE	Background. Older persons who are hospitalized for acute illnesses often lose Methods. We studied 651 patients 70 years of age or older who were admitted for general medical care at a teaching hospital; these patients were randomly assigned to receive usual care or to be cared for in a special unit designed to help older persons maintain or achieve independence in self-care activities. The key elements of this program were a specially prepared environment (with, for example, uncluttered hallways, large clocks and calendars, and handrails); patient-centered care emphasizing independence, including specific protocols for prevention of disability and for rehabilitation; discharge planning with the goal of returning the patient to his or her home; and intensive review of medical care to minimize the adverse effects of procedures and medications, The main outcome we measured was the change from admission to discharge in the number of five basic activities of dairy living (bathing, getting dressed, using the toilet, moving from a bed to a chair, and eating) that the patient could perform independently. Results. Twenty-four patients in each group died in the hospital. At the time of discharge, 65 (21 percent) of the 303 surviving patients in the intervention group were classified as much better in terms of their ability to perform basic activities of daily living, 39 (13 percent) as better, 151 (50 percent) as unchanged, 22 (7 percent) as worse, and 26 (9 percent) as much worse. In the usual-care group, 40 (13 percent) of the 300 surviving patients were classified as much better, 33 (11 percent) as better, 163 (54 percent) as unchanged, 39 (13 percent) as worse, and 25 (8 percent) as much worse (P=0.009), The difference between the groups remained significant (P=0.04) in a multivariable model in which we controlled for potentially confounding base-line characteristics of the patients. Lengths of stay and hospital charges were similar in the two groups. Fewer patients assigned to the intervention group were discharged to long-term care institutions (43 patients [14 percent], as compared with 67 patients [22 percent] in the usual-care group; P=0.01). Among the 493 patients discharged to private homes, similar proportions (about 10 percent) in the two groups were admitted to long-term care institutions during the three months after discharge. Conclusions. Specific changes in the provision of acute hospital care can improve the ability of a heterogeneous group of acutely ill older patients to perform basic activities of daily living at the time of discharge from the hospital and can reduce the frequency of discharge to institutions for long-term care.	CASE WESTERN RESERVE UNIV, DEPT MED, DIV GERIATR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT MED, DIV GEN INTERNAL MED & HLTH CARE RES, CLEVELAND, OH 44106 USA; UNIV HOSP CLEVELAND, CLEVELAND, OH USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	LANDEFELD, CS (corresponding author), VET AFFAIRS MED CTR, DIV GEN INTERNAL MED & HTLT CARE RES, 111 GW, 10701 E BLVD, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE ON AGING [P60AG010418] Funding Source: NIH RePORTER; NIA NIH HHS [AG-10418-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN CM, 1986, JAMA-J AM MED ASSOC, V255, P2617, DOI 10.1001/jama.255.19.2617; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BOX GEP, 1978, STATISTICS EXPT; Boyer N, 1986, Nurs Manage, V17, P22; BROSS IDJ, 1958, BIOMETRICS, V14, P18, DOI 10.2307/2527727; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collard A F, 1985, QRB Qual Rev Bull, V11, P180; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; EPSTEIN AM, 1990, NEW ENGL J MED, V323, P266, DOI 10.1056/NEJM199007263230410; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; GILCHRIST WJ, 1988, BRIT MED J, V297, P1116, DOI 10.1136/bmj.297.6656.1116; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; HAHN B, 1992, DHHS AHCPR930007 PUB; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HARRIS RD, 1991, AUST NZ J MED, V21, P230, DOI 10.1111/j.1445-5994.1991.tb00448.x; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOGAN DB, 1990, AGE AGEING, V19, P107, DOI 10.1093/ageing/19.2.107; INOUYE SK, 1993, J AM GERIATR SOC, V41, P1353, DOI 10.1111/j.1532-5415.1993.tb06487.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LANDEFELD CS, 1992, ANN INTERN MED, V116, P829, DOI 10.7326/0003-4819-116-10-829; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MEISSNER P, 1989, GERONTOLOGIST, V29, P524, DOI 10.1093/geront/29.4.524; NETER J, 1983, APPLIED LINEAR REGRE; PALMER RM, 1994, J AM GERIATR SOC, V42, P545, DOI 10.1111/j.1532-5415.1994.tb04978.x; Popplewell P Y, 1983, Aust Health Rev, V6, P23; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; SALTZ CC, 1988, GERONTOLOGIST, V28, P344, DOI 10.1093/geront/28.3.344; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; TEASDALE TA, 1983, J AM GERIATR SOC, V31, P529, DOI 10.1111/j.1532-5415.1983.tb02196.x; THOMAS DR, 1993, J AM GERIATR SOC, V41, P101, DOI 10.1111/j.1532-5415.1993.tb02040.x; WEINBERGER M, 1992, J AM GERIATR SOC, V40, P585, DOI 10.1111/j.1532-5415.1992.tb02107.x; WEINGARTEN SR, 1993, AM J MED, V94, P483, DOI 10.1016/0002-9343(93)90082-Z; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WINOGRAD CH, 1993, ARCH INTERN MED, V153, P2017, DOI 10.1001/archinte.153.17.2017; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x	49	576	585	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1338	1344		10.1056/NEJM199505183322006	http://dx.doi.org/10.1056/NEJM199505183322006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX857	7715644				2022-12-28	WOS:A1995QX85700006
J	GREENGOLD, MC				GREENGOLD, MC			SUDDEN-DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1496	1496		10.1001/jama.273.19.1496	http://dx.doi.org/10.1001/jama.273.19.1496			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739074				2022-12-28	WOS:A1995QX41800030
J	FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ				FERNANDEZSALGUERO, P; PINEAU, T; HILBERT, DM; MCPHAIL, T; LEE, SST; KIMURA, S; NEBERT, DW; RUDIKOFF, S; WARD, JM; GONZALEZ, FJ			IMMUNE-SYSTEM IMPAIRMENT AND HEPATIC-FIBROSIS IN MICE LACKING THE DIOXIN-BINDING AH RECEPTOR	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; GENETIC-DIFFERENCES; 2,3,7,8-TETRACHLORODIBENZO-PARA-DIOXIN; EXPRESSION; CLONING; CANCER; TOXICITY; LOCUS; CDNA	The aryl hydrocarbon (Ah) receptor (AHR) mediates many carcinogenic and teratogenic effects of environmentally toxic chemicals such as dioxin. An AHR-deficient (Ahr(-/-)) mouse line was constructed by homologous recombination in embryonic stem cells. Almost half of the mice died shortly after birth, whereas survivors reached maturity and were fertile. The Ahr(-/-) mice showed decreased accumulation of lymphocytes in the spleen and lymph nodes, but not in the thymus. The livers of Ahr(-/-) mice were reduced in size by 50 percent and showed bile duct fibrosis. Ahr(-/-) mice were also nonresponsive with regard to dioxin-mediated induction of genes encoding enzymes that catalyze the metabolism of foreign compounds, Thus, the AHR plays an important role in the development of the liver and the immune system.	NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; NCI,GENET LAB,BETHESDA,MD 20892; NIMH,MOLEC GENET UNIT,BETHESDA,MD 20892; UNIV CINCINNATI,MED CTR,DEPT ENVIRONM HLTH,CINCINNATI,OH 45267; NCI,OFF LAB ANIM SCI,VET & TUMOR PATHOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fernandez-Salguero, Pedro M./J-8437-2014	Fernandez-Salguero, Pedro M./0000-0003-2839-5027	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096, R01ES006811] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES06096, R01 ES06811] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004; BIRNBAUM LS, 1994, ENVIRON HEALTH PERSP, V102, P676, DOI 10.2307/3432197; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; DEVITO MJ, 1994, TOXICOL APPL PHARM, V124, P82, DOI 10.1006/taap.1994.1011; DOLWICK KM, 1993, MOL PHARMACOL, V44, P911; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GONZALEZ FJ, 1985, NUCLEIC ACIDS RES, V13, P7269, DOI 10.1093/nar/13.20.7269; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; HUOSKONEN H, 1994, TOXICOL APPL PHARM, V124, P174; KIMURA S, 1986, MOL CELL BIOL, V6, P1471, DOI 10.1128/MCB.6.5.1471; LI H, 1994, J BIOL CHEM, V269, P28098; LI W, 1994, ARCH BIOCHEM BIOPHYS, V315, P279, DOI 10.1006/abbi.1994.1501; LUCIER GW, 1993, ENVIRON HEALTH PERSP, V101, P36, DOI 10.2307/3431569; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; NEBERT DW, 1994, BIOCHEM PHARMACOL, V47, P25, DOI 10.1016/0006-2952(94)90434-0; NEBERT DW, 1989, CRIT REV TOXICOL, V20, P153, DOI 10.3109/10408448909017908; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; ROBERTSON RW, 1994, NUCLEIC ACIDS RES, V22, P1741, DOI 10.1093/nar/22.9.1741; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SHEN ZY, 1994, DNA CELL BIOL, V13, P763, DOI 10.1089/dna.1994.13.763; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343	34	885	909	2	49	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					722	726		10.1126/science.7732381	http://dx.doi.org/10.1126/science.7732381			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732381				2022-12-28	WOS:A1995QW60300050
J	LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R				LOWE, J; STOCK, D; JAP, R; ZWICKL, P; BAUMEISTER, W; HUBER, R			CRYSTAL-STRUCTURE OF THE 20S PROTEASOME FROM THE ARCHAEON T-ACIDOPHILUM AT 3.4-ANGSTROM RESOLUTION	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEXES; ATP-DEPENDENT PROTEASES; THERMOPLASMA-ACIDOPHILUM; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; MECHANISM; GENE; REFINEMENT; PEPTIDASE; FEATURES	The three-dimensional structure of the proteasome from the archaebacterium Thermoplasma acidophilum has been elucidated by x-ray crystallographic analysis by means of isomorphous replacement and cyclic averaging. The atomic model was built and refined to a crystallographic R factor of 22.1 percent. The 673-kilodalton protease complex consists of 14 copies of two different subunits, alpha and beta, forming a barrel-shaped structure of four stacked rings. The two inner rings consist of seven beta subunits each, and the two outer rings consist of seven alpha subunits each. A narrow channel controls access to the three inner compartments. The alpha(7) beta(7) beta(7) alpha(7) subunit assembly has 72-point group symmetry. The structures of the alpha and beta subunits are similar, consisting of a core of two antiparallel beta sheets that is flanked by alpha helices on both sides. The binding of a peptide aldehyde inhibitor marks the active site in the central cavity at the amino termini of the beta subunits and suggests a novel proteolytic mechanism.	MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,STRUKT BIOL ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society			Löwe, Jan/B-3882-2011; Löwe, Jan/X-6998-2019	Lowe, Jan/0000-0002-5218-6615				BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BROTHERS HM, 1990, BIOCHEMISTRY-US, V29, P7468, DOI 10.1021/bi00484a016; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BRUENGER AT, 1992, XPLOR VERSION 3 1 SY; CHEN CCH, 1993, J MOL BIOL, V234, P165, DOI 10.1006/jmbi.1993.1571; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DAUTER Z, 1990, ACTA CRYSTALLOGR B, V46, P833, DOI 10.1107/S0108768190008059; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20887; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; DJABALLAH H, 1992, BIOCHEMISTRY-US, V31, P4133, DOI 10.1021/bi00131a033; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FINKE RG, 1986, J AM CHEM SOC, V108, P2947, DOI 10.1021/ja00271a025; GHUYSEN JM, 1981, TOP MOL PHARM, V1, P63; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JAP B, 1983, J MOL BIOL, V234, P881; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLY JA, 1989, J MOL BIOL, V209, P281, DOI 10.1016/0022-2836(89)90277-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN PJ, 1965, INORG CHEM, V4, P1482, DOI 10.1021/ic50032a028; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LUPAS A, 1994, FEBS LETT, V354, P45, DOI 10.1016/0014-5793(94)01082-X; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2579; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Puehler Gabriela, 1994, Systematic and Applied Microbiology, V16, P734; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; RECHSTEINER M, 1993, J BIOL CHEM, V268, P60; RICHTERRUOFF B, 1993, FEBS LETT, V336, P34, DOI 10.1016/0014-5793(93)81603-W; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; STEIGEMANN W, 1991, CRYSTALLOGRAPHIC COM, V5; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TANAKA K, 1992, NEW BIOL, V4, P173; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; TURK D, 1992, THESIS TU MUNCHEN; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1990, J STRUCT BIOL, V103, P197, DOI 10.1016/1047-8477(90)90037-D; ZWICKL P, 1991, FEBS LETT, V278, P217, DOI 10.1016/0014-5793(91)80120-R; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004; 1979, CCP4 SERC4 DAR LAB S	68	1330	1356	1	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					533	539		10.1126/science.7725097	http://dx.doi.org/10.1126/science.7725097			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725097				2022-12-28	WOS:A1995QV40700028
J	HARRIS, JM; PARKER, AJ				HARRIS, JM; PARKER, AJ			INDEPENDENT NEURAL MECHANISMS FOR BRIGHT AND DARK INFORMATION IN BINOCULAR STEREOPSIS	NATURE			English	Article							SPATIAL-INTERVAL DISCRIMINATION; VISUAL-SYSTEM; EFFICIENCY; SEGREGATION; AFFERENTS; DISPARITY; CHANNELS; VISION; CORTEX	EARLY visual processing is organized into a number of independent channels. In the retina, increments and decrements of brightness are processed independently by different groups of neurons', For psychophysical measurements of human vision, independence can be tested statistically, Using this criterion in a depth judgement task, we show here that, for binocular stereo vision, increments and decrements are treated independently, at least as far as the level at which information from the left and right eyes is first combined, At later stages of stereo processing, the information from the two channels is no longer independent, Because the signals for stereo vision are first combined at the visual cortex, these results suggest that the neural 'on' and 'off' channels remain independent right up to early cortical stages, Theoretical studies of stereo vision have proposed that visual features in the views of the two eyes are matched on the basis of 'similarity'(2). Our results show that stereo matching treats features as statistically independent (and therefore dissimilar) if they appear perceptually bright and dark relative to the background, If features differ perceptually but only in the degree of brightness or darkness, human stereo vision treats them as similar.	SMITH KETTLEWELL EYE RES INST,SAN FRANCISCO,CA 94115	The Smith-Kettlewell Eye Research Institute	HARRIS, JM (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.		Parker, Andrew J/I-7867-2013	Parker, Andrew J/0000-0001-5800-0407; Harris, Julie/0000-0002-3497-4503	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAKER HH, 1981, 7TH P INT JOINT C AR, P631; BARLOW HB, 1979, VISION RES, V19, P783, DOI 10.1016/0042-6989(79)90154-8; BARLOW HB, 1978, VISION RES, V18, P637, DOI 10.1016/0042-6989(78)90143-8; BJORKLUND RA, 1981, PERCEPTION, V10, P511, DOI 10.1068/p100511; BURGESS A, 1983, VISION RES, V23, P811, DOI 10.1016/0042-6989(83)90204-3; BURTON GJ, 1977, BIOL CYBERN, V27, P189, DOI 10.1007/BF00344140; DEVALOIS KK, 1977, VISION RES, V17, P209, DOI 10.1016/0042-6989(77)90084-0; DOLAN RP, 1994, VISUAL NEUROSCI, V11, P23, DOI 10.1017/S095252380001107X; EDWARDS M, 1994, VISION RES, V34, P2849, DOI 10.1016/0042-6989(94)90054-X; HANLY M, 1979, EXP BRAIN RES, V35, P37; HARRIS JM, 1994, VISION RES, V34, P2761, DOI 10.1016/0042-6989(94)90231-3; HARRIS JM, 1992, J OPT SOC AM A, V1, P14; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KAUFMAN L, 1969, PERCEPT PSYCHOPHYS, V6, P10, DOI 10.3758/BF03210666; LEVI DM, 1987, J OPT SOC AM A, V4, P1304, DOI 10.1364/JOSAA.4.001304; LEVI DM, 1990, VISION RES, V30, P1735, DOI 10.1016/0042-6989(90)90156-F; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1976, SCIENCE, V194, P283, DOI 10.1126/science.968482; MCCONNELL SK, 1984, P NATL ACAD SCI-BIOL, V81, P1590, DOI 10.1073/pnas.81.5.1590; MORGAN MJ, 1991, VISION RES, V31, P2075, DOI 10.1016/0042-6989(91)90165-2; POLLARD SB, 1985, PERCEPTION, V14, P449, DOI 10.1068/p140449; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5; ZAHS KR, 1988, J NEUROPHYSIOL, V59, P1410, DOI 10.1152/jn.1988.59.5.1410	25	36	36	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					808	811		10.1038/374808a0	http://dx.doi.org/10.1038/374808a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723825				2022-12-28	WOS:A1995QV31500046
J	OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN				OAKLEY, A; BENDELOW, G; BARNES, J; BUCHANAN, M; HUSAIN, OAN			HEALTH AND CANCER PREVENTION - KNOWLEDGE AND BELIEFS OF CHILDREN AND YOUNG-PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To collect information from children and young people about their knowledge of and attitudes towards cancer and their understanding of health and health related behaviours to inform future health promotion work. Design-Questionnaire survey of 15-16 year olds, and interviews with play materials with 9-10 year old children. Setting-Six inner city, suburban, and rural schools. Subjects-226 children aged 15-16 years and 100 aged 9-10 years. Main outcome measures-Knowledge about different types of cancer; beliefs about health; sources of information; quality of research data obtainable from young children about cancer and health. Results-Both samples knew most about lung cancer, but there was also some knowledge of breast and skin cancer and leukaemia. Smoking, together with pollution and other environmental factors, were seen as the dominant causes of cancer. Environmental factors were mentioned more often by the inner city samples. Television and the media were the most important sources of information. Young people were more worried about unemployment than about ill health. More than half the young people did not describe their health as good, and most said they did not have a healthy lifestyle. Children were able to provide detailed information about their knowledge and understanding by using drawings as well as interviews. Conclusions-Children and young people possess considerable knowledge about cancer, especially about lung cancer and smoking, and show considerable awareness of predominant health education messages. Despite this knowledge, many lead less than healthy lifestyles. Health is not seen as the most important goal in life by many young people; the circumstances in which many children and young people live are not experienced as health promoting.	WOMENS NATIONWIDE CANC CONTROL CAMPAIGN,MED ADVISORY COMM,LONDON EC2A 3AR,ENGLAND		OAKLEY, A (corresponding author), UNIV LONDON,INST EDUC,SOCIAL SCI RES UNIT,LONDON WC1H 0NS,ENGLAND.		Bendelow, Gillian A/B-2943-2018	Bendelow, Gillian A/0000-0002-9293-5297				Backett K., 1991, HEALTH EDUC J, V50, P34, DOI [10.1177/001789699105000110, DOI 10.1177/001789699105000110]; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; BRANNEN J, 1993, YOUNG PEOPLE HLTH FA; Calnan M., 1987, HLTH ILLNESS LAY PER; Cornwell J., 1985, HARD EARNED LIVES AC; HARDING G, 1989, 9 T COR RES UN OCC P; IVERSON DC, 1983, J SCHOOL HEALTH, V53, P294, DOI 10.1111/j.1746-1561.1983.tb05347.x; KALNINS I, 1992, HEALTH PROMOT INT, V7, P55; MAYALL B, 1993, SOCIOL HEALTH ILL, V15, P464; OAKLEY A, 1989, SOCIOL HEALTH ILL, V11, P311, DOI 10.1111/1467-9566.ep11372513; Qvortrup J., 1994, CHILDHOOD MATTERS SO, P1; Qvortrup Jens, 1993, CHILDHOOD SOCIAL PHE; SONTAG Susan, 1977, ILLNESS METAPHOR; TONES K, 1990, HLTH ED J, V49, P2; 1990, INCIDENCE UK MALES F	15	73	74	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1029	1033		10.1136/bmj.310.6986.1029	http://dx.doi.org/10.1136/bmj.310.6986.1029			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV313	7728055	Green Accepted, Green Published			2022-12-28	WOS:A1995QV31300014
J	PHILIPSON, LH; STEINER, DF				PHILIPSON, LH; STEINER, DF			PAS DE DEUX OR MORE - THE SULFONYLUREA RECEPTOR AND K+ CHANNELS	SCIENCE			English	Editorial Material							PANCREATIC B-CELLS; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; INSULIN RELEASE; MOUSE ISLETS; CALCIUM; NUCLEOTIDES; SECRETION; GLUCOSE; PROTEIN		UNIV CHICAGO,COMM CELL PHYSIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,THE COLL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago; University of Chicago	PHILIPSON, LH (corresponding author), UNIV CHICAGO,DEPT MED,MAIL CODE 1027,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; ASHFORD MLJ, 1990, BRIT J PHARMACOL, V101, P531, DOI 10.1111/j.1476-5381.1990.tb14116.x; ASHFORD MLJ, 1994, DRUG DEVELOP RES, V370, P456; BEAVIS AD, 1993, J BIOL CHEM, V268, P997; BERNARDI H, 1988, P NATL ACAD SCI USA, V85, P9816, DOI 10.1073/pnas.85.24.9816; BOYD AE, 1988, DIABETES, V37, P847, DOI 10.2337/diabetes.37.7.847; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; CORKEY BE, 1988, J BIOL CHEM, V269, P4254; DASCAL N, 1995, BIOPHYS J, V68, pA353; de Weille J R, 1989, Pflugers Arch, V414 Suppl 1, pS80; DEAN PM, 1968, NATURE, V219, P389, DOI 10.1038/219389a0; Drumm M L, 1993, Mol Genet Med, V3, P33; DUKES ID, 1994, J BIOL CHEM, V269, P10979; GAINES KL, 1988, J BIOL CHEM, V263, P2589; GILON P, 1993, J BIOL CHEM, V8, P22265; GOPALAKRISHNAN M, 1993, DRUG DEVELOP RES, V28, P95, DOI 10.1002/ddr.430280202; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Hurley K. M., 1995, Biophysical Journal, V68, pA448; INAGAKI N, IN PRESS J BIOL CHEM; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OZANNE SE, 1995, DIABETOLOGIA, V38, P277; Pessia M., 1995, Biophysical Journal, V68, pA31; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; ROE MW, 1993, J BIOL CHEM, V268, P9953; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STURGESS NC, 1985, LANCET, V2, P474; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; YANG, 1995, BIOPHYS J, V68, pA362	43	68	71	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					372	373		10.1126/science.7716539	http://dx.doi.org/10.1126/science.7716539			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716539				2022-12-28	WOS:A1995QU57200025
J	UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV				UTSCHIG, LM; BRYSON, JW; OHALLORAN, TV			HG-199 NMR OF THE METAL RECEPTOR-SITE IN MERR AND ITS PROTEIN-DNA COMPLEX	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SOLID-STATE HG-199; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; METALLOREGULATORY PROTEIN; POPLAR PLASTOCYANIN; BIOSENSOR MERR; BINDING DOMAIN; THIOLATE; SPECTROSCOPY	Structural insights have been provided by mercury-199 nuclear magnetic resonance (NMR) into the metal receptor site of the MerR metalloregulatory protein alone and in a complex with the regulatory target, DNA, The one- and two-dimensional NMR data are consistent with a trigonal planar Hg-thiolate coordination environment consisting only of Cys side chains and resolve structural aspects of both metal ion recognition and the allosteric mechanism. These studies establish Hg-199 NMR techniques as useful probes of the metal coordination environment of regulatory proteins, copper enzymes, and zinc transcription factor complexes as large as 50 kilodaltons.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELLULAR BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059	NIGMS NIH HHS [GM-08061, GM-38784, R01 GM038784, GM-45972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038784, R01GM038784, R01GM045972, R37GM038784] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1995, NATURE, V374, P371; ARMITAGE IM, 1976, J AM CHEM SOC, V98, P5710, DOI 10.1021/ja00434a058; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BERTINI I, 1994, BIOINORG CHEM, P43; BLAKE PR, 1994, NEW J CHEM, V18, P387; BRYSON JW, UNPUB; CARSON GK, 1982, INORG CHIM A-BIOINOR, V66, P157, DOI 10.1016/S0020-1693(00)85806-5; CHURCH WB, 1986, J BIOL CHEM, V261, P234; COLEMAN JE, 1993, METHOD ENZYMOL, V227, P16; ELLIS PD, 1983, SCIENCE, V221, P1141, DOI 10.1126/science.221.4616.1141; FALCHUK KH, 1977, CHEM MERCURY, P260; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FREY MH, 1985, J AM CHEM SOC, V107, P6847, DOI 10.1021/ja00310a017; GARRETT TPJ, 1984, J BIOL CHEM, V259, P2822; GOVINDASWAMY N, 1992, INORG CHEM, V31, P5343, DOI 10.1021/ic00052a001; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUBICKI MM, 1981, J ORGANOMET CHEM, V219, P329, DOI 10.1016/S0022-328X(00)90018-4; Lippard S. J., 1994, PRINCIPLES BIOINORGA; LIVE DH, 1985, J AM CHEM SOC, V107, P3043, DOI 10.1021/ja00297a008; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MOORE JM, 1991, J MOL BIOL, V221, P533, DOI 10.1016/0022-2836(91)80071-2; NATAN MJ, 1990, J AM CHEM SOC, V112, P3255, DOI 10.1021/ja00164a080; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; OTVOS JD, 1985, J MAGN RESON, V61, P579, DOI 10.1016/0022-2364(85)90202-1; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SANTOS RA, 1991, J AM CHEM SOC, V113, P469, DOI 10.1021/ja00002a014; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SUDMEIER JL, 1977, J AM CHEM SOC, V99, P7732, DOI 10.1021/ja00465a067; SUMMERS MF, 1988, COORDIN CHEM REV, V86, P43, DOI 10.1016/0010-8545(88)85012-4; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; UTSCHIG LM, 1993, METHOD ENZYMOL, V226, P71, DOI 10.1016/0076-6879(93)26006-U; UTSCHIG LM, UNPUB; UTSCHIG LM, IN PRESS INORG CHEM; WATTON SP, 1990, J AM CHEM SOC, V112, P2824, DOI 10.1021/ja00163a067; Wrackmeyer B., 1992, ANN REP NMR SPECTROS, V24, P267, DOI [10.1016/S0066-4103(08)60200-8., DOI 10.1016/S0066-4103(08)60200-8]; WRIGHT JG, 1990, PROG INORG CHEM, V38, P323; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	43	147	149	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					380	385		10.1126/science.7716541	http://dx.doi.org/10.1126/science.7716541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716541				2022-12-28	WOS:A1995QU57200028
J	CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC				CHITTENDEN, T; HARRINGTON, EA; OCONNOR, R; FLEMINGTON, C; LUTZ, RJ; EVAN, GI; GUILD, BC			INDUCTION OF APOPTOSIS BY THE BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; SEQUENCE SIMILARITY; GENE; PROTEINS	CELLS are eliminated in a variety of physiological settings by apoptosis, a genetically encoded process of cellular suicide(1,2). Apoptosis comprises an intrinsic cellular defence against tumorigenesis, which, when suppressed, may contribute to the development of malignancies(3). The bcl-2 oncogene, which is activated in follicular lymphomas, functions as a potent suppressor of apoptosis under diverse conditions(4). Here we describe the complementary DNA cloning and functional analysis of a new Bcl-2 homologue, Bak, which promotes cell death and counteracts the protection from apoptosis provided by Bcl-2. Moreover, enforced expression of Bak induces rapid and extensive apoptosis of serum-deprived fibroblasts. This raises the possibility that Bak is directly involved in activating the cell death machinery.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK	CHITTENDEN, T (corresponding author), APOPTOSIS TECHNOL INC, 148 SIDNEY ST, CAMBRIDGE, MA 02139 USA.		O'Connor, Rosemary/B-7902-2014	O'Connor, Rosemary/0000-0002-0687-3422				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRASELMANN S, 1993, P NATL ACAD SCI USA, V90, P1657, DOI 10.1073/pnas.90.5.1657; ELLIS RE, 1991, REV CELL BIOL, V7, P663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	22	679	727	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					733	736		10.1038/374733a0	http://dx.doi.org/10.1038/374733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715730				2022-12-28	WOS:A1995QU30400053
J	BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J				BHATTI, N; LAW, MR; MORRIS, JK; HALLIDAY, R; MOOREGILLON, J			INCREASING INCIDENCE OF TUBERCULOSIS IN ENGLAND AND WALES - A STUDY OF THE LIKELY CAUSES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine factors responsible for the recent increase in tuberculosis in England and Wales. Design-Study of the incidence of tuberculosis (a) in the 403 local authority districts in England and Wales, ranked according to Jarman score, and (b) in one deprived inner city district, according to ethnic origin and other factors. Setting-(a) England and Wales 1980-92, and (b) the London borough of Hackney 1986-93. Main outcome measure-Age and sex adjusted rate of tuberculosis. Results-In England and Wales notifications of tuberculosis increased by 12% between 1988 and 1992. The increase was 35% in the poorest 10th of the population and 13% in the next two; and in the remaining 70% there was no increase. In Hackney the increase affected traditionally high risk and low risk ethnic groups to a similar extent. In the ''low risk'' white and West Indian communities the incidence increased by 58% from 1986-8 (78 cases) to 1991-3 (123), whereas in residents of Indian subcontinent origin the increase was 41% (from 51 cases to 72). Tuberculosis in recently arrived immigrants-refugees (11% of the Hackney population) and Africans (6%)-accounted for less than half of the overall increase, and the proportion of such residents was much higher than in most socioeconomically deprived districts. The local increase was not due to an increase in the proportion of cases notified, to HIV infection, nor to an increase in homeless people. Conclusions-The national rise in tuberculosis affects only the poorest areas. Within one such area all residents (white and established ethnic minorities) were affected to a similar extent. The evidence indicates a major role for socioeconomic factors in the increase in tuberculosis and only a minor role for recent immigration from endemic areas.	ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,DEPT ENVIRONM & PREVENT MED,LONDON EC1M 6BQ,ENGLAND; E LONDON & CITY DIST HLTH AUTHOR,DEPT PUBL HLTH,LONDON E3 2AN,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT RESP MED,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London				Morris, Joan/0000-0002-7164-612X				AWAIH J, 1992, HLTH CITY HACKNEY AN, P24; JACOBSON B, 1992, BRIT MED J, V305, P1344, DOI 10.1136/bmj.305.6865.1344; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; JENKINS SP, 1994, DISCUSSION PAPER SER, V9407; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1994, HLTH STATISTICS 1992; 1994, COMMUNICABLE DISEASE	9	119	119	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					967	969		10.1136/bmj.310.6985.967	http://dx.doi.org/10.1136/bmj.310.6985.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728031	Green Published			2022-12-28	WOS:A1995QT90400018
J	GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M				GROVER, SA; LOWENSTEYN, I; ESREY, KL; STEINERT, Y; JOSEPH, L; ABRAHAMOWICZ, M			DO DOCTORS ACCURATELY ASSESS CORONARY RISK IN THEIR PATIENTS - PRELIMINARY-RESULTS OF THE CORONARY HEALTH ASSESSMENT STUDY	BRITISH MEDICAL JOURNAL			English	Article							HEART-DISEASE; COST-EFFECTIVENESS; LIFE EXPECTANCY; CHOLESTEROL; HYPERCHOLESTEROLEMIA; PHYSICIANS; PREVENTION; FRAMINGHAM; HYPERLIPIDEMIA; INTERNISTS	Objective-To evaluate the ability of doctors in primary care to assess risk patients) risk of coronary heart disease. Design-Questionnaire survey. Setting-Continuing medical education meetings, Ontario and Quebec, Canada. Subjects-Community based doctors who agreed to enrol in the coronary health assessment study. Main outcome measure-Ratings of coronary risk factors and estimates by doctors of relative and absolute coronary risk of two hypothetical patients and the ''average'' 40 year old Canadian man and 70 year old Canadian woman. Results-253 doctors answered the questionnaire. For 30 year olds the doctors rated cigarette smoking as the most important risk factor and raised serum triglyceride concentrations as the least important; for 70 year old patients they rated diabetes as the most important risk factor and raised serum triglyceride concentrations as the least important. They rated each individual risk factor as significantly less important for 70 year olds than for 30 year olds (all risk factors, P < 0.001). They showed a strong understanding of the relative importance of specific risk factors, and most were confident in their ability to estimate coronary risk. While doctors accurately estimated the relative risk of a specific patient (compared with the average adult) they systematically overestimated the absolute baseline risk of developing coronary disease and the risk reductions associated with specific interventions. Conclusions-Despite guidelines on targeting patients at high risk of coronary disease accurate assessment of coronary risk remains difficult for many doctors. Additional strategies must be developed to help doctors to assess better their patients' coronary risk.	SIR MORTIMER B DAVIS JEWISH HOSP,DEPT FAMILY MED,MONTREAL,PQ H3T 1E2,CANADA	McGill University	GROVER, SA (corresponding author), MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA.			Abrahamowicz, Michal/0000-0002-3172-3952				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; DEFRIESE GH, 1990, PREVENTING DISEASE R, P460; DUNNIGAN MG, 1993, BRIT MED J, V306, P1355, DOI 10.1136/bmj.306.6889.1355; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1991, CAN MED ASSOC J, V144, P161; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, ARCH INTERN MED, V154, P1697, DOI 10.1001/archinte.154.15.1697; GROVER SA, 1993, CARDIOVASC DRUG THER, V7, P761, DOI 10.1007/BF00878927; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; LANGNER NR, 1989, CAN MED ASSOC J, V141, P33; LAUPACIS A, 1990, CAN MED ASSOC J, V142, P329; LEAVERTON PE, 1987, J CHRON DIS, V40, P775, DOI 10.1016/0021-9681(87)90129-9; MANN KV, 1989, PREV MED, V18, P45, DOI 10.1016/0091-7435(89)90053-4; MCBRIDE PE, 1992, AM HEART J, V123, P817, DOI 10.1016/0002-8703(92)90535-4; NAYLOR CD, 1990, J CLIN EPIDEMIOL, V43, P1021; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1993, CARDIOVASC DRUG THER, V7, P785, DOI 10.1007/BF00878931; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P779, DOI 10.1007/BF00878930; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; SCHWARTZ JS, 1991, ANN INTERN MED, V114, P46, DOI 10.7326/0003-4819-114-1-46; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; TANNENBAUM TN, 1990, CAN MED ASSOC J, V143, P875; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WILSON PWF, 1989, JAMA-J AM MED ASSOC, V262, P41, DOI 10.1001/jama.262.1.41; [No title captured]; 1981, 82538 HLTH WELF CAN; 1993, CAN MED ASSOC J, V148, P521; 1987, LANCET, V1, P377; 1993, JAMA-J AM MED ASSOC, V269, P3015; [No title captured]	34	130	131	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					975	978		10.1136/bmj.310.6985.975	http://dx.doi.org/10.1136/bmj.310.6985.975			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728035	Green Published, Green Submitted			2022-12-28	WOS:A1995QT90400022
J	HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N				HENRY, RW; SADOWSKI, CL; KOBAYASHI, R; HERNANDEZ, N			A TBP-TAF COMPLEX REQUIRED FOR TRANSCRIPTION OF HUMAN SNRNA GENES BY RNA-POLYMERASE-II AND RNA-POLYMERASE-III	NATURE			English	Article							TATA-BINDING PROTEIN; FACTOR-TFIIIB	THE TATA-box-binding protein TBP exists in the cell complexed with different sets of TBP-associated factors (TAFs)(1). In general, each of these TBP-TAP complexes is dedicated to transcription by a single RNA polymerase. Thus, SL1, TFIID and TFIIIB are required for transcription by polymerases I, II and III, respectively(2-10). Here we characterize a fourth TBP-TAF complex called SNAPc(11). Unlike the other TBP-TAF complexes, SNAPc is implicated in transcription by two types of polymerases; it is required for transcription of both the RNA polymerase II and III small-nuclear RNA genes and binds specifically to the proximal sequence element PSE, a non-TATA-box basal promoter element common to these two types of genes(11-13). In addition to TBP, SNAPc is composed of at least three TAFs, SNAP43, SNAP45 and SNAP50. The predicted amino-acid sequence of SNAP43 reveals that it corresponds to a new protein.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	HENRY, RW (corresponding author), COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, POB 100, COLD SPRING HARBOR, NY 11724 USA.			Hernandez, Nouria/0000-0003-1465-4585				COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; SADOWSKI CL, 1993, GENE DEV, V7, P1535, DOI 10.1101/gad.7.8.1535; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	126	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					653	656		10.1038/374653a0	http://dx.doi.org/10.1038/374653a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715707				2022-12-28	WOS:A1995QT18900063
J	BURTNESS, BA				BURTNESS, BA			ONCOLOGY AND HEMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES				BURTNESS, BA (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ARTEAGA CL, 1994, CANCER RES, V54, P3758; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; BRADDOCK PS, 1994, BRIT J CANCER, V69, P890, DOI 10.1038/bjc.1994.172; DERYNCK R, 1987, CANCER RES, V47, P707; EISENBERGER MA, 1994, CANCER TREAT REV, V20, P259, DOI 10.1016/0305-7372(94)90003-5; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MODJTAHEDI H, 1994, CANCER RES, V54, P1695; SAINSBURY JRC, 1987, LANCET, V2, P1398; SUNADA H, 1990, J CELL PHYSIOL, V142, P284, DOI 10.1002/jcp.1041420210; TAKANO S, 1994, CANCER RES, V54, P2654; VITETTA ES, 1994, CANCER RES, V54, P5301; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	16	1	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1702	1703		10.1001/jama.273.21.1702	http://dx.doi.org/10.1001/jama.273.21.1702			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752426				2022-12-28	WOS:A1995RB09700034
J	CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X				CHILLON, M; CASALS, T; MERCIER, B; BASSAS, L; LISSENS, W; SILBER, S; ROMEY, MC; RUIZROMERO, J; VERLINGUE, C; CLAUSTRES, M; NUNES, V; FEREC, C; ESTIVILL, X			MUTATIONS IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH CONGENITAL ABSENCE OF THE VAS-DEFERENS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGULATOR CFTR GENE; MESSENGER-RNA TRANSCRIPTS; HUMAN FETAL TISSUES; BILATERAL ABSENCE; CONDUCTANCE; EXPRESSION; IDENTIFICATION; DNA; FORM; MEN	Background. Congenital bilateral absence of the vas deferens (CBAVD) is a form of male infertility in which mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have been identified. The molecular basis of CBAVD is not completely understood. Although patients with cystic fibrosis have mutations in both copies of the CFTR gene, most patients with CBAVD have mutations in only one copy of the gene. Methods. To investigate CBAVD at the molecular level, we have characterized the mutations in the CFTR gene in 102 patients with this condition. None had clinical manifestations of cystic fibrosis. We also analyzed a DNA variant (the 5T allele) in a noncoding region of CFTR that causes reduced levels of the normal CFTR protein. Parents of patients with cystic fibrosis, patients with types of infertility other than CBAVD, and normal subjects were studied as controls. Results. Nineteen of the 102 patients with CBAVD had mutations in both copies of the CFTR gene, and none of them had the 5T allele. Fifty-four patients had a mutation in one copy of CFTR, and 34 of them (63 percent) had the 5T allele in the other CFTR gene. In 29 patients no CFTR mutations were found, but 7 of them (24 percent) had the 5T allele. In contrast, the frequency of this allele in the general population was about 5 percent. Conclusions. Most patients with CBAVD have mutations in the CFTR gene. The combination of the 5T allele in one copy of the CFTR gene with a cystic fibrosis mutation in the other copy is the most common cause of CBAVD. The 5T allele mutation has a wide range of clinical presentations, occurring in patients with CBAVD or moderate forms of cystic fibrosis and in fertile men.	HOSP DURAN & REYNALS, CANC RES INST, DEPT MOLEC GENET, E-08907 LHOSPITALET DE LLOBREGAT, SPAIN; UNIV HOSP BREST, INST BIOGENET, BREST, FRANCE; FDN PUIGVERT, INST UROL NEPHROL MED GENET, DEPT ANDROL, BARCELONA, SPAIN; ST LUKES HOSP, DEPT UROL & MICROSURG, ST LOUIS, MO USA; FREE UNIV BRUSSELS, DEPT MED GENET, BRUSSELS, BELGIUM; INST BIOL, BIOCHIM GENET LAB, MONTPELLIER, FRANCE; HOSP CLIN BARCELONA, GENET SERV, BARCELONA, SPAIN	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; CHU Brest; Universite de Bretagne Occidentale; Fundacio Puigvert; Saint Luke's Hospital - Missouri; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Barcelona; Hospital Clinic de Barcelona			Nunes, Virginia/AAD-1014-2019; Ferec, Claude/ABG-9699-2020; Lissens, Willy/B-2892-2013; ROMEY-CHATELAIN, Marie-Catherine/A-9623-2008; Estivill, Xavier/A-3125-2013; Chillon, Miguel/A-2466-2009	Nunes, Virginia/0000-0002-5747-9310; Ferec, Claude/0000-0002-2325-0710; Lissens, Willy/0000-0003-3875-9955; Estivill, Xavier/0000-0002-0723-2256; Chillon, Miguel/0000-0003-0840-2111				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; AUDREZET MP, 1993, HUM MOL GENET, V2, P51, DOI 10.1093/hmg/2.1.51; AUDREZET MP, 1993, HUM MOL GENET, V2, P496, DOI 10.1093/hmg/2.4.496-a; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; BREMER S, 1992, EUR J BIOCHEM, V206, P137, DOI 10.1111/j.1432-1033.1992.tb16911.x; CASALS T, 1995, HUM GENET, V95, P205; CHILLON M, 1994, HUM GENET, V93, P447; CHILLON M, 1995, AM J HUM GENET, V56, P623; CHILLON M, 1994, HUM MUTAT, V3, P223, DOI 10.1002/humu.1380030308; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CULARD JF, 1994, HUM GENET, V93, P467; CUPPENS H, 1994, HUM MOL GENET, V3, P607, DOI 10.1093/hmg/3.4.607; DELANEY SJ, 1993, NAT GENET, V4, P426, DOI 10.1038/ng0893-426; DORK T, 1994, HUM GENET, V93, P67; DUMUR V, 1990, LANCET, V336, P512, DOI 10.1016/0140-6736(90)92066-Q; Fleiss JL, 1981, STAT METHODS RATES P; GERVAIS R, 1993, NEW ENGL J MED, V328, P446, DOI 10.1056/NEJM199302113280619; HAMOSH A, 1993, NEW ENGL J MED, V329, P1308; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; JEQUIER AM, 1985, J ANDROL, V6, P15; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; MERCIER B, 1995, AM J HUM GENET, V56, P272; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; OSBORNE LR, 1993, HUM MOL GENET, V2, P1605, DOI 10.1093/hmg/2.10.1605; OSBORNE LR, 1993, HUM MOL GENET, V2, P1990; RIORDAN JR, 1989, SCIENCE, V245, P1437; RIORDAN JR, 1989, SCIENCE, V245, P1066; SLOMSKI R, 1992, HUM GENET, V89, P615; STRONG TV, 1993, HUM MOL GENET, V2, P225, DOI 10.1093/hmg/2.3.225; TIZZANO EF, 1993, HUM MOL GENET, V2, P219, DOI 10.1093/hmg/2.3.219; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	36	718	743	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1475	1480		10.1056/NEJM199506013322204	http://dx.doi.org/10.1056/NEJM199506013322204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739684	Green Published			2022-12-28	WOS:A1995RA14000004
J	ESCARCE, JJ; CHEN, W; SCHWARTZ, JS				ESCARCE, JJ; CHEN, W; SCHWARTZ, JS			FALLING CHOLECYSTECTOMY THRESHOLDS SINCE THE INTRODUCTION OF LAPAROSCOPIC CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPERIENCE; DISEASE	Objectives.-To determine whether cholecystectomy rates among the elderly increased following the introduction of laparoscopic cholecystectomy in 1989, and to assess whether changes in rates were accompanied by tower clinical thresholds for performing cholecystectomy. Design.-Time-series quasi-experimental design based on quarterly observations from 1986 to 1993, Data were obtained from Medicare hospital discharge files for Pennsylvania. Patients.-Medicare patients aged 65 years or older who resided in Pennsylvania, did not have end-stage renal disease, and underwent cholecystectomy in Pennsylvania from 1986 to 1993. Main Outcome Measures.-Cholecystectomy rates per 1000 elderly Medicare beneficiaries, stage of gallstone disease (uncomplicated vs complicated) at cholecystectomy, type of admission (elective vs urgent/emergent), patient age and comorbidities, and 30-day postoperative mortality. Results.-Cholecystectomy rates increased 22% from 1989 to 1993, The proportions of cholecystectomy patients with uncomplicated gallstone disease and with elective admissions declined from 1986 to 1989 but then increased rapidly after laparoscopic cholecystectomy was introduced. In contrast, the age distribution and comorbidities of cholecystectomy patients did not change during the study period, Postoperative mortality rates were stable from 1986 to 1989 but decreased thereafter. Conclusions.-Growth in cholecystectomy rates following the introduction of laparoscopic cholecystectomy was accompanied by evidence of lower clinical thresholds for performing surgery. The normative, or prescriptive, implications of lower cholecystectomy thresholds require further analyses that consider lower direct medical costs and indirect costs and reduced postoperative morbidity after laparoscopic cholecystectomy.	UNIV PENN, WHARTON SCH, DEPT HLTH CARE SYST, PHILADELPHIA, PA 19104 USA; UNIV PENN, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	ESCARCE, JJ (corresponding author), UNIV PENN, SCH MED,DIV GEN INTERNAL MED,RALSTON HOUSE, 3615 CHESTNUT ST, ROOM 314, PHILADELPHIA, PA 19104 USA.				AHRQ HHS [P01-HS06481] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; BASS EB, 1993, AM J SURG, V165, P466, DOI 10.1016/S0002-9610(05)80942-0; CAMPBELL DT, 1963, EXPT QUASI-EXPT DESI; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COOK J, 1994, HEALTH ECON, V3, P157, DOI 10.1002/hec.4730030305; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; ESCARCE JJ, 1995, MED CARE, V33, P256, DOI 10.1097/00005650-199503000-00005; Fendrick A M, 1993, Arch Fam Med, V2, P959, DOI 10.1001/archfami.2.9.959; FENDRICK AM, 1994, MED CARE, V32, P1058, DOI 10.1097/00005650-199410000-00007; GADACZ TR, 1993, AM J SURG, V165, P450, DOI 10.1016/S0002-9610(05)80939-0; GLENN F, 1981, SURG GYNECOL OBSTET, V153, P401; GONNELLA JS, 1984, JAMA-J AM MED ASSOC, V251, P637; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P1018, DOI 10.1001/jama.1993.03500080066034; Kaplan S. H., 1994, Journal of General Internal Medicine, V9, P58; Kmenta J., 1986, ELEMENTS ECONOMETRIC, V(2nd), DOI [https://doi.org/10.3998/mpub.15701, DOI 10.3998/MPUB.15701]; LARSON GM, 1992, AM J SURG, V163, P221, DOI 10.1016/0002-9610(92)90105-Z; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MOSES LE, 1986, MED USES STATISTICS, P235; ORLANDO R, 1993, ARCH SURG-CHICAGO, V128, P494; RANSOHOFF DF, 1993, ANN INTERN MED, V119, P606, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00010; SOPER NJ, 1992, SURG GYNECOL OBSTET, V174, P114; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; Warner KE, 1982, COST BENEFIT COST EF; 1991, INT CLASSIFICATION D; 1989, INT CLASSIFICATION D	30	124	124	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1581	1585		10.1001/jama.273.20.1581	http://dx.doi.org/10.1001/jama.273.20.1581			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745770				2022-12-28	WOS:A1995QY54100024
J	AIKEN, LH; GWYTHER, ME				AIKEN, LH; GWYTHER, ME			MEDICARE FUNDING OF NURSE EDUCATION - THE CASE FOR POLICY CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To determine the magnitude and distribution of US Medicare funding for nursing education and to assess the extent to which Medicare funding contributes to meeting national health care workforce priorities. Data Sources.-Medicare Hospital Cost Report Information System, American Hospital Association Annual Survey of Hospitals, and National League for Nursing national surveys of schools of nursing. Data Analysis.-Using hospital identifiers, data from three data sets were merged and analyzed to estimate percentage distributions of Medicare funding according to types of educational programs, hospital characteristics, and student enrollment. Results.-Fifteen percent of direct Medicare graduate medical education funding goes to hospitals for the training of nurses and paramedical personnel. Totaling approximately $174 million in 1991, 71% of these funds went to hospitals for nursing education costs. Most of the nation's teaching hospitals (289 of 381 Council of Teaching Hospitals member hospitals) and nurse education programs (1112 of 1484) do not qualify under existing policies for Medicare nursing education reimbursement. Sixty-six percent of Medicare nurse training funds, totaling $114 million in 1991, went to 145 hospitals operating diploma nursing programs; these programs produce less than 10% of nurse graduates. Three states (Pennsylvania, New Jersey, and Ohio) received nearly one half (48%) of the $114 million for diploma nursing education. Conclusions.-Medicare is the largest single source of federal support for nursing education. Yet, the majority of Medicare nursing education funding goes to hospitals affiliated with an increasingly smaller, idiosyncratic subset of nurse training programs. Unlike graduate medical education, Medicare supports primarily preprofessional education in nursing. Graduate education, including the preparation of nurse practitioners, does not generally qualify for reimbursement. Medicare reimbursement for nursing education must be retargeted.			AIKEN, LH (corresponding author), UNIV PENN,SCH NURSING,CTR HLTH SERV & POLICY RES,420 GUARDIAN DR,PHILADELPHIA,PA 19104, USA.							AIKEN LH, 1994, INQUIRY-J HEALTH CAR, V31, P318; BERLINER H, 1994, SUPPLY DEMAND HLTH W; CLAWSON DK, 1993, ROLES PHYSICIAN ASSI; FAGIN C, 1990, 412349 NAT LEAG NURS; Feldstein P., 1979, HLTH CARE EC; Flexner A., 1910, FLEXNER REPORT; GANEM JL, 1994, JAMA-J AM MED ASSOC, V272, P705; GOLDMARK J, 1984, NURSING NURSING ED U; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; YETT D, 1975, EC ANAL NURSE SHORTA; 1992, FED REG         0922, V57, P43659; 1993, HLTH PROFESSIONS ED; 1974, REPORT STUDY COSTS E; 1981, NURSING DATA REV 198; 1986, HLTH TECHNOLOGY CASE, V37; 1994, EFFECT HOSPITAL REST; 1993, NURSING WORLD FACTS; 1993, STATE APPROVED SCH N; 1972, AHA HOSPITAL STATIST; 1990, REGISTERED NURSE POP; 1988, REPORT C NURSING OTH; 1993, STATISTICAL ABSTRACT; 1994, FINAL REPORT REGISTE; 1994, CURRENT FUNDS REVENU, V8, P10; 1994, REGISTERED NURSE POP; 1994, NURSING DATA REV 199; 1992, HLTH PERSONNEL US 8T; 1990, 7TH REPORT PRESIDENT; 1994, AHA HOSPITAL STATIST	29	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1528	1532		10.1001/jama.273.19.1528	http://dx.doi.org/10.1001/jama.273.19.1528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739080				2022-12-28	WOS:A1995QX41800036
J	EMANUEL, L				EMANUEL, L			THE PRIVILEGE AND THE PAIN	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											EMANUEL, L (corresponding author), HARVARD UNIV, SCH MED, DIV MED ETH, 641 HUNTINGTON AVE, BOSTON, MA 02115 USA.								0	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					797	798		10.7326/0003-4819-122-10-199505150-00012	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717605				2022-12-28	WOS:A1995QX14700012
J	HOOPER, DC				HOOPER, DC			FROM FLUOROQUINOLONES TO 2-PYRIDONES	LANCET			English	Editorial Material							NALIDIXIC-ACID; DNA GYRASE				HOOPER, DC (corresponding author), MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114, USA.							ALDER JD, 1994, 34TH INT C ANT AG CH; CHIN NX, 1994, 34TH INT C ANT AG CH; CHU DTW, 1994, 34TH INT C ANT AG CH; ELIOPOULOS GM, 1994, 34TH INT C ANT AG CH; FLAMM RK, 1994, 34TH INT C ANT AG CH; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Hooper David C., 1993, P53; Hooper David C., 1993, P489; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; LESHER GY, 1962, J MED PHARMACEUT CH, V5, P1063, DOI 10.1021/jm01240a021; MEULBROEK JA, 1994, 34TH INT C ANT AG CH; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767	12	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1192	1193		10.1016/S0140-6736(95)91986-4	http://dx.doi.org/10.1016/S0140-6736(95)91986-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739303				2022-12-28	WOS:A1995QX86100004
J	ECKER, JR				ECKER, JR			THE ETHYLENE SIGNAL-TRANSDUCTION PATHWAY IN PLANTS	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; PROTEIN-KINASES; 2-COMPONENT REGULATORS; ACIDIC CHITINASE; GENE; EXPRESSION; TOBACCO; RAF; PHOSPHORYLATION; BIOSYNTHESIS	Ethylene (C2H4), the chemically simplest plant hormone, is among the best-characterized plant growth regulators. It participates in a variety of stress responses and developmental processes. Genetic studies in Arabidopsis have defined a number of genes in the ethylene signal transduction pathway. Isolation of two of these genes has revealed that plants sense this gas through a combination of proteins that resemble both prokaryotic and eukaryotic signaling proteins. Ethylene signaling components are likely conserved for responses as diverse as cell elongation, cell fate patterning in the root epidermis, and fruit ripening. Genetic manipulation of these genes will provide agriculture with new tools to prevent or modify ethylene responses in a variety of plants.			ECKER, JR (corresponding author), UNIV PENN, DEPT BIOL, INST PLANT SCI, PHILADELPHIA, PA 19104 USA.		Ecker, Joseph R/B-9144-2008	Ecker, Joseph R/0000-0001-5799-5895				Abeles F, 1992, ETHYLENE PLANT BIOL; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; ALONSO E, 1995, PLANT J, V7, P309, DOI 10.1046/j.1365-313X.1995.7020309.x; APELBAUM A, 1972, PLANT PHYSIOL, V50, P117, DOI 10.1104/pp.50.1.117; BENT AF, 1992, MOL PLANT MICROBE IN, V5, P372, DOI 10.1094/MPMI-5-372; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BROGLIE KE, 1989, PLANT CELL, V1, P599, DOI 10.1105/tpc.1.6.599; BUNNING E, 1951, PLANTA, V39, P126; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1994, RES MICROBIOL, V145, P481, DOI 10.1016/0923-2508(94)90097-3; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CORMACK HC, 1935, NEW PHYTOL, V34, P19; CREWSTER JL, 1994, SCIENCE, V259, P1760; DARWIN C, 1981, POWER MOVEMENT PLANT; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; ECKER JR, 1987, P NATL ACAD SCI USA, V84, P5202, DOI 10.1073/pnas.84.15.5202; ECKER JR, 1986, P NATL ACAD SCI USA, V83, P5372, DOI 10.1073/pnas.83.15.5372; ECKER JR, 1994, ARABIDOPSIS, P485; EYAL Y, 1993, PLANT J, V4, P225, DOI 10.1046/j.1365-313X.1993.04020225.x; FUJINO DW, 1989, J PLANT GROWTH REGUL, V8, P53, DOI 10.1007/BF02024926; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GOESCHL JD, 1966, PLANT PHYSIOL, V41, P877, DOI 10.1104/pp.41.5.877; GRAY RG, 1993, TRENDS GENET, V9, P438; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HALL MA, 1990, SYM SOC EXP BIOL, V44, P87; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPHAM NVJ, 1991, ANN BOT-LONDON, V68, P55, DOI 10.1093/oxfordjournals.aob.a088218; HART CM, 1993, PLANT MOL BIOL, V21, P121, DOI 10.1007/BF00039623; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; Hyodo H., 1991, PLANT HORMONE ETHYLE; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KANG BG, 1967, SCIENCE, V156, P658; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIEBER JJ, 1993, TRENDS GENET, V9, P356, DOI 10.1016/0168-9525(93)90041-F; KIEBER JJ, 1994, NATO ASI SERIES H, V81, P193; Knight LI, 1910, SCIENCE, V31, P636; KNIGHT LI, 1910, SCIENCE, V31, P635; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; LAWTON KA, 1994, PLANT CELL, V6, P581, DOI 10.1105/tpc.6.5.581; LEHMAN AB, UNPUB; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MASUCCI JD, 1994, PLANT PHYSIOL, V106, P1335, DOI 10.1104/pp.106.4.1335; MELLER Y, 1993, PLANT MOL BIOL, V23, P453, DOI 10.1007/BF00019294; MIZOGUCHI T, 1993, FEBS LETT, V336, P440, DOI 10.1016/0014-5793(93)80852-L; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; Neljubow D., 1901, BEIHEFTE ZUM BOT ZEN, V10, P128; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; OHMETAKAGI M, 1990, PLANT MOL BIOL, V15, P941, DOI 10.1007/BF00039434; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; RAZ V, 1992, PLANT CELL, V4, P1123, DOI 10.1105/tpc.4.9.1123; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; ROMAN G, 1995, GENETICS, V139, P1393; ROMAN G, UNPUB PHILOS T R S B; ROMAN G, UNPUB; ROSS AF, 1961, VIROLOGY, V14, P329, DOI 10.1016/0042-6822(61)90318-X; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SAMAC DA, 1991, PLANT CELL, V3, P1063, DOI 10.1105/tpc.3.10.1063; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Schiefelbein JW, 1994, ARABIDOPSIS, P335; SCHWARK A, 1993, PLANT PHYSIOL, V142, P562; SCHWARK A, 1993, PLANT PHYSIOL, V142, P585; SILK WK, 1978, AM J BOT, V65, P310, DOI 10.2307/2442271; SISLER EC, 1990, PLANT HORMONE ETHYLE, P81; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; SU WP, 1992, PLANT PHYSIOL, V99, P1569, DOI 10.1104/pp.99.4.1569; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	85	573	631	5	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					667	675						9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732375				2022-12-28	WOS:A1995QW60300035
J	FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL				FENTEANY, G; STANDAERT, RF; LANE, WS; CHOI, S; COREY, EJ; SCHREIBER, SL			INHIBITION OF PROTEASOME ACTIVITIES AND SUBUNIT-SPECIFIC AMINO-TERMINAL THREONINE MODIFICATION BY LACTACYSTIN	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; THERMOPLASMA-ACIDOPHILUM; MICROBIAL METABOLITE; NEUROBLASTOMA-CELLS; DEGRADATION; CYCLIN; GENE; SEQUENCE; PATHWAY	Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces neurite outgrowth in a murine neuroblastoma cell line. Tritium-labeled lactacystin was used to identify the 20S proteasome as its specific cellular target. Three distinct peptidase activities of this enzyme complex (trypsin-like, chymotrypsin-like, and peptidylglutamyl-peptide hydrolyzing activities) were inhibited by lactacystin, the first two irreversibly and all at different rates. None of five other proteases were inhibited, and the ability of lactacystin analogs to inhibit cell cycle progression and induce neurite outgrowth correlated with their ability to inhibit the proteasome. Lactacystin appears to modify covalently the highly conserved amino-terminal threonine of the mammalian proteasome subunit X (also called MB1), a close homolog of the LMP7 proteasome subunit encoded by the major histocompatibility complex. This threonine residue may therefore have a catalytic role, and subunit X/MB1 may be a core component of an amino-terminal-threonine protease activity of the proteasome.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Harvard University			Standaert, Robert F/D-9467-2013; Standaert, Robert F./AAI-1532-2021; Fenteany, Gabriel/F-4944-2018	Standaert, Robert F/0000-0002-5684-1322; Fenteany, Gabriel/0000-0001-7407-2195; Fenteany, Gabriel/0000-0003-0335-4587				AKIYAMA KY, 1994, SCIENCE, V265, P1231, DOI 10.1126/science.8066462; BELICH MP, 1994, CURR BIOL, V4, P769, DOI 10.1016/S0960-9822(00)00174-3; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DESS DB, 1991, J AM CHEM SOC, V113, P7277, DOI 10.1021/ja00019a027; DUGGLEBY HJ, 1995, NATURE, V373, P265; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRUH K, 1992, J BIOL CHEM, V267, P22131; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HAFFTER P, 1991, NUCLEIC ACIDS RES, V19, P5075, DOI 10.1093/nar/19.18.5075; HAGLER J, UNPUB; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; LEE LW, 1990, BIOCHIM BIOPHYS ACTA, V1037, P178, DOI 10.1016/0167-4838(90)90165-C; LILLEY KS, 1990, FEBS LETT, V262, P327, DOI 10.1016/0014-5793(90)80220-D; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; TANAKA K, 1992, NEW BIOL, V4, P173; TSUBUKI, 1993, BIOCHEM BIOPH RES CO, V96, P1195; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	35	1472	1531	5	105	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					726	731		10.1126/science.7732382	http://dx.doi.org/10.1126/science.7732382			6	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732382				2022-12-28	WOS:A1995QW60300051
J	GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD				GILBERT, RE; STANFORD, MR; JACKSON, H; HOLLIMAN, RE; SANDERS, MD			INCIDENCE OF ACUTE SYMPTOMATIC TOXOPLASMA RETINOCHOROIDITIS IN SOUTH LONDON ACCORDING TO COUNTRY OF BIRTH	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL TOXOPLASMOSIS; OCULAR TOXOPLASMOSIS; INFECTION; PREGNANCY; SEROPREVALENCE; PREVALENCE; WEST	Objective-To determine the incidence of acute symptomatic toxoplasma retinochoroiditis presenting to ophthalmologists for patients born in Britain and elsewhere. Design-Population based, cross sectional study. Setting-11 districts in south Greater London. Subjects-All patients presenting ophthalmologists with symptoms due toxoplasma retinochoroiditis in 1992-3. Main outcome measure-Intraocular inflammation in association with a retinochoroidal scar, active adjoining retinitis, and IgG serum antibodies to toxoplasma. Results-The estimated incidence of acute symptomatic retinochoroiditis for all people born in Britain was 0.4/100 000/year and for black people born in west Africa 57/100 000/year. If a mean of two symptomatic episodes per lifetime is assumed, 100 people born in Britain may be affected each year, about a fifth of the estimated 500-600 congenitally infected people born each year. Conclusions-A substantial proportion of people with acute symptomatic toxoplasma retinochoroiditis were born outside the country, and the number born in Britain was smaller than the number previously estimated to develop retinochoroidal lesions due to congenital toxoplasmosis. These findings suggest that prenatal screening for toxoplasmosis in Britain may be of limited benefit.	ST THOMAS HOSP,MED EYE UNIT,LONDON SE1 7EH,ENGLAND; ST GEORGE HOSP,DEPT OPHTHALMOL,LONDON SW17 0QT,ENGLAND; ST GEORGE HOSP,PUBL HLTH LAB SERV,TOXOPLASMA REFERENCE UNIT,LONDON SW17 0QT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; St Georges University London; Public Health England; St Georges University London	GILBERT, RE (corresponding author), INST CHILD HLTH,DEPT BIOSTAT & EPIDEMIOL,LONDON WC1N 1EH,ENGLAND.			Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADES AE, 1992, EPIDEMIOL INFECT, V108, P367, DOI 10.1017/S0950268800049839; ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; ADES AE, IN PRESS EPIDEMIC MO; BERREBI A, 1994, LANCET, V344, P36, DOI 10.1016/S0140-6736(94)91054-5; Chatterton JMW., 1992, HUMAN TOXOPLASMOSIS, P144; CHESTERTON JR, 1967, BRIT J OPHTHALMOL, V51, P617, DOI 10.1136/bjo.51.9.617; CONYNVANSPAENDO.MA, 1989, INT OPHTHALMOL, V13, P403; Couvreur J., 1988, Handbook of Clinical Neurology. Vol 52, Revised Series 8. Microbial Disease., P351; DESMONTS G, 1974, NEW ENGL J MED, V290, P1110, DOI 10.1056/NEJM197405162902003; DESMONTS G, 1990, LANCET, V336, P1017, DOI 10.1016/0140-6736(90)92485-Z; FATHY VC, 1993, PUBLIC HEALTH, V107, P19, DOI 10.1016/S0033-3506(05)80488-3; FRIEDMAN.CT, 1969, ARCH OPHTHALMOL-CHIC, V81, P481; GILBERT RE, 1993, BRIT MED J, V306, P185, DOI 10.1136/bmj.306.6871.185; GLASNER PD, 1992, AM J OPHTHALMOL, V114, P136, DOI 10.1016/S0002-9394(14)73976-5; GUERINA NG, 1994, NEW ENGL J MED, V330, P1858, DOI 10.1056/NEJM199406303302604; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HARTUP C, 1992, LANCET, V340, P118, DOI 10.1016/0140-6736(92)90444-8; HOLLIMAN RE, 1990, SERODIAG IMMUN INF D, V4, P83, DOI 10.1016/0888-0786(90)90031-I; HOYEN DO, 1992, HUMAN TOXOPLASMOSIS, P56; JOSS AWL, 1988, PUBLIC HEALTH, V102, P409, DOI 10.1016/S0033-3506(88)80078-7; JOSS AWL, 1990, PUBLIC HEALTH, V104, P9, DOI 10.1016/S0033-3506(05)80340-3; JOYNSON DHM, 1988, LANCET, V2, P795; KOPPE JG, 1989, INT OPHTHALMOL, V13, P387, DOI 10.1007/BF02306486; LAKHANPAL V, 1983, AM J OPHTHALMOL, V95, P605, DOI 10.1016/0002-9394(83)90378-1; NOKES DJ, 1993, PARASITOLOGY, V107, P33, DOI 10.1017/S0031182000079373; PERKINS ES, 1973, BRIT J OPHTHALMOL, V57, P1, DOI 10.1136/bjo.57.1.1; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; ROTHOVA A, 1993, BRIT J OPHTHALMOL, V77, P371, DOI 10.1136/bjo.77.6.371; SILVEIRA C, 1988, AM J OPHTHALMOL, V106, P362, DOI 10.1016/0002-9394(88)90382-0; STAGNO S, 1980, PEDIATRICS, V65, P706; Thalhammer O., 1979, PERINATAL MED, P51; THORP JM, 1988, NEW ENGL J MED, V319, P372, DOI 10.1056/NEJM198808113190615; THOUMSIN H, 1992, SCAND J INFECT DIS S, V84, P84; WILLIAMS KAB, 1981, J INFECTION, V3, P219, DOI 10.1016/S0163-4453(81)90773-8; WILSON CB, 1980, PEDIATRICS, V66, P767; 1994, ETHNIC GROUP COUNTRY, V1, P214; 1992, PRENATAL SCREENING T	37	38	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1037	1040		10.1136/bmj.310.6986.1037	http://dx.doi.org/10.1136/bmj.310.6986.1037			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728057	Green Published			2022-12-28	WOS:A1995QV31300016
J	RODRIGUEZ, LAG; MANNINO, S; WALLANDER, MA				RODRIGUEZ, LAG; MANNINO, S; WALLANDER, MA			OCULAR SAFETY OF ANTIULCER DRUGS	LANCET			English	Letter									UNIV G DANNUNZIO,DEPT HUMAN PATHOL & SOCIAL MED,CHAIR HYG,CHIETI,ITALY; ASTRA HASSLE AB,DRUG SAFETY & EPIDEMIOL,MOLNDAL,SWEDEN; UNIV UPPSALA,DEPT FAMILY MED,S-75105 UPPSALA,SWEDEN	G d'Annunzio University of Chieti-Pescara; Uppsala University	RODRIGUEZ, LAG (corresponding author), UNIV COMPLUTENSE MADRID,CTR ESPANOL INVEST FARMACOEPIDEMIOL,E-28040 MADRID,SPAIN.							COLINJONES D, 1994, LANCET, V343, P1369, DOI 10.1016/S0140-6736(94)92509-7; CREUTZFELDT WC, 1994, LANCET, V343, P1098, DOI 10.1016/S0140-6736(94)90207-0; FRAUNFELDER FT, 1989, DRUG INDUCED OCULAR; SCHONHOFER PS, 1994, LANCET, V343, P665, DOI 10.1016/S0140-6736(94)92654-9; 1993, ARZNEI TELEGRAMM, V7, P74	5	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1059	1060		10.1016/S0140-6736(95)90805-6	http://dx.doi.org/10.1016/S0140-6736(95)90805-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723534				2022-12-28	WOS:A1995QU57300064
J	RADICELLA, JP; PARK, PU; FOX, MS				RADICELLA, JP; PARK, PU; FOX, MS			ADAPTIVE MUTATION IN ESCHERICHIA-COLI - A ROLE FOR CONJUGATION	SCIENCE			English	Article							DIRECTED MUTATION; MUTANTS; ORIGIN	When subjected to selective conditions that impose starvation, a bacterial population can accumulate mutations, called adaptive, that allow colony formation. Here, the reversion of a lac allele under selective conditions, in a model system using Escherichia coli with the lac mutation on an F' plasmid, was shown to require the conjugational capacity of the plasmid. Reversion associated with transfer was shown, and when the same lac allele was chromosomal, reversion to Lac(+) was 25 to 50 times less frequent. Postplating reversion was 25 times less when mating was inhibited by the presence of detergent. Mutability associated with conjugation provides new ways of thinking about the origin of adaptive mutations.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; Park, Peter U./0000-0002-6892-3018	PHS HHS [A105388] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ACHTMAN M, 1978, J BACTERIOL, V135, P1053, DOI 10.1128/JB.135.3.1053-1061.1978; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHARLESWORTH D, 1988, NATURE, V336, P525, DOI 10.1038/336525a0; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, IN PRESS P NATL ACAD; FOX M, 1993, MOL GEN GENET, V240, P355, DOI 10.1007/BF00280386; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HAYES W, 1952, NATURE, V169, P118, DOI 10.1038/169118b0; LEDERBERG J, 1952, GENETICS, V37, P720; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1993, SCIENCE, V260, P1222, DOI 10.1126/science.260.5112.1222; LENSKI RE, 1988, NATURE, V336, P123; LICHTEN M, 1983, GENETICS, V103, P5; Luria SE, 1943, GENETICS, V28, P491; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOVICK A, 1950, P NATL ACAD SCI USA, V36, P708, DOI 10.1073/pnas.36.12.708; PARTRIDGE L, 1988, NATURE, V336, P22, DOI 10.1038/336022a0; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; RYAN FJ, 1959, J GEN MICROBIOL, V21, P530, DOI 10.1099/00221287-21-3-530; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SINGER M, 1989, MICROBIOL REV, V53, P1; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEWART FM, 1990, GENETICS, V124, P175; SYMONDS N, 1989, NATURE, V337, P119, DOI 10.1038/337119a0; TESSMAN I, 1988, NATURE, V336, P527, DOI 10.1038/336527b0	34	102	105	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					418	420		10.1126/science.7716545	http://dx.doi.org/10.1126/science.7716545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716545				2022-12-28	WOS:A1995QU57200040
J	OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A				OTT, A; BRETELER, MMB; VANHARSKAMP, F; CLAUS, JJ; VANDERCAMMEN, TJM; GROBBEE, DE; HOFMAN, A			PREVALENCE OF ALZHEIMERS-DISEASE AND VASCULAR DEMENTIA - ASSOCIATION WITH EDUCATION - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MENTAL STATE; HEALTH; EPIDEMIOLOGY; DIAGNOSIS; IMPACT	Objective-To estimate the prevalence of dementia and its subtypes in the general population and examine the relation of the disease to education. Design-Population based cross sectional study. Setting-Ommoord, a suburb of Rotterdam. Subjects-7528 participants of the Rotterdam study aged 55-106 years. Results-474 cases of dementia were detected, giving an overall prevalence of 6.3%, Prevalence ranged from 0.4% (5/1181 subjects) at age 55-59 years to 43.2% (19/44) at 95 years and over. Alzheimer's disease was the main subdiagnosis (339 cases; 72%); it was also the main cause of the pronounced increase in dementia with age. The relative proportion of vascular dementia (76 cases; 16%), Parkinson's disease dementia (30; 6%), and other dementias (24; 5%) decreased with age. A substantially higher prevalence of dementia was found in subjects with a low level of education. The association with education was not due to confounding by cardiovascular disease. Conclusions-The prevalence of dementia increases exponentially with age. About one third of the population aged 85 and over has dementia. Three quarters of all dementia is due to Alzheimer's disease. In this study an inverse dose-response relation was found between education and dementia -in particular, Alzheimer's disease.			OTT, A (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305				BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; COPELAND JRM, 1976, PSYCHOL MED, V6, P439, DOI 10.1017/S0033291700015889; DARTIGUES JF, 1991, REV NEUROL-FRANCE, V147, P225; DEWEY ME, 1990, CASE FINDING DEMENTI; FELDMAN JJ, 1989, AM J EPIDEMIOL, V129, P919, DOI 10.1093/oxfordjournals.aje.a115225; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1993, NEUROLOGY, V43, P246, DOI 10.1212/WNL.43.2.246; HASHINSKI V, 1983, NEUROL CLIN, V1, P27; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P735; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; KATZMAN R, 1993, NEUROLOGY, V43, P13, DOI 10.1212/WNL.43.1_Part_1.13; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; ROCCA WA, 1991, ANN NEUROL, V30, P381, DOI 10.1002/ana.410300310; ROCCA WA, 1990, NEUROLOGY, V40, P626, DOI 10.1212/WNL.40.4.626; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Roth M, 1988, CAMDEX CAMBRIDGE EXA; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1987, DIAGNOSTIC STATISTIC; 1987, SOI1978 NETH CENTR B; 1974, STATISTISCH JB	25	597	604	1	35	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					970	973		10.1136/bmj.310.6985.970	http://dx.doi.org/10.1136/bmj.310.6985.970			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT904	7728032	Green Published			2022-12-28	WOS:A1995QT90400019
J	SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R				SACKS, DL; KENNEY, RT; KREUTZER, RD; JAFFE, CL; GUPTA, AK; SHARMA, MC; SINHA, SP; NEVA, FA; SARAN, R			INDIAN KALA-AZAR CAUSED BY LEISHMANIA-TROPICA	LANCET			English	Note							OPERATION DESERT-STORM	Kala-azar, or visceral leishmaniasis, in India is generally assumed to be a result of infection with Leishmania donovani. 15 parasite isolates collected over the past 10 years from patients with classical disease were typed by monoclonal antibodies, isoenzymes, and kDNA analysis. 4 were shown to be L tropica, a species historically associated with cutaneous disease and more recently a mild ''visceralising'' disease from the Desert Storm experience. The results confirm that L tropica is a co-endemic agent of visceral leishmaniasis in India, and may shed light on the rising frequency of therapeutic unresponsiveness to sodium antimony gluconate, which complicates treatment of this lethal disease.	YOUNGSTOWN STATE UNIV,DEPT BIOL,YOUNGSTOWN,OH; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT PARASITOL,JERUSALEM,ISRAEL; INDIAN COUNCIL MED RES,RAJENDRA MEM RES INST,PATNA,BIHAR,INDIA	University System of Ohio; Youngstown State University; Hebrew University of Jerusalem; Indian Council of Medical Research (ICMR); ICMR - Rajendra Memorial Research Institute of Medical Sciences (RMRI)	SACKS, DL (corresponding author), NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892, USA.		Jaffe, Charles/AAU-8686-2020	Jaffe, Charles/0000-0002-2042-9993				JAFFE CL, 1987, J IMMUNOL, V138, P1310; KREUTZER RD, 1993, AM J TROP MED HYG, V49, P357, DOI 10.4269/ajtmh.1993.49.357; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MEBRAHTU Y, 1989, AM J TROP MED HYG, V41, P289, DOI 10.4269/ajtmh.1989.41.289; SCHNUR LF, 1989, NATO ADV SCI I SERIE, P939; SMYTH AJ, 1992, PARASITOLOGY, V105, P183, DOI 10.1017/S0031182000074096; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8	7	96	101	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					959	961		10.1016/S0140-6736(95)90703-3	http://dx.doi.org/10.1016/S0140-6736(95)90703-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715298				2022-12-28	WOS:A1995QT91900013
J	AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB				AFSHAR, K; BARTON, NR; HAWLEY, RS; GOLDSTEIN, LSB			DNA-BINDING AND MEIOTIC CHROMOSOMAL LOCALIZATION OF THE DROSOPHILA NOD KINESIN-LIKE PROTEIN	CELL			English	Article							DISTRIBUTIVE SEGREGATION; GENETIC-ANALYSIS; MELANOGASTER; SATELLITE; FEMALES; SPINDLE; DOMAIN	The Drosophila no distributive disjunction (nod) gene encodes a kinesin-like protein that has been proposed to push chromosomes toward the metaphase plate during female meiosis. We report that the nonmotor domain of the nod protein can mediate direct binding to DNA. Using an antiserum prepared against bacterially expressed nod protein, we show that during prometaphase nod protein is localized on oocyte chromosomes and is not restricted to either specific chromosomal regions or to the kinetochore. Thus, motor-based chromosome-microtubule interactions are not limited to the centromere, but extend along the chromosome arms, providing a molecular explanation for the polar ejection force.	UNIV CALIF SAN DIEGO,SCH MED,DEPT PHARMACOL,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093	University of California System; University of California San Diego	AFSHAR, K (corresponding author), UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616, USA.			Hawley, R. Scott/0000-0002-6478-0494				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ABERCROMBIE BD, 1978, EUR J BIOCHEM, V84, P173, DOI 10.1111/j.1432-1033.1978.tb12154.x; BAKER BS, 1972, GENETICS, V71, P255; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; CHODOSH LA, 1991, CURRENT PROTOCOLS MO, V2; CRIPPA MP, 1992, J MOL BIOL, V228, P442, DOI 10.1016/0022-2836(92)90833-6; FUGE H, 1990, PROTOPLASMA, V158, P1, DOI 10.1007/BF01323267; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRELL RF, 1976, GENET BIOL DROSOPHIL, P435; HARLOW E, 1988, ANTIBODIES LABORATOR; Hawley R.S., 1988, GENETIC RECOMBINATIO, P497; HAWLEY RS, 1993, ANNU REV GENET, V27, P281; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HAWLEY RS, 1993, DEV GENET, V13, P440; LE MH, 1995, IN PRESS GENETICS; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; RASOOLY RS, 1991, GENETICS, V129, P409; RASOOLY RS, 1994, MOL GEN GENET, V242, P145, DOI 10.1007/BF00391007; REEVES R, 1993, J BIOL CHEM, V268, P21137; Rhoades MM, 1942, GENETICS, V27, P0395; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sambrook J, 1989, MOL CLONING LABORATO; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	35	123	125	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					129	138		10.1016/0092-8674(95)90377-1	http://dx.doi.org/10.1016/0092-8674(95)90377-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720068	Bronze			2022-12-28	WOS:A1995QR97000014
J	CHANT, J; STOWERS, L				CHANT, J; STOWERS, L			GTPASE CASCADES CHOREOGRAPHING CELLULAR BEHAVIOR - MOVEMENT, MORPHOGENESIS, AND MORE	CELL			English	Review							RAS; YEAST; PROTEIN; DEFECT; GROWTH; GENES				CHANT, J (corresponding author), HARVARD UNIV,DEPT MOLEC & CELL BIOL,CAMBRIDGE,MA 02138, USA.		Stowers, Lisa/K-6137-2015	Stowers, Lisa/0000-0002-4403-1269				BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENEVERT J, 1994, GENETICS, V136, P1287; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STOWERS L, 1995, IN PRESS P NATL ACAD; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	25	272	276	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					1	4		10.1016/0092-8674(95)90363-1	http://dx.doi.org/10.1016/0092-8674(95)90363-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720065	Bronze			2022-12-28	WOS:A1995QR97000001
J	BEHRENS, RH; ROBERTS, JA				BEHRENS, RH; ROBERTS, JA			IS TRAVEL PROPHYLAXIS WORTH WHILE - ECONOMIC APPRAISAL OF PROPHYLACTIC MEASURES AGAINST MALARIA, HEPATITIS-A, AND TYPHOID IN TRAVELERS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; HEALTH	Objectives-To estimate the costs and benefits of prophylaxis against travel acquired malaria, typhoid fever, and hepatitis A in United Kingdom residents during 1991. Design-Retrospective analysis of national epidemiological and economic data. Main outcome measures-Incidence of travel associated infections in susceptible United Kingdom residents per visit; costs of prophylaxis provision from historical data; benefits to the health sector, community, and individuals in terms of avoided morbidity and mortality based on hospital and community costs of disease. Results-The high incidence of imported malaria (0.70%) and the low costs of providing chemoprophylaxis resulted in a cost-benefit ratio of 0.19 for chloroquine and proguanil and 0.57 for a regimen containing mefloquine. Hepatitis A infection occurred in 0.05% of visits and the cost of prophylaxis invariably exceeded the benefits for immunoglobulin (cost-benefit ratio 5.8) and inactivated hepatitis A vaccine (cost-benefit ratio 15.8). Similarly, low incidence of typhoid (0.02%) and its high cost gave whole cell killed, polysaccharide Vi, and oral Ty 21a typhoid vaccines cost-benefit ratios of 18.1, 18.0, and 22.0 respectively. Conclusions-Fewer than one third of travellers receive vaccines but the total cost of providing typhoid and hepatitis A prophylaxis of pound 25.8m is significantly higher than the treatment costs to the NHS (pound 1.03m) of cases avoided by prophylaxis. Neither hepatitis A prophylaxis nor typhoid prophylaxis is cost effective, but costs of treating malaria greatly exceed costs of chemoprophylaxis, which is therefore highly cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1T 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BEHRENS, RH (corresponding author), HOSP TROP DIS,TRAVEL CLIN,LONDON NW1 0PE,ENGLAND.							BEHRENS RH, 1990, T ROY SOC TROP MED H, V84, P611, DOI 10.1016/0035-9203(90)90123-V; BEHRENS RH, 1993, T ROY SOC TROP MED H, V87, P361; BRADDICK MR, 1993, PUBLIC HEALTH, V107, P193, DOI 10.1016/S0033-3506(05)80441-X; Bradley D J, 1993, Commun Dis Rep CDR Rev, V3, pR25; COSSAR JH, 1990, J INFECTION, V21, P27, DOI 10.1016/0163-4453(90)90600-D; Cumberland N S, 1994, J R Army Med Corps, V140, P71; DAVIDSON RN, 1993, J INFECTION, V26, P348, DOI 10.1016/0163-4453(93)96241-H; FORBES A, 1988, J ROY COLL PHYS LOND, V22, P237; MARIN A, 1983, 3 BANKS REV, V138, P20; Paris J A, 1992, Commun Dis Rep CDR Rev, V2, pR43; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; POLAKOFF S, 1990, J INFECTION, V21, P111, DOI 10.1016/0163-4453(90)90853-Z; STEFFEN R, 1991, T ROY SOC TROP MED H, V85, P156, DOI 10.1016/0035-9203(91)90005-J; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; STEFFEN R, 1987, J INFECT DIS, V156, P84, DOI 10.1093/infdis/156.1.84; TILZEY AJ, 1991, BMJ-BRIT MED J, V302, P1552, DOI 10.1136/bmj.302.6792.1552; WOODRUFF BA, 1991, JAMA-J AM MED ASSOC, V265, P756, DOI 10.1001/jama.265.6.756; ZUCKERMAN AJ, 1991, BRIT MED J, V303, P991, DOI 10.1136/bmj.303.6808.991-a; 1991, MA6 GOV STAT SERV CE; 1993, EMPLOYMENT GAZET JUN, P50; 1991, COMMUNICABLE DISEASE; 1990, GENERAL MED PRACTITI; 1994, INT TRAVEL HLTH VACC, P41; 1992, IMMUNISATION INFECTI; 1991, CHEM DRUGGIST, V32	25	83	84	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					918	922		10.1136/bmj.309.6959.918	http://dx.doi.org/10.1136/bmj.309.6959.918			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7726905	Green Published			2022-12-28	WOS:A1994PL78100018
J	BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB				BERRY, SM; LECOLIER, B; SMITH, RS; BERCAU, G; DOMBROWSKI, MP; PUDER, KS; KITHIER, K; BIDAT, L; JOHNSON, MP; COTTON, DB			PREDICTIVE VALUE OF FETAL SERUM BETA(2)-MICROGLOBULIN FOR NEONATAL RENAL-FUNCTION	LANCET			English	Note							BETA2-MICROGLOBULIN; MATURATION; INDEX	When fetal urinary-tract malformations (UTM) are discovered, management is based on the prediction of postnatal renal function, currently made by fetal urinary biochemistry and sonography, Serum beta(2)-microglobulin has been used postnatally to estimate renal function and does not cross the placenta. We investigated the relation between fetal serum beta(2)-microglobulin and renal function by comparing 64 unaffected fetuses and 15 fetuses with UTM. A beta(2)-microglobulin above a 5.6 mg/L cut-off gave cross-validated sensitivity of 88.9%, specificity of 98.6%, a positive predictive value of 88.9%, and a negative predictive value of 97.1% for our cohort study.	WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV REPROD GENET,DETROIT,MI 48201; WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT PATHOL,DETROIT,MI 48201; HOP NOTRE DAME DE BON SECOURS,CTR PRENATAL DIAG,PARIS,FRANCE	Wayne State University; Wayne State University	BERRY, SM (corresponding author), WAYNE STATE UNIV,HUTZEL HOSP,RECEIVING HOSP,DEPT OBSTET & GYNAECOL,DIV MATERNAL FETAL MED,DETROIT,MI 48201, USA.							ASSADI FK, 1985, KIDNEY INT, V28, P153, DOI 10.1038/ki.1985.135; EUGENE M, 1994, AM J OBSTET GYNECOL, V170, P595, DOI 10.1016/S0002-9378(94)70235-7; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; KITHIER K, 1974, CLIN CHIM ACTA, V52, P293, DOI 10.1016/0009-8981(74)90113-2; LIVERA LN, 1989, BRIT MED J, V298, P1421, DOI 10.1136/bmj.298.6685.1421; NICOLAIDES K H, 1992, Fetal Diagnosis and Therapy, V7, P1; NICOLINI U, 1992, BRIT J OBSTET GYNAEC, V99, P46, DOI 10.1111/j.1471-0528.1992.tb14391.x; NOLTE S, 1991, PEDIATR NEPHROL, V5, P573, DOI 10.1007/BF00856641; ONASSON LE, 1974, ACTA OBSTET GYNAECOL, V53, P48; WIBELL L, 1973, NEPHRON, V10, P320, DOI 10.1159/000180203	10	54	56	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1277	1278		10.1016/S0140-6736(95)90928-1	http://dx.doi.org/10.1016/S0140-6736(95)90928-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746060				2022-12-28	WOS:A1995QY93300012
J	BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH				BRITZCUNNINGHAM, SH; SHAH, MM; ZUPPAN, CW; FLETCHER, WH			MUTATIONS OF THE CONNEXIN43 GAP-JUNCTION GENE IN PATIENTS WITH HEART MALFORMATIONS AND DEFECTS OF LATERALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTATION MOUSE EMBRYO; CARDIAC DEFECTS; COMMUNICATION; PROTEIN; EXPRESSION; PHOSPHORYLATION; LOCALIZATION; CHANNEL; FAMILY; CELLS	Background. Gap junctions are thought to have a crucial role in the synchronized contraction of the heart and in embryonic development. Connexin43, the major protein of gap junctions in the heart, is targeted by several protein kinases that regulate myocardial cell-cell coupling. We hypothesized that mutations altering sites critical to this regulation would lead to functional or developmental abnormalities of the heart. Methods. Connexin43 DNA from 25 normal subjects and 30 children with a Variety of congenital heart diseases was amplified by the polymerase chain reaction and sequenced. Mutant DNA was expressed in cell culture and examined for its effect on the regulation of cell-cell communication. Results. The 25 normal subjects and 23 of the 30 children with heart disease had no amino acid substitutions in connexin43. All six children with syndromes that included complex heart malformations had substitutions of one or more phosphorylatable serine or threonine residues. Four of these children had two independent mutations, suggesting an autosomal recessive disorder. Five of these children had substitutions of proline for serine at position 364. A seventh child, with a different heart condition, also had a point mutation in connexin43. Transfected cells expressing the Ser364Pro mutant connexin43 sequence showed abnormalities in the regulation of cell-cell communication, as compared with cells expressing normal connexin43. Conclusions. Mutations in the connexin43 gap-junction gene, which lead to abnormally regulated cell-cell communication, are associated with visceroatrial heterotaxia.	LOMA LINDA UNIV, DEPT PATHOL & HUMAN ANAT, LOMA LINDA, CA 92354 USA; JERRY L PETTIS MEM VET AFFAIRS MED CTR, MOLEC CYTOL LAB, LOMA LINDA, CA USA	Loma Linda University	BRITZCUNNINGHAM, SH (corresponding author), LOMA LINDA UNIV, DEPT PHYSIOL, LOMA LINDA, CA 92354 USA.							ARNOLD GL, 1983, AM J MED GENET, V16, P35, DOI 10.1002/ajmg.1320160107; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; CARMI R, 1992, AM J MED GENET, V44, P246, DOI 10.1002/ajmg.1320440228; CASEY B, 1993, NAT GENET, V5, P403, DOI 10.1038/ng1293-403; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DRISCOLL DA, 1992, AM J HUM GENET, V50, P924; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FISHMAN GI, 1991, GENOMICS, V10, P250, DOI 10.1016/0888-7543(91)90507-B; FORSTHOEFEL KF, 1992, AM J CLIN PATHOL, V98, P98, DOI 10.1093/ajcp/98.1.98; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GODWIN AJ, 1993, MOL CELL BIOCHEM, V128, P293, DOI 10.1007/BF01076779; GOSHIMA K, 1971, EXP CELL RES, V65, P161, DOI 10.1016/S0014-4827(71)80062-9; HOWITT G, 1961, BRIT HEART J, V23, P494; KALIMI GH, 1988, J CELL BIOL, V107, P241, DOI 10.1083/jcb.107.1.241; KALIMI GH, 1989, J CELL BIOL, V109, P3015, DOI 10.1083/jcb.109.6.3015; KATZ AM, 1992, PHYSL HEART, P521; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOJIMA H, 1969, LANCET, V2, P701; LAIRD DW, 1990, J CELL SCI, V97, P109; LO CW, 1979, CELL, V18, P411, DOI 10.1016/0092-8674(79)90060-6; LO CW, 1979, CELL, V18, P399, DOI 10.1016/0092-8674(79)90059-X; Lynberg M C, 1990, MMWR CDC Surveill Summ, V39, P1; MCCHANE RH, 1989, SOUTHERN MED J, V82, P1312, DOI 10.1097/00007611-198910000-00032; MCKUSICK VA, 1995, MENDELIAN INHERITANC, V2, P1236; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; NOONAN JA, 1978, AM J DIS CHILD, V132, P17, DOI 10.1001/archpedi.1978.02120260019001; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; Sambrook J, 1989, MOL CLONING LABORATO; STAGG RB, 1990, ENDOCR REV, V11, P302, DOI 10.1210/edrv-11-2-302; SULLIVAN R, 1993, GENE, V130, P191, DOI 10.1016/0378-1119(93)90419-4; VANPATTEN SM, 1986, J BIOL CHEM, V261, P5514; VEENSTRA RD, 1986, SCIENCE, V233, P972, DOI 10.1126/science.2426781; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WHITE RL, 1985, AM J PHYSIOL, V249, pC447, DOI 10.1152/ajpcell.1985.249.5.C447; WILLECKE K, 1990, EUR J CELL BIOL, V53, P275; ZELLERS TM, 1990, AM J CARDIOL, V65, P523, DOI 10.1016/0002-9149(90)90825-L; 1989, MMWR-MORBID MORTAL W, V38, P633	45	330	349	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1323	1329		10.1056/NEJM199505183322002	http://dx.doi.org/10.1056/NEJM199505183322002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715640	Bronze			2022-12-28	WOS:A1995QX85700002
J	TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ				TIAN, GL; VAINBERG, IE; TAP, WD; LEWIS, SA; COWAN, NJ			SPECIFICITY IN CHAPERONIN-MEDIATED PROTEIN-FOLDING	NATURE			English	Article							CYTOPLASMIC CHAPERONIN; COMPLEX; TUBULIN; HOMOLOG	CHAPERONINS are ubiquitous multisubunit toroidal complexes that aid protein folding in an ATP-dependent manner(1-6). Current models of folding by the bacterial chaperonin GroEL depict its role as unfolding and releasing molecules that have misfolded, so that they can return to a potentially productive folding pathway in solution(7,8). Accordingly, a given target polypeptide might require several cycles of binding and ATP-driven release from different chaperonin complexes before reaching the native state. Surprisingly, cycling of a target protein does not guarantee its folding, and we report here that unfolded beta-actin or alpha-tubulin both form tight complexes when presented to either GroEL or its mitochondrial homologue, and both undergo cycles of release and rebinding upon incubation with ATP, but no native protein is produced. We conclude that different chaperonins produce distinctive spectra of folding intermediates.	NYU,MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016	New York University								BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; GAO Y, 1994, J CELL BIOL, V125, P989, DOI 10.1083/jcb.125.5.989; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HORWICH AL, 1994, CELL, V74, P909; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VINH DBN, 1994, P NATL ACAD SCI USA, V91, P9116, DOI 10.1073/pnas.91.19.9116; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	19	118	120	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					250	253		10.1038/375250a0	http://dx.doi.org/10.1038/375250a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746329				2022-12-28	WOS:A1995QY88100068
J	ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA				ELLERBECK, EF; JENCKS, SF; RADFORD, MJ; KRESOWIK, TF; CRAIG, AS; GOLD, JA; KRUMHOLZ, HM; VOGEL, RA			QUALITY OF CARE FOR MEDICARE PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A 4-STATE PILOT-STUDY FROM THE COOPERATIVE CARDIOVASCULAR PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUIDELINES; SURVIVAL; SMOKING	Objective.-To develop and test indicators of the quality of care for patients with acute myocardial infarction (AMI). Design.-Retrospective medical record review. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, and Wisconsin. Patients.-All hospitalizations for Medicare patients discharged with a principal diagnosis of AMI between June 1, 1992, and February 28, 1993, were identified (N=16 869). Main Outcome Measure.-Percentage of patients receiving appropriate interventions as defined by 11 quality-of-care indicators derived from clinical practice guidelines that were modified and updated in consultation with a national group of physicians and other health care professionals. Results.-We abstracted data from 16 124 (96%) of the hospitalizations, representing 14 108 primary hospitalizations and 2016 hospitalizations resulting from transfers. Potential exclusions to the use of standard treatments in AMI care were common with 90% and 70% of patients having potential exclusions for thrombolytics and beta-blockers, respectively. In cohorts of ''ideal candidates'' for specific interventions, 83% received aspirin, 69% received thrombolytics, and 70% received heparin during the initial hospitalization; 77% received aspirin and 45% received beta-blockers at discharge. Conclusions.-These data demonstrate that many Medicare patients may not be ideal candidates for standard AMI therapies, but these treatments are underused, even in the absence of discernible contraindications. Hospitals and physicians who apply these quality indicators to their practices are likely to find opportunities for improvement.	HLTH CARE FINANCING ADM,BUR HLTH STAND & QUAL,BALTIMORE,MD; CONNECTICUT PEER REVIEW ORG,MIDDLETOWN,CT; UNIV CONNECTICUT,DEPT CARDIOL,FARMINGTON,CT; IOWA FDN MED CARE,DES MOINES,IA; UNIV IOWA,DEPT SURG,IOWA CITY,IA 52242; ALABAMA QUAL ASSURANCE FDN,BIRMINGHAM,AL; UNIV ALABAMA,DEPT INTERNAL MED,BIRMINGHAM,AL; WISCONSIN PEER REVIEW ORG,MADISON,WI; MED COLL WISCONSIN,DEPT PREVENT MED,MILWAUKEE,WI 53226; UNIV WISCONSIN,MADISON,WI; YALE UNIV,SCH MED,CARDIOVASC SECT,NEW HAVEN,CT; UNIV MARYLAND,DEPT CARDIOL,BALTIMORE,MD	University of Connecticut; University of Iowa; University of Alabama System; University of Alabama Birmingham; Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; Yale University; University System of Maryland; University of Maryland Baltimore			Ellerbeck, Edward/I-8438-2014; , Harlan/AAI-2875-2020	Ellerbeck, Edward/0000-0002-7774-2729; Kresowik, Timothy/0000-0003-4163-1573; Radford, Martha/0000-0001-7503-9557				[Anonymous], 1988, INT CLASSIFICATION D; AUDET AM, 1994, ANN INTERN MED, V120, P423, DOI 10.7326/0003-4819-120-5-199403010-00011; CHADDA K, 1986, CIRCULATION, V73, P503, DOI 10.1161/01.CIR.73.3.503; FISHER EB, 1990, AM REV RESPIR DIS, V142, P702, DOI 10.1164/ajrccm/142.3.702; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KJEKSHUS J, 1990, EUR HEART J, V11, P43, DOI 10.1093/oxfordjournals.eurheartj.a059591; KRUMHOLZ HM, 1994, J AM GERIATR SOC, V42, P127, DOI 10.1111/j.1532-5415.1994.tb04938.x; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; LAMBERTHUBER DA, 1994, CLIN PERFORMANCE QUA, V2, P219; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MCGUIRE LB, 1990, ANN INTERN MED, V113, P705, DOI 10.7326/0003-4819-113-9-705; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RUBIN HR, 1992, JAMA-J AM MED ASSOC, V267, P2349, DOI 10.1001/jama.267.17.2349; SULLIVAN LW, 1992, 1992 HLTH CAR FIN AD; TIEFENBRUNN AJ, 1992, CIRCULATION, V85, P2311, DOI 10.1161/01.CIR.85.6.2311; VLIETSTRA RE, 1986, JAMA-J AM MED ASSOC, V255, P1023, DOI 10.1001/jama.255.8.1023; 1992, JAMA-J AM MED ASSOC, V268, P2199; 1994, EMERGENCY DEP RAPID; 1985, AM J CARDIOL, V56, pG1; 1990, JAMA-J AM MED ASSOC, V263, P2753; 1990, STATA RELEASE 2 REFE	26	343	344	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1509	1514		10.1001/jama.273.19.1509	http://dx.doi.org/10.1001/jama.273.19.1509			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739077				2022-12-28	WOS:A1995QX41800033
J	KASS, DM; YUNG, YL				KASS, DM; YUNG, YL			LOSS OF ATMOSPHERE FROM MARS DUE TO SOLAR WIND-INDUCED SPUTTERING	SCIENCE			English	Article							OXYGEN ION PRECIPITATION; SPATIAL DISTRIBUTIONS; ENERGY DEPOSITION; EVOLUTION; CLIMATE; VENUS; CONSEQUENCES	Because Mars does not have a strong intrinsic magnetic field, the atmosphere is eroded by interactions with the solar wind. Early solar-system conditions enhanced the sputtering loss. It is calculated that similar to 3 bars of carbon dioxide (CO2) have been sputtered over the last 3.5 billion years. This significant increase over the previous estimate by Luhmann et al. of similar to 0.14 bar of CO2 is the result of the development of a more complete model. The model also predicts slightly greater loss of water-similar to 80 meters instead of the similar to 50 meters predicted by Luhmann et al. Because estimates of CO2 on early Mars range from 0.5 to 5 bars, the 0.14-bar estimate is insignificant but the similar to 3-bar estimate will have a large effect on our understanding of the planet's evolution.			KASS, DM (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.		Yung, Yuk/AAM-4850-2021	Yung, Yuk/0000-0002-4263-2562				FANALE FP, 1982, ICARUS, V50, P381, DOI 10.1016/0019-1035(82)90131-2; HODGES RR, 1993, J GEOPHYS RES-PLANET, V98, P10833, DOI 10.1029/93JE00998; HUNTEN DM, 1993, SCIENCE, V259, P915, DOI 10.1126/science.259.5097.915; ISHIMOTO M, 1986, J GEOPHYS RES, V91, P5793, DOI 10.1029/JA091iA05p05793; JAKOSKY BM, 1991, ICARUS, V94, P14, DOI 10.1016/0019-1035(91)90138-J; JOHNSON RE, 1992, J GEOPHYS RES-SPACE, V97, P13911, DOI 10.1029/92JA01142; KASTING JF, 1991, ICARUS, V94, P1, DOI 10.1016/0019-1035(91)90137-I; LUHMANN JG, 1992, GEOPHYS RES LETT, V19, P2151, DOI 10.1029/92GL02485; LUHMANN JG, 1991, J GEOPHYS RES-SPACE, V96, P5457, DOI 10.1029/90JA01753; McElroy M. B., 1977, Journal of Geophysical Research, V82, P4379, DOI 10.1029/JS082i028p04379; MCKAY CP, 1991, ICARUS, V90, P214, DOI 10.1016/0019-1035(91)90102-Y; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; SMITH PH, 1978, SPACE SCI REV, V22, P301, DOI 10.1007/BF00239804; STEBBINGS RF, 1964, J GEOPHYS RES, V69, P2349, DOI 10.1029/JZ069i011p02349; ZAHNLE KJ, 1982, REV GEOPHYS, V20, P280, DOI 10.1029/RG020i002p00280; [No title captured]	16	84	85	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					697	699		10.1126/science.7732377	http://dx.doi.org/10.1126/science.7732377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732377				2022-12-28	WOS:A1995QW60300041
J	ABRAMS, P				ABRAMS, P			MANAGING LOWER URINARY-TRACT SYMPTOMS IN OLDER MEN	BRITISH MEDICAL JOURNAL			English	Article											ABRAMS, P (corresponding author), SOUTHMEAD GEN HOSP, BRISTOL UROL INST, BRISTOL BS10 5NB, AVON, ENGLAND.							ABRAMS P, 1994, BRIT MED J, V308, P929, DOI 10.1136/bmj.308.6934.929; ABRAMS P, 1993, 2ND INTERNATIONAL CONSULTATION ON BENIGN PROSTATIC HYPERPLASIA (BPH): PROCEEDINGS, P153; ABRAMS PH, 1978, UROL INT, V33, P171, DOI 10.1159/000280194; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; CHAPPLE CR, 1994, NEUROL URODYN, V13, P486; JONLER M, 1994, PROG CLIN BIOL RES, V386, P291; KADOW C, 1988, BRIT J UROL, V61, P432, DOI 10.1111/j.1464-410X.1988.tb06591.x; KIRBY RS, 1994, BRIT MED J, V309, P716, DOI 10.1136/bmj.309.6956.716	8	37	37	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1113	1117		10.1136/bmj.310.6987.1113	http://dx.doi.org/10.1136/bmj.310.6987.1113			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742679	Green Published			2022-12-28	WOS:A1995QW61800019
J	YELLEN, JE; BROOKS, AS; CORNELISSEN, E; MEHLMAN, MJ; STEWART, K				YELLEN, JE; BROOKS, AS; CORNELISSEN, E; MEHLMAN, MJ; STEWART, K			A MIDDLE STONE-AGE WORKED BONE INDUSTRY FROM KATANDA, UPPER SEMLIKI VALLEY, ZAIRE	SCIENCE			English	Article							MODERN HUMANS; PROTEIN DIAGENESIS; CAVE; EVOLUTION; ISRAEL; ORIGIN; AFRICA; SITE	Three archaeological sites at Katanda on the Upper Semliki River in the Western Rift Valley of Zaire have provided evidence for a well-developed bone industry in a Middle Stone Age context. Artifacts include both barbed and unbarbed points as well as a daggerlike object. Dating by both direct and indirect means indicate an age of similar to 90,000 years or older. Together with abundant fish (primarily catfish) remains, the bone technology indicates that a complex subsistence specialization had developed in Africa by this time. The level of behavioral competence required is consistent with that of upper Paleolithic Home sapiens sapiens. These data support an African origin of behaviorally as well as biologically modern humans.	GEORGE WASHINGTON UNIV,DEPT ANTHROPOL,WASHINGTON,DC 20052; MUSEE ROYAL AFRIQUE,PREHIST SECT,B-3080 TERVUREN,BELGIUM; UNIV CALIF SANTA CRUZ LIB,SANTA CRUZ,CA 95064; CANADIAN MUSEUM NAT,DIV RES,OTTAWA,ON K1P 6P4,CANADA	George Washington University; University of California System; University of California Santa Cruz	YELLEN, JE (corresponding author), NATL SCI FDN,ARCHAEOL PROGRAM,4201 WILSON BLVD,ARLINGTON,VA 22230, USA.		Klein, Richard G/B-5910-2009					AMBROSE SH, 1992, 11TH BIENN M SOC AFR; ANIKOVICH M, 1992, J WORLD PREHIST, V6, P205, DOI 10.1007/BF00975550; [Anonymous], COMMUNICATION, P17; BEAUMONT PB, 1978, S AFR J SCI, V74, P409; BRAIN CK, 1988, S AFR J SCI, V84, P828; Brooks A. S., 1990, WORLD 18000 BP, V2, P121; Brooks A. S., 1987, AFRICAN ARCHAEOL REV, V5, P65, DOI DOI 10.1007/BF01117083; BROOKS AS, 1995, SCIENCE, V268, P548, DOI 10.1126/science.7725099; BROOKS AS, 1990, NATURE, V344, P288, DOI 10.1038/344288a0; BROOKS AS, 1990, SCIENCE, V248, P60, DOI 10.1126/science.248.4951.60; BROOKS AS, IN PRESS FOUILLES MO; BROOKS AS, 1988, ENCY HUMAN EVOLUTION, P346; Butzer K.W., 1969, QUATERNARIA, V11, P15; Clark J.D., 1982, CAMBRIDGE HIST AFRIC, V1, P248; CLARK JD, 1988, J WORLD PREHIST, V2, P235, DOI 10.1007/BF00975618; DEACON HJ, 1989, HUMAN REVOLUTION, P547; DEHEINZELIN J, 1957, FOUILLES ISHANGO EXP; FRIDRICH J, 1976, 9TH P INT UN PRE PRO, P8; GOULD RA, 1987, J ANTHROPOL ARCHAEOL, V6, P77, DOI 10.1016/0278-4165(87)90017-1; Greenwood PH, 1968, PREHISTORY NUBIA, P100; GRUN R, 1990, CURR ANTHROPOL, V31, P427, DOI 10.1086/203866; GRUN R, 1991, ARCHAEOMETRY, V33, P153, DOI 10.1111/j.1475-4754.1991.tb00696.x; Hare P. E., 1993, CARNEGIE I WASHINGTO, V92, P80; HELGREN D, COMMUNICATION; JONES R, 1989, HUMAN REVOLUTION, P743; KLEIN RG, 1989, HUMAN CAREER; KNECHT H, 1994, SCI AM, V271, P82, DOI 10.1038/scientificamerican0794-82; Knecht H., 1993, ARCHEOLOGICAL PAPERS, V4, P33; Kokis J.E., 1993, CARNEGIE I WASHINGTO, V92, P95; KRUPSHA C, 1993, THESIS G WASHINGTON; LEVEQUE F, 1993, MONOGR WORLD PREHIST, V16; Mania D., 1986, BILZINGSLEBEN 3, V39, P9; Marks A.E., 1968, PREHISTORY NUBIA, V1, P315; MCBREARTY S, 1990, MAN, V25, P129, DOI 10.2307/2804113; MEHLMAN MJ, 1987, J ARCHAEOL SCI, V14, P133, DOI 10.1016/0305-4403(87)90003-3; MEHLMAN MJ, 1979, WORLD ARCHAEOL, V11, P80, DOI 10.1080/00438243.1979.9979751; MEHLMAN MJ, 1992, 11TH BIENN M SOC AFR; MILLER GH, 1992, PHILOS T ROY SOC B, V337, P149, DOI 10.1098/rstb.1992.0092; MUGANGU TE, COMMUNICATION; ROBBINS L, 1992, 11TH BIENN M SOC AFR; ROBERTS RG, 1990, NATURE, V345, P153, DOI 10.1038/345153a0; SCHWARCZ HP, 1988, J HUM EVOL, V17, P733, DOI 10.1016/0047-2484(88)90063-2; Shiner J.L., 1968, PREHISTORY NUBIA EDI, P630; Singer R., 1982, MIDDLE STONE AGE KLA; SMITH FH, 1994, AM J PHYS ANTHROPOL, V93, P275, DOI 10.1002/ajpa.1330930210; Straus L.G., 1992, ARCHEOLOGICAL PAPERS; TROENIG J, 1993, ACTA ARCHAEOL LUND 8, V21; VALLADAS H, 1988, NATURE, V331, P614, DOI 10.1038/331614a0; VANNOTEN F, 1977, ANTIQUITY, V51, P35; VERNIERS J, 1990, VIRGINIA MUS NAT HIS, V1, P17; Volman T.P., 1984, P169; Yellen J.E., 1977, STUDIES ARCHEOLOGY	52	202	214	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					553	556		10.1126/science.7725100	http://dx.doi.org/10.1126/science.7725100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV407	7725100				2022-12-28	WOS:A1995QV40700033
J	GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E				GUO, LF; DEGENSTEIN, L; DOWLING, J; YU, QC; WOLLMANN, R; PERMAN, B; FUCHS, E			GENE TARGETING OF BPAG1 - ABNORMALITIES IN MECHANICAL STRENGTH AND CELL-MIGRATION IN STRATIFIED EPITHELIA AND NEUROLOGIC DEGENERATION	CELL			English	Article							BULLOUS PEMPHIGOID ANTIGEN; BASEMENT-MEMBRANE ADHESION; CDNA CLONING; HEMIDESMOSOMES; INTEGRIN; ALPHA-6-BETA-4; IDENTIFICATION; EXPRESSION; COMPONENT; PROTEIN	BPAG1 is the major antigenic determinant of autoimmune sera of bullous pemphigoid (BP) patients. It is made by stratified squamous epithelia, where it localizes to the inner surface of specialized integrin-mediated adherens junctions (hemidesmosomes). To explore the function of BPAG1 iind its relation to BP, we targeted the removal of the BPAG1 gene in mice. Hemidesmosomes are otherwise normal, but they lack the inner plate and have no cytoskeleton attached. Though not affecting cell growth or substratum adhesion, this compromises mechanical integrity and influences migration. Unexpectedly, the mice also develop severe dystonia and sensory nerve degeneration typical of dystonia musculorum (dt/dt) mice. We show that in at least one other strain of dt/dt mice, BPAG1 gene is defective.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago	GUO, LF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.		Fuchs, Elaine/G-1565-2016					ANTON-LAMPBRECHT I, 1983, J INVEST DERMATOL S, V81, P149; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; BROWN A, 1994, GENOMICS, V20, P371, DOI 10.1006/geno.1994.1190; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1993, GENOMICS, V15, P180, DOI 10.1006/geno.1993.1027; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DIAZ LA, 1977, J IMMUNOL, V118, P455; Duchen L W, 1976, Adv Neurol, V14, P353; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIUDICE GJ, 1991, J CLIN INVEST, V87, P734, DOI 10.1172/JCI115054; HERTLE MD, 1991, DEVELOPMENT, V112, P193; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; Hogan B, 1994, MANIPULATING MOUSE E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LABIB RS, 1986, J IMMUNOL, V136, P1231; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MESSER A, 1980, NEUROSCIENCE, V5, P543, DOI 10.1016/0306-4522(80)90051-2; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; OWARIBE K, 1990, DIFFERENTIATION, V45, P207, DOI 10.1111/j.1432-0436.1990.tb00475.x; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1994, J INVEST DERMATOL, V103, P651, DOI 10.1111/1523-1747.ep12398405; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STAPPENBECK TS, 1992, J CELL BIOL, V116, P1197, DOI 10.1083/jcb.116.5.1197; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; SUGI T, 1989, J CLIN INVEST, V84, P1050, DOI 10.1172/JCI114266; TANAKA T, 1990, J INVEST DERMATOL, V94, P617, DOI 10.1111/1523-1747.ep12876200; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229	41	390	395	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					233	243		10.1016/0092-8674(95)90333-X	http://dx.doi.org/10.1016/0092-8674(95)90333-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736575	Bronze			2022-12-28	WOS:A1995QV41000012
J	KITCHEN, VS; SKINNER, C; ARIYOSHI, K; LANE, EA; DUNCAN, IB; BURCKHARDT, J; BURGER, HU; BRAGMAN, K; PINCHING, AJ; WEBER, JN				KITCHEN, VS; SKINNER, C; ARIYOSHI, K; LANE, EA; DUNCAN, IB; BURCKHARDT, J; BURGER, HU; BRAGMAN, K; PINCHING, AJ; WEBER, JN			SAFETY AND ACTIVITY OF SAQUINAVIR IN HIV-INFECTION	LANCET			English	Article							INHIBITOR; PROTEASE; MATURATION	We evaluated saquinavir, an orally active, selective inhibitor of HIV proteinase, in a randomised, double-blind, dose-ranging study in 49 zidovudine-naive HIV-positive patients with few or no symptoms and CD4 cell counts of 500 or less. The study was designed to assess the antiviral activity and tolerability of saquinavir. Patients were randomised to receive 25, 75, 200, or 600 mg of saquinavir three times daily for 16 weeks. No serious adverse events ocurred. CD4 cell counts showed a trend indicative of a dose response in favour of the 600 mg dosage, the maximum increase being seen around week 4. In none of the 8 patients with positive plasma viraemia at baseline did cultures become negative after treatment; peripheral blood mononuclear cell cell and plasma-viral load by culture and DNA and RNA PCR all showed a trend towards reduction at higher doses of saquinovir. Saquinavir was well tolerated in this group of previously untreated patients with few or no symptoms; this study shows that an HIV-proteinase inhibitor is active in HIV-infected patients.	ST BARTHOLOMEWS HOSP,SCH MED,DEPT IMMUNOL,LONDON,ENGLAND; ROCHE PROD LTD,WELWYN GARDEN CIT,HERTS,ENGLAND; ROCHE PROD LTD,BASEL,SWITZERLAND; ROCHE PROD LTD,STRASBOURG,FRANCE	University of London; Queen Mary University London; Roche Holding; Roche Holding	KITCHEN, VS (corresponding author), ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED & COMMUN DIS,LONDON W2 1NY,ENGLAND.							ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; HO DD, 1989, NEW ENGL J MED, V321, P1622; KRAMER RA, 1986, SCIENCE, V231, P1580, DOI 10.1126/science.2420008; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; STIEGER M, 1991, J VIROL METHODS, V34, P148	9	173	174	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					952	955		10.1016/S0140-6736(95)90699-1	http://dx.doi.org/10.1016/S0140-6736(95)90699-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715294				2022-12-28	WOS:A1995QT91900009
J	LAUPACIS, A				LAUPACIS, A			RESEARCH BY COLLABORATION	LANCET			English	Editorial Material											LAUPACIS, A (corresponding author), OTTAWA CIVIC HOSP, CLIN EPIDEMIOL UNIT, OTTAWA, ON, CANADA.							LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; POYNARD T, 1991, NEW ENGL J MED, V324, P1532, DOI 10.1056/NEJM199105303242202; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K	4	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 15	1995	345	8955					938	938		10.1016/S0140-6736(95)90695-9	http://dx.doi.org/10.1016/S0140-6736(95)90695-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715290				2022-12-28	WOS:A1995QT91900005
J	STEEL, M				STEEL, M			TELOMERASE THAT SHAPES OUR ENDS	LANCET			English	Editorial Material							HUMAN FIBROBLASTS; CELLS				STEEL, M (corresponding author), UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS,FIFE,SCOTLAND.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENIS H, 1993, TRENDS GENET, V9, P7, DOI 10.1016/0168-9525(93)90065-P; GILSON E, 1993, TRENDS CELL BIOL, V33, P128; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; STEEL CM, 1994, BRIT MED BULL, V50, P536, DOI 10.1093/oxfordjournals.bmb.a072909	11	11	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					935	936		10.1016/S0140-6736(95)90692-4	http://dx.doi.org/10.1016/S0140-6736(95)90692-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715287				2022-12-28	WOS:A1995QT91900002
J	BRANDSTATER, ME				BRANDSTATER, ME			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BRANDSTATER, ME (corresponding author), LOMA LINDA UNIV,LOMA LINDA,CA 92350, USA.							AGRE JC, 1991, ARCH PHYS MED REHAB, V72, P923, DOI 10.1016/0003-9993(91)90013-9; BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P934; BORGSTEIN J, 1993, J HEAD TRAUMA REHAB, V8, P103; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Saal J A, 1990, Orthop Rev, V19, P691; SAAL JS, 1990, SPINE, V15, P674, DOI 10.1097/00007632-199007000-00011; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured]; B HLTH INSURANCE ASS, V287	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1710	1712		10.1001/jama.273.21.1710	http://dx.doi.org/10.1001/jama.273.21.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752431				2022-12-28	WOS:A1995RB09700039
J	AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N				AOKI, K; KAJIURA, S; MATSUMOTO, Y; OGASAWARA, M; OKADA, S; YAGAMI, Y; GLEICHER, N			PRECONCEPTIONAL NATURAL-KILLER-CELL ACTIVITY AS A PREDICTOR OF MISCARRIAGE	LANCET			English	Note							PREGNANCY	There is no immunological test for the prospective identification of alloimmune causes of miscarriage. We investigated whether activity of natural killer cells was predictive of subsequent abortion in women who had had unexplained recurrent abortions and had received no treatment. 24 women with high preconceptional NK activity, defined as mean plus 1 SD of NK activity of 47 controls, had a significantly higher abortion rate in the next pregnancy than 44 women with normal levels of NK activity (71 vs 20%; relative risk 3.5; 95% CI 1.8-6.5), The preconceptional evaluation of NK activity in women with recurrent miscarriages may thus be predictive of the risk of pregnancy loss at the next conception,	CTR HUMAN REPROD,CHICAGO,IL; FDN REPROD MED,CHICAGO,IL		AOKI, K (corresponding author), NAGOYA CITY UNIV,SCH MED,DEPT OBSTET & GYNAECOL,NAGOYA,AICHI 467,JAPAN.							BULMER JN, 1991, HUM REPROD, V6, P791, DOI 10.1093/oxfordjournals.humrep.a137430; CLARK DA, 1994, CELL IMMUNOL, V154, P143, DOI 10.1006/cimm.1994.1064; COULAM CB, 1992, AM J OBSTET GYNECOL, V167, P1844, DOI 10.1016/0002-9378(92)91785-9; HIGUCHI K, 1995, AM J REPROD IMMUNOL, V33, P221, DOI 10.1111/j.1600-0897.1995.tb00888.x; KING A, 1990, CELL IMMUNOL, V129, P435, DOI 10.1016/0008-8749(90)90219-H; MAKIDA R, 1991, LANCET, V338, P579, DOI 10.1016/0140-6736(91)91153-L; TARTOF D, 1984, CLIN EXP IMMUNOL, V57, P502; TODER V, 1984, J CLIN LAB IMMUNOL, V14, P129; 1994, AM J REPROD IMMUNOL, V32, P55	9	262	271	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1340	1342		10.1016/S0140-6736(95)92539-2	http://dx.doi.org/10.1016/S0140-6736(95)92539-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752757				2022-12-28	WOS:A1995RA14800010
J	ROSS, D				ROSS, D			VITAMIN-A PLUS MEASLES VACCINATION - THE DOWNSIDE OF CONVENIENCE	LANCET			English	Editorial Material											ROSS, D (corresponding author), LONDON SCH HYG & TROP MED,MATERNAL & CHILD EPIDEMIOL UNIT,LONDON WC1,ENGLAND.							BEATON GH, 1993, 13 NUTR POL DISC PAP; COHEN N, 1993, 15 IVACG CONS GROUP, P90; Levin HM, 1993, DIS CONTROL PRIORITI, P421; 1987, 1987 EPI GLOB ADV GR; 1993, WORLD SUMMIT CHILDRE, P1; 1987, WEEKLY EPIDEMIOL REC, V62, P13; 1992, 1992 EPI GLOB ADV GR	7	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1317	1318		10.1016/S0140-6736(95)92531-7	http://dx.doi.org/10.1016/S0140-6736(95)92531-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752749				2022-12-28	WOS:A1995RA14800002
J	HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y				HAYASHI, N; ITO, I; YANAGISAWA, A; KATO, Y; NAKAMORI, S; IMAOKA, S; WATANABE, H; OGAWA, M; NAKAMURA, Y			GENETIC DIAGNOSIS OF LYMPH-NODE METASTASIS IN COLORECTAL-CANCER	LANCET			English	Article							SOMATIC MUTATIONS; APC GENE; TUMORS; OCCUR	If a regional lymph node taken during surgery for colorectal cancer is found to be free of tumour on histological examination this is taken to be a good sign. However, conventional staining may not be sensitive enough. Mutant-allele-specific amplification (MASA) is a technique that can detect, at the level of an individual cell, micrometastases to lymph nodes that are histologically diagnosed as negative. To examine the prognostic significance of such genetically detectable tumour cells we screened 120 colorectal cancers from patients who had no histologically detectable lymph-node metastasis at the time of surgery for mutations in K-ras (codons 12, 13, and 61) or p53 (exons 5-8). Somatic mutations were identified by MASA in 71 tumours, We next examined preserved tissues from corresponding regional lymph nodes, using MASA to look for the specific mutation found in the primary. Of 37 patients with genetically positive lymph nodes 27 had had a tumour recurrence within 5 years of surgery; none of the 34 patients who were MASA negative for lymph node metastasis had had a recurrence. Genetic diagnosis of lymph node metastasis may be a useful prognostic factor in colorectal cancer, and it could also serve as a selective marker for intensive postoperative adjuvant chemotherapy.	INST CANC RES,DEPT BIOCHEM,TOKYO,JAPAN; INST CANC RES,DEPT PATHOL,TOKYO,JAPAN; CTR ADULT DIS,DEPT SURG ONCOL,OSAKA 537,JAPAN; NIIGATA UNIV,SCH MED,DEPT PATHOL 1,NIIGATA 95021,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT SURG 2,KUMAMOTO 860,JAPAN; UNIV TOKYO,INST MED SCI,MOLEC MED LAB,MINATO KU,TOKYO 108,JAPAN	Japanese Foundation for Cancer Research; Japanese Foundation for Cancer Research; Niigata University; Kumamoto University; University of Tokyo								BAKER SJ, 1990, CANCER RES, V50, P7717; BOS JL, 1989, CANCER RES, V49, P4682; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V69, P322, DOI 10.1002/1097-0142(19920115)69:2<322::AID-CNCR2820690208>3.0.CO;2-B; COHEN AM, 1991, CANCER, V67, P1859, DOI 10.1002/1097-0142(19910401)67:7<1859::AID-CNCR2820670707>3.0.CO;2-A; HAYASHI N, 1994, CANCER RES, V54, P3853; KRONBORG O, 1993, EUR J CANCER, V29A, P575, DOI 10.1016/S0959-8049(05)80155-8; KUNE GA, 1990, DIS COLON RECTUM, V33, P938, DOI 10.1007/BF02139103; LEVINE AJ, 1991, NATURE, V358, P453; LOSI L, 1992, EUR J CANCER, V28A, P1115, DOI 10.1016/0959-8049(92)90468-H; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; PURDIE CA, 1991, AM J PATHOL, V138, P807; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209	16	272	285	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1257	1259		10.1016/S0140-6736(95)90922-2	http://dx.doi.org/10.1016/S0140-6736(95)90922-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746054				2022-12-28	WOS:A1995QY93300006
J	ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F				ROGGERO, E; ZUCCA, E; PINOTTI, G; PASCARELLA, A; CAPELLA, C; SAVIO, A; PEDRINIS, E; PATERLINI, A; VENCO, A; CAVALLI, F			ERADICATION OF HELICOBACTER-PYLORI INFECTION IN PRIMARY LOW-GRADE GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE	ANNALS OF INTERNAL MEDICINE			English	Note							DISEASE; MALT	Objective: To determine the effect of eradicating Helicobacter pylori infection on the course of low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Design: Prospective cohort study. Setting: University internal medicine clinics, a referral oncology center in southern Switzerland, and a gastroenterology referral center in northern Italy. Patients: 26 patients with localized primary low-grade gastric MALT lymphoma. Intervention: Treatment for H. pylori infection (bismuth or omeprazole or both, amoxicillin, and metronidazole for 14 days). Main Outcome Measures: Endoscopic biopsy specimens of the gastric mucosa were obtained every 3 to 6 months after treatment for H. pylori infection. Results: Helicobacter pylori was completely eradicated in 25 of 26 patients, but 4 patients needed second-line antibiotic treatment to eradicate the microorganism. Disappearance or almost total regression of the lymphomatous tissue was observed in 15 of the 25 evaluable patients (60%; CI, 39% to 79%); however, disappearance or almost total regression was evident in the first biopsy specimen after treatment for H. pylori infection in only 8 of the 15 patients. Conclusions: Our study confirms recent anecdotal reports of regression of gastric MALT lymphoma after eradication of H. pylori and indicates that the growth of these extranodal lymphomas may depend on H. pylori.	OSPED SAN GIOVANNI BELLINZONA, SERV ONCOL, CH-6500 BELLINZONA, SWITZERLAND; OSPED MULTIZONALE, VARESE, ITALY; FBF, OSPED S ORSOLA, BRESCIA, ITALY; IST CANTONALE PATOL, LOCARNO, SWITZERLAND	Regional Hospital of Bellinzona & Valleys, San Giovanni				Zucca, Emanuele/0000-0002-5522-6109				BENAYED F, 1989, CANCER, V63, P1251, DOI 10.1002/1097-0142(19890401)63:7<1251::AID-CNCR2820630704>3.0.CO;2-H; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PINOTTI G, 1992, HAEMATOLOGICA, V77, P405; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; SPATARO V, 1994, ANN ONCOL, V5, P954, DOI 10.1093/oxfordjournals.annonc.a058738; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, 1992, HISTOPATHOLOGY, V20, P29, DOI 10.1111/j.1365-2559.1992.tb00912.x	12	376	386	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					767	769		10.7326/0003-4819-122-10-199505150-00006	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717599				2022-12-28	WOS:A1995QX14700006
J	ALLEN, GJ; MUIR, SR; SANDERS, D				ALLEN, GJ; MUIR, SR; SANDERS, D			RELEASE OF CA2+ FROM INDIVIDUAL PLANT VACUOLES BY BOTH INSP(3) AND CYCLIC ADP-RIBOSE	SCIENCE			English	Article							INOSITOL TRISPHOSPHATE; CYTOPLASMIC CALCIUM; CHANNELS; MICROSOMES; MEMBRANE; PATHWAYS	Calcium mobilization from intracellular pools couples many stimuli to responses in plant cells. Cyclic adenosine 5'-diphosphoribose (cADPR), which interacts with a ryanodine receptor in certain animal cells, was shown to elicit calcium release at the vacuolar membrane of beet storage root. The vacuolar calcium release pathway showed similarities to cADPR-gated calcium release in animal cells, including inhibition by ruthenium red, ryanodine activation, and high affinity for cADPR [Michaelis constant (K-m) = 24 +/- 7 nanomolar]. Analysis by patch-clamping demonstrated that the cADPR-gated pathway in beet is voltage-dependent over the physiological range, does not spontaneously desensitize, and is colocalized with an inositol 1,4,5-trisphosphate (InsP(3))-gated calcium release pathway in individual vacuoles.			ALLEN, GJ (corresponding author), UNIV YORK, DEPT BIOL, PLANT LAB, POB 373, YORK YO1 5YW, N YORKSHIRE, ENGLAND.							ALEXANDRE J, 1990, NATURE, V343, P567, DOI 10.1038/343567a0; ALLEN GJ, 1994, PLANT CELL, V6, P685, DOI 10.1105/tpc.6.5.685; ALLEN GJ, 1994, PLANT J, V6, P687, DOI 10.1046/j.1365-313X.1994.6050687.x; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BERTL A, 1992, SCIENCE, V258, P873, DOI 10.1126/science.1439795; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROSNAN JM, 1990, NATURE, V344, P593, DOI 10.1038/344593b0; BROSNAN JM, 1990, FEBS LETT, V260, P70, DOI 10.1016/0014-5793(90)80068-T; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; GALIONE A, 1994, MOL CELL ENDOCRINOL, V98, P125, DOI 10.1016/0303-7207(94)90130-9; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GEHRING CA, 1990, NATURE, V345, P528, DOI 10.1038/345528a0; GILROY S, 1993, J CELL SCI, V106, P453; HEDRICH R, 1987, NATURE, V329, P833, DOI 10.1038/329833a0; JOHANNES E, 1992, PLANT J, V2, P97, DOI 10.1111/j.1365-313X.1992.00097.x; JOHANNES E, 1992, PHILOS T R SOC B, V338, P105, DOI 10.1098/rstb.1992.0134; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; SITSAPESAN R, 1994, CIRC RES, V75, P596, DOI 10.1161/01.RES.75.3.596; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WARD JM, 1994, PLANT CELL, V6, P669; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X	32	282	296	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					735	737		10.1126/science.7732384	http://dx.doi.org/10.1126/science.7732384			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732384				2022-12-28	WOS:A1995QW60300053
J	CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA				CARROLL, SB; WEATHERBEE, SD; LANGELAND, JA			HOMEOTIC GENES AND THE REGULATION AND EVOLUTION OF INSECT WING NUMBER	NATURE			English	Article							DROSOPHILA EMBRYOS; ORIGIN; EXPRESSION; PROTEIN; SNAIL; LEG	THE evolution of wings catalysed the radiation of insects which make up some 75 per cent of known animals, Fossil evidence suggests that wings evolved from a segment of the leg(1) and that early pterygotes bore wings on all thoracic and abdominal segments(2). The pterygote body plan subsequently diverged producing orders bearing three, two or just one pair of thoracic wings. We have investigated the role of homeotic genes in pterygote evolution by examining their function in Drosophila wing development and their expression in a primitive apterygote. Wing formation is not promoted by any homeotic gene, but is repressed in different segments by different homeotic genes, We suggest here that wings first arose without any homeotic gene involvement in an ancestor with a homeotic 'groundplan' similar to modern winged insects and that wing formation subsequently fell under the negative control of individual homeotic genes at different stages of pterygote evolution.	UNIV WISCONSIN,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	CARROLL, SB (corresponding author), HOWARD HUGHES MED INST,1525 LINDEN DR,MADISON,WI 53706, USA.			Weatherbee, Scott/0000-0002-0915-1329				AKAM M, 1988, DEVELOPMENT, V104, P123; ALBERGA A, 1991, DEVELOPMENT, V111, P983; ANDREW DJ, 1994, EMBO J, V13, P1132, DOI 10.1002/j.1460-2075.1994.tb06362.x; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; BATE M, 1991, DEVELOPMENT, V112, P755; BRAND AH, 1993, DEVELOPMENT, V119, P401; Brower, 1991, DROSOPHILA INFORMATI, V70, P52; CARROLL SB, 1986, CELL, V47, P113, DOI 10.1016/0092-8674(86)90372-7; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; HINZ U, 1994, CELL, V76, P77, DOI 10.1016/0092-8674(94)90174-0; KEISH R, 1994, DEV GENET, V15, P19; Kukalova-Peck J., 1991, INSECTS AUSTR, VI, P141; KUKALOVAPECK J, 1978, J MORPHOL, V156, P53, DOI 10.1002/jmor.1051560104; KUKALOVAPECK J, 1983, CAN J ZOOL, V61, P1618, DOI 10.1139/z83-217; LEVINE M, 1983, EMBO J, V2, P2037, DOI 10.1002/j.1460-2075.1983.tb01697.x; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MAHAFFEY JW, 1987, GENETICS, V117, P51; MANN RS, 1994, DEVELOPMENT, V121, P3205; MAUHIN V, 1993, NUCLEIC ACIDS RES, V21, P3951, DOI 10.1093/nar/21.17.3951; Raff R.A., 1983, EMBRYOS GENES EVOLUT; RILEY PD, 1987, GENE DEV, V1, P716, DOI 10.1101/gad.1.7.716; SIMPSON P, 1983, GENETICS, V105, P615; Snodgrass RE, 1935, PRINCIPLES INSECT MO; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; VACHON G, 1992, CELL, V71, P437, DOI 10.1016/0092-8674(92)90513-C; WHITE RAH, 1985, EMBO J, V4, P2035, DOI 10.1002/j.1460-2075.1985.tb03889.x; WILLIAMS JA, 1991, GENE DEV, V5, P2481, DOI 10.1101/gad.5.12b.2481; WILLIAMS JA, 1994, NATURE, V368, P298; WOOTTON R J, 1972, Palaeontology (Oxford), V15, P662	30	158	161	3	69	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					58	61		10.1038/375058a0	http://dx.doi.org/10.1038/375058a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723843				2022-12-28	WOS:A1995QW60400054
J	TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT				TINETTI, ME; INOUYE, SK; GILL, TM; DOUCETTE, JT			SHARED RISK-FACTORS FOR FALLS, INCONTINENCE, AND FUNCTIONAL DEPENDENCE - UNIFYING THE APPROACH TO GERIATRIC SYNDROMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PERSONS; URINARY-INCONTINENCE; COMMUNITY; PREDICTORS; PEOPLE	Objective.-To determine whether a set of factors representing impairments in multiple areas could be identified that predisposes to falling, incontinence, and functional dependence. Design.-Population-based cohort with a 1-year follow-up. Setting.-General community. Participants.-A total of 927 New Haven, Conn, residents, aged 72 years and older who completed the baseline and 1-year interviews. Main Outcome Measures.-At least one episode of urinary incontinence per week, at least two falls during the follow-up year, and dependence on human help for one or more basic activities of daily living. Results.-At 1 year, urinary incontinence was reported by 16%, at least two falls by 10%, and functional dependence by 20% of participants. The four independent predisposing factors for the outcomes of incontinence, falling, and functional dependence included slow timed chair stands (lower extremity impairment), decreased arm strength (upper extremity impairment), decreased vision and hearing (sensory impairment), and either a high anxiety or depression score (affective impairment). There was a significant increase in each of incontinence, falling, and functional dependence as the number of these predisposing factors increased. For example, the proportion of participants experiencing functional dependence doubled (7% to 14% to 28% to 60%) (chi(2)=119.8; P<.001) as the number of predisposing factors increased from zero to one to two to at least three. Conclusions.-Our findings suggest that predisposition to geriatric syndromes and functional dependence may result when impairments in multiple domains compromise compensatory ability. It may be possible to restore compensatory ability and prevent or delay the onset of several geriatric syndromes and, perhaps, functional dependence by modifying a shared set of predisposing factors. Perhaps it is time to take a more unified approach to the geriatric syndromes and functional dependence.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA	Yale University	TINETTI, ME (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, 333 CEDAR ST, POB 208025, NEW HAVEN, CT 06520 USA.		Inouye, Sharon/R-7216-2019; Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NIA NIH HHS [P60AG10469, AG07449] Funding Source: Medline; PHS HHS [K08AB00524] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469, R01AG007449] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALEXANDER NB, 1994, J AM GERIATR SOC, V42, P93, DOI 10.1111/j.1532-5415.1994.tb06081.x; [Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Cahalan D., 1969, AM DRINKING PRACTICE; CORNONIHUNTLEY J, 1986, DHHS NIH862443 NAT I; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1992, JAMA-J AM MED ASSOC, V267, P827; HERZOG AR, 1990, J AM GERIATR SOC, V38, P273, DOI 10.1111/j.1532-5415.1990.tb03504.x; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; Houston K A, 1993, Clin Geriatr Med, V9, P157; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; LIPSITZ LA, 1992, JAMA-J AM MED ASSOC, V267, P1806, DOI 10.1001/jama.267.13.1806; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MARTIN GR, 1993, ANNU REV MED, V44, P419, DOI 10.1146/annurev.me.44.020193.002223; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; NUTT JG, 1993, NEUROLOGY, V43, P268, DOI 10.1212/WNL.43.2.268; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RESNICK NM, 1994, J AM GERIATR SOC, V42, P202, DOI 10.1111/j.1532-5415.1994.tb04953.x; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1992, HOSP PRACT      1015, P552; Reuben D. B., 1991, GERIATRICS REV SYLLA, P117; RISCH HA, 1988, AM J EPIDEMIOL, V128, P420, DOI 10.1093/oxfordjournals.aje.a114982; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; SIU AL, 1993, J AM GERIATR SOC, V41, P78, DOI 10.1111/j.1532-5415.1993.tb05952.x; SMITH LA, 1990, J AM GERIATR SOC, V38, P993, DOI 10.1111/j.1532-5415.1990.tb04422.x; Spielberger C., 1983, STAI MANUAL; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; TINETTI ME, IN PRESS J AM GERIAT; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212	33	599	616	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1348	1353		10.1001/jama.273.17.1348	http://dx.doi.org/10.1001/jama.273.17.1348			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715059				2022-12-28	WOS:A1995QV30700019
J	KHUROO, MS; KAMILI, S; JAMEEL, S				KHUROO, MS; KAMILI, S; JAMEEL, S			VERTICAL TRANSMISSION OF HEPATITIS-E VIRUS	LANCET			English	Note							NON-B HEPATITIS; NON-A	Little is known about vertical transmission of hepatitis E virus from infected mothers to their infants. We studied eight babies born to mothers infected with hepatitis fin third trimester. One baby was icteric at birth with elevated transaminases and four babies had anicteric hepatitis. Two babies were born with hypothermia and hypoglycaemia and died within 24 h; one had massive hepatic necrosis. Hepatitis E virus RNA was detected by PCR in cord or birth blood samples of five infants. Six infants had evidence of hepatitis E infection. We conclude that hepatitis E virus is commonly transmitted from infected mothers to their babies with significant perinatal morbidity and mortality.	INT CTR GENET ENGN & BIOTECHNOL,NEW DELHI,INDIA	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	KHUROO, MS (corresponding author), SHERIKASHMIR INST MED SCI,DEPT GASTROENTEROL,POST BOX 27,SRINAGAR 190001,JAMMU & KASHMIR,INDIA.		Khuroo, Mohammad Sultan/N-3571-2014	Khuroo, Mohammad Sultan/0000-0003-2823-8814				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; JAMEEL S, 1992, J MED VIROL, V37, P263, DOI 10.1002/jmv.1890370405; KHUROO MS, 1981, AM J MED, V70, P252, DOI 10.1016/0002-9343(81)90758-0; KHUROO MS, 1980, AM J MED, V68, P818, DOI 10.1016/0002-9343(80)90200-4	4	218	228	3	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1025	1026		10.1016/S0140-6736(95)90761-0	http://dx.doi.org/10.1016/S0140-6736(95)90761-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723501				2022-12-28	WOS:A1995QU57300013
J	LABIANCA, R; MARSONI, S; PANCERA, G; TORRI, V; ZANIBONI, A; ERLICHMAN, C; PATER, J; SHEPHERD, L; ZEE, B; SEITZ, JF; MILAN, C; PIGNON, JP; AITINI, E; APOLONE, G; AUZZANI, A; BANDUCCI, S; BARNI, S; BERETTA, GD; BIFFI, O; BUCCI, F; CARDI, G; CIFATTE, D; COLUCCI, G; COMANDONE, A; COMELLA, G; CONFALONIERI, C; CONFU, A; COSTANZO, M; CRESPI, C; DAMIANI, E; DEGIORGI, D; DONGIOVANNI, V; FABRIS, G; FABRIZIO, G; FACENDOLA, G; FANTONI, PA; FERRAGNI, A; FIORI, B; FLORIANELLO, F; FRONTINI, L; GALLI, E; GARATTINI, P; GHERARDI, G; GIOVANELLI, A; GUILIANI, F; GOSSO, P; JANNIELLO, GP; KILDANI, B; LEO, S; LIBERATI, A; MAFFIONE, G; MAIELLO, E; MAIORINO, L; MANENTE, P; MARTIGNONI, GC; MARZOLA, M; MASTRODONATO, M; MERIGGI, F; MOLINARI, B; MOLINARI, GF; MONFERRONI, N; NASCIMBEN, O; NATALE, C; NEGRETTI, S; PALAZZO, S; PANVINI, D; PARISI, V; PEDICINI, T; PERADOTTO, F; PESSA, S; PIATTO, E; PIZZI, G; PROSPERI, A; PRUSCIANO, F; RABBI, C; RAINA, A; RUGGIERO, A; SAVA, C; SCANZI, F; CARRARO, PS; SMERIERI, F; STIVALA, B; TAIANA, A; TARDIO, B; TESTORE, F; TINAZZI, A; TURCATO, G; ZONATO, S; AYOUB, J; BELANGER, K; BIRON, G; BODURTHA, AJ; BOOS, G; BURNELL, M; CANO, P; CHARPENTIER, D; CHOW, WSW; CHRITCHLEY, J; CRIPPS, C; DANG, SP; DAVIS, ML; DAVIDSON, M; DINGLE, B; DRYER, D; FERLAND, E; FIELDS, A; FINE, S; JOLIVET, J; KAISER, L; KERR, I; KOCHA, WI; KOTWALL, C; KRIEGER, H; LEPINEMARTIN, M; LITTLE, C; LOFTERS, WS; MAHEU, M; MOORE, M; PRESSNAIL, B; RAGAZ, J; RAUNER, H; REZNICK, R; ROSS, T; ROTSTEIN, L; RUDINSKAS, L; SCHACTER, B; SHAH, A; SKILLINGS, J; STERN, H; TWEEDDALE, M; VANDENBERG, T; WALDE, D; WATT, HJ; WONG, KWA; YOSHIDA, S; BALDIT, C; BARONI, JL; BAZIN, JP; BEDENNE, L; BLANCHI, A; BOGNEL, JC; BOSSET, JF; BOUCHE, O; BRANDONE, JM; BRICOT, R; BURTIN, P; CADOR, L; CHARBIT, M; CHARLIER, A; COUROUBLE, Y; COUZIGOU, P; CUILLERET, J; DELPERO, JR; DUCREUX, M; DUMAS, F; ECHINARD, E; ETIENNE, PL; FRIGUET, JL; GIGNOUX, M; GIOVANNINI, M; HERR, JP; LAFON, J; LETREUT, P; LATRIVE, JP; LAUVAUX, C; LOUVET, C; MACKIEWICZ, R; MAUREL, C; MESSERSCHMITT, C; MORAND, L; MOREAU, J; MORIN, T; NORDLINGER, B; NOTERDAEME, PM; OLLIER, JC; PICAUD, R; PEINKOWSKI, P; PLACHOT, JP; PORTET, R; DUBATY, HR; ROUGIER, P; ROZENTAL, G; SASTRE, B; VOTTELAMBERT, A; WATRIN, B; ZEITOUN, P				LABIANCA, R; MARSONI, S; PANCERA, G; TORRI, V; ZANIBONI, A; ERLICHMAN, C; PATER, J; SHEPHERD, L; ZEE, B; SEITZ, JF; MILAN, C; PIGNON, JP; AITINI, E; APOLONE, G; AUZZANI, A; BANDUCCI, S; BARNI, S; BERETTA, GD; BIFFI, O; BUCCI, F; CARDI, G; CIFATTE, D; COLUCCI, G; COMANDONE, A; COMELLA, G; CONFALONIERI, C; CONFU, A; COSTANZO, M; CRESPI, C; DAMIANI, E; DEGIORGI, D; DONGIOVANNI, V; FABRIS, G; FABRIZIO, G; FACENDOLA, G; FANTONI, PA; FERRAGNI, A; FIORI, B; FLORIANELLO, F; FRONTINI, L; GALLI, E; GARATTINI, P; GHERARDI, G; GIOVANELLI, A; GUILIANI, F; GOSSO, P; JANNIELLO, GP; KILDANI, B; LEO, S; LIBERATI, A; MAFFIONE, G; MAIELLO, E; MAIORINO, L; MANENTE, P; MARTIGNONI, GC; MARZOLA, M; MASTRODONATO, M; MERIGGI, F; MOLINARI, B; MOLINARI, GF; MONFERRONI, N; NASCIMBEN, O; NATALE, C; NEGRETTI, S; PALAZZO, S; PANVINI, D; PARISI, V; PEDICINI, T; PERADOTTO, F; PESSA, S; PIATTO, E; PIZZI, G; PROSPERI, A; PRUSCIANO, F; RABBI, C; RAINA, A; RUGGIERO, A; SAVA, C; SCANZI, F; CARRARO, PS; SMERIERI, F; STIVALA, B; TAIANA, A; TARDIO, B; TESTORE, F; TINAZZI, A; TURCATO, G; ZONATO, S; AYOUB, J; BELANGER, K; BIRON, G; BODURTHA, AJ; BOOS, G; BURNELL, M; CANO, P; CHARPENTIER, D; CHOW, WSW; CHRITCHLEY, J; CRIPPS, C; DANG, SP; DAVIS, ML; DAVIDSON, M; DINGLE, B; DRYER, D; FERLAND, E; FIELDS, A; FINE, S; JOLIVET, J; KAISER, L; KERR, I; KOCHA, WI; KOTWALL, C; KRIEGER, H; LEPINEMARTIN, M; LITTLE, C; LOFTERS, WS; MAHEU, M; MOORE, M; PRESSNAIL, B; RAGAZ, J; RAUNER, H; REZNICK, R; ROSS, T; ROTSTEIN, L; RUDINSKAS, L; SCHACTER, B; SHAH, A; SKILLINGS, J; STERN, H; TWEEDDALE, M; VANDENBERG, T; WALDE, D; WATT, HJ; WONG, KWA; YOSHIDA, S; BALDIT, C; BARONI, JL; BAZIN, JP; BEDENNE, L; BLANCHI, A; BOGNEL, JC; BOSSET, JF; BOUCHE, O; BRANDONE, JM; BRICOT, R; BURTIN, P; CADOR, L; CHARBIT, M; CHARLIER, A; COUROUBLE, Y; COUZIGOU, P; CUILLERET, J; DELPERO, JR; DUCREUX, M; DUMAS, F; ECHINARD, E; ETIENNE, PL; FRIGUET, JL; GIGNOUX, M; GIOVANNINI, M; HERR, JP; LAFON, J; LETREUT, P; LATRIVE, JP; LAUVAUX, C; LOUVET, C; MACKIEWICZ, R; MAUREL, C; MESSERSCHMITT, C; MORAND, L; MOREAU, J; MORIN, T; NORDLINGER, B; NOTERDAEME, PM; OLLIER, JC; PICAUD, R; PEINKOWSKI, P; PLACHOT, JP; PORTET, R; DUBATY, HR; ROUGIER, P; ROZENTAL, G; SASTRE, B; VOTTELAMBERT, A; WATRIN, B; ZEITOUN, P			EFFICACY OF ADJUVANT FLUOROURACIL AND FOLINIC ACID IN COLON-CANCER	LANCET			English	Article							THERAPY; COMBINATION; LEVAMISOLE; CARCINOMA	The role of fluorouracil and folinic acid and adjuvant therapy for colon cancer is not clear. We undertook independently three randomised trials to find out the efficacy of fluorouracil and high-dose folinic acid after surgery for Dukes' B and C stage colon cancer. The three studies by the Gruppo Interdisciplinare Valutazione Interventi Oncologia (GIVIO), the National Cancer Institute Canada Clinical Trials Group (NCIC-CTG), and the Fondation Francaise de Cancerologie Digestive (FFCD) were pooled for combined analysis. Each trial was multicentre and used the same treatment regimen (fluorouracil 370-400 mg/m(2) plus folinic acid 200 mg/m(2) daily for 5 days, every 28 days for 6 cycles). A pooled analysis of the results was done on the basis of a previously agreed protocol when there were sufficient events to detect at least a 10% reduction in mortality with 80% power. 1526 patients with resected B (56%) and C (44%) carcinoma of the colon were enrolled and 1493 were confirmed as eligible. 736 were assigned to the treatment group and 757 to the control group. Fluorouracii/folinic acid significantly reduced mortality by 22% (95% Cl 3-38; p=0.029) and events by 35% (22-46; p<0.0001), increasing 3-year event-free survival from 62% to 71% and overall survival from 78% to 83%. Compliance with treatment was good; more than 80% of patients completed the planned treatment. Side-effects were clinically acceptable with only 1 treatment-related death. The commonest side-effects were gastrointestinal, but severe toxic effects (WHO grade 4) occurred in fewer than 3% of cases. We conclude that fluorouracil plus high-dose folinic acid is a well-tolerated and effective 6-month adjuvant regimen for colon cancer.	IST MARIO NEGRI,CANC CLIN EPIDEMIOL LAB,I-20157 MILAN,ITALY; NATL CANC INST CANADA,CTG,TORONTO,ON,CANADA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Queens University - Canada; Canadian Cancer Trials Group			Zee, Benny Chung Ying/G-5606-2017; Ducreux, Michel/L-7012-2019; Ducreux, Michel/AAG-9415-2019	Zee, Benny Chung Ying/0000-0002-7238-845X; Ducreux, Michel/0000-0001-8649-7449; Kaiser, Laurent/0000-0002-0857-2252				BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; GRAY R, 1991, BRIT J CANCER, V63, P841, DOI 10.1038/bjc.1991.187; GREM JL, 1987, CANCER TREAT REP, V71, P1249; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P170; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MILLER JP, 1991, CONTROLLED CLIN TRIA, V12, P630; MOERTEL C, 1992, P ASCO, V11, P457; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P552; PATER JL, 1994, STAT MED, V13, P1337, DOI 10.1002/sim.4780131307; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; ZANIBONI A, 1993, P AM SOC CLIN ONCOL, V12, P555; ZEE B, 1993, CONTROL CLIN TRIALS, V15, P439; 1990, FDA DRUG B, V20, P4; 1992, J CLIN ONCOL, V10, P896; 1989, CLIN ONCOL ALERT, V8, P84; 1990, APR NAT I HLTH CONS	21	779	791	0	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					939	944						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715291				2022-12-28	WOS:A1995QT91900006
J	MCKENDRICK, MW; WOOD, MJ				MCKENDRICK, MW; WOOD, MJ			ACYCLOVIR AND POSTHERPETIC NEURALGIA - 2 OTHER PARTICIPATING STUDY CENTERS REPORT DIFFERENT RESULTS	BRITISH MEDICAL JOURNAL			English	Letter							ORAL ACYCLOVIR; ZOSTER		BIRMINGHAM HEARTLANDS HOSP,DEPT INFECT & TROP MED,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND	Heart of England NHS Foundation Trust; University of Birmingham	MCKENDRICK, MW (corresponding author), ROYAL HALLAMSHIRE HOSP,DEPT INFECT DIS & MED,GLOSSOP RD,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND.		Wood, Malissa/ABI-4543-2020	Wood, Malissa/0000-0003-0482-1116				HUFF JC, 1988, AM J MED, V85, P84; MCGILL JI, 1994, BRIT MED J, V309, P1124, DOI 10.1136/bmj.309.6962.1124; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; MCKENDRICK MW, 1989, BRIT MED J, V298, P431, DOI 10.1136/bmj.298.6671.431; MORTON P, 1989, NEW ZEAL MED J, V102, P93	5	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					1005	1005		10.1136/bmj.310.6985.1005	http://dx.doi.org/10.1136/bmj.310.6985.1005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728001	Green Published			2022-12-28	WOS:A1995QT90400052
J	KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R				KAMPER, J; REICHMANN, M; ROMEIS, T; BOLKER, M; KAHMANN, R			MULTIALLELIC RECOGNITION - NONSELF-DEPENDENT DIMERIZATION OF THE BE AND BW HOMEODOMAIN PROTEINS IN USTILAGO-MAYDIS	CELL			English	Article							AUTONOMOUS PLASMIDS; FILAMENTOUS GROWTH; SEXUAL DEVELOPMENT; 2-HYBRID SYSTEM; U-MAYDIS; A-ALPHA; LOCUS; ALLELES; GENES; YEAST	In the plant pathogenic fungus Ustilago maydis, sexual and pathogenic development are controlled by the multiallelic b mating-type locus. The b locus encodes a pair of unrelated homeodomain proteins termed bE and bW, with allelic differences clustering in the N-terminal domains of both polypeptides. Only combinations of bE and bW of different allelic origin are active. We have investigated the underlying molecular mechanism for this intracellular self/nonself recognition phenomenon. By using the two-hybrid system, we were able to show that bE and bW dimerize only if they are derived from different alleles. Dimerization involves the N-terminal variable domains. Different point mutants of bE2 were isolated that function in combination with bW2. The majority of such bE2 mutant polypeptides were also able to form heterodimers with bW2 in the two-hybrid system. Nonself-dependent dimerization of bE and bW was supported with a biochemical interaction assay with immobilized proteins. Our results suggest a model for self/nonself recognition in which variable cohesive contacts direct dimerization.			KAMPER, J (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,D-80638 MUNICH,GERMANY.			Bolker, Michael/0000-0002-7366-3855				BAKKEREN G, 1993, PLANT CELL, V5, P123, DOI 10.1105/tpc.5.1.123; BANUETT F, 1991, P NATL ACAD SCI USA, V88, P3922, DOI 10.1073/pnas.88.9.3922; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BERGEMANN J, 1993, THESIS FREIE U BERLI; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTENSEN JJ, 1963, AM PHYTOPATHOL SOC M, V2; DAHL M, 1991, ADV MOL GENETICS PLA, V1, P264; DAY PR, 1971, P NATL ACAD SCI USA, V68, P533, DOI 10.1073/pnas.68.3.533; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HO CY, 1994, EMBO J, V13, P1403, DOI 10.1002/j.1460-2075.1994.tb06394.x; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HOLLIDAY R, 1961, GENET RES, V2, P204, DOI 10.1017/S0016672300000719; HURST HC, 1994, PROTEIN PROFILE, V1, P125; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KUES U, 1992, TRENDS GENET, V8, P154, DOI 10.1016/0168-9525(92)90207-K; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; Miller J. H, 1972, EXPT MOL GENETICS; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; PUHALLA JE, 1968, GENETICS, V60, P461; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROWELL JB, 1955, PHYTOPATHOLOGY, V45, P370; ROWELL JB, 1954, PHYTOPATHOLOGY, V44, P356; Sambrook J, 1989, MOL CLONING LABORATO; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; Sherman F., 1986, METHODS YEAST GENETI; SPECHT CA, 1992, P NATL ACAD SCI USA, V89, P7174, DOI 10.1073/pnas.89.15.7174; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; SPELLIG T, 1994, EMBO J, V13, P1620, DOI 10.1002/j.1460-2075.1994.tb06425.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUKUDA T, 1988, MOL CELL BIOL, V8, P3703, DOI 10.1128/MCB.8.9.3703; WONG GJ, 1985, T BRIT MYCOL SOC, V84, P95, DOI 10.1016/S0007-1536(85)80223-0; YEE AR, 1993, P NATL ACAD SCI USA, V90, P664, DOI 10.1073/pnas.90.2.664; [No title captured]	44	203	210	2	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					73	83		10.1016/0092-8674(95)90372-0	http://dx.doi.org/10.1016/0092-8674(95)90372-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720075	hybrid			2022-12-28	WOS:A1995QR97000009
J	GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML				GRAY, DR; MORGAN, T; CHRETIEN, SD; KASHYAP, ML			EFFICACY AND SAFETY OF CONTROLLED-RELEASE NIACIN IN DYSLIPOPROTEINEMIC VETERANS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERLIPIDPROTEINEMIA; NIACIN; DELAYED-ACTION PREPARATIONS; HEPATITIS, TOXIC; DIABETES MELLITUS	DENSITY-LIPOPROTEIN CHOLESTEROL; NICOTINIC-ACID; HEPATIC-FAILURE; DRUG; THERAPY; TRIGLYCERIDES; MECHANISM; INGESTION; BENEFIT; RATIO	Objective: To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia. Design: A retrospective cohort study. Setting: A Department of Veterans Affairs Medical Center. Patients: A consecutive sample of 969 predominantly elderly male veterans treated for dyslipoproteinemia with controlled-release niacin between October 1988 and October 1991. Main Outcome Measures: Primary outcomes were lipid levels and lipoprotein cholesterol response, alterations in levels of hepatic enzymes and blood chemistry test results, and characterization of niacin-induced hepatotoxicity abstracted from the patient's medical, laboratory, and pharmacy records. Results: 93% (896 of 969) of the cohort was evaluable. Patients (age, 61.7 years [9.4 years], mean [SD]) were treated for 1 to 36 months (13.0 months [9.7 months]) with an average maintenance dose of 1.67 g/d (0.8 g/d). Niacin was discontinued in 48.5% (435 of 896) of the patients primarily because of adverse effects. Poor glycemic control led to discontinuation in 40.6% (43 of 106) of the patients with diabetes mellitus. The lipoprotein response was dose-related and favorable (levels of total cholesterol, -19.10/b; low-density lipoprotein cholesterol, -24.0%; high-density lipoprotein cholesterol, +5.7%; and triglycerides, -32.5%). Statistically but not clinically meaningful dose-related increases were seen in levels of liver enzymes and serum glucose (aspartate aminotransferase, +29%; alanine aminotransferase, +23%; alkaline phosphatase, +25%; and glucose, +7%; P= 0.0001). Twenty of 896 (12.2%) and 42 of 896 (4.7%) patients met biochemical criteria for probable and for possible or probable niacin-induced hepatotoxicity, respectively. Predisposing factors included high dose, alcohol use, preexisting liver disease, and concurrent oral sulfonylurea therapy. Conclusions: Controlled-release niacin is effective in treating dyslipoproteinemia in selected middle-aged and elderly veterans, but approximately one half of patients discontinued the drug because of adverse effects or other causes including noncompliance. Niacin should be avoided in patients with hepatic dysfunction or a history of liver disease, patients with diabetes mellitus, and patients who abuse alcohol. Because controlled-release niacin seems to be more potent than crystalline niacin, product substitution without dose adjustment should be avoided.	UNIV CALIF IRVINE, IRVINE, CA 92717 USA	University of California System; University of California Irvine	GRAY, DR (corresponding author), VET AFFAIRS MED CTR 119, 5901 E 7TH ST, LONG BEACH, CA 90822 USA.			Kashyap, Moti/0000-0002-0052-8302				ALDERMAN JD, 1989, AM J CARDIOL, V64, P725, DOI 10.1016/0002-9149(89)90754-6; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ALTSCHUL R, 1955, ARCH BIOCHEM BIOPHYS, V54, P558, DOI 10.1016/0003-9861(55)90070-9; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CHRISTENSEN N, 1961, JAMA-J AM MED ASSOC, V177, P546, DOI 10.1001/jama.1961.03040340010003; ETCHASON JA, 1991, MAYO CLIN PROC, V66, P23, DOI 10.1016/S0025-6196(12)61171-9; FERENCHICK G, 1989, AM J MED SCI, V298, P191, DOI 10.1097/00000441-198909000-00009; FIGGE HL, 1988, PHARMACOTHERAPY, V8, P287; FIGGE HL, 1988, J CLIN PHARMACOL, V28, P1136, DOI 10.1002/j.1552-4604.1988.tb05731.x; FOSSATI P, 1982, CLIN CHEM, V28, P2077; GARG A, 1990, JAMA-J AM MED ASSOC, V264, P723, DOI 10.1001/jama.264.6.723; GRUNDY SM, 1981, J LIPID RES, V22, P24; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HENKIN Y, 1991, AM J MED, V91, P239, DOI 10.1016/0002-9343(91)90122-E; HENKIN Y, 1990, JAMA-J AM MED ASSOC, V264, P241, DOI 10.1001/jama.264.2.241; HODIS HN, 1990, JAMA-J AM MED ASSOC, V264, P181, DOI 10.1001/jama.1990.03450020033012; KAHN SE, 1989, DIABETES, V38, P562, DOI 10.2337/diabetes.38.5.562; KEENAN JM, 1991, ARCH INTERN MED, V151, P1424, DOI 10.1001/archinte.151.7.1424; KNOPP RH, 1985, METABOLISM, V34, P642, DOI 10.1016/0026-0495(85)90092-7; LASAGNA L, 1994, JAMA-J AM MED ASSOC, V271, P709, DOI 10.1001/jama.271.9.709; LAVIE CJ, 1992, AM J CARDIOL, V69, P1083, DOI 10.1016/0002-9149(92)90868-Y; LURIA MH, 1988, ARCH INTERN MED, V148, P2493, DOI 10.1001/archinte.148.11.2493; MCKENNEY JM, 1994, JAMA-J AM MED ASSOC, V271, P672, DOI 10.1001/jama.271.9.672; MULLIN GE, 1989, ANN INTERN MED, V111, P253, DOI 10.7326/0003-4819-111-3-253; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; NEUVONEN PJ, 1991, BRIT J CLIN PHARMACO, V32, P473, DOI 10.1111/j.1365-2125.1991.tb03933.x; PARSONS WB, 1961, ARCH INTERN MED, V107, P653, DOI 10.1001/archinte.1961.03620050019003; SQUIRES RW, 1992, MAYO CLIN PROC, V67, P855, DOI 10.1016/S0025-6196(12)60824-6; STERN RH, 1991, CLIN PHARMACOL THER, V50, P66, DOI 10.1038/clpt.1991.104	31	47	49	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					252	258		10.7326/0003-4819-121-4-199408150-00003	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7741833				2022-12-28	WOS:A1994PB10200003
J	CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R				CANDELIERE, GA; GLORIEUX, FH; PRUDHOMME, J; STARNAUD, R			INCREASED EXPRESSION OF THE C-FOS PROTOONCOGENE IN BONE FROM PATIENTS WITH FIBROUS DYSPLASIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MCCUNE-ALBRIGHT SYNDROME; STIMULATORY G-PROTEIN; TRANSGENIC MICE; ADENYLYL CYCLASE; TUMORS; CELLS; PROTOONCOGENE; TRANSCRIPTION; CALCITRIOL; MUTATIONS	Background. Fibrous dysplasia is characterized by intense marrow fibrosis and increased rates of bone turnover. The lesions of fibrous dysplasia resemble those described in the long bones of transgenic mice overexpressing the c-fos proto-oncogene. Activating mutations in the a subunit of the stimulatory guanine-nucleotide-binding protein (G(s) alpha) linked to adenylate cyclase have recently been described in bone cells from patients with the McCune-Albright syndrome and fibrous dysplasia. Methods. We used in situ hybridization to determine the level of expression of c-fos in bone-biopsy specimens from two normal subjects, eight patients with fibrous dysplasia, and six patients with other bone disorders characterized by high rates of bone turnover. The probe used corresponded to the fourth exon of the c-fos gene. Results. High levels of c-fos expression were detected in the bone lesions from all eight patients with fibrous dysplasia. No expression of c-fos was detected in bone specimens from the normal subjects or from specimens of normal bone obtained from patients with fibrous dysplasia. The cells that expressed c-fos in the dysplastic lesions were fibroblastic and populated the marrow space. A very low level of c-fos expression was detected in the biopsy specimens from the patients with other bone diseases. One patient with polyostotic fibrous dysplasia and one patient with the McCune-Albright syndrome were tested for the previously described G(s) alpha gene mutations and were found to express these mutations in bone. Conclusions. Increased expression of the c-fos proto-oncogene, presumably a consequence of increased adenylate cyclase activity, may be important in the pathogenesis of the bone lesions in patients with fibrous dysplasia.	MCGILL UNIV,SHRINERS HOSP CRIPPLED CHILDREN,GENET UNIT,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL,PQ H3A 2T5,CANADA; MCGILL UNIV,DEPT HUMAN GENET,MONTREAL,PQ H3A 2T5,CANADA	McGill University; McGill University; McGill University								Abate C, 1990, Semin Cancer Biol, V1, P19; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COLE DEC, 1983, AM J MED GENET, V14, P725, DOI 10.1002/ajmg.1320140414; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GLORIEUX FH, 1980, NEW ENGL J MED, V303, P1023, DOI 10.1056/NEJM198010303031802; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750; WALLACH S, 1991, Current Opinion in Rheumatology, V3, P472, DOI 10.1097/00002281-199106000-00022; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WATKINS S, 1989, CURRENT PROTOCOLS MO; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WU JX, 1990, ONCOGENE, V5, P989; YABUT SM, 1988, CLIN ORTHOP RELAT R, V228, P281; ZELLER R, 1989, CURRENT PROTOCOLS MO	27	115	118	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1546	1551		10.1056/NEJM199506083322304	http://dx.doi.org/10.1056/NEJM199506083322304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739708	Bronze			2022-12-28	WOS:A1995RB19600004
J	EISENBERG, JM				EISENBERG, JM			ECONOMICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EISENBERG, JM (corresponding author), GEORGETOWN UNIV,SCH MED,WASHINGTON,DC 20057, USA.							Baker L C, 1994, HMO Pract, V8, P53; BILLI JE, 1993, HEALTH SERV RES, V28, P563; EMMONS DW, 1994, STUDIES SOCIOECONOMI; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; KERSTEIN J, 1994, HEALTH SERV RES, V29, P17; LURIE N, 1994, ANN INTERN MED, V120, P506, DOI 10.7326/0003-4819-120-6-199403150-00010; MILLER RH, 1994, JAMA-J AM MED ASSOC, V271, P1512, DOI 10.1001/jama.271.19.1512; RETCHIN SM, 1992, HLTH SERV RES, V27, P652; ROULIDIS ZC, 1994, J FAM PRACTICE, V39, P446; STEARNS SC, 1992, INQUIRY-J HEALTH CAR, V29, P416; 1994, EFFECTS MANAGED CARE; 1992, 1992 ANN REP; 1993, MANAGED HLTH CARE EF; 1994, MEDICARE CHANGES HMO	14	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1670	1671		10.1001/jama.273.21.1670	http://dx.doi.org/10.1001/jama.273.21.1670			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752409				2022-12-28	WOS:A1995RB09700017
J	KORENBERG, JR; RIMOIN, DL				KORENBERG, JR; RIMOIN, DL			MEDICAL GENETICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											KORENBERG, JR (corresponding author), UNIV CALIF LOS ANGELES,CEDARS SINAI MED CTR,SCH MED,LOS ANGELES,CA 90048, USA.							ALTON E, 1994, NAT GENET, V8, P8, DOI 10.1038/ng0994-8; BROWN MS, 1994, NAT GENET, V7, P349, DOI 10.1038/ng0794-349; CULVER K, 1994, GENE THERAPY HDB PHY; DAVIES K, 1994, NATURE, V372, P202, DOI 10.1038/372202a0; ENGEL E, 1993, AM J MED GENET, V46, P670, DOI 10.1002/ajmg.1320460613; FRANCOMANO CA, 1995, NEW ENGL J MED, V332, P58, DOI 10.1056/NEJM199501053320113; LEDBETTER DH, 1995, METABOLIC MOL BASES, P811; LIU J, 1994, JAMA-J AM MED ASSOC, V272, P1858, DOI 10.1001/jama.272.23.1858; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MURRAY JC, 1994, SCIENCE, V265, P2049, DOI 10.1126/science.8091227; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213; 1994, NAT GENET, V8, P310	14	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1692	1693		10.1001/jama.273.21.1692	http://dx.doi.org/10.1001/jama.273.21.1692			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752420				2022-12-28	WOS:A1995RB09700028
J	GOLDMAN, L				GOLDMAN, L			THE ACADEMIC HEALTH-CARE SYSTEM - PRESERVING THE MISSIONS AS THE PARADIGM SHIFTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							REFORM				GOLDMAN, L (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,505 PARNASSUS AVE,SAN FRANCISCO,CA 94143, USA.							BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P1812, DOI 10.1056/NEJM199312093292413; COHEN JJ, 1993, NEW ENGL J MED, V329, P1810, DOI 10.1056/NEJM199312093292412; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1167, DOI 10.1056/NEJM199410273311719; IGLEHART JK, 1994, NEW ENGL J MED, V331, P1391, DOI 10.1056/NEJM199411173312025; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; ROGERS MC, 1994, NEW ENGL J MED, V331, P1374, DOI 10.1056/NEJM199411173312013; THIER SO, 1994, ACAD MED, V69, P185, DOI 10.1097/00001888-199403000-00003; WARTMAN SA, 1994, ARCH INTERN MED, V154, P2539, DOI 10.1001/archinte.154.22.2539	9	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1549	1552		10.1001/jama.273.19.1549	http://dx.doi.org/10.1001/jama.273.19.1549			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739085				2022-12-28	WOS:A1995QX41800041
J	SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR				SULLIVAN, EA; KREISWIRTH, BN; PALUMBO, L; KAPUR, V; MUSSER, JM; EBRAHIMZADEH, A; FRIEDEN, TR			EMERGENCE OF FLUOROQUINOLONE-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY	LANCET			English	Note							CIPROFLOXACIN	22 patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis in New York City were identified between January, 1991, and November, 1993. In 16 patients resistance arose as a result of inadequate or inappropriate treatment. 6 patients had primary infection with fluoroquinolone-resistant organisms; 5 acquired the organisms nosocomially. Seven distinct patterns of restriction-fragment length polymorphism were identified in isolates from 21 patients. Fluoroquinolones should be restricted to patients with multidrug-resistant disease or intolerance to other antituberculosis drugs. All patients with multidrug-resistant tuberculosis should be on directly observed therapy.	NEW YORK CITY DEPT HLTH,NEW YORK,NY 10013; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; PUBL HLTH RES INST,CTR TB,NEW YORK,NY; BAYLOR COLL MED,DEPT PATHOL,MOLEC PATHOBIOL SECT,HOUSTON,TX 77030	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Baylor College of Medicine			Sullivan, Elizabeth A/V-6742-2017; Kapur, Vivek/F-7610-2013	Sullivan, Elizabeth A/0000-0002-8718-2753; Kapur, Vivek/0000-0002-9648-0138	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009238] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-09238, AI-37004] Funding Source: Medline; NIDA NIH HHS [DA-09238] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CAMBAU E, 1994, J INFECT DIS, V170, P479, DOI 10.1093/infdis/170.2.479; COLLINS CH, 1985, J ANTIMICROB CHEMOTH, V16, P575, DOI 10.1093/jac/16.5.575; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P2051, DOI 10.1128/JCM.28.9.2051-2058.1990; HOFFKEN G, 1985, EUR J CLIN MICROBIOL, V4, P345, DOI 10.1007/BF02013667; KAHANA LM, 1992, DCIP ANN PHARMACOTHE, V25, P919; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KENNEDY N, 1993, AM REV RESPIR DIS, V148, P1547, DOI 10.1164/ajrccm/148.6_Pt_1.1547; Kent PT, 1985, GUIDE LEVEL 3 LAB; TAKIFF HE, 1994, ANTIMICROB AGENTS CH, V38, P773, DOI 10.1128/AAC.38.4.773; 1992, TUBERCLE LUNG DIS, V73, P59	10	105	112	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1148	1150		10.1016/S0140-6736(95)90980-X	http://dx.doi.org/10.1016/S0140-6736(95)90980-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723548				2022-12-28	WOS:A1995QW62200012
J	JOHNSON, RL; TABIN, C				JOHNSON, RL; TABIN, C			THE LONG AND SHORT OF HEDGEHOG SIGNALING	CELL			English	Review							LIMB				JOHNSON, RL (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P295; FIETZ MJ, 1995, IN PRESS CURR BIOL; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; HONIG LS, 1981, NATURE, V291, P72, DOI 10.1038/291072a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NUSSLEINVOLHARD C, 1960, NATURE, V287, P795; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P446; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SCOTT MP, 1994, CELL, V79, P1121, DOI 10.1016/0092-8674(94)90001-9; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; SMITH JC, 1994, CELL, V76, P193, DOI 10.1016/0092-8674(94)90325-5; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	21	119	126	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					313	316		10.1016/0092-8674(95)90381-X	http://dx.doi.org/10.1016/0092-8674(95)90381-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736584	Bronze			2022-12-28	WOS:A1995QW89400002
J	PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W				PREKER, PJ; LINGNER, J; MINVIELLESEBASTIA, L; KELLER, W			THE FIP1 GENE ENCODES A COMPONENT OF A YEAST PRE-MESSENGER-RNA POLYADENYLATION FACTOR THAT DIRECTLY INTERACTS WITH POLY(A) POLYMERASE	CELL			English	Article							MESSENGER-RNA POLYADENYLATION; SACCHAROMYCES-CEREVISIAE; 3' END; POLY(A)-BINDING PROTEIN; BINDING DOMAIN; EXPRESSION; SEQUENCE; PURIFICATION; CLEAVAGE; COMPLEX	We have identified an essential gene, called FIP1, encoding a 327 amino acid protein interacting with yeast poly(A) polymerase (PAP1) in the two-hybrid assay, Recombinant FIP1 protein forms a 1:1 complex with PAP1 in vitro. At 37 degrees C, a thermosensitive allele of FIP1 shows a shortening of poly(A) tails and a decrease in the steady-state level of actin transcripts. When assayed for 3'-end processing in vitro, fip1 mutant extracts exhibit normal cleavage activity, but fail to polyadenylate the upstream cleavage product. Polyadenylation activity is restored by adding polyadenylation factor I (PF I). Antibodies directed against FIP1 specifically recognize a polypeptide in these fractions. Coimmunoprecipitation experiments reveal that RNA14, a subunit of cleavage factor I (CF I), directly interacts with FIP1, but not with PAP1, We propose a model in which PF I tethers PAP1 to CF I, thereby conferring specificity to poly(A) polymerase for pre-mRNA substrates.			PREKER, PJ (corresponding author), UNIV BASEL, BIOZENTRUM, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND.		Minvielle-Sebastia, Lionel/M-7154-2014	Lingner, Joachim/0000-0002-2853-5803				ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; AGUILERA A, 1994, GENETICS, V136, P87; BARDWELL AJ, 1993, MOL MICROBIOL, V8, P1177, DOI 10.1111/j.1365-2958.1993.tb01662.x; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BLOCH JC, 1978, MOL GEN GENET, V165, P123, DOI 10.1007/BF00269900; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, GUIDE YEAST GENETICS; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; IRNIGER S, 1991, MOL CELL BIOL, V11, P3060, DOI 10.1128/MCB.11.6.3060; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; LINGNER J, 1993, NUCLEIC ACIDS RES, V21, P2917, DOI 10.1093/nar/21.12.2917; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PELTZ SW, 1994, PROG NUCLEIC ACID RE, V47, P271, DOI 10.1016/S0079-6603(08)60254-8; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; Sambrook J, 1989, MOL CLONING LABORATO; SEE PY, 1989, PROTEIN STRUCTURE PR, P1; SMITH HE, 1990, MOL CELL BIOL, V10, P6103, DOI 10.1128/MCB.10.12.6103; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1991, J BIOL CHEM, V266, P3131; WAHLE E, 1991, EMBO J, V10, P4251, DOI 10.1002/j.1460-2075.1991.tb05003.x; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	54	113	115	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					379	389		10.1016/0092-8674(95)90391-7	http://dx.doi.org/10.1016/0092-8674(95)90391-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736590	Bronze			2022-12-28	WOS:A1995QW89400010
J	TORRENS, PR; LYNCH, BS; BONNIE, RJ				TORRENS, PR; LYNCH, BS; BONNIE, RJ			GROWING-UP TOBACCO FREE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											TORRENS, PR (corresponding author), INST MED,COMM PREVENTING NICOTINE ADDICT CHILDREN & YOUTH,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1326	1326						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715049				2022-12-28	WOS:A1995QV30700003
J	LINDHOLM, LH; EKBOM, T; DASH, C; ERIKSSON, M; TIBBLIN, G; SCHERSTEN, B				LINDHOLM, LH; EKBOM, T; DASH, C; ERIKSSON, M; TIBBLIN, G; SCHERSTEN, B			THE IMPACT OF HEALTH-CARE ADVICE GIVEN IN PRIMARY-CARE ON CARDIOVASCULAR RISK	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; CHOLESTEROL; PREVENTION; PLASMA; SERUM; TRIAL; DIET	Objective-To evaluate the additional benefit of ''intensive'' health care advice through six group sessions, compared with the advice usually offered to subjects with multiple risk factors for cardiovascular disease. Design-Prospective, randomised controlled clinical study tasting 18 months. Setting-681 subjects aged 30-59 years, with at least two cardiovascular risk factors in addition to moderately high lipid concentrations: total cholesterol greater than or equal to 6.5 mmol/l on three occasions, triglycerides <4.0 mmol/l, and ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol >4.0. Most (577) of the subjects were men. Main outcome measure-Percentage reduction in total cholesterol concentration (target 15%); quantification of the differences between the two types of health care advice (intensive v usual) for the Framingham cardiovascular risk and for individual risk factors. Results-In the group receiving intensive health care advice total cholesterol concentration decreased by 0.15 mmol/l more (95% confidence interval 0.04 to 0.26) than in the group receiving usual advice. The overall Framingham risk dropped by 0.068 more (0.014 to 0.095) in the group receiving intensive advice, and most of the risk factors showed a greater change in a favourable direction in this group than in the group receiving usual advice, but the differences were seldom significant. The results from questionnaires completed at the group sessions showed that the subjects improved their lifestyle and diet. Conclusion-Limited additional benefit was gained from being in the group receiving the intensive health care advice. It is difficult to make an important impact on cardiovascular risk in primary care by using only the practice staff. Better methods of communicating the messages need to be devised.	CENT MIDDLESEX HOSP TRUST,LONDON,ENGLAND; UNIV UPPSALA,UPPSALA,SWEDEN	Uppsala University	LINDHOLM, LH (corresponding author), LUND UNIV,HLTH SCI CTR DALBY,HELGEANDSGATAN 16,S-22354 LUND,SWEDEN.							DANIELSSON B, 1978, SCAND J CLIN LAB INV, V38, P113, DOI 10.1080/00365517809156078; DAYTON S, 1968, LANCET, V2, P1060, DOI 10.1016/S0140-6736(68)91531-6; DOWNIE RS, 1993, HLTH PROMOTION MODEL; FESTINGER L, 1964, CONFLICT DECISION DI; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HJERMANN I, 1981, LANCET, V2, P1303; JOHANNESSON M, 1993, SCAND J CLIN LAB INV, V53, P725, DOI 10.3109/00365519309092577; Kannel W.B., 1987, FRAMINGHAM STUDY EPI; KANNEL WB, 1961, ANN INTERN MED, V55, P33, DOI 10.7326/0003-4819-55-1-33; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LEREN P, 1966, ACTA MED SCAND, V446, P1; Lingfors H., 1994, Scandinavian Journal of Nutrition/Naringsforskning, V38, P106; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; ROESCHLA.P, 1974, Z KLIN CHEM KLIN BIO, V12, P226; ROSE G, 1983, LANCET, V1, P1062; Tibblin G, 1990, Scand J Prim Health Care Suppl, V1, P33; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; WAHLEFELD AW, 1974, METHOD ENZYMAT AN, P1874; 1968, LANCET, V2, P693; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1987, TREATMENT MILD HYPER	23	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1105	1109		10.1136/bmj.310.6987.1105	http://dx.doi.org/10.1136/bmj.310.6987.1105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742677	Green Published			2022-12-28	WOS:A1995QW61800017
J	KLAGES, N; STRUBIN, M				KLAGES, N; STRUBIN, M			STIMULATION OF RNA-POLYMERASE-II TRANSCRIPTION INITIATION BY RECRUITMENT OF TBP IN-VIVO	NATURE			English	Article							TATA-BINDING PROTEIN; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ACTIVATION DOMAIN; YEAST; PROMOTER; DNA; ELEMENTS; COMPLEX; REGION	EUKARYOTIC transcriptional activators may stimulate RNA polymerase II activity by promoting assembly of preinitiation complexes on promoters through their interactions with one or more components of the basal machinery(1,2). On the basis of its central role in initiating transcription-complex formation upon binding to the TATA box, the general transcription factor TFIID, which includes the TATA-binding protein (TBP) and several TBP-associated factors(3-5), has been implicated as a target for activators. Consistent with this idea, an increasing number of activators have been reported to bind directly to TBP6-9. To assess the functional importance of these in vitro interactions for transcriptional regulation in vivo, we made use of a novel strategy in yeast to show that a physical interaction with TBP is sufficient for a sequence-specific DNA-binding protein to increase initiation of transcription by RNA polymerase II. These results imply that binding of TFIID to promoter elements is a limiting step in transcription complex assembly in vivo.			KLAGES, N (corresponding author), UNIV GENEVA,CTR MED,DEPT GENET & MICROBIOL,9 AVE CHAMPEL,CH-1211 GENEVA 4,SWITZERLAND.							AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KINGSTON RE, 1994, CURR BIOL, V4, P325, DOI 10.1016/S0960-9822(00)00071-3; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; SIKORSKI RS, 1989, GENETICS, V122, P19; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	25	162	162	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					822	823		10.1038/374822a0	http://dx.doi.org/10.1038/374822a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723829				2022-12-28	WOS:A1995QV31500051
J	BEELMAN, CA; PARKER, R				BEELMAN, CA; PARKER, R			DEGRADATION OF MESSENGER-RNA IN EUKARYOTES	CELL			English	Review							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; BINDING-PROTEIN; CODING REGION; CAENORHABDITIS-ELEGANS; DESTABILIZING ELEMENTS; POLY(A) TAIL; YEAST; DEADENYLATION; TURNOVER		UNIV ARIZONA,HOWARD HUGHES MED INST,TUCSON,AZ 85721	Howard Hughes Medical Institute; University of Arizona	BEELMAN, CA (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721, USA.							ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BASERGA SJ, 1992, P NATL ACAD SCI USA, V89, P2935, DOI 10.1073/pnas.89.7.2935; Belasco J.G., 2012, CONTROL MESSENGER RN; BELGRADER P, 1994, MOL CELL BIOL, V14, P8219, DOI 10.1128/MCB.14.12.8219; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; COUTTS M, 1993, BIOCHIM BIOPHYS ACTA, V1173, P57, DOI 10.1016/0167-4781(93)90242-6; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DRUMMOND DR, 1985, NUCLEIC ACIDS RES, V13, P7375, DOI 10.1093/nar/13.20.7375; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HIGGS DC, 1994, PLANT CELL, V6, P1007, DOI 10.1105/tpc.6.7.1007; HODGKIN J, 1989, GENETICS, V123, P301; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KUMAGAI H, 1992, BIOCHIM BIOPHYS ACTA, V13, P45; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LEEDS P, 1991, GENE DEV, V5, P2303, DOI 10.1101/gad.5.12a.2303; LEEDS P, 1992, MOL CELL BIOL, V12, P2165, DOI 10.1128/MCB.12.5.2165; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; LOWELL JE, 1992, GENE DEV, V6, P2088, DOI 10.1101/gad.6.11.2088; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; MUHLRAD D, 1994, NATURE, V340, P578; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NIELSEN FC, 1992, J BIOL CHEM, V267, P19404; NUSS DL, 1975, CELL, V6, P21, DOI 10.1016/0092-8674(75)90069-0; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG A, 1995, MOL CELL BIOL, V15, P2231; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	59	551	563	0	26	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					179	183		10.1016/0092-8674(95)90326-7	http://dx.doi.org/10.1016/0092-8674(95)90326-7			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736570	Bronze			2022-12-28	WOS:A1995QV41000005
J	ASCH, DA; HERSHEY, JC				ASCH, DA; HERSHEY, JC			WHY SOME HEALTH POLICIES DONT MAKE SENSE AT THE BEDSIDE	ANNALS OF INTERNAL MEDICINE			English	Article							DECISION-ANALYSIS; INDIVIDUAL PATIENTS; PORTFOLIO THEORY; UTILITY; RISK	Cost-effectiveness analysis and other forms of decision analysis are becoming more common in the medical literature and are increasingly influential in the development of health policy. Nevertheless, many clinicians find it difficult to apply policies developed from these analyses to individual encounters with patients. We examine the assumptions behind these analyses and argue that the perspective they embody can make clinical strategies appear to be less risky in theory than they are at the bedside. We believe that this problem underlies the intuitive concern many physicians have about policy analyses and calls into question the value of these analyses in shaping clinical practice. These analyses aggregate the benefits and burdens of alternative interventions across different individual persons. Thus, overall population risk appears blunted, as it would in a diversified portfolio of stocks that react differently to financial forces or in a herd of cattle that react differently to veterinary interventions. The assumptions behind these analyses make sense if aggregate outcome is what matters, but not if one cares about each individual investment or animal. Because such aggregation tends to understate individual risk, when applied to human health policy, it may misrepresent the interests of patients and cannot be assumed to provide useful guidelines for decision making at the bedside.	VET AFFAIRS MED CTR, PHILADELPHIA, PA USA; UNIV PENN, WHARTON SCH, PHILADELPHIA, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania				Asch, David/0000-0002-7970-286X	NHGRI NIH HHS [R011HG00621, R011HG00616] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000621, R01HG000616] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ASCH DA, 1990, NEW ENGL J MED, V323, P922; BRETT AS, 1981, NEW ENGL J MED, V305, P1150, DOI 10.1056/NEJM198111053051911; BURRIS JF, 1993, ANN INTERN MED, V119, P1151, DOI 10.7326/0003-4819-119-11-199312010-00023; CHEW SH, 1988, J RISK UNCERTAINTY, V1, P125; DEBER RB, 1990, MED DECIS MAKING, V10, P181, DOI 10.1177/0272989X9001000305; FEAGIN OT, 1993, ANN INTERN MED, V119, P1150, DOI 10.7326/0003-4819-119-11-199312010-00022; FEINSTEIN AR, 1977, CLIN PHARMACOL THER, V21, P482; GALLIGAN DT, 1991, J DAIRY SCI, V74, P2138, DOI 10.3168/jds.S0022-0302(91)78386-0; GALLIGAN DT, 1988, PREV VET MED, V5, P251, DOI 10.1016/0167-5877(88)90011-6; GALLIGAN DT, 1987, PREV VET MED, V5, P79, DOI 10.1016/0167-5877(87)90013-4; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; LUFT HS, 1976, PUBLIC POLICY, V24, P437; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; PAUKER SG, 1993, ANN INTERN MED, V118, P901, DOI 10.7326/0003-4819-118-11-199306010-00013; PAUKER SG, 1993, ANN INTERN MED, V119, P1152, DOI 10.7326/0003-4819-119-11-199312010-00026; RANSOHOFF DF, 1976, YALE J BIOL MED, V49, P165; Rawls John, 1971, THEORY JUSTICE, P27; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SAMUELSON PA, 1963, SCIENTIA, V98, P108; SCHAPIRA MM, 1993, ANN INTERN MED, V118, P838, DOI 10.7326/0003-4819-118-11-199306010-00002; SCHAPIRA MM, 1993, ANN INTERN MED, V119, P1152, DOI 10.7326/0003-4819-119-11-199312010-00027; SCHWARTZ WB, 1979, NEW ENGL J MED, V300, P556, DOI 10.1056/NEJM197903083001011; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	26	74	75	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					846	850		10.7326/0003-4819-122-11-199506010-00007	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741370				2022-12-28	WOS:A1995RA13900007
J	OLIN, JW; PIEDMONTE, MR; YOUNG, JR; DEANNA, S; GRUBB, M; CHILDS, MB				OLIN, JW; PIEDMONTE, MR; YOUNG, JR; DEANNA, S; GRUBB, M; CHILDS, MB			THE UTILITY OF DUPLEX ULTRASOUND SCANNING OF THE RENAL-ARTERIES FOR DIAGNOSING SIGNIFICANT RENAL-ARTERY STENOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						RENAL ARTERY; RENAL ARTERY OBSTRUCTION; ULTRASONOGRAPHY, DOPPLER, DUPLEX; ANGIOGRAPHY; HYPERTENSION, RENOVASCULAR	RENOVASCULAR HYPERTENSION; RESISTIVE INDEX; DISEASE; DOPPLER; ANGIOGRAPHY	Objective: To determine the utility of duplex ultrasound scanning of the renal arteries in identifying patients with renal artery stenosis of 60% or more and in excluding patients with either normal renal arteries or renal artery stenosis of less than 60%. Design: A prospective, blinded study. Setting: Large tertiary referral center. Patients: 102 consecutive patients (44 men and 58 women with a mean age [+/-SD] of 63.3 +/- 13.4 years) who had both duplex ultrasound scanning of the renal arteries and renal arteriography. All patients who were studied had hypertension that was difficult to control, unexplained azotemia, or associated peripheral vascular disease (alone or in combination), giving them a high pretest likelihood of renovascular disease. Main Outcome Measurements: Peak systolic and end diastolic velocities, renal-aortic ratios, resistive index, and kidney sizes. Results: Sixty-two of 63 arteries with stenosis of less than 60% using arteriography were correctly identified by duplex ultrasound scanning. Thirty-one of 32 arteries with 60% to 79% stenosis using arteriography were correctly identified as having 60% to 99% stenosis on duplex ultrasound, whereas 67 of 69 arteries with 80% to 99% stenosis on arteriography were correctly identified as having 60% to 99% stenosis on ultrasound. Twenty-two of 23 arteries with total occlusion on arteriography were correctly identified by duplex ultrasound. The overall sensitivity of duplex ultrasound compared with arteriography was 0.98, the specificity was 0.98, the positive predictive value was 0.99, and the negative predictive value was 0.97. Conclusion: Duplex ultrasound scanning of the renal arteries is an ideal screening test because it is noninvasive and can predict the presence or absence of renal artery stenosis with a high degree of accuracy.	CLEVELAND CLIN FDN, DEPT BIOSTAT & EPIDEMIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation	OLIN, JW (corresponding author), CLEVELAND CLIN FDN, DEPT VASC MED, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							Altman DG, 1991, PRACTICAL STATISTICS; BLANKENHORN DH, 1994, ARTERIOSCLER THROMB, V14, P177, DOI 10.1161/01.ATV.14.2.177; BURNS PN, 1987, J CLIN ULTRASOUND, V15, P567, DOI 10.1002/jcu.1870150903; DAVIDSON RA, 1992, JAMA-J AM MED ASSOC, V268, P3353, DOI 10.1001/jama.268.23.3353; DEBATIN JF, 1991, AM J ROENTGENOL, V157, P981, DOI 10.2214/ajr.157.5.1927823; EDWARDS JM, 1992, J VASC SURG, V15, P604, DOI 10.1016/0741-5214(92)90004-R; HANSEN KJ, 1990, J VASC SURG, V12, P227, DOI 10.1067/mva.1990.22791; HOFFMANN U, 1991, KIDNEY INT, V39, P1232, DOI 10.1038/ki.1991.156; KIM SH, 1992, CLIN RADIOL, V45, P85, DOI 10.1016/S0009-9260(05)80060-1; KOHLER TR, 1986, J VASC SURG, V4, P450, DOI 10.1067/mva.1986.avs0040450; LEWIN JS, 1992, INVEST RADIOL, V27, pS84, DOI 10.1097/00004424-199212002-00015; MANN SJ, 1992, ANN INTERN MED, V117, P845, DOI 10.7326/0003-4819-117-10-845; NEUMYER MM, 1987, J VASC TECH, V11, P30; NORRIS CS, 1984, J SURG RES, V36, P230, DOI 10.1016/0022-4804(84)90092-1; OLIN JW, 1990, AM J MED, V88, pN46; OLIN JW, 1994, UROL CLIN N AM, V21, P215; OLIN JW, 1991, TXB PERIPHERAL VASCU, P267; RIMMER JM, 1993, ANN INTERN MED, V118, P712, DOI 10.7326/0003-4819-118-9-199305010-00010; RUBIN GD, 1993, J VASC SURG, V18, P656, DOI 10.1016/0741-5214(93)90075-W; STRANDNESS DE, 1990, SURG CLIN N AM, V70, P109; TAYLOR DC, 1988, J VASC SURG, V7, P363, DOI 10.1067/mva.1988.avs0070363; VEGLIO F, 1992, AM J HYPERTENS, V5, P431, DOI 10.1093/ajh/5.7.431	22	277	290	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					833	838		10.7326/0003-4819-122-11-199506010-00004	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741367				2022-12-28	WOS:A1995RA13900004
J	GLASER, C; JOHNSON, E				GLASER, C; JOHNSON, E			EHRLICHIOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									UNIV CALIF DAVIS,DAVIS,CA 94116	University of California System; University of California Davis	GLASER, C (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94105, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1417	1417		10.1056/NEJM199505253322105	http://dx.doi.org/10.1056/NEJM199505253322105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723798				2022-12-28	WOS:A1995QY94100005
J	MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE				MARRERO, MB; SCHIEFFER, B; PAXTON, WG; HEERDT, L; BERK, BC; DELAFONTAINE, P; BERNSTEIN, KE			DIRECT STIMULATION OF JAK/STAT PATHWAY BY THE ANGIOTENSIN-II AT(1) RECEPTOR	NATURE			English	Article							PROTEIN-TYROSINE KINASE; SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; JAK2	THE peptide angiotensin II is the effector molecule of the renin-angiotensin system. All the haemodynamic effects of angiotensin II, including vasoconstriction! and adrenal aldosterone release, are mediated through a single class of cell-surface receptors known as AT(1) (refs 1, 2). These receptors contain the structural features of the G-protein-coupled receptor superfamily(3). We show here that angiotensin II induces the rapid phosphorylation of tyrosine in the intracellular kinases Jak2 and Tyk2 in rat aortic smooth-muscle cells and that this phosphorylation is associated with increase activity of Jak2. The Jak family substrates STAT1 and STAT2 (for signal transducers and activators of transcription) are rapidly tyrosine-phosphorylated in response to angiotensin II. We also find that Jak2 co-precipitates with the AT(1) receptor, indicating that G-protein-coupled receptors may be able to signal through the intracellular phosphorylation pathways used by cytokine receptors(4,5).	EMORY UNIV,DEPT PATHOL & LAB MED,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,DIV CARDIOL,ATLANTA,GA 30322; SANTA CRUZ BIOTECHNOL INC,SANTA CRUZ,CA 95060; UNIV WASHINGTON,DEPT MED,DIV CARDIOL,SEATTLE,WA 98195	Emory University; Emory University; University of Washington; University of Washington Seattle				Bernstein, Kenneth/0000-0001-8097-3272; Berk, Bradford/0000-0002-2767-4115; Delafontaine, Patrice/0000-0003-3744-3617				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MIURA O, 1994, BLOOD, V84, P1501; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PEACH MJ, 1977, PHYSIOL REV, V57, P313, DOI 10.1152/physrev.1977.57.2.313; PEACH MJ, 1981, BIOCHEM PHARMACOL, V30, P2745, DOI 10.1016/0006-2952(81)90410-X; RUI H, 1994, J BIOL CHEM, V269, P5364; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TIMMERMANS PBMWM, 1991, TRENDS PHARMACOL SCI, V12, P55, DOI 10.1016/0165-6147(91)90498-H; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	28	645	664	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					247	250		10.1038/375247a0	http://dx.doi.org/10.1038/375247a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746328				2022-12-28	WOS:A1995QY88100067
J	MOY, E; BARTMAN, BA				MOY, E; BARTMAN, BA			PHYSICIAN RACE AND CARE OF MINORITY AND MEDICALLY INDIGENT PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RACIAL-DIFFERENCES; YOUNG PHYSICIANS; HEALTH-CARE; SERVICES; BLACK; EMERGENCY; SURVIVAL; MEDICINE; CHILDREN; ACCESS	Objective.-To examine the relationship between physician race and care of racial minority and ethnic minority patients and medically indigent patients. Design.-Secondary analysis of data from the 1987 National Medical Expenditure Survey, a cross-sectional survey of Americans designed to provide national estimates of health care utilization and expenditures. Setting.-A sample representative of the total civilian noninstitutionalized US population with oversampling of minorities and the medically indigent. Patients.-Survey respondents aged 18 years or older who identified a specific physician as their usual source of care (n=15 081, corresponding to a national population estimate of 116 million Americans). Main Outcome Measure.-Identification of a nonwhite physician as usual source of care. Results.-Of adult Americans who identified a usual-source-of-care physician, 14.4% identified a nonwhite physician as that source of care. Minority patients were more than four times more likely to receive care from nonwhite physicians than were non-Hispanic white patients. Low-income, Medicaid, and uninsured patients were also more likely to receive care from nonwhite physicians. Individuals who receive care from nonwhite physicians were more likely to report worse health, visit an emergency department, and be hospitalized. Individuals who receive care from nonwhite physicians reported more acute complaints, chronic conditions, functional limitations, and psychological symptoms as well as longer visits. Conclusions.-Nonwhite physicians are more likely to care for minority, medically indigent, and sicker patients. Caring for less affluent and sicker patients may financially penalize nonwhite physicians and make them particularly vulnerable to capitation arrangements.	UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT EPIDEMIOL & PREVENT MED,BALTIMORE,MD 21201; DEPT VET AFFAIRS MED CTR,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore								[Anonymous], 1993, ACCESS HLTH CARE AM; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; BROUSSARD BA, 1991, AM J CLIN NUTR, V53, pS1535, DOI 10.1093/ajcn/53.6.1535S; BYRD WM, 1994, J NATL MED ASSOC, V86, P191; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; COHEN JW, 1993, INQUIRY-J HEALTH CAR, V30, P281; COHEN S, 1991, US PHS AHCPR910037 P; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; Cornelius L J, 1991, J Health Care Poor Underserved, V2, P374; Cornelius L J, 1993, J Assoc Acad Minor Phys, V4, P16; CORNELIUS LJ, 1993, J NATL MED ASSOC, V85, P281; CUNNINGHAM PJ, 1993, MED CARE, V31, P600, DOI 10.1097/00005650-199307000-00003; EDWARDS W, 1989, DHHS PHS893450 PUBL; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HADLEY J, 1992, ACAD MED, V67, P180, DOI 10.1097/00001888-199203000-00010; HAHN B, 1994, MED CARE, V32, P227, DOI 10.1097/00005650-199403000-00004; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129; JOHNSON DG, 1989, ACAD MED, V54, P87; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KEITH SN, 1985, NEW ENGL J MED, V313, P1519, DOI 10.1056/NEJM198512123132406; KEITH SN, 1988, J NATL MED ASSOC, V80, P153; KOCHANEK KD, 1994, AM J PUBLIC HEALTH, V84, P938, DOI 10.2105/AJPH.84.6.938; LAVEIST TA, 1994, HEALTH SERV RES, V29, P1; LLOYD SM, 1978, J MED EDUC, V53, P640; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; MOY E, 1993, ARCH INTERN MED, V153, P1815, DOI 10.1001/archinte.153.15.1815; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; PADGETT DK, 1994, AM J PUBLIC HEALTH, V84, P222, DOI 10.2105/AJPH.84.2.222; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; QUAM L, 1993, MED CARE, V131, P498; ROCHELEAU B, 1978, PUBLIC HEALTH REP, V93, P278; SHORT PF, 1992, MED CARE, V30, P766, DOI 10.1097/00005650-199209000-00002; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STODDARD JJ, 1994, NEW ENGL J MED, V330, P1421, DOI 10.1056/NEJM199405193302006; STUART ME, 1993, MED CARE, V31, P1119, DOI 10.1097/00005650-199312000-00005; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; 1992, MONITORING ACCESS ME; 1994, ANN REPORT C 1994; 1991, HLTH STATUS QUESTION; 1993, LOSS PRIMARY CARE HL; 1993, MONITORING ACCESS ME; 1993, SUDAAN SURVEY DATA A; 1973, OCCUPATIONAL CHARACT; 1991, MINORITY STUDES MED, V6	52	296	296	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1515	1520		10.1001/jama.273.19.1515	http://dx.doi.org/10.1001/jama.273.19.1515			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739078				2022-12-28	WOS:A1995QX41800034
J	HERBERT, J				HERBERT, J			THE AGE OF DEHYDROEPIANDROSTERONE	LANCET			English	Editorial Material							SULFATE; MEN		UNIV CAMBRIDGE,MRC,CAMBRIDGE CTR BRAIN REPAIR,CAMBRIDGE,ENGLAND	University of Cambridge	HERBERT, J (corresponding author), UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE,ENGLAND.							ABADIE JM, 1993, DIABETES, V42, P662, DOI 10.2337/diabetes.42.5.662; BARRETTCONNOR E, 1994, J AM GERIATR SOC, V42, P420, DOI 10.1111/j.1532-5415.1994.tb07491.x; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BLAUER KL, 1991, ENDOCRINOLOGY, V129, P3174, DOI 10.1210/endo-129-6-3174; BROOKSGUNN J, 1989, CHILD DEV, V60, P40, DOI 10.1111/j.1467-8624.1989.tb02693.x; CASSON PR, 1993, AM J OBSTET GYNECOL, V169, P1536, DOI 10.1016/0002-9378(93)90431-H; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; EBELING P, 1994, LANCET, V343, P1479, DOI 10.1016/s0140-6736(94)92587-9; EICH DM, 1993, CIRCULATION, V87, P261, DOI 10.1161/01.CIR.87.1.261; GOODYER IM, IN RESS PSYCHOL MED; GRAY A, 1991, PSYCHOSOM MED, V53, P375, DOI 10.1097/00006842-199107000-00003; HEDMAN M, 1992, CLIN EXP RHEUMATOL, V10, P25; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Sapolsky RM, 1992, STRESS AGING BRAIN M; SCHLEGEL ML, 1985, PHYSIOL BEHAV, V34, P867, DOI 10.1016/0031-9384(85)90005-8; SCHNEIDER LS, 1992, BIOL PSYCHIAT, V34, P867; WILLIAMS DP, 1993, J CLIN ENDOCR METAB, V77, P80, DOI 10.1210/jc.77.1.80	20	76	77	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1193	1194		10.1016/S0140-6736(95)91987-2	http://dx.doi.org/10.1016/S0140-6736(95)91987-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739304				2022-12-28	WOS:A1995QX86100005
J	GABBARD, GO; NADELSON, C				GABBARD, GO; NADELSON, C			PROFESSIONAL BOUNDARIES IN THE PHYSICIAN-PATIENT RELATIONSHIP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUAL CONTACT; EXPLOITATION; MISCONDUCT; PREVALENCE; DOCTOR		HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	GABBARD, GO (corresponding author), MENNINGER CLIN,POB 829,TOPEKA,KS 66601, USA.							BRADSHAW S, 1976, B MENNINGER CLIN, V40, P665; Brodsky A. M, 1989, SEXUAL EXPLOITATION, P15; BRODY H, 1992, HEALERS POWER; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; Chu J A, 1992, J Psychother Pract Res, V1, P259; EPSTEIN RS, 1990, B MENNINGER CLIN, V54, P450; Epstein RS, 1994, KEEPING BOUNDARIES; FELDMANSUMMERS S, 1984, J CONSULT CLIN PSYCH, V52, P1054, DOI 10.1037/0022-006X.52.6.1054; Frick DE, 1994, AMER P PR R, V13, P415; GABBARD GO, 1994, AMER P PR R, V13, P433; GARTRELL N, 1986, AM J PSYCHIAT, V143, P1126; GARTRELL NK, 1992, WESTERN J MED, V157, P139; GECHTMAN L, 1989, SEXUAL EXPLOITATION, P27; GOLEMAN D, 1991, NY TIMES        1022, pB5; GUTHEIL TG, 1993, AM J PSYCHIAT, V150, P188; JOHNSON SH, 1993, JAMA-J AM MED ASSOC, V270, P1596, DOI 10.1001/jama.270.13.1596; KARDENER SH, 1973, AM J PSYCHIAT, V130, P1077, DOI 10.1176/ajp.130.10.1077; Kluft R. P, 1990, INCEST RELATED DISOR, P263; LAMONT JA, 1994, CAN MED ASSOC J, V150, P1433; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; POPE KS, 1989, SEXUAL EXPLOITATION, P163; ROBINSON TE, 1994, CAN MED ASSOC J, V150, P1427; Schoener G. R., 1989, PSYCHOTHERAPISTS SEX; STRASBURGER LH, 1992, AM J PSYCHOTHER, V46, P544, DOI 10.1176/appi.psychotherapy.1992.46.4.544; WILBERS D, 1992, BRIT MED J, V304, P1531, DOI 10.1136/bmj.304.6841.1531; WILLIAMS MH, 1992, AM PSYCHOL, V47, P412, DOI 10.1037/0003-066X.47.3.412; 1991, JAMA-J AM MED ASSOC, V266, P2741; 1992, NEWSLETT MED COUNCIL, V6, P4; 1992, DOCTOR PATIENT SEXUA; 1991, FINAL REPORT TASK FO; 1992, NOV COMM PHYS SEX MI; 1994, GENERAL GUIDELINES R; 1980, FED REGISTER, V45, P7467	33	139	142	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1445	1449		10.1001/jama.273.18.1445	http://dx.doi.org/10.1001/jama.273.18.1445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW279	7723159				2022-12-28	WOS:A1995QW27900033
J	WEINBERG, RA				WEINBERG, RA			THE RETINOBLASTOMA PROTEIN AND CELL-CYCLE CONTROL	CELL			English	Review							TRANSCRIPTION FACTOR E2F; GENE-PRODUCT; DEPENDENT KINASES; P53 PROTEIN; EXPRESSION; RB; BINDING; MOUSE; PHOSPHORYLATION; ACTIVATION				WEINBERG, RA (corresponding author), MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.							BATES S, 1994, ONCOGENE, V9, P1633; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL PA, 1993, ONCOGENE, V8, P203; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1992, CANCER RES, V52, P2980; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAMMIE GA, 1991, ONCOGENE, V6, P439; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, CANCER RES, V54, P6078; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORI T, 1994, CANCER RES, V54, P3396; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1992, CANCER SURV, V12, P43; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZHOU XL, 1994, ONCOGENE, V9, P3737	83	4262	4370	1	287	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					323	330		10.1016/0092-8674(95)90385-2	http://dx.doi.org/10.1016/0092-8674(95)90385-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736585	Bronze			2022-12-28	WOS:A1995QW89400004
J	FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S				FITTEN, LJ; PERRYMAN, KM; WILKINSON, CJ; LITTLE, RJ; BURNS, MM; PACHANA, N; MERVIS, JR; MALMGREN, R; SIEMBIEDA, DW; GANZELL, S			ALZHEIMER AND VASCULAR DEMENTIAS AND DRIVING - A PROSPECTIVE ROAD AND LABORATORY STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GERIATRIC SUBJECTS; DISEASE; PERFORMANCE; ATTENTION; PERCEPTION; SKILLS	Objective.-To characterize on-the-road, behind-the-wheel driving abilities and related laboratory performances of subjects with mild Alzheimer's disease (AD) and vascular dementia. Design.-Prospective, experimental study involving two mild dementia and three age and health control groups. Road test reliability and validity were assessed. Setting.-Greater western Los Angeles. Subjects were enrolled from the community by referral and from the Veterans Affairs dementia and diabetes clinics. Participants.-Eighty-seven driving subjects were enrolled; 83 completed the study. A sample of eligible dementia clinic subjects consisting of 15 mild AD patients met National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association probable AD criteria, while 12 met Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition and Hachinski diagnostic criteria for multi-infarct dementia (vascular dementia). Clinic control subjects consisted of 15 age-matched patients with diabetes and without a history of stroke or dementia. Community controls consisted of 26 healthy, age-matched, older subjects (>60 years) and 16 young subjects (20 to 35 years). Main Outcome Measures.-Drive score from the Sepulveda (Calif) road test and laboratory measures of attention, perception, and memory. Results.-The drive scores in the mild AD group (mean, 22.1; SD, 3.8) and in the vascular dementia group (mean, 24.0; SD, 7.8) differed significantly (P<.001 studentized range test) from the drive scores in the diabetic control group (mean, 31.5; SD, 3.9), the older control group (mean, 32.6; SD, 2.8), and the young control group (mean, 33.6; SD, 3.2). Drive score among the three control groups did not vary significantly. Short-term memory (Sternberg), visual tracking, and Folstein Mini-Mental State Examination scores correlated best with drive score, with a cumulative R(2) of 0.68. Drive score and number of collisions and moving violations per 1000 miles driven were negatively correlated (r=-0.38; P<.02). Conclusions.-Based on this study, type and degree of cognitive impairment are better predictors of driving skills than age or medical diagnosis per se. Specific testing protocols for drivers with potential cognitive impairment may detect unsafe drivers more effectively than using age or medical diagnosis alone as criteria for license restriction or revocation.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOMATH,LOS ANGELES,CA 90024; DEPT VET AFFAIRS MED CTR,GERIATR PSYCHIAT SECT,SEPULVEDA,CA 91343; SO CALIF RES INST,CULVER CITY,CA; UNIV MICHIGAN,DEPT BIOMATH,ANN ARBOR,MI; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Michigan System; University of Michigan; University of California System; University of California Los Angeles			Little, Roderick/H-2440-2011; Pachana, Nancy A./C-6807-2016; Pachana, Nancy A./AAB-9235-2022; Pachana, Nancy A./HCI-4798-2022	Pachana, Nancy A./0000-0002-8927-4205; 				[Anonymous], ALZHEIMERS DIS; BRURSSON B, 1989, SCAND J SOC MED, V17, P253; BURNS M, 1990, J OCCUP ENVIRON MED, V32, P320, DOI 10.1097/00043764-199004000-00012; BURNS M, 1986, J CLIN PSYCHIAT, V47, P252; CARR D, 1990, J AM GERIATR SOC, V38, P1145, DOI 10.1111/j.1532-5415.1990.tb01379.x; CROSS PS, 1986, EPIDEMIOLOGY DEMENTI; DIXON WJ, 1988, BMDP STATISTICAL SOF, V2; DUBINSKY RM, 1992, J AM GERIATR SOC, V40, P1112, DOI 10.1111/j.1532-5415.1992.tb01799.x; EVANS L, 1988, J GERONTOLOGY S, V43, pS189; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRIEDLAND RP, 1988, ANN NEUROL, V24, P782, DOI 10.1002/ana.410240613; GILLEY DW, 1991, ARCH INTERN MED, V151, P941, DOI 10.1001/archinte.151.5.941; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GRACA JL, 1988, CLIN GERIATR MED, V2, P577; HILLS BL, 1980, PERCEPTION, V9, P183, DOI 10.1068/p090183; HUNT LA, 1990, ANN NEUROL, V28, P228; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; LOGSDON RG, 1992, J GEN INTERN MED, V7, P583, DOI 10.1007/BF02599195; LUCASBLAUSTEIN MJ, 1988, J AM GERIATR SOC, V36, P1087, DOI 10.1111/j.1532-5415.1988.tb04394.x; Mackworth J, 1970, VIGILANCE ATTENTION; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; MIRSKY AF, 1987, ENVIRON HEALTH PERSP, V74, P191, DOI 10.2307/3430449; MORRISON JH, 1987, BRAIN RES, V416, P331, DOI 10.1016/0006-8993(87)90914-0; MORRISON JH, 1990, IMAGING CEREBRAL TOP, P19; MOSKOWITZ H, 1986, NEUROPSYCHOBIOLOGY, V15, P38, DOI 10.1159/000118285; OLSON PL, 1986, HUM FACTORS, V28, P91, DOI 10.1177/001872088602800110; PARASURAMAN R, 1991, HUM FACTORS, V33, P539, DOI 10.1177/001872089103300506; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SCHAFER JL, 1991, THESIS HARVARD U BOS; STERNBERG S, 1975, Q J EXP PSYCHOL, V27, P1, DOI 10.1080/14640747508400459; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; WOLFKLEIN GP, 1989, J AM GERIATR SOC, V37, P730, DOI 10.1111/j.1532-5415.1989.tb02234.x; 1987, DIAGNOSTIC STATISTIC; 1992, STATISTICAL ABSTRACT, P612	37	192	193	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1360	1365		10.1001/jama.273.17.1360	http://dx.doi.org/10.1001/jama.273.17.1360			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715061				2022-12-28	WOS:A1995QV30700021
J	OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B				OUSLANDER, JG; SCHNELLE, JF; UMAN, G; FINGOLD, S; NIGAM, JG; TUICO, E; BATESJENSEN, B			PREDICTORS OF SUCCESSFUL PROMPTED VOIDING AMONG INCONTINENT NURSING-HOME RESIDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							URINARY-INCONTINENCE; MUSCLE EXERCISE; CARE; MANAGEMENT; FACILITIES; PATIENT; WOMEN	Objective.-To develop a simple, noninvasive assessment strategy that will enable nursing home staff to identify incontinent residents who respond well to prompted voiding. Design.-Incontinent nursing home residents underwent an extensive clinical and functional assessment and then 7 days of prompted voiding. Data from the assessment and the first 3 days of prompted voiding were used to predict responsiveness to the intervention. Setting.-Seven nursing homes. Patients.-A cohort of 191 incontinent, long-stay nursing home residents who passed a simple behavioral screen (able to state their name or reliably point to one of two named objects). Intervention.-Prompted voiding was carried out by trained research nurse's aides from 7 AM to 7 PM for 7 days, The intervention was maintained in responsive residents 5 days per week for an additional 9 weeks. Main Outcome Measures.-Physical checks for wetness were done by research staff hourly from 7 AM to 7 PM for 3 days in a baseline condition, during days 5 through 7 of the 7-day prompted voiding intervention, and for 3 days at the end of 9 weeks of prompted voiding in the responsive group. Outcome measures were percentage of checks wet and response to prompted voiding, with ''responders'' defined as residents with an average of one or fewer wet episode per day on days 5 through 7 of prompted voiding. Results.-Seventy-eight (41%) of the residents were responders. Their wet percentage went from 26.7% to 6.4% at the end of 1 week and was maintained at 9.6% after 9 weeks of prompted voiding. The best predictors of responsiveness were the wet percentage and the appropriate toileting percentage during the first 3 days of prompted voiding, the self-care subscale score of the Multidimensional Observational Scale for the Elderly, and the ability to ambulate without human assistance. The best sensitivity and specificity in identifying responders was achieved when either the wet percentage was lower than 20% or the appropriate toileting percentage was higher than 66% during the first 3 days of prompted voiding (sensitivity, 87%; specificity, 69%). Those residents falsely identified as responders by these criteria still had a 46% relative reduction in wetness. Conclusions.-A substantial proportion of nursing home residents respond well to prompted voiding, The most responsive residents can be easily identified using data collected during a 3-day trial of the intervention, The assessment strategy is consistent with federal guidelines and could be used to facilitate quality control by assessing changes in percentage of wetness from the expected norm.	UNIV CALIF LOS ANGELES,BORUN CTR GERONTOL RES,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,MULTICAMPUS PROGRAM GERIATR MED & GERONTOL,LOS ANGELES,CA 90024; JEWISH HOME AGING,RESEDA,CA 91335	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Bates-Jensen, Barbara/ABA-3726-2020		NATIONAL INSTITUTE ON AGING [R37AG008678] Funding Source: NIH RePORTER; NIA NIH HHS [R37AGO8678] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BURGIO LD, 1994, J AM GERIATR SOC, V42, P315, DOI 10.1111/j.1532-5415.1994.tb01758.x; BURNS PA, 1993, J GERONTOL, V48, pM167; BURTON JR, 1988, J AM GERIATR SOC, V36, P693, DOI 10.1111/j.1532-5415.1988.tb07170.x; COLLING J, 1988, NURS CLIN N AM, V23, P279; COLLING J, 1992, J AM GERIATR SOC, V39, P135; ELBADAWI A, 1993, J UROLOGY, V150, P1650, DOI 10.1016/S0022-5347(17)35866-4; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; HU TW, 1989, JAMA-J AM MED ASSOC, V261, P2656, DOI 10.1001/jama.261.18.2656; Igou J, 1986, Clin Geriatr Med, V2, P873; OUSLANDER J, 1989, J AM GERIATR SOC, V37, P715, DOI 10.1111/j.1532-5415.1989.tb02232.x; OUSLANDER JG, 1987, J GERONTOL, V42, P631, DOI 10.1093/geronj/42.6.631; OUSLANDER JG, IN PRESS ANN INTERN; OUSLANDER JG, 1991, MED CARE NURSING HOM, P163; RESNICK NM, 1987, JAMA-J AM MED ASSOC, V257, P3076, DOI 10.1001/jama.257.22.3076; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; SCHNELLE JF, 1990, GERONTOLOGIST, V30, P373, DOI 10.1093/geront/30.3.373; SCHNELLE JF, 1993, J AM GERIATR SOC, V41, P1259, DOI 10.1111/j.1532-5415.1993.tb07312.x; SCHNELLE JF, 1991, J AM GERIATR SOC, V39, P165, DOI 10.1111/j.1532-5415.1991.tb01620.x; SCHNELLE JF, 1991, MANAGING URINARY INC; SCHNELLE JF, 1992, GERONTOLOGIST, V33, P114; WELLS TJ, 1990, J AM GERIATR SOC, V38, P333, DOI 10.1111/j.1532-5415.1990.tb03515.x; 1992, AHCPR920038 AG HLTH; 1991, RESIDENT ASSESSMENT; 1991, FED REG         0926, V56, P48865	25	91	91	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1366	1370						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715062				2022-12-28	WOS:A1995QV30700022
J	CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P				CHENG, KK; DUFFY, SW; DAY, NE; LAM, TH; CHUNG, SF; BADRINATH, P			STOPPING DRINKING AND RISK OF ESOPHAGEAL CANCER	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; ESOPHAGEAL CANCER; ALCOHOL; CONSUMPTION	Objective-To examine the effect of stopping drinking on the risk of oesophageal cancer. Design-Hospital based case-control study. Setting-Surgical departments of four district general hospitals and general practices in Hong Kong. Subjects-Cases were 400 consecutive admissions of patients with histologically confirmed diagnosis of oesophageal cancer during a 21 month period in 1989-90 (87% response rate). Controls were 1598 patients selected from the same surgical departments as the cases and from the general practices from which the cases were originally referred (95% response rate). Main outcome measure-Relative risk of developing oesophageal cancer after stopping drinking (adjusted for age, education, place of birth, smoking, and diet). Results-Current light drinking (<200 g ethanol/week) was not associated with significant increase in risk. Among former drinkers risk fell more quickly in moderate (200-599 g/week) than heavy (greater than or equal to 600 g/week) drinkers. Even among heavy drinkers, however, risk had dropped substantially after five to nine years of not drinking. The results suggest that the time taken for risk to return to that in subjects who never drink was 10-14 years for moderate drinkers and 15 years or more, if ever, for heavy drinkers. Conclusion-Risk of oesophageal cancer decreases fairly rapidly with time after abstaining from drinking. This new finding could be used in health promotion to encourage behavioural changes, especially in heavy drinkers, who have a very high risk of developing oesophageal cancer. It also suggests that alcoholic beverages have a strong effect on the late stage of carcinogenesis.	MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND; UNIV HONG KONG,DEPT COMMUNITY MED,HONG KONG,HONG KONG; UNIV CAMBRIDGE,DEPT COMMUNITY MED,CAMBRIDGE,ENGLAND	MRC Biostatistics Unit; University of Hong Kong; University of Cambridge	CHENG, KK (corresponding author), UNIV BIRMINGHAM,DEPT EPIDEMIOL & PUBL HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.		Cheng, Kar/AAL-8899-2021; Lam, Tai Hing/C-4317-2009	Cheng, Kar/0000-0002-1516-1857; Lam, Tai Hing/0000-0002-2033-9971; Chung, Siu Fung/0000-0001-6640-5893				Alcohol Drinking, 1988, IARC MONOGRAPHS EVAL; ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Breslow N, 1980, STATISTICAL METHODS, V32; BYERS T, 1982, LANCET, V1, P799; CHENG KK, 1992, LANCET, V339, P1314, DOI 10.1016/0140-6736(92)91960-G; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; DAY NE, 1980, JNCI-J NATL CANCER I, V64, P977; HIATT RA, 1988, CANCER RES, V48, P2284; MARTINEZ I, 1969, J NATL CANCER I, V42, P1069; ROSENBERG L, 1982, LANCET, V1, P267; SHOPLAND DR, 1990, IARC SCI PUBL, V103, P77; VICTORA CG, 1987, INT J CANCER, V39, P710, DOI 10.1002/ijc.2910390610; [No title captured]; [No title captured]	14	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1094	1097		10.1136/bmj.310.6987.1094	http://dx.doi.org/10.1136/bmj.310.6987.1094			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742674	Green Published, Green Submitted			2022-12-28	WOS:A1995QW61800013
J	HERD, B; HERD, A; MATHERS, N				HERD, B; HERD, A; MATHERS, N			THE WIZARD AND THE GATEKEEPER - OF CASTLES AND CONTRACTS	BRITISH MEDICAL JOURNAL			English	Article								The wizards and the gatekeepers were unhappy. There were many reasons for their unhappiness. They worked hard but felt that too much was being demanded of them. The poorly people's charter was resulting in unrealistic expectations, and changes in the apprenticeship for wizards were putting great strain on their mentors. The wizards enjoyed their work less and less, and it was getting difficult to find new gatekeepers. On the other hand, the way the system worked meant that there had to be plenty of goblins and the number of scrolls that had to be filled in was rising sharply. The wizards and gatekeepers tried to point out ways to improve things that would ensure that poorly people were better treated, but there was no easy solution. With the ominous sign that the recruitment of wizards and gatekeepers was becoming more difficult, an answer was needed- and soon.	HLTH CTR,SPENNYMOOR DL16 6ED,DURHAM,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT GEN PRACTICE,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Sheffield	HERD, B (corresponding author), N TEES NHS TRUST,STOCKTON ON TEES TS19 8PE,CLEVELAND,ENGLAND.							Brindle David, 1994, GUARDIAN        1107, P2; Brookfield S., 1986, UNDERSTANDING FACILI; CAPLAN RP, 1994, BRIT MED J, V309, P1261, DOI 10.1136/bmj.309.6964.1261; Galen RS, 1975, NORMALITY PREDICTIVE; GALLOWAY M, 1995, HOSP DOCTOR     0309, P1; MATHERS N, 1989, BRIT MED J, V298, P172, DOI 10.1136/bmj.298.6667.172; MATHERS N, 1992, BRIT MED J, V304, P969, DOI 10.1136/bmj.304.6832.969; SMITH R, 1994, BRIT MED J, V309, P1247, DOI 10.1136/bmj.309.6964.1247; TACK, 1995, BMA NEWS REV    0222, P22; 1994, NAHAT74 NAT ASS HLTH, P1; 1993, HOSPITAL DOCTORS TRA; 1995, PATIENTS CHARTER YOU	12	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1042	1044		10.1136/bmj.310.6986.1042	http://dx.doi.org/10.1136/bmj.310.6986.1042			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728059	Green Published			2022-12-28	WOS:A1995QV31300018
J	VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O				VANMEERVELT, L; VLIEGHE, D; DAUTANT, A; GALLOIS, B; PRECIGOUX, G; KENNARD, O			HIGH-RESOLUTION STRUCTURE OF A DNA HELIX-FORMING (C-CENTER-DOT-G)ASTERISK-G BASE TRIPLETS	NATURE			English	Article								TRIPLE helices result from interaction between single- and double-stranded nucleic acids. Their formation is a possible mechanism for recombination of homologous gene sequences in nature and provides, inter alia, a basis for artificial control of gene activity, Triple-helix motifs have been extensively studied by a variety of techniques, but few high-resolution structural data are available, The only triplet structures characterized so far by X-ray diffraction were in protein-DNA complexes(1,2) studied at about 3 Angstrom resolution, We report here the X-ray analysis of a DNA nonamer, d(GCGAATTCG), to a resolution of 2.05 Angstrom, in which the extended crystal structure contains (C . G)*G triplets as a fragment of triple helix. The guanosine-containing chains are in a parallel orientation, This arrangement is a necessary feature of models for homologous recombination which results ultimately in replacement of one length of DNA by another of similar sequence, The present-structure agrees with many published predictions of tripler organization, and provides an accurate representation of an element that allows sequence-specific association between single- and double-stranded nucleic acids.	UNIV BORDEAUX 1, CRISTALLOG LAB, CNRS, ERS 133, F-33405 TALENCE, FRANCE; CAMBRIDGE CRYSTALLOG DATA CTR, CAMBRIDGE CB2 1EZ, ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Cambridge	VANMEERVELT, L (corresponding author), KATHOLIEKE UNIV LEUVEN, DEPT CHEM, CELESTIJNENLAAN 200F, B-3001 HEVERLEE, BELGIUM.		Van Meervelt, Luc/AAD-2878-2022	Van Meervelt, Luc/0000-0003-2186-5209				ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; [Anonymous], 1989, EMBO J, V8, P1; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHENG YK, 1992, J AM CHEM SOC, V114, P4465, DOI 10.1021/ja00038a004; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OUALI M, 1993, J AM CHEM SOC, V115, P4264, DOI 10.1021/ja00063a049; PIRIOU JM, 1994, BIOPHYS CHEM, V50, P323, DOI 10.1016/0301-4622(93)E0103-C; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; ZHURKIN VB, 1994, J MOL BIOL, V239, P181, DOI 10.1006/jmbi.1994.1362	12	63	64	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					742	744		10.1038/374742a0	http://dx.doi.org/10.1038/374742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715732				2022-12-28	WOS:A1995QU30400056
J	YEE, GC; STANLEY, DL; PESSA, LJ; COSTA, TD; BELTZ, SE; RUIZ, J; LOWENTHAL, DT				YEE, GC; STANLEY, DL; PESSA, LJ; COSTA, TD; BELTZ, SE; RUIZ, J; LOWENTHAL, DT			EFFECT OF GRAPEFRUIT JUICE ON BLOOD CYCLOSPORINE CONCENTRATION	LANCET			English	Note							IDENTIFICATION	Grapefruit juice increases blood concentrations of some dihydropyridine calcium-channel blockers, which are metabolised by the P450 enzymes that also metabolise cyclosporin. We evaluated, in a randomised cross-over study, the effect of grapefruit juice on blood cyclosporin concentrations in 14 healthy adults. Each subject was given oral cyclosporin 300 mg with 250 mL grapefruit juice, orange juice, or water. Area-under-the-curve (AUG) was significantly higher with grapefruit juice than with water or orange juice (means 7057, 4871, and 4932 ng h/mL, respectively; p<0.0001). Thus grapefruit juice may provide a non-toxic and inexpensive alternative to drugs that are used to reduce cyclosporin dose.	UNIV FLORIDA,COLL PHARM,DEPT PHARMACEUT,GAINESVILLE,FL 32611; UNIV FLORIDA,SHANDS HOSP,DEPT PHARM SERV,GAINESVILLE,FL 32611; UNIV FLORIDA,COLL MED,DEPT MED,GAINESVILLE,FL 32611; VET AFFAIRS MED CTR,GAINESVILLE,FL	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA)	YEE, GC (corresponding author), UNIV FLORIDA,HLTH SCI CTR,COLL PHARM,DEPT PHARM PRACTICE,POB 100486,GAINESVILLE,FL 32610, USA.		Costa, Teresa CT Dalla/A-6617-2013	Costa, Teresa CT Dalla/0000-0001-9227-2991	NCRR NIH HHS [RR00082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197; DUCHARME MP, 1993, BRIT J CLIN PHARMACO, V36, P457, DOI 10.1111/j.1365-2125.1993.tb00395.x; FIRST MR, 1993, TRANSPLANTATION, V55, P1000, DOI 10.1097/00007890-199305000-00009; GUENGERICH FP, 1990, CARCINOGENESIS, V11, P2275, DOI 10.1093/carcin/11.12.2275; HERLITZ H, 1993, NEPHROL DIAL TRANSPL, V8, P375; KOLARS JC, 1992, J CLIN INVEST, V90, P1871, DOI 10.1172/JCI116064; PATTON PR, 1994, TRANSPLANTATION, V57, P889, DOI 10.1097/00007890-199403270-00021; VALANTINE H, 1992, J HEART LUNG TRANSPL, V11, P1; YEE GC, 1992, APPL PHARMACOKINETIC, V28, P1	10	151	156	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					955	956		10.1016/S0140-6736(95)90700-9	http://dx.doi.org/10.1016/S0140-6736(95)90700-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715295				2022-12-28	WOS:A1995QT91900010
J	KEELEY, D				KEELEY, D			SCREENING FOR MELANOMA RISK IS MISGUIDED	BRITISH MEDICAL JOURNAL			English	Editorial Material																		COCHRANE AL, 1971, BRIT MED BULL, V27, P3, DOI 10.1093/oxfordjournals.bmb.a070810; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; NEWTON JN, 1995, BRIT MED J, V310, P502, DOI 10.1136/bmj.310.6978.502; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P40	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					916	916		10.1136/bmj.310.6984.916	http://dx.doi.org/10.1136/bmj.310.6984.916			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719185	Green Published			2022-12-28	WOS:A1995QR97200028
J	CRAFT, N				CRAFT, N			SECRECY IN THE NHS	BRITISH MEDICAL JOURNAL			English	Article																		FRANKEL M, 1994, NEW SCI         1203, P51; SHEARD S, 1994, BRIT MED J, V309, P1643, DOI 10.1136/bmj.309.6969.1643; SMITH R, 1987, BRIT MED J, V295, P1633, DOI 10.1136/bmj.295.6613.1633	3	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1994	309	6969					1640	1643		10.1136/bmj.309.6969.1640a	http://dx.doi.org/10.1136/bmj.309.6969.1640a			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY220	7726915	Green Published			2022-12-28	WOS:A1994PY22000035
J	KOFF, RS				KOFF, RS			GASTROENTEROLOGY AND HEPATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; HOMOLOG				KOFF, RS (corresponding author), METROWEST MED CTR,FRAMINGHAM,MA 01701, USA.							AKAHANE Y, 1994, ANN INTERN MED, V120, P748, DOI 10.7326/0003-4819-120-9-199405010-00005; BENMENACHEM T, 1994, ANN INTERN MED, V121, P568, DOI 10.7326/0003-4819-121-8-199410150-00003; BJORO K, 1994, NEW ENGL J MED, V331, P1607, DOI 10.1056/NEJM199412153312402; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; POUPON RE, 1994, NEW ENGL J MED, V330, P1342, DOI 10.1056/NEJM199405123301903; SAMUEL D, 1993, NEW ENGL J MED, V329, P1842, DOI 10.1056/NEJM199312163292503; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1994, JAMA-J AM MED ASSOC, V272, P65	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1679	1680						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752413				2022-12-28	WOS:A1995RB09700021
J	STEER, ML; WAXMAN, I; FREEDMAN, S				STEER, ML; WAXMAN, I; FREEDMAN, S			MEDICAL PROGRESS - CHRONIC-PANCREATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC CALCIFYING PANCREATITIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; SHOCK-WAVE LITHOTRIPSY; FINE-NEEDLE BIOPSY; TERM FOLLOW-UP; STONE PROTEIN; LONG-TERM; STENT PLACEMENT; PAIN; DRAINAGE		BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; BETH ISRAEL HOSP, CTR PANCREATICO BILIARY DIS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	STEER, ML (corresponding author), BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ADLER G, 1986, DIAGNOSTIC PROCEDURE, P231; ALLAN J, 1974, DIGESTION, V11, P428, DOI 10.1159/000197611; AMMANN RW, 1984, GASTROENTEROLOGY, V86, P820; AMMANN RW, 1987, PANCREAS, V2, P368, DOI 10.1097/00006676-198707000-00002; AMMANN RW, 1994, PANCREAS, V9, P365, DOI 10.1097/00006676-199405000-00014; AMMANN RW, 1990, GASTROENTEROL CLIN N, V19, P905; AMMANN RW, 1973, DIGESTION, V9, P404, DOI 10.1159/000197469; Andren-Sandberg A, 1989, Int J Pancreatol, V5 Suppl, P51; AXON ATR, 1984, GUT, V25, P1107, DOI 10.1136/gut.25.10.1107; BASTID C, 1990, PANCREAS, V5, P524, DOI 10.1097/00006676-199009000-00005; BEGER HG, 1985, SURGERY, V97, P467; BENGTSSON M, 1990, ACTA CHIR SCAND, V156, P285; BERNARD JP, 1993, GASTROENTEROLOGY, V104, pA295; BLAIR AJ, 1984, ANN SURG, V200, P590, DOI 10.1097/00000658-198411000-00006; BRUGGE WR, 1980, GASTROENTEROLOGY, V78, P937; BURDICK JS, 1991, ENDOSCOPY, V23, P155; CAMPBELL D, 1985, GASTROENTEROLOGY, V88, P1341; Clark Eugene, 1942, AMER JOUR DIGEST DIS, V9, P428; CREMER M, 1989, GASTROINTEST ENDOSC, V35, P1, DOI 10.1016/S0016-5107(89)72677-8; CREMER M, 1991, ENDOSCOPY, V23, P171, DOI 10.1055/s-2007-1010649; CRIADO E, 1992, SURG GYNECOL OBSTET, V175, P293; Del Favero G, 1988, Int J Pancreatol, V3 Suppl 1, pS137; DELHAYE M, 1992, GASTROENTEROLOGY, V102, P610, DOI 10.1016/0016-5085(92)90110-K; DELMASCHIO A, 1991, RADIOLOGY, V178, P95, DOI 10.1148/radiology.178.1.1984331; DEVIERE J, 1994, GUT, V35, P122, DOI 10.1136/gut.35.1.122; DEVIERE J, 1990, GASTROINTEST ENDOSC, V36, P96, DOI 10.1016/S0016-5107(90)70959-5; Dobrilla G, 1989, Int J Pancreatol, V5 Suppl, P17; DURBEC JP, 1978, DIGESTION, V18, P337, DOI 10.1159/000198221; FREEDMAN SD, 1993, GASTROENTEROLOGY, V104, pA304; FREEDMAN SD, 1993, J CLIN INVEST, V92, P83, DOI 10.1172/JCI116602; FREY CF, 1987, PANCREAS, V2, P701, DOI 10.1097/00006676-198711000-00014; Frey CF, 1990, CHRONIC PANCREATITIS, P415; GEENEN JE, 1991, GASTROINTEST ENDOSC, V37, P377, DOI 10.1016/S0016-5107(91)70739-6; GRIMM H, 1989, ENDOSCOPY, V21, P70, DOI 10.1055/s-2007-1012903; GULLIVER DJ, 1992, AM J ROENTGENOL, V159, P751, DOI 10.2214/ajr.159.4.1529836; GULLO L, 1988, GASTROENTEROLOGY, V95, P1063, DOI 10.1016/0016-5085(88)90184-9; GULLO L, 1986, DIAGNOSTIC PROCEDURE, P201; GUY O, 1983, GASTROENTEROLOGY, V84, P102; HARADA H, 1983, ACTA MED OKAYAMA, V37, P227; HARADA H, 1981, Gastroenterologia Japonica, V16, P563; HARADA H, 1982, GASTROENTEROL JPN, V38, P463; HAYAKAWA T, 1989, DIGEST DIS SCI, V34, P33, DOI 10.1007/BF01536151; HUIBREGTSE K, 1988, GASTROINTEST ENDOSC, V34, P9, DOI 10.1016/S0016-5107(88)71221-3; IMRIE CW, 1990, CHRONIC PANCREATITIS, P411; ISAKSSON G, 1983, DIGEST DIS SCI, V28, P97, DOI 10.1007/BF01315137; JACOBSON DG, 1984, NEW ENGL J MED, V310, P1307, DOI 10.1056/NEJM198405173102007; KLOPPEL G, 1992, VIRCHOWS ARCH A, V420, P1, DOI 10.1007/BF01605976; KOZAREK RA, 1990, GASTROINTEST ENDOSC, V36, P93, DOI 10.1016/S0016-5107(90)70958-3; KOZAREK RA, 1991, GASTROENTEROLOGY, V100, P1362; LANG C, 1986, DIAGNOSTIC PROCEDURE, P215; LANKISCH PG, 1993, DIGESTION, V54, P148, DOI 10.1159/000201029; LANKISCH PG, 1983, DIGEST DIS SCI, V28, P490, DOI 10.1007/BF01308149; LANKISCH PG, 1993, PANCREAS, V8, P123, DOI 10.1097/00006676-199301000-00022; LANKISCH PG, 1986, DIAGNOSTIC PROCEDURE, P223; LAYER P, 1994, GASTROENTEROLOGY, V107, P1481, DOI 10.1016/0016-5085(94)90553-3; LAYER P, 1990, CHRONIC PANCREATITIS, P35; LEUNG JWC, 1983, BRIT J SURG, V70, P730, DOI 10.1002/bjs.1800701212; LITTENBERG G, 1979, MEDICINE, V58, P385, DOI 10.1097/00005792-197911000-00001; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; LUETMER PH, 1989, RADIOLOGY, V171, P353, DOI 10.1148/radiology.171.2.2704799; MARKS IN, 1973, DIGESTION, V9, P447, DOI 10.1159/000197473; MARKS IN, 1985, BOCKUS GASTROENTEROL, V6, P4020; MCCARTHY J, 1988, GASTROINTEST ENDOSC, V34, P16, DOI 10.1016/S0016-5107(88)71222-5; MIYAKE H, 1987, PANCREAS, V2, P378, DOI 10.1097/00006676-198707000-00003; MOSSNER J, 1992, DIGESTION, V53, P54, DOI 10.1159/000200971; MOTTALEB A, 1973, GUT, V14, P835, DOI 10.1136/gut.14.11.835; MULTIGNER L, 1985, GASTROENTEROLOGY, V89, P387, DOI 10.1016/0016-5085(85)90341-5; MULTIGNER L, 1983, BIOCHEM BIOPH RES CO, V110, P69, DOI 10.1016/0006-291X(83)91261-5; NAGATA A, 1981, GASTROENTEROLOGY, V81, P884; NAKAMURA K, 1972, GASTROENTEROLOGY, V62, P942; NATTERMANN C, 1993, ENDOSCOPY, V25, P565, DOI 10.1055/s-2007-1010406; NEALON WH, 1988, ANN SURG, V208, P321, DOI 10.1097/00000658-198809000-00009; NEALON WH, 1993, ANN SURG, V217, P458, DOI 10.1097/00000658-199305010-00005; NEUHAUS H, 1991, ENDOSCOPY, V23, P161, DOI 10.1055/s-2007-1010647; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1973, DOI 10.1016/0016-5085(85)90029-0; OKAZAKI K, 1988, AM J GASTROENTEROL, V83, P820; OPEKUN AR, 1993, GASTROENTEROLOGY, V104, pA326; OWYANG C, 1994, J NUTR, V124, pS1321, DOI 10.1093/jn/124.suppl_8.1321S; Owyang C, 1991, TXB GASTROENTEROLOGY, V2, P1874; PARSONS L, 1989, ARCH SURG-CHICAGO, V124, P681; PARTINGTON PF, 1960, ANN SURG, V152, P1037, DOI 10.1097/00000658-196012000-00015; PITCHUMONI CS, 1984, CLIN GASTROENTEROL, V13, P941; PITCHUMONI CS, 1990, CHRONIC PANCREATITIS, P15; PUESTOW CB, 1958, ARCH SURG-CHICAGO, V76, P898; ROSSI RL, 1987, ARCH SURG-CHICAGO, V122, P416; SACHEL J, 1979, DIGEST DIS SCI, V24, P897; SAHEL J, 1991, ENDOSCOPY, V23, P181, DOI 10.1055/s-2007-1010651; SAMER M, 1984, GUT, V25, P756; Sarles H., 1979, EXOCRINE PANCREAS, P402; SAWADA Y, 1989, ACTA CYTOL, V33, P870; SCHMIEGEL W, 1990, GASTROENTEROLOGY, V99, P1421, DOI 10.1016/0016-5085(90)91171-2; SEMELKA RC, 1991, RADIOLOGY, V181, P785, DOI 10.1148/radiology.181.3.1947098; SHEMESH E, 1990, CANCER, V65, P893, DOI 10.1002/1097-0142(19900215)65:4<893::AID-CNCR2820650412>3.0.CO;2-G; SIEGEL JH, 1990, ENDOSCOPY, V22, P129, DOI 10.1055/s-2007-1010727; SINGER MV, 1985, GASTROENTEROLOGY, V89, P683, DOI 10.1016/0016-5085(85)90468-8; SLAFF J, 1984, GASTROENTEROLOGY, V87, P44; STEINBERG W, 1990, AM J GASTROENTEROL, V85, P350; Toskes P. P., 1993, Pancreas, V8, P774; TOSKES PP, 1973, GASTROENTEROLOGY, V65, P662; TRAVERSO LW, 1978, SURG GYNECOL OBSTET, V146, P959; TSURUMI T, 1984, ACTA MED OKAYAMA, V38, P169; VALENTINI M, 1981, ENDOSCOPY, V13, P64, DOI 10.1055/s-2007-1021649; VITAS GJ, 1992, SURGERY, V111, P123; WALSH TN, 1992, GUT, V33, P1566, DOI 10.1136/gut.33.11.1566; WARSHAW AL, 1984, GASTROENTEROLOGY, V86, P987; Whipple AO, 1935, ANN SURG, V102, P763, DOI 10.1097/00000658-193510000-00023; Wiersema Maurits J., 1994, P291; ZUCCARO G, 1992, ENDOSCOPY, V24, P347, DOI 10.1055/s-2007-1010497	108	485	518	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1482	1490		10.1056/NEJM199506013322206	http://dx.doi.org/10.1056/NEJM199506013322206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739686				2022-12-28	WOS:A1995RA14000006
J	CHROUSOS, GP				CHROUSOS, GP			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS AND IMMUNE-MEDIATED INFLAMMATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORTICOTROPIN-RELEASING HORMONE; TUMOR-NECROSIS-FACTOR; SUSCEPTIBLE LEWIS RATS; CENTRAL NERVOUS-SYSTEM; RHEUMATOID-ARTHRITIS; MESSENGER-RNA; STIMULATED ADRENOCORTICOTROPIN; ARGININE-VASOPRESSIN; SUBSTANCE-P; T-CELLS				CHROUSOS, GP (corresponding author), NICHHD, DEV ENDOCRINOL BRANCH, BLDG 10, RM 10N262, BETHESDA, MD 20892 USA.							AIRD F, 1993, P NATL ACAD SCI USA, V90, P7104, DOI 10.1073/pnas.90.15.7104; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; ALMAWI WY, 1991, J IMMUNOL, V146, P3523; ANDREIS PG, 1992, ENDOCRINOLOGY, V131, P69, DOI 10.1210/en.131.1.69; BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993; BATEMAN A, 1989, ENDOCR REV, V10, P92, DOI 10.1210/edrv-10-1-92; BERCZI I, 1986, PITUITARY FUNCTION I, P185; Berczi I, 1986, PITUITARY FUNCTION I, P161; BERNARDINI R, 1990, ENDOCRINOLOGY, V126, P2876, DOI 10.1210/endo-126-6-2876; BLALOCK JE, 1989, PHYSIOL REV, V69, P1, DOI 10.1152/physrev.1989.69.1.1; BLAUER KL, 1991, ENDOCRINOLOGY, V129, P3174, DOI 10.1210/endo-129-6-3174; BOUMPAS DT, 1993, ANN INTERN MED, V119, P1198, DOI 10.7326/0003-4819-119-12-199312150-00007; BURNS G, 1989, ENDOCRINOLOGY, V125, P1365, DOI 10.1210/endo-125-3-1365; CALOGERO AE, 1992, METABOLISM, V41, P839, DOI 10.1016/0026-0495(92)90164-6; CALOGERO AE, 1992, NEUROENDOCRINOLOGY, V55, P600, DOI 10.1159/000126173; CARNES M, 1990, ENDOCRINOLOGY, V126, P1904, DOI 10.1210/endo-126-4-1904; CELANDER O, 1953, ACTA PHYSIOL SCAND, V29, P359, DOI 10.1111/j.1748-1716.1953.tb01031.x; CHAPMAN LF, 1964, ANN NY ACAD SCI, V116, P990, DOI 10.1111/j.1749-6632.1964.tb52564.x; CHIKANZA IC, 1992, ARTHRITIS RHEUM, V35, P1281, DOI 10.1002/art.1780351107; CHROUSOS GP, 1992, ENDOCRIN METAB CLIN, V21, P833, DOI 10.1016/S0889-8529(18)30191-9; CHROUSOS GP, 1993, ANN INTERN MED, V119, P1113, DOI 10.7326/0003-4819-119-11-199312010-00009; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V268, P200; CID MC, 1994, J CLIN INVEST, V93, P17, DOI 10.1172/JCI116941; CODERRE TJ, 1989, J NEUROPHYSIOL, V62, P48, DOI 10.1152/jn.1989.62.1.48; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026, DOI 10.1164/ajrccm/144.5.page; COVESMITH JR, 1978, BRIT MED J, V2, P253, DOI 10.1136/bmj.2.6132.253; CROFFORD LJ, 1992, J CLIN INVEST, V90, P2555, DOI 10.1172/JCI116150; CROFFORD LJ, 1993, J IMMUNOL, V151, P1587; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; CULMAN J, 1993, BRAIN RES, V625, P75, DOI 10.1016/0006-8993(93)90139-E; DALLMAN MF, 1993, TRENDS ENDOCRIN MET, V4, P62, DOI 10.1016/S1043-2760(05)80017-7; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; DE GOEIJ DCE, 1991, NEUROENDOCRINOLOGY, V53, P150, DOI 10.1159/000125712; DEKARIS D, 1993, JAMA-J AM MED ASSOC, V270, P595, DOI 10.1001/jama.270.5.595; DESIMONI MG, 1990, J EXP MED, V171, P1773, DOI 10.1084/jem.171.5.1773; DIBATTISTA JA, 1993, J CLIN ENDOCR METAB, V76, P1128, DOI 10.1210/jc.76.5.1128; DLUHY RG, 1990, J CLIN ENDOCR METAB, V70, P563; EKMAN R, 1993, J NEUROIMMUNOL, V44, P7, DOI 10.1016/0165-5728(93)90262-W; ELKABIR DR, 1990, REGUL PEPTIDES, V28, P199, DOI 10.1016/0167-0115(90)90018-R; ENGEL D, 1978, RES EXP MED, V173, P1, DOI 10.1007/BF01851368; ENGELMAN EG, 1993, 57TH ANN SCI M AM CO, pS92; ENGLER D, 1989, NEUROENDOCRINOLOGY, V49, P367, DOI 10.1159/000125141; EUSTACHIO B, 1563, OPUSCULA ANATOMICA; GAILLARD RC, 1990, ENDOCRINOLOGY, V127, P101, DOI 10.1210/endo-127-1-101; GALLIN JI, 1988, INFLAMMATION BASIC P, P1; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; Gordon B. L., 1949, MED ANTIQUITY; GORDON ML, 1950, ENDOCRINOLOGY, V47, P347, DOI 10.1210/endo-47-5-347; HARBUZ MS, 1992, J ENDOCRINOL, V134, P327, DOI 10.1677/joe.0.1340327; HARKNESS JAL, 1982, BMJ-BRIT MED J, V284, P551, DOI 10.1136/bmj.284.6315.551; HENCH PS, 1949, P STAFF M MAYO CLIN, V24, P181; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HINSON JP, 1990, J ENDOCRINOL, V124, P7, DOI 10.1677/joe.0.1240007; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HOLMES MC, 1986, NATURE, V319, P326, DOI 10.1038/319326a0; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; IMURA H, 1991, CLIN ENDOCRINOL, V35, P107, DOI 10.1111/j.1365-2265.1991.tb03506.x; IXART G, 1987, NEUROSCI LETT, V74, P85, DOI 10.1016/0304-3940(87)90056-5; JAATTELA M, 1991, ENDOCRINOLOGY, V128, P623; JESSOP DS, 1992, J ENDOCRINOL, V132, P331, DOI 10.1677/joe.0.1320331; KAM JC, 1993, J IMMUNOL, V151, P3460; KARALIS K, 1991, SCIENCE, V254, P421, DOI 10.1126/science.1925600; KIDESS AI, 1993, MAYO CLIN PROC, V68, P435, DOI 10.1016/S0025-6196(12)60188-8; KIRKHAM BW, 1991, J RHEUMATOL, V18, P821; KLEIN A, 1990, J RHEUMATOL, V17, P30; KOWAKI G, 1994, NEUROIMMUNOMODULAT, V1, P127; LAMBERTS SWJ, 1984, J CLIN ENDOCR METAB, V58, P298, DOI 10.1210/jcem-58-2-298; LARSEN PJ, 1993, J NEUROENDOCRINOL, V5, P99, DOI 10.1111/j.1365-2826.1993.tb00368.x; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; MASI AT, 1993, 57TH ANN SCI M AM CO, pS176; MASTORAKOS G, 1994, J CLIN ENDOCR METAB, V79, P934, DOI 10.1210/jc.79.4.934; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; MASTORAKOS G, IN PRESS REPRODUCTIV; MEIKLE AW, 1992, J STEROID BIOCHEM, V42, P293, DOI 10.1016/0960-0760(92)90132-3; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NAITOH Y, 1988, BIOCHEM BIOPH RES CO, V155, P1459, DOI 10.1016/S0006-291X(88)81305-6; NAKANO T, 1990, J BIOL CHEM, V265, P12745; NEECK G, 1990, J RHEUMATOL, V17, P24; NIKOLARAKIS KE, 1986, BRAIN RES, V399, P152, DOI 10.1016/0006-8993(86)90610-4; NORBIATO G, 1992, J CLIN ENDOCR METAB, V74, P608, DOI 10.1210/jc.74.3.608; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; OTTENWELLER JE, 1982, ENDOCRINOLOGY, V111, P1334, DOI 10.1210/endo-111-4-1334; PARKER LN, 1985, J CLIN ENDOCR METAB, V60, P947, DOI 10.1210/jcem-60-5-947; PATCHEV VK, 1993, NEUROENDOCRINOLOGY, V58, P106, DOI 10.1159/000126519; PATCHEV VK, 1992, ENDOCRINOLOGY, V131, P1453, DOI 10.1210/en.131.3.1453; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAYAN DG, 1985, J IMMUNOL, V135, pS783; PERLSTEIN RS, 1993, ENDOCRINOLOGY, V132, P946, DOI 10.1210/en.132.3.946; PERLSTEIN RS, 1991, LYMPHOKINE CYTOK RES, V10, P141; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; Ravache ES, 1986, PITUITARY FUNCTION I, P283; REDEKOPP C, 1986, ENDOCRINOLOGY, V118, P1410, DOI 10.1210/endo-118-4-1410; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; Reincke Martin, 1994, Neuroimmunomodulation, V1, P14, DOI 10.1159/000095930; RITTMASTER RS, 1987, J CLIN ENDOCR METAB, V64, P371, DOI 10.1210/jcem-64-2-371; ROH MS, 1987, SURGERY, V102, P140; ROTHWELL PM, 1991, LANCET, V337, P582, DOI 10.1016/0140-6736(91)91641-7; SALAS MA, 1990, CLIN EXP IMMUNOL, V79, P470; SAPER CB, 1976, BRAIN RES, V117, P305, DOI 10.1016/0006-8993(76)90738-1; SAWCHENKO PE, 1993, CIBA F SYMP, V172, P5; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; SCHLAGHECKE R, 1992, ARTHRITIS RHEUM-US, V35, P740, DOI 10.1002/art.1780350704; SCHULTZBERG M, 1989, NEUROSCIENCE, V30, P805, DOI 10.1016/0306-4522(89)90171-1; SCOPA CD, 1994, AM J PATHOL, V145, P1159; Selye H, 1936, NATURE, V138, P32, DOI 10.1038/138032a0; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575, DOI 10.1210/endo-125-1-575; STAPOLSKY R, 1987, SCIENCE, V238, P522; STEPHANOU A, 1990, BRAIN BEHAV IMMUN, V4, P67, DOI 10.1016/0889-1591(90)90007-D; STERNBERG EM, 1993, J RHEUMATOL, V20, P418; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; SUZUKI T, 1991, CLIN IMMUNOL IMMUNOP, V61, P202, DOI 10.1016/S0090-1229(05)80024-8; SWAIN MG, 1993, J CLIN INVEST, V91, P1903, DOI 10.1172/JCI116408; TILDERS FJH, 1994, PSYCHONEUROENDOCRINO, V19, P209, DOI 10.1016/0306-4530(94)90010-8; TOMINAGA T, 1991, ENDOCRINOLOGY, V128, P526, DOI 10.1210/endo-128-1-526; UEHARA A, 1987, NEUROENDOCRINOLOGY, V45, P343, DOI 10.1159/000124757; VAMVAKOPOULOS NC, 1993, J CLIN INVEST, V92, P1896, DOI 10.1172/JCI116782; VANDEVENTER SJH, 1990, BLOOD, V76, P2520; VANGOOL J, 1990, CLIN IMMUNOL IMMUNOP, V57, P200, DOI 10.1016/0090-1229(90)90034-N; VANKELECOM H, 1990, ENDOCRINOLOGY, V126, P2919, DOI 10.1210/endo-126-6-2919; VANKELECOM H, 1989, NEUROENDOCRINOLOGY, V49, P102, DOI 10.1159/000125097; VINSON GP, 1988, ACTIONS ALPHA MSH AD, V2, P87; VISHWANATH BS, 1993, J CLIN INVEST, V92, P1974, DOI 10.1172/JCI116791; WHITNALL MH, 1989, NEUROENDOCRINOLOGY, V50, P702, DOI 10.1159/000125302; WITORSCH RJ, 1972, ENDOCRINOLOGY, V90, P1160, DOI 10.1210/endo-90-5-1160; WOODS RJ, 1994, J CLIN ENDOCR METAB, V78, P73, DOI 10.1210/jc.78.1.73; ZANKER B, 1990, TRANSPLANTATION, V49, P183, DOI 10.1097/00007890-199001000-00040; ZITNIK RJ, 1994, AM J RESP CELL MOL, V10, P643, DOI 10.1165/ajrcmb.10.6.7516173; 1951, PRIX NOBEL 1951, P195	133	1943	2007	2	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1351	1362		10.1056/NEJM199505183322008	http://dx.doi.org/10.1056/NEJM199505183322008			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715646				2022-12-28	WOS:A1995QX85700008
J	MULLAN, F; POLITZER, RM; DAVIS, CH				MULLAN, F; POLITZER, RM; DAVIS, CH			MEDICAL MIGRATION AND THE PHYSICIAN WORKFORCE - INTERNATIONAL MEDICAL GRADUATES AND AMERICAN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOREIGN	Objective.-Because of the size and growth of the international medical graduate (IMG) contribution to graduate medical education (GME) in the United States, and subsequently to the US physician workforce, it is essential to understand the demographics and patterns of IMG training and practice as well as the routes of entry into the United States. Data Sources.-Published data from the American Medical Association, the American Osteopathic Association, and the Association of American Medical Colleges; tabular runs of county-level data contained on the Bureau of Health Professions' Area Resource File. Results.-The majority of IMGs who participate in GME in the United States ultimately enter US practices. A significant proportion of exchange visitors eventually enter into permanent practice in the United States, contrary to the intent of the J-1 visa-based GME training as an international educational exchange program. International medical graduates gravitate toward initial residency programs in internal medicine and pediatrics, many of which have unfilled positions; however, IMGs subspecialize at a disproportionately high rate, reducing their net contribution to the generalist pool. Patterns of ultimate practice location of IMGs parallel the patterns of US medical graduates (USMGs). Conclusions.-In recent years, participation of IMGs in GME and practice has increased significantly. Most IMGs in GME are not exchange visitors, but are either permanent residents or US citizens. Patterns of specialization and location of IMGs ultimately mirror those of USMGs. National IMG policy must be examined in light of the projected surplus of physicians in the United States, The best option for long-term control of the number of physicians in practice, USMG or IMG, is a system of specifying the number of GME positions nationally.	US BUR HLTH PROFESS,OFF RES & PLANNING,WORKFACE ANAL & RES BRANCH,ROCKVILLE,MD 20857; US BUR HLTH PROFESS,DIV MED,ROCKVILLE,MD 20857		MULLAN, F (corresponding author), US BUR HLTH PROFESS,OFF DIRECTOR,5600 FISHER LN,PARKLAWN BLDG,ROOM 8-05,ROCKVILLE,MD 20857, USA.							COOPER RA, 1994, JAMA-J AM MED ASSOC, V272, P680, DOI 10.1001/jama.272.9.680; CROZIER D, 1984, HLTH AFF MILLWOO WIN, P122; Dublin T.D., 1980, CHANGING ROLE FOREIG; EISENBERG J, 1986, DOCTORS DECISIONS CO; GAMLIEL S, IN PRESS HLTH AFF MI; GAMLIEL S, 1994, PATIENT CARE PHYSICI; GINSBERG E, 1992, JAMA-J AM MED ASSOC, V268, P3115; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HUGHES JS, 1991, JAMA-J AM MED ASSOC, V265, P2347, DOI 10.1001/jama.265.18.2347; IGLEHART JK, 1985, JAMA-J AM MED ASSOC, V254, P1785, DOI 10.1001/jama.254.13.1785; LETSCH SW, 1993, HLTH AFFAIRS     SPR, P94; LUFT H, 1986, HLTH AFF MILLWOO WIN, P31; MICK S, 1992, 1987 CAREER CHARACTE; MICK SS, 1975, SCI AM, V232, P14, DOI 10.1038/scientificamerican0275-14; MICK SS, 1984, AM J PUBLIC HEALTH, V74, P698, DOI 10.2105/AJPH.74.7.698; MICK SS, 1993, HEALTH POLICY, V24, P213, DOI 10.1016/0168-8510(93)90041-M; MICK SS, 1984, MED CARE, V22, P1014, DOI 10.1097/00005650-198411000-00004; MULLAN F, 1993, HEALTH AFFAIR, V12, P138, DOI 10.1377/hlthaff.12.suppl_1.138; POLITZER R, 1983, DHHS HRSPOD832 US DE; POLITZER RM, 1989, MED CARE, V27, P1046, DOI 10.1097/00005650-198911000-00006; STEVENS R, 1975, SCIENCE, V190, P439, DOI 10.1126/science.1101381; STEVENS R, 1978, ALIEN DOCTORS; Stevens R A, 1974, Inquiry, V11, P112; TARLOV A, 1986, HLTH AFFAIRS     SPR, P23; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; WENNBERG JE, 1993, HLTH AFFAIRS     SUM, P89; 1993, PRIMARY CARE WORKFOR; 1993, TAKING CHARGE GRADUA; 1993, ANN REPORT C 1993; 1980, SUMMARY REPORT SECRE; 1988, 1ST REPORT COUNCIL, P1; 1992, PHYSICIAN CHARACTERI; 1992, 3RD REPROT IMPROVING; 1994, SPECIAL TABULATIONS	35	113	113	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1521	1527		10.1001/jama.273.19.1521	http://dx.doi.org/10.1001/jama.273.19.1521			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739079				2022-12-28	WOS:A1995QX41800035
J	DELEEUW, E				DELEEUW, E			EUROPEAN SCHOOLS OF PUBLIC-HEALTH IN STATE OF FLUX	LANCET			English	Article								In 1992 there were in Europe 54 schools of public health and six out of eight possible structures were represented. To meet future needs two types (the US style school of public health as a stand-alone academic entity and the cross-school programme in public health with formal lies to national public health authorities) seem to be the most promising alternatives. New schools should strive to take on one of these shapes, and the rejuvenation of existing schools might, via accreditation procedures, evolve in those directions too.	ASSOC SCH PUBL HLTH EUROPEAN REG,MAASTRICHT,NETHERLANDS				de Leeuw, Evelyne/R-9219-2019					DELEEUW E, IN PRESS INT MED REV; LAASER U, 1995, SCI F EUROPEAN PUBLI; 1994, TRAINING RES PUBL HL, V1; 1993, ASPHER DIRECTORY; 1994, LANCET, V343, P429; 1994, TRAINING RES PUBL HL, V2; 1994, ASPHER COLLABORATION	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1158	1160		10.1016/S0140-6736(95)90983-4	http://dx.doi.org/10.1016/S0140-6736(95)90983-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723551				2022-12-28	WOS:A1995QW62200015
J	FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG				FLEG, JL; SHAPIRO, EP; OCONNOR, F; TAUBE, J; GOLDBERG, AP; LAKATTA, EG			LEFT-VENTRICULAR DIASTOLIC FILLING PERFORMANCE IN OLDER MALE-ATHLETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECHOCARDIOGRAPHIC MEASUREMENTS; HEART-RATE; EXERCISE; AGE; HYPERTROPHY; CONTRACTION; POPULATION; INDEXES; PRELOAD; HUMANS	Objective.-To determine whether older men who have undergone intensive endurance training over many years demonstrate less age-associated impairment of early diastolic left ventricular (LV) filling performance than their sedentary peers. Design.-Cross-sectional prospective study. Setting.-Community-dwelling research volunteers. Participants.-Sixteen older competitive male endurance athletes aged 52 through 76 years and 17 young (40 years) and 23 older (52 through 76 years) sedentary control subjects from the Baltimore Longitudinal Study of Aging. Intervention.-All subjects underwent resting Doppler echocardiography and determination of maximal aerobic capacity (Vo(2)max) during graded treadmill exercise. Doppler echocardiographic studies were interpreted without knowledge of the subject's age or exercise habits. Main Outcome Measures.-Doppler-derived measures of LV diastolic filling performance: peak early (E) filling velocity, peak late (A) filling velocity, ratio of peak E to peak A velocities (E/A), and atrial filling fraction. Results.-Older athletes demonstrated higher Vo(2)max (47+/-6 mL/kg per minute [mean+/-SD]) than either the young controls (41 +/-7 mL/kg per minute) or older controls (30+/-7 mL/kg per minute) (P<.05) as evidence of their superior conditioning status. However, peak E diastolic LV filling velocity was higher in young controls (79+/-17 cm/s) than in older athletes (56+/-15 cm/s) or older controls 68+/-18 cm/s) (P<.001). This age difference persisted after normalizing peak E velocity for mitral stroke volume. Peak EIA ratio and atrial filling fraction were also similar in older athletes (1.2+/-0.5 and 0.41+/-0.1, respectively) and older controls (1.1+/-0.4 and 0.41+/-0.1, respectively), and differed significantly from corresponding values of 1.7+/-0.4 and 0.33+/-0.1 in young controls (P<.001 and P<.05, respectively), By multiple regression analysis, age but not treadmill Vo(2)max was a significant predictor of peak E velocity, peak A velocity, peak E/A ratio, and atrial filling fraction. Conclusion.-Older men with a long history of intensive endurance training demonstrate impaired early diastolic LV filling similar to that of their sedentary peers. Thus, impairment of early diastolic filling appears to be intrinsic to normative aging and not secondary to the reduction in aerobic capacity that accompanies the aging process.	JOHNS HOPKINS UNIV,BAYVIEW MED CTR,DIV CARDIOL,BALTIMORE,MD; UNIV MARYLAND,SCH MED,DIV GERONTOL,BALTIMORE,MD	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore	FLEG, JL (corresponding author), NIA,GERONTOL RES CTR,CARDIOVASC SCI LAB,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.		Lakatta, Edward G/AAL-1447-2020; Shapiro, Edward/AAG-1611-2020	Lakatta, Edward/0000-0002-4772-0035	NIA NIH HHS [AG-04402, R01-AG-07660] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007660, P01AG004402] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLETON CP, 1991, J AM COLL CARDIOL, V17, P227, DOI 10.1016/0735-1097(91)90731-N; ARORA RR, 1987, J AM COLL CARDIOL, V9, P1255, DOI 10.1016/S0735-1097(87)80464-3; BONOW RO, 1988, J AM COLL CARDIOL, V11, P50, DOI 10.1016/0735-1097(88)90166-0; BOWMAN LK, 1988, J AM COLL CARDIOL, V12, P937, DOI 10.1016/0735-1097(88)90458-5; BRYG RJ, 1987, AM J CARDIOL, V59, P971, DOI 10.1016/0002-9149(87)91136-2; CHOONG CY, 1987, J AM COLL CARDIOL, V10, P800, DOI 10.1016/S0735-1097(87)80273-5; COLAN SD, 1985, J AM COLL CARDIOL, V6, P545, DOI 10.1016/S0735-1097(85)80111-X; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DOUGLAS PS, 1992, J APPL PHYSIOL, V72, P1969, DOI 10.1152/jappl.1992.72.5.1969; DOUGLAS PS, 1986, AM J CARDIOL, V58, P805, DOI 10.1016/0002-9149(86)90358-9; FAGARD R, 1987, J AM COLL CARDIOL, V9, P1250, DOI 10.1016/S0735-1097(87)80463-1; FINKELHOR RS, 1986, J AM COLL CARDIOL, V8, P289, DOI 10.1016/S0735-1097(86)80042-0; FLEG JL, 1988, J APPL PHYSIOL, V65, P1147, DOI 10.1152/jappl.1988.65.3.1147; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; FORTNEY S, 1992, J APPL PHYSIOL, V73, P2693, DOI 10.1152/jappl.1992.73.6.2693; GARDIN JM, 1979, J CLIN ULTRASOUND, V7, P439, DOI 10.1002/jcu.1870070606; GERSTENBLITH G, 1977, CIRCULATION, V56, P273, DOI 10.1161/01.CIR.56.2.273; GRANGER CB, 1985, J AM COLL CARDIOL, V5, P862, DOI 10.1016/S0735-1097(85)80424-1; GWATHMEY JK, 1990, J APPL PHYSIOL, V69, P1366, DOI 10.1152/jappl.1990.69.4.1366; HARRISON MR, 1991, AM J CARDIOL, V87, P622; KITZMAN DW, 1991, J AM COLL CARDIOL, V18, P1243, DOI 10.1016/0735-1097(91)90542-H; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; MATSUDA M, 1983, J APPL PHYSIOL, V55, P323, DOI 10.1152/jappl.1983.55.2.323; MIYATAKE K, 1984, AM J CARDIOL, V53, P587; Rose G, 1968, CARDIOVASCULAR SURVE; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SARTORI MP, 1987, AM J CARDIOL, V59, P1179, DOI 10.1016/0002-9149(87)90871-X; SCHULMAN SP, 1992, AM J PHYSIOL, V263, pH1932, DOI 10.1152/ajpheart.1992.263.6.H1932; SHAPIRO LM, 1983, BRIT HEART J, V50, P534; SHOCK NW, 1984, NIH842450 PUBL, P45; SPURGEON HA, 1983, AM J PHYSIOL, V244, pH513, DOI 10.1152/ajpheart.1983.244.4.H513; STARNES JW, 1983, AM J PHYSIOL, V245, P560; STODDARD MF, 1989, CIRCULATION, V79, P1226, DOI 10.1161/01.CIR.79.6.1226; SWINNE CJ, 1992, AM J CARDIOL, V69, P823, DOI 10.1016/0002-9149(92)90518-4; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; TATE CA, 1990, AM J PHYSIOL, V258, pH431, DOI 10.1152/ajpheart.1990.258.2.H431	36	80	80	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1371	1375		10.1001/jama.273.17.1371	http://dx.doi.org/10.1001/jama.273.17.1371			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715063				2022-12-28	WOS:A1995QV30700023
J	KANE, RL				KANE, RL			IMPROVING THE QUALITY OF LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PATIENTS; OUTCOMES; IMPACT	Quality of long-term care can be improved by changing the strategies used to monitor it. Nursing home care has been the subject of intensive regulations, while it has been neglected by physicians. Newer forms of long-term care are coming under stricter oversight, which may stifle the innovations they offer. Greater but different attention is needed: more creativity can be fostered with better accountability by emphasizing long-term care outcomes. It is unrealistic to require that long-term care patients will improve; good outcomes are defined as doing as well as or better than expected. The Minimum Data Set for nursing homes offers a mechanism to generate data on many pertinent outcomes. An outcomes focus would encourage more collective action by the various parties involved in providing long-term care, including physicians. Clinicians are reluctant to assume responsibility for outcomes they feel unable to strongly influence, but they must recognize that part of their role is to engender cooperation from the myriad participants in long-term care, including patients and their families. Better-quality long-term care may cost more, but it may be possible to use less expensive personnel more creatively if current regulations are modified. Managed care arrangements offer one vehicle for reorganizing care and could provide the appropriate incentives to make positive changes. However, they could also lead to minimalist strategies. Accountability for realistic outcomes can provide the needed countervailing regulatory pressure.			KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNESOTA CHAIR LONG TERM CARE & AGING,420 DELAWARE ST SE,BOX 197,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE ON AGING [K07AG000622] Funding Source: NIH RePORTER; NIA NIH HHS [5K07-AG00622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELSTEIN AS, 1972, J MED EDUC, V47, P85; FOX PD, 1991, INITIATIVES SERVICE; FRIEDMAN B, 1993, J AM GERIATR SOC, V41, P1144, DOI 10.1111/j.1532-5415.1993.tb06465.x; GARRARD J, 1990, MED CARE, V28, P271, DOI 10.1097/00005650-199003000-00007; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Institute of Medicine report, 1986, IMPROVING QUALITY CA; Kane R.A., 1981, ASSESSING ELDERLY; Kane R L, 1976, J Community Health, V2, P1, DOI 10.1007/BF01349487; Kane R L, 1976, J Community Health, V1, P233, DOI 10.1007/BF01324582; KANE RA, 1994, HEALTH CARE FINANC R, V16, P69; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; Kane RA, 1993, ASSISTED LIVING US N; KANE RA, IN PRESS MILBANK Q; KANE RA, 1995, DELEGATION NURSING A; KANE RA, 1990, EVERYDAY ETHICS SOLV; KANE RL, 1983, GERONTOLOGIST, V23, P200, DOI 10.1093/geront/23.2.200; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1991, J AM GERIATR SOC, V39, P359, DOI 10.1111/j.1532-5415.1991.tb02900.x; KANE RL, 1993, ANNU REV PUBL HEALTH, V14, P545, DOI 10.1146/annurev.pu.14.050193.002553; KUROWSKI BD, 1982, HE222C182 US DEP HLT; MALONE JK, 1993, J HLTH CARE BENE JAN, P51; MANGEN DJ, 1984, HLTH PROGRAM EVALUAT; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MENDELSON MA, 1974, TENDER LOVING GREED; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS R, 1974, GERONTOLOGIST, V14, P14, DOI 10.1093/geront/14.1.14; MORRIS R, 1980, AM J PUBLIC HEALTH, V70, P471, DOI 10.2105/AJPH.70.5.471; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P35; SIU AL, 1993, J CLIN EPIDEMIOL, V46, P1093, DOI 10.1016/0895-4356(93)90108-D; TERESI JA, 1992, GERONTOLOGIST, V32, P148, DOI 10.1093/geront/32.2.148; Vladeck B.C., 1980, UNLOVING CARE NURSIN; WEISSERT WG, 1989, HLTH CARE ELDERLY IN; 1990, MEDICARE STRATEGY QU; 1993, MEDICARE AM HLTH CAR	40	68	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1376	1380		10.1001/jama.273.17.1376	http://dx.doi.org/10.1001/jama.273.17.1376			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715064				2022-12-28	WOS:A1995QV30700024
J	BROOKS, AS; HELGREN, DM; CRAMER, JS; FRANKLIN, A; HORNYAK, W; KEATING, JM; KLEIN, RG; RINK, WJ; SCHWARCZ, H; SMITH, JNL; STEWART, K; TODD, NE; VERNIERS, J; YELLEN, JE				BROOKS, AS; HELGREN, DM; CRAMER, JS; FRANKLIN, A; HORNYAK, W; KEATING, JM; KLEIN, RG; RINK, WJ; SCHWARCZ, H; SMITH, JNL; STEWART, K; TODD, NE; VERNIERS, J; YELLEN, JE			DATING AND CONTEXT OF 3 MIDDLE STONE-AGE SITES WITH BONE POINTS IN THE UPPER SEMLIKI VALLEY, ZAIRE	SCIENCE			English	Article							TOOTH ENAMEL; RESONANCE	The extent to which the earliest anatomically modern humans in Africa exhibited behavioral and cognitive traits typical of Home sapiens sapiens is controversial. In eastern Zaire, archaeological sites with bone points have yielded dates older than 89(-15)(+22) thousand years ago by several techniques. These include electron spin resonance, thermoluminescence, optically stimulated luminescence, uranium series, and amino acid racemization. Faunal and stratigraphic data are consistent with this age.	SAN JOSE STATE UNIV,DEPT GEOG & ENVIRONM STUDIES,SAN JOSE,CA 95192; HARVARD UNIV,DEPT ANTHROPOL,CAMBRIDGE,MA 02138; UNIV MARYLAND,DEPT PHYS,COLLEGE PK,MD 20742; STANFORD UNIV,DEPT ANTHROPOL,PALO ALTO,CA 94305; MCMASTER UNIV,DEPT GEOL,HAMILTON,ON L8S 4M1,CANADA; SYRACUSE UNIV,DEPT ANTHROPOL,SYRACUSE,NY 13244; CANADIAN MUSEUM NAT,DIV ZOOARCHEOL RES,OTTAWA,ON K1P 6P4,CANADA; STATE UNIV GHENT,DEPT GEOL,PALEONTOL LAB,B-9000 GHENT,BELGIUM; NATL FUND SCI RES,BRUSSELS,BELGIUM; NATL SCI FDN,ARCHEOL PROGRAM,ARLINGTON,VA 22230	California State University System; San Jose State University; Harvard University; University System of Maryland; University of Maryland College Park; Stanford University; McMaster University; Syracuse University; Ghent University; Fonds de la Recherche Scientifique - FNRS; National Science Foundation (NSF)	BROOKS, AS (corresponding author), GEORGE WASHINGTON UNIV,DEPT ANTHROPOL,GEOBIOL PROGRAM,WASHINGTON,DC 20052, USA.		Klein, Richard G/B-5910-2009; Verniers, Jacques/B-8024-2009	Verniers, Jacques/0000-0002-2939-7684				ADAM W, 1959, ANN MUS R CONGO BE 8, V25; AMBROSE SH, 1992, 11TH BIENN M SOC AFR; [Anonymous], 1986, AFR ARCHAEOL REV, DOI [DOI 10.1007/BF01117035, 10.1007/BF01117035]; BELLOMO R, MASCA RES PAPERS S S, V11; BELLOMO RV, 1993, J ARCHAEOL SCI, V20, P525, DOI 10.1006/jasc.1993.1033; BITANKOKAMUANGA MW, 1991, AUX ORIGINES AFRIQUE; BOAZ NT, 1992, J HUM EVOL, V22, P505, DOI 10.1016/0047-2484(92)90083-L; BOAZ NT, 1994, INTEGRATIVE PATHS PA, P321; BOAZ NT, 1990, MEM VIRGINIA MUSEUM, V1; Brooks A., 1987, AFR ARCHAEOL REV, V5, P67; Brooks A. S., 1990, WORLD 18000 BP, V2, P121; CAHEN D, 1986, ANTHROPOLOGIE, V80, P573; CLARK JD, 1988, J WORLD PREHIST, V2, P235, DOI 10.1007/BF00975618; COOKE HBS, 1990, MEM VIRGINIA MUSEUM, V1, P197; Damas H., 1940, Revue de Zoologie et de Botanique Africaines, V33, P265; DEHEINZELIN J, 1987, MUS R AFR CENT RAPP, P141; DEHEINZELIN J, 1957, EXPLORATION PARC NAT; DEHEINZELIN J, 1994, INTEGRATIVE PATHS PA, P313; DEHEINZELIN J, 1961, EXPLORATION PARC NAT; DEHEINZELIN J, 1955, EXPLORATION PARC NAT; DeHEINZELIN JEAN, 1962, SCI AMER, V206, P105; FUCHS VE, 1931, GEOL MAG, V72, P145; FUCHS VE, 1930, GEOL MAG, V71, P97; GAUTIER A., 1967, P73; Gautier A., 1970, ANN MUSEE ROYAL AF 8, V67, P1; GREENWOOD PH, 1959, EXPLORATION PARC NAT, P1; GRUN R, 1987, CAN J EARTH SCI, V24, P1022, DOI 10.1139/e87-099; GRUN R, 1988, NUCL TRACKS RAD MEAS, V14, P237; HAR PE, 1993, CARNEGIE I WASHINGTO, V92, P80; HARRIS JWK, 1987, J HUM EVOL, V16, P701, DOI 10.1016/0047-2484(87)90020-0; HAY RL, 1990, GEOLOGICAL SOC AM SP, V242, P23; HELGREN DM, 1983, J ARCHAEOL SCI, V10, P181, DOI 10.1016/0305-4403(83)90051-1; HOPWOOD AT, 1959, EXPLORATION PARC NAT, P111; KALB JE, 1993, NEWSL STRATIGR, V29, P21; KALB JE, 1993, T AM PHILOS SOC, V83, P1; KAYLOR R, 1993, ANCIENT TL, V11, P40; Kokis J.E., 1993, CARNEGIE I WASHINGTO, V92, P95; KOKIS JE, 1988, THESIS G WASHINGTON; LEPERSONNE J, 1970, ANN MUS ROY AFR, V67, P169; LEPERSONNE J, 1949, ANN SOC GEOL BELG, V72, P1; MCBREARTY S, 1991, MONOGR ROMISCH GERMA, V19, P159; MCDERMOTT F, 1993, NATURE, V363, P252, DOI 10.1038/363252a0; MEHLMAN MJ, 1987, J ARCHAEOL SCI, V14, P133, DOI 10.1016/0305-4403(87)90003-3; MEHLMAN MJ, 1979, WORLD ARCHAEOL, V11, P80, DOI 10.1080/00438243.1979.9979751; MILLER GH, 1992, PHILOS T ROY SOC B, V337, P149, DOI 10.1098/rstb.1992.0092; MISAGO K, 1989, NSI, V5, P23; MISAGO K, 1990, MEM VIRGINIA MUSEUM, V1, P301; MUGANGU TE, COMMUNICATION; MUGANGUTRINTO E, 1989, MAMMALIA, V53, P511, DOI 10.1515/mamm.1989.53.4.511; PAVLAKIS PP, 1990, MEM VIRGINIA MUSEUM, V1, P203; Peters J., 1990, Revue de Paleobiologie, V9, P73; PHILLIPSON DW, 1976, MEM BRIT I E AFRICA, V6; SANDERS WJ, 1990, MEM VIRGINIA MUSEUM, V1, P171; SCHOLZ CA, 1988, SCIENCE, V240, P1645, DOI 10.1126/science.240.4859.1645; SCHWARCZ H, UNPUB; SCHWARCZ HP, 1992, PHILOS T ROY SOC B, V337, P145, DOI 10.1098/rstb.1992.0091; STEWART KM, 1990, MEM VIRGINIA MUSEUM, V1, P141; STEWART KM, 1989, CAMBRIDGE MONOGRAPHS, V34; Tappen M.J, 1992, THESIS HARVARD U; TWIESSELMAN F, 1958, EXPLORATION PARC NAT; VANNOTEN F, 1977, ANTIQUITY, V51, P35; VERHEYEN R, 1959, EXPLORATION PARC NAT, P109; WILLIAMSON PG, 1990, VIRGINIA MUS NAT HIS, V1, P125; YELLEN JE, 1995, SCIENCE, V268, P553, DOI 10.1126/science.7725100; [No title captured]	65	147	149	0	17	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					548	553		10.1126/science.7725099	http://dx.doi.org/10.1126/science.7725099			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV407	7725099				2022-12-28	WOS:A1995QV40700032
J	SAMANI, NJ; MARTIN, DS; BRACK, M; CULLEN, J; CHAUHAN, A; LODWICK, D; HARLEY, A; SWALES, JD; DEBONO, DP; GERSHLICK, AH				SAMANI, NJ; MARTIN, DS; BRACK, M; CULLEN, J; CHAUHAN, A; LODWICK, D; HARLEY, A; SWALES, JD; DEBONO, DP; GERSHLICK, AH			INSERTION DELETION POLYMORPHISM IN THE ANGIOTENSIN-CONVERTING ENZYME GENE AND RISK OF RESTENOSIS AFTER CORONARY ANGIOPLASTY	LANCET			English	Article							PROLIFERATION; INJURY	Early restenosis in over 30% of cases limits the benefits of percutaneous transluminal coronary angioplasty (PTCA). The mechanisms that underlie restenosis are uncertain, although experimental evidence suggests that the renin-angiotensin system is involved in the vascular response to angioplasty. An insertion(I)/deletion(D) polymorphism in the angiotensin-converting enzyme (ACE) gene, which influences plasma ACE level, has been associated with an increased risk of myocardial infarction in those with the DD genotype. To investigate whether this polymorphism influences the risk of restenosis after PTCA, 233 patients who underwent single-vessel angioplasty in the Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) study were genotyped for the I/D polymorphism and pre-PTCA, post-PTCA, and 4-month clinical and quantitative angiographic data were compared in the three genotype groups. The groups, (II 53, ID 117, and DD 63) were well matched for baseline clinical and both pre- and post-PTCA angiographic features. At 4-month follow-up there was no significant difference between the genotype groups with respect to any of the quantitative angiographic criteria of restenosis: minimal luminal diameter at the site of the angioplasty (DD 1.35 [SE 0.10] mm, ID/II 1.43 [0.05] mm, difference -0.08 [95% CI -0.30 to 0.14]), numbers of subjects with more than 50% diameter stenosis (DD 49%, ID/II 46%, relative risk 1.06 [0.79 to 1.43]), or the number of subjects with more than 50% loss of the acute diameter gain after PTCA (DD 54%, ID/II 43%, 1.26 [0.94 to 1.67]). Likewise, there was no difference in the number of subjects with angina or a positive exercise stress test. We conclude that, in patients undergoing elective PTCA, the I/D polymorphism in the ACE gene does not influence the extent of restenosis, and typing for the polymorphism will not be a useful predictor of risk before the procedure.	UNIV LEICESTER,DEPT CARDIOL,LEICESTER,LEICS,ENGLAND; UNIV LEICESTER,DEPT MED,LEICESTER,LEICS,ENGLAND; PAPWORTH HOSP,REG CARDIAC UNIT,CAMBRIDGE,ENGLAND; CTR CARDIOTHORAC,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Leicester; University of Leicester; Papworth Hospital			Martin, Daniel S/F-7997-2010	Martin, Daniel/0000-0001-6220-8235				ALVAREZ LG, 1992, AM HEART J, V123, P1500, DOI 10.1016/0002-8703(92)90801-2; ARMITAGE P, 1971, STATISTICAL METHODS, P356; BRACK M, 1994, BRIT HEART J, V71, pP29; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; FUSTER V, 1992, NEW ENGL J MED, V326, P310; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; NOBUYOSHI M, 1988, J AM COLL CARDIOL, V12, P616, DOI 10.1016/S0735-1097(88)80046-9; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRESCOTT MF, 1991, AM J PATHOL, V139, P1291; RAKUGI H, 1994, J CLIN INVEST, V93, P339, DOI 10.1172/JCI116965; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SCHELLING P, 1991, J HYPERTENS, V9, P3; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3; 1992, CIRCULATION, V86, P153; 1992, CIRCULATION, V86, P100	20	64	64	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1013	1016		10.1016/S0140-6736(95)90756-4	http://dx.doi.org/10.1016/S0140-6736(95)90756-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723497				2022-12-28	WOS:A1995QU57300008
J	TERRIET, G; KESSELS, AGH; KNIPSCHILD, P				TERRIET, G; KESSELS, AGH; KNIPSCHILD, P			RANDOMIZED CLINICAL-TRIAL OF ULTRASOUND TREATMENT FOR PRESSURE ULCERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TERRIET, G (corresponding author), UNIV LIMBURG, DEPT EPIDEMIOL, POB 616, 6200 MD MAASTRICHT, NETHERLANDS.		Riet, Gerben ter/A-6943-2011	Riet, Gerben ter/0000-0002-2231-7637				BERG W, 1990, LANCET, V335, P1445, DOI 10.1016/0140-6736(90)91459-N; McDiarmid T, 1985, PHYSIOTHERAPY, V71, P66; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P307; TERRIET G, 1992, CLIN EXP DERMATOL, V17, P328, DOI 10.1111/j.1365-2230.1992.tb00222.x; TERRIET G, 1994, THESIS U LIMBURG MAA, P77	5	18	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	1995	310	6986					1040	1041		10.1136/bmj.310.6986.1040	http://dx.doi.org/10.1136/bmj.310.6986.1040			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728058	Green Published			2022-12-28	WOS:A1995QV31300017
J	LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB				LI, CJ; FRIEDMAN, DJ; WANG, CL; METELEV, V; PARDEE, AB			INDUCTION OF APOPTOSIS IN UNINFECTED LYMPHOCYTES BY HIV-1 TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRAMMED CELL-DEATH; T-CELLS; PERIPHERAL-BLOOD; ACTIVATION; AIDS; INDIVIDUALS; EXPRESSION; INFECTION; CD4	Infection by human immunodeficiency virus-type 1 (HIV-1) is typified by the progressive depletion of CD4 T lymphocytes and deterioration of immune function in most patients. A central unresolved issue in acquired immunodeficiency syndrome (AIDS) pathogenesis is the mechanism underlying this T cell depletion. HIV-1 Tat protein was shown to induce cell death by apoptosis in a T cell line and in cultured peripheral blood mononuclear cells from uninfected donors, This Tat-induced apoptosis was inhibitable by growth factors and was associated with enhanced activation of cyclin-dependent kinases.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; WORCESTER FDN EXPTL BIOL INC, SHREWSBURY, MA 01545 USA	Harvard University; Harvard Medical School; Worcester Foundation for Biomedical Research	LI, CJ (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CELL GROWTH & REGULAT, 44 BINNEY ST, BOSTON, MA 02115 USA.		Metelev, Valeri/I-3238-2012	Friedman, David/0000-0002-0301-9298	NIAID NIH HHS [AI-35511] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMEISEN JC, 1992, IMMUNOL TODAY, V13, P388, DOI 10.1016/0167-5699(92)90086-M; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V6, P778; CARBONARI M, 1994, BLOOD, V83, P1268; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1993, CANCER RES, V53, P1493; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ESTAQUIER J, 1994, P NATL ACAD SCI USA, V91, P9431, DOI 10.1073/pnas.91.20.9431; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FINKEL TH, 1994, CURR OPIN IMMUNOL, V6, P605, DOI 10.1016/0952-7915(94)90149-X; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GOUGEON ML, 1993, SCIENCE, V262, P1356, DOI 10.1126/science.262.5138.1356; Green D R, 1992, Semin Immunol, V4, P379; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HELLAND DE, 1991, J VIROL, V65, P4547, DOI 10.1128/JVI.65.8.4547-4549.1991; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HORAK ID, 1990, NATURE, V348, P557, DOI 10.1038/348557a0; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEDERMAN MM, COMMUNICATION; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li C, UNPUB; LI CJ, 1993, P NATL ACAD SCI USA, V90, P1839, DOI 10.1073/pnas.90.5.1839; LI CJ, 1994, J BIOL CHEM, V269, P7051; MARTIN SJ, 1994, J IMMUNOL, V152, P330; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PANTALEO G, 1994, CURR OPIN IMMUNOL, V6, P600, DOI 10.1016/0952-7915(94)90148-1; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; ROSEN CA, 1986, J VIROL, V57, P379, DOI 10.1128/JVI.57.1.379-384.1986; ROSSI AD, 1994, VIROLOGY, V198, P234; SCHNITTMAN SM, 1989, SCIENCE, V245, P305, DOI 10.1126/science.2665081; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; ZAULI G, 1993, CANCER RES, V53, P4481	47	532	553	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 21	1995	268	5209					429	431		10.1126/science.7716549	http://dx.doi.org/10.1126/science.7716549			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716549				2022-12-28	WOS:A1995QU57200044
J	MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W				MULLER, KJ; ROMANO, N; GERSTNER, O; GARCIAMAROTO, F; POZZI, C; SALAMINI, F; ROHDE, W			THE BARLEY HOODED MUTATION CAUSED BY A DUPLICATION IN A HOMEOBOX GENE INTRON	NATURE			English	Article							EXPRESSION; KNOTTED-1; ANTIRRHINUM; VECTORS; FAMILY; FATES; LOCUS	IN barley (Hordeum vulgare L.) the unit of inflorescence is the spikelet, which bears a fertile bract, the lemma, and the floret consisting of palea, two lodicules, three stamens and the pistil(1). The Hooded mutation causes the appearance of an extra flower of inverse polarity on the lemma(2). This phenotype is governed by the single dominant genetic locus K-3 Here we show that the homeobox gene Knox3 represents this locus, Ectopic Knox3 gene expression in the primordium of the extra floret is caused by a 305-base pair duplication in inh on 4, and phenocopies of the mutation are obtained in the heterologous tobacco system by Knox3 overexpression. It is concluded that homeotic genes of the Knox gene family are involved in floral evocation. Furthermore, the study of polarity of reproductive organs in K and related mutants can now focus on homeobox genes.	UNIV POLITECN MADRID,ETS INGN AGRON,DEPT BIOQUIM & BIOL MOLEC,E-28040 MADRID,SPAIN	Universidad Politecnica de Madrid	MULLER, KJ (corresponding author), MAX PLANCK INST ZUCHTUNGSFORSCH,CARL VON LINNE WEG 10,D-50829 COLOGNE,GERMANY.		Maroto, Federico Garcia/G-8616-2013	Maroto, Federico Garcia/0000-0002-0565-6995; Pozzi, Carlo Massimo/0000-0002-2899-177X				BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Bossinger G., 1992, Barley: genetics, biochemistry, molecular biology and biotechnology., P231; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CLANCY M, 1994, PLANT SCI, V98, P151, DOI 10.1016/0168-9452(94)90005-1; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Dahlgren R.M.T., 1985, FAMILIES MONOCOTYLED, P520, DOI [10.1007/978-3-642-61663-1, DOI 10.1007/978-3-642-61663-1]; DECANDOLLE C, 1891, MEM SOC PHYS HIST S, V6, P1; DICKINSON TA, 1978, BOT REV, V44, P181, DOI 10.1007/BF02919079; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HAKE S, 1992, TRENDS GENET, V8, P109, DOI 10.1016/0168-9525(92)90065-C; HALFORD NG, 1992, PLANT J, V2, P791, DOI 10.1046/j.1365-313X.1992.t01-16-00999.x; HARLAN HARRY V., 1931, JOUR HEREDITY, V22, P264; JACKSON D, 1994, DEVELOPMENT, V120, P405; Nilan R.A., 1964, CYTOLOGY GENETICS BA; Sambrook J., 1989, MOL CLONING; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; SMITH LG, 1992, DEVELOPMENT, V116, P21; Stebbins G.L., 1974, FLOWERING PLANTS EVO, DOI 10.4159/harvard.9780674864856; STEBBINS GL, 1966, GENETICS, V54, P727; TAKAHASHI R, 1953, OHARA I LANDW FORSCH, V10, P29; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; Weberling F, 1989, MORPHOLOGY FLOWERS I; WOLF N, 1992, MOL GEN GENET, V234, P33, DOI 10.1007/BF00272342; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	26	163	176	3	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					727	730		10.1038/374727a0	http://dx.doi.org/10.1038/374727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715728				2022-12-28	WOS:A1995QU30400051
J	LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M				LIN, AN; MINDEN, A; MARTINETTO, H; CLARET, FX; LANGECARTER, C; MERCURIO, F; JOHNSON, GL; KARIN, M			IDENTIFICATION OF A DUAL-SPECIFICITY KINASE THAT ACTIVATES THE JUN KINASES AND P38-MPK2	SCIENCE			English	Article							PROTEIN-KINASE; C-JUN; PHOSPHORYLATION; SERINE-63; PATHWAY; FAMILY; YEAST; RAF; MEK	One Ras-dependent protein kinase cascade leading from growth factor receptors to the ERK (extracellular signal-regulated kinases) subgroup of mitogen-activated protein kinases (MAPKs) is dependent on the protein kinase Raf-1, which activates the MEK(MAPK or ERK kinase) dual specificity kinases. A second protein kinase cascade leading to activation of the Jun kinases (JNKs) is dependent on MEKK (MEK kinase). A dual-specificity kinase that activates JNK, named JNKK, was identified that functions between MEKK and JNK. JNKK activated the JNKs but did not activate the ERKs and was unresponsive to Raf-1 in transfected Hela cells. JNKK also activated another MAPK, p38 (Mpk2; the mammalian homolog of HOG1 from yeast), whose activity is regulated similarly to that of the JNKs.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; SIGNAL PHARMACEUT, SAN DIEGO, CA 92110 USA	University of California System; University of California San Diego; National Jewish Health			Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Lange, Carol/0000-0003-2751-3976				AMMERER G, 1994, CURR OPIN GENET DEV, V4, P90, DOI 10.1016/0959-437X(94)90096-5; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CHOI KY, 1994, CELL, V78, P499; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RE, UNPUB; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER C, UNPUB; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AL, UNPUB; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, UNPUB; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SU B, UNPUB; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	37	716	746	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					286	290		10.1126/science.7716521	http://dx.doi.org/10.1126/science.7716521			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716521				2022-12-28	WOS:A1995QT18500038
J	FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A				FRANCO, B; MERONI, G; PARENTI, G; LEVILLIERS, J; BERNARD, L; GEBBIA, M; COX, L; MAROTEAUX, P; SHEFFIELD, L; RAPPOLD, GA; ANDRIA, G; PETIT, C; BALLABIO, A			A CLUSTER OF SULFATASE GENES ON XP22.3 - MUTATIONS IN CHONDRODYSPLASIA PUNCTATA (CDPX) AND IMPLICATIONS FOR WARFARIN EMBRYOPATHY	CELL			English	Article							KALLMANN SYNDROME GENE; HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; STEROID-SULFATASE; X-CHROMOSOME; NUCLEOTIDE-SEQUENCE; LINKED ICHTHYOSIS; Y-CHROMOSOME; SHORT ARM; EXPRESSION	X-linked recessive chondrodysplasia punctata (CDPX) is a congenital defect of bone and cartilage development characterized by aberrant bone mineralization, severe underdevelopment of nasal cartilage, and distal phalangeal hypoplasia. A virtually identical phenotype is observed in the warfarin embryopathy, which is due to the teratogenic effects of coumarin derivatives during pregnancy, We have cloned the genomic region within Xp22.3 where the CDPX gene has been assigned and isolated three adjacent genes showing highly significant homology to the sulfatase gene family. Point mutations in one of these genes were identified in five patients with CDPX, Expression of this gene in COS cells resulted in a heat-labile arylsulfatase activity that is inhibited by warfarin. A deficiency of a heat-labile arylsulfatase activity was demonstrated in patients with deletions spanning the CDPX region. These data indicate that CDPX is caused by an inherited deficiency of a navel sulfatase and suggest that warfarin embryopathy might involve drug-induced inhibition of the same enzyme.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; UNIV NAPLES,DEPT PEDIAT,I-80134 NAPLES,ITALY; INST PASTEUR,UNITE GENET MOLEC HUMAINE,CNRS,UNITE A1445,F-75724 PARIS 15,FRANCE; MURDOCH INST,ROYAL CHILDRENS HOSP,MELBOURNE,VIC 3050,AUSTRALIA; UNIV HEIDELBERG,INST HUMANGENET,D-69120 HEIDELBERG,GERMANY; UNIV SIENA,DEPT BIOL MOLEC,I-53100 SIENA,ITALY	Baylor College of Medicine; University of Naples Federico II; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Ruprecht Karls University Heidelberg; University of Siena			BALLABIO, Andrea/AAL-2672-2020; Melis, Daniela/AAD-3623-2019; Bernard, Loris/K-5953-2014; andria, generoso/V-7172-2019; FRANCO, Brunella/S-2882-2018	BALLABIO, Andrea/0000-0003-1381-4604; Melis, Daniela/0000-0002-9458-3926; parenti, giancarlo/0000-0002-6287-5748; Petit, Christine/0000-0002-9069-002X; FRANCO, Brunella/0000-0001-5588-4569	NINDS NIH HHS [NS31367-01] Funding Source: Medline; Telethon [TGM94000, TGM06S01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031367] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALL, 1995, METABOLIC MOL BASES, P2999; BALLABIO A, 1987, P NATL ACAD SCI USA, V84, P4519, DOI 10.1073/pnas.84.13.4519; BALLABIO A, 1985, HUM GENET, V70, P315, DOI 10.1007/BF00295367; Ballabio Andrea, 1992, Human Molecular Genetics, V1, P221, DOI 10.1093/hmg/1.4.221; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROWN CJ, 1990, NUCLEIC ACIDS RES, V18, P4191, DOI 10.1093/nar/18.14.4191; BURCH M, 1986, CLIN GENET, V30, P409; CHANG PL, 1985, ANAL BIOCHEM, V144, P362, DOI 10.1016/0003-2697(85)90129-0; CHANG PL, 1990, AM J HUM GENET, V46, P729; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; CURRY CJR, 1984, NEW ENGL J MED, V311, P1010, DOI 10.1056/NEJM198410183111603; DANIELS DL, 1992, SCIENCE, V257, P771, DOI 10.1126/science.1379743; DELCASTILLO I, 1992, NAT GENET, V2, P305, DOI 10.1038/ng1292-305; FASCO MJ, 1982, J BIOL CHEM, V257, P1210; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALL JG, 1980, AM J MED, V68, P122, DOI 10.1016/0002-9343(80)90181-3; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HOWE AM, 1992, TERATOLOGY, V46, P379, DOI 10.1002/tera.1420460408; INCERTI B, 1992, NAT GENET, V2, P311, DOI 10.1038/ng1292-311; Kolodny E.H., 1995, METABOLIC MOL BASES, V7th, P2693; MAROTEAUX P, 1989, HUM GENET, V82, P167, DOI 10.1007/BF00284052; MUNROE DG, 1987, AM J HUM GENET, V40, P102; MUROOKA Y, 1990, J BACTERIOL, V172, P2131, DOI 10.1128/jb.172.4.2131-2140.1990; NEUFELD EF, 1995, METABOLIC MOL BASES, P2645; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PAULI RM, 1987, AM J HUM GENET, V41, P566; PAULI RM, 1988, PATHOL IMMUNOPATH R, V7, P107, DOI 10.1159/000157104; PETERS C, 1990, J BIOL CHEM, V265, P3374; PRICE PA, 1985, VITAM HORM, V42, P65; ROBERTSON DA, 1988, BIOCHEM BIOPH RES CO, V157, P215; SASAKI H, 1988, EUR J BIOCHEM, V177, P9, DOI 10.1111/j.1432-1033.1988.tb14338.x; SCHAEFER L, 1993, NAT GENET, V4, P272, DOI 10.1038/ng0793-272; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; SHEFFIELD LJ, 1976, J PEDIATR-US, V89, P916, DOI 10.1016/S0022-3476(76)80596-3; SMITH MJ, 1994, HUM MOL GENET, V3, P1575, DOI 10.1093/hmg/3.9.1575; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SPRANGER JW, 1970, HUM GENET, V11, P190; STEIN C, 1989, J BIOL CHEM, V264, P13865; STEIN C, 1989, J BIOL CHEM, V264, P1252; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; WANG I, 1995, IN PRESS GENOMICS; WAPENAAR MC, 1994, HUM MOL GENET, V3, P1155, DOI 10.1093/hmg/3.7.1155; WICKER G, 1991, J BIOL CHEM, V266, P21386; WILSON PJ, 1990, P NATL ACAD SCI USA, V87, P8531, DOI 10.1073/pnas.87.21.8531; YEN PH, 1988, CELL, V55, P1123, DOI 10.1016/0092-8674(88)90257-7; YEN PH, 1987, CELL, V49, P443, DOI 10.1016/0092-8674(87)90447-8	48	191	210	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					15	25		10.1016/0092-8674(95)90367-4	http://dx.doi.org/10.1016/0092-8674(95)90367-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720070	Green Published, Bronze			2022-12-28	WOS:A1995QR97000004
J	SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D				SEATON, A; MACNEE, W; DONALDSON, K; GODDEN, D			PARTICULATE AIR-POLLUTION AND ACUTE HEALTH-EFFECTS	LANCET			English	Note							TIME-SERIES ANALYSIS; RESPIRATORY HEALTH; PULMONARY TOXICITY; PM-10 POLLUTION; PARTICLES; MORTALITY; ULTRAFINE; CHILDREN; DISEASE; UTAH	Epidemiological studies have consistently shown an association between particulate air pollution and not only exacerbations of illness in people with respiratory disease but also rises in the numbers of deaths from cardiovascular and respiratory disease among older people. Meta-analyses of these studies indicate associations are unlikely to be explained any confounder, and suggest that they represent cause and effect. We propose that the explanation lies in the nature of the urban particulate cloud, which may contain up to 100000 nanometer-sized particles per mt, in what may be a gravimetric concentration of only 100-200 mu g/m3 of pollutant. We suggest that such ultra-fine particles are able to provoke alveolar inflammation, with release of mediators capable, in susceptible individuals, of causing exacerbations of lung disease and of increasing blood coagulability, thus also explaining the observed increases in cardiovascular deaths associated with urban pollution episodes. This hypothesis is testable both experimentally and epidemiologically.	UNIV EDINBURGH,EDINBURGH,MIDLOTHIAN,SCOTLAND; NAPIER UNIV,EDINBURGH,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Edinburgh Napier University	SEATON, A (corresponding author), UNIV ABERDEEN,SCH MED,DEPT ENVIRONM & OCCUPAT MED,FORESTERHILL,ABERDEEN AB9 2ZD,SCOTLAND.			MacNee, William/0000-0002-3692-1448				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; [Anonymous], [No title captured]; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; BRAUER M, 1989, ENVIRON SCI TECHNOL, V23, P1408, DOI 10.1021/es00069a013; CHOU JC, 1992, ATMOS ENVIRON, V24, P693; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; FERIN J, 1990, J AEROSOL SCI, V21, P381, DOI 10.1016/0021-8502(90)90064-5; FERIN J, 1992, AM J RESP CELL MOL, V6, P535, DOI 10.1165/ajrcmb/6.5.535; HELIN H, 1986, MED BIOL, V64, P167; HILLS BA, 1982, THORAX, V37, P713, DOI 10.1136/thx.37.10.713; HURLEY JF, 1990, MORTALITY 1967 1987; LAWTHER PJ, 1968, PROC R SOC LON SER-A, V307, P223, DOI 10.1098/rspa.1968.0186; LOWE GDO, 1993, THROMBOSIS AND ITS MANAGEMENT, P31; LOWE GDO, 1992, CLIN HEMORHEOL, V12, P535; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MILLER BG, 1985, BRIT J IND MED, V42, P723; OTTAWAY CA, 1984, J CLIN IMMUNOL, V4, P348, DOI 10.1007/BF00917137; POPE CA, 1991, AM REV RESPIR DIS, V144, P668, DOI 10.1164/ajrccm/144.3_Pt_1.668; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211, DOI 10.1080/00039896.1992.9938351; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90, DOI 10.1080/00039896.1991.9937434; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336, DOI 10.1164/ajrccm/147.6_Pt_1.1336; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118, DOI 10.1164/ajrccm/147.1.118; RUOSS K, 1991, J AEROSOL SCI, V22, pS629, DOI 10.1016/S0021-8502(05)80180-6; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826, DOI 10.1164/ajrccm/147.4.826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185, DOI 10.1093/oxfordjournals.aje.a115473; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; TEPPER JS, 1994, AM J RESP CRIT CARE, V149, pA839; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WARHEIT DB, 1990, EXP MOL PATHOL, V52, P309, DOI 10.1016/0014-4800(90)90072-L	30	1531	1592	3	252	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					176	178		10.1016/S0140-6736(95)90173-6	http://dx.doi.org/10.1016/S0140-6736(95)90173-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741860				2022-12-28	WOS:A1995QC55000016
J	BRYANT, H; BRASHER, P				BRYANT, H; BRASHER, P			BREAST IMPLANTS AND BREAST-CANCER - REANALYSIS OF A LINKAGE STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP	Background. In 1992, Berkel and colleagues reported in the Journal the results of their study of the potential association of breast augmentation and breast cancer. The study reported that women who had breast augmentation had a significantly lower subsequent risk of breast cancer (P<0.01) than the general population, with a standardized incidence ratio of 0.48 overall. Assuming a 10-year induction period (that is, assuming that cancers found within 10 years of the augmentation might have been the result of a process begun before surgery and therefore should not be considered), the reported standardized incidence ratio was 0.16. Problems were later identified involving some of the study methods. This paper reports a second analysis of these data. Methods. We used a data set from Alberta Health Care to identify eligible women with bilateral breast augmentation. Using a combination of deterministic and probabilistic methods, we linked this data set to the Alberta Cancer Registry to identify subsequent breast cancers that developed during the study period. Multiple estimates of standardized incidence ratios were calculated on the basis of differing study-eligibility dates, induction periods, and types of breast-cancer (invasive only or invasive plus in situ). Results. The reanalysis found substantial differences in the numbers of person-years at risk, resulting in higher standardized incidence ratios than in the original analysis. The final ratios for all breast cancers, with October 1, 1973, used as the starting date of the study, were 0.76 (95 percent confidence interval, 0.55 to 1.02), 0.85 (95 percent confidence interval, 0.58 to 1.19), and 0.68 (95 percent confidence interval, 0.32 to 1.25) for induction periods of 0, 5, and 10 years, respectively. None of these standardized incidence ratios were significantly different from 1. Conclusions. On the basis of this reanalysis, the incidence of breast cancer among the women who had breast augmentation could not be said to be either significantly higher or lower than that among the general population over the period during which this cohort was followed.			BRYANT, H (corresponding author), ALBERTA CANC BOARD,DIV EPIDEMIOL PREVENT & SCREENING,1040 7TH AVE SW,SUITE 120,CALGARY,AB T2P 3G9,CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; BRYANT H, 1994, NEW ENGL J MED, V330, P293, DOI 10.1056/NEJM199401273300419; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; WAJDA A, 1992, LINKPRO USERS MANUAL; 1993, STATISTICS CANADA	7	87	88	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1535	1539		10.1056/NEJM199506083322302	http://dx.doi.org/10.1056/NEJM199506083322302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739707	Bronze			2022-12-28	WOS:A1995RB19600002
J	RIES, AL; KAPLAN, RM; LIMBERG, TMK; PREWITT, LM				RIES, AL; KAPLAN, RM; LIMBERG, TMK; PREWITT, LM			EFFECTS OF PULMONARY REHABILITATION ON PHYSIOLOGICAL AND PSYCHOSOCIAL OUTCOMES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						LUNG DISEASES, OBSTRUCTIVE; REHABILITATION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); EXERCISE; BREATHING EXERCISES	MORTALITY; EXERCISE; INSUFFICIENCY; QUALITY; TRENDS; COPD	Objective: To compare the effects of comprehensive pulmonary rehabilitation with those of education alone on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Design: Randomized clinical trial. Setting: University medical center. Patients: 119 outpatients with chronic obstructive pulmonary disease that was stable while patients received a standard medical regimen. Intervention: Patients were randomly assigned to either an 8-week comprehensive pulmonary rehabilitation program or to an 8-week education program. Pulmonary rehabilitation consisted of twelve 4-hour sessions that included education, physical and respiratory care instruction, psychosocial support, and supervised exercise training. Monthly reinforcement sessions were held for 1 year. The education group attended four 2-hour sessions that included videotapes, lectures, and discussions but not individual instruction or exercise training. Measurements: Pulmonary function, maximum exercise tolerance and endurance, gas exchange, symptoms of perceived breathlessness and muscle fatigue with exercise, shortness of breath, self-efficacy for walking, depression, general quality of well-being, and hospitalizations associated with pulmonary diseases. Patients were followed for 6 years. Results: Compared with education alone, comprehensive pulmonary rehabilitation produced a significantly greater increase in maximal exercise tolerance (+1.5 metabolic equivalents [METS] compared with +0.6 METS [P < 0.001]; maximal oxygen uptake, +0.11 L/min compared with +0.03 L/min [P = 0.06]), exercise endurance (+10.5 minutes compared with +1.3 minutes [P < 0.001]), symptoms of perceived breathlessness (score of -1.5 compared with +0.2 [P < 0.001]) and muscle fatigue (score of -1.4 compared with -0.2 [P < 0.01]), shortness of breath (score of -7.0 compared with +0.6 [P < 0.01]), and self-efficacy for walking (score of +1.4 compared with +0.1 [P < 0.05]). There were slight but nonsignificant differences in survival (67% compared with 56% [P = 0.32]) and duration of hospital stay (-2.4 days/patient per year compared with +1.3 days/patient per year [P = 0.20]). Measures of lung function, depression, and general quality of life did not differ between groups. Differences tended to diminish after 1 year of follow-up. Conclusions: Comprehensive pulmonary rehabilitation significantly improved exercise performance and symptoms for patients with moderate to severe chronic obstructive pulmonary disease. Benefits were partially maintained for at least 1 year and tended to diminish after that time.			RIES, AL (corresponding author), UNIV CALIF SAN DIEGO, MED CTR, DIV PULM & CRIT CARE MED, 200 W ARBOR DR 8377, SAN DIEGO, CA 92103 USA.		KAPLAN, Robert/AAK-7342-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002215, R01HL034732] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00827] Funding Source: Medline; NHLBI NIH HHS [K07 HL 02215, R01 HL 34732] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGLE DP, 1973, PSYCHOSOM MED, V35, P41, DOI 10.1097/00006842-197301000-00005; [Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; Archibald C. J., 1987, CANADIAN J REHABILIT, V1, P45; BELMAN MJ, 1993, THORAX, V48, P936, DOI 10.1136/thx.48.9.936; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Casaburi R, 1993, PRINCIPLES PRACTICE; CLAUSEN JL, 1982, PULMONARY FUNCTION T; CONNORS G, 1993, AM ASS CARDIOVASCULA; Ellis B, 1991, J CARDIOPULM REHABIL, V11, P227; EMERY CF, 1991, CHEST, V100, P613, DOI 10.1378/chest.100.3.613; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9, DOI 10.1164/ajrccm/140.3_Pt_2.S9; GARDNER RM, 1988, ANN INTERN MED, V108, P217, DOI 10.7326/0003-4819-108-2-217; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; GUYATT G, 1988, EUR RESPIR J, V1, P560; HIGGINS MW, 1989, CLIN EPIDEMIOLOGY CH, P23; Hodgkin J., 1993, PULMONARY REHABILITA, V2nd; Hodgkin J E, 1981, Am Rev Respir Dis, V124, P663; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HUDSON LD, 1976, CHEST, V70, P606, DOI 10.1378/chest.70.5.606; JENSEN PS, 1983, ARCH GEN PSYCHIAT, V40, P1203; JOHNSON HR, 1980, RESPIRATORY THER MAY, P15; Jones NL., 1988, CLIN EXERCISE TESTIN, V3rd edn; Kaplan R., 1990, QUALITY LIFE ASSESSM, P131; KAPLAN RM, 1984, HEALTH PSYCHOL, V3, P223, DOI 10.1037/0278-6133.3.3.223; KAPLAN RM, 1984, J CHRON DIS, V37, P85, DOI 10.1016/0021-9681(84)90050-X; KAPLAN RM, 1988, HEALTH SERV RES, V23, P203; LERTZMAN MM, 1976, AM REV RESPIR DIS, V114, P1145; LIECHTENSTEIN E, 1983, INT HDB BEHAVIOR MOD; MARLATT GA, 1982, ADHERENCE COMPLIANCE; MARTIN JE, 1982, J CONSULT CLIN PSYCH, V50, P1004, DOI 10.1037/0022-006X.50.6.1004; MCGAVIN CR, 1977, THORAX, V32, P307, DOI 10.1136/thx.32.3.307; ORENSTEIN DM, 1989, CHEST, V95, P344, DOI 10.1378/chest.95.2.344; PETTY TL, 1969, ANN INTERN MED, V70, P1109, DOI 10.7326/0003-4819-70-6-1109; PUNZAL PA, 1991, CHEST, V100, P618, DOI 10.1378/chest.100.3.618; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RIES AL, 1988, PULMONARY DISEASES D, P1325; RIES AL, 1990, J CARDIOPULM REHABIL, V10, P418; RUMBOUT R, 1981, 31ST P ANN M SOC STU; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; SHERRILL DL, 1990, CLIN CHEST MED, V11, P375; SUTHERLAND JE, 1990, JAMA-J AM MED ASSOC, V264, P3178, DOI 10.1001/jama.264.24.3178; Toshima MT, 1992, J CARDIOPULM REHABIL, V12, P261; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; WADDEN TA, 1984, BEHAVIORAL HLTH, P608; WALLSTONKA, 1981, RES LOCUS CONTROL CO; Wasserman K., 1987, PRINCIPLES EXERCISE; WEISSMAN MM, 1977, AM J EPIDEMIOL, V106, P203, DOI 10.1093/oxfordjournals.aje.a112455; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; 1981, J R COLL PHYSICIANS, V15, P69	51	600	623	1	51	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					823	832		10.7326/0003-4819-122-11-199506010-00003	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741366				2022-12-28	WOS:A1995RA13900003
J	PALMER, J; FELDMAN, R; MANCINI, GBJ; ZIMMERMAN, M				PALMER, J; FELDMAN, R; MANCINI, GBJ; ZIMMERMAN, M			GLYCERYL TRINITRATE REVERSAL OF POST-SUMATRIPTAN CORONARY-ARTERY NARROWING	LANCET			English	Letter											PALMER, J (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.							EVERS S, 1995, LANCET, V345, P198, DOI 10.1016/S0140-6736(95)90205-8; MACINTYRE PD, 1992, BRIT J CLIN PHARMACO, V34, P541; MACINTYRE PD, 1993, CIRCULATION, V87, P501; MANCINI GBJ, 1987, CIRCULATION, V75, P452, DOI 10.1161/01.CIR.75.2.452	4	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1366	1366		10.1016/S0140-6736(95)92563-5	http://dx.doi.org/10.1016/S0140-6736(95)92563-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752771				2022-12-28	WOS:A1995RA14800040
J	MOOSA, AA; QUORTUM, HA; IBRAHIM, MD				MOOSA, AA; QUORTUM, HA; IBRAHIM, MD			RAPID DIAGNOSIS OF BACTERIAL-MENINGITIS WITH REAGENT STRIPS	LANCET			English	Article								Laboratory examination of cerebrospinal fluid (CSF) is not available in many parts of the world, and without knowledge of CSF glucose, protein, and cells, a diagnosis of meningitis may be missed. Testing CSF with urine reagent strips that measure glucose and protein has given variable results. We tested CSF samples from 234 children with suspected meningitis for glucose, protein, and leucocytes with Combur9 reagent strips. The results were compared with those obtained from the laboratory and also interpreted as indicating bacterial or viral meningitis. There was good agreement between the strip and laboratory method of estimating CSF glucose, protein, and leucocytes. All but 4 of the cases of meningitis were correctly identified by the strip method (sensitivity 97%). 2 (2.9%) of 69 cases of bacterial meningitis were judged by an independent observer to be viral, and 2 (3.3%) of 60 cases of viral meningitis as normal. No normal CSF was diagnosed as meningitis (specificity 100%). The results indicate that Combur9 reagent strips can distinguish normal from infected CSF and are of value in the diagnosis of meningitis.	FARWANIYA HOSP,MINIST PUBL HLTH,KUWAIT,KUWAIT		MOOSA, AA (corresponding author), KUWAIT UNIV,FAC MED,DEPT PAEDIAT,POB 24923,SAFAT 13110,KUWAIT.							FEINBLOO.RI, 1969, J PEDIATR, V74, P615, DOI 10.1016/S0022-3476(69)80047-8; MULLER PD, 1987, ANN TROP PAEDIATR, V7, P287, DOI 10.1080/02724936.1987.11748527; SCHWARTZ RP, 1971, J PEDIATR-US, V78, P677, DOI 10.1016/S0022-3476(71)80474-2	3	68	70	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1290	1291		10.1016/S0140-6736(95)90931-1	http://dx.doi.org/10.1016/S0140-6736(95)90931-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746063				2022-12-28	WOS:A1995QY93300015
J	MANGION, JR				MANGION, JR			OSTIUM-SECUNDUM ATRIAL SEPTAL-DEFECT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MANGION, JR (corresponding author), BAYSTATE MED CTR,SPRINGFIELD,MA 01199, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1336	1336		10.1056/NEJM199505183322004	http://dx.doi.org/10.1056/NEJM199505183322004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715642				2022-12-28	WOS:A1995QX85700004
J	THOMPSON, C				THOMPSON, C			LASER TACKLES BONE	LANCET			English	Editorial Material																		Charlton A., 1990, LASER MED SCI, V5, P365, DOI DOI 10.1007/BF02032593; COLLIER MA, 1993, ARTHROSCOPY, V9, P536, DOI 10.1016/S0749-8063(05)80401-3; DEVLIN H, IN PRESS LASERS MED; FREEMONT AJ, 1992, LASER MED SCI, V7, P440; KONIG HJ, 1993, NEUROCHIRURGIA, V36, P105	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1001	1001		10.1016/S0140-6736(95)90752-1	http://dx.doi.org/10.1016/S0140-6736(95)90752-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723494				2022-12-28	WOS:A1995QU57300004
J	TILZEY, AJ				TILZEY, AJ			HEPATITIS-B VACCINE BOOSTING - THE DEBATE CONTINUES	LANCET			English	Editorial Material							IMMUNOGENICITY; EFFICACY				TILZEY, AJ (corresponding author), ST THOMAS HOSP,GUYS & ST THOMAS HOSP TRUST,DEPT VIROL,LONDON,ENGLAND.							GESEMANN M, 1995, LANCET, V345, P395, DOI 10.1016/S0140-6736(95)90387-9; GILKS WR, 1995, LANCET, V345, P395; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; TILZEY AJ, 1994, LANCET, V344, P1438, DOI 10.1016/S0140-6736(94)90609-2; VANHATTUM J, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P774; VENTO S, 1989, LANCET, V1, P332; WAINWRIGHT RB, 1989, JAMA-J AM MED ASSOC, V261, P2362, DOI 10.1001/jama.261.16.2362; 1992, IMMUNISATION INFECTI; 1991, MMWR-MORBID MORTAL W, V40, P1; 1993, PROTECTING HLTH CARE	11	27	27	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1000	1001		10.1016/S0140-6736(95)90751-3	http://dx.doi.org/10.1016/S0140-6736(95)90751-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723493				2022-12-28	WOS:A1995QU57300003
J	THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J				THOMAS, PM; COTE, GJ; WOHLLK, N; HADDAD, B; MATHEW, PM; RABL, W; AGUILARBRYAN, L; GAGEL, RF; BRYAN, J			MUTATIONS IN THE SULFONYLUREA RECEPTOR GENE IN FAMILIAL PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY	SCIENCE			English	Article							CYSTIC-FIBROSIS; POLYMORPHISM; CHANNELS; LINKAGE; MAP; DNA	Familial persistent hyperinsulinemic hypoglycemia of infancy (PHHI), an autosomal recessive disorder characterized by unregulated insulin secretion, is linked to chromosome 11p14-15.1. The newly cloned high-affinity sulfonylurea receptor (SUR) gene, a regulator of insulin secretion, was mapped to 11p15.1 by means of fluorescence in situ hybridization, Two separate SUR gene splice site mutations, which segregated with disease phenotype, were identified in affected individuals from nine different families, Both mutations resulted in aberrant processing of the RNA sequence and disruption of the putative second nucleotide binding domain of the SUR protein. Abnormal insulin secretion in PHHI appears to be caused by mutations in the SUR gene.	BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; ARAMCO,DHAHRAN HLTH CTR,DIV SPECIALTY PEDIAT,DHAHRAN 31311,SAUDI ARABIA; TECH UNIV MUNICH,KINDERKLIN,D-80804 MUNICH,GERMANY; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine; Saudi Aramco; Technical University of Munich; Baylor College of Medicine; Baylor College of Medicine	THOMAS, PM (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MED SPECIALTIES,ENDOCRINOL SECT,BOX 15,HOUSTON,TX 77030, USA.			Wohllk, Nelson/0000-0002-7354-6894	NIDDK NIH HHS [DK44311, DK38146] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311, R01DK038146] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AUSUBEL FM, 1989, CURRENT PROTOCOLS MO, pCH6; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; GLASER B, 1994, NAT GENET, V7, P185, DOI 10.1038/ng0694-185; GRANDCHAMP B, 1989, NUCLEIC ACIDS RES, V17, P6637, DOI 10.1093/nar/17.16.6637; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAISER N, 1990, DIABETOLOGIA, V33, P482, DOI 10.1007/BF00405110; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3425, DOI 10.1093/nar/22.16.3425; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LOU H, 1994, MOL ENDOCRINOL, V8, P1618, DOI 10.1210/me.8.12.1618; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; MATSUTANI A, 1992, GENOMICS, V12, P319, DOI 10.1016/0888-7543(92)90380-B; MATSUTANI A, 1992, GENOMICS, V13, P495, DOI 10.1016/0888-7543(92)90116-A; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; SATOKATA I, 1990, P NATL ACAD SCI USA, V87, P9908, DOI 10.1073/pnas.87.24.9908; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; STOFFEL M, 1993, DIABETES, V42, P1215, DOI 10.2337/diabetes.42.8.1215; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; THOMAS P, UNPUB; THOMAS PM, 1995, AM J HUM GENET, V56, P416; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WEIL D, 1989, J BIOL CHEM, V264, P16804	28	653	678	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					426	429		10.1126/science.7716548	http://dx.doi.org/10.1126/science.7716548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716548				2022-12-28	WOS:A1995QU57200043
J	ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P				ANTSON, AA; OTRIDGE, J; BRZOZOWSKI, AM; DODSON, EJ; DODSON, GG; WILSON, KS; SMITH, TM; YANG, M; KURECKI, T; GOLLNICK, P			THE STRUCTURE OF TRP RNA-BINDING ATTENUATION PROTEIN	NATURE			English	Article							BACILLUS-SUBTILIS; TRANSCRIPTION ATTENUATION; ESCHERICHIA-COLI; OPERON; EXPRESSION; GENE; ANTITERMINATION; PROGRAM	The crystal structure of the trp RNA-binding attenuation protein of Bacillus subtilis solved at 1.8 Angstrom resolution reveals a novel structural arrangement in which the eleven subunits are stabilized through eleven intersubunit beta-sheets to form a beta-wheel with a large central hole. The nature of the binding of L-tryptophan in clefts between adjacent beta-sheets in the beta-wheel suggests that this binding induces conformational changes in the flexible residues 25-33 and 49-52. It is argued that upon binding, the messenger RNA target forms a matching circle in which eleven U/GAG repeats are bound to the surface of the protein ondecamer modified by the binding of L-tryptophan.	SUNY BUFFALO,DEPT BIOL SCI,BUFFALO,NY 14260; DESY,EUROPEAN MOLEC BIOL LAB,D-22603 HAMBURG,GERMANY	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	ANTSON, AA (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Antson, Alfred/N-2551-2016	Antson, Alfred/0000-0002-4533-3816; Wilson, Keith/0000-0002-3581-2194				AMZEL LM, 1979, JA REV BIOCH, V48, P967; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ANTSON AA, 1994, J MOL BIOL, V243, P1; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; CRUTZ AM, 1990, J BACTERIOL, V172, P1043, DOI 10.1128/jb.172.2.1043-1050.1990; DEBARBOUILLE M, 1990, J BACTERIOL, V172, P3966, DOI 10.1128/jb.172.7.3966-3973.1990; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; GOLLNICK P, 1990, P NATL ACAD SCI USA, V87, P8726, DOI 10.1073/pnas.87.22.8726; HOFFMAN RJ, 1995, J BACTERIOL, V177, P839, DOI 10.1128/jb.177.3.839-842.1995; HOUMAN F, 1990, CELL, V62, P1153, DOI 10.1016/0092-8674(90)90392-R; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KLEYWEGT GJ, 1994, FIRST MAP FINAL MODE, P59; KONG XP, 1993, CELL, V69, P425; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUODA MI, 1988, J BACTERIOL, V170, P3080; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLDFIELD TJ, 1992, J MOL GRAPHICS, V10, P247, DOI 10.1016/0263-7855(92)80077-Q; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SHEVITZ RW, 1985, NATURE, V317, P782; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; TURNER RJ, 1994, J BACTERIOL, V176, P7211; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YANOFSKY C, 1981, NATURE, V289, P751, DOI 10.1038/289751a0; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181; [No title captured]	38	177	184	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					693	700		10.1038/374693a0	http://dx.doi.org/10.1038/374693a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715723				2022-12-28	WOS:A1995QU30400041
J	CLARK, AL; COATS, AJS				CLARK, AL; COATS, AJS			SEVERITY OF HEART-FAILURE AND DOSAGE OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article											CLARK, AL (corresponding author), NATL HEART & LUNG INST,DEPT CARDIAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.		Coats, Andrew J Stewart/E-4451-2012	Coats, Andrew J Stewart/0000-0002-2771-4260				[Anonymous], 1993, LANCET, V342, P821; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; KLEBER FX, 1992, BRIT HEART J, V67, P289; MCMURRAY J, 1993, BR J MED EC, V6, P99; 1991, NEW ENGL J MED, V352, P293	5	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					973	974		10.1136/bmj.310.6985.973	http://dx.doi.org/10.1136/bmj.310.6985.973			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728033	Green Published			2022-12-28	WOS:A1995QT90400020
J	GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL				GERBER, HP; HAGMANN, M; SEIPEL, K; GEORGIEV, O; WEST, MAL; LITINGTUNG, Y; SCHAFFNER, W; CORDEN, JL			RNA-POLYMERASE-II C-TERMINAL DOMAIN REQUIRED FOR ENHANCER-DRIVEN TRANSCRIPTION	NATURE			English	Article							LARGEST SUBUNIT; STIMULATES TRANSCRIPTION; PROMOTER; ACTIVATION; EXPRESSION; REPEAT; CELLS; GENE; PROTEIN; INVITRO	THE RNA polymerase II carboxy-terminal domain (CTD) consists of tandem repeats of the sequence Tyr-Ser-Pro-Thr-Ser-Pro-Ser(1-3). The CTD may participate in activated transcription through interaction with a high-molecular-weight mediator complex(4-6). Such a role would be consistent with observations that some genes are preferentially sensitive to CTD mutations(7,8). Here we investigate the function of the mouse RNA polymerase CTD in enhancer-driven transcription. Transcription by alpha-amanitin-resistant CTD-deletion mutants was tested by transient transfection of tissue culture cells in the presence of alpha-amanitin in order to inhibit endogenous RNA polymerase II. Removal of most of the CTD abolishes transcriptional activation by all enhancers tested, whereas transcription from promoters driven by Sp1, a factor that typically activates housekeeping genes from positions proximal to the initiation sites, is not affected. These findings show that the CTD is essential in mediating 'enhancer'-type activation of mammalian transcription.	UNIV CALIF DAVIS,DIV BIOL SCI,PLANT BIOL SECT,DAVIS,CA 95616; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California Davis; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	GERBER, HP (corresponding author), UNIV ZURICH,INST MOLEK BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.			Seipel, Katja/0000-0003-3128-1573				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BARTOLOMEI MS, 1987, MOL CELL BIOL, V7, P586, DOI 10.1128/MCB.7.2.586; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORDEN JL, 1992, TRANSCRIPTIONAL REGU, P81; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GUARENTE L, 1984, CELL, V36, P799, DOI 10.1016/0092-8674(84)90028-X; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RUSCONI S, 1990, GENE, V89, P211, DOI 10.1016/0378-1119(90)90008-F; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHATT MD, 1990, EMBO J, V9, P481, DOI 10.1002/j.1460-2075.1990.tb08134.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WIELAND S, 1990, ACTIVATION HORMONE G, P215; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351	28	142	144	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					660	662		10.1038/374660a0	http://dx.doi.org/10.1038/374660a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715709				2022-12-28	WOS:A1995QT18900065
J	TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D				TOHTONG, R; YAMASHITA, H; GRAHAM, M; HAEBERLE, J; SIMCOX, A; MAUGHAN, D			IMPAIRMENT OF MUSCLE FUNCTION CAUSED BY MUTATIONS OF PHOSPHORYLATION SITES IN MYOSIN REGULATORY LIGHT-CHAIN	NATURE			English	Article							RABBIT SKELETAL-MUSCLE; INDIRECT FLIGHT-MUSCLE; DROSOPHILA-MELANOGASTER; STRETCH-ACTIVATION; STRIATED-MUSCLE; CROSS-BRIDGES; INSECT; KINETICS; FIBERS; MECHANISM	MYOSIN regulatory light chain is phosphorylated by myosin light chain kinase at conserved serine and threonine residues in a number of species(1). Phosphorylation of myosin regulatory light chain regulates smooth muscle contraction, but appears to have a modulatory role in striated muscle contraction(2). We assessed the in vivo role of myosin regulatory light chain phosphorylation in the striated muscles of Drosophila melanogaster by substituting alanine at each or both conserved myosin light chain kinase-dependent phosphorylation sites, serine 66 and serine 67. We report here that myosin light chain kinase-dependent phosphorylation is not required for myofibrillogenesis or for the development of maximal isometric force in Indirect flight muscles. However, mutants with substitutions at the major phosphorylation site (serine 66) or with the double substitutions had reduced power output in isolated flight muscle fibres and reduced flight ability, showing that myosin regulatory light chain phosphorylation is a key determinant of the stretch activation response in Drosophila.	OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH; UNIV VERMONT,DEPT MOLEC PHYSIOL & BIOPHYS,BURLINGTON,VT 05405	University System of Ohio; Ohio State University; University of Vermont								ABBOTT RH, 1984, J MUSCLE RES CELL M, V5, P387, DOI 10.1007/BF00818257; BERNSTEIN SI, 1993, INT REV CYTOL, V143, P63; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; DRUMMOND DR, 1991, MOL GEN GENET, V226, P70, DOI 10.1007/BF00273589; GRANZIER HLM, 1993, J GEN PHYSIOL, V101, P235, DOI 10.1085/jgp.101.2.235; GUTH K, 1981, BIOPHYS STRUCT MECH, V7, P139, DOI 10.1007/BF00539176; HYATT CJ, 1994, BIOPHYS J, V67, P1149, DOI 10.1016/S0006-3495(94)80582-X; JEWELL BR, 1966, PROC R SOC SER B-BIO, V164, P428, DOI 10.1098/rspb.1966.0042; Kawai M, 1980, J Muscle Res Cell Motil, V1, P279, DOI 10.1007/BF00711932; LAURIEAHLBERG CC, 1985, GENETICS, V111, P845; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOLLOY J, 1993, MECH MYOFILAMENT SLI, P165; PECKHAM M, 1992, J EXP BIOL, V168, P57; PECKHAM M, 1990, J MUSCLE RES CELL M, V11, P203, DOI 10.1007/BF01843574; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; PRINGLE JWS, 1978, PROC R SOC SER B-BIO, V201, P107, DOI 10.1098/rspb.1978.0035; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; SQUIRE JM, 1992, J MUSCLE RES CELL M, V13, P183, DOI 10.1007/BF01874155; Steiger G.J., 1977, P221; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; TAKAHASHI S, 1987, ZOOL SCI, V4, P833; TAKAHASHI S, 1990, COMP BIOCHEM PHYS B, V95, P179, DOI 10.1016/0305-0491(90)90267-W; TAWADA K, 1990, BIOPHYS J, V57, P643, DOI 10.1016/S0006-3495(90)82582-0; THORSON J, 1983, J PHYSIOL-LONDON, V343, P59, DOI 10.1113/jphysiol.1983.sp014881; THORSON J, 1969, BIOPHYS J, V9, P360, DOI 10.1016/S0006-3495(69)86392-7; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; WRAY JS, 1979, NATURE, V280, P325, DOI 10.1038/280325a0	30	112	114	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					650	653		10.1038/374650a0	http://dx.doi.org/10.1038/374650a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715706				2022-12-28	WOS:A1995QT18900062
J	BARBER, N				BARBER, N			WHAT CONSTITUTES GOOD PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article							DRUG	Drugs are the mainstay of medical treatment, yet there are few reports on what constitutes ''good prescribing.'' What is more, the existing guidance tends to imply that right answers exist, rather than recognising the complex trade offs that have to be made between conflicting aims. This paper proposes four aims that a prescriber should try to achieve, both on first prescribing a drug and on subsequently monitoring it. They are: to maximise effectiveness, minimise risks, minimise costs, and respect the patient's choices. This model of good prescribing brings together the traditional balancing of risks and benefits with the need to reduce costs and the right of the patient to make choices in treatment. The four aims are shown as a diagram plotting their commonest conflicts, which may be used as an aid to discussion and decision making.			BARBER, N (corresponding author), UNIV LONDON,SCH PHARM,29-39 BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND.							Barber N., 1991, PHARM J, V246, P671; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; FINNEY DJ, 1965, J CHRON DIS, V18, P77, DOI 10.1016/0021-9681(65)90054-8; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; PARISH PA, 1973, J ROY SOC HEALTH, V4, P213; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; 1992, RISK ANAL PERCEPTION, P2	7	78	81	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					923	925		10.1136/bmj.310.6984.923	http://dx.doi.org/10.1136/bmj.310.6984.923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719188	Green Published			2022-12-28	WOS:A1995QR97200032
J	HAZELL, P; OCONNELL, D; HEATHCOTE, D; ROBERTSON, J; HENRY, D				HAZELL, P; OCONNELL, D; HEATHCOTE, D; ROBERTSON, J; HENRY, D			EFFICACY OF TRICYCLIC DRUGS IN TREATING CHILD AND ADOLESCENT DEPRESSION - A METAANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-LEVEL DESIGN; DOUBLE-BLIND; SUDDEN-DEATH; DISORDERS; IMIPRAMINE; AMITRIPTYLINE; NORTRIPTYLINE; DESIPRAMINE; TRIALS	Objective-To examine whether tricyclic antidepressants are superior to placebo in the treatment of child and adolescent depression. Design-Meta-analysis of 12 randomised controlled trials comparing the efficacy of tricyclic antidepressants with placebo in depressed subjects aged 6-18 years. Main outcome measures-Most studies employed several depression rating scales. For each study the ''best available'' measure was chosen by using objective criteria, and individual and pooled effect sizes were calculated as the number of standard deviations by which the change scores for the treatment groups exceeded those for the control groups. Where authors had reported numbers ''responding'' to treatment we calculated individual and pooled ratios for the odds of improvement in treated compared with control subjects. Results-From the six studies presenting data which enabled an estimation of effect size the pooled effect size was 0.35 standard deviations (95% confidence interval of -0.16 to 0.86) indicating no significant benefit of treatment. From the five studies presenting data on the number of ''responders'' in each group, the ratio of the odds of a response in the treated compared with the control subjects was calculated and the pooled odds ratio was 1.08 (95% confidence interval of 0.53 to 2.17); again indicating no significant benefit of treatment. The pooled sample had more than an 80% chance of detecting a treatment effect of 0.5 standard deviations or greater. There was an inverse relation between study quality and estimated treatment effect. Conclusions-Tricyclic antidepressants appear to be no more effective than placebo in the treatment of depression in children and adolescents.	UNIV NEWCASTLE,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle	HAZELL, P (corresponding author), UNIV NEWCASTLE,FAC MED & HLTH SCI,DISCIPLINE PSYCHIAT,CALLAGHAN,NSW 2308,AUSTRALIA.		Henry, David/AAJ-4332-2020; Henry, David/AAU-4650-2020	Henry, David/0000-0003-2934-2242; Henry, David/0000-0001-7169-7704				AKISKAL HS, 1987, PSYCHOPHARMACOL BULL, V23, P68; AMBROSINI PJ, 1993, J AM ACAD CHILD PSY, V32, P1, DOI 10.1097/00004583-199301000-00001; AMBROSINI PJ, 1993, J AM ACAD CHILD PSY, V32, P483, DOI 10.1097/00004583-199305000-00001; BARBER JP, 1992, RES PSYCHIAT ISSUES, P331; BEIDERMAN J, 1991, J AM ACAD CHILD ADOL, V30, P495; BERNEY T, 1981, BRIT J PSYCHIAT, V138, P110, DOI 10.1192/bjp.138.2.110; BERNSTEIN GA, 1990, J AM ACAD CHILD PSY, V29, P773, DOI 10.1097/00004583-199009000-00016; BOULOS C, 1991, PSYCHOPHARMACOL BULL, V27, P59; BYRNE MM, 1989, ACTA PSYCHIAT SCAND, V80, P138, DOI 10.1111/j.1600-0447.1989.tb07194.x; CAMPBELL M, 1988, J AM ACAD CHILD PSY, V27, P269, DOI 10.1097/00004583-198805000-00001; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; Conners C K, 1992, J Child Adolesc Psychopharmacol, V2, P11, DOI 10.1089/cap.1992.2.11; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ELLIOTT GR, J CHILD ADOL PSYCHOP, V2, P7; FISHER S, 1993, J NERV MENT DIS, V181, P345, DOI 10.1097/00005053-199306000-00002; GELLER B, 1992, J AM ACAD CHILD PSY, V31, P34, DOI 10.1097/00004583-199201000-00007; GELLER B, 1990, PSYCHOPHARMACOL BULL, V26, P85; GELLER B, 1989, PSYCHOPHARMACOL BULL, V25, P101; GELLER B, 1993, J AM ACAD CHILD PSY, V32, P43, DOI 10.1097/00004583-199301000-00007; Hedges L, 1985, STATISTICAL METHODS; HUGHES CW, 1990, PSYCHOPHARMACOL BULL, V26, P235; Jensen P S, 1992, J Child Adolesc Psychopharmacol, V2, P31, DOI 10.1089/cap.1992.2.31; KASHANI JH, 1984, J AM ACAD CHILD PSY, V23, P348, DOI 10.1016/S0002-7138(09)60515-X; KRAMER AD, 1981, J AM ACAD CHILD PSY, V20, P636, DOI 10.1016/S0002-7138(09)61650-2; MEHTA C, 1991, STATXACT STATISTICAL; PETTI TA, 1985, PSYCHOPHARMACOL BULL, V21, P951; PETTI TA, 1982, J CLIN PSYCHOPHARM, V2, P107; Popper C W, 1992, J Child Adolesc Psychopharmacol, V2, P1, DOI 10.1089/cap.1992.2.1; PRESKORN SH, 1982, J CLIN PSYCHIAT, V43, P450; PUIGANTICH J, 1987, ARCH GEN PSYCHIAT, V44, P81; RIDDLE MA, 1993, J AM ACAD CHILD PSY, V32, P792, DOI 10.1097/00004583-199307000-00013; RIDDLE MA, 1991, J AM ACAD CHILD PSY, V30, P104, DOI 10.1097/00004583-199101000-00016; Rosenberg ML., 1989, SUICIDE YOUTH PERSPE, pp. 203; Ryan N D, 1990, J Child Adolesc Psychopharmacol, V1, P21, DOI 10.1089/cap.1990.1.21; RYAN ND, 1992, PSYCHIAT CLIN N AM, V15, P29; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SHELDON TA, 1993, BRIT MED J, V306, P1126, DOI 10.1136/bmj.306.6885.1126-c; Strober M, 1992, J Child Adolesc Psychopharmacol, V2, P23, DOI 10.1089/cap.1992.2.23; WELLER EB, 1991, CHILD ADOL PSYCH CL, P646; [No title captured]	40	206	210	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					897	901		10.1136/bmj.310.6984.897	http://dx.doi.org/10.1136/bmj.310.6984.897			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR972	7719178	Green Published			2022-12-28	WOS:A1995QR97200019
J	COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE				COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE			THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; SEX-HORMONES; MORTALITY; WEIGHT; EPIDEMIOLOGY; PROGESTOGENS; SURVEILLANCE; HEIGHT	Background. The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. Methods. To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breastcancer. Results. The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. Conclusions. The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women, The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40956] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LILIENFELD AM, 1956, CANCER, V9, P927, DOI 10.1002/1097-0142(195609/10)9:5<927::AID-CNCR2820090510>3.0.CO;2-3; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; MORRISON AS, 1979, AM J EPIDEMIOL, V109, P709, DOI 10.1093/oxfordjournals.aje.a112734; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSE DP, 1977, OBSTET GYNECOL, V49, P80; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; 1991, ORAL CONTRACEPTIVES	33	1283	1328	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1589	1593		10.1056/NEJM199506153322401	http://dx.doi.org/10.1056/NEJM199506153322401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753136				2022-12-28	WOS:A1995RC19200001
J	NIPARKO, JK; JOHNS, ME				NIPARKO, JK; JOHNS, ME			OTOLARYNGOLOGY - HEAD AND NECK-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDIALIZATION				NIPARKO, JK (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							BLUESTONE CD, 1994, ARCH OTOLARYNGOL, V120, P1051; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BRENNAN JA, IN PRESS N ENGL J ME; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CUMMINGS CW, 1993, ANN OTO RHINOL LARYN, V102, P843, DOI 10.1177/000348949310201104; GATES GA, 1993, ARCH OTOLARYNGOL, V119, P156; HARRIS JP, 1995, ARCH OTOLARYNGOL, V121, P398; JOHNS ME, 1994, ARCH OTOLARYNGOL, V120, P801; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; LANZA DC, 1992, J ALLERGY CLIN IMMUN, V90, P505, DOI 10.1016/0091-6749(92)90175-2; LEE AJ, 1994, AM J OTOL, V15, P10; MOORE J, 1994, AM J OTOL, V14, P588; NETTERVILLE JL, 1993, ANN OTO RHINOL LARYN, V102, P413, DOI 10.1177/000348949310200602; PICCIRILLO JF, 1994, ANN OTO RHINOL LARYN, V103, P83, DOI 10.1177/000348949410300201; SUN JC, 1994, LARYNGOSCOPE, V104, P1255; WYATT R, 1995, AM J OTOL, V16, P46	16	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1705	1706						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752428				2022-12-28	WOS:A1995RB09700036
J	WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM				WESSELY, S; CHALDER, T; HIRSCH, S; PAWLIKOWSKA, T; WALLACE, P; WRIGHT, DJM			POSTINFECTIOUS FATIGUE - PROSPECTIVE COHORT STUDY IN PRIMARY-CARE	LANCET			English	Article							POSTVIRAL FATIGUE; VIRUS; POPULATION; SYMPTOMS; ANTIBODY; SIGNS	The idea that chronic fatigue has an infectious origin has become popular, but the main evidence for such an association has come from retrospective case-control studies, which are subject to ascertainment bias. We report a prospective study of the outcome of clinically diagnosed infections in patients presenting to UK general practitioners. Questionnaires assessing fatigue and psychiatric morbidity were sent to all patients aged 18-45 years in the study practices. The prevalence of chronic fatigue and chronic fatigue syndrome was then ascertained among 1199 people aged 18-45 who presented to the general practitioners with symptomatic infections and in 1167 people who attended the surgeries for other reasons, 84% were followed up at 6 months. 9.9% of cases and 11.7% of controls reported chronic fatigue (odds ratio 1.0 [95% CI 0.6-1.1]). There were no differences in the proportions who met various criteria for chronic fatigue syndrome. No effect of infection was noted when we excluded subjects who reported fatigue or psychological morbidity at the baseline screening. The strongest independent predictors of postinfectious fatigue were fatigue assessed before presentation with clinical infection (3.0 [1.9-4.7]) and psychological distress before presentation (1.8 [1.2-2.9]) and at presentation with the acute infection (1.8 [1.1-2.8]). There was no effect of sex or social class. Our study shows no evidence that common infective episodes in primary care are related to the onset of chronic fatigue or chronic fatigue syndrome.	INST PSYCHIAT,DEPT PSYCHOL MED,LONDON SE5 8AF,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT PSYCHIAT,LONDON,ENGLAND; CHARING CROSS HOSP,SCH MED,DEPT MED MICROBIOL,LONDON,ENGLAND; THE SURGERY,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT PRIMARY CARE,LONDON,ENGLAND	University of London; King's College London; Imperial College London; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	WESSELY, S (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT PSYCHOL MED,DENMARK HILL,LONDON SE5 9RS,ENGLAND.		Wessely, Simon C/A-8713-2008; Chalder, Trudie/A-5717-2011	Chalder, Trudie/0000-0003-0775-1045; Wessely, Simon Charles/0000-0002-6743-9929				BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BUTLER S, 1961, J NEUROL NEUROSUR PS, V54, P153; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; CHALDER T, 1990, THESIS CITY U LONDON; COPE H, 1994, LANCET, V344, P864, DOI 10.1016/S0140-6736(94)92833-9; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Goldberg DP., 1972, DETECTION PSYCHIATRI; GOLDENBERG D L, 1989, Journal of Rheumatology, V16, P91; Gore, 1987, HLTH LIFESTYLE SURVE; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HELLINGER WC, 1988, JAMA-J AM MED ASSOC, V260, P971; Hinds G. M. E., 1993, P R COLL PHYSICIANS, V23, P10; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; IMBODEN JB, 1961, ARCH INTERN MED, V108, P393, DOI 10.1001/archinte.1961.03620090065008; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MILLER NA, 1991, BMJ-BRIT MED J, V302, P140, DOI 10.1136/bmj.302.6769.140; POWELL R, 1990, J PSYCHOSOM RES, V34, P665, DOI 10.1016/0022-3999(90)90111-G; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STRAUS SE, 1985, ANN INTERN MED, V102, P7, DOI 10.7326/0003-4819-102-1-7; TYRRELL DAJ, 1993, EPIDEMIOL INFECT, V111, P143, DOI 10.1017/S0950268800056764; Ware J. E., 1992, MEASURING FUNCTIONIN, P277; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940; WESSELY S, 1991, BRIT MED BULL, V47, P919, DOI 10.1093/oxfordjournals.bmb.a072521; WHITE P, IN PRESS PSYCHOL MED; WITTENBORN J, 1979, ARCH GEN PSYCHIAT, V84, P118; [No title captured]	29	141	141	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1333	1338		10.1016/S0140-6736(95)92537-6	http://dx.doi.org/10.1016/S0140-6736(95)92537-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752755				2022-12-28	WOS:A1995RA14800008
J	PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD				PSATY, BM; KOEPSELL, TD; YANEZ, ND; SMITH, NL; MANOLIO, TA; HECKBERT, SR; BORHANI, NO; GARDIN, JM; GOTTDIENER, JS; RUTAN, GH; SISCOVICK, DS; FURBERG, CD			TEMPORAL PATTERNS OF ANTIHYPERTENSIVE MEDICATION USE AMONG OLDER ADULTS, 1989 THROUGH 1992 - AN EFFECT OF THE MAJOR CLINICAL-TRIALS ON CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; HIP FRACTURE; HYPERTENSION; DISEASE; RISK	Objective.-To describe the changing patterns of antihypertensive medication use in the years immediately before and after the publication of the results of three major clinical trials of the treatment of hypertension in older adults. Design.-In this cohort study, adults 65 years or older were examined annually on four occasions between June 1989 and May 1992, and the use of antihypertensive medications was assessed by inventory at each visit. The four visits defined the boundaries of three study periods. For each study period, participants receiving antihypertensive therapy were either continuous users (n = 1667, 1643, and 1605, respectively) or starters (n = 157, 142, 120) of hypertensive therapy. The large clinical trials that convincingly proved the efficacy and safety of low-dose diuretic therapy in older adults were published during the latter parts of period 2 and the early parts of period 3. Results.-Among starters, the proportion initiating therapy on diuretics increased from 35.9% in period 2 to 47.5% in period 3, significantly so among women (P=.04). The proportions initiating other drugs displayed no significant trends. Among continuous users, the use of diuretics, beta-blockers, and vasodilators generally decreased over the 3-year period, while the use of calcium channel blockers and angiotensin-converting enzyme inhibitors increased significantly in each of the three periods (P<.05). The decline of 2.7% in the prevalence of diuretic use in period 1 abated during period 2 (1.8% decline), and it slowed significantly (P=.03) to almost a complete halt during period 3 (0.2% decline). The rate of increase in the use of calcium channel blockers slowed significantly (P=.01) between period 1 (+6.7%) and period 3 (+2.8%). Conclusions.-Although other factors such as cost may have been important, the temporal trends in antihypertensive drug therapy coincided in time with and may have reflected in part the influence of the major clinical trials on the patterns of clinical practice.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT HLTH SERV,SEATTLE,WA 98101; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98101; UNIV WASHINGTON,CTR CARDIOVASC HLTH STUDY COORDINATING,SEATTLE,WA 98101; NHLBI,BETHESDA,MD 20892; UNIV CALIF IRVINE,DIV CARDIOL,IRVINE,CA 92717; GEORGETOWN UNIV HOSP,DIV CARDIOL,WASHINGTON,DC 20007; VET ADM MED CTR,MEMPHIS,TN 38104; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of California System; University of California Irvine; Georgetown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	PSATY, BM (corresponding author), UNIV WASHINGTON,DEPT MED,CARDIOVASC HLTH RES UNIT,1730 MINOR AVE,SUITE 1360,SEATTLE,WA 98101, USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085081, N01HC085080, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85079, N01-HC-85080, H01-HC-85081] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; FURBERG CD, 1994, J INTERN MED, V235, P387, DOI 10.1111/j.1365-2796.1994.tb01093.x; HEIDRICH FE, 1991, ANN INTERN MED, V115, P1, DOI 10.7326/0003-4819-115-1-1; HUNE AL, 1993, PHARMACOTHERAPY, V13, P244; LACROIX AZ, 1990, NEW ENGL J MED, V322, P286, DOI 10.1056/NEJM199002013220502; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NORUSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; OPARIL S, 1993, NEW ENGL J MED, V328, P959, DOI 10.1056/NEJM199304013281311; PASTY BM, 1993, HYPERTENSION PRIMER, P197; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; PSATY BM, 1992, JAMA-J AM MED ASSOC, V268, P1287, DOI 10.1001/jama.268.10.1287; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; RAY WA, 1989, LANCET, V1, P687; RAY WA, 1986, AM J MED, V81, P9, DOI 10.1016/0002-9343(86)90522-X; SISCOVICK DS, 1994, NEW ENGL J MED, V330, P1852, DOI 10.1056/NEJM199406303302603; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; 1993, ARCH INTERN MED, V153, P154; 1994, HYPERTENSION, V23, P275; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1988, ARCH INTERN MED, V148, P1023	23	66	68	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1436	1438		10.1001/jama.273.18.1436	http://dx.doi.org/10.1001/jama.273.18.1436			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723157				2022-12-28	WOS:A1995QW27900031
J	SILVERSTEIN, MJ; POLLER, DN; WAISMAN, JR; COLBURN, WJ; BARTH, A; GIERSON, ED; LEWINSKY, B; GAMAGAMI, P; SLAMON, DJ				SILVERSTEIN, MJ; POLLER, DN; WAISMAN, JR; COLBURN, WJ; BARTH, A; GIERSON, ED; LEWINSKY, B; GAMAGAMI, P; SLAMON, DJ			PROGNOSTIC CLASSIFICATION OF BREAST DUCTAL CARCINOMA-IN-SITU	LANCET			English	Article							ESTROGEN-RECEPTOR; INSITU; CANCER; EXPRESSION; ONCOGENE; PROTEIN	We present a new prognostic classification designated the Van Nuys classification for ductal carcinoma-in-situ (DCIS). The classification combines high nuclear grade and comedo-type necrosis to predict cinical recurrence. Three groups of DCIS patients were defined by the presence or absence of high nuclear grade and comedo-type necrosis: 1-non-high-grade DCIS without comedo type necrosis, 2-non-high-grade DCIS with comedo-type necrosis, 3-high-grade DCIS with or without comedo-type necrosis. There were 31 local recurrences in 238 patients after breast-conservation surgery 3.8% (3/80) in group 1, 11.1% (10/90) in group 2, and 26.5% (18/68) in group 3. The 8-year actuarial disease-free survivals were 93%, 84%, and 61%, respectively (all p less than or equal to 0.05). The Van Nuys classification defines three distinct and easily recognisable groups, each of which has a different likelihood of local recurrence if treated with breast conservation.	BREAST CTR,DIV PATHOL,VAN NUYS,CA 91405; BREAST CTR,DIV MED ONCOL,VAN NUYS,CA 91405; BREAST CTR,DIV RADIAT THERAPY,VAN NUYS,CA 91405; BREAST CTR,DIV BREAST IMAGING RADIOL,VAN NUYS,CA 91405; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA; UNIV BERN,BERN,SWITZERLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Bern; Gloucestershire Royal Hospital	SILVERSTEIN, MJ (corresponding author), BREAST CTR,DIV SURG ONCOL,14624 SHERMAN WAY,6TH FLOOR,VAN NUYS,CA 91405, USA.				NATIONAL CANCER INSTITUTE [R01CA036827] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DM, 1991, BREAST CANCER RES TR, V18, P11, DOI 10.1007/BF01975438; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; BOBROW LG, 1994, SEMIN DIAGN PATHOL, V11, P199; BUR ME, 1992, CANCER-AM CANCER SOC, V69, P1174; FAVERLY DRG, 1994, SEMIN DIAGN PATHOL, V11, P193; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; HOLLAND R, 1994, SEMIN DIAGN PATHOL, V11, P167; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LAKHANI SR, IN PRESS J CLIN PATH; LAMPEJO OT, 1994, SEMIN DIAGN PATHOL, V11, P215; LIU E, 1992, ONCOGENE, V7, P1027; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; OMALLEY FP, 1994, LAB INVEST, V71, P67; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; Page DL, 1987, DIAGNOSTIC HISTOPATH, P157; POLLER DN, 1994, MODERN PATHOL, V7, P257; POLLER DN, 1993, BRIT J CANCER, V68, P156, DOI 10.1038/bjc.1993.305; POLLER DN, 1993, HUM PATHOL, V24, P463, DOI 10.1016/0046-8177(93)90157-C; POLLER DN, IN PRESS PROGR PATHO, V2; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; SILVERSTEIN MJ, 1994, CANCER, V73, P2985, DOI 10.1002/1097-0142(19940615)73:12<2985::AID-CNCR2820731216>3.0.CO;2-A; SIMPSON JF, 1994, AM J CLIN PATHOL, V102, P3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLOANE JP, 1994, EUR J CANCER, V10, P1414; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; Tavassoli F, 1992, PATHOLOGY BREAST, P229; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902	30	537	556	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1154	1157						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723550				2022-12-28	WOS:A1995QW62200014
J	LU, KP; HUNTER, T				LU, KP; HUNTER, T			EVIDENCE FOR A NIMA-LIKE MITOTIC PATHWAY IN VERTEBRATE CELLS	CELL			English	Article							CYCLIN-DEPENDENT KINASES; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ASPERGILLUS-NIDULANS; MAMMALIAN-CELLS; XENOPUS-OOCYTE; MOUSE OOCYTES; MITOSIS; ACTIVATION	NIMA is essential for entry into mitosis in Aspergillus nidulans. To examine whether there is a NIMA-like pathway in other eukaryotic cell cycles, we expressed NIMA and its dominant negative mutants in two different eukaryotic systems. In Xenopus oocytes, NIMA induced germinal vesicle breakdown without activating Mos, CDC2, or MAP kinase. In HeLa cells, NIMA induced premature mitotic events without activating CDCS, whereas the mutants caused a specific G2 arrest but did not block mutant CDC2(T14AY15F)-induced premature entry into mitosis. A sequence essential for both these phenotypes was mapped to a region of similar to 100 amino acids lying just after the catalytic domain of NIMA that shows a significant similarity to protein interaction domains in other proteins. These results provide evidence for the existence of a NIMA-like mitotic pathway in vertebrate cells.			LU, KP (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NCRR NIH HHS [RR04050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; CHAN EKL, 1991, J EXP MED, V174, P1239, DOI 10.1084/jem.174.5.1239; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI T, 1991, DEVELOPMENT, V113, P789; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GARD DL, 1993, METHOD CELL BIOL, V38, P241; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; GAVIN AC, 1994, J CELL SCI, V107, P275; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HAMAGUCHI JR, 1992, J CELL BIOL, V117, P1041, DOI 10.1083/jcb.117.5.1041; HARPER JW, 1993, CELL, V75, P805; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; JUNG T, 1993, INT J DEV BIOL, V37, P595; KITAGAWA M, 1994, ONCOGENE, V9, P2549; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1989, P NATL ACAD SCI USA, V86, P4982, DOI 10.1073/pnas.86.13.4982; LETWIN K, 1992, EMBO J, V10, P3521; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; MERRIAM RW, 1971, EXP CELL RES, V68, P81, DOI 10.1016/0014-4827(71)90589-1; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1991, EMBO J, V10, P2669, DOI 10.1002/j.1460-2075.1991.tb07810.x; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	47	146	154	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					413	424		10.1016/0092-8674(95)90394-1	http://dx.doi.org/10.1016/0092-8674(95)90394-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736593	Bronze			2022-12-28	WOS:A1995QW89400013
J	KERWIN, RW				KERWIN, RW			CLOZAPINE - BACK TO THE FUTURE FOR SCHIZOPHRENIA RESEARCH	LANCET			English	Editorial Material											KERWIN, RW (corresponding author), INST PSYCHIAT,CLIN NEUROPHARMACOL SECT,DE CRESPIGNY PK,LONDON,ENGLAND.							ALLEBECK P, 1986, ARCH GEN PSYCHIAT, V43, P650; CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140; COWARD DM, 1989, PSYCHOPHARMACOLOGY, V99, pS5; HIPPIUS H, 1989, PSYCHOPHARMACOLOGY, V99, pS3, DOI 10.1007/BF00442551; IDANPAAN HJ, 1977, EUR J CLIN PHARMACOL, V11, P194; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1994, J CLIN PSYCHIATRY SB; LINDSTROM LH, 1988, ACTA PSYCHIAT SCAND, V77, pS24; 1992, LANCET, V339, P276	9	6	6	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1063	1064		10.1016/S0140-6736(95)90811-0	http://dx.doi.org/10.1016/S0140-6736(95)90811-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715333				2022-12-28	WOS:A1995QV41100003
J	KEW, MC				KEW, MC			PROTECTIVE EFFICACY OF HEPATITIS-B VACCINATION	LANCET			English	Editorial Material							VIRUS				KEW, MC (corresponding author), UNIV WITWATERSRAND, DEPT MED, MRC, MOLEC HEPATOL RES UNIT, JOHANNESBURG 2001, SOUTH AFRICA.							Barin F, 1981, Prog Med Virol, V27, P148; BEASLEY RP, 1977, AM J EPIDEMIOL, V105, P94, DOI 10.1093/oxfordjournals.aje.a112370; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BOTHA JF, 1984, LANCET, V1, P1210; BROWN SE, 1984, LANCET, V2, P184; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; COURSAGET P, 1987, J MED VIROL, V22, P1, DOI 10.1002/jmv.1890220102; FORTUIN M, 1994, J INFECT DIS, V169, P1374, DOI 10.1093/infdis/169.6.1374; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; OKAMOTO H, 1992, PEDIATR RES, V32, P264, DOI 10.1203/00006450-199209000-00002; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SCHOUB BD, 1991, BMJ-BRIT MED J, V302, P313, DOI 10.1136/bmj.302.6772.313; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; 1995, LANCET, V345, P1089	14	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	1995	345	8957					1065	1066		10.1016/S0140-6736(95)90813-7	http://dx.doi.org/10.1016/S0140-6736(95)90813-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715335				2022-12-28	WOS:A1995QV41100005
J	CASTIELLO, U; SCARPA, M; BENNETT, K				CASTIELLO, U; SCARPA, M; BENNETT, K			A BRAIN-DAMAGED PATIENT WITH AN UNUSUAL PERCEPTUOMOTOR DEFICIT	NATURE			English	Article							CORTEX; PERCEPTION	WHEN interacting,vith objects, the pattern of movements is influenced by such object characteristics as size and position(1-4). Little is known about the effect of higher level categorical encoding of objects upon movements. Here we present evidence for an approval-for-action process which takes into account such encoding. For the brain-damaged subject L.P., the ability to complete actions involving two objects in central vision is influenced by the semantic or functional relationship between the objects. Even though she perceives only one object, she can integrate two related objects into a coordinated action. If the objects are not related she is unable to integrate them into a single motor act, We propose that selection-for-action systems(5) include processes which gate conceptually the behavioural disposition to action.	UNIV MODENA,NEUROL CLIN,I-41100 MODENA,ITALY; EUROPEAN MED CTR,BOLOGNA,ITALY; UNIV BOLOGNA,DIPARTIMENTO PSICOL,I-40127 BOLOGNA,ITALY	Universita di Modena e Reggio Emilia; University of Bologna				Castiello, Umberto/0000-0003-0629-1286				Allport D. A., 1987, PERSPECTIVES PERCEPT, V15, P395; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; [Anonymous], 1982, BOSTON NAMING TEST; Arbib M. A., 2011, HDB PHYSL NERVOUS SY, P1449, DOI [DOI 10.1016/J.JPHYSPARIS.2008.03.001, 10.1002/cphy.cp010233]; CASTIELLO U, 1993, EXP BRAIN RES, V94, P165; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FERRIGNO G, 1985, IEEE T BIO-MED ENG, V32, P943, DOI 10.1109/TBME.1985.325627; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; Goodglass H., 2001, ASSESSMENT APHASIA R; HUMPHREYS GW, 1994, COGNITIVE NEUROPSYCH, V11, P393, DOI 10.1080/02643299408251980; JAKOBSON LS, 1991, EXP BRAIN RES, V86, P199; JEANNEROD M, 1994, NEUROPSYCHOLOGIA, V32, P369, DOI 10.1016/0028-3932(94)90084-1; JEANNEROD M, 1988, OXFORD SCI PUBLICATI, V15; Jeannerod M., 1981, ATTENTION PERFORM, P153; KINSBOURNE M, 1963, BRAIN, V86, P697, DOI 10.1093/brain/86.4.697; KINSBOURNE M, 1962, BRAIN, V85, P461, DOI 10.1093/brain/85.3.461; Kugler P.N., 1980, TUTORIALS MOTOR BEHA, P49, DOI DOI 10.1016/S0166-4115(08)61937-8; LAIACONA M, 1993, CORTEX, V29, P727, DOI 10.1016/S0010-9452(13)80293-6; MILNER AD, 1991, BRAIN, V114, P405, DOI 10.1093/brain/114.1.405; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Roy E. A., 1985, NEUROPSYCHOLOGICAL S, P45; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; WARRINGTON EK, 1978, PERCEPTION, V7, P695, DOI 10.1068/p070695; WARRINGTON EK, 1984, BRAIN, V107, P829, DOI 10.1093/brain/107.3.829; Weir PL, 1994, ADV PSYCHOL, V105, P129, DOI [10.1016/S0166-4115(08)61276-5, DOI 10.1016/S0166-4115(08)61276-5]	27	13	13	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					805	808		10.1038/374805a0	http://dx.doi.org/10.1038/374805a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV315	7723824				2022-12-28	WOS:A1995QV31500045
J	TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P				TUGENDREICH, S; TOMKIEL, J; EARNSHAW, W; HIETER, P			CDC27HS COLOCALIZES WITH CDC16HS TO THE CENTROSOME AND MITOTIC SPINDLE AND IS ESSENTIAL FOR THE METAPHASE TO ANAPHASE TRANSITION	CELL			English	Article							EXPRESSED SEQUENCE TAGS; ASPERGILLUS-NIDULANS; SNAP HELIX; MITOSIS; FAMILY; IDENTIFICATION; PROTEINS; ENCODES; GENES; MOTIF	have isolated cDNAs and raised antibodies corresponding to the human homologs of the S. cerevisiae CDC27 and CDC16 proteins, which are tetratrico peptide repeat (TPR)-containing proteins essential for mitosis in budding yeast. We find that the CDC27Hs and CDC16Hs proteins colocalize to the centrosome at all stages of the mammalian cell circle, and to the mitotic spindle. Injection of affinity-purified anti-CDC27Hs antibodies into logarithmically growing HeLa cells causes a highly reproducible cell cycle arrest in metaphase with apparently normal spindle structure. We conclude that CDC27 and CDC16 are evolutionarily conserved components of the centrosome and mitotic spindle that control the onset of postmetaphase events during mitosis.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University	TUGENDREICH, S (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.		Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; HARLOW E, 1988, ANTIBODIES LABORATOR; HARTWELL LH, 1974, SCIENCE, V183, P48; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; IRNIGER S, 1995, CELL, V81; JORDAN MA, 1992, J CELL SCI, V102, P401; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; ODONNELL KL, 1991, J CELL SCI, V99, P711; PRINGLE JR, 1981, MOL BIOL YEAST SACCH; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; WEINERT TA, 1993, GENETICS, V134, P63; WOOTTON JC, 1993, COMPUT CHEM, V17, P149, DOI 10.1016/0097-8485(93)85006-X	30	316	322	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					261	268		10.1016/0092-8674(95)90336-4	http://dx.doi.org/10.1016/0092-8674(95)90336-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736578	Bronze			2022-12-28	WOS:A1995QV41000015
J	CLARK, EA; BRUGGE, JS				CLARK, EA; BRUGGE, JS			INTEGRINS AND SIGNAL-TRANSDUCTION PATHWAYS - THE ROAD TAKEN	SCIENCE			English	Review							FOCAL ADHESION KINASE; INSULIN-RECEPTOR SUBSTRATE-1; BINDING PROTEIN-RHO; TYROSINE PHOSPHORYLATION; CELL-ADHESION; EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; ACTIN CYTOSKELETON; MAP-KINASE; 3T3 CELLS	Adhesive interactions play critical roles in directing the migration, proliferation, and differentiation of cells; aberrations in such interactions can lead to pathological disorders. These adhesive interactions, mediated by cell surface receptors that bind to ligands on adjacent cells or in the extracellular matrix, also regulate intracellular signal transduction pathways that control adhesion-induced changes in cell physiology. Though the extracellular molecular interactions involving many adhesion receptors have been well characterized, the adhesion-dependent intracellular signaling events that regulate these physiological alterations have only begun to be elucidated. This article will focus on recent advances in our understanding of intracellular signal transduction pathways regulated by the integrin family of adhesion receptors.			CLARK, EA (corresponding author), ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA.							ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BARRY ST, 1994, J CELL SCI, V107, P2033; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DEFILIPPI P, 1994, CELL ADHES COMMUN, V2, P75, DOI 10.3109/15419069409014203; DEFOUGEROLLES AR, 1994, J EXP MED, V179, P619, DOI 10.1084/jem.179.2.619; DESIMONE DW, 1994, CURR OPIN CELL BIOL, V6, P747, DOI 10.1016/0955-0674(94)90103-1; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, UNPUB; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Huhtala P., 1994, Molecular Biology of the Cell, V5, p64A; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON RP, 1995, NATURE, V373, P261, DOI 10.1038/373261a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MALEK AM, 1994, J HYPERTENS, V12, P989; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NAKAMURA S, 1994, J BIOCHEM, V115, P1029, DOI 10.1093/oxfordjournals.jbchem.a124451; OKAMURA H, 1994, ONCOGENE, V9, P2293; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PAVALKO FM, 1994, P SOC EXP BIOL MED, V205, P282; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, UNPUB; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1994, J BIOL CHEM, V269, P11133; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SOMOGYI L, 1994, BIOCHEM J, V299, P603, DOI 10.1042/bj2990603; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; THERIOT JA, 1993, CELL, V75, P835, DOI 10.1016/0092-8674(93)90527-W; TOBE K, 1993, J BIOL CHEM, V268, P11167; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VUORI K, 1993, J BIOL CHEM, V268, P21459; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1992, J CELL SCI, V101, P277; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHANG J, 1993, J BIOL CHEM, V268, P22251	108	2759	2854	3	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					233	239		10.1126/science.7716514	http://dx.doi.org/10.1126/science.7716514			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716514				2022-12-28	WOS:A1995QT18500022
J	GHOSH, A; GREENBERG, ME				GHOSH, A; GREENBERG, ME			CALCIUM SIGNALING IN NEURONS - MOLECULAR MECHANISMS AND CELLULAR CONSEQUENCES	SCIENCE			English	Review							DEPENDENT PROTEIN-KINASE; NERVE GROWTH-FACTOR; LONG-TERM POTENTIATION; CYCLIC ADP-RIBOSE; SEA-URCHIN EGGS; MUSCLE SARCOPLASMIC-RETICULUM; GLUTAMATE-RECEPTOR CHANNELS; SUPERIOR CERVICAL-GANGLION; CEREBELLAR PURKINJE-CELLS; IMMEDIATE EARLY GENES	Neuronal activity can lead to marked increases in the concentration of cytosolic calcium, which then functions as a second messenger that mediates a wide range of cellular responses. Calcium binds to calmodulin and stimulates the activity of a variety of enzymes, including calcium-calmodulin kinases and calcium-sensitive adenylate cyclases. These enzymes transduce the calcium signal and effect short-term biological responses, such as the modification of synaptic proteins and long-lasting neuronal responses that require changes in gene expression. Recent studies of calcium signal-transduction mechanisms have revealed that, depending on the route of entry into a neuron, calcium differentially affects processes that are central to the development and plasticity of the nervous system, including activity-dependent cell survival, modulation of synaptic strength, and calcium-mediated cell death.	CHILDRENS HOSP, DEPT NEUROL, DIV NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28829] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; Amundson J, 1993, Curr Opin Neurobiol, V3, P375, DOI 10.1016/0959-4388(93)90131-H; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; ARTALEJO CR, 1992, NATURE, V358, P63, DOI 10.1038/358063a0; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BUCK WR, 1994, DEV BIOL, V163, P1, DOI 10.1006/dbio.1994.1118; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COLLINGRIDGE GL, 1992, CIBA F SYMP, V164, P162; COLLINS F, 1991, J NEUROSCI, V11, P2582; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; ENAVI Y, 1992, TRENDS NEUROSCI, V15, P333; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FONG YL, 1989, J BIOL CHEM, V264, P16759; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; FRIEL DD, 1994, J NEUROSCI, V14, P4007; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; Hille B., 1992, IONIC CHANNELS EXCIT; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HOLZ GG, 1988, J NEUROSCI, V8, P463; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JEFFERSON AB, 1991, J BIOL CHEM, V266, P346; KANO M, 1992, NATURE, V356, P601, DOI 10.1038/356601a0; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; KELLY PT, 1988, P NATL ACAD SCI USA, V85, P4991, DOI 10.1073/pnas.85.14.4991; KERR LM, 1984, NATURE, V308, P282, DOI 10.1038/308282a0; KOCSIS JD, 1993, BRAIN RES, V616, P273, DOI 10.1016/0006-8993(93)90218-C; KOKAIA M, 1994, MOL BRAIN RES, V23, P323, DOI 10.1016/0169-328X(94)90242-9; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LU B, 1991, P NATL ACAD SCI USA, V88, P6289, DOI 10.1073/pnas.88.14.6289; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MA J, 1988, SCIENCE, V242, P99, DOI 10.1126/science.2459777; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLS LR, 1994, J NEUROSCI, V14, P6815; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORRISSETTE J, 1993, FEBS LETT, V330, P270, DOI 10.1016/0014-5793(93)80886-Y; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NESTLER EJ, 1982, NATURE, V296, P452, DOI 10.1038/296452a0; NESTLER EJ, 1982, J NEUROSCI, V2, P1011; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHSAKO S, 1991, J BIOCHEM-TOKYO, V109, P137, DOI 10.1093/oxfordjournals.jbchem.a123334; PATTON BL, 1993, MOL BIOL CELL, V4, P159, DOI 10.1091/mbc.4.2.159; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PRZYWARA DA, 1991, FASEB J, V5, P217, DOI 10.1096/fasebj.5.2.2004666; RANDALL RD, 1992, J NEUROSCI, V12, P1882; REGEHR WG, 1990, NATURE, V345, P807, DOI 10.1038/345807a0; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SAKURADA K, 1993, J BIOL CHEM, V268, P410; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SELBER MA, 1994, MOL CELL BIOL, V14, P6107; SELBERT ME, COMMUNICATION; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; STANTON PK, 1984, J NEUROSCI, V4, P3080; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUN Y, 1992, J NEUROSCI, V12, P3717; SUZUKI T, 1992, P NATL ACAD SCI USA, V89, P109, DOI 10.1073/pnas.89.1.109; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P3330, DOI 10.1073/pnas.89.8.3330; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; XU Z, 1994, DEVELOPMENT, V120, P1851; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; YOON JK, 1993, J BIOL CHEM, V268, P9148; YOVELL Y, 1992, J NEUROCHEM, V59, P1736, DOI 10.1111/j.1471-4159.1992.tb11005.x; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037; ZAFRA F, 1992, J NEUROSCI, V12, P4793; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	183	1235	1259	1	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					239	247		10.1126/science.7716515	http://dx.doi.org/10.1126/science.7716515			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716515				2022-12-28	WOS:A1995QT18500023
J	TANIGUCHI, T				TANIGUCHI, T			CYTOKINE SIGNALING THROUGH NONRECEPTOR PROTEIN-TYROSINE KINASES	SCIENCE			English	Review							RECEPTOR-BETA-CHAIN; COLONY-STIMULATING FACTOR; IL-2 RECEPTOR; INTERLEUKIN-2 RECEPTOR; CELL-LINE; GAMMA-CHAIN; TRANSDUCTION PATHWAY; FUNCTIONAL COMPONENT; CYTOPLASMIC REGION; MOLECULAR-CLONING	Cytokines are a family of soluble mediators of cell-to-cell communication that includes interleukins, interferons, and colony-stimulating factors. The characteristic features of cytokines lie in their functional redundancy and pleiotropy. Most of the cytokine receptors that constitute distinct superfamilies do not possess intrinsic protein tyrosine kinase (PTK) domains, yet receptor stimulation usually invokes rapid tyrosine phosphorylation of intracellular proteins, including the receptors themselves. It is now clear that these receptors are capable of recruiting or activating (or both) a variety of nonreceptor PTKs to induce downstream signaling pathways. Thus, the intracytoplasmic structure of cytokine receptors has evolved so as to allow the combined action of different PTK family members expressed in different cell types, which may ultimately determine the activity of cytokines.			TANIGUCHI, T (corresponding author), UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,HONGO 7-3-1,TOKYO 113,JAPAN.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; AZAM M, IN PRESS; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; BURNS LA, 1993, J BIOL CHEM, V268, P17659; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cooper Jonathan A., 1994, Seminars in Cell Biology, V5, P377, DOI 10.1006/scel.1994.1045; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; Fujii H, UNPUB; FUJII H, IN PRESS P NATL ACAD; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; GILMOUR KC, 1994, P NATL ACAD SCI USA, V91, P6850, DOI 10.1073/pnas.91.15.6850; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREENBERG PS, COMMUNICATION; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, IN PRESS EMBO J; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HELDIN CH, 1995, SEMIN CELL BIOL, V80, P213; HITOSHI Y, 1993, INT IMMUNOL, V5, P1183, DOI 10.1093/intimm/5.9.1183; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Howard Maureen C., 1993, P763; HUNTER T, 1994, NATURE, V366, P114; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; IHLE JN, COMMUNICATION; IHLE JN, 1994, 1994 TAN S REG HEM S; JACOBSON NS, IN PRESS; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KAWAHARA A, UNPUB; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEUNG S, IN PRESS MOL CELL BI; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANO H, 1995, BLOOD, V85, P343; MATSUDA T, IN PRESS BLOOD; MCKNIGHT SL, COMMUNICATION; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1995, CURR OPIN CELL BIOL, V7, P156, DOI 10.1016/0955-0674(95)80023-9; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P243; Minami Y., UNPUB; MIU AL, IN PRESS; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MIYAZAKI T, IN PRESS CELL; Miyazaki T., UNPUB; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLER M, 1994, NATURE, V366, P129; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NIELSEN M, 1994, EUR J IMMUNOL, V24, P3082, DOI 10.1002/eji.1830241225; NISHIKAWA S, COMMUNICATION; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OCONNOR R, 1992, BLOOD, V80, P1017; OPPENHEIM JJ, 1993, FUNDAMENTAL IMMUNOLO, P801; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERLMUTTER R, COMMUNICATION; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; QUELLE FW, IN PRESS MOL CELL BI; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SATOH T, 1992, J BIOL CHEM, V267, P25423; SECKINGER P, 1994, J IMMUNOL, V153, P97; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH AG, 1992, DEV BIOL, V151, P339, DOI 10.1016/0012-1606(92)90174-F; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TIAN S, IN PRESS BLOOD; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; TORIGOE T, 1992, BLOOD, V80, P617; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VENKITARAMAN AR, 1992, P NATL ACAD SCI USA, V89, P12083, DOI 10.1073/pnas.89.24.12083; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHU XY, 1994, J BIOL CHEM, V269, P5518; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	119	671	694	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					251	255		10.1126/science.7716517	http://dx.doi.org/10.1126/science.7716517			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716517				2022-12-28	WOS:A1995QT18500025
J	BULSTRODE, CJK				BULSTRODE, CJK			RECENT ADVANCES - ORTHOPEDIC AND TRAUMA SURGERY	BRITISH MEDICAL JOURNAL			English	Article							REPLACEMENT				BULSTRODE, CJK (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT ORTHOPAED SURG,OXFORD OX3 9DU,ENGLAND.							BOEREE NR, 1994, J BONE JOINT SURG BR, V76B, P525, DOI 10.1302/0301-620X.76B4.8027133; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BULSTRODE C, 1987, BRIT MED J, V295, P514, DOI 10.1136/bmj.295.6597.514; BULSTRODE CJK, 1993, BRIT MED J, V306, P732, DOI 10.1136/bmj.306.6880.732; Cameron I D, 1993, Disabil Rehabil, V15, P29; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DANDY DJ, 1994, SOME CLIN ASPECTS RE; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; Kennie David C., 1994, P27; MURRAY DW, IN PRESS J BONE JOIN; NILSSON R, 1991, INT J EPIDEMIOL, V20, P1018, DOI 10.1093/ije/20.4.1018; OWEN TD, 1994, J BONE JOINT SURG BR, V76B, P258, DOI 10.1302/0301-620X.76B2.8113287; PALEY D, 1988, J PEDIATR ORTHOPED, V8, P73, DOI 10.1097/01241398-198801000-00018; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SKINNER DV, 1993, INJURY, V24, P147, DOI 10.1016/0020-1383(93)90277-D; SPIERS ASD, 1993, J BONE JOINT SURG BR, V75, P49, DOI 10.1302/0301-620X.75B1.8421033; TENNANT A, 1994, ESTIMATING NUMBER PE; VINCE KG, 1989, J BONE JOINT SURG BR, V71, P793, DOI 10.1302/0301-620X.71B5.2584249; 1992, BRIT MED J, V305, P567	20	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					917	919		10.1136/bmj.310.6984.917	http://dx.doi.org/10.1136/bmj.310.6984.917			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719186	Green Published			2022-12-28	WOS:A1995QR97200030
J	WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ				WITKE, W; SHARPE, AH; HARTWIG, JH; AZUMA, T; STOSSEL, TP; KWIATKOWSKI, DJ			HEMOSTATIC, INFLAMMATORY, AND FIBROBLAST RESPONSES ARE BLUNTED IN MICE LACKING GELSOLIN	CELL			English	Article							ACTIN DEPOLYMERIZING FACTOR; FILAMENT-SEVERING PROTEIN; D-BINDING-PROTEIN; F-ACTIN; CAPPING PROTEIN; SKELETAL-MUSCLE; PLASMA GELSOLIN; CALCIUM-ION; STEM-CELLS; POLYMERIZATION	Gelsolin, an 82 kDa actin-binding protein, has potent actin filament-severing activity in vitro. To investigate the in vivo function of gelsolin, transgenic gelsolinnull (Osn(-)) mice were generated and found to have normal embryonic development and longevity. However, platelet shape changes are decreased in Gsn(-) mice, causing prolonged bleeding times. Neutrolphil migration in vivo into peritoneal exudates and in vitro is delayed. Gsn(-) dermal fibroblasts have excessive actin stress fibers and migrate more slowly than wildtype fibroblasts, but have increased contractility in vitro. These observations establish the requirement of gelsolin for rapid motile responses in cell types involved in stress responses such as hemostasis, inflammation, and wound healing. Neither gelsolin nor other proteins with similar actin filament-severing activity are expressed in early embryonic cells, indicating that this mechanism of actin filament dynamics is not essential for motility during early embryogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	WITKE, W (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19429, HL 48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbondanzo SJ, 1993, GUIDE TECHNIQUES MOU, P803; ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; ANKENBAUER T, 1988, J CELL BIOL, V107, P1489, DOI 10.1083/jcb.107.4.1489; BAMBURG JR, 1980, FEBS LETT, V121, P178, DOI 10.1016/0014-5793(80)81292-0; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CASELLA JF, 1987, J CELL BIOL, V105, P371, DOI 10.1083/jcb.105.1.371; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CONDELLIS J, 1994, ANN RV CELL BIOL, V9, P411; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; DELCASTILLO AR, 1992, THROMB HAEMOSTASIS, V67, P248; DIFFENBACH CW, 1989, J BIOL CHEM, V264, P13281; GRINNELL F, 1984, J CELL SCI, V66, P51; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; ISENBERG G, 1980, NATURE, V288, P455, DOI 10.1038/288455a0; JANMEY PA, 1987, BLOOD, V70, P524; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH M, 1984, J BIOL CHEM, V2598, P7473; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P8239; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P13857; KWIATKOWSKI DJ, 1988, J BIOL CHEM, V263, P5910; KWIATKOWSKI DJ, 1989, J CELL BIOL, V108, P1717, DOI 10.1083/jcb.108.5.1717; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LEE J, 1993, NATURE, V3622, P167; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIND SE, 1986, J CLIN INVEST, V78, P736, DOI 10.1172/JCI112634; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; MARUYAMA K, 1965, BIOCHIM BIOPHYS ACTA, V94, P208, DOI 10.1016/0926-6585(65)90026-9; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YONEZAWA N, 1985, J BIOL CHEM, V260, P4410; YOUNG WO, 1987, J LAB CLIN MED, V110, P83; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912	59	370	387	1	19	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					41	51		10.1016/0092-8674(95)90369-0	http://dx.doi.org/10.1016/0092-8674(95)90369-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720072	Bronze			2022-12-28	WOS:A1995QR97000006
J	KEY, LL; RODRIGUIZ, RM; WILLI, SM; WRIGHT, NM; HATCHER, HC; EYRE, DR; CURE, JK; GRIFFIN, PP; RIES, WL				KEY, LL; RODRIGUIZ, RM; WILLI, SM; WRIGHT, NM; HATCHER, HC; EYRE, DR; CURE, JK; GRIFFIN, PP; RIES, WL			LONG-TERM TREATMENT OF OSTEOPETROSIS WITH RECOMBINANT HUMAN INTERFERON-GAMMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; INFANTILE OSTEOPETROSIS; FREE-RADICALS; RESORPTION; INVITRO; OSTEOCLASTS; REDUCTION; DEFECT; MICE	Background. Congenital osteopetrosis is a rare osteosclerotic bone disease characterized by both a defect in osteoclastic function and reduced generation of superoxide by leukocytes. The disease is frequently fatal during the first decade of life. A six-month trial of therapy with recombinant human interferon gamma-lb in eight patients with osteopetrosis provided evidence of benefit, prompting this study of more prolonged therapy. Methods. We studied 14 patients with severe osteopetrosis treated with subcutaneous injections of recombinant human interferon gamma-1b (1.5 mu g per kilogram of body weight per dose) three times per week for at least 6 months; 11 patients were treated for 18 months. We assessed the effect of therapy by evaluating the patients' clinical status, measuring blood counts and biochemical markers of bone turnover, and performing bone marrow imaging and bone biopsies. Results. After 6 months of therapy, all 14 patients had decreases in trabecular-bone area (determined by histomorphometric analysis of bone-biopsy specimens) and increases in bone marrow space (determined by marrow imaging), and the improvement was sustained in the 11 patients treated for 18 months. The mean (+/-SD) hemoglobin concentration increased from 7.5+/-2.9 to 10.5+/-0.3 g per deciliter (P=0.05), and superoxide generation by granulocyte-macrophage colonies increased (P<0.001) after 18 months of therapy. In six patients for whom pretreatment data were available, there was a 96 percent decrease in the frequency of infections requiring antibiotic therapy during interferon treatment. There were no side effects necessitating the discontinuation of therapy. Conclusions. Long-term therapy with interferon gamma in patients with osteopetrosis increases bone resorption and hematopoiesis and improves leukocyte function.	MED UNIV S CAROLINA,DEPT RADIOL,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT ORTHOPED,CHARLESTON,SC 29425; UNIV WASHINGTON,DEPT ORTHOPAED,SEATTLE,WA 98195	Medical University of South Carolina; Medical University of South Carolina; University of Washington; University of Washington Seattle	KEY, LL (corresponding author), MED UNIV S CAROLINA,DEPT PEDIAT ENDOCRINOL,CSB 316E,96 JONATHAN LUCAS AVE,CHARLESTON,SC 29425, USA.			Willi, Steven/0000-0002-4910-2425	NCRR NIH HHS [M01-RR-01070, M01 RR001070] Funding Source: Medline; NIAMS NIH HHS [R37 AR037318, R01 AR036794] Funding Source: Medline; FDA HHS [FDR-000768] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR037318, R01AR036794] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FDA HHS; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEARD CJ, 1986, J LAB CLIN MED, V108, P498; COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301; ELSTER AD, 1992, RADIOLOGY, V182, P507, DOI 10.1148/radiology.182.2.1732971; EZEKOWITZ RAB, 1988, NEW ENGL J MED, V319, P146, DOI 10.1056/NEJM198807213190305; FISCHER A, 1991, BLOOD, V77, P249; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; GOWEN M, 1986, J IMMUNOL, V136, P2478; GOWEN M, 1986, J BONE MINER RES, V1, P469; HANSON DA, 1992, J BONE MINER RES, V7, P1251; KEY L, 1984, NEW ENGL J MED, V310, P409, DOI 10.1056/NEJM198402163100701; KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4; KEY LL, 1992, J PEDIATR-US, V121, P119, DOI 10.1016/S0022-3476(05)82557-0; KEY LL, 1990, BONE, V11, P115, DOI 10.1016/8756-3282(90)90058-7; KEY LL, 1987, CPC SERIES CASES MET, V2, P1; MANN GN, 1994, ENDOCRINOLOGY, V135, P1077, DOI 10.1210/en.135.3.1077; REEVES JD, 1979, PEDIATRICS, V64, P202; RIES WL, 1992, J BONE MINER RES, V7, P931; RODRIGUIZ RM, 1993, PEDIATR RES, V33, P384; SATO K, 1992, CANCER RES, V52, P444; SHAPIRO F, 1980, J BONE JOINT SURG AM, V62, P384, DOI 10.2106/00004623-198062030-00008	20	178	183	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1594	1599		10.1056/NEJM199506153322402	http://dx.doi.org/10.1056/NEJM199506153322402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753137	Bronze			2022-12-28	WOS:A1995RC19200002
J	BOWMAN, MA; SCHWENK, TL				BOWMAN, MA; SCHWENK, TL			FAMILY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA	University of Michigan System; University of Michigan	BOWMAN, MA (corresponding author), BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA.		bowman, marjorie a/F-7235-2013	bowman, marjorie a/0000-0002-1945-9212				AICKIN R, 1994, BRIT MED J, V309, P223, DOI 10.1136/bmj.309.6949.223; BROX JI, 1993, BMJ-BRIT MED J, V307, P899, DOI 10.1136/bmj.307.6909.899; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; HAYNES RB, 1994, JAMA-J AM MED ASSOC, V271, P1256, DOI 10.1001/jama.271.16.1256; HOMBERG L, 1994, ARCH INTERN MED, V154, P1805; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; SAUVE JS, 1994, ANN INTERN MED, V120, P633, DOI 10.7326/0003-4819-120-8-199404150-00002; STEWART DE, 1994, OBSTET GYNECOL, V83, P583, DOI 10.1097/00006250-199404000-00016; VEGA GL, 1994, ARCH INTERN MED, V154, P73, DOI 10.1001/archinte.154.1.73; WORCESTER MC, 1993, BRIT MED J, V307, P1244, DOI 10.1136/bmj.307.6914.1244; 1994, JAMA-J AM MED ASSOC, V271, P1011	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1676	1677						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752412				2022-12-28	WOS:A1995RB09700020
J	EVENS, RG				EVENS, RG			RADIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EVENS, RG (corresponding author), WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110, USA.							BRINK JA, 1994, AM J ROENTGENOL, V163, P307, DOI 10.2214/ajr.163.2.8037020; CRADDUCK TD, 1994, J NUCL MED, V35, pN30; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; FORMAN HP, 1994, AM J ROENTGENOL, V162, P1125, DOI 10.2214/ajr.162.5.8165996; FRANK MS, 1993, AM J ROENTGENOL, V160, P473, DOI 10.2214/ajr.160.3.8430538; KOPANS DB, 1994, NEW ENGL J MED, V331, P1521, DOI 10.1056/NEJM199412013312213; LINDFORS KK, 1994, RADIOLOGY, V190, P217, DOI 10.1148/radiology.190.1.8259408; MARIN LM, 1994, J VASC SURG, V20, P466; REINUS WR, 1994, INVEST RADIOL, V2, P606; SCHWARTZ LB, 1994, RADIOLOGY, V192, P55, DOI 10.1148/radiology.192.1.8208966; THURFJELL EL, 1994, RADIOLOGY, V191, P241, DOI 10.1148/radiology.191.1.8134580; Wu Y, 1993, J Digit Imaging, V6, P117; ZEMAN RK, 1994, AM J ROENTGENOL, V162, P1425, DOI 10.2214/ajr.162.6.8192012	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1720	1721						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752436				2022-12-28	WOS:A1995RB09700044
J	POYNARD, T; BEDOSSA, P; CHEVALLIER, M; MATHURIN, P; LEMONNIER, C; TREPO, C; COUZIGOU, P; PAYEN, JL; SAJUS, M; COSTA, JM; VIDAUD, M; CHAPUT, JC				POYNARD, T; BEDOSSA, P; CHEVALLIER, M; MATHURIN, P; LEMONNIER, C; TREPO, C; COUZIGOU, P; PAYEN, JL; SAJUS, M; COSTA, JM; VIDAUD, M; CHAPUT, JC			A COMPARISON OF 3 INTERFERON ALFA-2B REGIMENS FOR THE LONG-TERM TREATMENT OF CHRONIC NON-A, NON-B-HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS	Background. We studied the effects of long-term treatment with interferon on histologic features of the liver and serum alanine aminotransferase concentrations in patients with chronic non-A, non-B hepatitis. Methods. Consecutive patients who met the inclusion criteria were enrolled in the study, The diagnosis of chronic non-A, non-B hepatitis was established on the basis of the liver-biopsy findings and an abnormal serum alanine aminotransferase value (more than 1.5 times the normal value) for at least one year. All patients were treated for 6 months with 3 million units of interferon alfa-2b given subcutaneously three times a week and were then randomly assigned to the same treatment for an additional 12 months (group 1), a regimen of 1 million units three times a week for 12 months (group 2), or no further treatment (group 3). Patients in group 3 who had elevated serum alanine aminotransferase concentrations for three consecutive months underwent the initial regimen once again. Follow-up continued for two years after the discontinuation of treatment. Histologic improvement was defined as a decrease of at least one point in the score for necroinflammatory activity (0, no activity; 1, mild; 2, moderate; or 3, severe) between the first liver biopsy and a biopsy performed at 18 months. Results. Of the 329 patients initially treated, 303 were randomized: 103 to group 1, 101 to group 2, and 99 to group 3. Of the 286 patients tested, 252 (88.1 percent) had antibodies to hepatitis C virus. In an intention-to-treat analysis, 46 of the patients in group 1 (44.7 percent) had normal serum alanine aminotransferase values at 18 months, as compared with 27 of the patients in group 2 (26.7 percent, P=0.008) and 30 of those in group 3 (30.3 percent, P=0.04). Between 19 and 42 months, 23 of the patients in group 1 (22.3 percent) continued to have normal serum alanine aminotransferase values (measured every 6 months), as compared with 10 of the patients in group 2 (9.9 percent, P=0.02) and 8 of those in group 3 (8.1 percent, P=0.005). Among the 176 patients with repeated liver biopsies at 18 months, more patients in group 1 had improved histologic-activity scores (69.6 percent) than in group 2 (47.6 percent, P=0.02) or group 3 (38.6 percent, P<0.001). Conclusions. Among patients with chronic non-A, non-B hepatitis, a regimen of 3 million units of interferon alfa-2b given three times a week for 18 months produced better histologic findings and serum alanine aminotransferase values than regimens involving a lower dose or a shorter duration of treatment.	HOP ANTOINE BECLERE, SERV HEPATOGASTROENTEROL, F-92141 CLAMART, FRANCE; HOP BICETRE, SERV ANAT PATHOL, LE KREMLIN BICETRE, FRANCE; CNRS, URA 1484, PARIS, FRANCE; INST PASTEUR, LYON, FRANCE; SCHERING PLOUGH LABS, LEVALLOIS PERRET, FRANCE; HOP HOTEL DIEU, SERV HEPATOGASTROENTEROL, F-69288 LYON, FRANCE; HOP HAUT LEVEQUE, PESSAC, FRANCE; HOP REG TOULOUSE, TOULOUSE, FRANCE; HOP AMER PARIS, NEUILLY, FRANCE; HOP AMER PARIS, CNRS, URA 1484, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Merck & Company; Schering Plough Corporation; Schering-Plough Research Institute; CHU Lyon; CHU Bordeaux; Centre National de la Recherche Scientifique (CNRS)			Mathurin, Philippe/A-9121-2018; Poynard, Thierry/C-1355-2010; Vidaud, Michel/O-7346-2017	Mathurin, Philippe/0000-0003-3447-2025; Poynard, Thierry/0000-0002-3726-7230; Bedossa, Pierre/0000-0002-8487-7322; Poynard, Thierry/0000-0002-2050-640X				BEDOSSA P, 1994, HEPATOLOGY, V20, P15; COOKSLEY WGE, 1986, HEPATOLOGY, V6, P345; DIXON WJ, 1991, BMDP STATISTICAL SOF, V1; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; SAJUS, 1994, HEPATOLOGY, V20, pA244; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; 1995, VIDAL 1995, P757; 1995, PHYSICIANS DESK REFE, P2266	10	459	464	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1457	1462		10.1056/NEJM199506013322201	http://dx.doi.org/10.1056/NEJM199506013322201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739681				2022-12-28	WOS:A1995RA14000001
J	STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM				STEPHENS, R; SPURGEON, A; CALVERT, IA; BEACH, J; LEVY, LS; BERRY, H; HARRINGTON, JM			NEUROPSYCHOLOGICAL EFFECTS OF LONG-TERM EXPOSURE TO ORGANOPHOSPHATES IN SHEEP DIP	LANCET			English	Article							BEHAVIORAL-EVALUATION; PESTICIDES; WORKERS; SYSTEM	Organophosphate-based pesticides are widely used throughout the world. The acute effects of over-exposure to such compounds are well known. Concern has also been expressed that long-term exposure may result in damage to the nervous system. In a cross-sectional study, we compared neuropsychological performance in 146 sheep farmers who were exposed to organophosphates in the course of sheep dipping with 143 non-exposed quarry workers (controls). The farmers performed significantly worse than controls in tests to assess sustained attention and speed of information processing. These effects remained after adjustment for covariates. The farmers also showed greater vulnerability to psychiatric disorder than did the controls as measured by the General Health Questionnaire. There were no observed effects on short-term memory and learning. Repeated exposure to organophosphate-based pesticides appears to be associated with subtle changes in the nervous system. Measures should be taken to reduce exposure to organophosphates as far as possible during agricultural operations.	UNIV BIRMINGHAM,INST OCCUPAT HLTH,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; HLTH & SAFETY EXECUT,OCCUPAT MED & HYG LAB,SHEFFIELD S3 7HQ,S YORKSHIRE,ENGLAND	University of Birmingham			Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975				BAKER EL, 1985, J OCCUP ENVIRON MED, V27, P206; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; DAVIES JE, 1991, AM J IND MED, V18, P327; DILLNER L, 1994, BRIT MED J, V308, P1001, DOI 10.1136/bmj.308.6935.1001; Gallo M.A., 1991, HDB PESTICIDE TOXICO, V2; GOLDBERG D, 1985, BRIT MED J, V291, P161, DOI 10.1136/bmj.291.6489.161; MAIZLISH N, 1987, AM J IND MED, V12, P153, DOI 10.1002/ajim.4700120205; MEARNS J, 1994, J CLIN PSYCHOL, V50, P286, DOI 10.1002/1097-4679(199403)50:2<286::AID-JCLP2270500223>3.0.CO;2-P; NIVEN KJM, 1993, IOM TM9303 I OCC MED; NUTLEY BP, 1993, PESTIC SCI, V38, P315, DOI 10.1002/ps.2780380406; RODNITZKY RL, 1975, ARCH ENVIRON HEALTH, V30, P98, DOI 10.1080/00039896.1975.10666651; ROSENSTOCK L, 1991, LANCET, V338, P223, DOI 10.1016/0140-6736(91)90356-T; SAVAGE EP, 1988, ARCH ENVIRON HEALTH, V43, P38, DOI 10.1080/00039896.1988.9934372; STEENLAND K, 1994, AM J PUBLIC HEALTH, V84, P5; STOLLERY BT, 1988, SCAND J WORK ENV HEA, V14, P45, DOI 10.5271/sjweh.1951; STOLLERY BT, 1990, MICROCOMPUTERS PSYCH	16	240	250	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1135	1139		10.1016/S0140-6736(95)90976-1	http://dx.doi.org/10.1016/S0140-6736(95)90976-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723544				2022-12-28	WOS:A1995QW62200008
J	SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y				SHIMIZU, S; EGUCHI, Y; KOSAKA, H; KAMIIKE, W; MATSUDA, H; TSUJIMOTO, Y			PREVENTION OF HYPOXIA-INDUCED CELL-DEATH BY BCL-2 AND BCL-XL	NATURE			English	Article							PRE-B-CELLS; CHROMOSOMAL BREAKPOINT; FOLLICULAR LYMPHOMA; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; PROTEIN; INVOLVEMENT; EXPRESSION	THE proto-oncogene bcl-2, isolated from the t(14;18) chromosomal breakpoint in follicular B-lymphoma(1-3), and a bcl-2related gene bcl-x (ref. 4) prevent apoptotic cell death induced by various treatments(5-8). Although a mechanism has been proposed that involves Bcl-2 activity on reactive oxygen species (ROS)(910) expression of Bcl-2 or Bcl-xL prevents cell death induced by withdrawal of oxygen (hypoxia), which drastically decreases the net formation of oxygen free radicals and does not increase oxidized lipid, protein or DNA. Furthermore, neither ROS scavenger nor inhibitor of ROS scavenger affects cell death, regardless of the expression of Bcl-2 or Bcl-xL. Thus our data suggest that Bcl-2 and Bcl-xL exert an anti-fell death function by a mechanism other than regulation of ROS activity.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MED GENET,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROTA K, 1987, CANCER RES, V47, P3742; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1993, J IMMUNOL, V151, P621; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; KU RH, 1986, ARCH BIOCHEM BIOPHYS, V247, P183, DOI 10.1016/0003-9861(86)90547-3; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SHIGENAGA MK, 1990, METHOD ENZYMOL, V186, P521; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAKEUCHI T, 1993, BIOCHEM BIOPH RES CO, V194, P57, DOI 10.1006/bbrc.1993.1784; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	28	606	625	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					811	813		10.1038/374811a0	http://dx.doi.org/10.1038/374811a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723826				2022-12-28	WOS:A1995QV31500047
J	CURTIS, D; LEHMANN, R; ZAMORE, PD				CURTIS, D; LEHMANN, R; ZAMORE, PD			TRANSLATIONAL REGULATION IN DEVELOPMENT	CELL			English	Review							XENOPUS OOCYTE MATURATION; MATERNAL MESSENGER-RNAS; 3' UNTRANSLATED REGION; C-ELEGANS; SECONDARY STRUCTURE; POLY(A) ELONGATION; BINDING PROTEINS; CELL-FORMATION; INITIATION; NANOS				CURTIS, D (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, DEPT BIOL, CAMBRIDGE, MA 02142 USA.		Zamore, Phillip D/A-8941-2013	Zamore, Phillip/0000-0002-4505-9618				AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMBROS V, 1989, CELL, V57, P49, DOI 10.1016/0092-8674(89)90171-2; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; BALLANTYNE S, 1995, RNA, V1, P64; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BILGER A, 1994, GENE DEV, V8, P1106, DOI 10.1101/gad.8.9.1106; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; CERVERA M, 1981, CELL, V23, P113, DOI 10.1016/0092-8674(81)90276-2; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; CURTIS D, 1995, DEVELOPMENT, V121, P1899; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEBAUER F, 1994, EMBO J, V13, P5712, DOI 10.1002/j.1460-2075.1994.tb06909.x; GEBAUER F, 1995, IN PRESS MOL CELL BI; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GRAY NK, 1994, EMBO J, V13, P3882, DOI 10.1002/j.1460-2075.1994.tb06699.x; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HAMILL D, 1994, J CELL BIOL, V127, P973, DOI 10.1083/jcb.127.4.973; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HESS MA, 1994, J BIOL CHEM, V269, P10913; HODGKIN J, 1987, DEVELOPMENT, V101, P5; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KEMPE E, 1993, DEV GENET, V14, P449, DOI 10.1002/dvg.1020140606; KIMHA J, 1995, IN PRESS CELL, V81; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; LANTZ V, 1992, DEVELOPMENT, V115, P75; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEGAGNEUX V, 1992, DEVELOPMENT, V116, P1193; LIANG L, 1994, DEVELOPMENT, V120, P1201; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MARELLO K, 1992, NUCLEIC ACIDS RES, V20, P5593, DOI 10.1093/nar/20.21.5593; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; RICHTER JD, 1995, TRANSLATIONAL CONTRO; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SCHMID HP, 1983, FEBS LETT, V157, P105, DOI 10.1016/0014-5793(83)81125-9; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; SIELIWANOWICZ B, 1987, BIOCHIM BIOPHYS ACTA, V908, P54, DOI 10.1016/0167-4781(87)90021-2; SIMON R, 1994, MOL CELL BIOL, V14, P7867, DOI 10.1128/MCB.14.12.7867; SIMON R, 1992, GENE DEV, V6, P2580, DOI 10.1101/gad.6.12b.2580; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; STEBBINSBOAZ B, 1994, MOL CELL BIOL, V14, P5870, DOI 10.1128/MCB.14.9.5870; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; THACH RE, 1992, CELL, V68, P177, DOI 10.1016/0092-8674(92)90461-K; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2	77	365	369	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					171	178		10.1016/0092-8674(95)90325-9	http://dx.doi.org/10.1016/0092-8674(95)90325-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736569	Bronze			2022-12-28	WOS:A1995QV41000004
J	NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA				NOWAK, MW; KEARNEY, PC; SAMPSON, JR; SAKS, ME; LABARCA, CG; SILVERMAN, SK; ZHONG, W; THORSON, JS; ABELSON, JN; DAVIDSON, N; SCHULTZ, PG; DOUGHERTY, DA; LESTER, HA			NICOTINIC RECEPTOR-BINDING SITE PROBED WITH UNNATURAL AMINO-ACID-INCORPORATION IN INTACT-CELLS	SCIENCE			English	Article							TRANSFER RNA-SYNTHETASE; ACETYLCHOLINE-RECEPTOR; ALPHA-SUBUNIT; RECOGNITION; PHENYLALANINE; CONSTRUCTION; SUPPRESSION; NUCLEOTIDES; MUTATIONS; ANTICODON	The nonsense codon suppression method for unnatural amino acid incorporation has been applied to intact Cells and combined with electrophysiological analysis to probe structure-function relations in the nicotinic acetylcholine receptor, Functional receptors were expressed in Xenopus oocytes when tyrosine and phenylalanine derivatives were incorporated at positions 93, 190, and 198 in the binding site of the a subunit, Subtle changes in the structure of an individual side chain produced readily detectable changes in the function of this large channel protein, At each position, distinct features of side chain structure dominated the dose-response relation, probably by governing the agonist-receptor binding.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, DEPT CHEM, BERKELEY, CA 94720 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Berkeley	NOWAK, MW (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.		Thorson, Jon S/L-3696-2013	Thorson, Jon S/0000-0002-7148-0721; Silverman, Scott/0000-0001-8166-3460; Nowak, Mark/0000-0001-5097-2682				ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; AYLWIN ML, 1994, MOL PHARMACOL, V46, P1149; BAIN JD, 1989, J AM CHEM SOC, V111, P8013, DOI 10.1021/ja00202a052; BIENZ M, 1980, NUCLEIC ACIDS RES, V8, P5169, DOI 10.1093/nar/8.22.5169; CACCHI S, 1992, TETRAHEDRON LETT, V33, P3939, DOI 10.1016/S0040-4039(00)74824-6; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORNISH VW, 1994, P NATL ACAD SCI USA, V91, P2910, DOI 10.1073/pnas.91.8.2910; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; ELLMAN JA, 1992, METHOD ENZYMOL, V202, P301; England T E, 1980, Methods Enzymol, V65, P65; GALZI JL, 1990, J BIOL CHEM, V265, P10430; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Hammett LP, 1937, J AM CHEM SOC, V59, P96, DOI 10.1021/ja01280a022; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; LESTER HA, 1992, ANNU REV BIOPH BIOM, V21, P267, DOI 10.1146/annurev.bb.21.060192.001411; LEVITT LS, 1976, PROG PHYS ORG CHEM, V12, P119; LIN SX, 1984, BIOCHEMISTRY-US, V23, P4109, DOI 10.1021/bi00313a015; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P3957, DOI 10.1073/pnas.87.10.3957; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; QUICK MW, 1994, ION CHANNELS EXCITAB, P261; ROBERTSON SA, 1991, J AM CHEM SOC, V113, P2722, DOI 10.1021/ja00007a055; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; SAMPSON JR, 1992, BIOCHEMISTRY-US, V31, P4161, DOI 10.1021/bi00132a002; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SINE SM, 1994, J BIOL CHEM, V269, P8808; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; THORSON JS, IN PRESS J AM CHEM S; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; Topsom, 1976, PROG PHYS ORG CHEM, V12, P1, DOI DOI 10.1002/9780470171912.CHL; Unger S.H., 1976, PROG PHYS ORG CHEM, V12, P91, DOI 10.1002/9780470171912.ch4; URRY DW, 1993, J AM CHEM SOC, V115, P7509, DOI 10.1021/ja00069a063; YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149; YOSHII K, 1987, J GEN PHYSIOL, V90, P553, DOI 10.1085/jgp.90.4.553	42	209	276	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					439	442		10.1126/science.7716551	http://dx.doi.org/10.1126/science.7716551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716551				2022-12-28	WOS:A1995QU57200047
J	KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P				KOLETZKO, S; HAISCH, M; SEEBOTH, I; BRADEN, B; HENGELS, K; KOLETZKO, B; HERING, P			ISOTOPE-SELECTIVE NONDISPERSIVE INFRARED SPECTROMETRY FOR DETECTION OF HELICOBACTER-PYLORI INFECTION WITH C-13-UREA BREATH TEST	LANCET			English	Note								C-13-urea breath tests were sampled in 51 subjects with an isotope-selective non-dispersive infrared spectrometer (NDIRS) and compared with the results of conventional isotope-ratio mass-spectrometry (IRMS). Delta-over-baseline values oi both methods correlated well (r=0.976 at 15 min and 0.985 at 30 min, both p<0.0005). With a cut-off for delta-over-baseline values of 5 parts per thousand (ie, 5 per thousand), both methods correctly classified all 36 Helicobacter-pylori-negative and all 15 H-pylori-positive subjects. All infected subjects had values over 11 parts per thousand in all samples with both methods. NDIRS is of equal value as IRMS for the diagnosis of H pylori infection. Because NDIRS gives on-line results and is easier and cheaper, we consider NDIRS useful for clinical practice.	UNIV DUSSELDORF,INST LASER MED,DUSSELDORF,GERMANY; UNIV DUSSELDORF,MED KLIN,DUSSELDORF,GERMANY; UNIV FRANKFURT,MED KLIN,FRANKFURT,GERMANY; MAX PLANCK INST QUANTUM OPT,GARCHING,GERMANY	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Goethe University Frankfurt; Max Planck Society	KOLETZKO, S (corresponding author), UNIV MUNICH,KINDERPOLIKLIN,PETTENKOFERSTR 8A,D-80336 MUNICH,GERMANY.		Braden, Barbara/AAI-7869-2020; Braden, Barbara/AAH-8693-2021	Braden, Barbara/0000-0002-8534-6873; 				BRADEN B, 1994, Z GASTROENTEROL, V32, P198; CRAIG H, 1957, GEOCHIM COSMOCHIM AC, V12, P133, DOI 10.1016/0016-7037(57)90024-8; DEMMELMAIR H, IN PRESS J PEDIATR G; DILL S, 1990, GUT, V31, P1237, DOI 10.1136/gut.31.11.1237; EGGERS RH, 1990, EUR J GASTROEN HEPAT, V2, P437; GHOOS YF, 1993, GASTROENTEROLOGY, V104, P1640, DOI 10.1016/0016-5085(93)90640-X; HAISCH M, IN PRESS ISOTOPENPRA; LOTTERER E, 1991, Z GASTROENTEROL, V29, P590; VANDENPLAS Y, 1992, PEDIATRICS, V90, P608	9	156	160	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					961	962		10.1016/S0140-6736(95)90704-1	http://dx.doi.org/10.1016/S0140-6736(95)90704-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715299				2022-12-28	WOS:A1995QT91900014
J	CASEY, PJ				CASEY, PJ			PROTEIN LIPIDATION IN CELL SIGNALING	SCIENCE			English	Article							RAB GERANYLGERANYL TRANSFERASE; ANCHORED PROTEINS; TYROSINE KINASES; PHOSPHOLIPASE-D; BETA-GAMMA; MEMBRANE; SUBUNIT; PALMITOYLATION; BIOSYNTHESIS; PRENYLATION	The ability of cells to communicate with and respond to their external environment is critical for their continued existence. A universal feature of this communication is that the external signal must in some way penetrate the lipid bilayer surrounding the cell. In most cases of such signal acquisition, the signaling entity itself does not directly enter the cell but rather transmits its information to specific proteins present on the surface of the cell membrane. These proteins then communicate with additional proteins associated with the intracellular face of the membrane. Membrane localization and function of many of these proteins are dependent on their covalent modification by specific lipids, and it is the processes involved that form the focus of this article.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University	CASEY, PJ (corresponding author), DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710, USA.			Casey, Patrick/0000-0002-7366-9309				AMES JB, 1994, BIOCHEMISTRY-US, V33, P10743, DOI 10.1021/bi00201a023; Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CINEK T, 1992, J IMMUNOL, V149, P2262; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COX AD, 1994, J BIOL CHEM, V269, P19203; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUKADA Y, 1994, J BIOL CHEM, V269, P5163; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HAGA K, 1992, J BIOL CHEM, V267, P2222; HALLAK H, 1994, J BIOL CHEM, V269, P4713; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HIGGINS JB, 1994, J BIOL CHEM, V269, P9067; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOKAME K, 1993, NATURE, V359, P749; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUESNEL S, 1994, BIOCHEMISTRY-US, V33, P13340, DOI 10.1021/bi00249a021; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SCHAFER WR, 1992, ANNU REV GENET, V25, P209; SCHLESINGER MJ, 1993, LIPID MODIFICATION P, P1; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	65	709	738	0	43	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					221	225		10.1126/science.7716512	http://dx.doi.org/10.1126/science.7716512			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716512				2022-12-28	WOS:A1995QT18500020
J	MOSS, F; MCNICOL, M				MOSS, F; MCNICOL, M			RETHINKING CONSULTANTS - ALTERNATIVE MODELS OF ORGANIZATION ARE NEEDED	BRITISH MEDICAL JOURNAL			English	Article								Anyone considering a fundamental rethink of the role of consultants risks exposing tensions in the medical profession that have characterised the development of medical practice since the 18th century. That tense story was one of beds and money, power and domination. Rethinking the role of consultants must now take into account the relationship between consultants and their specialist colleagues and general practitioners; examine the distribution of work between consultants and junior doctors; and relate the contribution of the consultant as specialist to that of other health professionals. After half a century of a national health service characterised by equity of access to care, we urgently need to debate the roles of those who work in it and in doing so to focus primarily on the needs of patients.			MOSS, F (corresponding author), CENT MIDDLESEX HOSP NHS TRUST,LONDON NW10 7NS,ENGLAND.							Abel-Smith B., 1964, HOSPITALS 1800 1948; [Anonymous], 1961, REPORT JOINT WORKING; BUCKNALL CE, 1988, LANCET, V1, P748; CALMAN K, 1993, HOSPITAL DOCTORS TRA; CAMPLING EA, 1992, REPORT NATIONAL CONF; COZENS JF, 1992, QUAL HEALTH CARE, V1, P252; DAY JL, 1988, DIABETIC MED, V5, P372, DOI 10.1111/j.1464-5491.1988.tb01008.x; Grimshaw J, 1995, Qual Health Care, V4, P55, DOI 10.1136/qshc.4.1.55; GRIMSHAW J, 1994, QUALITY HLTH CARE, V3, P37; HONIGSBAUM F, 1979, DIVISION BRIT MED; JENKINS AM, 1986, BRIT J SURG, V73, P395, DOI 10.1002/bjs.1800730528; Lomas J, 1993, Int J Technol Assess Health Care, V9, P11; MCKEE M, 1992, SOC SCI MED, V34, P549, DOI 10.1016/0277-9536(92)90210-H; Roland M, 1992, HOSPITAL REFERRALS; SIMPSON J, 1992, MANAGEMENT DOCTORS; Stevens Rosemary, 1966, MED PRACTICE MODERN; 1994, HLTH PERSONAL SOCIAL; 1995, DOCTORS TALE WORK HO; 1878, BRIT MED J, V1, P197; 1948, REPORT; 1886, BRIT MED J, V3, P1124; 1886, BRIT MED J, V3, P1114; 1992, FUNDING HOSPITAL MED	23	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					925	928		10.1136/bmj.310.6984.925	http://dx.doi.org/10.1136/bmj.310.6984.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719189	Green Published			2022-12-28	WOS:A1995QR97200033
J	KRONAUER, CM; BUHLER, H				KRONAUER, CM; BUHLER, H			SKIN FINDINGS IN A PATIENT WITH SCURVY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KRONAUER, CM (corresponding author), CITY HOSP WAID,CH-8037 ZURICH,SWITZERLAND.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1611	1611		10.1056/NEJM199506153322405	http://dx.doi.org/10.1056/NEJM199506153322405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753140				2022-12-28	WOS:A1995RC19200005
J	BERMAN, S				BERMAN, S			CURRENT CONCEPTS - OTITIS-MEDIA IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MIDDLE-EAR EFFUSION; RANDOMIZED CLINICAL-TRIAL; TERM SULFONAMIDE THERAPY; ANTIBIOTIC-TREATMENT; RECURRENT; EFFICACY; ADENOIDECTOMY; SULFAMETHOXAZOLE; TONSILLECTOMY; TRIMETHOPRIM		UNIV COLORADO,SCH MED,DEPT PEDIAT,DENVER,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	BERMAN, S (corresponding author), CHILDRENS HOSP,1056 E 19TH AVE,BOX B032,DENVER,CO 80218, USA.							ALHO OP, 1991, INT J PEDIATR OTORHI, V21, P201, DOI 10.1016/0165-5876(91)90001-R; AROLA M, 1990, J PEDIATR-US, V116, P697, DOI 10.1016/S0022-3476(05)82650-2; BERMAN S, 1994, PEDIATRICS, V93, P353; BERMAN S, 1993, PEDIATR INFECT DIS J, V12, P20, DOI 10.1097/00006454-199301000-00006; BERMAN S, 1987, AM J DIS CHILD, V141, P690, DOI 10.1001/archpedi.1987.04460060106048; BERMAN S, 1990, PEDIATR INFECT DIS J, V9, P533, DOI 10.1097/00006454-199008000-00001; BERMAN S, 1992, PEDIATR INFECT DIS J, V11, P63, DOI 10.1097/00006454-199202000-00001; BERNARD PAM, 1991, PEDIATRICS, V88, P215; BIEDEL CW, 1978, AM J DIS CHILD, V132, P681, DOI 10.1001/archpedi.1978.02120320041009; BLUESTONE CD, 1988, OTITIS MEDIA INFANTS, P2; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; CARLIN SA, 1991, J PEDIATR-US, V118, P178, DOI 10.1016/S0022-3476(05)80479-2; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; CHONMAITREE T, 1992, J PEDIATR-US, V120, P856, DOI 10.1016/S0022-3476(05)81950-X; CLAESSEN JQPJ, 1992, CLIN OTOLARYNGOL, V17, P251, DOI 10.1111/j.1365-2273.1992.tb01838.x; CUNNINGHAM AS, 1994, CONT PEDIATR, V11, P17; DEMPSTER JH, 1991, CLIN OTOLARYNGOL, V16, P157, DOI 10.1111/j.1365-2273.1991.tb01967.x; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GATES GA, 1987, NEW ENGL J MED, V317, P1444, DOI 10.1056/NEJM198712033172305; GIEBINK GS, 1982, PEDIATR INFECT DIS J, V1, P98, DOI 10.1097/00006454-198203000-00007; GREEN SM, 1993, PEDIATRICS, V91, P23; HATHAWAY TJ, 1994, PEDIATRICS, V94, P143; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Howie V M, 1993, Pediatr Rev, V14, P320, DOI 10.1542/pir.14-8-320; KALEIDA PH, 1991, PEDIATRICS, V87, P466; KLEIN JO, 1993, PEDIATR INFECT DIS J, V12, P973, DOI 10.1097/00006454-199312000-00001; KLEIN JO, 1982, SEMINARS INFECTIOUS, V4; LE CT, 1991, CONT PEDIATR, V8, P11; MARCHANT CD, 1992, J PEDIATR-US, V120, P72, DOI 10.1016/S0022-3476(05)80601-8; MAW AR, 1986, LANCET, V1, P1399; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; NELSON CT, 1994, PEDIATR INFECT DIS J, V13, P585, DOI 10.1097/00006454-199407000-00001; PARADISE JL, 1984, NEW ENGL J MED, V310, P674, DOI 10.1056/NEJM198403153101102; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; PRATT L W, 1970, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V74, P1146; PRINCIPI N, 1989, AM J DIS CHILD, V143, P1414, DOI 10.1001/archpedi.1989.02150240036013; PRINCIPI N, 1980, AM J DIS CHILD, V144, P1180; RIDING KH, 1978, J PEDIATR-US, V93, P739, DOI 10.1016/S0022-3476(78)81069-5; ROSENFELD RM, 1991, ARCH OTOLARYNGOL, V117, P984; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; RUDBERG RD, 1954, ACTA OTO-LARYNGOL, V113, P9; RUUSKANEN O, 1991, PEDIATR INFECT DIS J, V10, P425, DOI 10.1097/00006454-199106000-00001; SCHILDER AGM, 1993, RECENT ADV OTITIS ME, P585; SCHULLER DE, 1983, PEDIATR INFECT DIS J, V2, P280, DOI 10.1097/00006454-198307000-00004; STOOL SE, 1994, DHHS AHCPR940622 DEP; TEELE DW, 1981, J PEDIATR-US, V98, P537, DOI 10.1016/S0022-3476(81)80755-X; TOS M, 1993, RECENT ADV OTITIS ME, P582; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; VANBUCHEM FL, 1981, LANCET, V2, P883; VAYDA E, 1977, CAN MED ASSOC J, V116, P1263; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; WILLIAMS RL, 1994, JAMA-J AM MED ASSOC, V271, P430; YARDLEY MPJ, 1992, J LARYNGOL OTOL, V106, P299, DOI 10.1017/S0022215100119346; 1992, ADV DATA VITAL HLTH, V214	55	215	221	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1560	1565		10.1056/NEJM199506083322307	http://dx.doi.org/10.1056/NEJM199506083322307			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739711				2022-12-28	WOS:A1995RB19600007
J	CUNNINGHAMRUNDLES, C				CUNNINGHAMRUNDLES, C			ALLERGY AND IMMUNOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MICE				CUNNINGHAMRUNDLES, C (corresponding author), MT SINAI SCH MED,NEW YORK,NY 10029, USA.							BARGETZI MJ, 1993, CANCER RES, V53, P4010; CASEY LC, 1993, ANN INTERN MED, V21, P771; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DINARELLO CA, 1991, BLOOD, V72, P1627; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; Kaufmann Stefan H. E., 1994, Trends in Microbiology, V2, P235, DOI 10.1016/0966-842X(94)90628-9; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; MACDONALD TT, 1994, CURR BIOL, V4, P178, DOI 10.1016/S0960-9822(94)00044-8; NUSSENBLATT RB, 1994, 6TH P INT C BEHC DIS, P641; OPPENHEIM JJ, 1994, CLIN APPLICATIONS CY; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHIJNS VECJ, 1994, J IMMUNOL, V153, P2029; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VITOLO D, 1993, EUR J CANCER, V3, P371; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; Wells HG, 1911, J INFECT DIS, V8, P147	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1659	1660						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752403				2022-12-28	WOS:A1995RB09700011
J	ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ				ALMOND, N; KENT, K; CRANAGE, M; RUD, E; CLARKE, B; STOTT, EJ			PROTECTION BY ATTENUATED SIMIAN IMMUNODEFICIENCY VIRUS IN MACAQUES AGAINST CHALLENGE WITH VIRUS-INFECTED CELLS	LANCET			English	Note							SIV INFECTION; NEF GENE	A vaccine against AIDS will probably have to protect against challenge both by viable virus-infected cells and by cell-free virus. Eight cynomolgus macaques infected with attenuated simian immunodeficiency virus (SIV) were challenged (four each) with cell-free and cell-associated SIV, All were protected, whereas eight controls were all infected after challenge. These findings show that live-attenuated vaccine can confer protection against SIV in macaques, Extrapolation to human beings will require extensive evaluation of the safety of attenuated retroviruses. Alternatively, the mechanism of this potent protection must be understood and reproduced by less hazardous means.	CTR APPL MICROBIOL & RES,SALISBURY,WILTS,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; HLTH CANADA,LAB CTR DIS CONTROL,BUR HIV AIDS,OTTAWA,ON,CANADA	GlaxoSmithKline; Wellcome Research Laboratories; Health Canada	ALMOND, N (corresponding author), NATL INST BIOL STAND & CONTROLS,BLANCHE LANE S MIMMS,POTTERS BAR EN6 3QG,HERTS,ENGLAND.		Rud, Erling/P-5359-2016	Rud, Erling/0000-0001-8615-0277; Almond, Neil/0000-0001-6105-0616	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KENT K, 1995, AIDS RES HUM RETROV, V10, P189; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; MILLS KHG, 1992, J MED PRIMATOL, V21, P50; MITCHELL T, 1992, J VIROL, V66, P5696, DOI 10.1128/JVI.66.9.5696-5702.1992; ROSE J, 1995, J VIROL METHODS, V57, P229; RUD EW, 1994, J GEN VIROL, V75, P529, DOI 10.1099/0022-1317-75-3-529; SABIN AB, 1992, P NATL ACAD SCI USA, V89, P8852, DOI 10.1073/pnas.89.18.8852; STOTT EJ, 1991, 6EME C CENT GARD PAR, P261	10	211	213	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1342	1344		10.1016/S0140-6736(95)92540-6	http://dx.doi.org/10.1016/S0140-6736(95)92540-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752758				2022-12-28	WOS:A1995RA14800011
J	SIMPSON, DIH				SIMPSON, DIH			THE FILOVIRUS ENIGMA	LANCET			English	Editorial Material											SIMPSON, DIH (corresponding author), QUEENS UNIV BELFAST,DEPT MICROBIOL & IMMUNOL,BELFAST,ANTRIM,NORTH IRELAND.							SIMPSON DIS, 1986, EPIDEMIOLOGY CONTROL, V1	1	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1252	1253		10.1016/S0140-6736(95)90918-4	http://dx.doi.org/10.1016/S0140-6736(95)90918-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746050				2022-12-28	WOS:A1995QY93300002
J	PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW				PENNINGER, JM; WEN, T; TIMMS, E; POTTER, J; WALLACE, VA; MATSUYAMA, T; FERRICK, D; SYDORA, B; KRONENBERG, M; MAK, TW			SPONTANEOUS RESISTANCE TO ACUTE T-CELL LEUKEMIAS IN TCRV-GAMMA-1.1J-GAMMA-4C-GAMMA-4 TRANSGENIC MICE	NATURE			English	Article							DELTA-LYMPHOCYTES-T; GAMMA-DELTA; MYCOBACTERIUM-TUBERCULOSIS; ANTIGEN; RECEPTOR; EXPRESSION	THE concept of tumour surveillance implies that specific and nonspecific components of the immune system eliminate rumours in the early phase of malignancy(1,2). The immunological mechanisms that control growth-of preneoplastic cells are, however, not known. T cells expressing gamma delta T-cell receptors (TCR) were first described as lymphocytes with reactivity against various tumour cells, which suggests that gamma delta T cells could mediate tumour surveillance(3-6). Here we show that TCRV gamma 1.1J gamma 4C gamma 4 transgenic mice(7) are spontaneously resistant to acute T-cell leukaemias but cannot reject non-haematopoietic tumours. TCRV gamma 1.1J gamma 4C gamma 4(+) hybridomas isolated from these mice react in vitro against almost all haematopoietic tumour cell lines tested. Recognition of tumour cells depends on the gamma delta TCR but is independent of major histocompatibility complex (MHC) class I, MHC class II, or TAP-2 peptide transporter expression. Ligand recognition is influenced by the murine Nromp gene, which confers resistance or susceptibility to tuberculosis, lepra and leishmaniasis(8,9). These data indicate that TCRV gamma 1.1(+) T cells confer spontaneous immunity against haematopoietic rumours in vivo and link innate resistance to bacterial infections with tissue-specific tumour surveillance by gamma delta(+) T cells.	UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5X 1K9,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5X 1K9,CANADA; UNIV CALIF DAVIS,DEPT VET MICROBIOL & IMMUNOL,DAVIS,CA 95616; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of Toronto; University of Toronto; University of California System; University of California Davis; University of California System; University of California Los Angeles	PENNINGER, JM (corresponding author), UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,500 SHERBOURNE ST,TORONTO,ON M5X 1K9,CANADA.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; BARTON CH, 1994, J EXP MED, V179, P1683, DOI 10.1084/jem.179.5.1683; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092-8674(89)90923-9; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; KABELITZ D, 1991, J EXP MED, V173, P1331, DOI 10.1084/jem.173.6.1331; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; KLEIN G, 1993, CURR OPIN IMMUNOL, V5, P687, DOI 10.1016/0952-7915(93)90122-9; KRONENBERG M, 1994, CURR OPIN IMMUNOL, V6, P64, DOI 10.1016/0952-7915(94)90035-3; MOMBAERTS P, 1993, NATURE, V365, P53, DOI 10.1038/365053a0; MUNK ME, 1990, J IMMUNOL, V145, P2434; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OBRIEN RL, 1989, CELL, V57, P667, DOI 10.1016/0092-8674(89)90135-9; PARDOLL DM, 1993, CURR OPIN IMMUNOL, V5, P719, DOI 10.1016/0952-7915(93)90127-E; RADZIOCH D, 1991, J LEUKOCYTE BIOL, V50, P263, DOI 10.1002/jlb.50.3.263; RAULET DH, 1989, ANNU REV IMMUNOL, V7, P175, DOI 10.1146/annurev.iy.07.040189.001135; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SILVA CL, 1993, IMMUNOLOGY, V78, P35; UYEMURA K, 1992, J EXP MED, V174, P683; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; YEUNG RA, 1989, CELL, V59, P5	23	35	36	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					241	244		10.1038/375241a0	http://dx.doi.org/10.1038/375241a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746326				2022-12-28	WOS:A1995QY88100065
J	OUSLANDER, JG; SCHAPIRA, M; SCHNELLE, JF; UMAN, G; FINGOLD, S; TUICO, E; NIGAM, JG				OUSLANDER, JG; SCHAPIRA, M; SCHNELLE, JF; UMAN, G; FINGOLD, S; TUICO, E; NIGAM, JG			DOES ERADICATING BACTERIURIA AFFECT THE SEVERITY OF CHRONIC URINARY-INCONTINENCE IN NURSING-HOME RESIDENTS	ANNALS OF INTERNAL MEDICINE			English	Article						NURSING HOMES; URINARY INCONTINENCE; BACTERIURIA; AGED	ASYMPTOMATIC BACTERIURIA; ANTIBIOTIC USE; ELDERLY WOMEN; EPIDEMIOLOGY; MEN	Objective: To determine the effects of eradicating otherwise asymptomatic bacteriuria on the severity of chronic urinary incontinence among nursing home residents. Design: Residents were categorized as nonbacteriuric or bacteriuric on the basis of urine cultures. Bacteriuric residents were then randomly assigned to immediate and delayed treatment groups. The delayed treatment group was included to control for spontaneous changes in the severity of incontinence. The immediate treatment group received antimicrobial therapy for 7 days; after outcome measures had been repeated, the delayed treatment group was treated. Setting: 6 community-based nursing homes. Patients: Nursing home residents with chronic urinary incontinence. Measurements: The frequency and volume of urinary incontinence were determined by physical checks for wetness by trained research aides hourly between 7 a.m. and 7 p.m. for 3 days in all patient groups (nonbacteriuric, bacteriuric with immediate treatment, and bacteriuric with delayed treatment) at baseline, after the immediate treatment group was treated, and again after the delayed treatment group was treated. Results: 191 residents were enrolled, and 176 completed the study. Bacteriuria was eradicated by antimicrobial therapy in 71 residents (40%), and 17 residents (10%) had bacteriuria before and after therapy. The percentage of hourly checks at which the residents were found wet and other measures of incontinence severity remained essentially the same after bacteriuria was eradicated. In the nonbacteriuric group, the percentage of checks that were wet increased from 29% (95% Cl, 26% to 32%) at baseline to 30% (Cl, 27% to 34%) on repeated measurement. In the bacteriuric groups, the percentage increased from 34% (Cl, 30% to 38%) before treatment to 35% (Cl, 31% to 39%) after bacteriuria was eradicated. The presence of pyuria did not affect the results. Conclusion: Eradicating bacteriuria has no short-term effects on the severity of chronic urinary incontinence among nursing home residents. Our data support the practice of not treating asymptomatic bacteriuria in this population and validate the recommendations in the Health Care Financing Administration's Resident Assessment Protocol for urinary incontinence.	BORUN CTR GERONTOL RES, LOS ANGELES, CA USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	OUSLANDER, JG (corresponding author), JEWISH HOME AGING, 18855 VICTORY BLVD, RESEDA, CA 91335 USA.				NIA NIH HHS [R37AGO8678] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG008678] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRUTYN E, 1991, J AM GERIATR SOC, V39, P388, DOI 10.1111/j.1532-5415.1991.tb02905.x; ABRUTYN E, 1994, ANN INTERN MED, V120, P827, DOI 10.7326/0003-4819-120-10-199405150-00003; AKHTAR A J, 1972, Age and Ageing, V1, P48, DOI 10.1093/ageing/1.1.48; BOSCIA JA, 1986, AM J MED, V81, P979, DOI 10.1016/0002-9343(86)90391-8; BOSCIA JA, 1989, ANN INTERN MED, V110, P404, DOI 10.7326/0003-4819-110-5-404; BROCKLEHURST JC, 1968, GERONTOL CLIN, V10, P242, DOI 10.1159/000245189; BURGIO L, 1988, GERONTOLOGIST, V28, pA200; EBERLE CM, 1993, J GERONTOL, V48, pM266, DOI 10.1093/geronj/48.6.M266; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; KATZ PR, 1990, ARCH INTERN MED, V150, P1465, DOI 10.1001/archinte.150.7.1465; KUNIN CM, 1992, CLIN INFECT DIS, V15, P1041, DOI 10.1093/clind/15.6.1041; NICOLLE LE, 1987, AM J MED, V83, P27, DOI 10.1016/0002-9343(87)90493-1; OUSLANDER J, 1995, IN PRESS J AM GERIAT; OUSLANDER JG, 1989, J AM GERIATR SOC, V37, P197, DOI 10.1111/j.1532-5415.1989.tb05893.x; OUSLANDER JG, 1987, ARCH INTERN MED, V147, P286, DOI 10.1001/archinte.147.2.286; OUSLANDER JG, 1987, J GERONTOL, V42, P631, DOI 10.1093/geronj/42.6.631; OUSLANDER JG, 1991, MED CARE NURSING HOM, P163; OUSLANDER JG, 1995, J AM GERIATR SOC, V43, P1; PICKERING TD, 1994, J AM GERIATR SOC, V42, P28, DOI 10.1111/j.1532-5415.1994.tb06069.x; RESNICK NM, 1985, NEW ENGL J MED, V313, P800, DOI 10.1056/NEJM198509263131307; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; SCHNELLE JF, 1990, J AM GERIATR SOC, V38, P356, DOI 10.1111/j.1532-5415.1990.tb03521.x; SENAY H, 1991, J UROLOGY, V145, P1201, DOI 10.1016/S0022-5347(17)38575-0; STARER P, 1985, J AM GERIATR SOC, V33, P842, DOI 10.1111/j.1532-5415.1985.tb05436.x; WARREN JW, 1991, J AM GERIATR SOC, V39, P963, DOI 10.1111/j.1532-5415.1991.tb04042.x; YOSHIKAWA TT, 1984, AGING CLIN PRACTICES; ZIMMER JG, 1986, J AM GERIATR SOC, V34, P703, DOI 10.1111/j.1532-5415.1986.tb04301.x; 1991, RESIDENT ASSESSMENT	28	128	130	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					749	754		10.7326/0003-4819-122-10-199505150-00003	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX147	7717597				2022-12-28	WOS:A1995QX14700003
J	MCFADDEN, ER; HEJAL, R				MCFADDEN, ER; HEJAL, R			ASTHMA	LANCET			English	Article							ACUTE BRONCHIAL-ASTHMA; EMERGENCY ROOM TREATMENT; NEBULIZED IPRATROPIUM BROMIDE; METERED-DOSE INHALER; ATROPINE SULFATE; METAPROTERENOL SULFATE; INTRAVENOUS MAGNESIUM; CONTROLLED TRIAL; HOLDING CHAMBER; SALBUTAMOL		CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University	MCFADDEN, ER (corresponding author), UNIV CLEVELAND HOSP,DIV PULM & CRIT CARE MED,11100 EUCLID AVE,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL037117] Funding Source: NIH RePORTER; NCRR NIH HHS [MO RR00080] Funding Source: Medline; NHLBI NIH HHS [HL-37117] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1993, THORAX, V48, pS1; APPEL D, 1989, J ALLERGY CLIN IMMUN, V84, P90, DOI 10.1016/0091-6749(89)90182-6; APPEL D, 1983, AM J MED, V75, P580, DOI 10.1016/0002-9343(83)90436-9; BECK R, 1985, J PEDIATR-US, V107, P605, DOI 10.1016/S0022-3476(85)80033-0; BECKER AB, 1983, J PEDIATR-US, V102, P465, DOI 10.1016/S0022-3476(83)80679-9; BRENNER BE, 1983, AM J MED, V74, P1005, DOI 10.1016/0002-9343(83)90802-1; BRYANT DH, 1985, CHEST, V88, P24, DOI 10.1378/chest.88.1.24; CENTOR RM, 1984, NEW ENGL J MED, V310, P577, DOI 10.1056/NEJM198403013100907; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; CHEONG B, 1988, BRIT MED J, V297, P448, DOI 10.1136/bmj.297.6646.448; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COLACONE A, 1993, CHEST, V104, P835, DOI 10.1378/chest.104.3.835; COLACONE A, 1990, CHEST, V97, P693, DOI 10.1378/chest.97.3.693; EMERMAN CL, 1991, ANN EMERG MED, V20, P1090, DOI 10.1016/S0196-0644(05)81381-2; FANTA CH, 1986, AM J MED, V80, P5, DOI 10.1016/0002-9343(86)90041-0; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FIEL SB, 1983, AM J MED, V75, P259, DOI 10.1016/0002-9343(83)91202-0; FISCHL MA, 1981, NEW ENGL J MED, V305, P783, DOI 10.1056/NEJM198110013051402; FITZGERALD JM, 1990, CAN MED ASSOC J, V142, P591; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; GRAHAM VAL, 1982, LANCET, V1, P418; GREEN SM, 1992, ANN EMERG MED, V21, P260, DOI 10.1016/S0196-0644(05)80885-6; GUILL MF, 1987, ANN ALLERGY, V59, P367; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HASKELL RJ, 1983, ARCH INTERN MED, V143, P1324, DOI 10.1001/archinte.143.7.1324; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; IDRIS AH, 1993, CHEST, V103, P665, DOI 10.1378/chest.103.3.665; INGRAM RH, 1970, AM REV RESPIR DIS, V101, P364; JANSON C, 1990, EUR RESPIR J, V3, P163; JENKINS CR, 1988, THORAX, V42, P378; KARPEL JP, 1986, AM REV RESPIR DIS, V133, P727; KONIG P, 1983, ARCH INTERN MED, V143, P1361, DOI 10.1001/archinte.143.7.1361; LEAHY BC, 1983, BRIT J DIS CHEST, V77, P159, DOI 10.1016/0007-0971(83)90022-0; LEW DB, 1990, ANN ALLERGY, V64, P195; LIN RY, 1993, ANN EMERG MED, V22, P71; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; MCFADDEN ER, 1993, AM REV RESPIR DIS, V147, P1306, DOI 10.1164/ajrccm/147.5.1306; MCFADDEN ER, 1995, UNPUB AM J MED; MCNAMARA RM, 1993, ANN EMERG MED, V22, P1829, DOI 10.1016/S0196-0644(05)80409-3; MIYAMOTO T, 1970, J ALLERGY, V45, P248, DOI 10.1016/0021-8707(70)90135-8; ODRISCOLL BR, 1989, LANCET, V1, P1418; OWENS MW, 1991, CHEST, V99, P1084, DOI 10.1378/chest.99.5.1084; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; ROSE CC, 1984, NEW ENGL J MED, V310, P573, DOI 10.1056/NEJM198403013100906; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SALMERON S, 1994, AM J RESP CRIT CARE, V149, P1466, DOI 10.1164/ajrccm.149.6.8004299; SCARFONE RJ, 1993, PEDIATRICS, V92, P513; SHIM C, 1978, LANCET, V1, P530; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; SKOBELOFF EM, 1989, JAMA-J AM MED ASSOC, V262, P1210; SPITERI MA, 1988, THORAX, V43, P19, DOI 10.1136/thx.43.1.19; STEIN LM, 1990, ANN INTERN MED, V112, P822, DOI 10.7326/0003-4819-112-11-822; SUMMERS QA, 1990, CHEST, V97, P430; TAI E, 1967, LANCET, V1, P644; WARD MJ, 1981, BRIT MED J, V282, P598, DOI 10.1136/bmj.282.6264.598; WARD MJ, 1985, BRIT J DIS CHEST, V79, P374, DOI 10.1016/0007-0971(85)90071-3; WEBB JR, 1986, BMJ-BRIT MED J, V292, P1045, DOI 10.1136/bmj.292.6527.1045; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WENG TR, 1969, AM REV RESPIR DIS, V101, P274; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WILLIAMS S, 1977, THORAX, V32, P555, DOI 10.1136/thx.32.5.555; WRENN K, 1991, ANN INTERN MED, V115, P241, DOI 10.7326/0003-4819-115-4-241; YOUNG GP, 1991, ANN EMERG MED, V20, P513, DOI 10.1016/S0196-0644(05)81605-1; 1992, NHLBI NIH923091 INT; 1991, NHLBI NAEP913042A NA	69	30	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1215	1220		10.1016/S0140-6736(95)91995-3	http://dx.doi.org/10.1016/S0140-6736(95)91995-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739310				2022-12-28	WOS:A1995QX86100013
J	BOGOD, D				BOGOD, D			ADVANCES IN EPIDURAL ANALGESIA FOR LABOR - PROGRESS VERSUS PRUDENCE	LANCET			English	Editorial Material											BOGOD, D (corresponding author), CITY HOSP,DEPT ANAESTHESIA,NOTTINGHAM NG5 1PB,ENGLAND.							CHAMBERLAIN G, 1993, PAIN ITS RELIEF CHIL, P50; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; GAMBLING DR, 1988, ANESTH ANALG, V33, P249; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1129	1130		10.1016/S0140-6736(95)90973-7	http://dx.doi.org/10.1016/S0140-6736(95)90973-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723541				2022-12-28	WOS:A1995QW62200005
J	THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ				THOMPSON, NP; MONTGOMERY, SM; POUNDER, RE; WAKEFIELD, AJ			IS MEASLES VACCINATION A RISK FACTOR FOR INFLAMMATORY BOWEL-DISEASE	LANCET			English	Article							CROHNS-DISEASE; ULCERATIVE-COLITIS; VIRUS-INFECTION; EPIDEMIOLOGY	Measles virus may persist in intestinal tissue, particularly that affected by Crohn's disease, and early exposure to measles may be a risk factor for the development of Crohn's disease. Crohn's disease and ulcerative colitis occur in the same families and may share a common aetiology. in view of the rising incidence of inflammatory bowel disease (Crohn's disease and ulcerative colitis), we examined the impact of measles vaccination upon these conditions. Prevalences of Crohn's disease, ulcerative colitis, coeliac disease, and peptic ulceration were determined in 3545 people who had received live measles Vaccine in 1964 as part of a measles vaccine trial. A longitudinal birth cohort of 11 407 subjects was one unvaccinated comparison cohort, and 2541 partners of those vaccinated was another. Compared with the birth cohort, the relative risk of developing Crohn's disease in the vaccinated group was 3.01 (95% CI 1.45-6.23) end of developing ulcerative colitis was 2.53 (1.15-5.58). There was no significant difference between these two groups in coeliac disease prevalence. Increased prevalence of inflammatory bowel disease, but not coeliac disease or peptic ulceration, was found in the vaccinated cohort compared with their partners. These findings suggest that measles virus may play a part in the development not only of Crohn's disease but also of ulcerative colitis.	CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON,ENGLAND	City University London	THOMPSON, NP (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT MED,INFLAMMATORY BOWEL DIS STUDY GRP,ROWLAND HILL ST,LONDON NW3 2PF,ENGLAND.							BARTON JR, 1989, GUT, V30, P618, DOI 10.1136/gut.30.5.618; Butler N.R., 1963, PERINATAL MORTALITY; EKBOM A, 1994, LANCET, V334, P508; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HALL AJ, 1993, BRIT MED J, V307, P1294, DOI 10.1136/bmj.307.6915.1294; LEWIN J, 1995, GUT, V36, P564, DOI 10.1136/gut.36.4.564; MILLER C, 1992, INT J EPIDEMIOL, V21, P998, DOI 10.1093/ije/21.5.998; RAMSAY MEB, 1994, EPIDEMIOL INFECT, V112, P409, DOI 10.1017/S0950268800057824; RIIS P, 1990, INFLAMMATORY BOWEL D; SANDLER RS, 1994, EPIDEMIOLOGY INFLAMM, P10; STEVENS CE, 1992, PEDIATRICS, V90, P170; THOMPSON NP, IN PRESS EUR J GASTR; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WHELAN G, 1990, MED CLIN N AM, V74, P1; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342; 1966, BRIT MED J, V1, P441; 1975, OPCS SERIES MB2, V2	18	162	164	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1071	1074		10.1016/S0140-6736(95)90816-1	http://dx.doi.org/10.1016/S0140-6736(95)90816-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715338				2022-12-28	WOS:A1995QV41100008
J	GALITSKI, T; ROTH, JR				GALITSKI, T; ROTH, JR			EVIDENCE THAT F-PLASMID TRANSFER REPLICATION UNDERLIES APPARENT ADAPTIVE MUTATION	SCIENCE			English	Article							DIRECTED MUTATION; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; MUTAGENESIS; SELECTION; HYPOTHESIS; REVERSION; UNICORNS	Escherichia coli K12 strain, FC40, has been used extensively in the analysis of adaptive mutability. This strain carries a revertible mutant lac allele on an F plasmid and accumulates Lac(+) (lactose utilizing) revertants, but not unselected mutants, when placed on selective medium. These adaptive mutations are a subset of spontaneous types and their formation depends on the RecABC functions. Data presented here suggest that this phenomenon depends on transfer functions of the F factor. Fertility inhibition eliminates RecA-dependent adaptive reversion. Thus, ''adaptive'' revertants may form during replication from the transfer origin, whereas loci in the nonreplicating chromosome show little mutation.			GALITSKI, T (corresponding author), UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027068] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07464-15, GM27068] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERKOWIT.D, 1968, J BACTERIOL, V96, P215, DOI 10.1128/JB.96.1.215-220.1968; BRIDGES BA, 1994, MUTAT RES, V307, P149, DOI 10.1016/0027-5107(94)90287-9; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CHEAH KC, 1986, J GEN MICROBIOL, V132, P3269; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DEMPSEY WB, 1993, BACTERIAL CONJUGATIO, P53; FISHER KW, 1957, J GEN MICROBIOL, V16, P136, DOI 10.1099/00221287-16-1-136; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, GENETICS, V138, P253; FOSTER PL, 1992, J BACTERIOL, V174, P1711, DOI 10.1128/jb.174.6.1711-1716.1992; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FOSTER PL, 1991, BOST STUD PHILOS SCI, V129, P213; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; GALITSKI T, UNPUB; GASSON MJ, 1975, J BACTERIOL, V122, P518, DOI 10.1128/JB.122.2.518-525.1975; Hall BG, 1992, CURR OPIN GENET DEV, V2, P943, DOI 10.1016/S0959-437X(05)80120-0; HALL BG, 1992, P NATL ACAD SCI USA, V89, P4300, DOI 10.1073/pnas.89.10.4300; HALL BG, 1993, J BACTERIOL, V175, P6411, DOI 10.1128/jb.175.20.6411-6414.1993; HALL BG, 1994, MOL BIOL EVOL, V11, P159; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; KOCH WH, 1992, J BACTERIOL, V174, P2809, DOI 10.1128/JB.174.9.2809-2815.1992; LEDERBERG J, 1952, J BACTERIOL, V63, P399, DOI 10.1128/JB.63.3.399-406.1952; LENSKI RE, 1993, SCIENCE, V259, P188, DOI 10.1126/science.7678468; LENSKI RE, 1989, P NATL ACAD SCI USA, V86, P2775, DOI 10.1073/pnas.86.8.2775; Luria SE, 1943, GENETICS, V28, P491; MACPHEE DG, 1993, MUTAT RES, V285, P109, DOI 10.1016/0027-5107(93)90058-N; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; MCINTIRE SA, 1987, NUCLEIC ACIDS RES, V15, P2029, DOI 10.1093/nar/15.5.2029; Miller J.H., 1972, EXPT MOL GENETICS; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; MITTLER JE, 1992, NATURE, V356, P446, DOI 10.1038/356446a0; OVERBYE KM, 1981, J BACTERIOL, V146, P170, DOI 10.1128/JB.146.1.170-178.1981; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; SANDERSON KE, 1983, CAN J MICROBIOL, V29, P1205, DOI 10.1139/m83-184; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; STAHL FW, 1992, GENETICS, V132, P865; STEELE DF, 1992, GENETICS, V132, P9; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; Wilkins B, 1993, BACTERIAL CONJUGATIO, P105; WILLETTS N, 1987, CELLULAR MOL BIOL, P1110; WING JP, 1968, J BACTERIOL, V95, P1828, DOI 10.1128/JB.95.5.1828-1834.1968	46	118	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					421	423		10.1126/science.7716546	http://dx.doi.org/10.1126/science.7716546			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716546	Green Submitted			2022-12-28	WOS:A1995QU57200041
J	WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B				WISNIEWSKI, T; LALOWSKI, M; GOLABEK, A; VOGEL, T; FRANGIONE, B			IS ALZHEIMERS-DISEASE AN APOLIPOPROTEIN-E AMYLOIDOSIS	LANCET			English	Note							BINDING; PEPTIDE; ALLELE	The presence of the apolipoprotein E4 allele has been identified as a major risk factor for late-onset Alzheimer's disease. Apolipoprotein E has also been found immunohistochemically in Alzheimer's disease lesions. We biochemically isolated amyloid beta from senile plaques and found that a carboxyl-terminal fragment (residues 216-299) of apolipoprotein E co-purified. In vitro this fragment from recombinant apolipoprotein E could form amyloid-like fibrils, which were Congo-red positive. Thus senile plaques may contain both amyloid beta and apolipoprotein E amyloid fibrils.	NYU,MED CTR,DEPT NEUROL,NEW YORK,NY 10016; BIOTECHNOL GEN LTD,REHOVOT,ISRAEL	New York University	WISNIEWSKI, T (corresponding author), NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016, USA.		Wisniewski, Thomas/Q-6525-2019; Lalowski, Maciej/AAB-4151-2019	Wisniewski, Thomas/0000-0002-3379-8966; Lalowski, Maciej/0000-0002-3683-4096	NATIONAL INSTITUTE ON AGING [R01AG008721, R01AG005891, R35AG010953, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG05891, AG08721, AG10953] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; PEPYS MB, 1995, IMMUNOLOGICAL DISEAS, P637; Prelli F., 1994, Society for Neuroscience Abstracts, V20, P1642; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	10	147	151	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					956	958		10.1016/S0140-6736(95)90701-7	http://dx.doi.org/10.1016/S0140-6736(95)90701-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715296	hybrid			2022-12-28	WOS:A1995QT91900011
J	YOUVAN, DC				YOUVAN, DC			GREEN FLUORESCENT PETS	SCIENCE			English	Editorial Material											YOUVAN, DC (corresponding author), PALO ALTO INST MOLEC MED,MT VIEW,CA 94043, USA.							CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305	2	4	4	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					264	264		10.1126/science.7716519	http://dx.doi.org/10.1126/science.7716519			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716519				2022-12-28	WOS:A1995QT18500028
J	LITTLE, P; KEEFE, M; WHITE, J				LITTLE, P; KEEFE, M; WHITE, J			SELF SCREENING FOR RISK OF MELANOMA - VALIDITY OF SELF MOLE COUNTING BY PATIENTS IN A SINGLE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DANISH CASE-CONTROL; MELANOCYTIC NEVI; SUNBURN; NAEVI; AUSTRALIA; EXPOSURE; WOMEN	Objective-To validate self screening by patients of high mole counts, assess the within family association of sun protection behaviour and mole counts, and estimate prevalence of risk factors for melanoma. Setting and subjects-Systematic sample of families from a single affluent general practice population in Wessex. Design-Subjects completed a questionnaire about risk factors for melanoma and counted their moles. Subsequently a mole count was done by a general practitioner trained at dermatology clinics. Main outcome measures-Validation of self counts by observer's count. Within family association of sun protection behaviour and mole counts; self reported risk factors. Results-199/237 subjects (84%) returned the questionnaire; 212/237 (89%) were examined, High counts by patients on the front of the trunk (>7 moles of greater than or equal to 2 mm) were reasonably sensitive (79%), predictive (75%), and specific (97%) of the observer's mole counts (kappa=0.74), unlike arm or total body counts. Sun protection behaviour correlated between individuals and other family members (Spearman's coefficient r=0.50, P<0.01), In the past three months 15/114 adults (13.2%, 95% confidence interval 7.0% to 19.1%) reported any change in a mole and 6/114 (5.3%, 2.0% to 11.1%) ''major'' changes; 6/109 adults (5.5%, 2.1% to 11.6%) had both high mole counts and freckling. Conclusions-Asking patients to count trunk moles could be a feasible way of identifying patients at high risk of melanoma. Concentrating on reported major changes in moles should avoid considerable workload in general practice. The generalisability of these findings and the adverse effects, net benefit in earlier diagnosis and prevention, and workload implications of such self screening need further research.	UNIV SOUTHAMPTON,DEPT DERMATOL,SOUTHAMPTON,HANTS,ENGLAND; HLTH CTR,THAME OX9 3JZ,OXON,ENGLAND	University of Southampton	LITTLE, P (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873				BAIN C, 1988, AM J EPIDEMIOL, V127, P703, DOI 10.1093/oxfordjournals.aje.a114851; BERAL V, 1983, BRIT J DERMATOL, V109, P165, DOI 10.1111/j.1365-2133.1983.tb07077.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BONETT A, 1986, MED J AUSTRALIA, V144, P680, DOI 10.5694/j.1326-5377.1986.tb113693.x; BYLES JE, 1944, BRIT J DERMATOL, V130, P51; CLARK WM, 1988, ARCH DERMATOL, V114, P732; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; COOKE KR, 1985, J EPIDEMIOL COMMUNIT, V39, P52; DARCY C, 1994, J NATL CANCER I, V72, P257; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, BRIT J CANCER, V51, P543, DOI 10.1038/bjc.1985.77; ELWOOD JM, 1994, INT J CANCER, V35, P427; ELWOOD JM, 1994, BRIT MED J, V288, P99; ENGLISH DR, 1988, BRIT MED J, V296, P1285, DOI 10.1136/bmj.296.6632.1285; ENGLISH JSC, 1988, BRIT J DERMATOL, V118, P641, DOI 10.1111/j.1365-2133.1988.tb02564.x; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MACHIE R, 1985, BRIT J DERMATOL, V113, P167; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; MARKS R, 1994, BRIT MED J, V308, P75, DOI 10.1136/bmj.308.6921.75; MARTEAU T, 1991, BRIT MED J, V301, P26; NEWTON JA, 1994, BRIT MED BULL, V50, P677, DOI 10.1093/oxfordjournals.bmb.a072916; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PACK GT, 1952, AMA ARCH SURG, V65, P862, DOI 10.1001/archsurg.1952.01260020856010; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P406, DOI 10.1111/j.1365-2230.1990.tb02132.x; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P	36	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					912	916		10.1136/bmj.310.6984.912	http://dx.doi.org/10.1136/bmj.310.6984.912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719184	Green Published			2022-12-28	WOS:A1995QR97200027
J	GILL, TM; FEINSTEIN, AR				GILL, TM; FEINSTEIN, AR			A CRITICAL-APPRAISAL OF THE QUALITY OF QUALITY-OF-LIFE MEASUREMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							STAGE RENAL-DISEASE; KARNOFSKY PERFORMANCE STATUS; RANDOMIZED CONTROLLED TRIAL; INFLAMMATORY BOWEL-DISEASE; SICKNESS IMPACT PROFILE; CANCER-PATIENTS; BREAST-CANCER; HEALTH-STATUS; ANTIHYPERTENSIVE THERAPY; TRANSPLANT RECIPIENTS	Objective.-To evaluate how well quality of life is being measured in the medical literature and to offer a new approach to the measurement. Data Sources.-Original English-language articles having the term ''quality of life'' in their titles were identified from a recent Quality-of-Life Bibliography and from two MEDLINE searches. Articles were eligible for review only a they described or used one or more ''quality-of-life'' instruments. Study Selection.-Twenty-five articles were randomly selected from each of the three data sources. Data Extraction.-Each article was reviewed for its compliance with two sets of criteria having several components, which are cited under ''Data Synthesis.'' Data Synthesis.-(1) Investigators conceptually defined quality of life in only tl (15%) Of the 75 articles; identified the targeted domains in only 35 (47%); gave reasons for selecting the chosen quality-of-life instruments in only 27 (36%); and aggregated their results into a composite quality-of-life score in only 27 (38%) of 71 eligible articles. (2) No article distinguished ''overall'' quality of life from health-related quality of life; patients were invited to give their own separate rating for quality of life in only 13 articles (17%); and among 71 eligible articles, patients were asked to supplement the stipulated items with personal responses in only nine (13%) and to rate the importance of individual items in only six (8.5%). Conclusions.-Because quality of life is a uniquely personal perception, denoting the way that individual patients feel about their health status and/or nonmedical aspects of their lives, most measurements of quality of life in the medical literature seem to aim at the wrong target. Quality of life can be suitably measured only by determining the opinions of patients and by supplementing (or replacing) the instruments developed by ''experts.''	YALE UNIV, SCH MED, DEPT EPIDEMIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, PROGRAM GERIATR, NEW HAVEN, CT USA; VET ADM MED CTR, CTR COORDINATING, COOPERAT STUDIES PROGRAM, W HAVEN, CT USA	Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	GILL, TM (corresponding author), YALE UNIV, SCH MED,DEPT MED,333 CEDAR ST,17 TMP, POB 208025, NEW HAVEN, CT 06520 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368				AHLMEN J, 1990, SCAND J UROL NEPHROL, P43; ANDRYKOWSKI MA, 1990, TRANSPLANTATION, V50, P399, DOI 10.1097/00007890-199009000-00009; [Anonymous], 1991, LANCET, V338, P350; APPLEGATE WB, 1991, ARCH INTERN MED, V151, P1817, DOI 10.1001/archinte.151.9.1817; AULIKKI N, 1991, J CLIN EPIDEMIOL, V44, P989; BAIRD AD, 1985, REHABIL PSYCHOL, V30, P145, DOI 10.1037//0090-5550.30.3.145; BAKER F, 1991, SOC SCI MED, V32, P697, DOI 10.1016/0277-9536(91)90149-7; BARR H, 1991, CANCER, V68, P1660, DOI 10.1002/1097-0142(19911001)68:7<1660::AID-CNCR2820680733>3.0.CO;2-L; BERGNER M, 1989, MED CARE, V27, pS148, DOI 10.1097/00005650-198903001-00012; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERNHEIM JL, 1983, J PSYCHOSOC ONCOL, V15, P25; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BONNEY S, 1978, ARCH INTERN MED, V138, P1510, DOI 10.1001/archinte.138.10.1510; Bowling A., 1991, MEASURING HLTH REV Q; BREMER BA, 1986, HEALTH PSYCHOL, V5, P171, DOI 10.1037/0278-6133.5.2.171; CAINE N, 1991, BMJ-BRIT MED J, V302, P511, DOI 10.1136/bmj.302.6775.511; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; COX DR, 1992, J ROY STAT SOC A STA, V155, P353, DOI 10.2307/2982889; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; CUNNINGHAM AJ, 1991, PATIENT EDUC COUNS, V17, P71, DOI 10.1016/0738-3991(91)90052-7; DAUGHTON D, 1983, PERCEPT MOTOR SKILL, V57, P359, DOI 10.2466/pms.1983.57.2.359; DEHAES JCJ, 1987, QUALITY LIFE CANCER, P215; DENISTON OL, 1989, HEALTH SERV RES, V24, P555; DEWEERDT I, 1991, DIABETIC MED, V8, P338; DEYO RA, 1991, ANN INTERN MED, V114, P695, DOI 10.7326/0003-4819-114-8-695; EPSTEIN AM, 1989, MED CARE, V27, pS91, DOI 10.1097/00005650-198903001-00008; EVANS DR, 1985, AM J COMMUN PSYCHOL, V13, P305, DOI 10.1007/BF00914935; EVANS RW, 1990, JAMA-J AM MED ASSOC, V263, P825; EVANS RW, 1985, TRANSPLANT P, V17, P1579; FALLOWFIELD L, 1990, QUALITY LIFE; FARMER RG, 1992, CLEV CLIN J MED, V59, P35, DOI 10.3949/ccjm.59.1.35; FEINSTEIN AR, 1987, J CHRON DIS, V40, P635, DOI 10.1016/0021-9681(87)90027-0; Feinstein AR, 1987, CLINIMETRICS; FERRELL BR, 1989, CANCER, V63, P2321, DOI 10.1002/1097-0142(19890601)63:11<2321::AID-CNCR2820631142>3.0.CO;2-T; FLETCHER A, 1988, LANCET, V2, P4; FOLKS DG, 1986, SOUTHERN MED J, V79, P397, DOI 10.1097/00007611-198604000-00002; FOSSA SD, 1990, PROG CLIN BIOL RES, V357, P199; FOWLER FJ, 1988, JAMA-J AM MED ASSOC, V259, P3018, DOI 10.1001/jama.259.20.3018; GANZ PA, 1991, CANCER, V67, P3131, DOI 10.1002/1097-0142(19910615)67:12<3131::AID-CNCR2820671232>3.0.CO;2-4; GANZ PA, 1990, J CLIN EPIDEMIOL, V43, P75, DOI 10.1016/0895-4356(90)90059-X; GANZ PA, 1988, CANCER, V61, P849, DOI 10.1002/1097-0142(19880215)61:4<849::AID-CNCR2820610435>3.0.CO;2-B; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; George L., 1980, QUALITY LIFE OLDER P; GERBER A, 1984, J CLIN GASTROENTEROL, V6, P513, DOI 10.1097/00004836-198412000-00005; GLIMELIUS B, 1989, EUR J CANCER CLIN ON, V25, P829, DOI 10.1016/0277-5379(89)90128-4; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; GRIECO A, 1984, HEALTH PSYCHOL, V3, P129, DOI 10.1037/0278-6133.3.2.129; Guez D, 1988, Am J Med, V84, P53; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; HADORN DC, 1991, MED CARE, V29, P829, DOI 10.1097/00005650-199109000-00004; HARRIS DCH, 1991, AUST NZ J MED, V21, P693, DOI 10.1111/j.1445-5994.1991.tb01372.x; HUNSKAAR S, 1991, J AM GERIATR SOC, V39, P378, DOI 10.1111/j.1532-5415.1991.tb02903.x; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; JANES G, 1990, PROF NURSE, V10, P26; JAYAWARDHANA BNM, 1989, BRIT MED J, V299, P1503, DOI 10.1136/bmj.299.6714.1503; KAPLAN RM, 1987, J GEN INTERN MED, V2, P220, DOI 10.1007/BF02596443; Ketiku K K, 1990, Clin Oncol (R Coll Radiol), V2, P153, DOI 10.1016/S0936-6555(05)80149-9; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LADEFOGED K, 1981, JPEN-PARENTER ENTER, V5, P132, DOI 10.1177/0148607181005002132; LANCASTER TR, 1991, ARCH INTERN MED, V151, P1944, DOI 10.1001/archinte.151.10.1944; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LOMAS J, 1987, MED CARE, V25, P764, DOI 10.1097/00005650-198708000-00009; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MALM U, 1981, SCHIZOPHRENIA BULL, V7, P477, DOI 10.1093/schbul/7.3.477; MAYOU R, 1990, J PSYCHOSOM RES, V34, P1, DOI 10.1016/0022-3999(90)90002-L; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; MELTZER HY, 1990, HOSP COMMUNITY PSYCH, V41, P892; MITCHELL A, 1988, J CLIN GASTROENTEROL, V10, P306, DOI 10.1097/00004836-198806000-00014; Monahan M L, 1988, Oncol Nurs Forum, V15, P795; MOODY L, 1990, J BEHAV MED, V13, P297, DOI 10.1007/BF00846836; MOR V, 1987, J CHRON DIS, V40, P535, DOI 10.1016/0021-9681(87)90011-7; MORRIS JN, 1987, J CHRON DIS, V40, P545, DOI 10.1016/0021-9681(87)90012-9; MORTON RP, 1984, CLIN OTOLARYNGOL, V9, P181, DOI 10.1111/j.1365-2273.1984.tb01493.x; MULROW CD, 1990, ANN INTERN MED, V113, P188, DOI 10.7326/0003-4819-113-3-188; NORTH CA, 1990, CANCER, V66, P6, DOI 10.1002/1097-0142(19900701)66:1<6::AID-CNCR2820660103>3.0.CO;2-F; OBRIEN BJ, 1988, J EPIDEMIOL COMMUN H, V42, P232, DOI 10.1136/jech.42.3.232; OBRIEN BJ, 1987, J CHRON DIS, V40, pS137, DOI 10.1016/S0021-9681(87)80043-7; OLDENBURG B, 1988, J CLIN EPIDEMIOL, V41, P555, DOI 10.1016/0895-4356(88)90059-5; OLESKE DM, 1990, CANCER NURS, V13, P158, DOI 10.1097/00002820-199006000-00005; OSBAND ME, 1990, LANCET, V335, P994, DOI 10.1016/0140-6736(90)91064-H; PADILLA GV, 1983, RES NURS HEALTH, V6, P117, DOI 10.1002/nur.4770060305; Patrick D. L., 1993, HLTH STATUS HLTH POL; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Schag C A, 1990, Oncology (Williston Park), V4, P135; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SIEGRIST J, 1987, J CHRON DIS, V40, P571, DOI 10.1016/0021-9681(87)90016-6; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; Spilker B, 1990, Med Care, V28, pDS1; Spilker B., 1990, QUALITY LIFE ASSESSM; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STRANG P, 1990, ANTICANCER RES, V10, P109; SUNDAR S, 1991, ACTA CARDIOL, V46, P227; SUTHERLAND HJ, 1990, J CLIN EPIDEMIOL, V43, P661, DOI 10.1016/0895-4356(90)90036-O; TESTA MA, 1991, AM J HYPERTENS, V4, P363, DOI 10.1093/ajh/4.4.363; TUGWELL P, 1990, ARCH INTERN MED, V150, P59, DOI 10.1001/archinte.150.1.59; VANKNIPPENBERG FCE, 1988, J CLIN EPIDEMIOL, V41, P1043, DOI 10.1016/0895-4356(88)90073-X; WIKLUND I, 1991, CLIN CARDIOL, V14, P204, DOI 10.1002/clc.4960140306; WIKLUND I, 1987, SCAND J PSYCHOL, V28, P220, DOI 10.1111/j.1467-9450.1987.tb00758.x; WILKIN D, 1992, MEASURES NEED OUTCOM; Zubrod C.G., 1960, J CHRON DIS, V11, P7	102	1483	1527	2	101	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					619	626		10.1001/jama.272.8.619	http://dx.doi.org/10.1001/jama.272.8.619			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	7726894				2022-12-28	WOS:A1994PC39800033
J	GOSTIN, LO				GOSTIN, LO			LAW AND MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD	Johns Hopkins University	GOSTIN, LO (corresponding author), GEORGETOWN UNIV,CTR LAW,WASHINGTON,DC 20057, USA.							Cranford Ronald, 1992, Law Med Health Care, V20, P307; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1688	1689						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752418				2022-12-28	WOS:A1995RB09700026
J	WILSON, MD; JOFFE, A				WILSON, MD; JOFFE, A			ADOLESCENT MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUAL RISK-TAKING				WILSON, MD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.							COHEN DA, 1994, PEDIATRICS, V94, P368; CROMER BA, 1994, PEDIATRICS, V94, P5687; ELSTER AB, 1993, AMA GUIDELINES ADOLE; EMANS SJ, 1987, JAMA-J AM MED ASSOC, V257, P3377, DOI 10.1001/jama.257.24.3377; FINKELHOR D, 1994, PEDIATRICS, V94, P413; HATCHER RA, 1994, CONTRACEPTIVE TECHNO, P571; JOHNSTON LD, 1994, 943809 NAT I DRUG AB; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P253, DOI 10.2307/2135776; KIRBY D, 1992, J SCHOOL HEALTH, V62, P280, DOI 10.1111/j.1746-1561.1992.tb01244.x; KOO HP, 1994, FAM PLANN PERSPECT, V26, P206, DOI 10.2307/2135940; KOO HP, 1994, FAMILY PLANNING PERS, V26, P217; NAGY S, 1994, PEDIATRICS, V93, P570; POLANECZKY M, 1994, NEW ENGL J MED, V331, P1201, DOI 10.1056/NEJM199411033311806; SINGER MI, 1995, JAMA-J AM MED ASSOC, V273, P477, DOI 10.1001/jama.273.6.477; STEINBERG L, 1994, PEDIATRICS, V93, P1060; WOODS ER, 1992, AM J OBSTET GYNECOL, V166, P901, DOI 10.1016/0002-9378(92)91359-I; 1992, NATIONAL CRIME SURVE	17	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1657	1659		10.1001/jama.273.21.1657	http://dx.doi.org/10.1001/jama.273.21.1657			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752402				2022-12-28	WOS:A1995RB09700010
J	BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ				BROTCHIE, PR; ANDERSEN, RA; SNYDER, LH; GOODMAN, SJ			HEAD POSITION SIGNALS USED BY PARIETAL NEURONS TO ENCODE LOCATIONS OF VISUAL-STIMULI	NATURE			English	Article							SACCADE-RELATED ACTIVITY; LATERAL INTRAPARIETAL AREA; ASSOCIATION CORTEX; EYE-MOVEMENTS; SPACE; GAZE; MACAQUE; MEMORY; 7A	THE mechanism for object location in the environment, and the perception of the external world as stable when eyes, head and body are moved, have long been thought to be centred on the posterior parietal cortex(1-8). However, head position signals, and their integration with visual and eye position signals to form a representation of space referenced to the body, have never been examined in any area of the cortex. Here we show that the visual and saccadic activities of parietal neurons are strongly affected by head position. The eye and head position effects are equivalent for individual neurons, indicating that the modulation is a function of gaze direction, regardless of whether the eyes or head are used to direct gaze. These data are consistent with the idea that the posterior parietal cortex contains a distributed representation of space in body-centred coordinates.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Snyder, Lawrence H/A-4593-2017					ANDERSEN RA, 1987, EXP BRAIN RES, V67, P316; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1990, J NEUROSCI, V10, P1176; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; Andersen RA, 1987, HDB PHYSL 1, VV, P483; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BIGUER B, 1988, BRAIN, V11, P1405; Critchley M., 1953, PARIETAL LOBES; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; FOGASSI L, 1992, EXP BRAIN RES, V89, P686, DOI 10.1007/BF00229894; FULLER JH, 1983, BRAIN RES, V271, P241, DOI 10.1016/0006-8993(83)90286-X; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOODMAN SJ, 1990, P INT JOINT C NEUR N, P381; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; HYVARINEN J, 1982, PARIETAL CORTEX MONK; LACKNER JR, 1984, EXP NEUROL, V47, P177; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; LYNCH JC, 1980, BEHAV BRAIN SCI, V3, P485, DOI 10.1017/S0140525X00006324; MOUNTCASTLE V B, 1976, Neurosciences Research Program Bulletin, V14, P1; ROLL R, 1991, EXP BRAIN RES, V85, P423; SAKATA H, 1985, VISION RES, V25, P453, DOI 10.1016/0042-6989(85)90070-7; Snyder L. H., 1993, Society for Neuroscience Abstracts, V19, P770; TAYLOR JL, 1991, BRAIN, V114, P755, DOI 10.1093/brain/114.2.755; TOMLINSON RD, 1990, J NEUROPHYSIOL, V64, P1873, DOI 10.1152/jn.1990.64.6.1873; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	28	260	263	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					232	235		10.1038/375232a0	http://dx.doi.org/10.1038/375232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746323				2022-12-28	WOS:A1995QY88100062
J	CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD				CONOVER, JC; ERICKSON, JT; KATZ, DM; BIANCHI, LM; POUEYMIROU, WT; MCCLAIN, J; PAN, L; HELGREN, M; IP, NY; BOLAND, P; FRIEDMAN, B; WIEGAND, S; VEJSADA, R; KATO, AC; DECHIARA, TM; YANCOPOULOS, GD			NEURONAL DEFICITS, NOT INVOLVING MOTOR-NEURONS, IN MICE LACKING BDNF AND/OR NT4	NATURE			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; CELL-DEATH; BRAIN; MOTONEURONS; RECEPTORS	NERVE growth factor and other neurotrophins signal to neurons through the Trk family of receptor tyrosine kinases(1-6). TrkB is relatively promiscuous in vitro, acting as a receptor for brain-derived neurotrophic factor (BDNF), neurotrophin-4 (NT4) and, to a lesser extent, NT3 (refs 3-5). Mice lacking TrkB(7) show a more severe phenotype than mice lacking BDNF8,9, suggesting that TrkB may act as a receptor for additional ligands in vivo. To explore this possibility, we generated mice lacking NT4 or BDNF as well as mice lacking both neurotrophins. Unlike mice lacking other Trks(7,10,11) or neurotrophins(8,9,12-14), NT4-deficient mice are long-lived and show no obvious neurological defects. Analysis of mutant phenotypes revealed distinct neuronal populations with different neurotrophin requirements. Thus vestibular and trigeminal sensory neurons require BDNF but not NT4, whereas nodose-petrosal sensory neurons require both BDNF and NT4. Motor neurons, whose numbers are drastically reduced in mice lacking TrkB, are not affected even in mice lacking both BDNF and NT4. These results suggest that another ligand, perhaps NT3, does indeed act on TrkB in vivo.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; UNIV GENEVA,MED CTR,DEPT PHARMACOL,CH-1211 GENEVA,SWITZERLAND; UNIV GENEVA,MED CTR,DIV CLIN NEUROMUSCULAR RES,CH-1211 GENEVA,SWITZERLAND	Case Western Reserve University; Regeneron; University of Geneva; University of Geneva				Ip, Nancy Yuk-Yu/0000-0002-2763-8907; Bianchi, Lynne/0000-0002-5064-6972				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; BARBACID MJ, 1994, NEUROBIOLOGY, V25, P1386; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; EIDE FF, 1993, EXP NEUROL, V121, P200, DOI 10.1006/exnr.1993.1087; EMFORS P, 1994, NATURE, V368, P147; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HERTZBERG T, 1994, DEV BIOL, V166, P801, DOI 10.1006/dbio.1994.1358; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1994, NATURE, V368, P249, DOI 10.1038/368249a0; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI L, 1994, J NEUROBIOL, V15, P759; MALSONPIERRE PC, 1990, NEURON, V5, P501; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THALER CD, 1994, DEV BIOL, V161, P338, DOI 10.1006/dbio.1994.1035; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VEJSADA R, 1995, EUR J NEUROSCI, V7, P108, DOI 10.1111/j.1460-9568.1995.tb01025.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	355	361	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					235	238		10.1038/375235a0	http://dx.doi.org/10.1038/375235a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746324				2022-12-28	WOS:A1995QY88100063
J	WATTS, RA; SCOTT, DGI				WATTS, RA; SCOTT, DGI			RASHES AND VASCULITIS	BRITISH MEDICAL JOURNAL			English	Article									NORFOLK & NORWICH HOSP,DEPT RHEUMATOL,NORWICH,NORFOLK,ENGLAND	Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	WATTS, RA (corresponding author), IPSWICH HOSP,DEPT RHEUMATOL,IPSWICH,SUFFOLK,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1128	1132		10.1136/bmj.310.6987.1128	http://dx.doi.org/10.1136/bmj.310.6987.1128			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742684	Green Published			2022-12-28	WOS:A1995QW61800025
J	MCBEATH, MK; SHAFFER, DM; KAISER, MK				MCBEATH, MK; SHAFFER, DM; KAISER, MK			HOW BASEBALL OUTFIELDERS DETERMINE WHERE TO RUN TO CATCH FLY BALLS	SCIENCE			English	Article							FREE-FALL TRAJECTORIES; ACCELERATION; INFORMATION; PERCEPTION; CURVATURE; MOTION	Current theory proposes that baseball outfielders catch fly balls by selecting a running path to achieve optical acceleration cancellation of the ball. Yet people appear to lack the ability to discriminate accelerations accurately. This study supports the idea that outfielders convert the temporal problem to a spatial one by selecting a running path that maintains a linear optical trajectory (LOT) for the ball. The LOT model is a strategy of maintaining ''control'' over the relative direction of optical ball movement in a manner that is similar to simple predator tracking behavior.	NASA, AMES RES CTR, HUMAN & SYST TECHNOL BRANCH, MOFFETT FIELD, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	MCBEATH, MK (corresponding author), KENT STATE UNIV, DEPT PSYCHOL, KENT, OH 44242 USA.							ADAIR R, 1990, PHYSICS BASEBALL; ADAMS JA, 1961, PSYCHOL BULL, V58, P55, DOI 10.1037/h0041559; BABLER TG, 1993, J EXP PSYCHOL HUMAN, V19, P15, DOI 10.1037/0096-1523.19.1.15; BRANCAZIO PJ, 1985, AM J PHYS, V53, P849, DOI 10.1119/1.14350; CALDERONE JB, 1989, PERCEPT PSYCHOPHYS, V45, P391, DOI 10.3758/BF03210711; CHAPMAN S, 1968, AM J PHYS, V36, P868, DOI 10.1119/1.1974297; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; CUTTING JE, IN PRESS PSYCHOL REV; de Mestre N, 1990, MATH PROJECTILES SPO; DIENES Z, 1993, PERCEPTION, V22, P1427, DOI 10.1068/p221427; GOTTSDANKER R, 1961, BRIT J PSYCHOL, V52, P31, DOI 10.1111/j.2044-8295.1961.tb00765.x; HOPKINS JR, 1976, CHILD DEV, V47, P1166, DOI 10.1111/j.1467-8624.1976.tb02300.x; KAISER MK, 1993, J EXP PSYCHOL HUMAN, V19, P1028, DOI 10.1037/0096-1523.19.5.1028; LANCHESTER BS, 1975, J EXP BIOL, V63, P627; LEE DN, 1983, Q J EXP PSYCHOL-A, V35, P333, DOI 10.1080/14640748308402138; MCBEATH MK, 1990, PERCEPTION, V19, P545, DOI 10.1068/p190545; MCLEOD P, 1993, NATURE, V362, P23, DOI 10.1038/362023a0; MCLEOD P, IN PRESS J EXP PSYCH; Michaels Claire F., 1992, Ecological Psychology, V4, P199, DOI 10.1207/s15326969eco0404_1; REGAN D, 1979, SCI AM, V241, P136, DOI 10.1038/scientificamerican0779-136; REGAN DM, 1986, HDB PRECEPTION HUMAN, V1; RIGGS LA, 1973, SCIENCE, V181, P1070, DOI 10.1126/science.181.4104.1070; ROSCOE SN, 1968, HUM FACTORS, V10, P321, DOI 10.1177/001872086801000402; ROSENBAUM DA, 1975, J EXP PSYCHOL HUMAN, V1, P395, DOI 10.1037/0096-1523.1.4.395; RUNESON S, 1974, PSYCHOL RES-PSYCH FO, V37, P3, DOI 10.1007/BF00309076; SAVELSBERGH GJP, 1988, ERGONOMICS, V31, P1655, DOI 10.1080/00140138808966815; SAXBERG BVH, 1987, BIOL CYBERN, V56, P159, DOI 10.1007/BF00317991; SAXBERG BVH, 1987, BIOL CYBERN, V56, P177, DOI 10.1007/BF00317992; SCHMERLER J, 1976, PERCEPTION, V5, P167, DOI 10.1068/p050167; TOATES FM, 1975, CONTROL THEORY BIOL, P151; TODD JT, 1981, J EXP PSYCHOL HUMAN, V7, P795, DOI 10.1037/0096-1523.7.4.795; TRESILIAN JR, 1990, PERCEPTION, V19, P223, DOI 10.1068/p190223; WATT RJ, 1982, VISION RES, V22, P449, DOI 10.1016/0042-6989(82)90193-6; Watts R., 1990, KEEP YOUR EYE BALL; WICKENS CD, 1992, ENG PSYCHOL HUMAN PE, P466	35	263	264	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					569	573		10.1126/science.7725104	http://dx.doi.org/10.1126/science.7725104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QV407	7725104				2022-12-28	WOS:A1995QV40700038
J	MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N				MOUGNEAU, E; ALTARE, F; WAKIL, AE; ZHENG, SC; COPPOLA, T; WANG, ZE; WALDMANN, R; LOCKSLEY, RM; GLAICHENHAUS, N			EXPRESSION CLONING OF A PROTECTIVE LEISHMANIA ANTIGEN	SCIENCE			English	Article							MAJOR SURFACE-ANTIGEN; T-CELL LINES; CUTANEOUS LEISHMANIASIS; MURINE LEISHMANIASIS; INTERFERON-GAMMA; MICE; MACROPHAGES; INFECTION; PROMASTIGOTES; RECEPTORS	Parasite-specific CD4(+) T cells have been shown to transfer protection against Leishmania major in susceptible BALB/c mice. An epitope-tagged expression library was used to identify the antigen recognized by a protective CD4(+) T cell clone, The expression library allowed recombinant proteins made in bacteria to be captured by macrophages for presentation to T cells restricted to major histocompatibility complex class II. A conserved 36-kilodalton member of the tryptophan-aspartic acid repeat family of proteins was identified that was expressed in both stages of the parasite life Cycle. A 24-kilodalton portion of this antigen protected susceptible mice when administered as a vaccine with interleukin-12 before infection.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; CNRS, UPR 411, INST PHARMACOL MOLEC & CELLULAIRE, F-06560 VALBONNE, FRANCE; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Centre National de la Recherche Scientifique (CNRS); University of California System; University of California San Francisco			Coppola, Thierry/I-5036-2016; Waldmann, Rainer/Q-2108-2016; altare, frederic/K-8664-2015	Coppola, Thierry/0000-0003-1018-722X; Waldmann, Rainer/0000-0002-4599-2926; altare, frederic/0000-0002-5077-4616	NIAID NIH HHS [AI26918] Funding Source: Medline; NIDDK NIH HHS [T32 DK07007] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; BRAKE DA, 1988, J IMMUNOL, V140, P1989; BRAKE DA, 1986, J IMMUNOL, V137, P345; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; COLOMERGOULD V, 1985, J EXP MED, V162, P902, DOI 10.1084/jem.162.3.902; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; JONES TC, 1987, J INFECT DIS, V156, P73, DOI 10.1093/infdis/156.1.73; LANG T, 1994, J CELL SCI, V107, P2137; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MORRIS L, 1992, J IMMUNOL, V149, P2715; MOUGNEAU E, UNPUB; MULLER I, 1989, IMMUNOL REV, V112, P95, DOI 10.1111/j.1600-065X.1989.tb00554.x; MULLER I, 1988, IMMUNOL LETT, V19, P251, DOI 10.1016/0165-2478(88)90151-4; MULLER I, 1989, EUR J IMMUNOL, V19, P865, DOI 10.1002/eji.1830190513; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NICKELL SP, 1987, J IMMUNOL, V138, P914; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; SCOTT P, 1990, J IMMUNOL, V144, P1075; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SCOTT P, 1989, IMMUNOL REV, V112, P161, DOI 10.1111/j.1600-065X.1989.tb00557.x; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; WANG Z, UNPUB; WANG ZE, 1994, P NATL ACAD SCI USA, V91, P12932, DOI 10.1073/pnas.91.26.12932; WANG ZE, 1993, J IMMUNOL, V151, P2077; WANG ZE, 1994, J EXP MED, V179, P1367, DOI 10.1084/jem.179.4.1367; WHITE J, 1989, J IMMUNOL, V143, P1822	36	320	345	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					563	566		10.1126/science.7725103	http://dx.doi.org/10.1126/science.7725103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725103				2022-12-28	WOS:A1995QV40700036
J	MURRAY, A				MURRAY, A			CYCLIN UBIQUITINATION - THE DESTRUCTIVE END OF MITOSIS	CELL			English	Review							MATURATION-PROMOTING FACTOR; CLAM EMBRYO; DEGRADATION; TRANSITION; ANAPHASE; COMPLEX				MURRAY, A (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,BOX 0444,SAN FRANCISCO,CA 94143, USA.							AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JABBEN M, 1989, J BIOL CHEM, V264, P4998; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x	26	258	267	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					149	152		10.1016/0092-8674(95)90322-4	http://dx.doi.org/10.1016/0092-8674(95)90322-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736567	Bronze			2022-12-28	WOS:A1995QV41000001
J	LIPSKY, JJ				LIPSKY, JJ			THE GLIMMER OF HIV PROTEINASE-INHIBITORS	LANCET			English	Editorial Material									MAYO CLIN & MAYO FDN,DEPT PHARMACOL,CLIN PHARMACOL UNIT,ROCHESTER,MN	Mayo Clinic	LIPSKY, JJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT MED,CLIN PHARMACOL UNIT,ROCHESTER,MN 55905, USA.							HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; MORROW CD, 1994, AM J PHYSIOL, V266, pC1135, DOI 10.1152/ajpcell.1994.266.5.C1135; PAGANO PJ, 1995, J INFECT DIS, V171, P61, DOI 10.1093/infdis/171.1.61; PARASCANDOLA J, 1981, J HIST MED ALL SCI, V36, P19; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; 1993, JAMA-J AM MED ASSOC, V270, P694	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					936	937		10.1016/S0140-6736(95)90693-2	http://dx.doi.org/10.1016/S0140-6736(95)90693-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715288				2022-12-28	WOS:A1995QT91900003
J	PEEL, N; EASTELL, R				PEEL, N; EASTELL, R			OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article											PEEL, N (corresponding author), UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,S YORKSHIRE,ENGLAND.							CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605	2	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					989	992		10.1136/bmj.310.6985.989	http://dx.doi.org/10.1136/bmj.310.6985.989			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728039	Green Published			2022-12-28	WOS:A1995QT90400027
J	ARTAVANISTSAKONAS, S; MATSUNO, K; FORTINI, ME				ARTAVANISTSAKONAS, S; MATSUNO, K; FORTINI, ME			NOTCH SIGNALING	SCIENCE			English	Review							EPIDERMAL GROWTH-FACTOR; DROSOPHILA NEUROGENIC GENE; NEURONAL PRECURSOR CELLS; LOOP-HELIX PROTEINS; C-ELEGANS EMBRYOS; OF-SPLIT COMPLEX; EGF-LIKE REPEATS; CAENORHABDITIS-ELEGANS; TRANSMEMBRANE PROTEIN; CELLULAR INTERACTIONS	The Notch/Lin-12/Glp-1 receptor family mediates the specification of numerous cell fates during development in Drosophila and Caenorhabditis elegans. Studies on the expression, mutant phenotypes, and developmental consequences of unregulated receptor activation have implicated these proteins in a general mechanism of local cell signaling, which includes interactions between equivalent cells and between different cell types. Genetic approaches in flies and worms have identified putative components of the signaling cascade, including a conserved family of extracellular ligands and two cellular factors that may associate with the Notch Intracellular domain. One factor, the Drosophila Suppressor of Hairless protein, is a DNA-binding protein, which suggests that Notch signaling may involve relatively direct signal transmission from the cell surface to the nucleus. Several vertebrate Notch receptors have also been discovered recently and play important roles in normal development and tumorigenesis.	YALE UNIV,BOYER CTR MOLEC MED,DEPT CELL BIOL,NEW HAVEN,CT 06536	Yale University	ARTAVANISTSAKONAS, S (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.		Honjo, Tasuku/N-4470-2016		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026084, R01NS026084] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26084] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad I., UNPUB; AKAM M, 1987, DEVELOPMENT, V101, P1; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARTAVANISTSAKON.S, 1991, TRENDS GENET, V7, P403; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BAKER NE, 1995, MECH DEVELOP, V49, P173, DOI 10.1016/0925-4773(94)00314-D; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BATE M, 1993, DEVELOPMENT, P149; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENDER LB, 1993, GENETICS, V133, P967; BIERKAMP C, 1993, MECH DEVELOP, V43, P87, DOI 10.1016/0925-4773(93)90027-U; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; BROU C, 1994, GENE DEV, V8, P2491, DOI 10.1101/gad.8.20.2491; BUSSEAU I, 1994, GENETICS, V136, P585; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; COUSO JP, 1994, CELL, V79, P259, DOI 10.1016/0092-8674(94)90195-3; COYLETHOMPSON CA, 1993, DEVELOPMENT, V119, P377; CRITTENDEN SL, 1994, DEVELOPMENT, V120, P2901; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1993, P NATL ACAD SCI USA, V90, P4037, DOI 10.1073/pnas.90.9.4037; DELACONCHA A, 1988, GENETICS, V118, P499; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DELIDAKIS C, 1991, GENETICS, V129, P803; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FITZGERALD K, 1993, DEVELOPMENT, V119, P1019; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FORTINI ME, UNPUB; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GORMAN MJ, 1992, GENETICS, V131, P99; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; GU Y, 1995, DEVELOPMENT, V121, P855; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEBERLEIN U, 1993, DEV BIOL, V160, P51, DOI 10.1006/dbio.1993.1285; HEITZLER P, 1993, DEVELOPMENT, V117, P1113; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HENDERSON ST, 1994, DEVELOPMENT, V120, P2913; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HING H, UNPUB; HING HK, 1994, MECH DEVELOP, V47, P261, DOI 10.1016/0925-4773(94)90044-2; HOCH M, 1994, DEVELOPMENT, V120, P3439; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUTTER H, 1994, DEVELOPMENT, V120, P2051; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JAN YN, 1993, P NATL ACAD SCI USA, V90, P8305, DOI 10.1073/pnas.90.18.8305; JENNINGS B, 1994, DEVELOPMENT, V120, P3537; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KNUST E, 1992, GENETICS, V132, P505; KOOH PJ, 1993, DEVELOPMENT, V117, P493; KOPAN R, 1993, J CELL BIOL, V121, P631, DOI 10.1083/jcb.121.3.631; KOPAN R, 1994, DEVELOPMENT, V120, P2385; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LARDELLI M, 1993, EXP CELL RES, V204, P364, DOI 10.1006/excr.1993.1044; LARDELLI M, 1994, MECH DEVELOP, V46, P123, DOI 10.1016/0925-4773(94)90081-7; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIEBER T, 1992, NEURON, V9, P847, DOI 10.1016/0896-6273(92)90238-9; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; LINDSELL CE, UNPUB; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MAIER D, 1992, MECH DEVELOP, V38, P143, DOI 10.1016/0925-4773(92)90006-6; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MATSUNO K, UNPUB; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NYE JS, 1994, DEVELOPMENT, P2421; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; PARODY TR, 1993, GENETICS, V135, P527; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; PREISS A, COMMUNICATION; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; RABINOW L, 1990, GENETICS, V125, P41; REAUME AG, 1992, DEV BIOL, V154, P377, DOI 10.1016/0012-1606(92)90076-S; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; REBAY I, 1993, THESIS YALE U; ROEHL H, 1993, NATURE, V364, P632, DOI 10.1038/364632a0; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHRONS H, 1992, GENETICS, V132, P481; SCHWEISGUTH F, 1994, DEVELOPMENT, V120, P1433; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SIMPSON P, 1989, DEVELOPMENT, V106, P57; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; STERNBERG PW, 1993, CURR BIOL, V3, P763, DOI 10.1016/0960-9822(93)90025-J; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; TAX FE, 1994, NATURE, V368, P150, DOI 10.1038/368150a0; THOMAS U, 1991, DEVELOPMENT, V111, P749; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WAITZER L, 1994, EMBO J, V13, P5633; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WEINMASTER G, 1992, DEVELOPMENT, V116, P931; WELSHONS WJ, 1965, SCIENCE, V150, P1122, DOI 10.1126/science.150.3700.1122; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WILKINSON HA, 1994, CELL, V79, P1187, DOI 10.1016/0092-8674(94)90010-8; XU T, 1990, GENE DEV, V4, P464, DOI 10.1101/gad.4.3.464; XU T, 1990, GENETICS, V126, P665; XU T, 1992, DEVELOPMENT, V115, P913; XU T, 1990, THESIS YALE U; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; ZAGOURAS P, IN PRESS P NATL ACAD; ZIMMERSTROBL U, 1994, EMBO J, V13, P4973; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	150	1341	1418	2	108	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					225	232		10.1126/science.7716513	http://dx.doi.org/10.1126/science.7716513			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716513				2022-12-28	WOS:A1995QT18500021
J	YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T				YIN, JCP; DELVECCHIO, M; ZHOU, H; TULLY, T			CREB AS A MEMORY MODULATOR - INDUCED EXPRESSION OF A DCREB2 ACTIVATOR ISOFORM ENHANCES LONG-TERM-MEMORY IN DROSOPHILA	CELL			English	Article							CAMP-RESPONSIVE-ELEMENT; APLYSIA SENSORY NEURONS; WITHDRAWAL REFLEX; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; PROTEIN-SYNTHESIS; GILL-WITHDRAWAL; BINDING; MELANOGASTER; PHOSPHORYLATION	Genetic studies of memory formation in Drosophila have revealed that the formation of a protein synthesis-dependent long-term memory (LTM) requires multiple training sessions. LTM is blocked specifically by induced expression of a repressor isoform of the cAMP-responsive element-binding protein (CREB). Here, we report an enhancement of LTM formation after induced expression of an activator isoform of dCREB2. Maximum LTM is achieved after one training session, and its formation depends on phosphorylation of the activator transgene. A model of LTM formation based on differential regulation of CREB isoforms is proposed.			YIN, JCP (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032245] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32245] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARMSTRONG RC, 1993, ANNU REV NEUROSCI, V16, P17, DOI 10.1146/annurev.ne.16.030193.000313; BACKSAI BJ, 1993, SCIENCE, V260, P222; BAILEY CH, 1994, SEMIN NEUROSCI, V6, P35; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BUONOMANO DV, 1990, SCIENCE, V249, P420, DOI 10.1126/science.2165631; Byrne John H., 1993, V27, P47; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CAREW TJ, 1972, SCIENCE, V175, P451, DOI 10.1126/science.175.4020.451; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; Ebbinghaus, 1885, GEDACHTNIS; ERBER J, 1976, J COMP PHYSIOL PSYCH, V90, P41, DOI 10.1037/h0077258; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALL CM, 1991, MEMORY ORG LOCUS CHA, P301; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, TRENDS NEUROSCI, V9, P492, DOI 10.1016/0166-2236(86)90157-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENOUGH WT, 1984, TRENDS NEUROSCI, V7, P229, DOI 10.1016/S0166-2236(84)80211-8; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hintzman D. L., 1974, THEORIES COGNITIVE P, P77; Huang Y Y, 1994, Learn Mem, V1, P74; JAFFE K, 1980, PHYSIOL BEHAV, V25, P367, DOI 10.1016/0031-9384(80)90275-9; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KANDEL ER, 1987, SYNAPTIC FUNCTION, P471; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LEWIS D, 1960, QUANTITATIVE METHODS; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NAZIF FA, 1991, BRAIN RES, V539, P324, DOI 10.1016/0006-8993(91)91638-H; PALMERINO CC, 1980, SCIENCE, V208, P753, DOI 10.1126/science.7367891; PIROTTA V, 1988, SURVEY MOL CLONING V, P427; QIU YH, 1993, GENE DEV, V7, P1447, DOI 10.1101/gad.7.7b.1447; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Sokal R. R, 1981, BIOMETRY; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STEWART MG, 1991, NEURAL BEHAVIOURAL P, P305; SUN P, 1984, GENE DEV, V8, P2527; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1993, J NEUROGENET, V9, P55, DOI 10.3109/01677069309167275; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	67	545	570	2	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					107	115		10.1016/0092-8674(95)90375-5	http://dx.doi.org/10.1016/0092-8674(95)90375-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720066	Bronze			2022-12-28	WOS:A1995QR97000012
J	LEFKOVITS, J; PLOW, EF; TOPOL, EJ				LEFKOVITS, J; PLOW, EF; TOPOL, EJ			MECHANISMS OF DISEASE - PLATELET GLYCOPROTEIN IIB/IIIA RECEPTORS IN CARDIOVASCULAR MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IIB-IIIA COMPLEX; FIBRINOGEN-BINDING-PROPERTIES; VONWILLEBRAND-FACTOR BINDING; MURINE MONOCLONAL-ANTIBODY; STIMULATED HUMAN-PLATELETS; ARG-GLY-ASP; GPIIB-IIIA; RECOGNITION SITE; GAMMA-CHAIN; GLANZMANNS THROMBASTHENIA		CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA; CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation				Topol, Eric/0000-0002-1478-4729				AGUIRRE F, 1993, CIRCULATION, V88, P252; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON HV, 1994, J AM COLL CARDIOL, V23, P1031, DOI 10.1016/0735-1097(94)90586-X; [Anonymous], 1994, BMJ, V308, P159; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARKER PL, 1992, J MED CHEM, V35, P2040, DOI 10.1021/jm00089a014; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CHARO IF, 1987, J BIOL CHEM, V262, P9935; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHOI ET, 1994, J VASC SURG, V19, P125, DOI 10.1016/S0741-5214(94)70127-X; COLLEN D, 1994, THROMB HAEMOSTASIS, V71, P95; COLLER BS, 1986, BLOOD, V68, P783; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; COLLER BS, 1991, HEART CARDIOVASCULAR, V1, P219; COX D, 1994, MED RES REV, V14, P195, DOI 10.1002/med.2610140203; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; ELLIS SG, 1993, CORONARY ARTERY DIS, V4, P167, DOI 10.1097/00019501-199302000-00007; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FITZGERALD LA, 1987, HEMOSTASIS THROMBOSI, P572; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; FUSTER V, 1994, TXB INTERVENTIONAL C, V1, P3; GAN ZR, 1988, J BIOL CHEM, V263, P19827; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GOGSTAD GO, 1982, BLOOD, V60, P663; GOLD HK, 1988, CIRCULATION, V77, P670, DOI 10.1161/01.CIR.77.3.670; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HANSON SR, 1988, J CLIN INVEST, V81, P149, DOI 10.1172/JCI113286; HANTGAN RR, 1990, BLOOD, V76, P345; HUANG TF, 1989, BIOCHEMISTRY-US, V28, P661, DOI 10.1021/bi00428a037; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JANG YS, 1994, J AM COLL CARDIOL, V24, P1591, DOI 10.1016/0735-1097(94)90162-7; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; KUNICKI TJ, 1981, BLOOD, V58, P268; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LAGES B, 1994, BLOOD, V83, P2549, DOI 10.1182/blood.V83.9.2549.bloodjournal8392549; LEFKOVITS J, 1995, J AM COLL CARDIOL, pA81; LINCOFF AM, 1995, J AM COLL CARDIOL, V25, pA80; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; MUSIAL J, 1990, CIRCULATION, V82, P261, DOI 10.1161/01.CIR.82.1.261; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OHMAN EM, 1994, CIRCULATION, V90, P564; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1988, BLOOD, V71, P831; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1987, BIOCHEM PHARMACOL, V36, P4035, DOI 10.1016/0006-2952(87)90558-2; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1992, J LAB CLIN MED, V120, P198; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RAO AK, 1986, SEMIN HEMATOL, V23, P102; ROTE WE, 1994, J CARDIOVASC PHARM, V23, P681, DOI 10.1097/00005344-199404000-00025; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAELMAN EUM, 1994, BLOOD, V83, P1244; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCHULMAN SP, 1993, CIRCULATION, V88, P608; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; SMYTH, 1994, BLOOD, V83, P2013; SMYTH SS, 1993, BLOOD, V81, P2827; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TCHENG JE, 1994, CIRCULATION, V90, P1757, DOI 10.1161/01.CIR.90.4.1757; THEROUX P, 1994, CIRCULATION, V90, P232; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; YAMADA T, 1993, J BIOL CHEM, V268, P10588; YASUDA T, 1988, J CLIN INVEST, V81, P1284, DOI 10.1172/JCI113446; 1994, BRIT MED J, V308, P1540	83	658	685	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1553	1559		10.1056/NEJM199506083322306	http://dx.doi.org/10.1056/NEJM199506083322306			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739710				2022-12-28	WOS:A1995RB19600006
J	STEINER, M; STEINBERG, S; STEWART, D; CARTER, D; BERGER, C; REID, R; GROVER, D; STREINER, D				STEINER, M; STEINBERG, S; STEWART, D; CARTER, D; BERGER, C; REID, R; GROVER, D; STREINER, D			FLUOXETINE IN THE TREATMENT OF PREMENSTRUAL DYSPHORIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; MOOD DISORDERS; DOUBLE-BLIND; WOMEN; DEPRESSION; SEROTONIN; SCALES; CLOMIPRAMINE; OVARIECTOMY; PREVALENCE	Background. Premenstrual dysphoria shares certain features with depression and anxiety states, which have been linked to serotonergic dysregulation. We evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria. Methods. The trial consisted of a single-blind, placebo washout period lasting two menstrual cycles, followed by a randomized, double-blind, placebo-controlled trial of fluoxetine at a dose of either 20 mg or 60 mg per day or placebo for six menstrual cycles. Healthy women meeting criteria for what was then called late-luteal-phase dysphoric disorder were recruited at seven university-affiliate women's health clinics in Canada. The primary outcome measure consisted of visual-analogue scales for tension, irritability, and dysphoria during the late luteal phase of each cycle. Results. Of 405 women enrolled in the placebo washout period, 313 subsequently entered the randomized phase of the study, which lasted six menstrual cycles, and 180 completed it. Fluoxetine at a dose of 20 or 60 mg per day was significantly superior to placebo in reducing symptoms of tension, irritability, and dysphoria, as measured by the visual-analogue scales (P<0.001). The women who received 60 mg of fluoxetine per day reported significantly more side effects than those who received 20 mg per day or placebo (P<0.001). Conclusions. Fluoxetine is useful in the treatment of premenstrual dysphoria. Treatment with fluoxetine at a dose of 20 mg per day reduces the potential for side effects while maximizing therapeutic efficacy.	MCMASTER UNIV, ST JOSEPHS HOSP, DEPT BIOMED SCI, HAMILTON, ON L8N 4A6, CANADA; MCGILL UNIV, ST MARYS HOSP, DEPT PSYCHIAT, MONTREAL, PQ, CANADA; UNIV TORONTO, ST MICHAELS HOSP, DEPT PSYCHIAT, TORONTO, ON M5B 1W8, CANADA; UNIV BRITISH COLUMBIA HOSP, DEPT PSYCHIAT, VANCOUVER, BC, CANADA; CONCORDIA UNIV, MONTREAL GEN HOSP, DEPT PSYCHIAT, MONTREAL, PQ, CANADA; QUEENS UNIV, DEPT OBSTET & GYNECOL, KINGSTON, ON, CANADA; UNIV ALBERTA HOSP, DEPT PSYCHIAT, EDMONTON, AB T6G 2B7, CANADA; MCMASTER UNIV, DEPT PSYCHIAT, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA	McGill University; McMaster University; McGill University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; Concordia University - Canada; McGill University; Queens University - Canada; University of Alberta; McMaster University; McMaster University	STEINER, M (corresponding author), MCMASTER UNIV, ST JOSEPHS HOSP, DEPT PSYCHIAT, 50 CHARLTON AVE E, HAMILTON, ON L8N 4A6, CANADA.		Stewart, Donna Eileen E/J-2844-2016; Steiner, Meir/B-2121-2016; Streiner, David/E-6563-2011	Stewart, Donna Eileen E/0000-0002-8157-7746; Streiner, David/0000-0003-0610-6271				[Anonymous], 1992, Arch Gen Psychiatry, V49, P139; BACHYRITA P, 1994, SCIENCE, V264, P642, DOI 10.1126/science.8171313; BARONDES SH, 1994, SCIENCE, V263, P1102, DOI 10.1126/science.8108727; BENFIELD P, 1986, DRUGS, V32, P481, DOI 10.2165/00003495-198632060-00002; BERGER CP, 1994, OBSTET GYNECOL, V84, P379; BRZEZINSKI AA, 1990, OBSTET GYNECOL, V76, P296; CASPER RF, 1990, AM J OBSTET GYNECOL, V162, P105, DOI 10.1016/0002-9378(90)90831-Q; CASPER RF, 1986, AM J OBSTET GYNECOL, V155, P862, DOI 10.1016/S0002-9378(86)80040-0; CASSON P, 1990, AM J OBSTET GYNECOL, V162, P99, DOI 10.1016/0002-9378(90)90830-Z; CONDON JT, 1993, BRIT J PSYCHIAT, V162, P481, DOI 10.1192/bjp.162.4.481; DAAMEN MJ, 1992, J CLIN PSYCHIAT, V53, P210; DIXON WJ, 1992, BMDP STATISTICAL SOF, V2; ENDICOTT J, 1993, J AFFECT DISORDERS, V29, P193, DOI 10.1016/0165-0327(93)90033-G; ERIKSSON E, 1990, ACTA PSYCHIAT SCAND, V81, P87, DOI 10.1111/j.1600-0447.1990.tb06455.x; FREEMAN EW, 1992, AM J PSYCHIAT, V149, P531; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; HARRISON WM, 1990, ARCH GEN PSYCHIAT, V47, P270; HASKETT RF, 1980, BIOL PSYCHIAT, V15, P121; HASKETT RF, 1987, 140TH ANN M AM PSYCH; HURT SW, 1992, AM J PSYCHIAT, V149, P525; JOHNSON SR, 1988, J REPROD MED, V33, P340; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; LEPAGE P, 1991, ROY SOC MED INT CONG, V165, P131; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; MENKES DB, 1993, INT CLIN PSYCHOPHARM, V8, P95, DOI 10.1097/00004850-199300820-00003; MENKES DB, 1992, BRIT MED J, V305, P346, DOI 10.1136/bmj.305.6849.346; MORTOLA JF, 1991, J CLIN ENDOCR METAB, V72, pA252; MUSE KN, 1984, NEW ENGL J MED, V311, P1345, DOI 10.1056/NEJM198411223112104; PEARLSTEIN TB, 1990, J AFFECT DISORDERS, V20, P129, DOI 10.1016/0165-0327(90)90126-S; RAPKIN AJ, 1992, CLIN OBSTET GYNECOL, V35, P629, DOI 10.1097/00003081-199209000-00022; Reid R.L., 1985, OBSTET GYNECOLOGY FE; REID RL, 1991, NEW ENGL J MED, V324, P1208, DOI 10.1056/NEJM199104253241710; RICKELS K, 1990, CURR THER RES CLIN E, V48, P161; RIVERATOVAR AD, 1990, AM J PSYCHIAT, V147, P1634; ROBINSON GE, 1990, CAN J PSYCHIAT, V35, P199, DOI 10.1177/070674379003500301; ROJANSKY N, 1991, GYNECOL OBSTET INVES, V31, P146, DOI 10.1159/000293135; RUBINOW DR, 1984, AM J PSYCHIAT, V141, P684; SCHMIDT PJ, 1993, ARCH GEN PSYCHIAT, V50, P467; SEVERINO SK, 1989, PREMENSTRUAL SYNDROM, P162; STEINBERG S, 1991, LIFE SCI, V49, P767, DOI 10.1016/0024-3205(91)90244-6; STEINER M, 1980, ACTA PSYCHIAT SCAND, V62, P177, DOI 10.1111/j.1600-0447.1980.tb00605.x; STEINER M, 1992, CLIN OBSTET GYNECOL, V35, P599, DOI 10.1097/00003081-199209000-00020; STEINER M, 1994, INT J GYNECOL OBSTET, V46, P122; STEWART DE, 1994, BIOL PSYCHIAT, V36, P201, DOI 10.1016/0006-3223(94)91226-2; STONE AB, 1990, PSYCHOPHARMACOL BULL, V26, P331; STONE AB, 1991, J CLIN PSYCHIAT, V52, P290; STREINER DL, 1993, CAN J PSYCHIAT, V38, P9, DOI 10.1177/070674379303800104; SUNDBLAD C, 1992, ACTA PSYCHIAT SCAND, V85, P39, DOI 10.1111/j.1600-0447.1992.tb01440.x; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; VEENINGA AT, 1990, PSYCHOPHARMACOLOGY, V102, P414, DOI 10.1007/BF02244113; WERNICKE JF, 1985, J CLIN PSYCHIAT, V46, P59; WOOD SH, 1992, OBSTET GYNECOL, V80, P339; WURTMAN JJ, 1993, J AFFECT DISORDERS, V29, P183, DOI 10.1016/0165-0327(93)90032-F; YATHAM LN, 1993, CAN J PSYCHIAT, V38, P662, DOI 10.1177/070674379303801007; 1987, DIAGNOSTIC STATISTIC, P367; 1993, NEUROPSYCHOPHARMACOL, V8, P177; 1994, DIAGNOSTIC STATISTIC, P717	58	346	357	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1529	1534		10.1056/NEJM199506083322301	http://dx.doi.org/10.1056/NEJM199506083322301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB196	7739706				2022-12-28	WOS:A1995RB19600001
J	REIDENBERG, MM				REIDENBERG, MM			CLINICAL-PHARMACOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POOR METABOLIZERS; DEBRISOQUINE; SPARTEINE				REIDENBERG, MM (corresponding author), CORNELL UNIV,COLL MED,NEW YORK,NY 10021, USA.							APSELOFF G, 1994, CLIN PHARMACOL THER, V56, P460, DOI 10.1038/clpt.1994.161; BERTILSSON L, 1993, LANCET, V341, P63, DOI 10.1016/0140-6736(93)92546-6; EPSTEIN AE, 1993, JAMA-J AM MED ASSOC, V270, P2451, DOI 10.1001/jama.270.20.2451; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; OTTON SV, 1993, CLIN PHARMACOL THER, V54, P463, DOI 10.1038/clpt.1993.177; SINDRUP SH, 1993, PAIN, V53, P335, DOI 10.1016/0304-3959(93)90229-I; SINDRUP SH, 1990, CLIN PHARMACOL THER, V48, P686, DOI 10.1038/clpt.1990.212; 1994, LANCET, V343, P871	8	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1664	1665						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752406				2022-12-28	WOS:A1995RB09700014
J	BEALE, J				BEALE, J			AN ATTENUATED VACCINE FOR AIDS	LANCET			English	Editorial Material											BEALE, J (corresponding author), PRIESTS HOUSE,SISSINGHURST CASTLE,KENT,ENGLAND.							DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; PAUL WE, 1995, SCIENCE, V267, P633, DOI 10.1126/science.7839138; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; WEIR X, 1995, NATURE, V373, P117	5	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1318	1319		10.1016/S0140-6736(95)92532-5	http://dx.doi.org/10.1016/S0140-6736(95)92532-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752750				2022-12-28	WOS:A1995RA14800003
J	WISSOW, LS				WISSOW, LS			CURRENT CONCEPTS - CHILD-ABUSE AND NEGLECT	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEXUAL ABUSE; RETINAL HEMORRHAGE; PREPUBERTAL GIRLS; GENITAL FINDINGS; YOUNG-CHILDREN; VIOLENCE; INJURIES; SUGGESTIBILITY; RESUSCITATION; MECHANISMS		JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21287 USA	Johns Hopkins University	WISSOW, LS (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, CMSC 338, 600N WOLFE ST, BALTIMORE, MD 21287 USA.				NIMH NIH HHS [MH-46134] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046134] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; [Anonymous], 1993, UNDERSTANDING CHILD; BARRY F, 1993, ADVISORY BOARD CHILD, P92; BATH HI, 1993, CHILD ABUSE NEGLECT, V17, P213, DOI 10.1016/0145-2134(93)90041-3; BERENSON AB, 1992, PEDIATRICS, V89, P387; BULKLEY J, 1992, ABA JUVENILE CHILD W, V11, P125; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CECI SJ, 1993, PSYCHOL BULL, V113, P403, DOI 10.1037/0033-2909.113.3.403; COHEN BA, 1990, ARCH DERMATOL, V126, P1575, DOI 10.1001/archderm.126.12.1575; COHN AH, 1987, CHILD ABUSE NEGLECT, V11, P433, DOI 10.1016/0145-2134(87)90016-0; Daro D., 1988, CONFRONTING CHILD AB; DODGE KA, 1990, SCIENCE, V250, P1678, DOI 10.1126/science.2270481; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DURFEE MJ, 1992, JAMA-J AM MED ASSOC, V267, P3172, DOI 10.1001/jama.267.23.3172; ELLER AW, 1983, PEDIATR CLIN N AM, V30, P1087; EMANS SJ, 1987, PEDIATRICS, V79, P778; ERICKSON MF, 1987, SCHOOL PSYCHOL REV, V16, P156; EVERSON MD, 1989, J AM ACAD CHILD PSY, V28, P230, DOI 10.1097/00004583-198903000-00014; FURBY L, 1989, PSYCHOL BULL, V105, P3, DOI 10.1037/0033-2909.105.1.3; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; GOETTING MG, 1990, PEDIATRICS, V85, P585; GOLEMAN D, 1994, NY TIMES        0531, pC1; GREEN AH, 1993, J AM ACAD CHILD PSY, V32, P890, DOI 10.1097/00004583-199309000-00002; GUSTAVSSON NS, 1994, CRITICAL ISSUES CHIL, P91; GUTMAN LT, 1993, PEDIATRICS, V91, P31; HEGER A, 1992, EVALUATION SEXUALLY; HOLMES SJ, 1988, PSYCHIATRY, V51, P24, DOI 10.1080/00332747.1988.11024377; JAFFE P, 1986, AM J PSYCHIAT, V143, P74; JENNY C, 1987, PEDIATRICS, V80, P399; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KAUFMAN J, 1987, AM J ORTHOPSYCHIAT, V57, P186, DOI 10.1111/j.1939-0025.1987.tb03528.x; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; LEWIT EM, 1992, FUTURE CHILD, V2, P127; LOFTUS EF, 1993, AM PSYCHOL, V48, P518, DOI 10.1037/0003-066X.48.5.518; LUDWIG S, 1992, CHILD ABUSE MED REFE; MARR WG, 1962, AM J OPHTHALMOL, V54, P693, DOI 10.1016/0002-9394(62)92201-8; MARTINEZ P, 1993, PSYCHIATRY, V56, P22; MCCANN J, 1990, PEDIATRICS, V86, P428; MCCANN J, 1992, PEDIATRICS, V89, P307; MCCLAIN PW, 1993, PEDIATRICS, V91, P338; MCKIBBEN L, 1989, PEDIATRICS, V84, P531; OATES K, 1991, MED SCI LAW, V31, P4, DOI 10.1177/002580249103100102; OLDS DL, 1990, PEDIATRICS, V86, P108; PARADISE JE, 1988, PEDIATRICS, V81, P835; PELCOVITZ D, 1994, J AM ACAD CHILD PSY, V33, P305, DOI 10.1097/00004583-199403000-00002; Putnam F, 1994, CHILD ADOLESCENT PSY, V3, P663; Reece RM, 1994, CHILD ABUSE MED DIAG; ROSENBERG DA, 1987, CHILD ABUSE NEGLECT, V11, P547, DOI 10.1016/0145-2134(87)90081-0; SALZINGER S, 1993, CHILD DEV, V64, P169, DOI 10.2307/1131444; SAYWITZ KJ, 1992, J APPL PSYCHOL, V77, P744, DOI 10.1037/0021-9010.77.5.744; Sgroi S, 1982, HDB CLIN INTERVENTIO; SORENSEN T, 1991, CHILD WELFARE, V70, P3; STURKIE K, 1994, CHILD ADOLESCENT PSY, V3, P813; THOMAS SA, 1991, PEDIATRICS, V88, P471; WARREN A, 1991, LAW HUMAN BEHAV, V15, P273, DOI 10.1007/BF01061713; WISSOW LS, 1994, PEDIATRICS, V94, P587; WISSOW LS, 1990, CHILD ADVOCACY CLIN; 1994, GUIDE REFERENCES RES, P107; 1986, OTABPH33 OFF TECHN A; 1988, STUDY FINDINGS STUDY	62	62	63	2	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1425	1431		10.1056/NEJM199505253322107	http://dx.doi.org/10.1056/NEJM199505253322107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QY941	7723800				2022-12-28	WOS:A1995QY94100007
J	LIAO, YL; COOPER, RS; MCGEE, DL; MENSAH, GA; GHALI, JK				LIAO, YL; COOPER, RS; MCGEE, DL; MENSAH, GA; GHALI, JK			THE RELATIVE EFFECTS OF LEFT-VENTRICULAR HYPERTROPHY, CORONARY-ARTERY DISEASE, AND VENTRICULAR DYSFUNCTION ON SURVIVAL AMONG BLACK ADULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL DEATH INDEX; ESSENTIAL-HYPERTENSION; SYSTEMIC HYPERTENSION; RACIAL-DIFFERENCES; MORBID EVENTS; MASS; ECHOCARDIOGRAPHY; MORTALITY; WOMEN; MEN	Objective.-To evaluate the effect of echocardiographically determined left ventricular hypertrophy (LVH) on survival in comparison with number of stenosed vessels and left ventricular systolic dysfunction. Design.-Cohort study based on a consecutive sample from a hospital registry, with a mean follow-up of 5 years. Setting.-An inner-city public hospital in Chicago, Ill. Patients.-The study included 1089 consecutive black patients who underwent both coronary angiography and M-mode echocardiography as part of a diagnostic evaluation. Results.-Nonstenosed coronary arteries, single-vessel disease, and multivessel disease were found in 48%, 16%, and 36% of patients, respectively; LVH (left ventricular mass index >131 g/m(2) in men and >100 g/m(2) in women) was detected in 50% of patients. Hypertrophy without coexistent obstructive coronary disease was associated with a lower survival rate than that observed for single-vessel disease and was similar to multivessel disease. When LVH, number of diseased vessels, and left ventricular dysfunction were subjected to multivariate analysis, hypertrophy conferred a relative risk (RR) of 2.4 (95% confidence interval [CI], 1.7 to 3.2). By comparison, the presence of a single stenosed vessel did not increase the risk of death. Multivessel disease and ejection fraction less than 45% were associated with an RR of 1.6 (95% CI, 1.1 to 2.2) and 2.0 (95% CI, 1.4 to 2.7), respectively. Calculation of the attributable risk fraction demonstrated that for every 100 deaths in this cohort, LVH independently accounted for 37. The corresponding attributable risk fractions were 1%, 22%, and 9% for single-vessel disease, multivessel disease, and ventricular dysfunction, respectively. Conclusions.-Left ventricular hypertrophy was associated with a greater RR and attributable risk than the traditional measures of coronary disease severity. The high prevalence and powerful risk of LVH make an important contribution to the adverse survival rates among black patients with heart disease and may account for much of the black-white differential.	COOK CTY HOSP,DIV CARDIOL,CHICAGO,IL 60612; VANDERBILT UNIV,SCH MED,DIV CARDIOL,NASHVILLE,TN 37212	John H Stroger Junior Hospital Cook County; Vanderbilt University	LIAO, YL (corresponding author), LOYOLA UNIV,MED CTR,DEPT EPIDEMIOL & PREVENT MED,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.			Mensah, George/0000-0002-0387-5326	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038557] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL38557] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNETT D K, 1992, Ethnicity and Disease, V2, P10; BLACK HR, 1991, AM J CARDIOL, V67, P1027, DOI 10.1016/0002-9149(91)90178-N; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CASALE PN, 1986, ANN INTERN MED, V105, P173, DOI 10.7326/0003-4819-105-2-173; CASTANER A, 1988, ANN INTERN MED, V109, P38; CHATURVEDI N, 1994, J AM COLL CARDIOL, V24, P1499, DOI 10.1016/0735-1097(94)90146-5; COOPER RS, 1990, AM J CARDIOL, V65, P441, DOI 10.1016/0002-9149(90)90807-D; DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; DEVEREUX RB, 1987, HYPERTENSION, V9, P69; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; EAGLE KA, 1993, J HUM HYPERTENS, V7, P341; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; FISHER SG, 1995, AM J EPIDEMIOL, V141, P242, DOI 10.1093/oxfordjournals.aje.a117426; GHALI JK, 1992, ANN INTERN MED, V117, P831, DOI 10.7326/0003-4819-117-10-831; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; KOREN MJ, 1993, AM J HYPERTENS, V6, P815, DOI 10.1093/ajh/6.10.815; LEE DK, 1992, JAMA-J AM MED ASSOC, V267, P3294, DOI 10.1001/jama.267.24.3294; LEE ET, 1980, STATISTICAL METHODS; LEFANT C, 1994, CIRCULATION, V90, P1613; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LIAO YL, 1992, JAMA-J AM MED ASSOC, V268, P1867, DOI 10.1001/jama.268.14.1867; LIEBSON PR, 1993, CIRCULATION, V87, P476, DOI 10.1161/01.CIR.87.2.476; MAYNARD C, 1987, AM J CARDIOL, V60, P513, DOI 10.1016/0002-9149(87)90296-7; PATTERSON JE, 1985, PUBLICATION INTERNAL, V1299, P245; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TROY BL, 1972, CIRCULATION, V45, P602, DOI 10.1161/01.CIR.45.3.602; WHITE CC, 1987, CLOSING GAP BURDEN U, P43; XIE XY, 1994, AM J CARDIOL, V73, P564, DOI 10.1016/0002-9149(94)90334-4; 1991, SAS P217 SAS I INC T; 1984, NIH841088 US DEP HLT; 1989, NIH892925 US DEP HLT; 1989, REDUCING HLTH CONSEQ	37	262	267	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1592	1597		10.1001/jama.273.20.1592	http://dx.doi.org/10.1001/jama.273.20.1592			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745772				2022-12-28	WOS:A1995QY54100026
J	CARLEN, PL; GORDON, M				CARLEN, PL; GORDON, M			CARDIOPULMONARY-RESUSCITATION AND NEUROLOGICAL COMPLICATIONS IN THE ELDERLY	LANCET			English	Editorial Material									UNIV TORONTO,BAYCREST CTR GERIATR CARE,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Baycrest	CARLEN, PL (corresponding author), TORONTO HOSP,RES INST,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA.		Carlen, Peter Louis/GLN-7260-2022	Carlen, Peter/0000-0002-3339-8102				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEDELL SE, 1983, NEW ENGL J MED, V309, P570; DATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; GORDON M, 1995, CARDIOL ELDER, V3, P53; JOHNSTON MV, 1994, NEUROBIOL AGING, V15, P235, DOI 10.1016/0197-4580(94)90119-8; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P	16	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1253	1254		10.1016/S0140-6736(95)90919-2	http://dx.doi.org/10.1016/S0140-6736(95)90919-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746051				2022-12-28	WOS:A1995QY93300003
J	SLOANE, JP				SLOANE, JP			MOLECULES AND MICROMETASTASES	LANCET			English	Editorial Material							COLORECTAL-CANCER; LYMPH-NODES; CLEARANCE				SLOANE, JP (corresponding author), ROYAL MARSDEN NHS TRUST,DEPT HISTOPATHOL,SUTTON,SURREY,ENGLAND.							CAWTHORN SJ, 1986, BRIT J SURG, V73, P58, DOI 10.1002/bjs.1800730124; CUTAIT R, 1991, DIS COLON RECTUM, V34, P917, DOI 10.1007/BF02049708; FISHER ER, 1978, CANCER, V42, P2025, DOI 10.1002/1097-0142(197810)42:4<2025::AID-CNCR2820420452>3.0.CO;2-J; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; HABOUBI NY, 1992, J ROY SOC MED, V85, P386; JASS JR, 1986, INT J COLORECTAL DIS, V1, P155, DOI 10.1007/BF01648442; Prognostic importance of occult axillary lymph node micrometastases from breast cancers, 1990, LANCET, V335, P1565; SMITH B, 1991, LANCET, V338, P1227, DOI 10.1016/0140-6736(91)92100-G	8	21	22	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1255	1256		10.1016/S0140-6736(95)90921-4	http://dx.doi.org/10.1016/S0140-6736(95)90921-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746053				2022-12-28	WOS:A1995QY93300005
J	WARKENTIN, TE; LEVINE, MN; HIRSH, J; HORSEWOOD, P; ROBERTS, RS; GENT, M; KELTON, JG				WARKENTIN, TE; LEVINE, MN; HIRSH, J; HORSEWOOD, P; ROBERTS, RS; GENT, M; KELTON, JG			HEPARIN-INDUCED THROMBOCYTOPENIA IN PATIENTS TREATED WITH LOW-MOLECULAR-WEIGHT HEPARIN OR UNFRACTIONATED HEPARIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; INTRAVENOUS STANDARD HEPARIN; ELECTIVE HIP-SURGERY; PLATELET-AGGREGATION; RANDOMIZED TRIAL; PREVENTION; MECHANISM; DIAGNOSIS; ANTIBODY; FRAGMIN	Background. Heparin-induced thrombocytopenia, defined by the presence of heparin-dependent IgG antibodies, typically occurs five or more days after the start of heparin therapy and can be complicated by thrombotic events. The frequency of heparin-induced thrombocytopenia and of heparin-dependent IgG antibodies, as well as the relative risk of each in patients given low-molecular-weight heparin, is unknown. Methods. We obtained daily platelet counts in 665 patients in a randomized, double-blind clinical trial comparing unfractionated heparin with low-molecular-weight heparin as prophylaxis after hip surgery. Heparin-induced thrombocytopenia was defined as a decrease in the platelet count below 150,000 per cubic millimeter that began five or more days after the start of heparin therapy, and a positive test for heparin-dependent IgG antibodies. We also tested a representative subgroup of 387 patients for heparin-dependent IgG antibodies regardless of their platelet counts. Results. Heparin-induced thrombocytopenia occurred in 9 of 332 patients who received unfractionated heparin and in none of 333 patients who received low-molecular-weight heparin (2.7 percent vs. 0 percent; P=0.0018). Eight of the 9 patients with heparin-induced thrombocytopenia also had one or more thrombotic events (venous in 7 and arterial in 1), as compared with 117 of 656 patients without heparin-induced thrombocytopenia (88.9 percent vs. 17.8 percent; odds ratio, 36.9; 95 percent confidence interval, 4.8 to 1638; P<0.001). In the subgroup of 387 patients, the frequency of heparin-dependent IgG antibodies was higher among patients who received unfractionated heparin (7.8 percent, vs, 2.2 percent among patients who received low-molecular-weight heparin; P=0.02). Conclusions. Heparin-induced thrombocytopenia, associated thrombotic events, and heparin-dependent IgG antibodies are more common in patients treated with unfractionated heparin than in those treated with low-molecular-weight heparin.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON,CANADA; MCMASTER UNIV,DEPT MED,HAMILTON,ON,CANADA; HAMILTON CIV HOSP,RES CTR,HAMILTON,ON,CANADA; MCMASTER UNIV,MED CTR,HAMILTON,ON,CANADA	McMaster University; McMaster University; McMaster University; McMaster University; McMaster University	WARKENTIN, TE (corresponding author), HAMILTON CIV HOSP,DEPT LAB MED,DIV GEN,237 BARTON ST E,HAMILTON,ON L8L 2X2,CANADA.							ADELMAN B, 1989, J LAB CLIN MED, V113, P204; ALBADA J, 1989, CIRCULATION, V80, P935, DOI 10.1161/01.CIR.80.4.935; AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95; Beyer WH, 1968, CRC HDB PROBABILITY, P219; BOSHKOV LK, 1993, BRIT J HAEMATOL, V84, P322, DOI 10.1111/j.1365-2141.1993.tb03072.x; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; CHONG BH, 1993, THROMB HAEMOSTASIS, V69, P344; CHONG BH, 1993, BLOOD, V81, P988; CHONG BH, 1989, BRIT J HAEMATOL, V73, P235, DOI 10.1111/j.1365-2141.1989.tb00258.x; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; COLWELL CW, 1994, J BONE JOINT SURG AM, V76, P4741; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; FRIEDMAN LM, 1981, FUNDAMENTALS CLIN TR, P174; GREEN D, 1994, PHARMACOL REV, V46, P89; GREINACHER A, 1992, THROMB HAEMOSTASIS, V67, P545; GREINACHER A, 1994, THROMB HAEMOSTASIS, V71, P247; HIRSH J, 1992, BLOOD, V79, P1; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; ISENHART CE, 1993, AM J CLIN PATHOL, V99, P324, DOI 10.1093/ajcp/99.3.324; KELTON JG, 1988, BLOOD, V72, P925; KELTON JG, 1994, BLOOD, V83, P3232; KING DJ, 1984, ANN INTERN MED, V100, P535, DOI 10.7326/0003-4819-100-4-535; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1991, BRIT MED J, V303, P1243; LINDMARKER P, 1994, THROMB HAEMOSTASIS, V72, P186; LOPACIUK S, 1992, THROMB HAEMOSTASIS, V68, P14; MATTHEWS DE, 1988, USING UNDERSTANDING, P20; Ninet J., 1991, THROMB HAEMOSTASIS, V65, P251; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; SHERIDAN D, 1986, BLOOD, V67, P27; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; VISENTIN GP, 1994, J CLIN INVEST, V93, P81, DOI 10.1172/JCI116987; Warkentin T E, 1991, Prog Hemost Thromb, V10, P1; WARKENTIN TE, 1994, BLOOD, V84, P3691, DOI 10.1182/blood.V84.11.3691.bloodjournal84113691; WARKENTIN TE, 1992, J LAB CLIN MED, V120, P371; WARKENTIN TE, 1994, LOW MOL WEIGHT HEPAR, V19, P75; 1992, ARCH ORTHOP TRAUMA S, V111, P110	40	1844	1895	3	86	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1330	1335		10.1056/NEJM199505183322003	http://dx.doi.org/10.1056/NEJM199505183322003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715641	Bronze			2022-12-28	WOS:A1995QX85700003
J	FRIBERG, TR				FRIBERG, TR			RETINAL TEAR AFTER TEETH CLEANING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							DENTAL EXTRACTION				FRIBERG, TR (corresponding author), UNIV PITTSBURGH,PITTSBURGH,PA 15260, USA.							GOPER G, 1977, ZAHN MUND KIEFERHEIL, V65, P278; JAFFE NS, 1984, CATARACT SURG ITS CO, P246; KING LP, 1993, GRAEF ARCH CLIN EXP, V231, P667, DOI 10.1007/BF00921963; MALDEN N, 1993, BRIT DENT J, V174, P334, DOI 10.1038/sj.bdj.4808168; YOUNG LM, 1994, PRINCIPLES PRACTICE, V2, P1084	5	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1493	1493		10.1001/jama.273.19.1493	http://dx.doi.org/10.1001/jama.273.19.1493			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739072				2022-12-28	WOS:A1995QX41800028
J	PICKWORTH, WB				PICKWORTH, WB			CAFFEINE DEPENDENCE	LANCET			English	Editorial Material							DISCRIMINATION				PICKWORTH, WB (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							GLASS RM, 1994, JAMA-J AM MED ASSOC, V272, P1065, DOI 10.1001/jama.272.13.1065; GRIFFITHS RR, 1990, J PHARMACOL EXP THER, V252, P970; HUGHES JR, J SUB ABUSE, V1, P67; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SILVERMAN K, 1992, J EXP ANAL BEHAV, V57, P91, DOI 10.1901/jeab.1992.57-91; Spitzer R., 1985, STRUCTURED CLIN INTE; STRAIN EC, 1994, JAMA-J AM MED ASSOC, V272, P1043, DOI 10.1001/jama.272.13.1043; 1994, BASIS DRUG DEPENDENC; 1994, DIAGNOSTIC STATISTIC	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1066	1066		10.1016/S0140-6736(95)90814-5	http://dx.doi.org/10.1016/S0140-6736(95)90814-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715336				2022-12-28	WOS:A1995QV41100006
J	WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G				WIJNEN, RMH; BOOSTER, MH; STUBENITSKY, BM; DEBOER, J; HEINEMAN, E; KOOTSTRA, G			OUTCOME OF TRANSPLANTATION OF NON-HEART-BEATING DONOR KIDNEYS	LANCET			English	Article							MACHINE PERFUSION; CANINE PANCREAS; PRESERVATION; GRAFTS; PROCUREMENT; REJECTION; ISCHEMIA; TISSUE	To reduce the shortage of kidneys for transplantation, we started a non-heart-beating (NHB) donor programme, and compared the short-term and long-term outcomes of kidneys from NHB donors with those of a matched group of kidneys from heart-beating (HB) donors. 57 NHB kidneys were procured at the University Hospital in Msaastricht and at three regional hospitals in the Netherlands, and were transplanted in 21 transplant centres within the Eurotransplant exchange organisation. 114 matched controls from HB donors were selected from Eurotransplant files. Mean follow-up was 85 months. At 5 years, graft survival was 54% for NHB kidneys and 55% for HB kidneys; patient survival was 75% and 77%. Kidneys from NHB donors had a significantly higher rate of delayed graft function (60% vs 35%), resulting in a longer hospital stay. Primary non-function of the graft was seen as frequently in the NHB donor-kidney group as in the HB group (14% vs 8%, p=0.3). We conclude that NHB donors are a valuable source of kidneys for transplantation.	UNIV LIMBURG HOSP,DEPT SURG,6202 AZ MAASTRICHT,NETHERLANDS; EUROTRANSPLANT FDN,LEIDEN,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC)			Heineman, Erik/ABG-9592-2021; Wijnen, R.M.H./L-4758-2015					ARIAS J, 1991, TRANSPLANT P, V23, P2581; BELZER FO, 1967, LANCET, V2, P536; BOOSTER MH, 1993, TRANSPLANT P, V25, P3012; BOOSTER MH, 1993, TRANSPLANT P, V25, P3006; BOOSTER MH, 1992, TRANSPLANTATION, V56, P613; BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; CANAFAX DM, 1986, TRANSPLANTATION, V41, P177, DOI 10.1097/00007890-198602000-00009; CASTELAO AM, 1991, TRANSPLANT P, V23, P2584; COHEN B, 1993, 1992 EUR ANN REP, P31; FUJINO Y, 1993, TRANSPLANTATION, V56, P1083, DOI 10.1097/00007890-199311000-00006; GARVIN PJ, 1980, ARCH SURG-CHICAGO, V115, P180; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GROENEWOUD AF, 1992, TRANSPLANT INT, V5, pS429; HOFFMANN RM, 1989, TRANSPLANTATION, V47, P32, DOI 10.1097/00007890-198901000-00008; KALLERHOFF M, 1987, UROL RES, V15, P5; KOOTSTRA G, 1991, TRANSPLANT P, V23, P912; KOZAKI M, 1991, TRANSPLANT P, V23, P2575; LAND W, 1994, TRANSPLANTATION, V57, P211, DOI 10.1097/00007890-199401001-00010; MATSUNO N, 1994, TRANSPLANTATION, V57, P293; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PHILLIPS AO, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575a; PLOEG RJ, 1992, LANCET, V340, P129, DOI 10.1016/0140-6736(92)93212-6; PREUSCHOF L, 1991, TRANSPLANT P, V23, P1300; RIJKSEN JFW, 1972, EUROTRANSPLANT MANUA, P30; SCHLUMPF R, 1992, TRANSPLANT INT, V5, pS424; SCHWEIZER RT, 1981, TRANSPLANTATION, V32, P482, DOI 10.1097/00007890-198112000-00005; VARTY K, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575; VERDUYN W, 1993, HUM IMMUNOL, V37, P59, DOI 10.1016/0198-8859(93)90143-O; VROEMEN JPA, 1983, NETH J SURG, V35, P50; WAHLBERG JA, 1987, TRANSPLANTATION, V43, P5, DOI 10.1097/00007890-198701000-00002	30	243	247	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1067	1070		10.1016/S0140-6736(95)90815-3	http://dx.doi.org/10.1016/S0140-6736(95)90815-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715337				2022-12-28	WOS:A1995QV41100007
J	KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U				KARLOVICH, CA; BONFINI, L; MCCOLLAM, L; ROGGE, RD; DAGA, A; CZECH, MP; BANERJEE, U			IN-VIVO FUNCTIONAL-ANALYSIS OF THE RAS EXCHANGE FACTOR SON OF SEVENLESS	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; DROSOPHILA-RETINA; ADAPTER PROTEIN; GENE-PRODUCT; SH3 DOMAINS; PATHWAY; ACTIVATION; LIGAND; CELLS	The Son of sevenless (Sos) protein functions as a guanine nucleotide transfer factor for Ras and interacts with the receptor tyrosine kinase Sevenless through the protein Drk, a homolog of mammalian Grb2. In vivo structure-function analysis revealed that the amino terminus of Sos was essential for its function in flies. A molecule lacking the amino terminus was a potent dominant negative. In contrast, a Sos fragment lacking the Drk binding sites was functional and its activity was dependent on the presence of the Sevenless receptor. Furthermore, membrane localization of Sos was independent of Drk. A possible role for Drk as an activator of Sos is discussed and a Drk-independent interaction between Sos and Sevenless is proposed that is likely mediated by the pleckstrin homology domain within the amino terminus.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester			daga, andrea/J-1865-2018	daga, andrea/0000-0001-8935-5489; Rogge, Ronald/0000-0002-1875-3938	NATIONAL EYE INSTITUTE [R01EY008152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY08152-06] Funding Source: Medline; NIGMS NIH HHS [GM-07104, GM-08375] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; FRANCESCHINI N, 1971, KYBERNETIK, V9, P159, DOI 10.1007/BF02215177; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KARLOVICH CA, UNPUB; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, UNPUB; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; ROGGE R, 1992, P NATL ACAD SCI USA, V89, P5271, DOI 10.1073/pnas.89.12.5271; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STERNBERG PW, 1993, ANNU REV GENET, V27, P497, DOI 10.1146/annurev.ge.27.120193.002433; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	25	78	80	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					576	579		10.1126/science.7725106	http://dx.doi.org/10.1126/science.7725106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725106				2022-12-28	WOS:A1995QV40700040
J	KIEHNTOPF, M; ESQUIVEL, EL; BRACH, MA; HERRMANN, F				KIEHNTOPF, M; ESQUIVEL, EL; BRACH, MA; HERRMANN, F			CLINICAL-APPLICATIONS OF RIBOZYMES	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTISENSE OLIGONUCLEOTIDES; MESSENGER-RNA; IN-VITRO; EXPRESSION; CLEAVAGE; ENZYMES; DNA		FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, ROBERT ROSSLE CANC CTR, DEPT MED ONCOL & APPL MOLEC BIOL, D-13122 BERLIN, GERMANY; MAX DELBRUCK CTR MOLEC MED, D-13122 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine								BARINAGA M, 1993, SCIENCE, V262, P1512, DOI 10.1126/science.8248799; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; CANTOR GH, 1993, P NATL ACAD SCI USA, V90, P10932, DOI 10.1073/pnas.90.23.10932; CECH TR, 1994, NATURE, V372, P39, DOI 10.1038/372039a0; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DEGOLS G, 1992, ANN NY ACAD SCI, V660, P331, DOI 10.1111/j.1749-6632.1992.tb21104.x; Dropulic B, 1993, Antisense Res Dev, V3, P87; FORSTER AC, 1987, COLD SPRING HARB SYM, V52, P249, DOI 10.1101/SQB.1987.052.01.030; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; HENDRY P, 1992, NUCLEIC ACIDS RES, V20, P5737, DOI 10.1093/nar/20.21.5737; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HOLM PS, 1994, BRIT J CANCER, V70, P239, DOI 10.1038/bjc.1994.286; KASHANI SM, 1994, CANCER RES, V54, P900; Kashani-Sabet M, 1992, Antisense Res Dev, V2, P3; KIEHNTOPF M, 1994, EMBO J, V13, P4645, DOI 10.1002/j.1460-2075.1994.tb06787.x; KOBAYASHI H, 1994, CANCER RES, V54, P1271; KOIZUMI M, 1989, NUCLEIC ACIDS RES, V17, P7059, DOI 10.1093/nar/17.17.7059; LANGE W, 1993, LEUKEMIA, V7, P1786; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; Netter H J, 1993, Prog Clin Biol Res, V382, P373; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; Sarver N, 1991, Antisense Res Dev, V1, P373; SHORE SK, 1993, ONCOGENE, V8, P3183; SNYDER DS, 1993, BLOOD, V82, P600; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; Tone Takeshi, 1993, In Vivo (Athens), V7, P471; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VONAHSEN U, 1993, BIOESSAYS, V15, P299, DOI 10.1002/bies.950150503; WRIGHT L, 1993, EXP HEMATOL, V21, P1714; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUYAMA N, 1992, BIOCHEM BIOPH RES CO, V186, P1271, DOI 10.1016/S0006-291X(05)81543-8	38	33	37	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	1995	345	8956					1027	1031		10.1016/S0140-6736(95)90762-9	http://dx.doi.org/10.1016/S0140-6736(95)90762-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723502				2022-12-28	WOS:A1995QU57300014
J	POUNTAIN, G; HAZLEMAN, B				POUNTAIN, G; HAZLEMAN, B			POLYMYALGIA-RHEUMATICA AND GIANT-CELL ARTERITIS	BRITISH MEDICAL JOURNAL			English	Article									ADDENBROOKES HOSP,CAMBRIDGE,ENGLAND	Addenbrooke's Hospital; University of Cambridge	POUNTAIN, G (corresponding author), HINCHINGBROOKE HOSP,HUNTINGDON,ENGLAND.							SKINGLE SJ, 1994, LANCET, V344, P543, DOI 10.1016/S0140-6736(94)91932-1	1	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1057	1059		10.1136/bmj.310.6986.1057	http://dx.doi.org/10.1136/bmj.310.6986.1057			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728064	Green Published			2022-12-28	WOS:A1995QV31300025
J	GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM				GLUCKSMANNKUIS, MA; TAYBER, O; WOOLF, EA; BOUGUELERET, L; DENG, NH; ALPERIN, GD; IRIS, F; HAWKINS, F; MUNRO, C; LAKEY, N; DUYK, G; SCHNEIDER, MC; GENG, L; ZHANG, F; ZHAO, ZH; TOROSIAN, S; ZHOU, J; REEDERS, ST; BORK, P; POHLSCHMIDT, M; LOHNING, C; KRAUS, B; NOWICKA, U; LEUNG, ALS; FRISCHAUF, AM			POLYCYSTIC KIDNEY-DISEASE - THE COMPLETE STRUCTURE OF THE PKD1 GENE AND ITS PROTEIN	CELL			English	Article							CELL-ADHESION; CARBOHYDRATE-RECOGNITION; SEQUENCE; GLYCOPROTEINS; DOMAINS; LOCALIZATION; INTEGRINS; MEMBRANES; EPITHELIA; POLARITY	Mutations in the PKD1 gene sire the most common cause of autosomal dominant polycystic kidney disease (ADPKD). Other PKD1-like loci on chromosome 16 are approximately 97% identical to PKD1. To determine the authentic PKD1 sequence, we obtained the genomic sequence of the PKD1 locus and assembled a PKD1 transcript from the sequence of 46 exons. The 14.5 kb PKD1 transcript encodes a 4304 amino acid protein that has a novel domain architecture. The amino-terminal half of the protein consists of a mosaic of previously described domains, including leucine-rich repeats flanked by characteristic cysteine-rich structures, LDL-A and C-type lectin domains, and 14 units of a novel 80 amino acid domain. The presence of these domains suggests that the PKD1 protein is involved in adhesive protein-protein and protein-carbohydrate interactions in the extracellular compartment. We propose a hypothesis that links the predicted properties of the protein with the diverse phenotypic features of ADPKD.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA; EUROPEAN MOLEC BIOL LAB,PROT DESIGN GRP,D-69117 HEIDELBERG,GERMANY; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Max Delbruck Center for Molecular Medicine; Cancer Research UK	GLUCKSMANNKUIS, MA (corresponding author), MILLENNIUM PHARMACEUT INC,CAMBRIDGE,MA 02139, USA.		Bork, Peer/F-1813-2013	Bork, Peer/0000-0002-2627-833X				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; [Anonymous], 1994, CELL, V77, P881; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; BEZOUSKA K, 1991, J BIOL CHEM, V226, P11604; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BORK P, 1995, TRENDS BIOCH SCI, V20; BROCKL G, 1991, EUR J BIOCHEM, V199, P147, DOI 10.1111/j.1432-1033.1991.tb16102.x; BUTOWSKI RJ, 1985, KIDNEY INT, V28, P744; CALVET JP, 1993, KIDNEY INT, V43, P101, DOI 10.1038/ki.1993.17; CALVET JP, 1994, CURR OPIN NEPHROL HY, V3, P330; CARONE FA, 1994, LAB INVEST, V70, P437; CARONE FA, 1989, KIDNEY INT, V35, P1034, DOI 10.1038/ki.1989.87; CARONE FA, 1993, LAB INVEST, V70, P648; DAOUST MC, 1995, GENOMICS, V25, P733, DOI 10.1016/0888-7543(95)80020-M; DEAR S, 1991, NUCLEIC ACIDS RES, V19, P3907, DOI 10.1093/nar/19.14.3907; DOOLITTLE RF, 1993, SCI AM, V269, P50, DOI 10.1038/scientificamerican1093-50; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DVERGSTEN J, 1994, KIDNEY INT, V45, P828, DOI 10.1038/ki.1994.109; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; FOSSDAL R, 1993, HUM GENET, V91, P609; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; GERMINO GG, 1992, GENOMICS, V13, P144, DOI 10.1016/0888-7543(92)90214-D; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HAVERTY TP, 1988, LAB INVEST, V58, P245; HENIKOFF S, 1993, PROTEINS, V17, P97; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P325; HIMMELBAUER H, 1991, AM J HUM GENET, V48, P1017; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KLINGEL R, 1993, NEPHRON, V65, P111, DOI 10.1159/000187451; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KOONIN EV, 1994, EMBO J, V13, P493, DOI 10.1002/j.1460-2075.1994.tb06287.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KWON BS, 1993, J INVEST DERMATOL, V100, P134; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; MYERS KA, 1994, J BIOL CHEM, V269, P9319; PETERS DJM, 1993, NAT GENET, V5, P359, DOI 10.1038/ng1293-359; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; REEDERS ST, 1992, NAT GENET, V1, P235, DOI 10.1038/ng0792-235; RODRIGUEZBOULAN E, 1989, SCIENCE, V247, P718; ROHDE K, 1993, COMPUT APPL BIOSCI, V9, P183; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTH GJ, 1991, BLOOD, V77, P5; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SNAREY A, 1994, AM J HUM GENET, V55, P365; SOMLO S, 1992, GENOMICS, V13, P152, DOI 10.1016/0888-7543(92)90215-E; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEIS WI, 1992, COLD SPRING HARB SYM, V57, P281, DOI 10.1101/SQB.1992.057.01.033; WELLING LW, 1972, J CLIN INVEST, V51, P1063, DOI 10.1172/JCI106898; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAO R, 1994, BBA-GENE STRUCT EXPR, V1219, P697, DOI 10.1016/0167-4781(94)90230-5; YOSHIHARA K, 1994, J BACTERIOL, V176, P6489, DOI 10.1128/JB.176.21.6489-6496.1994	68	525	533	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					289	298						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736581	Bronze			2022-12-28	WOS:A1995QV41000018
J	IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K				IRNIGER, S; PIATTI, S; MICHAELIS, C; NASMYTH, K			GENES INVOLVED IN SISTER-CHROMATID SEPARATION ARE NEEDED FOR B-TYPE CYCLIN PROTEOLYSIS IN BUDDING YEAST	CELL			English	Article							MATURATION-PROMOTING FACTOR; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; INTERPHASE EXTRACTS; ESCHERICHIA-COLI; DNA-REPLICATION; AMPHIBIAN EGGS; M-PHASE; TRANSCRIPTION	B-type cyclin destruction is necessary for exit from mitosis and the initiation of a new cell cycle. Through the isolation of mutants, we have identified three essential yeast genes, CDC16, CDC23, and CSE1, which are required for proteolysis of the B-type cyclin CLBS but not of other unstable proteins. cdc23-1 mutants are defective in both entering and exiting anaphase. Their failure to exit anaphase can be explained by defective cyclin proteolysis. CDC23 is required at the metaphase/anaphase transition to separate sister chromatids, and we speculate that it might promote proteolysis of proteins that hold sister chromatids together. Proteolysis of CLB2 is initiated in early anaphase, but a fraction of CLB2 remains stable until anaphase is complete.			IRNIGER, S (corresponding author), RES INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nasmyth, Kim/0000-0001-7030-4403; Piatti, Simonetta/0000-0003-1958-8919				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AULT JG, 1994, CURR OPIN CELL BIOL, V6, P41, DOI 10.1016/0955-0674(94)90114-7; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LORCA T, 1992, J CELL SCI, V102, P55; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; Maniatis T., 1982, MOL CLONING; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; ROSE MD, 1990, LABORATORY COURSE MA; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TUGENDREICH S, 1995, CELL, V81; WAN J, 1992, J BIOL CHEM, V267, P11274; XIAO ZX, 1993, MOL CELL BIOL, V13, P4691, DOI 10.1128/MCB.13.8.4691; YANO R, 1994, P NATL ACAD SCI USA, V91, P6880, DOI 10.1073/pnas.91.15.6880	43	377	384	0	9	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					269	278		10.1016/0092-8674(95)90337-2	http://dx.doi.org/10.1016/0092-8674(95)90337-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736579	Bronze			2022-12-28	WOS:A1995QV41000016
J	GARTRY, DS				GARTRY, DS			FORTNIGHTLY REVIEW - TREATING MYOPIA WITH THE EXCIMER-LASER - THE PRESENT POSITION	BRITISH MEDICAL JOURNAL			English	Article							PHOTOREFRACTIVE KERATECTOMY; RADIAL KERATOTOMY; SIGHTED EYES; FOLLOW-UP; TOPICAL CORTICOSTEROIDS; CORNEAL HAZE; MULTICENTER; EXPERIENCE; SURGERY				GARTRY, DS (corresponding author), MOORFIELDS EYE HOSP,CITY RD,LONDON EC1V 2PD,ENGLAND.							BORES LD, 1981, ANN OPHTHALMOL, V13, P941; DUTT S, 1994, ARCH OPHTHALMOL-CHIC, V112, P1427, DOI 10.1001/archopht.1994.01090230041018; EPSTEIN D, 1994, OPHTHALMOLOGY, V101, P1558; FICKER LA, 1993, EYE, V7, P617, DOI 10.1038/eye.1993.143; FYODOROV SN, 1979, ANNOPHTHALMOL, V11, P1185; GARTRY D, 1991, BRIT J OPHTHALMOL, V75, P258, DOI 10.1136/bjo.75.5.258; Gartry D S, 1991, Refract Corneal Surg, V7, P420; GARTRY DS, 1992, ARCH OPHTHALMOL-CHIC, V110, P944, DOI 10.1001/archopht.1992.01080190050028; GARTRY DS, 1993, EYE, V7, P584, DOI 10.1038/eye.1993.127; GARTRY DS, 1992, OPHTHALMOLOGY, V99, P1209; GELENDER H, 1982, AM J OPHTHALMOL, V93, P323, DOI 10.1016/0002-9394(82)90533-5; GELENDER H, 1983, ARCH OPHTHALMOL-CHIC, V101, P1229; KIM JH, 1994, J CATARACT REFR SURG, V20, P229, DOI 10.1016/S0886-3350(13)80758-4; KIM YJ, 1994, J CATARACT REFR SURG, V20, P387, DOI 10.1016/S0886-3350(13)80172-1; LEAHEY AB, 1994, ARCH OPHTHALMOL-CHIC, V112, P1512, DOI 10.1001/archopht.1994.01090240018009; LEIDENIX MJ, 1994, ARCH OPHTHALMOL-CHIC, V112, P1513, DOI 10.1001/archopht.1994.01090240019010; LESJARDINS SL, 1994, J CATARACT REFR SURG, V20, P223; LIPSCHITZ I, 1994, ARCH OPHTHALMOL-CHIC, V112, P1510; Machat J J, 1993, Refract Corneal Surg, V9, pS16; MACRAE S, 1989, AM J OPHTHALMOL, V107, P262, DOI 10.1016/0002-9394(89)90310-3; MAGUEN E, 1994, OPHTHALMOLOGY, V101, P1548; MARSHALL J, 1988, OPHTHALMOLOGY, V95, P1411; MARSHALL J, 1985, OPHTHALMOLOGY, V92, P749; MCDONALD MB, 1991, OPHTHALMOLOGY, V98, P1327; MUNOERLYN CR, 1988, J CATARACT REFR SURG, V14, P46; OBRART DPS, 1994, OPHTHALMOLOGY, V101, P1565; OBRART DPS, 1994, REF CORNEAL SURG, V10, P87; ORSSAUD C, 1994, J REFRACT CORNEAL S, V10, pS199; PIEBENGA LW, 1993, OPHTHALMOLOGY, V100, P1335; RASHID ER, 1989, SURV OPHTHALMOL, V34, P73, DOI 10.1016/0039-6257(89)90037-4; ROGERS CM, 1994, J REFRACT CORNEAL S, V10, pS171; SALZ JJ, 1993, OPHTHALMOLOGY, V100, P873; Sato T, 1939, ACTA SOC OPHTHALMOL, V43, P544; Seiler T, 1990, Refract Corneal Surg, V6, P165; SEILER T, 1991, OPHTHALMOLOGY, V98, P1156; SEILER T, 1994, OPHTHALMOLOGY, V101, P153; SHER NA, 1994, OPHTHALMOLOGY, V101, P1575; SHER NA, 1991, ARCH OPHTHALMOL-CHIC, V109, P1525, DOI 10.1001/archopht.1991.01080110061035; SHER NA, 1992, ARCH OPHTHALMOL-CHIC, V110, P935, DOI 10.1001/archopht.1992.01080190041027; SHER NA, 1993, REFRACT CORNEAL SURG, V9, P425; SHIMIZU K, 1994, J REFRACT CORNEAL S, V10, pS178; SIMMONS KB, 1987, OPHTHALMOLOGY, V94, P148; SORSBY A, 1960, BRIT MED J, V1, P1394, DOI 10.1136/bmj.1.5183.1394; SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011; SRINIVASAN R, 1982, APPL PHYS LETT, V41, P576, DOI 10.1063/1.93601; TAYLOR HR, 1993, ARCH OPHTHALMOL-CHIC, V111, P1621, DOI 10.1001/archopht.1993.01090120043019; TENGROTH B, 1993, OPHTHALMOLOGY, V100, P739; TROKEL SL, 1983, AM J OPHTHALMOL, V96, P710, DOI 10.1016/S0002-9394(14)71911-7; TUFT SJ, 1993, BRIT J OPHTHALMOL, V77, P243, DOI 10.1136/bjo.77.4.243; WARING GO, 1991, OPHTHALMOLOGY, V98, P1164; WARING GO, 1988, J REFRACT SURG, V4, P204; WARING GO, 1992, REFRACTIVE KERATOTOM, P166; 1993, GLANCE GIDE CURRENT, P19	53	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					979	985		10.1136/bmj.310.6985.979	http://dx.doi.org/10.1136/bmj.310.6985.979			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728036	Green Published			2022-12-28	WOS:A1995QT90400024
J	HAYES, TM				HAYES, TM			CONTINUING MEDICAL-EDUCATION - A PERSONAL VIEW	BRITISH MEDICAL JOURNAL			English	Editorial Material								Over many generations doctors have kept up to date in ways which reflect their own learning styles. The current fashion for formalised and policed continuing medical education may prove ineffective unless it is recognised that individual needs must be taken into account. Attendance at formal courses based on lectures and papers may not suit a large proportion of those who attend to acquire the necessary points to satisfy their royal college. The ability to show that health care teams are up to date should come from effective clinical audit, which should also identify local educational needs.			HAYES, TM (corresponding author), UNIV WALES COLL MED,DEPT POSTGRAD MED & DENT EDUC,CARDIFF CF4 4XN,S GLAM,WALES.							DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; KERRISON S, 1994, EVALUATING NHS REFOR, P155; LEWIS CE, 1970, NEW ENGL J MED, V282, P254, DOI 10.1056/NEJM197001292820506; MILLER GE, 1967, J MED EDUC, V42, P320; Rogers EM., 1983, DIFFUSION INNOVATION; 1988, ILLINOIS MED J, V173, P273; 1993, CONTINUING MED ED	7	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					994	996		10.1136/bmj.310.6985.994	http://dx.doi.org/10.1136/bmj.310.6985.994			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728041	Green Published			2022-12-28	WOS:A1995QT90400030
J	MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R				MARSH, K; FORSTER, D; WARUIRU, C; MWANGI, I; WINSTANLEY, M; MARSH, V; NEWTON, C; WINSTANLEY, P; WARN, P; PESHU, N; PASVOL, G; SNOW, R			INDICATORS OF LIFE-THREATENING MALARIA IN AFRICAN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL MALARIA; CLINICAL-FEATURES; FALCIPARUM-MALARIA	Background. About 90 percent of the deaths from malaria are in African children, but criteria to guide the recognition and management of severe malaria have not been validated in them. Methods. We conducted a prospective study of all children admitted to the pediatric ward of a Kenyan district hospital with a primary diagnosis of malaria. We calculated the frequency and mortality rate for each of the clinical and laboratory criteria in the current World Health Organization (WHO) definition of severe malaria, and then used logistic-regression analysis to identify the variables with the greatest prognostic value. Results. We studied 1844 children (mean age, 26.4 months) with a primary diagnosis of malaria, Not included were 18 children who died on arrival and 4 who died of other causes. The mortality rate was 3.5 percent (95 percent confidence interval, 2.7 to 4.3 percent), and 84 percent of the deaths occurred within 24 hours of admission. Logistic-regression analysis identified four key prognostic indicators: impaired consciousness (relative risk, 3.3; 95 percent confidence interval, 1.6 to 7.0), respiratory distress (relative risk, 3.9; 95 percent confidence interval, 2.0 to 7.7), hypoglycemia (relative risk, 3.3; 95 percent confidence interval, 1.6 to 6.7), and jaundice (relative risk, 2.6; 95 percent confidence interval, 1.1 to 6.3). Of the 64 children who died, 54 were among those with impaired consciousness (n = 336; case fatality rate, 11.9 percent) or respiratory distress (n = 251; case fatality rate, 13.9 percent), or both. Hence, this simple bedside index identified 84.4 percent of the fatal cases, as compared with the 79.7 percent identified by the current WHO criteria. Conclusions. In African children with malaria, the presence of impaired consciousness or respiratory distress can identify those at high risk for death.	JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND; JOHN RADCLIFFE HOSP, DEPT PAEDIAT, OXFORD OX3 9DU, ENGLAND	University of Oxford; University of Oxford	MARSH, K (corresponding author), KENYA GOVT MED RES CTR, CLIN RES CTR, KILIFI UNIT, POB 230, KILIFI, KENYA.		Newton, Charles/C-6222-2009; Pasvol, Geoffrey/B-7113-2009; Newton, Charles RJC/B-7578-2014; Snow, Robert William/AFR-1436-2022	Newton, Charles RJC/0000-0002-6999-5507; Snow, Robert William/0000-0003-3725-6088; Marsh, Vicki/0000-0002-5178-4250	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; KRISHNA S, 1994, T ROY SOC TROP MED H, V88, P67, DOI 10.1016/0035-9203(94)90504-5; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MOLYNEUX ME, 1989, J ROY SOC MED, V82, P35; MOLYNEUX ME, 1989, Q J MED, V71, P441; NEWTON CRJC, 1990, LANCET, V335, P472, DOI 10.1016/0140-6736(90)90703-8; NEWTON CRJC, 1991, LANCET, V337, P573, DOI 10.1016/0140-6736(91)91638-B; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; PASVOL G, 1991, AM J TROP MED HYG, V45, P702, DOI 10.4269/ajtmh.1991.45.702; SNOW RW, 1993, T ROY SOC TROP MED H, V87, P386, DOI 10.1016/0035-9203(93)90007-D; TAYLOR TE, 1993, Q J MED, V86, P99; WARRELL DA, 1987, PARASITOLOGY, V94, pS53, DOI 10.1017/S0031182000085826; White N. J., 1986, Clinics in Tropical Medicine and Communicable Diseases, V1, P55; 1993, 1993 WORLD BANK WORL; [No title captured]	15	779	791	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1399	1404		10.1056/NEJM199505253322102	http://dx.doi.org/10.1056/NEJM199505253322102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723795				2022-12-28	WOS:A1995QY94100002
J	FIEDLER, K; SIMONS, K				FIEDLER, K; SIMONS, K			THE ROLE OF N-GLYCANS IN THE SECRETORY PATHWAY	CELL			English	Review							APICAL SECRETION; PROTEIN; GLYCOPROTEINS; MEMBRANE; GOLGI; GLYCOSYLATION; COMPARTMENT; TRANSPORT; MOIETIES; CELLS				FIEDLER, K (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.			Simons, Kai/0000-0002-9231-9996; Fiedler, Klaus/0000-0001-9398-1116				ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; GONZALEZ A, 1993, J BIOL CHEM, V268, P6662; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GREEN RF, 1981, J CELL BIOL, V89, P230, DOI 10.1083/jcb.89.2.230; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; MIQUELIS R, 1993, J CELL BIOL, V123, P1695, DOI 10.1083/jcb.123.6.1695; MORAN P, 1992, J CELL BIOL, V119, P763, DOI 10.1083/jcb.119.4.763; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NEWTON SA, 1987, VERTEBRAE LECTINS, P211; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PLOEGH HL, 1981, J IMMUNOL, V126, P270; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SIMONS K, 1995, IN PRESS HARVEY LECT; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697	30	266	276	0	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					309	312		10.1016/0092-8674(95)90380-1	http://dx.doi.org/10.1016/0092-8674(95)90380-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736583	Bronze			2022-12-28	WOS:A1995QW89400001
J	SCHAFER, WR; KENYON, CJ				SCHAFER, WR; KENYON, CJ			A CALCIUM-CHANNEL HOMOLOG REQUIRED FOR ADAPTATION TO DOPAMINE AND SEROTONIN IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							GENETICS; NEURONS	PROCESSING and storage of information by the nervous system requires the ability to modulate the response of excitable cells to neurotransmitter. A simple process of this type, known as adaptation or desensitization, occurs when prolonged stimulation triggers processes that attenuate the response to neurotransmitter. Here we report that the Caenorhabditis elegans gene unc-2 is required for adaptation to two neurotransmitters, dopamine and serotonin. A loss-of-function mutation in unc-2 resulted in failure to adapt either to paralysis by dopamine or to stimulation of egg laying by serotonin. In addition, unc-2 mutants displayed behaviours similar to those induced by serotonin treatment. We found that unc-2 encodes a homologue of a voltage-sensitive calcium-channel alpha-1 subunit. Expression of unc-2 occurs in two types of neurons implicated in the control of egg laying, a behaviour regulated by serotonin, Unc-2 appears to be required in modulatory neurons to downregulate the response of the egg-laying muscles to serotonin, We propose that adaptation to serotonin occurs through activation of an Unc-2-dependent calcium influx, which modulates the postsynaptic response to serotonin, perhaps by inhibiting the release of a potentiating neuropeptide.			SCHAFER, WR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Schafer, William/0000-0002-6676-8034				AKERIB CC, 1994, GENETICS, V138, P1105; ALBERTSON DG, 1993, GENETICS, V134, P211; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BRENNER S, 1974, GENETICS, V77, P71; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; HERMAN RK, 1984, GENETICS, V108, P165; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; SCHINKMANN K, 1992, J COMP NEUROL, V316, P251, DOI 10.1002/cne.903160209; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SEYDOUX G, IN PRESS METH CELL B; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; YANDELL MD, 1994, P NATL ACAD SCI USA, V91, P1381, DOI 10.1073/pnas.91.4.1381; ZHAO C, 1995, NATURE, V373, P74, DOI 10.1038/373074a0	23	225	237	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					73	78		10.1038/375073a0	http://dx.doi.org/10.1038/375073a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723846				2022-12-28	WOS:A1995QW60400058
J	VONKRIES, R; HACHMEISTER, A; GOBEL, U				VONKRIES, R; HACHMEISTER, A; GOBEL, U			REPEATED ORAL VITAMIN-K PROPHYLAXIS IN WEST-GERMANY - ACCEPTANCE AND EFFICACY	BMJ-BRITISH MEDICAL JOURNAL			English	Article											VONKRIES, R (corresponding author), UNIV DUSSELDORF, KINDERKLIN, D-40225 DUSSELDORF, GERMANY.							GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; Schmidt E, 1993, MONATSSCHR KINDERH, V141, P758; VONKRIES R, 1993, THROMB HAEMOSTASIS, V69, P293; 1993, DTSCH ARZTEBLAN, V90, P53; 1992, VITAMIN K PROPHYLAXI	5	24	24	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	1995	310	6987					1097	1098		10.1136/bmj.310.6987.1097	http://dx.doi.org/10.1136/bmj.310.6987.1097			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742675	Green Published			2022-12-28	WOS:A1995QW61800014
J	FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R				FARROW, SN; WHITE, JHM; MARTINOU, I; RAVEN, T; PUN, KT; GRINHAM, CJ; MARTINOU, JC; BROWN, R			CLONING OF A BCL-2 HOMOLOG BY INTERACTION WITH ADENOVIRUS E1B 19K	NATURE			English	Article							PROGRAMMED CELL-DEATH; HUMAN B-CELLS; APOPTOSIS; PROTEIN; 19-KDA; GENE	NUMBER Of DNA viruses carry apoptosis-inhibiting genes which enable the virus to escape from the host reponse(1-5). The adenovirus E1B 19K protein can inhibit apoptosis induced by E1A, tumour-necrosis factor-alpha, FAS antigen and nerve growth factor deprivation(6-9). The molecular basis of this inhibition remains poorly understood, but the fact that protection is seen in the absence of other viral proteins suggests that E1B 19K targets cellular proteins. We report here the identification of three cellular proteins that bind E1B 19K, One of these is a new member of the bcl-2 family(10-16), which we have called bak (for bcl-2 homologous antagonist/killer). This protein, which is expressed in a wide variety of cell types, binds to E1B 19K and to the Bcl-2 homologue Bcl-x(L) (ref, 17) in yeast, In addition, overexpression of bak in sympathetic neurons deprived of nerve growth factor accelerates apoptosis and blocks the protective effect of co-injected E1B 19K.	GLAXO RES & DEV LTD,DEPT MOLEC VIROL,GREENFORD UB6 0HE,MIDDX,ENGLAND; GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND	GlaxoSmithKline; GlaxoSmithKline				martinou, Jean-claude/0000-0002-9847-2051; Pun, Tao/0000-0001-5241-2187				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HASHIMOTO S, 1991, INT IMMUN, V343, P343; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	27	464	492	2	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					731	733		10.1038/374731a0	http://dx.doi.org/10.1038/374731a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715729				2022-12-28	WOS:A1995QU30400052
J	LU, Q; MILLER, C				LU, Q; MILLER, C			SILVER AS A PROBE OF PORE-FORMING RESIDUES IN A POTASSIUM CHANNEL	SCIENCE			English	Article							K+ CHANNELS; CYSTEINE-SUBSTITUTION; RECEPTOR-SITE; TEA BLOCKADE; AMINO-ACIDS; ION; SELECTIVITY; STOICHIOMETRY; INACTIVATION; PERMEATION	In voltage-dependent potassium channels, the molecular determinants of ion selectivity are found in the P (pore) region, a stretch of 21 contiguous residues. Cysteine was introduced at each P region position in a Shaker potassium channel. Residues projecting side chains into the pore were identified by means of channel inhibition by a sulfhydryl-reactive potassium ion analog, silver ion. The pattern of silver ion reactivity contradicts a beta barrel architecture of potassium channel pores.	BRANDEIS UNIV,HOWARD HUGHES MED INST,WALTHAM,MA 02254; BRANDEIS UNIV,GRAD DEPT BIOCHEM,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute; Brandeis University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031768, R01GM031768] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ANDERSEN OS, COMMUNICATION; BOGUSZ S, 1992, PROTEIN ENG, V5, P295; BOLAND LM, 1994, BIOPHYS J, V66, P694, DOI 10.1016/S0006-3495(94)80843-4; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; DANCE IG, 1986, POLYHEDRON, V5, P1037, DOI 10.1016/S0277-5387(00)84307-7; DEBIASI M, 1993, BIOPHYS J, V65, P1235, DOI 10.1016/S0006-3495(93)81154-8; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEIGENBOTHAM L, 1993, THESIS HARVARD U; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LIESEGANG GW, 1977, J AM CHEM SOC, V99, P3240, DOI 10.1021/ja00452a006; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1993, SCIENCE, V261, P1692, DOI 10.1126/science.8397443; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NYHOLM RS, 1961, P CHEM SOC LONDON, P273; PEROZO E, 1993, NEURON, V11, P353, DOI 10.1016/0896-6273(93)90190-3; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; XU M, 1993, J BIOL CHEM, V268, P21505; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4; YELLEN G, 1984, J GEN PHYSIOL, V84, P157, DOI 10.1085/jgp.84.2.157; ZHULKE RD, 1994, SOC NEUR ABSTR, V20, P864	38	175	177	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					304	307		10.1126/science.7716526	http://dx.doi.org/10.1126/science.7716526			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716526				2022-12-28	WOS:A1995QT18500043
J	ORME, R; NOVOSADEK, A; LEE, JR				ORME, R; NOVOSADEK, A; LEE, JR			ABNORMALITY RATES ON BARIUM MEAL EXAMINATION IN DIFFERENT RACIAL GROUPS	BRITISH MEDICAL JOURNAL			English	Article							ETHNIC-DIFFERENCES		GEN HOSP,DEPT RADIOL,BIRMINGHAM B4 6NH,W MIDLANDS,ENGLAND; DUDLEY RD GEN HOSP,DEPT RADIOL,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND									BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; GILLAM SJ, 1989, BRIT MED J, V299, P953, DOI 10.1136/bmj.299.6705.953; JOHNSON MRD, 1983, POSTGRAD MED J, V59, P664, DOI 10.1136/pgmj.59.696.664; WILLIAMS B, 1988, LANCET, V2, P1349; 1992, COUNTRY MONITORS	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					909	910		10.1136/bmj.310.6984.909	http://dx.doi.org/10.1136/bmj.310.6984.909			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719182	Green Published			2022-12-28	WOS:A1995QR97200023
J	GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H				GLOVER, DM; LEIBOWITZ, MH; MCLEAN, DA; PARRY, H			MUTATIONS IN AURORA PREVENT CENTROSOME SEPARATION LEADING TO THE FORMATION OF MONOPOLAR SPINDLES	CELL			English	Article							MICROTUBULE-ORGANIZING CENTERS; DEPENDENT PROTEIN-KINASE; EARLY DROSOPHILA EMBRYOS; SEA-URCHIN EGGS; CELL-CYCLE; ABNORMAL SPINDLE; DNA-SYNTHESIS; MELANOGASTER; ANAPHASE; MITOSIS	We show that female sterile mutations of aurora (aur) are allelic to mutations in the lethal complementation group ck(10). This lies in a cytogenetic interval, 87A7-A9, that contains eight transcription units. A 250 bp region upstream of both a ur and a divergent transcription unit corresponds to the site of a specific chromatin structure (scs') previously proposed to be a barrier to insulate enhancers of the major hsp70 gene at 87A7. Syncytial embryos derived from aur mothers display closely paired centrosomes at inappropriate mitotic stages and develop interconnected spindles in which the poles are shared. Amorphic alleles result in pupal lethality and in mitotic arrest in which condensed chromosomes are arranged on circular monopolar spindles. The size of the single centrosomal body in these circular figures suggests that lass of function of the serine-threonine protein kinase encoded by aur leads to a failure of the centrosomes to separate and form a bipolar spindle.			GLOVER, DM (corresponding author), UNIV DUNDEE,INST MED SCI,DEPT ANAT & PHYSIOL,CANC RES CAMPAIGN CELL CYCLE GENET GRP,DUNDEE DD1 4HN,SCOTLAND.			Glover, David/0000-0003-0956-0103				BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BAJER AS, 1982, J CELL BIOL, V93, P33, DOI 10.1083/jcb.93.1.33; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAGGESE C, 1979, P NATL ACAD SCI USA, V76, P2385, DOI 10.1073/pnas.76.5.2385; CALLAINI G, 1990, J CELL SCI, V97, P539; CASSIMERIS L, 1994, J CELL SCI, V107, P285; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; FRASCH M, 1986, J CELL SCI, V82, P155; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GATTI M, 1989, GENE DEV, V3, P438, DOI 10.1101/gad.3.4.438; GAUSZ J, 1981, GENETICS, V98, P775; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GONZALEZ C, 1990, J CELL SCI, V96, P605; GONZALEZ C, 1988, J CELL SCI, V89, P39; GONZALEZ C, 1993, CELL CYCLE PRACTICAL, P163; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HECK MMS, 1993, J CELL BIOL, V123, P665, DOI 10.1083/jcb.123.3.665; HUETTNER ALFRED F., 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P119, DOI 10.1007/BF00587553; ISHHOROWICZ D, 1980, J MOL BIOL, V142, P231, DOI 10.1016/0022-2836(80)90047-9; ISHHOROWICZ D, 1979, CELL, V17, P565, DOI 10.1016/0092-8674(79)90264-2; KARR TL, 1986, J CELL BIOL, V102, P1494, DOI 10.1083/jcb.102.4.1494; KELLOGG DR, 1992, MOL BIOL CELL, V3, P1, DOI 10.1091/mbc.3.1.1; KERYER G, 1990, J CELL SCI, V97, P553; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LEWIN B, 1994, GENES, V5; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; NAGANO H, 1981, DEV BIOL, V85, P409, DOI 10.1016/0012-1606(81)90272-4; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; RIPOLL P, 1985, CELL, V41, P907, DOI 10.1016/S0092-8674(85)80071-4; ROBERTSON HM, 1988, GENETICS, V118, P461; SLUDER G, 1990, J CELL BIOL, V110, P2025, DOI 10.1083/jcb.110.6.2025; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P897, DOI 10.1083/jcb.100.3.897; SLUDER G, 1986, BIOL BULL, V170, P538; SPIERER P, 1983, J MOL BIOL, V168, P35, DOI 10.1016/S0022-2836(83)80321-0; SULLIVAN W, 1990, DEVELOPMENT, V110, P331; SUNKEL CE, 1988, J CELL SCI, V89, P25; SZABAD J, 1982, DEV BIOL, V93, P240, DOI 10.1016/0012-1606(82)90256-1; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VESSEY KB, 1991, J CELL SCI, V98, P233; WANG RJ, 1983, J CELL BIOL, V96, P301, DOI 10.1083/jcb.96.1.301; WARN RM, 1985, EXP CELL RES, V163, P201; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; WHITFIELD WGF, 1988, J CELL SCI, V89, P467	58	670	685	1	30	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					95	105		10.1016/0092-8674(95)90374-7	http://dx.doi.org/10.1016/0092-8674(95)90374-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720077	Bronze			2022-12-28	WOS:A1995QR97000011
J	NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ				NOMURA, A; STEMMERMANN, GN; CHYOU, PH; PEREZPEREZ, GI; BLASER, MJ			HELICOBACTER-PYLORI INFECTION AND THE RISK FOR DUODENAL AND GASTRIC-ULCERATION	ANNALS OF INTERNAL MEDICINE			English	Article						HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; DUODENAL ULCER; PEPTIC ULCER	CAMPYLOBACTER-PYLORI; GASTRODUODENAL DISEASE; SURFACE-PROTEINS; PATHOGENESIS; ERADICATION; RECURRENCE; HAWAII; INFLAMMATION; CARCINOMA; ULCERS	Objective: To determine whether a preexisting Helicobacter pylori infection increases the risk for developing duodenal or gastric ulcer. Design: A nested case-control study based on a cohort of 5443 Japanese-American men who had a physical examination and a phlebotomy from 1967 to 1970. Setting: All 10 general hospitals on the Hawaiian island of Oahu. Patients: 150 patients with gastric ulcer and 65 patients with duodenal ulcer identified in the cohort of study participants after a hospital surveillance period of more than 20 years. Measurements: Stored serum specimens from patients and from matched controls were tested for the presence of serum IgG antibody to H. pylori using enzyme-linked immunosorbent assay. st Results: 93% of the 150 patients with gastric ulcer and 78% of the matched controls had a positive antibody level for H. pylori-specific IgG, yielding an odds ratio of 3.2 (95% Cl, 1.6 to 6.5). For duodenal ulcer, 92% of the 65 patients and 78% of the matched controls had a positive test result, yielding an odds ratio of 4.0 (Cl, 1.1 to 14.2). As the level of antibody to H. pylori increased, a statistically significant increase was noted in the risk for gastric and duodenal ulcer. The association with H. pylori infection was statistically significant for both types of ulcer, even when the diagnosis was made 10 or more years after the serum sample had been obtained. Conclusion: Preexisting H. pylori infection increases the risk for subsequent development of either duodenal or gastric ulcer disease.	UNIV CINCINNATI, SCH MED, DEPT PATHOL, CINCINNATI, OH 45267 USA; VANDERBILT UNIV, MED CTR, SCH MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA	University System of Ohio; University of Cincinnati; Vanderbilt University	NOMURA, A (corresponding author), KUAKINI MED CTR, JAPAN HAWAII CANC STUDY, 347 N KUAKINI ST, HONOLULU, HI 96817 USA.			Perez Perez, Guillermo/0000-0002-0131-5798	NCI NIH HHS [R01 CA 33644] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033644] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLASER MJ, 1992, GASTROENTEROLOGY, V102, P720, DOI 10.1016/0016-5085(92)90126-J; BLASER MJ, 1991, REV INFECT DIS, V13, pS704; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BRESLOW NE, 1980, IARC SCI PUBL, V32, P164; COGHLAN JG, 1987, LANCET, V2, P1109; COVER TL, 1992, J BIOL CHEM, V267, P10570; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DRUMM B, 1990, NEW ENGL J MED, V322, P359, DOI 10.1056/NEJM199002083220603; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; GLASSMAN MS, 1990, DIGEST DIS SCI, V35, P993, DOI 10.1007/BF01537248; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1653, DOI 10.1016/0016-5085(91)90665-8; GRAHAM DY, 1992, ANN INTERN MED, V116, P705, DOI 10.7326/0003-4819-116-9-705; Harrell F., 1983, SUGI SUPPLEMENTAL LI, P267; HENTSCHEL E, 1993, NEW ENGL J MED, V328, P308, DOI 10.1056/NEJM199302043280503; IMAI K, 1991, HELICOBACTER PYLORI, V3, P26; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MACMAHON B, 1970, EPIDEMIOLOGY PRINCIP, P207; MAI UEH, 1991, J CLIN INVEST, V87, P894, DOI 10.1172/JCI115095; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1988, LANCET, V2, P1437; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; PETERSON WL, 1991, NEW ENGL J MED, V324, P1043, DOI 10.1056/NEJM199104113241507; RABENECK L, 1991, AM J MED, V91, P566; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SIPPONEN P, 1989, GUT, V30, P922, DOI 10.1136/gut.30.7.922; SIPPONEN P, 1990, SCAND J GASTROENTERO, V25, P966, DOI 10.3109/00365529008997621; STEER HW, 1984, GUT, V25, P1203, DOI 10.1136/gut.25.11.1203; STEMMERMANN GN, 1968, JNCI-J NATL CANCER I, V41, P627; STRAUSS RM, 1990, AM J MED, V89, P464, DOI 10.1016/0002-9343(90)90377-P; TAYLOR DN, 1991, EPIDEMIOL REV, V13, P42, DOI 10.1093/oxfordjournals.epirev.a036078; WORMSLEY KG, 1989, SCAND J GASTROENTERO, V24, P53, DOI 10.3109/00365528909091736; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841	38	289	298	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1994	120	12					977	981		10.7326/0003-4819-120-12-199406150-00001	http://dx.doi.org/10.7326/0003-4819-120-12-199406150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ964	7741826				2022-12-28	WOS:A1994NQ96400001
J	DUFFY, TP				DUFFY, TP			COSTLY ERRORS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DUFFY, TP (corresponding author), YALE UNIV,SCH MED,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							DACIE JV, 1985, HAEMOLYTIC ANAEMIAS, V3; NYDEGGER UE, 1991, SEMIN HEMATOL, V28, P66	2	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1503	1505		10.1056/NEJM199506013322209	http://dx.doi.org/10.1056/NEJM199506013322209			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739689				2022-12-28	WOS:A1995RA14000009
J	SMITH, LG; NAQVI, T				SMITH, LG; NAQVI, T			TENSION PNEUMOPERICARDIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									SUNY STONY BROOK,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	SMITH, LG (corresponding author), MT SINAI MED CTR,NEW YORK,NY 10029, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1481	1481		10.1056/NEJM199506013322205	http://dx.doi.org/10.1056/NEJM199506013322205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739685				2022-12-28	WOS:A1995RA14000005
J	WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L				WONG, F; SNIDERMAN, K; LIU, P; ALLIDINA, Y; SHERMAN, M; BLENDIS, L			TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT - EFFECTS ON HEMODYNAMICS AND SODIUM HOMEOSTASIS IN CIRRHOSIS AND REFRACTORY ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODYNAMICS; SODIUM; ASCITES; LIVER CIRRHOSIS; PORTOSYSTEMIC SHUNT, SURGICAL	PORTAL-HYPERTENSION; ELECTROCHEMICAL DETECTION; SYSTEMIC HEMODYNAMICS; RENAL SODIUM; NITRIC-OXIDE; TIPS; PLASMA; CATECHOLAMINES; RETENTION; RENIN	Objective: To assess the effects of transjugular intrahepatic portosystemic shunt (TIPS) on systemic and renal hemodynamics, neurohumoral factors, and sodium homeostasis in patients with cirrhosis and refractory ascites. Design: Prospective study with 1-year follow-up. Setting: Tertiary referral center and university-affiliated hospital. Patients: 7 patients with cirrhosis and refractory ascites had metabolic studies done while receiving a 22 mmol/d sodium, 1 L/d fluid diet. Intervention: TIPS insertion. Measurements: Urinary sodium excretion, systemic and renal hemodynamics, hormonal profile, and central blood volume were measured before, at day 1 after, and at 1 month after TIPS insertion. Results: Immediately after TIPS insertion, mean corrected sinusoid pressure decreased from 18.2 +/- 2.2 mm Hg to 7.7 +/- 1.3 mm Hg (P < 0.001); mean cardiac output increased from 6.83 +/- 0.68 L/min to 8.62 L/min (P = 0.005); and mean systemic Vascular resistance decreased from 1018 +/- 103 dyne.s.cm(-5) to 762 +/- 46 dyne.s.cm(-5) (P = 0.011). Mean plasma renin activity, serum aldosterone levels, and 24-hour urinary sodium excretion (5.8 +/- 0.7 mmol/d before TIPS insertion compared with 6.0 a 1.8 mmol/d 1 day after insertion) were unchanged; mean elevated plasma norepinephrine levels significantly increased. By 1 month after insertion, mean proximal tubular reabsorption of sodium had decreased, and this had led to a mean natriuresis of 15.1 +/- 3.1 mmol/d (P = 0.02 compared with baseline), which was associated with a decrease in plasma renin activity and aldosterone levels to within the normal range. Conclusions: Our results suggest that natriuresis associated with TIPS is delayed and occurs in the presence of increased systemic vasodilatation at 1 month after insertion and that TIPS insertion should not be done in any patients with refractory ascites without careful attention to cardiac and renal status. However, in carefully selected patients, TIPS is a safe and effective means of managing refractory ascites.	TORONTO HOSP, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto								AZOULAY D, 1994, HEPATOLOGY, V19, P129, DOI 10.1016/0270-9139(94)90063-9; BOER WH, 1987, EUR J CLIN INVEST, V17, P442, DOI 10.1111/j.1365-2362.1987.tb01140.x; BOSCH J, 1980, GASTROENTEROLOGY, V78, P92; BRUN C, 1951, J LAB CLIN MED, V37, P955; BURCHELL AR, 1968, ANN SURG, V168, P655, DOI 10.1097/00000658-196810000-00012; CAMPBELL V, 1982, HEPATOLOGY, V2, P54; CHENG KH, 1994, EUR J GASTROEN HEPAT, V6, P749, DOI 10.1097/00042737-199408000-00020; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1016/0270-9139(93)90205-2; ERIKSSON BM, 1982, J CHROMATOGR, V228, P143, DOI 10.1016/S0378-4347(00)80427-2; FERRAL H, 1993, RADIOLOGY, V189, P795, DOI 10.1148/radiology.189.3.8234706; GOODMAN JM, 1992, CAN J CARDIOL, V8, P363; GORDON FD, 1994, GASTROENTEROLOGY, V106, pA900; HUONKER M, 1993, HEPATOLOGY, V18, pA281, DOI 10.1016/0270-9139(93)92647-I; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LANG F, 1991, HEPATOLOGY, V14, P590, DOI 10.1016/0270-9139(91)90043-U; LEVY M, 1987, AM J PHYSIOL, V253, pF664, DOI 10.1152/ajprenal.1987.253.4.F664; LOTTERER E, 1993, HEPATOLOGY, V18, pA102, DOI 10.1016/0270-9139(93)91938-O; MORALI GA, 1992, J HEPATOL, V16, P249, DOI 10.1016/S0168-8278(05)80128-X; PAK JM, 1994, J HEPATOL, V20, P825, DOI 10.1016/S0168-8278(05)80156-4; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; POMIERLAYRARGUE G, 1993, HEPATOLOGY, V18, pA103; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RECTOR WG, 1990, HEPATOLOGY, V12, P455, DOI 10.1002/hep.1840120302; RECTOR WG, 1986, LIVER, V6, P221; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SCHRIER RW, 1988, HEPATOLOGY, V8, P1151, DOI 10.1002/hep.1840080532; SCHROEDER ET, 1979, KIDNEY INT, V15, P54, DOI 10.1038/ki.1979.8; THOMAS SH, 1991, DIGEST DIS SCI, V36, P1243, DOI 10.1007/BF01307516; THOMSEN K, 1969, PFLUG ARCH EUR J PHY, V308, P180, DOI 10.1007/BF00587025; TOBE SW, 1993, AM J KIDNEY DIS, V21, P472, DOI 10.1016/S0272-6386(12)80392-1; TOMINAGA T, 1988, LIFE SCI, V42, P1861, DOI 10.1016/0024-3205(88)90025-2; TONG L, 1993, GASTROENTEROLOGY, V104, pA1009; WALSER M, 1955, J CLIN INVEST, V34, P1520, DOI 10.1172/JCI103204; WEICKER H, 1984, CLIN CHIM ACTA, V141, P17, DOI 10.1016/0009-8981(84)90162-1; WENSING G, 1990, HEPATOLOGY, V12, P13, DOI 10.1002/hep.1840120104; WONG F, 1993, HEPATOLOGY, V18, P519, DOI 10.1002/hep.1840180308; WONG F, 1994, HEPATOLOGY, V20, P873, DOI 10.1002/hep.1840200415; WONG F, 1995, HEPATOLOGY, V21, P717; WONG F, 1994, HEPATOLOGY, V19, P312	41	181	184	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					816	822		10.7326/0003-4819-122-11-199506010-00002	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741365				2022-12-28	WOS:A1995RA13900002
J	TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK				TRACEY, I; SCOTT, RB; THOMPSON, CH; DUNN, JF; BARNES, PRJ; STYLES, P; KEMP, GJ; RAE, CD; PIKE, M; RADDA, GK			BRAIN ABNORMALITIES IN DUCHENNE MUSCULAR-DYSTROPHY - P-31 MAGNETIC-RESONANCE SPECTROSCOPY AND NEUROPSYCHOLOGICAL STUDY	LANCET			English	Article							MUSCLE; IMPAIRMENT; METABOLISM; SKELETAL; NEURONS; CELLS	Duchenne muscular dystrophy (DMD) is one of a range of muscular dystrophies caused by abnormalities of the short arm of the X chromosome (Xp21), which often cause mental retardation in addition to progressive muscular weakness. Normal dystrophin expression is lacking in both skeletal muscle and brain of affected subjects. Phosphorus-Si magnetic resonance spectroscopy has shown several abnormalities in skeletal muscle in DMD. We looked for similar abnormalities in brain in patients with DMD and related the findings to neuropsychological test results. We studied by magnetic resonance spectroscopy 19 boys (aged 76-167 months) diagnosed as having DMD and 19 control boys of similar age (87-135 months). intelligence quotient (IQ) was assessed with the Wechsler Intelligence Scale for children. The DMD patients had significantly higher values than the controls in the brain ratios of inorganic phosphate to adenosine triphosphate (mean 0.53 [SD 0.21] vs 0.36 [0.09], p=0.003), to phosphomonoesters (0.40 [0.07] vs 0.29 [0.07], p=0.0001), and to phosphocreatine (0.44 [0.10] vs 0.37 [0.08], p=0.02). There were significant differences between the DMD patients and the controls in full-scale IQ (76 [16] vs 101 [16], p=0.0001), performance IQ (78 [17] vs 94 [14], p=0.003), and verbal IQ (78 [17] vs 106 [17], p=0.0001). These altered metabolite ratios parallel the findings in dystrophic muscle and suggest bioenergetic similarities in tissues that lack dystrophin.	OXFORD RADCLIFFE HOSP,MRC,BIOCHEM & CLIN MAGNET RESONANCE UNIT,OXFORD OX3 9DU,ENGLAND; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; RADCLIFFE INFIRM NHS TRUST,DEPT NEUROSURG,RUSSELL CAIRNS UNIT,OXFORD,ENGLAND; JOHN RADCLIFFE HOSP,DEPT PAEDIAT,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford; Radcliffe Infirmary; University of Oxford			Thompson, Campbell/E-2885-2010; Kemp, Graham J/A-7540-2008; Rae, Caroline/B-7537-2008	Thompson, Campbell/0000-0002-5164-3327; Kemp, Graham J/0000-0002-8324-9666; Rae, Caroline/0000-0003-0673-8084; Tracey, Irene/0000-0003-4134-6115	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALQUDAH AA, 1990, PEDIATR NEUROL, V6, P57, DOI 10.1016/0887-8994(90)90081-B; ARCHIBALD K C, 1959, Arch Phys Med Rehabil, V40, P150; BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61; BATTOCLETTI JH, 1979, MED BIOL ENG COMPUT, V17, P183, DOI 10.1007/BF02440927; Blake Derek J., 1994, Trends in Cell Biology, V4, P19, DOI 10.1016/0962-8924(94)90034-5; BULLFIELD G, 1984, P NATL ACAD SCI USA, V81, P1189; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; DUBOWITZ V, 1969, BRAIN, V92, P805, DOI 10.1093/brain/92.4.805; DUNN JF, 1993, P ROY SOC B-BIOL SCI, V251, P201, DOI 10.1098/rspb.1993.0030; DUNN JF, 1991, BIOCHIM BIOPHYS ACTA, V1096, P115, DOI 10.1016/0925-4439(91)90048-E; DUNN JF, 1991, J NEUROL SCI, V103, P226, DOI 10.1016/0022-510X(91)90168-7; DUNN JF, 1993, J NEUROL SCI, V114, P76, DOI 10.1016/0022-510X(93)90052-Z; ERVASTI JM, 1992, CELL, V66, P1121; HODGSON SV, 1992, NEUROMUSCULAR DISORD, V2, P269, DOI 10.1016/0960-8966(92)90059-F; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; HOPF FW, 1992, BRAIN RES, V578, P49; JAGADHA V, 1988, PEDIATR NEUROL, V4, P87, DOI 10.1016/0887-8994(88)90047-1; KARAGAN NJ, 1979, PSYCHOL BULL, V86, P250; KEMP GJ, 1993, J NEUROL SCI, V116, P201, DOI 10.1016/0022-510X(93)90326-T; KIM TW, 1992, P NATL ACAD SCI USA, V89, P11642, DOI 10.1073/pnas.89.23.11642; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MONACO AP, 1985, NATURE, V318, P842; Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960-8966(91)90059-2; ROSMAN NP, 1970, NEUROLOGY, V20, P324; SANCHEZ V, 1988, BIOPHYS J, V53, P438; SOLLEE ND, 1985, J CLIN EXP NEUROPSYC, V7, P486, DOI 10.1080/01688638508401280; TRACEY I, 1992, 11TH P ANN M SOC MAG, V2, P2125; WHELAN TB, 1987, DEV MED CHILD NEUROL, V29, P212; YOSHIOKA M, 1980, ARCH DIS CHILD, V55, P589, DOI 10.1136/adc.55.8.589	30	47	49	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1260	1264		10.1016/S0140-6736(95)90923-0	http://dx.doi.org/10.1016/S0140-6736(95)90923-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746055				2022-12-28	WOS:A1995QY93300007
J	LANG, RM; MARCUS, RH				LANG, RM; MARCUS, RH			OSTIUM-SECUNDUM ATRIAL SEPTAL-DEFECT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LANG, RM (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1337	1337		10.1056/NEJM199505183322005	http://dx.doi.org/10.1056/NEJM199505183322005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715643				2022-12-28	WOS:A1995QX85700005
J	PEI, DQ; WEISS, SJ				PEI, DQ; WEISS, SJ			FURIN-DEPENDENT INTRACELLULAR ACTIVATION OF THE HUMAN STROMELYSIN-3 ZYMOGEN	NATURE			English	Article							SECRETORY PATHWAY; METALLOPROTEINASES; PRECURSOR; CLEAVAGE; CELLS; ENDOPROTEASE; INHIBITION; PROTEIN; FUSION; GENE	HUMAN stromelysin-3, a new member of the matrix metalloproteinase family, is expressed in tissues undergoing the active remodelling associated with embryonic development, wound healing and tumour invasion(1-3). But like all other members of the matrix metalloproteinase gene family, stromelysin3 is synthesized as an inactive precursor that must be processed to its mature form in order to express enzymic activity(4,5). Here we identify stromelysin-3 as the first matrix metalloproteinase to be discovered that can be processed directly to its enzymically active form by an obligate intracellular proteolytic event that occurs within the constitutive secretory pathway. Intracellular activation is regulated by an unusual 10-amino-acid insert sandwiched between the pro- and catalytic-domains of stromelysin-3, which is encrypted with an Arg-X-Arg-X-Lys-Arg recognition motif for the Golgi-associated proteinase, furin, a mammalian homologue of the yeast Kex2 pheromone convertase(6,7). A furin-stromelysin-3 processing axis not only differentiates the regulation of this enzyme from all previously characterized matrix metalloproteinases, but also identifies pro-protein convertases as potential targets for therapeutic intervention in matrix-destructive disease states.	UNIV MICHIGAN,CTR COMPREHENS CANC,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Ausubel FM, 1994, CURR PROT MOL BIOL; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEN S, 1981, J BIOL CHEM, V256, P1816; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; DAVIES B, 1993, CANCER RES, V53, P2087; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1994, J BIOL CHEM, V269, P25849; REHEMTULLA A, 1992, BLOOD, V79, P2349; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TSUNEOKA M, 1993, J BIOL CHEM, V268, P26461; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; WATANABE T, 1993, FEBS LETT, V320, P215, DOI 10.1016/0014-5793(93)80589-M; WATANABE T, 1991, J BIOL CHEM, V267, P8270; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	27	518	534	1	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					244	247		10.1038/375244a0	http://dx.doi.org/10.1038/375244a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746327	Green Submitted			2022-12-28	WOS:A1995QY88100066
J	REUBEN, DB; BOROK, GM; WOLDETSADIK, G; ERSHOFF, DH; FISHMAN, LK; AMBROSINI, VL; LIU, YB; RUBENSTEIN, LZ; BECK, JC				REUBEN, DB; BOROK, GM; WOLDETSADIK, G; ERSHOFF, DH; FISHMAN, LK; AMBROSINI, VL; LIU, YB; RUBENSTEIN, LZ; BECK, JC			A RANDOMIZED TRIAL OF COMPREHENSIVE GERIATRIC ASSESSMENT IN THE CARE OF HOSPITALIZED-PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSULTATION TEAM; RECOMMENDATIONS; RELIABILITY; PREDICTORS; MORTALITY; CRITERIA; VALIDITY	Background. Although many studies describe benefits from the comprehensive assessment of elderly patients by an interdisciplinary team (comprehensive geriatric assessment), the most supportive evidence for the process has come from programs that rely on specialized inpatient units and long hospital stays. We examined whether an inpatient geriatric consultation service might also be beneficial in a trial involving four medical centers of a group-practice health maintenance organization (HMO). Methods. We conducted a randomized clinical trial with 2353 hospitalized patients 65 years of age or older in whom at least 1 of 13 screening criteria were present: stroke, immobility, impairment in any basic activity of daily living, malnutrition, incontinence, confusion or dementia, prolonged bed rest, recent falls, depression, social or family problems, an unplanned readmission to the hospital within three months of a previous hospital stay, a new fracture, and age of 80 years or older. Of the 1337 patients assigned to the experimental group, 1261 (94 percent) received a comprehensive geriatric assessment in the form of a consultation, with limited fellow-up; the 1016 patients assigned to the control group received usual care. The functional and health status of the patients was measured at base line and 3 and 12 months later; survival was assessed at 12 months. Subgroups df patients who might be presumed to benefit from comprehensive assessment were also studied. Results. The survival rate at 12 months was 74 percent in the experimental group and 75 percent in the control group. At base line, 3 months, and 12 months the scores of the two groups on measures of functional and health status were similar. The analysis of 16 subgroups did not identify any with either clearly improved functional status or improved survival. Conclusions. In this HMO, comprehensive geriatric assessment by a consultation team, with limited follow-up, did not improve the hearth or survival of hospitalized patients selected on the basis of screening criteria.	SO CALIF KAISER PERMANENTE,MED CARE PROGRAM,LOS ANGELES,CA	Kaiser Permanente	REUBEN, DB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,MULTICAMPUS PROGRAM GERIATR MED & GERONTOL,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.			Rubenstein, Laurence/0000-0001-5910-0266	NATIONAL INSTITUTE ON AGING [P60AG010415] Funding Source: NIH RePORTER; NIA NIH HHS [AG10415-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLEN CM, 1986, JAMA-J AM MED ASSOC, V255, P2617, DOI 10.1001/jama.255.19.2617; BOROK GM, 1994, J AM GERIATR SOC, V42, P536, DOI 10.1111/j.1532-5415.1994.tb04977.x; Burns R., 1993, Journal of the American Geriatrics Society, V41, pSA1; COHEN HJ, 1992, J AM GERIATR SOC, V40, P1231, DOI 10.1111/j.1532-5415.1992.tb03648.x; COLE MG, 1994, CAN MED ASSOC J, V151, P965; FRETWELL MD, 1990, J AM GERIATR SOC, V38, P1073, DOI 10.1111/j.1532-5415.1990.tb01368.x; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; GAYTON D, 1987, J AM GERIATR SOC, V35, P726, DOI 10.1111/j.1532-5415.1987.tb06350.x; HOGAN DB, 1987, CAN MED ASSOC J, V136, P713; HOGAN DB, 1990, AGE AGEING, V19, P107, DOI 10.1093/ageing/19.2.107; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JETTE AM, 1986, J GEN INTERN MED, V1, P427; KATON W, 1994, PSYCHOSOMATICS, V35, P268, DOI 10.1016/S0033-3182(94)71775-8; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; LEVENSON JL, 1992, AM J PSYCHIAT, V149, P631; PALSBO SE, 1993, HMO IND PROFILE 1993; REED RL, 1990, J FAM PRACTICE, V31, P389; Reuben D. B., 1993, Journal of the American Geriatrics Society, V41, pSA57; REUBEN DB, 1994, J GERONTOL, V49, pM209, DOI 10.1093/geronj/49.5.M209; REUBEN DB, 1992, J AM GERIATR SOC, V40, P482, DOI 10.1111/j.1532-5415.1992.tb02016.x; Silverman H A, 1990, Health Care Financ Rev, V12, P113; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; THOMAS DR, 1993, J AM GERIATR SOC, V41, P101, DOI 10.1111/j.1532-5415.1993.tb02040.x; WINOGRAD C H, 1991, Journal of the American Geriatrics Society, V39, p25S; WINOGRAD CH, 1993, ARCH INTERN MED, V153, P2017, DOI 10.1001/archinte.153.17.2017; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P778, DOI 10.1111/j.1532-5415.1991.tb02700.x; 1992, DISEASE STAGING PRED	28	176	179	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1345	1350		10.1056/NEJM199505183322007	http://dx.doi.org/10.1056/NEJM199505183322007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX857	7715645	Bronze			2022-12-28	WOS:A1995QX85700007
J	GELLERT, GA				GELLERT, GA			THE INFLUENCE OF MARKET ECONOMICS ON PRIMARY HEALTH-CARE IN VIETNAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									PROJECT HOPE, HO CHI MINH CITY, VIETNAM		GELLERT, GA (corresponding author), PROJECT HOPE, CTR HLTH SCI EDUC, HO CHI MINH CITY, VIETNAM.							BINH NV, 1993, PRIMARY HLTH CARE VI; CHEN L, 1993, HARVARD EXPLORATORY; CU ND, 1993, PRIMARY HLTH CARE VI; GRANT JP, 1987, 1ST INT C TROP PED B; GRIFFIN CC, 1990, ASIA REGIONAL SERIES; NORRIS J, 1995, PHU MY HUNG INT MED; 1993, VIET NAM TRANSITION; 1993, PRIMARY HLTH CARE VI; 1993, 1992 HLTH SERV HO CH; 1993, IMPROVE ARI CASE MAN; 1994, REPORT BUREAU HLTH S; 1995, 13442 WORLD BANK COU	12	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1498	1502						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739075				2022-12-28	WOS:A1995QX41800031
J	ALSTER, TS; WILLIAMS, CM				ALSTER, TS; WILLIAMS, CM			TREATMENT OF KELOID STERNOTOMY SCARS WITH 585 NM FLASHLAMP-PUMPED PULSED-DYE LASER	LANCET			English	Article							577 NM; EXCISION; STAINS	Despite increasing knowledge of wound healing and collagen metabolism, hypertrophic scars and keloid scars are difficult to eradicate. Median sternotomy scars are often hypertrophic or keloidal. We treated them with a 585 nm flashlamp-pumped pulsed-dye laser, which selectively injures cutaneous microvessels without inducing scars. 16 adult patients with hypertrophic or keloidal median sternotomy scars after heart surgery received two treatments to one half of their previously untreated scars every 6-8 weeks and were reviewed at 6 months. Symptoms and clinical, histological, photographic, and surface texture assessments were obtained for treated and untreated areas of scar and evaluated independently by two observers blind to the treatment and by digital image analysis of skin surface casts. There was a significant improvement in erythema, scar height, skin surface texture, and pruritis in laser-treated scar areas; this improvement persisted for at least 6 months.	GEORGE WASHINGTON UNIV,MED CTR,DEPT DERMATOL,WASHINGTON,DC 20037; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20037; GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,WASHINGTON,DC 20007	George Washington University; Georgetown University; Georgetown University								ALSTER TS, 1994, ANN PLAS SURG, V32, P478, DOI 10.1097/00000637-199405000-00007; ALSTER TS, 1994, ANN PLAS SURG, V32, P186, DOI 10.1097/00000637-199402000-00015; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; APFELBERG DB, 1989, LASER SURG MED, V9, P382, DOI 10.1002/lsm.1900090411; COSMAN B, 1961, PLAST RECONSTR SURG, V27, P335, DOI 10.1097/00006534-196104000-00001; DIFFEY BL, 1984, BRIT J DERMATOL, V111, P993; GROVE GL, 1989, J AM ACAD DERMATOL, V21, P631, DOI 10.1016/S0190-9622(89)70230-9; GROVE GL, 1981, BIOENGINEERING SKIN, P1783; NAKAGAWA H, 1985, J INVEST DERMATOL, V84, P396, DOI 10.1111/1523-1747.ep12265478; NORRIS JEC, 1991, PLAST RECONSTR SURG, V87, P44, DOI 10.1097/00006534-199101000-00008; STERN JC, 1989, ARCH OTOLARYNGOL, V115, P1107; SULLIVAN T, 1990, Journal of Burn Care and Rehabilitation, V11, P256, DOI 10.1097/00004630-199005000-00014; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; TAN OT, 1988, J INVEST DERMATOL, V90, P395, DOI 10.1111/1523-1747.ep12456478; TONG AKF, 1987, J INVEST DERMATOL, V88, P747, DOI 10.1111/1523-1747.ep12470418; TOPOL BM, 1981, PLAST RECONSTR SURG, V68, P231	16	273	282	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1198	1200		10.1016/S0140-6736(95)91989-9	http://dx.doi.org/10.1016/S0140-6736(95)91989-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739306	hybrid			2022-12-28	WOS:A1995QX86100007
J	ROBERTSON, MP; MILLER, SL				ROBERTSON, MP; MILLER, SL			PREBIOTIC SYNTHESIS OF 5-SUBSTITUTED URACILS - A BRIDGE BETWEEN THE RNA WORLD AND THE DNA-PROTEIN WORLD	SCIENCE			English	Article							EARTHS PRIMITIVE ATMOSPHERE; ORIGIN; FORMALDEHYDE; EVOLUTION; CARBON; MODEL; WATER; CH4; CO2	Under prebiotic conditions, formaldehyde adds to uracil at the C-5 position to produce 5-hydroxymethyluracil with favorable rates and equilibria. Hydroxymethyluracil adds a variety of nucleophiles, such as ammonia, glycine, guanidine, hydrogen sulfide, hydrogen cyanide, imidazole, indole, and phenol, to give 5-substituted uracils with the side chains of most of the 20 amino acids in proteins. These reactions are sufficiently robust that, if uracil had been present on the primitive Earth, then these substituted uracils would also have been present. The ribozymes of the RNA world would have included many of the functional groups found in proteins today, and their catalytic activities may have been considerably greater than presently assumed.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARNUN A, 1983, J GEOPHYS RES-OCEANS, V88, P6662, DOI 10.1029/JC088iC11p06662; BARNUN A, 1978, ORIGINS LIFE EVOL B, V9, P93, DOI 10.1007/BF00931407; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DEISTER U, 1990, BER BUNSEN PHYS CHEM, V94, P594, DOI 10.1002/bbpc.19900940512; FERRIS JP, 1966, J AM CHEM SOC, V88, P1074, DOI 10.1021/ja00957a050; FERRIS JP, 1979, J ORG CHEM, V44, P1273, DOI 10.1021/jo01322a019; FERRIS JP, 1975, J AM CHEM SOC, V97, P2962, DOI 10.1021/ja00844a007; FRIEDMANN N, 1971, CHEM EVOLUTION ORIGI, P123; GIBSON HW, 1969, CHEM REV, V69, P673, DOI 10.1021/cr60261a005; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; MILLER SL, 1984, ORIGINS LIFE EVOL B, V14, P83, DOI 10.1007/BF00933643; MOORE ML, 1949, ORG REACTIONS, V5, P301; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORO J, 1984, ORIGINS LIFE EVOL B, V14, P237, DOI 10.1007/BF00933663; PINTO JP, 1980, SCIENCE, V210, P183, DOI 10.1126/science.210.4466.183; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROBERTSON MP, UNPUB; SANCHEZ RA, 1967, J MOL BIOL, V30, P223; SCHLESINGER G, 1983, J MOL EVOL, V19, P383, DOI 10.1007/BF02101643; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WEBER AL, 1981, J MOL EVOL, V17, P273, DOI 10.1007/BF01795749; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C, 1967, GENETIC CODE, P179; WONG JTF, 1991, ORIGINS LIFE EVOL B, V21, P165, DOI 10.1007/BF01809445; YANAGAWA H, 1992, J BIOL CHEM, V267, P13320; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	30	72	73	0	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					702	705		10.1126/science.7732378	http://dx.doi.org/10.1126/science.7732378			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732378				2022-12-28	WOS:A1995QW60300043
J	ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM				ROELINK, H; PORTER, JA; CHIANG, C; TANABE, Y; CHANG, DT; BEACHY, PA; JESSELL, TM			FLOOR PLATE AND MOTOR-NEURON INDUCTION BY DIFFERENT CONCENTRATIONS OF THE AMINO-TERMINAL CLEAVAGE PRODUCT OF SONIC HEDGEHOG AUTOPROTEOLYSIS	CELL			English	Article							CELL-CELL COMMUNICATION; POLARITY GENE HEDGEHOG; NERVOUS-SYSTEM; CHICK-EMBRYO; DROSOPHILA; TRANSCRIPTION; EXPRESSION; NOTOCHORD; PROTEINS; PATTERN	The differentiation of floor plate cells and motor neurons can be induced by Sonic hedgehog (SHH), a secreted signaling protein that undergoes autoproteolytic cleavage to generate amino- and carboxy-terminal products. We have found that both floor plate cells and motor neurons are induced by the aminoterminal cleavage product of SHH (SHH-N). the threshold concentration of SHH-N required for motor neuron induction is about 5-fold lower than that required for floor plate induction. Higher concentrations of SHH-N can induce floor plate cells at the expense of motor neuron differentiation. Our results suggest that the induction of floor plate cells and motor neurons by the notochord In vivo is mediated by exposure of neural plate cells to different concentrations of the aminoterminal product of SHH autoproteolytic cleavage.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	ROELINK, H (corresponding author), COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA.							ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1995, IN PRESS MOL CELL NE; ALTABA ARI, 1995, IN PRESS DEV BIOL; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AVERBUCHHELLER L, 1994, P NATL ACAD SCI USA, V91, P3247, DOI 10.1073/pnas.91.8.3247; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURNCROT DA, 1995, MOL CELL BIOL, V15, P2294; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; ERICSON J, 1995, IN PRESS CELL, V81; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEBER SM, 1990, J NEUROSCI, V10, P2451; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1992, DEVELOPMENT, V115, P957; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TASHIRO S, 1993, GENE, V124, P183; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	59	748	780	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					445	455		10.1016/0092-8674(95)90397-6	http://dx.doi.org/10.1016/0092-8674(95)90397-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736596	hybrid			2022-12-28	WOS:A1995QW89400016
J	ROSENBERG, W; DONALD, A				ROSENBERG, W; DONALD, A			EVIDENCE BASED MEDICINE - AN APPROACH TO CLINICAL PROBLEM-SOLVING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ATRIAL-FIBRILLATION; QUALITY; TRIAL	Doctors within the NHS are confronting major changes at work. While we endeavour to improve the quality of health care, junior doctors' hours have been reduced and the emphasis on continuing medical education has increased. We are confronted by a growing body of information, much of it invalid or irrelevant to clinical practice. This article discusses evidence based medicine, a process of turning clinical problems into questions and then systematically locating, appraising, and using contemporaneous research findings as the basis for clinical decisions. The computerisation of bibliographies and the development of software that permits the rapid location of relevant evidence have made it easier for busy clinicians to make best use of the published literature. Critical appraisal can be used to determine the validity and applicability of the evidence, which is then used to inform clinical decisions. Evidence based medicine can be taught to, and practised by, clinicians at all levels of seniority and can be used to close the gulf between good clinical research and clinical practice. In addition it can help to promote self directed learning and teamwork and produce faster and better doctors.	ANGLIA & OXFORD REG HLTH AUTHOR, PUBL HLTH & HLTH POLICY, OXFORD OX3 7LF, ENGLAND		ROSENBERG, W (corresponding author), JOHN RADCLIFFE HOSP, NUFFIELD DEPT CLIN MED, OXFORD OX3 9DU, ENGLAND.		Rosenberg, William/ABA-1071-2021	Rosenberg, William/0000-0002-2732-2304				ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; AUDET N, 1993, CAN MED ASSOC J, V148, P945; BENNETT KJ, 1987, JAMA-J AM MED ASSOC, V257, P2451, DOI 10.1001/jama.257.18.2451; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CROWLEY P, 1990, BRIT J OBSTET GYNAEC, V97, P11, DOI 10.1111/j.1471-0528.1990.tb01711.x; Dunning M, 1994, Health Serv J, V104, P24; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FABER RG, 1993, BRIT MED J, V307, P383, DOI 10.1136/bmj.307.6900.383; FARBEY R, 1993, BRIT MED J, V307, P66, DOI 10.1136/bmj.307.6895.66; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT G, 1993, MED TEACH, V15, P147, DOI 10.3109/01421599309006708; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; JADAD AR, 1993, BMJ-BRIT MED J, V307, P66, DOI 10.1136/bmj.307.6895.66-a; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LOCK S, 1988, BRIT MED J, V297, P156, DOI 10.1136/bmj.297.6642.156; MARSHALL JG, 1992, B MED LIBR ASSOC, V80, P169; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MILNE R, 1993, J EPIDEMIOL COMMUN H, V47, P169, DOI 10.1136/jech.47.3.169; PETERSEN P, 1989, LANCET, V1, P175; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHELDON T, 1994, HEALTH ECON, V3, P201, DOI 10.1002/hec.4730030308; SHIN JH, 1993, CAN MED ASSOC J, V148, P969; SMITH R, 1993, BRIT MED J, V307, P1403; WEST R, 1992, J EPIDEMIOL COMMUN H, V46, P321, DOI 10.1136/jech.46.4.321; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; 1993, JAMA-J AM MED ASSOC, V270, P2598; LANCET, V343, P687	31	644	663	2	59	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 29	1995	310	6987					1122	1126		10.1136/bmj.310.6987.1122	http://dx.doi.org/10.1136/bmj.310.6987.1122			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742682	Green Published			2022-12-28	WOS:A1995QW61800023
J	LIPTON, RJ				LIPTON, RJ			DNA SOLUTION OF HARD COMPUTATIONAL PROBLEMS	SCIENCE			English	Article								DNA experiments are proposed to solve the famous ''SAT'' problem of computer science. This is a special case of a more general method that can solve NP-complete problems. The advantage of these results is the huge parallelism inherent in DNA-based computing. It has the potential to yield vast speedups over conventional electronic-based computers for such search problems.			LIPTON, RJ (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08540 USA.							ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Garey M.R., 1979, COMPUTERS INTRACTABI; LIPTON RJ, 1994, UNPUB SPEEDING COMPU; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI	5	716	849	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					542	545		10.1126/science.7725098	http://dx.doi.org/10.1126/science.7725098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725098				2022-12-28	WOS:A1995QV40700030
J	BREM, H; PIANTADOSI, S; BURGER, PC; WALKER, M; SELKER, R; VICK, NA; BLACK, K; SISTI, M; BREM, S; MOHR, G; MULLER, P; MORAWETZ, R; SCHOLD, SC				BREM, H; PIANTADOSI, S; BURGER, PC; WALKER, M; SELKER, R; VICK, NA; BLACK, K; SISTI, M; BREM, S; MOHR, G; MULLER, P; MORAWETZ, R; SCHOLD, SC			PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS	LANCET			English	Article							INTERSTITIAL CHEMOTHERAPY; MALIGNANT GLIOMA; GLIOBLASTOMA; BRAIN; BCNU	Chemotherapy for brain tumours has been limited because of difficulty in achieving adequate exposure to the tumour without systemic toxicity. We have developed a method for local sustained release of chemotherapeutic agents by their incorporation into biodegradable polymers. Implantation of the drug-impregnated polymer at the tumour site allows prolonged local exposure with minimal systemic exposure. We conducted a randomised, placebo-controlled, prospective study to evaluate the effectiveness of biodegradable polymers impregnated with carmustine to treat recurrent malignant gliomas. In 27 medical centres, 222 patients with recurrent malignant tumours requiring re-operation were randomly assigned to receive surgically implanted biodegradable polymer discs with or without 3.85% carmustine. Randomisation balanced the treatment groups for all of the prognostic factors examined. Median survival of the 110 patients who received carmustine polymers was 31 weeks compared with 23 weeks for the 112 patients who received only placebo polymers (hazard ratio=0.67, p=0006, after accounting for the effects of prognostic factors). Among patients with glioblastoma, 6-month survival in those treated with carmustine-polymer discs was 50% greater than in those treated with placebo (mortality=32 of 72 [44%] vs 47 of 73 [64%], p=0.02). There were no clinically important adverse reactions related to the carmustine polymer, either in the brain or systemically. Interstitial chemotherapy delivered with polymers directly to brain tumours at the time of surgery seems to be a safe and effective treatment for recurrent malignant gliomas.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NINCDS,BETHESDA,MD 20892; WESTERN PENN HOSP,DIV NEUROSURG,PITTSBURGH,PA 15224; EVANSTON HOSP CORP,DEPT NEUROL,EVANSTON,IL; UNIV CALIF LOS ANGELES,DEPT NEUROL SURG,LOS ANGELES,CA; NEUROL INST,DEPT NEUROSURG,NEW YORK,NY 10032; NORTHWESTERN UNIV,DEPT NEUROL SURG,CHICAGO,IL 60611; MCGILL UNIV,DIV NEUROSURG,MONTREAL,PQ,CANADA; UNIV TORONTO,DIV NEUROSURG,TORONTO,ON,CANADA; UNIV ALABAMA,DEPT NEUROSURG,BIRMINGHAM,AL; UNIV TEXAS,SW MED CTR,DEPT NEUROL,DALLAS,TX 75235	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); West Penn Hospital; NorthShore University Health System; University of California System; University of California Los Angeles; Northwestern University; McGill University; University of Toronto; University of Alabama System; University of Alabama Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	BREM, H (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL SURG,HUNTERIAN 817,725 N WOLFE ST,BALTIMORE,MD 21205, USA.			Black, Keith/0000-0002-0546-4934	NCI NIH HHS [U01-CA62474, U01-CA52857] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA062474, U01CA052857] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACK PM, 1991, NEW ENGL J MED, V324, P1471, DOI 10.1056/NEJM199105233242105; BOYKO OB, 1994, ARCH PATHOL LAB MED, V118, P219; BREM H, 1991, J NEUROSURG, V74, P441, DOI 10.3171/jns.1991.74.3.0441; BREM H, 1994, J NEUROSURG, V80, P283, DOI 10.3171/jns.1994.80.2.0283; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; BURGER PC, 1991, SURGICAL PATHOLOGY N; CHASIN M, 1988, BIOPHARM MANUF, V1, P33; COX DR, 1972, J R STAT SOC B, V34, P187; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; DIRKS P, 1993, CAN J SURG, V36, P271; FLORELL RC, 1992, J NEUROSURG, V76, P179, DOI 10.3171/jns.1992.76.2.0179; GROSSMAN SA, 1992, J NEUROSURG, V76, P640, DOI 10.3171/jns.1992.76.4.0640; HOCHBERG FH, 1985, J NEUROSURG, V63, P876, DOI 10.3171/jns.1985.63.6.0876; JUDY K, 1995, J NEUROSURG, V82, P103; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1959, J NATL CANCER I, V22, P719; MATHIOWITZ E, 1988, J APPL POLYM SCI, V35, P755, DOI 10.1002/app.1988.070350316; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; OLIVI A, 1993, CANCER CHEMOTH PHARM, V31, P449, DOI 10.1007/BF00685034; PHILLIPS PC, 1994, CANCER RES, V54, P1008; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; TAMARGO RJ, 1991, J NEUROSURG, V74, P956, DOI 10.3171/jns.1991.74.6.0956; TAMARGO RJ, 1993, CANCER RES, V53, P329; TENNEY JH, 1985, J NEUROSURG, V62, P243, DOI 10.3171/jns.1985.62.2.0243; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; WALTER KA, 1994, CANCER RES, V54, P2207; WEINGART J, 1993, 3RD NIH DRUG DISC DE; WEINGART JD, 1995, J NEUROSURG, V82, P635, DOI 10.3171/jns.1995.82.4.0635	28	1045	1106	2	91	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1008	1012		10.1016/S0140-6736(95)90755-6	http://dx.doi.org/10.1016/S0140-6736(95)90755-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723496	hybrid			2022-12-28	WOS:A1995QU57300007
J	HENRY, D; OCONNELL, D				HENRY, D; OCONNELL, D			TRIAL OF STREPTOKINASE IN ISCHEMIC STROKE	LANCET			English	Letter									ROYAL NEWCASTLE HOSP,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2300,AUSTRALIA	University of Newcastle	HENRY, D (corresponding author), ROYAL NEWCASTLE HOSP,FAC MED & HLTH SCI,DEPT CLIN PHARMACOL,NEWCASTLE,NSW 2300,AUSTRALIA.		Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242				DONNAN, 1995, LANCET          0304, P578; SHALER, 1995, LANCET          0304, P578; 1995, LANCET          0107; 1995, LANCET          0304, P578	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1053	1053		10.1016/S0140-6736(95)90794-7	http://dx.doi.org/10.1016/S0140-6736(95)90794-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723524				2022-12-28	WOS:A1995QU57300049
J	WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ				WONG, ROL; CHERNJAVSKY, A; SMITH, SJ; SHATZ, CJ			EARLY FUNCTIONAL NEURAL NETWORKS IN THE DEVELOPING RETINA	NATURE			English	Article							IMMEDIATE EARLY GENES; CALCIUM WAVES; MAMMALIAN RETINA; GANGLION-CELLS; FERRET RETINA; GLUTAMATE; ASTROCYTES; EXPRESSION; PATTERNS; NEURONS	IN the adult mammalian retina, the principal direction of information flow is along a vertical pathway from photoreceptors to retinal interneurons to ganglion cells, the output neurons of the retina. We report here, however, that initially in development, at a time when the photoreceptors are not yet even present, there are already functionally defined networks within the retina. These networks are spontaneously active rather than visually driven, and they involve horizontal rather than vertical pathways. By means of optical recording using the calcium-sensitive dye Fura-2, we have found that sets of retinal ganglion cells and amacrine cells, a type of retinal interneuron, undergo synchronized oscillations in intracellular calcium concentration, These oscillations are highly correlated among subgroups of neighbouring cells, and spread in a wave-like fashion tangentially across the retina, Thus, in development of retinal circuitry, the initial patterning of neuronal function occurs in the horizontal domain before the adult pattern of vertical information transfer emerges.	STANFORD UNIV, BECKMAN CTR, DEPT PHYSIOL, STANFORD, CA 94305 USA; UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA; UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; STANFORD UNIV, SCH MED, DEPT NEUROBIOL, STANFORD, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Stanford University								BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; COOK JE, 1991, TRENDS NEUROSCI, V14, P397, DOI 10.1016/0166-2236(91)90028-S; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; Ginty D D, 1992, Curr Opin Neurobiol, V2, P312, DOI 10.1016/0959-4388(92)90121-Z; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GREINER JV, 1981, EXP EYE RES, V33, P315, DOI 10.1016/S0014-4835(81)80055-3; HENDERSON Z, 1988, J NEUROSCI, V8, P1194; Katz L C, 1993, Curr Opin Neurobiol, V3, P93, DOI 10.1016/0959-4388(93)90041-V; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; PENN AA, 1994, J NEUROSCI, V14, P3805; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POW DV, 1994, VISUAL NEUROSCI, V11, P1115, DOI 10.1017/S0952523800006933; RAMOA AS, 1988, J NEUROSCI, V8, P4239; REDBURN DA, 1992, NEUROCHEM RES, V17, P61, DOI 10.1007/BF00966865; ROBINSON SR, 1991, VISION VISUAL DYSFUN, V3, P69; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SPITZER NC, 1994, TRENDS NEUROSCI, V17, P115, DOI 10.1016/0166-2236(94)90120-1; Vaney D.I., 1990, PROGR RETINAL RES, V9, P49, DOI [10.1016/0278-4327(90)90004-2, DOI 10.1016/0278-4327(90)90004-2]; Wong R O, 1993, Curr Opin Neurobiol, V3, P595, DOI 10.1016/0959-4388(93)90061-3; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; YUSTE R, 1992, SCIENCE, V257, P666, DOI 10.1126/science.1496379; YUSTE R, 1991, NEURON, V6, P333, DOI 10.1016/0896-6273(91)90243-S; ZORUMSKI CF, 1992, PROG NEUROBIOL, V39, P295, DOI 10.1016/0301-0082(92)90020-F	29	238	240	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					716	718		10.1038/374716a0	http://dx.doi.org/10.1038/374716a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715725				2022-12-28	WOS:A1995QU30400048
J	JENNER, JR; BARRY, M				JENNER, JR; BARRY, M			ABC OF RHEUMATOLOGY - LOW-BACK-PAIN	BRITISH MEDICAL JOURNAL			English	Article									JAMES CONNOLLY MEM HOSP,DEPT RHEUMATOL,DUBLIN,IRELAND		JENNER, JR (corresponding author), ADDENBROOKES NHS TRUST,DEPT RHEUMATOL,CAMBRIDGE,ENGLAND.							Kellgren JH, 1939, CLIN SCI, V4, P35; MATHEWS JA, 1987, BRIT J RHEUMATOL, V26, P416; WADELL G, 1983, SPINE, V9, P209; WADELL G, 1987, SPINE, V12, P632	4	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					929	932		10.1136/bmj.310.6984.929	http://dx.doi.org/10.1136/bmj.310.6984.929			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719190	Green Published			2022-12-28	WOS:A1995QR97200034
J	MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W				MALCOLM, PN; CHAN, TYK; LI, PL; RICHARDS, J; HATELY, W			MANAGEMENT OF DYSPEPSIA AMONG ASIANS BY GENERAL-PRACTITIONERS IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							CONSULTATIONS		ROYAL LONDON TRUST,DEPT RADIOL,LONDON E1 1BB,ENGLAND; E LONDON & CITY HLTH AUTHOR,DEPT PUBL HLTH MED,LONDON E3 2AN,ENGLAND	St Georges University London								BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; CONRY BG, 1989, BMJ-BRIT MED J, V299, P1443, DOI 10.1136/bmj.299.6713.1443; MURRAY J, 1986, SOC PSYCH PSYCH EPID, V21, P139, DOI 10.1007/BF00582684; 1994, CENSUS USER GUIDE 58; 1993, CENSUS COUNTY REPO 1, V1	5	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					910	911		10.1136/bmj.310.6984.910	http://dx.doi.org/10.1136/bmj.310.6984.910			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719183	Green Published			2022-12-28	WOS:A1995QR97200024
J	SCHIFF, GD; BINDMAN, AB; BRENNAN, TA				SCHIFF, GD; BINDMAN, AB; BRENNAN, TA			A BETTER-QUALITY ALTERNATIVE - SINGLE-PAYER NATIONAL-HEALTH SYSTEM REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; UNITED-STATES; MANAGED COMPETITION; MEDICAL-PRACTICE; IMPERFECT WORLD; PUBLIC-POLICY; RISK-FACTORS; INSURANCE; PHYSICIANS; COST		COOK CTY HOSP, DIV GEN MED & PRIMARY CARE, CHICAGO, IL USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DIV GEN INTERNAL MED, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA	John H Stroger Junior Hospital Cook County; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Harvard University; Harvard T.H. Chan School of Public Health								ALPERT S, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562918; ANSELL DA, 1987, JAMA-J AM MED ASSOC, V257, P1500, DOI 10.1001/jama.257.11.1500; Batalden P B, 1993, Jt Comm J Qual Improv, V19, P424; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLENDON RJ, 1993, JAMA-J AM MED ASSOC, V269, P2573, DOI 10.1001/jama.269.19.2573; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; BODENHEIMER T, 1992, NEW ENGL J MED, V327, P274, DOI 10.1056/NEJM199207233270412; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BRENNAN TA, 1991, JUST DOCTORING MED E; BROOK RH, 1991, ANN INTERN MED, V115, P486, DOI 10.7326/0003-4819-115-6-486; BROWN ER, 1991, INT J HEALTH SERV, V21, P441, DOI 10.2190/AKCP-L5A4-MXXQ-DW9K; BURACK RC, 1993, MED CARE, V31, P322, DOI 10.1097/00005650-199304000-00004; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CAMPBELL ES, 1993, J HEALTH POLIT POLIC, V18, P905, DOI 10.1215/03616878-18-4-905; CARPENTER WT, 1994, NEW ENGL J MED, V330, P681, DOI 10.1056/NEJM199403103301006; CASSEL CK, 1985, J HEALTH POLIT POLIC, V10, P549, DOI 10.1215/03616878-10-3-549; Cleary P D, 1993, Qual Manag Health Care, V2, P31; DETSKY AS, 1993, NEW ENGL J MED, V328, P805, DOI 10.1056/NEJM199303183281113; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DONABEDIAN A, 1988, INQUIRY-J HEALTH CAR, V25, P90; DONABEDIAN A, 1991, STRIVING QUALITY HLT, P61; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; EPSTEIN AM, 1993, NEW ENGL J MED, V329, P1672, DOI 10.1056/NEJM199311253292229; EVANS GT, 1988, J CONSEIL, V44, P111; FIELD MJ, 1992, GUIDELINES CLIN PRAC, P135; FRANKS P, 1993, JAMA-J AM MED ASSOC, V270, P737, DOI 10.1001/jama.270.6.737; FRIEDMAN E, 1991, HEALTHCARE FORUM J, V346, P12; FUCHS VR, 1993, JAMA-J AM MED ASSOC, V269, P631; FULTON J, 1993, CANADAS HLTH SYSTEM; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; GREEN JA, 1988, ANN INTERN MED, V109, P234, DOI 10.7326/0003-4819-109-3-234; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; GRUMBACH K, 1993, AM J PUBLIC HEALTH, V83, P372, DOI 10.2105/AJPH.83.3.372; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; Gustafson D H, 1992, QRB Qual Rev Bull, V18, P333; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hill RB., 1988, AUTOPSY MED PRACTICE; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; HILLMAN AL, 1992, QUAL HLTH CARE OUTCO, V2, P1; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; James B C, 1993, Front Health Serv Manage, V10, P3; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; JOST TS, 1994, JAMA-J AM MED ASSOC, V271, P1508, DOI 10.1001/jama.271.19.1508; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; KUSSEROW RP, 1987, JAMA-J AM MED ASSOC, V257, P820; LEAPE LL, 1989, NEW ENGL J MED, V321, P653, DOI 10.1056/NEJM198909073211006; LEAPE LL, 1992, ANNU REV PUBL HEALTH, V13, P363, DOI 10.1146/annurev.pu.13.050192.002051; LEW EA, 1973, AM J MED, V55, P281, DOI 10.1016/0002-9343(73)90130-7; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANASSE HR, 1989, AM J HOSP PHARM, V46, P929, DOI 10.1093/ajhp/46.5.929; MANASSE HR, 1989, AM J HOSP PHARM, V46, P1141, DOI 10.1093/ajhp/46.6.1141; Murrey K O, 1992, QRB Qual Rev Bull, V18, P423; NORMAN GR, 1993, JAMA-J AM MED ASSOC, V270, P1046; PRIESTER R, 1992, HEALTH AFFAIR, V11, P84, DOI 10.1377/hlthaff.11.1.84; RANDALL T, 1993, JAMA-J AM MED ASSOC, V270, P160, DOI 10.1001/jama.270.2.160; RELMAN AS, 1993, NEW ENGL J MED, V329, P1574, DOI 10.1056/NEJM199311183292113; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; RUSSELL LB, 1993, NEW ENGL J MED, V329, P352, DOI 10.1056/NEJM199307293290511; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SCHROEDER SA, 1993, ANN INTERN MED, V119, P945, DOI 10.7326/0003-4819-119-9-199311010-00014; Smith T, 1990, Int J Risk Saf Med, V1, P45, DOI 10.3233/JRS-1990-1106; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; STARR P, 1992, LOGIC HLTH REFORM; TERRIS M, 1990, ANNU REV PUBL HEALTH, V11, P39; VLADECK BC, 1988, INQUIRY-J HEALTH CAR, V25, P100; Walton Mary, 1986, DEMING MANAGEMENT ME; Weiler PC, 1993, MEASURE MALPRACTICE; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; WELCH CE, 1991, MED CARE, V29, pAS8; Wennberg J E, 1984, Health Manage Q, P6, DOI 10.1377/hlthaff.3.2.6; WILLIAMSON JW, 1993, AM J MED QUAL, V82, P37; WOLFE SM, 1991, PUBL CITIZEN HLTH RE, V7, P1; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; WOOLHANDLER S, 1993, NEW ENGL J MED, V329, P400, DOI 10.1056/NEJM199308053290606; [No title captured]; 1986, NOV STAT INT C HLTH; 1990, PEPPER COMMISSION US; 1994, ANN INTERN MED, V120, P423; 1993, ELECTRONIC MED REC N, V2, P1; 1993, QUAL MANAGE HLTH CAR, V2, P72; 1993, OTABPH112 US C OFF T; 1991, GAOHRD9190 US GOVT A; 1992, LANCET, V340, P458; 1991, COMPUTER BASED PATIE; 1993, GAOIMTEC9317 US GOVT; 1990, MED STRATEGY QUALITY, P1	94	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					803	808		10.1001/jama.272.10.803	http://dx.doi.org/10.1001/jama.272.10.803			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	7741842				2022-12-28	WOS:A1994PF18800030
J	KOLLEF, MH; BOCK, KR; RICHARDS, RD; HEARNS, ML				KOLLEF, MH; BOCK, KR; RICHARDS, RD; HEARNS, ML			THE SAFETY AND DIAGNOSTIC-ACCURACY OF MINIBRONCHOALVEOLAR LAVAGE IN PATIENTS WITH SUSPECTED VENTILATOR-ASSOCIATED PNEUMONIA	ANNALS OF INTERNAL MEDICINE			English	Article						BRONCHALVEOLAR LAVAGE FLUID; PNEUMONIA; VENTILATORS, MECHANICAL; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL	PROTECTED SPECIMEN BRUSH; QUANTITATIVE CULTURE TECHNIQUES; RESPIRATORY-DISTRESS SYNDROME; NOSOCOMIAL PNEUMONIA; BRONCHOALVEOLAR LAVAGE; INTUBATED PATIENTS; BACTERIAL PNEUMONIA; CRITICALLY ILL; MORTALITY; FAILURE	Objectives: To assess the safety of minibronchoalveolar lavage done by respiratory therapists for the evaluation of suspected ventilator-associated pneumonia and to determine the diagnostic agreement between quantitative lower airway cultures obtained by the minibronchoalveolar lavage and protected specimen brush techniques. Design: A prospective direct comparison of two diagnostic techniques. Setting: An academic tertiary care center in St. Louis, Missouri. Patients: 72 consecutive patients suspected of having ventilator-associated pneumonia on the basis of clinical evidence. Interventions: Sampling of lower airway secretions using the protected specimen brush and minibronchoalveolar lavage techniques. Main Outcome Measures: Clinical complications and quantitative cultures of respiratory secretions. Results: 72 patients suspected of having ventilator-associated pneumonia (first episode) were evaluated using minibronchoalveolar lavage. In 42 patients, lower airway secretions were also obtained using the protected specimen brush technique. No change in arterial blood oxygen saturation or heart rate occurred after minibronchoalveolar ravage (P > 0.2). Mean arterial pressure slightly increased with minibronchoalveolar lavage (baseline mean pressure, 90.1 mm Hg [CI, 88.4 to 91.7 mm Hg]; average within-person change, 2.6 mm Hg; P = 0.024). Good diagnostic agreement was shown for quantitative cultures obtained with the protected specimen brush and minibronchoalveolar ravage techniques (kappa statistic, 0.63; concordance, 83.3%); 10(3) colony forming units/mL was used as the threshold for a clinically significant culture result. Conclusions: Minibronchoalveolar ravage is a safe and technically simple procedure for obtaining quantitative lower airway cultures in patients requiring mechanical ventilation. Quantitative culture results obtained by minibronchoalveolar ravage are similar to those obtained by the protected specimen brush technique.	BARNES HOSP, ST LOUIS, MO 63110 USA		KOLLEF, MH (corresponding author), WASHINGTON UNIV, SCH MED, DIV PULM & CRIT CARE MED, BOX 8052, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.							BAIGELMAN W, 1986, CRIT CARE MED, V14, P864, DOI 10.1097/00003246-198610000-00006; BAKER AM, 1995, CHEST, V107, P85, DOI 10.1378/chest.107.1.85; BASELSKI VS, 1992, CHEST, V102, pS571, DOI 10.1378/chest.102.5_Supplement_1.571S; BELL RC, 1983, ANN INTERN MED, V99, P293, DOI 10.7326/0003-4819-99-3-293; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHASTRE J, 1992, Intensive Care Medicine, V18, pS10, DOI 10.1007/BF01752971; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CHASTRE J, 1988, AM J MED, V85, P499; CLARKE WR, 1992, J CRIT CARE, V7, P230, DOI 10.1016/0883-9441(92)90020-8; COOK DJ, 1994, CRIT CARE MED, V22, P1314, DOI 10.1097/00003246-199408000-00016; DOTSON RG, 1993, CHEST, V103, P541, DOI 10.1378/chest.103.2.541; DREYFUSS D, 1993, AM REV RESPIR DIS, V147, P946, DOI 10.1164/ajrccm/147.4.946; ELEBIARY M, 1993, AM REV RESPIR DIS, V148, P1552, DOI 10.1164/ajrccm/148.6_Pt_1.1552; FAGON JY, 1990, AM REV RESPIR DIS, V142, P1004, DOI 10.1164/ajrccm/142.5.1004; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1988, AM REV RESPIR DIS, V138, P110, DOI 10.1164/ajrccm/138.1.110; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; Hart T P, 1992, Respir Care, V37, P1260; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1994, HEART LUNG, V23, P363; KOLLEF MH, 1995, IN PRESS CHEST; LEALNOVAL SR, 1992, INTENS CARE MED, V18, P410, DOI 10.1007/BF01694343; MARQUETTE CH, 1993, AM REV RESPIR DIS, V148, P138, DOI 10.1164/ajrccm/148.1.138; MARQUETTE CH, 1993, AM REV RESPIR DIS, V147, P211, DOI 10.1164/ajrccm/147.1.211; MEDURI GU, 1991, AM REV RESPIR DIS, V143, P855, DOI 10.1164/ajrccm/143.4_Pt_1.855; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; MEDURI GU, 1992, CHEST, V102, pS551, DOI 10.1016/S0012-3692(16)34868-1; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; MIDDLETON R, 1992, AM J MED SCI, V304, P239, DOI 10.1097/00000441-199210000-00003; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PAPAZIAN L, 1993, CHEST, V103, P236, DOI 10.1378/chest.103.1.236; PHAM LH, 1991, AM REV RESPIR DIS, V143, P1055, DOI 10.1164/ajrccm/143.5_Pt_1.1055; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; RELLO J, 1994, AM J RESP CRIT CARE, V150, P1545, DOI 10.1164/ajrccm.150.6.7952612; ROUBY JJ, 1992, AM REV RESPIR DIS, V146, P1059, DOI 10.1164/ajrccm/146.4.1059; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SEIDENFELD JJ, 1986, AM REV RESPIR DIS, V134, P12; TIMSIT JF, 1993, CHEST, V104, P104, DOI 10.1378/chest.104.1.104; TORRES A, 1994, AM J RESP CRIT CARE, V149, P324, DOI 10.1164/ajrccm.149.2.8306025; TORRES A, 1988, AM REV RESPIR DIS, V138, P117, DOI 10.1164/ajrccm/138.1.117; TORRES A, 1993, AM REV RESPIR DIS, V147, P952, DOI 10.1164/ajrccm/147.4.952; WUNDERINK RG, 1993, CHEST, V104, P993, DOI 10.1378/chest.104.4.993b	46	160	161	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					743	748		10.7326/0003-4819-122-10-199505150-00002	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717596				2022-12-28	WOS:A1995QX14700002
J	WALKER, MD; MARLER, JR; GOLDSTEIN, M; GRADY, PA; TOOLE, JF; BAKER, WH; CASTALDO, JE; CHAMBLESS, LE; MOORE, WS; ROBERTSON, JT; YOUNG, B; HOWARD, VJ; PURVIS, S; VERNON, DD; NEEDHAM, K; BECK, P; DOZIER, M; LEFKOWITZ, DS; HOWARD, G; CROUSE, JR; HERRINGTON, DM; FURBERG, CD; ESSICK, K; HICKS, RM; NELSON, JJ; BALL, W; BLAND, E; CONDON, S; ELLIOTT, T; GRIZZLE, JE; HAYES, D; HENLEY, S; JOHNSON, J; LOCKLEAR, J; MISCH, MS; PATON, CC; SCHWARTZ, S; WALKER, C; WILLIAMS, OD; EASTON, JD; GOLDSTONE, J; HALLENBECK, JM; HOFF, JT; KARP, HR; KRONMAL, RA; BROTT, TG; TOMSICK, TA; BRODERICK, J; SAUERBECK, L; BLUM, C; DYKEN, M; BRUST, JCM; DICK, AR; GOTSHALL, RA; HEYMAN, A; SWANSON, PD; ADAMS, HP; DEMPSEY, R; ERNST, CB; ROTHROCK, J; COHEN, SN; NICHOLAS, G; LONGENECKER, J; BARBOUR, P; BERGER, A; CELANI, VJ; ECKERT, N; GOODREAU, J; HUTCHINSON, J; JENNY, D; LIN, ZS; MCDONALD, K; PISTONE, W; RAEGRANT, AD; REDENBAUGH, J; REX, J; WOHLBERG, CJ; KARANJIA, P; SWANSON, M; LOBNER, S; KOLTS, RL; KUEHNER, ME; HINER, BC; MADDEN, KP; CARLSON, RD; DAVIS, JS; GALLANT, T; WARNER, JJ; FAUST, A; FRYZA, N; HASENAUER, J; REGNER, M; RONKIN, L; SCHAEFER, S; STRACK, D; TURNER, LC; WALGENBACH, A; GRAVES, J; MICHALSKI, S; SCHUETTE, L; MOHR, JP; TATEMICHI, TK; MARSHALL, R; MAST, H; RAMOS, O; CORRELL, J; LIBMAN, R; PETTY, G; CABRERE, A; OROPEZA, L; GONZALEZ, T; PETTIGREW, C; SADLER, R; ENDEAN, E; SHERROW, J; HAUER, M; LEE, C; NORTON, J; MCQUILLEN, M; MATTINGLY, S; DEKOSKY, S; MASSEY, A; SIMARD, D; TURCOTTE, JF; BENGUIGUI, C; COTE, J; BOUCHARD, JM; ROBERGE, C; BRUNET, D; BEDARD, F; LANGELIER, R; LAJEUNESSE, M; BIGAOUETTE, JM; PARENT, J; LYDEN, P; HYE, R; LEWIS, S; CALI, G; BABCOCK, T; TAFTALVAREZ, B; BRODY, M; ZWEIFLER, R; SEDWITZ, M; STABILE, B; FREISCHLAG, JA; WOLF, YG; SIVO, J; FORSYTHE, J; ADAME, M; GUPTA, S; BURKE, K; GREISLER, HP; LITTOOY, FN; KELLY, MA; PULSINELLI, W; CAMPBELL, JA; CROCKARELL, J; WATRIDGE, C; ACKER, J; ERKULWATER, S; JACEWICZ, M; WALKER, G; OSULLIVAN, P; SAUER, C; VASU, K; GAINES, K; BAKHITIAN, B; BERTORINI, TE; BENNETT, S; THOMAS, T; STAHL, N; TAYLOR, C; GIAMPAPA, MA; CONNELL, J; RILEY, J; BRADLEY, A; DAVIS, J; NEWMAN, K; MANNING, R; MCCREA, M; HACHINSKI, V; FERGUSON, G; MAYER, C; BARNETT, JM; PEERLESS, SJ; BUCHAN, AM; REICHMAN, H; KERTESZ, A; LOWNIE, S; WHITE, C; FOX, A; RANKIN, R; SPENCE, JD; BARR, HWK; PADDOCKELIASZIW, L; ASSIS, LJP; PEXMAN, JHW; DICICCO, M; TATE, B; JAMES, C; RAKER, E; COATSWORTH, J; HARRIS, S; BEEBE, H; BIRCHFIELD, R; BUTLERLEVY, K; CRANE, R; FRYER, D; MACLEAN, J; PATTERSON, L; QUIGLEY, T; RAVITS, J; TAYLOR, L; PULLEN, S; BOSWELL, S; KENNY, K; BROTT, T; TOMSICK, T; ROEDERSHEIMER, LR; FOWL, R; TEW, J; KEMPCZINSKI, R; REED, R; WELLING, R; SCHOMAKER, B; LEFKOWITZ, D; MCWHORTER, JM; BRANCH, CL; SATTERFIELD, J; CORDELL, R; DEAN, R; PLONK, G; HARPOLD, G; WALKER, F; NUNN, C; MYERS, L; TEGELER, C; HARDIN, S; MEADS, D; LOFTUS, CM; VINING, LA; BENDIXEN, BH; BILLER, J; CORSON, JD; DAVIS, PH; GODERSKY, JC; GORDON, DL; JACOBY, MR; KAPPELLE, LJ; KRESOWIK, TF; MARSH, EE; LOVE, BB; SHAMMA, AR; GRIMSMAN, KJ; KARBOSKI, DM; MILLER, EV; JOHNSON, C; JONES, C; STONE, B; MAGUIRE, MP; EARLEY, C; KAPLAN, P; CAVALUZZI, J; WATERS, G; CHACHICH, B; AUER, A; LOGAN, W; WILCOX, M; GREEN, B; HURLEY, J; PENNELL, R; WOODS, J; LEVINE, R; NEPUTE, J; THOMASSON, J; BLACKBURN, C; FOLDES, M; KLEMP, K; NAPPIER, B; RUTHERFORD, K; SCHROER, S; HOGAN, J; THORPE, L; FEINBERG, WM; HUNTER, GC; BRUCK, DC; BERNHARD, VM; MCINTYRE, KE; CARTER, LP; LABADIE, EL; JOHNSON, DS; MOSCHONAS, CG; HAMILTON, RH; FORRER, SC; SEEGER, JF; CARMODY, RF; VOLD, BK; CARLSON, RL; LAGUNA, JE; KRIKAWA, JP; DEVINE, JJ; CASTRILLO, AM; KISTLER, SL; LEDBETTER, B; DORR, K; SMITH, RR; HAERER, AF; BROWN, RL; RUSSELL, W; RIGDON, E; RHODES, R; SMITH, E; GRAEBER, M; DOORENBOS, D; SUBRAMONY, SH; ATNIP, RG; BRENNAN, RW; FRIEDMAN, D; NEUMYER, MM; THIELE, BL; SMITH, F; BARR, JD; DUCKROW, RB; JANESKY, C; MEILSTRUP, JW; MCNAMARA, KP; RODICHOK, LD; STEWART, L; SULLIVAN, M; WENGROVITZ, M; CLAGETT, GP; UNWIN, H; BRYAN, W; MATKINS, C; PATTERSON, C; ALWAY, C; BOYD, P; INMAN, M; ALBISTON, C; SCOGGINS, E; SWILLING, J; WALDEN, KG; AHN, SS; AMOS, EC; BAKER, JD; DOBKIN, BH; DONAYRE, CE; GELABERT, HA; JORDAN, SE; MACHLEDER, HI; QUINONESBALDRICH, WJ; SAVER, JL; ELSADEN, SM; HOLGATE, RC; JABOUR, BA; JACOBS, JB; ABRAHAM, TM; VESCERA, CL; VONRAJCS, JA; CARTER, VL; CARTER, DT; DIXGOSS, DE; HERNANDEZ, EC; COULL, B; LOBOA, L; MONETA, G; PORTER, J; YEAGER, R; WHITTAKER, L; BRASS, LM; GUSBERG, RJ; LOVEJOY, AM; FAYAD, PB; SUMPIO, B; MEIER, GH; CHANG, VM; MARZITELLI, K; CHYATTE, D; HAMMERS, L; LEPORE, F; PAVALKIS, FJ; MELE, J; KISIEL, D; BARNES, RW; CHESSER, MZ; ARCHER, RL; THOMPSON, BW; MACDONALD, C; BARONE, GW; EIDT, JF; HARSHFIELD, D; MCFARLAND, D; NICKOLS, JR; HOWARD, C; NIX, ML; OVERSTREET, JK; TROILLETT, R; TAYLOR, J; LEE, HM; AKINS, P; HARBISON, JW; PRIDGEON, RM; FELTON, WL; POSNER, M; SOBEL, M; CLIFTON, G; CONWAY, C; COCKRELL, A; STRINGER, W; WINGO, J; NICHOLS, B; SMOKER, W; FISHER, R; SPETZLER, RF; FREY, JL; ZABRAMSKI, JM; HUNSLEY, SL; JAHNKE, H; PLENGE, KL; HOLLAND, R; TURNER, R; STRAVA, D; STUMPFF, S; HODAK, J; FLOM, RA; DEAN, BL; THOMPSON, RA; HUGHES, R; LEPLER, B; BOWEN, J; BENOIT, C; HOLLIER, L; OCHSNER, J; STRUB, R; LANG, V; CAHANIN, V; HOBSON, RW; WEISBROT, F; KAMIN, S; BACK, T; JAMIL, Z; ROGERS, C; LAINSON, B; HART, L; CAPLAN, L; ODONNELL, T; BARRON, L; PESSIN, M; DEWITT, D; MACKEY, W; BELKIN, M; MCGLAUGHLIN, R; HEGGERICK, P; WELCH, KMA; WILCZEWSKI, J; ROBERTSON, W; DALEY, S; ELLIOT, JP; REDDY, DJ; SHEPHARD, AD; SMITH, RF; LEVINE, S; RAMADAN, N; TIETJEN, G; MITSIAS, P; GORMAN, M; MCPHARLIN, M; PATEL, S; DEVESHWAR, R; LEE, N; KOKKINOS, J; WEINSTEIN, E; KUNKEL, J; KRATOCHVIL, A; JOHNSON, E; STEEL, S; NORRIS, J; ROWED, D; BOWYER, B; GAWEL, M; COOPER, PW; BRODIE, D; KIRKLAND, JS; SCHECTER, JA; FARRAR, NW; CAPPS, R; RHODES, EL; ROGERS, DM; GLASS, JT; NAGUSZEWSKI, R; NAGUSZEWSKI, W; MADDOX, B; DOLLISON, B; MOULTON, L; COLE, P; KINSELLA, P; ANSLEY, A; BRITZ, N; BIVINS, DH; WILLIAMS, EL; DAVIDSON, JT; ELIAS, W; ATKINS, D; TURNER, PB; BURCH, JG; NOLAN, DB; SPEESE, R; FOLEY, CD; MILLETTE, TJ; LANE, KH; ALMOND, C; MESTAYER, RJ; CALANCHINI, P; SZARNICKI, R; RADOSEVICH, P; ELIAS, L; MCCORMICK, P; GOULD, C; NORRIS, F; DENYS, E; BERNSTEIN, R; DUBONO, D; ATKINSON, K; PETERS, M; COHEN, B; YAO, J; ROSTON, S; BLACKBURN, D; SAVER, J; CHADWICK, L; MCCARTHY, W; PEARCE, W; FRANK, J; FERNANDEZBEER, E; PATRICK, J; GREEN, R; SATRAN, R; RICOTTA, J; DEWEESE, J; HOLLANDER, J; OBRIEN, M; MCNAMARA, J; ROSE, S; COHEN, D; FURLAN, A; LITTLE, J; BRYERTON, B; SILA, C; AWAD, I; CHIMOWITZ, M; ROBERTSON, S; BECKER, C; PAUSHTER, D; OLEARY, DH; JONES, AM; RICOTTA, JJ; GEE, W; SHEBEL, N; FISHER, MJ; SCHENK, EA; FURLAN, AJ; FUTRELL, NN; KELLY, M; MILLIKAN, CH; DIENER, HC; FIELDS, WS; FOLSTEIN, MF; GAUTIER, JC; HARRISON, MJG; HASS, WK; HENNERICI, MG; SPENCER, MP; VONREUTERN, GM				WALKER, MD; MARLER, JR; GOLDSTEIN, M; GRADY, PA; TOOLE, JF; BAKER, WH; CASTALDO, JE; CHAMBLESS, LE; MOORE, WS; ROBERTSON, JT; YOUNG, B; HOWARD, VJ; PURVIS, S; VERNON, DD; NEEDHAM, K; BECK, P; DOZIER, M; LEFKOWITZ, DS; HOWARD, G; CROUSE, JR; HERRINGTON, DM; FURBERG, CD; ESSICK, K; HICKS, RM; NELSON, JJ; BALL, W; BLAND, E; CONDON, S; ELLIOTT, T; GRIZZLE, JE; HAYES, D; HENLEY, S; JOHNSON, J; LOCKLEAR, J; MISCH, MS; PATON, CC; SCHWARTZ, S; WALKER, C; WILLIAMS, OD; EASTON, JD; GOLDSTONE, J; HALLENBECK, JM; HOFF, JT; KARP, HR; KRONMAL, RA; BROTT, TG; TOMSICK, TA; BRODERICK, J; SAUERBECK, L; BLUM, C; DYKEN, M; BRUST, JCM; DICK, AR; GOTSHALL, RA; HEYMAN, A; SWANSON, PD; ADAMS, HP; DEMPSEY, R; ERNST, CB; ROTHROCK, J; COHEN, SN; NICHOLAS, G; LONGENECKER, J; BARBOUR, P; BERGER, A; CELANI, VJ; ECKERT, N; GOODREAU, J; HUTCHINSON, J; JENNY, D; LIN, ZS; MCDONALD, K; PISTONE, W; RAEGRANT, AD; REDENBAUGH, J; REX, J; WOHLBERG, CJ; KARANJIA, P; SWANSON, M; LOBNER, S; KOLTS, RL; KUEHNER, ME; HINER, BC; MADDEN, KP; CARLSON, RD; DAVIS, JS; GALLANT, T; WARNER, JJ; FAUST, A; FRYZA, N; HASENAUER, J; REGNER, M; RONKIN, L; SCHAEFER, S; STRACK, D; TURNER, LC; WALGENBACH, A; GRAVES, J; MICHALSKI, S; SCHUETTE, L; MOHR, JP; TATEMICHI, TK; MARSHALL, R; MAST, H; RAMOS, O; CORRELL, J; LIBMAN, R; PETTY, G; CABRERE, A; OROPEZA, L; GONZALEZ, T; PETTIGREW, C; SADLER, R; ENDEAN, E; SHERROW, J; HAUER, M; LEE, C; NORTON, J; MCQUILLEN, M; MATTINGLY, S; DEKOSKY, S; MASSEY, A; SIMARD, D; TURCOTTE, JF; BENGUIGUI, C; COTE, J; BOUCHARD, JM; ROBERGE, C; BRUNET, D; BEDARD, F; LANGELIER, R; LAJEUNESSE, M; BIGAOUETTE, JM; PARENT, J; LYDEN, P; HYE, R; LEWIS, S; CALI, G; BABCOCK, T; TAFTALVAREZ, B; BRODY, M; ZWEIFLER, R; SEDWITZ, M; STABILE, B; FREISCHLAG, JA; WOLF, YG; SIVO, J; FORSYTHE, J; ADAME, M; GUPTA, S; BURKE, K; GREISLER, HP; LITTOOY, FN; KELLY, MA; PULSINELLI, W; CAMPBELL, JA; CROCKARELL, J; WATRIDGE, C; ACKER, J; ERKULWATER, S; JACEWICZ, M; WALKER, G; OSULLIVAN, P; SAUER, C; VASU, K; GAINES, K; BAKHITIAN, B; BERTORINI, TE; BENNETT, S; THOMAS, T; STAHL, N; TAYLOR, C; GIAMPAPA, MA; CONNELL, J; RILEY, J; BRADLEY, A; DAVIS, J; NEWMAN, K; MANNING, R; MCCREA, M; HACHINSKI, V; FERGUSON, G; MAYER, C; BARNETT, JM; PEERLESS, SJ; BUCHAN, AM; REICHMAN, H; KERTESZ, A; LOWNIE, S; WHITE, C; FOX, A; RANKIN, R; SPENCE, JD; BARR, HWK; PADDOCKELIASZIW, L; ASSIS, LJP; PEXMAN, JHW; DICICCO, M; TATE, B; JAMES, C; RAKER, E; COATSWORTH, J; HARRIS, S; BEEBE, H; BIRCHFIELD, R; BUTLERLEVY, K; CRANE, R; FRYER, D; MACLEAN, J; PATTERSON, L; QUIGLEY, T; RAVITS, J; TAYLOR, L; PULLEN, S; BOSWELL, S; KENNY, K; BROTT, T; TOMSICK, T; ROEDERSHEIMER, LR; FOWL, R; TEW, J; KEMPCZINSKI, R; REED, R; WELLING, R; SCHOMAKER, B; LEFKOWITZ, D; MCWHORTER, JM; BRANCH, CL; SATTERFIELD, J; CORDELL, R; DEAN, R; PLONK, G; HARPOLD, G; WALKER, F; NUNN, C; MYERS, L; TEGELER, C; HARDIN, S; MEADS, D; LOFTUS, CM; VINING, LA; BENDIXEN, BH; BILLER, J; CORSON, JD; DAVIS, PH; GODERSKY, JC; GORDON, DL; JACOBY, MR; KAPPELLE, LJ; KRESOWIK, TF; MARSH, EE; LOVE, BB; SHAMMA, AR; GRIMSMAN, KJ; KARBOSKI, DM; MILLER, EV; JOHNSON, C; JONES, C; STONE, B; MAGUIRE, MP; EARLEY, C; KAPLAN, P; CAVALUZZI, J; WATERS, G; CHACHICH, B; AUER, A; LOGAN, W; WILCOX, M; GREEN, B; HURLEY, J; PENNELL, R; WOODS, J; LEVINE, R; NEPUTE, J; THOMASSON, J; BLACKBURN, C; FOLDES, M; KLEMP, K; NAPPIER, B; RUTHERFORD, K; SCHROER, S; HOGAN, J; THORPE, L; FEINBERG, WM; HUNTER, GC; BRUCK, DC; BERNHARD, VM; MCINTYRE, KE; CARTER, LP; LABADIE, EL; JOHNSON, DS; MOSCHONAS, CG; HAMILTON, RH; FORRER, SC; SEEGER, JF; CARMODY, RF; VOLD, BK; CARLSON, RL; LAGUNA, JE; KRIKAWA, JP; DEVINE, JJ; CASTRILLO, AM; KISTLER, SL; LEDBETTER, B; DORR, K; SMITH, RR; HAERER, AF; BROWN, RL; RUSSELL, W; RIGDON, E; RHODES, R; SMITH, E; GRAEBER, M; DOORENBOS, D; SUBRAMONY, SH; ATNIP, RG; BRENNAN, RW; FRIEDMAN, D; NEUMYER, MM; THIELE, BL; SMITH, F; BARR, JD; DUCKROW, RB; JANESKY, C; MEILSTRUP, JW; MCNAMARA, KP; RODICHOK, LD; STEWART, L; SULLIVAN, M; WENGROVITZ, M; CLAGETT, GP; UNWIN, H; BRYAN, W; MATKINS, C; PATTERSON, C; ALWAY, C; BOYD, P; INMAN, M; ALBISTON, C; SCOGGINS, E; SWILLING, J; WALDEN, KG; AHN, SS; AMOS, EC; BAKER, JD; DOBKIN, BH; DONAYRE, CE; GELABERT, HA; JORDAN, SE; MACHLEDER, HI; QUINONESBALDRICH, WJ; SAVER, JL; ELSADEN, SM; HOLGATE, RC; JABOUR, BA; JACOBS, JB; ABRAHAM, TM; VESCERA, CL; VONRAJCS, JA; CARTER, VL; CARTER, DT; DIXGOSS, DE; HERNANDEZ, EC; COULL, B; LOBOA, L; MONETA, G; PORTER, J; YEAGER, R; WHITTAKER, L; BRASS, LM; GUSBERG, RJ; LOVEJOY, AM; FAYAD, PB; SUMPIO, B; MEIER, GH; CHANG, VM; MARZITELLI, K; CHYATTE, D; HAMMERS, L; LEPORE, F; PAVALKIS, FJ; MELE, J; KISIEL, D; BARNES, RW; CHESSER, MZ; ARCHER, RL; THOMPSON, BW; MACDONALD, C; BARONE, GW; EIDT, JF; HARSHFIELD, D; MCFARLAND, D; NICKOLS, JR; HOWARD, C; NIX, ML; OVERSTREET, JK; TROILLETT, R; TAYLOR, J; LEE, HM; AKINS, P; HARBISON, JW; PRIDGEON, RM; FELTON, WL; POSNER, M; SOBEL, M; CLIFTON, G; CONWAY, C; COCKRELL, A; STRINGER, W; WINGO, J; NICHOLS, B; SMOKER, W; FISHER, R; SPETZLER, RF; FREY, JL; ZABRAMSKI, JM; HUNSLEY, SL; JAHNKE, H; PLENGE, KL; HOLLAND, R; TURNER, R; STRAVA, D; STUMPFF, S; HODAK, J; FLOM, RA; DEAN, BL; THOMPSON, RA; HUGHES, R; LEPLER, B; BOWEN, J; BENOIT, C; HOLLIER, L; OCHSNER, J; STRUB, R; LANG, V; CAHANIN, V; HOBSON, RW; WEISBROT, F; KAMIN, S; BACK, T; JAMIL, Z; ROGERS, C; LAINSON, B; HART, L; CAPLAN, L; ODONNELL, T; BARRON, L; PESSIN, M; DEWITT, D; MACKEY, W; BELKIN, M; MCGLAUGHLIN, R; HEGGERICK, P; WELCH, KMA; WILCZEWSKI, J; ROBERTSON, W; DALEY, S; ELLIOT, JP; REDDY, DJ; SHEPHARD, AD; SMITH, RF; LEVINE, S; RAMADAN, N; TIETJEN, G; MITSIAS, P; GORMAN, M; MCPHARLIN, M; PATEL, S; DEVESHWAR, R; LEE, N; KOKKINOS, J; WEINSTEIN, E; KUNKEL, J; KRATOCHVIL, A; JOHNSON, E; STEEL, S; NORRIS, J; ROWED, D; BOWYER, B; GAWEL, M; COOPER, PW; BRODIE, D; KIRKLAND, JS; SCHECTER, JA; FARRAR, NW; CAPPS, R; RHODES, EL; ROGERS, DM; GLASS, JT; NAGUSZEWSKI, R; NAGUSZEWSKI, W; MADDOX, B; DOLLISON, B; MOULTON, L; COLE, P; KINSELLA, P; ANSLEY, A; BRITZ, N; BIVINS, DH; WILLIAMS, EL; DAVIDSON, JT; ELIAS, W; ATKINS, D; TURNER, PB; BURCH, JG; NOLAN, DB; SPEESE, R; FOLEY, CD; MILLETTE, TJ; LANE, KH; ALMOND, C; MESTAYER, RJ; CALANCHINI, P; SZARNICKI, R; RADOSEVICH, P; ELIAS, L; MCCORMICK, P; GOULD, C; NORRIS, F; DENYS, E; BERNSTEIN, R; DUBONO, D; ATKINSON, K; PETERS, M; COHEN, B; YAO, J; ROSTON, S; BLACKBURN, D; SAVER, J; CHADWICK, L; MCCARTHY, W; PEARCE, W; FRANK, J; FERNANDEZBEER, E; PATRICK, J; GREEN, R; SATRAN, R; RICOTTA, J; DEWEESE, J; HOLLANDER, J; OBRIEN, M; MCNAMARA, J; ROSE, S; COHEN, D; FURLAN, A; LITTLE, J; BRYERTON, B; SILA, C; AWAD, I; CHIMOWITZ, M; ROBERTSON, S; BECKER, C; PAUSHTER, D; OLEARY, DH; JONES, AM; RICOTTA, JJ; GEE, W; SHEBEL, N; FISHER, MJ; SCHENK, EA; FURLAN, AJ; FUTRELL, NN; KELLY, M; MILLIKAN, CH; DIENER, HC; FIELDS, WS; FOLSTEIN, MF; GAUTIER, JC; HARRISON, MJG; HASS, WK; HENNERICI, MG; SPENCER, MP; VONREUTERN, GM			ENDARTERECTOMY FOR ASYMPTOMATIC CAROTID-ARTERY STENOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATURAL-HISTORY; CLINICAL-TRIALS; OCCLUSION	Objective.-To determine whether the addition of carotid endarterectomy to aggressive medical management can reduce the incidence of cerebral infarction in patients with asymptomatic carotid artery stenosis. Design.-Prospective, randomized, multicenter trial. Setting.-Thirty-nine clinical sites across the United States and Canada. Patients.-Between December 1987 and December 1993, a total of 1662 patients with asymptomatic carotid artery stenosis of 60% or greater reduction in diameter were randomized; follow-up data are available on 1659. At baseline, recognized risk factors for stroke were similar between the two treatment groups. Intervention.-Daily aspirin administration and medical risk factor management for ail patients; carotid endarterectomy for patients randomized to receive surgery. Main Outcome Measures.-Initially, transient ischemic attack or cerebral infarction occurring in the distribution of the study artery and any transient ischemic attack, stroke, or death occurring in the perioperative period. In March 1993, the primary; outcome measures were changed to cerebral infarction occurring in the distribution of the study artery or any stroke or death occurring in the perioperative period. Results.-After a median follow-up of 2.7 years, with 4657 patient-years of observation, the aggregate risk over 5 years for ipsilateral stroke and any perioperative stroke or death was estimated to be 5.1% for surgical patients and 11.0% for patients treated medically (aggregate risk reduction of 53% [95% confidence interval, 22% to 72%]). Conclusion.-Patients with asymptomatic carotid artery stenosis of 60% or greater reduction in diameter and whose general health makes them good candidates for elective surgery will have a reduced 5-year risk of ipsilaterat stroke if carotid endarterectomy performed with less than 3% perioperative morbidity and mortality is added to aggressive management of modifiable risk factors.	WAKE FOREST UNIV, BOWMAN GRAY SCH MED, CTR STROKE, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROL, WINSTON SALEM, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center			Stringer, William/AAC-2147-2019; Buchan, Alastair M/B-9095-2009; Mohr, J/AAO-9694-2020; Tegeler, Charles/R-3623-2019; Spence, J. David/K-6396-2013; Diener, Hans-Christoph/AAF-7275-2019; Eidt, John/AAH-8842-2020	Buchan, Alastair M/0000-0002-2918-5200; Spence, J. David/0000-0001-7478-1098; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022611] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS22611] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDROV AV, 1993, STROKE, V24, P1292, DOI 10.1161/01.STR.24.9.1292; [Anonymous], 1992, Mayo Clin Proc, V67, P513; AUTRET A, 1987, LANCET, V1, P888; BROTT T, 1994, STROKE, V25, P1122, DOI 10.1161/01.STR.25.6.1122; Chervu A, 1994, Ann Vasc Surg, V8, P296, DOI 10.1007/BF02018179; COTE R, 1983, STROKE, V14, P898, DOI 10.1161/01.STR.14.6.898; DIENER HC, 1991, STROKE, V22, P1229; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HENNERICI M, 1987, BRAIN, V110, P777, DOI 10.1093/brain/110.3.777; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; Horn M, 1994, Ann Vasc Surg, V8, P221, DOI 10.1007/BF02018167; Howard G, 1991, J Stroke Cerebrovasc Dis, V1, P166, DOI 10.1016/S1052-3057(10)80013-8; JENNETT B, 1975, LANCET, V1, P480; JORGENSEN L, 1969, J NEUROL SCI, V9, P285, DOI 10.1016/0022-510X(69)90078-1; Kalbfleisch JD, 1980, STATISTICAL ANAL FAI, P14; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P289, DOI 10.1016/0197-2456(88)90045-1; LAUPACIS A, 1992, ACP J CLUB       MAY, pA12; Lefkowitz D S, 1992, J Stroke Cerebrovasc Dis, V2, P92, DOI 10.1016/S1052-3057(10)80213-7; MOORE WS, 1995, STROKE, V26, P188, DOI 10.1161/01.STR.26.1.188; MOORE WS, 1991, STROKE, V22, P1353, DOI 10.1161/01.STR.22.11.1353; MORASCH MD, IN PRESS ANN VASC SU; NICHOLLS SC, 1986, J VASC SURG, V4, P479, DOI 10.1067/mva.1986.avs0040479; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OHOLLERAN LW, 1987, AM J SURG, V154, P659, DOI 10.1016/0002-9610(87)90238-8; RILES TS, 1994, CURRENT CRITICAL PRO, V6, P264; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TILL JS, 1987, STROKE, V18, P823, DOI 10.1161/01.STR.18.5.823; TIMSIT SG, 1992, STROKE, V23, P486, DOI 10.1161/01.STR.23.4.486; Toole J F, 1994, J Neuroimaging, V4, P222; TOOLE JF, 1989, STROKE, V20, P844; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WILSON SE, 1988, SURGERY, V104, P932	35	3845	3957	2	124	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1421	1428		10.1001/jama.1995.03520420037035	http://dx.doi.org/10.1001/jama.1995.03520420037035			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723155				2022-12-28	WOS:A1995QW27900029
J	GRAHAM, JR				GRAHAM, JR			HELICOBACTER-PYLORI - HUMAN PATHOGEN OR SIMPLY AN OPPORTUNIST	LANCET			English	Editorial Material							PEPTIC-ULCER DISEASE; GASTRITIS; CAMPYLOBACTER; INFECTION				GRAHAM, JR (corresponding author), SYDNEY HOSP,ALAN MCGUINNESS GASTROENTEROL UNIT,SYDNEY,NSW 2000,AUSTRALIA.							Adelberg, 1982, REV MED MICROBIOLOGY; BAYERDORFFER E, 1993, NEW ENGL J MED, V329, P60, DOI 10.1056/NEJM199307013290116; CHANDRAKUMARAN K, 1994, GUT, V35, P1033, DOI 10.1136/gut.35.8.1033; FALLINGBORG J, 1992, SCAND J GASTROENTERO, V27, P388, DOI 10.3109/00365529209000093; FONG TL, 1991, GASTROENTEROLOGY, V100, P328, DOI 10.1016/0016-5085(91)90199-U; FORBES G, 1994, MED J AUSTRALIA, V161, P291, DOI 10.5694/j.1326-5377.1994.tb127445.x; FORBES GM, 1994, LANCET, V343, P258, DOI 10.1016/S0140-6736(94)91111-8; Gilman A., 1985, PHARM BASIS THERAPEU, Vseventh; KOOP H, 1991, DIGESTION, V48, P230, DOI 10.1159/000200698; MARSHALL BJ, 1988, LANCET, V2, P1437; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MCCORMICK PA, 1991, GUT, V32, P351, DOI 10.1136/gut.32.4.351; ROSS JS, 1992, AM J PATHOL, V141, P721; SAEED ZA, 1991, DIGEST DIS SCI, V36, P15, DOI 10.1007/BF01300080; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; SUNG JJY, 1995, NEW ENGL J MED, V332, P139, DOI 10.1056/NEJM199501193320302; TAHA AS, 1993, GUT, V34, P580, DOI 10.1136/gut.34.5.580; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; UPPAL R, 1991, ARCH INTERN MED, V151, P760, DOI 10.1001/archinte.151.4.760	19	34	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1095	1097		10.1016/S0140-6736(95)90824-2	http://dx.doi.org/10.1016/S0140-6736(95)90824-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715345				2022-12-28	WOS:A1995QV41100016
J	STRONG, RW				STRONG, RW			RENAL GRAFTS FROM NON-HEART-BEATING DONORS	LANCET			English	Editorial Material							NONHEARTBEATING DONORS				STRONG, RW (corresponding author), PRINCESS ALEXANDRA HOSP,BRISBANE,QLD 4102,AUSTRALIA.							HOWARD RJ, 1994, CLIN TRANSPLANT, V8, P527; LLIOVERAS J, 1993, TRANSPLANT P, V25, P3169; MATSUNO N, 1993, TRANSPLANT P, V25, P3095; PHILLIPS AO, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575a; VALERO R, 1993, TRANSPLANT P, V25, P3091; VARTY K, 1994, BRIT MED J, V308, P575, DOI 10.1136/bmj.308.6928.575; 1995, LANCET, V345, P1067	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1064	1065		10.1016/S0140-6736(95)90812-9	http://dx.doi.org/10.1016/S0140-6736(95)90812-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715334				2022-12-28	WOS:A1995QV41100004
J	WALTERS, WA; SIVANESARATNAM, V; HAMILTON, JD				WALTERS, WA; SIVANESARATNAM, V; HAMILTON, JD			EXTERNAL EXAMINERS	LANCET			English	Article							MEDICAL-EDUCATION		UNIV MALAYA,FAC MED,DEPT OBSTET & GYNAECOL,KUALA LUMPUR 59100,MALAYSIA	Universiti Malaya	WALTERS, WA (corresponding author), UNIV NEWCASTLE,FAC MED & HLTH SCI,NEWCASTLE,NSW 2308,AUSTRALIA.							CAMPBELL PN, 1991, BIOCHEM EDUC, V19, P13, DOI 10.1016/0307-4412(91)90131-Q; GONELLA JS, 1983, J MED EDUC, V58, P358; HAMILTON JD, 1990, MED J AUSTRALIA, V153, P541, DOI 10.5694/j.1326-5377.1990.tb126195.x; HAMILTON JD, 1991, LANCET, V338, P99, DOI 10.1016/0140-6736(91)90087-6; KAPPELMAN MM, 1983, J MED EDUC, V58, P300; LAWTON R, 1986, J GEOGR HIGHER EDUC, V10, P41, DOI 10.1080/03098268608708954; NICHOLLS SH, 1985, ASSESSMENT EVAL HIGH, V10, P29; NYSTRUP J, 1992, MED EDUC, V26, P350, DOI 10.1111/j.1365-2923.1992.tb00184.x; PIPER DW, 1985, STUD HIGH EDUC, V10, P331; 1985, EXTERNAL EXAMINER SY	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1093	1095		10.1016/S0140-6736(95)90823-4	http://dx.doi.org/10.1016/S0140-6736(95)90823-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715344				2022-12-28	WOS:A1995QV41100015
J	SEEMULLER, E; LUPAS, A; STOCK, D; LOWE, J; HUBER, R; BAUMEISTER, W				SEEMULLER, E; LUPAS, A; STOCK, D; LOWE, J; HUBER, R; BAUMEISTER, W			PROTEASOME FROM THERMOPLASMA-ACIDOPHILUM - A THREONINE PROTEASE	SCIENCE			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; EXPRESSION; SUBUNITS; PROTEOLYSIS; PITUITARY; SEQUENCE; DISTINCT; INTERFERON	The catalytic mechanism of the 20S proteasome from the archaebacterium Thermoplasma acidophilum has been analyzed by site-directed mutagenesis of the beta subunit and by inhibitor studies. Deletion of the amino-terminal threonine or its mutation to alanine led to inactivation of the enzyme. Mutation of the residue to serine led to a fully active enzyme, which was over ten times more sensitive to the serine protease inhibitor 3,4-dichloroisocoumarin. In combination with the crystal structure of a proteasome-inhibitor complex, the data show that the nucleophilic attack is mediated by the amino-terminal threonine of processed beta subunits. The conservation pattern of this residue in eukaryotic sequences suggests that at least three of the seven eukaryotic beta-type subunit branches should be proteolytically inactive.	MAX PLANCK INST BIOCHEM,STRUKT BIOL ABT,D-82152 MARTINSRIED,GERMANY; MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,D-82152 MARTINSRIED,GERMANY	Max Planck Society; Max Planck Society			Löwe, Jan/X-6998-2019; Ueno, Hiroshi/C-3301-2009; Löwe, Jan/B-3882-2011	Lowe, Jan/0000-0002-5218-6615				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BROWN MG, 1993, J IMMUNOL, V151, P1193; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLACKSON T, 1991, PCR PRACTICAL APPROA; DAHLMANN B, 1992, EUR J BIOCHEM, V208, P789, DOI 10.1111/j.1432-1033.1992.tb17249.x; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DJABALLAH H, 1992, EUR J BIOCHEM, V209, P629, DOI 10.1111/j.1432-1033.1992.tb17329.x; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ENZEL T, 1995, NAT STRUCT BIOL, V2, P199; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GAOZYNSKA M, 1994, P NATL ACAD SCI USA, V90, P9213; GLYNNE R, 1995, NATURE, V353, P357; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRZIWA A, 1992, J STRUCT BIOL, V109, P168, DOI 10.1016/1047-8477(92)90048-F; HASE J, 1980, BIOCHIM BIOPHYS ACTA, V611, P205, DOI 10.1016/0005-2744(80)90056-X; HEGERL R, 1991, FEBS LETT, V283, P117, DOI 10.1016/0014-5793(91)80567-M; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1994, FEBS LETT, V341, P193; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1993, J BIOL CHEM, V268, P3479; KELLY A, 1995, NATURE, V353, P667; KNIGHT CG, 1986, PROTEINASE INHIBITOR; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; LUPAS A, 1994, TRENDS BIOCHEM SCI, V19, P533, DOI 10.1016/0968-0004(94)90054-X; MARTINEZ CK, 1995, NATURE, V353, P664; MASON RW, 1990, BIOCHEM J, V265, P479, DOI 10.1042/bj2650479; MICHALEK MT, 1992, NATURE, V357, P552; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; ORTIZNAVARETTE V, 1995, NATURE, V353, P662; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PUHLER G, 1992, EMBO J, V11, P1607, DOI 10.1002/j.1460-2075.1992.tb05206.x; PUHLER G, 1994, SYST APPL MICROBIOL, V16, P734; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SCHAUER TM, 1993, J STRUCT BIOL, V111, P135, DOI 10.1006/jsbi.1993.1044; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TAMURA T, UNPUB; Tanaka K, COMMUNICATION; WENZEL T, 1993, FEBS LETT, V326, P215, DOI 10.1016/0014-5793(93)81793-Y; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765; ZWICKL P, 1992, FEBS LETT, V312, P157, DOI 10.1016/0014-5793(92)80925-7	60	584	592	1	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					579	582		10.1126/science.7725107	http://dx.doi.org/10.1126/science.7725107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725107				2022-12-28	WOS:A1995QV40700041
J	KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M				KASHIWABUCHI, N; IKEDA, K; ARAKI, K; HIRANO, T; SHIBUKI, K; TAKAYAMA, C; INOUE, Y; KUTSUWADA, T; YAGI, T; KANG, Y; AIZAWA, S; MISHINA, M			IMPAIRMENT OF MOTOR COORDINATION, PURKINJE-CELL SYNAPSE FORMATION, AND CEREBELLAR LONG-TERM DEPRESSION IN GLUR-DELTA-2 MUTANT MICE	CELL			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL-NERVOUS-SYSTEM; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; FAMILY; POTENTIATION; HIPPOCAMPUS; INDUCTION; CURRENTS; CALCIUM	Of the six glutamate receptor (GluR) channel subunit families identified by molecular cloning, five have been shown to constitute either the AMPA, kainate, or NMDA receptor channel, whereas the function of the delta subunit family remains unknown. The selective localization of the delta 2 subunit or the GluR delta subfamily in cerebellar Purkinje Cells prompted us to examine its possible physiological roles by the gene targeting technique. Analyses of the GluR delta 2 mutant mice reveal that the delta 2 subunit plays important roles in motor coordination, formation of parallel fiber-Purkinje cell synapses and climbing fiber-Purkinje cell synapses, and long-term depression of parallel fiber-Purkinje cell synaptic transmission. These! results suggest a close relationship between synaptic plasticity and synapse formation in the cerebellum.	NIIGATA UNIV,BRAIN RES INST,DEPT PHYSIOL,NIIGATA 951,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT ANAT,SAPPORO,HOKKAIDO 060,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,IBARAKI,OSAKA 305,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,TOKYO 113,JAPAN	Niigata University; Kyoto University; Hokkaido University; RIKEN; University of Tokyo	KASHIWABUCHI, N (corresponding author), NIIGATA UNIV,BRAIN RES INST,DEPT NEUROPHARMACOL,NIIGATA 951,JAPAN.		Ikeda, Kazutaka/I-4694-2013	Ikeda, Kazutaka/0000-0001-8342-0278				ARAKI K, 1993, BIOCHEM BIOPH RES CO, V197, P1267, DOI 10.1006/bbrc.1993.2614; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CREPEL F, 1991, J PHYSIOL-LONDON, V432, P123, DOI 10.1113/jphysiol.1991.sp018380; CREPEL F, 1982, TRENDS NEUROSCI, V5, P266, DOI 10.1016/0166-2236(82)90168-0; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Goldowitz Dan, 1992, V8, P271; HIRANO T, 1990, NEUROSCI LETT, V119, P145, DOI 10.1016/0304-3940(90)90819-U; HIRANO T, 1994, NEUROSCI LETT, V182, P172, DOI 10.1016/0304-3940(94)90790-0; HOGAN B, 1986, MANIPULATING MOUSE E; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; KONNERTH A, 1992, P NATL ACAD SCI USA, V89, P7051, DOI 10.1073/pnas.89.15.7051; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LINDEN DJ, 1994, NEURON, V12, P457, DOI 10.1016/0896-6273(94)90205-4; LOMELI H, 1993, FEBS LETT, V315, P318, DOI 10.1016/0014-5793(93)81186-4; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MISHINA M, 1993, ANN NY ACAD SCI, V707, P136, DOI 10.1111/j.1749-6632.1993.tb38049.x; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; PERKEL DJ, 1990, P ROY SOC B-BIOL SCI, V241, P116, DOI 10.1098/rspb.1990.0074; RABACCHI S, 1992, SCIENCE, V256, P1823, DOI 10.1126/science.1352066; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SAKURAI M, 1990, P NATL ACAD SCI USA, V87, P3383, DOI 10.1073/pnas.87.9.3383; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SHIBUKI K, 1992, NEUROREPORT, V3, P231, DOI 10.1097/00001756-199203000-00003; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMAKUNI T, 1984, NEUROSCI LETT, V45, P235, DOI 10.1016/0304-3940(84)90232-5; YAMAZAKI M, 1992, BIOCHEM BIOPH RES CO, V183, P886, DOI 10.1016/0006-291X(92)90566-4	36	482	485	1	12	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					245	252		10.1016/0092-8674(95)90334-8	http://dx.doi.org/10.1016/0092-8674(95)90334-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736576	Bronze			2022-12-28	WOS:A1995QV41000013
J	RADU, A; MOORE, MS; BLOBEL, G				RADU, A; MOORE, MS; BLOBEL, G			THE PEPTIDE REPEAT DOMAIN OF NUCLEOPORIN NUP98 FUNCTIONS AS A DOCKING SITE IN TRANSPORT ACROSS THE NUCLEAR-PORE COMPLEX	CELL			English	Article							WHEAT-GERM AGGLUTININ; PROTEIN IMPORT; NUCLEOCYTOPLASMIC TRANSPORT; MEMBRANE DOMAIN; 2 STEPS; ENVELOPE; NSP1; INHIBITION; SEQUENCE; CONTAINS	We report the cDNA deduced primary structure of a wheat germ agglutinin-reactive nuclear pore complex (NPC) protein of rat. The protein, termed Nup98 (for nucleoporin of 98 kDa), contains numerous GLFG and FG repeats and some FXFG repeats and is thus a vertebrate member of a family of GLFG nucleoporins that were previously discovered in yeast. Immunoelectron microscopy showed Nup98 to be asymmetrically located at the nucleoplasmic side of the NPC. Nup98 functions as one of several docking site nucleoporins in a cytosolic docking activity-mediated binding of a model transport substrate. The docking site of Nup98 was mapped to its N-terminal half, which contains all of the peptide repeats. A recombinant segment of this region depleted the docking activity of cytosol. We suggest that the peptide repeat domain of Nup98, together with peptide repeat domains of other nucleoporins, forms an array of sites for mediated docking of transport substrate, and that bidirectional transport across the NPC proceeds by repeated docking and undocking reactions.			RADU, A (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.							ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; CORDES VC, 1993, J CELL BIOL, V123, P1333, DOI 10.1083/jcb.123.6.1333; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DABAUVALLE MC, 1988, EXP CELL RES, V174, P291, DOI 10.1016/0014-4827(88)90163-2; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FABRE E, 1994, CELL, V78, P275, DOI 10.1016/0092-8674(94)90297-6; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P569; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; GROLICH D, 1991, CELL, V79, P767; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HURT EC, 1988, EMBO J, V7, P4323, DOI 10.1002/j.1460-2075.1988.tb03331.x; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; MEHLIN H, 1962, CELL, V69, P605; Mehlin Hans, 1993, Trends in Cell Biology, V3, P443, DOI 10.1016/0962-8924(93)90034-X; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2088; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; RADU A, 1994, J BIOL CHEM, V269, P17600; RADU A, 1993, J CELL BIOL, V121, P1, DOI 10.1083/jcb.121.1.1; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIS H, 1991, EMSA B, V21, P54; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; SCHLENSTEDT G, 1992, J CELL BIOL, V123, P785; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STERNEMARR R, 1992, J CELL BIOL, V116, P271, DOI 10.1083/jcb.116.2.271; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; WENTE SR, 1994, J CELL BIOL, V125, P955, DOI 10.1083/jcb.125.5.955; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; WOZNIAK RW, 1989, J CELL BIOL, V108, P2038; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7	52	411	419	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					215	222		10.1016/0092-8674(95)90331-3	http://dx.doi.org/10.1016/0092-8674(95)90331-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736573	Bronze			2022-12-28	WOS:A1995QV41000010
J	MOCHLYROSEN, D				MOCHLYROSEN, D			LOCALIZATION OF PROTEIN-KINASES BY ANCHORING PROTEINS - A THEME IN SIGNAL-TRANSDUCTION	SCIENCE			English	Article							ADRENERGIC-RECEPTOR KINASE; MICROTUBULE-ASSOCIATED PROTEIN-2; BETA-GAMMA-SUBUNITS; REGULATORY SUBUNIT; SUBCELLULAR-LOCALIZATION; INTRACELLULAR RECEPTORS; ADENYLATE-CYCLASE; C TRANSLOCATION; GOLGI-COMPLEX; II-BETA	A fundamental question in signal transduction is how stimulation of a specific protein kinase leads to phosphorylation of particular protein substrates throughout the cell. Recent studies indicate that specific anchoring proteins located at various sites in the cell compartmentalize the kinases to their sites of action. Inhibitors of the interactions between kinases and their anchoring proteins inhibit the functions mediated by the kinases. These data indicate that the location of these anchoring proteins provides some of the specificity of the responses mediated by each kinase and suggest that inhibitors of the interaction between the kinases and their anchoring proteins may be useful as therapeutic agents.			MOCHLYROSEN, D (corresponding author), STANFORD UNIV,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.			Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [R01 HL-43380] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043380] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; AITKEN A, 1990, NATURE, V344, P594; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BONEH A, 1988, BIOCHEM CELL BIOL, V66, P262, DOI 10.1139/o88-035; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FANTOZZI DA, 1994, J BIOL CHEM, V269, P2676; FORCE T, 1994, P NATL ACAD SCI USA, V91, P1270, DOI 10.1073/pnas.91.4.1270; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GOSH S, 1994, J BIOL CHEM, V269, P10000; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HAGIWARA M, 1990, ARCH BIOCHEM BIOPHYS, V280, P201, DOI 10.1016/0003-9861(90)90536-8; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; INGLESE J, 1993, J BIOL CHEM, V268, P23735; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAKEN S, 1992, PROTEIN KINASE C CUR, P237; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KIM CM, 1993, J BIOL CHEM, V268, P15412; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LOHMANN SM, 1984, ADV CYCLIC NUCLEOTID, P63; MISRA UK, 1987, BIOCHEM BIOPH RES CO, V145, P760, DOI 10.1016/0006-291X(87)91030-8; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURTHY ASN, 1985, J BIOL CHEM, V260, P4364; NDUBUKA C, 1993, J BIOL CHEM, V268, P7621; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBAR RA, 1989, NEURON, V3; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PAPADOPOULOS V, 1989, J CELL BIOL, V108, P553, DOI 10.1083/jcb.108.2.553; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROSENMUND C, 1994, NATURE, V368, P353; ROTEM R, 1990, P NATL ACAD SCI USA, V87, P7305, DOI 10.1073/pnas.87.18.7305; SCOTT JD, 1992, NEWS PHYSIOL SCI, V7, P143; SCOTT JD, 1990, J BIOL CHEM, V265, P21561; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; TRAVERSE S, 1993, ONCOGENE, V8, P3175; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WOLF M, 1986, J BIOL CHEM, V261, P3327; ZALEWSKI PD, 1988, BIOCHEM PHARMACOL, V37, P1415, DOI 10.1016/0006-2952(88)90802-7	74	828	860	1	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					247	251		10.1126/science.7716516	http://dx.doi.org/10.1126/science.7716516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716516				2022-12-28	WOS:A1995QT18500024
J	MURPHY, TD; KARPEN, GH				MURPHY, TD; KARPEN, GH			INTERACTIONS BETWEEN THE NOD(+) KINESIN-LIKE GENE AND EXTRACENTROMERIC SEQUENCES ARE REQUIRED FOR TRANSMISSION OF A DROSOPHILA MINICHROMOSOME	CELL			English	Article							DISTRIBUTIVE SEGREGATION; SATELLITE DNA; MELANOGASTER; CENTROMERE; PROTEIN; FEMALES; LOCUS; TRANSPOSITION; CHROMOSOMES; MUTATIONS	In this study, we demonstrate a role for extracentromeric sequences in chromosome inheritance. Genetic analyses indicate that transmission of the Drosophila minichromosome Dp1187 is sensitive to the dosage of nod(+), a kinesin-like gene required for the meiotic transmission of achiasmate chromosomes. Minichromosome deletions displayed increased loss rates in females heterozygous for a loss-of-function allele of nod (nod/+). We have analyzed the structures of nod-sensitive deletions and conclude that multiple regions of Dp1187 interact genetically with nod(+) to promote normal chromosome transmission. Most nod(+) interactions are observed with regions that are not essential for centromere function. We propose that normal chromosome transmission requires forces generated outside the kinetochore, perhaps to maintain tension on kinetochore microtubules and stabilize the attachment of achiasmate chromosomes to the metaphase spindle.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MURPHY, TD (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037, USA.							AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BRINKLEY BR, 1991, BIOESSAYS, V13, P675, DOI 10.1002/bies.950131210; CARPENTER AT, 1973, GENETICS, V73, P393; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CARPENTER ATC, 1984, COLD SPRING HARB SYM, V49, P23, DOI 10.1101/SQB.1984.049.01.005; CASSIMERIS L, 1994, J CELL SCI, V107, P285; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; FULLER MT, 1995, CELL, V81, P5, DOI 10.1016/0092-8674(95)90364-X; HAWLEY RS, 1993, DEV GENET, V13, P440; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HSIEH T, 1979, J MOL BIOL, V135, P465, DOI 10.1016/0022-2836(79)90447-9; John B, 1988, HETEROCHROMATIN MOL, P1; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1994, CURR OPIN GENET DEV, V4, P281, DOI 10.1016/S0959-437X(05)80055-3; KARPEN GH, 1990, CELL, V63, P97; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1991, P NATL ACAD SCI USA, V88, P7165, DOI 10.1073/pnas.88.16.7165; LE MH, IN PRESS GENETICS; LICA LM, 1986, J CELL BIOL, V103, P1145, DOI 10.1083/jcb.103.4.1145; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RASOOLY RS, 1991, GENETICS, V129, P409; REGAN CL, 1988, GENE DEV, V2, P82, DOI 10.1101/gad.2.1.82; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SLEISTER HM, 1992, NUCLEIC ACIDS RES, V20, P3419, DOI 10.1093/nar/20.13.3419; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THOMPSON SD, 1994, P NATL ACAD SCI USA, V91, P9042; TOWER J, 1993, GENETICS, V133, P347; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WRIGHT TRF, 1974, GENETICS, V76, P511; ZHANG P, 1993, GENETICS, V133, P361; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	37	55	57	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					139	148		10.1016/0092-8674(95)90378-X	http://dx.doi.org/10.1016/0092-8674(95)90378-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720069	Bronze			2022-12-28	WOS:A1995QR97000015
J	DOVER, JS; ARNDT, KA				DOVER, JS; ARNDT, KA			DERMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALCIPOTRIOL MC-903 OINTMENT; PSORIASIS-VULGARIS; PROLIFERATION; EFFICACY		HARVARD UNIV,SCH MED,BOSTON,MA; BETH ISRAEL HOSP,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215, USA.							ANDERSON RR, 1993, ARCH DERMATOL, V129, P1010, DOI 10.1001/archderm.129.8.1010; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BOURKE JF, 1993, CLIN EXP DERMATOL, V18, P504, DOI 10.1111/j.1365-2230.1993.tb01018.x; CUNLIFFE WJ, 1992, J AM ACAD DERMATOL, V26, P736, DOI 10.1016/0190-9622(92)70103-M; DUBERTRET L, 1992, J AM ACAD DERMATOL, V27, P983, DOI 10.1016/0190-9622(92)70299-U; Frappaz A, 1993, EUR J DERMATOL, V3, P351; GOODFIELD MJD, 1992, BRIT MED J, V304, P1151, DOI 10.1136/bmj.304.6835.1151; HOFMANN H, IN PRESS ARCH DERMAT; KILMER SL, 1994, ARCH DERMATOL, V130, P1515, DOI 10.1001/archderm.130.12.1515; KUOKKANEN K, 1992, J DERMATOL TREAT, V3, P115; MACLAUGHLIN JA, 1985, P NATL ACAD SCI USA, V82, P5409, DOI 10.1073/pnas.82.16.5409; ROBERTS DT, 1994, J AM ACAD DERMATOL S, V31, P78; TAYLOR CR, 1994, J AM ACAD DERMATOL, V30, P743, DOI 10.1016/S0190-9622(08)81505-8; WATANABE S, 1994, NEW ENGL J MED, V331, P1745, DOI 10.1056/NEJM199412293312604	14	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1668	1670						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752408				2022-12-28	WOS:A1995RB09700016
J	FLETCHER, RH; FLETCHER, SW				FLETCHER, RH; FLETCHER, SW			GENERAL INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER		HARVARD UNIV, COMMUNITY HLTH PLAN, BOSTON, MA USA	Harvard University	FLETCHER, RH (corresponding author), HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA.							ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AYANIAN JZ, 1994, NEW ENGL J MED, V331, P1136, DOI 10.1056/NEJM199410273311707; CARLSON KJ, 1994, ANN INTERN MED, V121, P124, DOI 10.7326/0003-4819-121-2-199407150-00009; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001; GODLEE F, 1994, BMJ-BRIT MED J, V309, P969, DOI 10.1136/bmj.309.6960.969; HAYNES RB, 1993, ACP J CLUB S3, V119, pA222; INUI TS, 1994, J GEN INTERN MED S1, V9, P1; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; MOORE GT, 1994, INQUIRY-J HEALTH CAR, V31, P276; NOBLE J, 1994, J GEN INTERN MED, V9, pS31, DOI 10.1007/BF02598116; SCHORLING JB, 1994, J GEN INTERN MED, V9, P248, DOI 10.1007/BF02599649; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; 1995, 950642 US DEP HLTH H	21	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1681	1682		10.1001/jama.273.21.1681	http://dx.doi.org/10.1001/jama.273.21.1681			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752414				2022-12-28	WOS:A1995RB09700022
J	LEVIN, LA				LEVIN, LA			OPHTHALMOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE OPTIC NEURITIS; ALZHEIMERS-DISEASE; CORTICOSTEROIDS; TRIAL				LEVIN, LA (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53706, USA.							BECK RW, 1993, NEW ENGL J MED, V329, P1764, DOI 10.1056/NEJM199312093292403; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; BECK RW, 1994, OPHTHALMOLOGY, V101, P1771; BECK RW, 1993, ARCH OPHTHALMOL-CHIC, V111, P773, DOI 10.1001/archopht.1993.01090060061023; BECK RW, 1995, ARCH OPHTHALMOL-CHIC, V113, P136, DOI 10.1001/archopht.1995.01100020014004; HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804; KATZ B, 1989, SURV OPHTHALMOL, V34, P31, DOI 10.1016/0039-6257(89)90127-6; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; SARAN BR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1159, DOI 10.1001/archopht.1994.01090210043015; SCHLACH W, 1992, FREE RADICALS AGING, P280; SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660; SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413; SHAFRAN SD, 1994, NEW ENGL J MED, V330, P438, DOI 10.1056/NEJM199402103300616; WARING GO, 1994, ARCH OPHTHALMOL-CHIC, V112, P1298, DOI 10.1001/archopht.1994.01090220048022; 1995, JAMA-J AM MED ASSOC, V273, P625	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1703	1705						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752427				2022-12-28	WOS:A1995RB09700035
J	LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH				LENNON, VA; KRYZER, TJ; GRIESMANN, GE; OSUILLEABHAIN, PE; WINDEBANK, AJ; WOPPMANN, A; MILJANICH, GP; LAMBERT, EH			CALCIUM-CHANNEL ANTIBODIES IN THE LAMBERT-EATON SYNDROME AND OTHER PARANEOPLASTIC SYNDROMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CARCINOMA; AMYOTROPHIC-LATERAL-SCLEROSIS; MYASTHENIC SYNDROME ANTIGEN; ACETYLCHOLINE-RECEPTORS; CA2+ CHANNELS; IGG; AUTOANTIBODIES; PROTEIN; ACTIVATION; RI	Background. Voltage-gated calcium channels in small-cell lung carcinomas may initiate autoimmunity in the paraneoplastic neuromuscular disorder Lambert-Eaton syndrome. The calcium-channel subtype that is responsible is not known. Methods. We compared the effects of antagonists of L-type, N-type, and P/Q-type neuronal calcium channels on the depolarization-dependent influx of calcium-45 in cultured carcinoma cells. Serum samples from patients with various disorders were tested for reactivity with P/Q-type channels solubilized from carcinoma and cerebellar membranes and N-type channels from cerebral cortex. Results. P/Q-type calcium-channel antagonists were the most potent inhibitors of depolarization-induced Ca-45 influx in cultured small-cell carcinoma cell lines. Anti-P/Q-type calcium-channel antibodies were found in serum from all 32 patients with the Lambert-Eaton syndrome and a diagnosis of cancer and in 91 percent of the 33 patients with the Lambert-Eaton syndrome without cancer. Anti-N-type calcium-channel antibodies were found in 49 percent of the 65 patients with the Lambert-Eaton syndrome. Lower titers of anti-P/Q-type and anti-N-type calcium-channel antibodies were found in 54 percent of 70 patients with a paraneoplastic encephalomyeloneuropathic complication of lung, ovarian, or breast carcinoma, 24 percent of 90 patients with cancer but no evident neurologic complications, 23 percent of 78 patients with sporadic amyotrophic lateral sclerosis, and less than 3 percent of 69 patients with myasthenia gravis, epilepsy, or scleroderma. Conclusions. The high frequency of P/Q-type calcium-channel antibodies found in patients with the Lambert-Eaton syndrome implies that antibodies of this specificity have a role in the presynaptic pathophysiology of this disorder.	MAYO CLIN & MAYO FDN,DEPT IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED,ROCHESTER,MN 55905; NEUREX CORP,MENLO PK,CA	Mayo Clinic; Mayo Clinic; Mayo Clinic				O'Suilleabhain, Padraig/0000-0002-2981-4791	NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER; NCI NIH HHS [CA-37343] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; BUCKANOVICH RJ, 1993, NEURON, V11, P657, DOI 10.1016/0896-6273(93)90077-5; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; CUNNINGHAM JM, 1985, J NEUROCHEM, V45, P159, DOI 10.1111/j.1471-4159.1985.tb05488.x; DEAIZPURUA HJ, 1988, CANCER RES, V48, P4719; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KIERS L, 1991, MAYO CLIN PROC, V66, P1209, DOI 10.1016/S0025-6196(12)62471-9; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LAMBERT EH, 1988, MUSCLE NERVE, V11, P1133, DOI 10.1002/mus.880111105; Lennon V, 1994, HDB MYASTHENIA GRAVI, P149; LENNON V A, 1990, Annals of Neurology, V28, P281; Lennon V. A., 1993, Society for Neuroscience Abstracts, V19, P1753; LENNON VA, 1994, NEUROLOGY, V44, P2236, DOI 10.1212/WNL.44.12.2236; LENNON VA, 1994, NEUROLOGY, V44, P2412, DOI 10.1212/WNL.44.12.2412; LENNON VA, 1989, MAYO CLIN PROC, V64, P1498, DOI 10.1016/S0025-6196(12)65705-X; LENNON VA, 1994, MUSCLE NERVE       S, V1, pS22; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEYS K, 1991, ANN NEUROL, V29, P307, DOI 10.1002/ana.410290313; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P11743, DOI 10.1073/pnas.90.24.11743; LOOSER P, 1980, SCHWEIZ MED WSCHR, V110, P1342; LUQUE FA, 1991, ANN NEUROL, V29, P241, DOI 10.1002/ana.410290303; MCCANN FV, 1981, SCIENCE, V212, P1155, DOI 10.1126/science.6262914; Oguro-Okano M., 1993, Society for Neuroscience Abstracts, V19, P1755; OGUROOKANO M, 1992, MAYO CLIN PROC, V67, P1150, DOI 10.1016/S0025-6196(12)61144-6; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OSUILLEABHAIN PE, 1994, NEUROLOGY, V44, pA157; ROBERTS A, 1985, NATURE, V317, P737, DOI 10.1038/317737a0; ROSENFELD MR, 1993, ANN NEUROL, V33, P113, DOI 10.1002/ana.410330126; SHER E, 1989, LANCET, V2, P640; SHER E, 1991, FASEB J, V5, P2677, DOI 10.1096/fasebj.5.12.1655547; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; TRIGGLE DJ, 1989, TRENDS PHARMACOL SCI, V10, P507, DOI 10.1016/0165-6147(89)90051-5; UCHITEL OD, 1992, P NATL ACAD SCI USA, V89, P330; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WILLIAMS CL, 1990, J BIOL CHEM, V265, P1443; WILLIAMS CL, 1991, CELL REGUL, V2, P373, DOI 10.1091/mbc.2.5.373; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	41	425	439	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1467	1474		10.1056/NEJM199506013322203	http://dx.doi.org/10.1056/NEJM199506013322203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739683				2022-12-28	WOS:A1995RA14000003
J	VANDEWERF, F; TOPOL, EJ; LEE, KL; WOODLIEF, LH; GRANGER, CB; ARMSTRONG, PW; BARBASH, GI; HAMPTON, JR; GUERCI, A; SIMES, RJ; ROSS, AM; CALIFF, RM				VANDEWERF, F; TOPOL, EJ; LEE, KL; WOODLIEF, LH; GRANGER, CB; ARMSTRONG, PW; BARBASH, GI; HAMPTON, JR; GUERCI, A; SIMES, RJ; ROSS, AM; CALIFF, RM			VARIATIONS IN PATIENT-MANAGEMENT AND OUTCOMES FOR ACUTE MYOCARDIAL-INFARCTION IN THE UNITED-STATES AND OTHER COUNTRIES - RESULTS FROM THE GUSTO TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSERVATIVE MANAGEMENT; PLASMINOGEN-ACTIVATOR; ANGIOPLASTY; ANGIOGRAPHY; THERAPY	Objective.-To examine differences in outcomes and patient management between patients in the United States and outside the United States undergoing thrombolysis for acute myocardial infarction. Design, Setting, and Patients.-Patients in the United States (n=23105) and 14 other countries (n=17916) were randomized to receive streptokinase plus either subcutaneous or intravenous (IV) heparin, accelerated recombinant tissue-type plasminogen activator (rt-PA) plus IV heparin, or combined streptokinase and rt-PA plus IV heparin. Outcome Measures.-Differences in 30-day mortality and patient management were compared among treatments and between US and non-US patients. Treatment-by-country interactions were assessed by logistic regression analyses. Expected mortality of US and non-US patients was estimated using a predictive model and was compared with observed mortality. Results.-Mortality reduction with accelerated rt-PA vs streptokinase was greater in the United States (1.2% absolute decrease vs 0.7% elsewhere), but the test for treatment-by-country interaction against streptokinase was not significant (P=.30). Benefits of accelerated rt-PA over combination therapy were observed in the United States, but not in other countries (P=.02). Despite differences in baseline characteristics and patient management, 30-day mortality was not significantly different: 6.8% in the United States vs 7.2% elsewhere (P=.09). After adjustment for baseline differences, observed vs predicted outcomes were slightly better in the United States (6.8% vs 7.0%) than elsewhere (7.2% vs 7.0%), indicating that enrollment in the United States was a marginally significant predictor of better survival (P=.047). Conclusions.-No significant evidence for a differentially greater benefit of accelerated rt-PA over streptokinase was found in US vs non-US patients, However, increased procedure and treatment use in the United States was associated with only a small decrease in short-term mortality. Long-term follow-up is required to clarify the relationship between survival and the more intensive US management approach.	CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA; WALTER C MACKENZIE HLTH SCI CTR, DEPT MED, EDMONTON, AB, CANADA; TEL AVIV ELIAS SOURASKY HOSP, TEL AVIV, ISRAEL; QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND; ST FRANCIS HOSP, ROSLYN, NY USA; UNIV SYDNEY, NATL HLTH & MED RES COUNCIL CLIN TRIALS CTR, SYDNEY, NSW 2006, AUSTRALIA; GEORGE WASHINGTON UNIV, MED CTR, DIV CARDIOL, WASHINGTON, DC 20037 USA	Cleveland Clinic Foundation; Duke University; Duke University; University of Alberta; University of Nottingham; University of Sydney; George Washington University	VANDEWERF, F (corresponding author), UNIV HOSP GASTHUISBERG, DEPT CARDIOL, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Simes, Robert John/P-1497-2014; Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Armstrong, Paul/0000-0002-0460-3445				[Anonymous], 1989, NEW ENGL J MED, V320, P618; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BARBASH GI, 1994, ARCH INTERN MED, V154, P2237, DOI 10.1001/archinte.154.19.2237; BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281, DOI 10.1016/0735-1097(93)90664-M; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1994, CIRCULATION, V90, P434; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; ELLIS SG, 1992, CIRCULATION, V86, P1400, DOI 10.1161/01.CIR.86.5.1400; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON J, 1993, LANCET, V342, P759; HOSMER EW, 1989, APPLIED LOGISTIC REG; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUOCCO NA, 1992, J AM COLL CARDIOL, V20, P1445, DOI 10.1016/0735-1097(92)90435-P; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TUHEY JW, 1977, SCIENCE, V198, P679; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	23	139	143	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1586	1591		10.1001/jama.273.20.1586	http://dx.doi.org/10.1001/jama.273.20.1586			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745771				2022-12-28	WOS:A1995QY54100025
J	LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C				LEGUENNO, B; FORMENTRY, P; WYERS, M; GOUNON, P; WALKER, F; BOESCH, C			ISOLATION AND PARTIAL CHARACTERIZATION OF A NEW STRAIN OF EBOLA VIRUS	LANCET			English	Article							ZAIRE; SUDAN	We have isolated a new strain of Ebola virus from a nonfatal human case infected during the autopsy of a wild chimpanzee in the Cote-d'lvoire. The wild troop to which this animal belonged has been decimated by outbreaks of haemorrhagic syndromes. This is the first time that a human infection has been connected to naturally-infected monkeys in Africa. Data from the long-term survey of this troop of chimpanzees could answer questions about the natural reservoir of the Ebola virus.	LAB CENT PATHOL ANIM,BINGERVILLE,COTE IVOIRE; ECOLE NATL VET,HISTOPATHOL ANIM LAB,F-44087 NANTES 30,FRANCE; INST PASTEUR,SERV MICROSCOPIE ELECTR,F-75724 PARIS 15,FRANCE; CHU BICHAT,HISTOPATHOL LAB,F-75877 PARIS 18,FRANCE; UNIV BASEL,INST ZOOL,CH-4051 BASEL,SWITZERLAND; CTR SUISSE RECH SCI,ABIDJAN,COTE IVOIRE	Ecole Nationale Veterinaire, Agroalimentaire et de l'Alimentation Nantes-Atlantique; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Basel	LEGUENNO, B (corresponding author), INST PASTEUR,WHO,COLLABORATING CTR ARBOVIRUSES & HAEMORRHAG FEVERS,25 RUE DR ROUX,F-75724 PARIS 15,FRANCE.							[Anonymous], 1978, Bull World Health Organ, V56, P271; [Anonymous], 1978, Bull World Health Organ, V56, P247; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BASKERVILLE A, 1978, J PATHOL, V125, P131, DOI 10.1002/path.1711250303; BOESCH C, 1989, AM J PHYS ANTHROPOL, V78, P547, DOI 10.1002/ajpa.1330780410; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541; HEYMANN DL, 1980, J INFECT DIS, V142, P372, DOI 10.1093/infdis/142.3.372; JAHRLING PB, 1990, LANCET, V335, P502, DOI 10.1016/0140-6736(90)90737-P; JOHNSON ED, 1993, T ROY SOC TROP MED H, V87, P536, DOI 10.1016/0035-9203(93)90077-4; JOHNSON KM, 1981, J INFECT DIS, V143, P749, DOI 10.1093/infdis/143.5.749; JOHNSON KM, 1977, LANCET, V1, P569; KSIAZEK TG, 1992, J CLIN MICROBIOL, V30, P947, DOI 10.1128/JCM.30.4.947-950.1992; MCCORMICK JB, 1983, J INFECT DIS, V147, P264, DOI 10.1093/infdis/147.2.264; MURPHY F, 1978, PATHOLOGY EBOLA VIRU	14	268	289	1	46	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1271	1274		10.1016/S0140-6736(95)90925-7	http://dx.doi.org/10.1016/S0140-6736(95)90925-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746057				2022-12-28	WOS:A1995QY93300009
J	TURNER, P; EDWARDS, R; WESTON, V; GAZIS, A; ISPAHANI, P; GREENWOOD, D				TURNER, P; EDWARDS, R; WESTON, V; GAZIS, A; ISPAHANI, P; GREENWOOD, D			SIMULTANEOUS RESISTANCE TO METRONIDAZOLE, CO-AMOXICLAV, AND IMIPENEM IN CLINICAL ISOLATE OF BACTEROIDES-FRAGILIS	LANCET			English	Note							SUSCEPTIBILITY	A blood-culture isolate of Bacteroides fragilis, taken from a woman after elective laparotomy, was resistant to metronidazole an had reduced susceptibility to imipenem and co-amoxiclav. After treatment with imipenem, pus drained from the pleural cavity yielded an identical isolate that had become highly resistant to imipenem and co-amoxiclav. Emergence of full resistance to the beta-lactam antibiotics was accompanied by a tenfold rise in the specific activity of a metallo-beta-lactamase. Clinicians need to be alert to simultaneous resistance to metronidazole, co-amoxiclav, and imipenem and development of high-level resistance to imipenem in B fragilis during treatment with this agent.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIV MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIV MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	TURNER, P (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM PUBL HTLH LAB,NOTTINGHAM NG7 2UH,ENGLAND.							CORNICK NA, 1990, J ANTIMICROB CHEMOTH, V25, P1011, DOI 10.1093/jac/25.6.1011; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P201, DOI 10.1093/jac/31.2.201; EDWARDS R, 1992, J MED MICROBIOL, V36, P89, DOI 10.1099/00222615-36-2-89; GOLDSTEIN EJC, 1993, J ANTIMICROB CHEMOTH, V31, P363, DOI 10.1093/jac/31.3.363; GREENWOOD D, 1991, ANAEROBES HUMAN DISE, P415; LIVERMORE DM, 1992, J ANTIMICROB CHEMOTH, V29, P609, DOI 10.1093/jac/29.6.609; PODGLAJEN I, 1992, FEMS MICROBIOL LETT, V91, P21, DOI 10.1016/0378-1097(92)90557-5; RASMUSSEN BA, 1993, CLIN INFECT DIS, V16, pS390, DOI 10.1093/clinids/16.Supplement_4.S390; TUNER K, 1993, CLIN INFECT DIS, V16, pS387, DOI 10.1093/clinids/16.Supplement_4.S387	9	51	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1275	1277		10.1016/S0140-6736(95)90927-3	http://dx.doi.org/10.1016/S0140-6736(95)90927-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746059				2022-12-28	WOS:A1995QY93300011
J	CHECOVICH, WJ; BOLGER, RE; BURKE, T				CHECOVICH, WJ; BOLGER, RE; BURKE, T			FLUORESCENCE POLARIZATION - A NEW TOOL FOR CELL AND MOLECULAR-BIOLOGY	NATURE			English	Article							HUMAN-PLASMA				CHECOVICH, WJ (corresponding author), PANVERA CORP,MADISON,WI 53711, USA.							BOLGER R, 1994, BIOTECHNIQUES, V17, P585; Bolger R, 1994, Am Biotechnol Lab, V12, P116; Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3; JOLLEY ME, 1981, J ANAL TOXICOL, V5, P236, DOI 10.1093/jat/5.5.236; LETILLY V, 1993, BIOCHEMISTRY-US, V32, P7753, DOI 10.1021/bi00081a021; MAEDA H, 1979, ANAL BIOCHEM, V92, P222, DOI 10.1016/0003-2697(79)90649-3; Perrin F, 1926, J PHYS-PARIS, V7, P390, DOI 10.1051/jphysrad:01926007012039000; RADEK JT, 1993, BIOCHEMISTRY-US, V32, P3527, DOI 10.1021/bi00065a002; WEI AP, 1993, ANAL CHEM, V65, P3372, DOI 10.1021/ac00071a007; YONEMURA K, 1982, J BIOCHEM-TOKYO, V92, P1297, DOI 10.1093/oxfordjournals.jbchem.a134048	10	158	191	1	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					254	256		10.1038/375254a0	http://dx.doi.org/10.1038/375254a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746330				2022-12-28	WOS:A1995QY88100072
J	MAXWELL, RJ				MAXWELL, RJ			SOUTH-AFRICA - A FRAGILE MIRACLE	LANCET			English	Article											MAXWELL, RJ (corresponding author), KINGS FUND,2 PALACE COURT,LONDON W2 4HS,ENGLAND.							HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; MAXWELL R, 1994, WHAT NEXT LONDONS HL; MAXWELL RJ, 1981, LANCET, V1, P1412; MCINTYRE D, 1994, STRUCTURE FINANCING; SIDLEY P, 1994, BRIT MED J, V308, P1525, DOI 10.1136/bmj.308.6943.1525; 1992, REPORT INQUIRY LONDO	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1222	1224		10.1016/S0140-6736(95)91997-X	http://dx.doi.org/10.1016/S0140-6736(95)91997-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739312				2022-12-28	WOS:A1995QX86100015
J	FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M				FAN, CM; PORTER, JA; CHIANG, C; CHANG, DT; BEACHY, PA; TESSIERLAVIGNE, M			LONG-RANGE SCLEROTOME INDUCTION BY SONIC HEDGEHOG - DIRECT ROLE OF THE AMINO-TERMINAL CLEAVAGE PRODUCT AND MODULATION BY THE CYCLIC-AMP SIGNALING PATHWAY	CELL			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; NOTOCHORD; PROTEIN; EMBRYO	A long-range signal encoded by the Sonic hedgehog (Shh) gene has been implicated as the ventral patterning influence from the notochord that induces sclerotome and represses dermomyotome in somite differentiation. Long-range effects of hedgehog (hh) signaling have been suggested to result either from local induction of a secondary diffusible signal or from the direct action of the highly diffusible carboxyterminal product of HH autoproteolytic cleavage. Here we provide evidence that the long-range somite patterning effects of SHH are instead mediated by a direct action of the amino-terminal cleavage product. We also show that pharmacological manipulations to increase the activity of cyclic AMP-dependent protein kinase A can selectively antagonize the effects of the amino-terminal cleavage product. Our results support the operation of a single evolutionarily conserved signaling pathway for both local and direct long-range inductive actions of HH family members.	UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL & NEUROSCI,SAN FRANCISCO,CA 94143; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; Johns Hopkins University	FAN, CM (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT ANAT,SAN FRANCISCO,CA 94143, USA.							BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIRAGYN A, 1994, J IMMUNOL METHODS, V168, P235, DOI 10.1016/0022-1759(94)90060-4; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COLAMARINO SA, 1985, IN PRESS CELL, V81; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GOULDING M, 1994, DEVELOPMENT, V120, P957; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JESSELL TM, 1992, HARVEY LECT, V86, P87; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; JOHNSON RD, 1994, CELL, V79, P1166; KEYNES RJ, 1988, DEVELOPMENT, V103, P413; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; KURATANI S, 1994, DEV BIOL, V161, P357, DOI 10.1006/dbio.1994.1037; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; READ AP, 1995, NAT GENET, V9, P333, DOI 10.1038/ng0495-333; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; ROELINK H, 1995, CELL, V81, P446; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUTT DI, 1995, NATURE, V373, P705, DOI 10.1038/373705a0; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANABE Y, 1995, IN PRESS CURR BIOL; TEILLET MA, 1983, DEV BIOL, V98, P192, DOI 10.1016/0012-1606(83)90349-4; WATTERSON RL, 1954, AM J ANAT, V95, P337, DOI 10.1002/aja.1000950302; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I	43	319	340	1	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					457	465		10.1016/0092-8674(95)90398-4	http://dx.doi.org/10.1016/0092-8674(95)90398-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736597	hybrid			2022-12-28	WOS:A1995QW89400017
J	QUAIL, PH; BOYLAN, MT; PARKS, BM; SHORT, TW; XU, Y; WAGNER, D				QUAIL, PH; BOYLAN, MT; PARKS, BM; SHORT, TW; XU, Y; WAGNER, D			PHYTOCHROMES - PHOTOSENSORY PERCEPTION AND SIGNAL-TRANSDUCTION	SCIENCE			English	Article							LIGHT-REGULATED DEVELOPMENT; ARABIDOPSIS-THALIANA; BIOLOGICAL-ACTIVITY; GENE-EXPRESSION; PROTEIN-PHOSPHORYLATION; TERMINAL DOMAIN; MUTANTS; PLANT; COP1; PHYCOCYANOBILIN	The phytochrome family of photoreceptors monitors the light environment and dictates patterns of gene expression that enable the plant to optimize growth and development in accordance with prevailing conditions. The enduring challenge is to define the biochemical mechanism of phytochrome action and to dissect the signaling circuitry by which the photoreceptor molecules relay sensory information to the genes they regulate. Evidence indicates that individual phytochromes have specialized photosensory functions. The amino-terminal domain of the molecule determines this photosensory specificity, whereas a short segment in the carboxyl-terminal domain is critical for signal transfer to downstream components. Heterotrimeric GTP-binding proteins, calcium-calmodulin, cyclic guanosine 5'-phosphate, and the COP-DET-FUS class of master regulators are implicated as signaling intermediates in phototransduction.	USDA ARS, CTR PLANT GENE EXPRESS, ALBANY, CA 94710 USA	United States Department of Agriculture (USDA)	QUAIL, PH (corresponding author), UNIV CALIF BERKELEY, DEPT PLANT BIOL, BERKELEY, CA 94720 USA.				NIGMS NIH HHS [GM47475] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047475] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; Batschauer Alfred, 1994, P559; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; BOYLAN M, 1994, PLANT CELL, V6, P449, DOI 10.1105/tpc.6.3.449; BOYLAN M, UNPUB; Cherry Joel R., 1994, P271; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; CHERRY JR, 1992, P NATL ACAD SCI USA, V89, P5039, DOI 10.1073/pnas.89.11.5039; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1992, DEVELOPMENT, V115, P337; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; CORNEJO J, 1992, J BIOL CHEM, V267, P14790; DEFORCE L, 1991, P NATL ACAD SCI USA, V88, P10392, DOI 10.1073/pnas.88.23.10392; DEFORCE L, 1993, BIOCHEMISTRY-US, V32, P14165, DOI 10.1021/bi00214a014; DEHESH K, 1993, PLANT CELL, V5, P1081, DOI 10.1105/tpc.5.9.1081; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DENG XW, 1991, GENE DEV, V5, P1172, DOI 10.1101/gad.5.7.1172; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; EDGERTON MD, 1993, BIOCHEMISTRY-US, V32, P8239, DOI 10.1021/bi00083a026; ELICH TD, 1994, PLANT MOL BIOL, V26, P1315, DOI 10.1007/BF00016477; FALLON KM, 1994, PLANT PHYSIOL, V105, P253, DOI 10.1104/pp.105.1.253; FALLON KM, 1993, PLANT PHYSIOL, V101, P1039, DOI 10.1104/pp.101.3.1039; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; HARTER K, 1994, PLANT CELL, V6, P545, DOI 10.1105/tpc.6.4.545; HARTER K, 1994, P NATL ACAD SCI USA, V91, P5038, DOI 10.1073/pnas.91.11.5038; Hartmann K.M., 1966, PHOTOCHEM PHOTOBIOL, V5, P349, DOI [10.1111/j.1751-1097.1966.tb05937.x, DOI 10.1111/J.1751-1097.1966.TB05937.X]; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; KANDRICK RE, 1994, PHOTOMORPHOGENESIS P; KENDRICK RE, 1991, PLANT J, V1, P133, DOI 10.1111/j.1365-313X.1991.00133.x; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; Koornneef Maarten, 1994, P601; KUNKEL T, 1993, EUR J BIOCHEM, V215, P587, DOI 10.1111/j.1432-1033.1993.tb18069.x; LI HM, 1994, GENE DEV, V8, P339, DOI 10.1101/gad.8.3.339; Li HM, 1993, CURR OPIN CELL BIOL, V5, P455, DOI 10.1016/0955-0674(93)90011-E; LI LM, 1994, P NATL ACAD SCI USA, V91, P12535, DOI 10.1073/pnas.91.26.12535; Mancinelli Alberto L., 1994, P211; MATHEWS S, IN PRESS ANAL MISSOU; MCCORMAC AC, 1993, PLANT J, V4, P19, DOI 10.1046/j.1365-313X.1993.04010019.x; MCMICHAEL RW, 1990, 9TH P ANN PLANT BIOC, P259; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MCNELLIS TW, 1994, PLANT CELL, V6, P1391, DOI 10.1105/tpc.6.10.1391; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; PARKS B, UNPUB; PARKS BM, 1993, PLANT CELL, V5, P39, DOI 10.1105/tpc.5.1.39; PEPPER A, 1994, CELL, V78, P109, DOI 10.1016/0092-8674(94)90577-0; POCH HLC, 1993, PLANT J, V4, P671, DOI 10.1046/j.1365-313X.1993.04040671.x; Pratt Lee H., 1994, P163; Quail Peter H., 1994, P71; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; QUAIL PH, 1994, CURR OPIN GENET DEV, V4, P652, DOI 10.1016/0959-437X(94)90131-L; QUAIL PH, 1982, TRENDS PHOTOBIOLOGY, P485; QUAIL PH, 1993, PAST PRESENT FUTURE, P87; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; SCHNEIDERPOETSCH HAW, 1994, PHYSIOL PLANTARUM, V91, P241, DOI 10.1111/j.1399-3054.1994.tb00425.x; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SHARROCK RA, 1989, GENE DEV, V3, P1745, DOI 10.1101/gad.3.11.1745; SHINOMURA T, 1994, PLANT PHYSIOL, V104, P363, DOI 10.1104/pp.104.2.363; SHORT T, UNPUB; SINGH BR, 1990, PHOTOCHEM PHOTOBIOL, V52, P249, DOI 10.1111/j.1751-1097.1990.tb01781.x; SMITH H, 1990, PLANT CELL ENVIRON, V13, P695, DOI 10.1111/j.1365-3040.1990.tb01084.x; SMITH H, UNPUB; Smith Harry, 1994, P377; SOMERS DE, 1991, PLANT CELL, V3, P1263, DOI 10.1105/tpc.3.12.1263; STOCKHAUS J, 1992, GENE DEV, V6, P2364, DOI 10.1101/gad.6.12a.2364; TOBIN E, 1994, SEMINARS CELL BIOL, P1; VANTUINEN A, 1995, MOL GEN GENET, V246, P133, DOI 10.1007/BF00294675; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; VONARNIM AG, 1993, J BIOL CHEM, V268, P19626; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; Wagner D., UNPUB; WAHLEITHNER JA, 1991, P NATL ACAD SCI USA, V88, P10387, DOI 10.1073/pnas.88.23.10387; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; WHITELAM GC, 1994, PLANT CELL ENVIRON, V17, P615, DOI 10.1111/j.1365-3040.1994.tb00153.x; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757; YANOVSKY MJ, IN PRESS PLANT CELL	84	631	668	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					675	680		10.1126/science.7732376	http://dx.doi.org/10.1126/science.7732376			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732376				2022-12-28	WOS:A1995QW60300036
J	KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL				KUNANUSONT, C; FOY, HM; KREISS, JK; RERKSNGARM, S; PHANUPHAK, P; RAKTHAM, S; PAU, CP; YOUNG, NL			HIV-1 SUBTYPES AND MALE-TO-FEMALE TRANSMISSION IN THAILAND	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HETEROSEXUAL TRANSMISSION; DISEASE STAGE; RISK-FACTORS; TYPE-1; INFECTION; POPULATIONS; AIDS; PROSTITUTES; ASSOCIATION	We examined the risk factors for heterosexual transmission of HIV in a case-control study of couples in Thailand. 90 HIV-positive men and their regular sex partners were enrolled at the immune clinic, Chulalongkorn Hospital, where 92% of male index cases had HIV-1 serotype A (subtype E). Most index cases had acquired HIV through sexual intercourse. 95 couples were enrolled at 15 detoxification clinics, where 79% of them had HIV-1 serotype B (subtype B). Most men had acquired HIV through injecting drug use (IDU). The HIV seroconcordance rate was higher in the immune clinic (69%) than in the IDU clinics (48% overall, and 27% after excluding female partners who were IDUs) (p<0.01). The rate was also higher among couples in whom the male index case was infected with serotype A (subtype E) compared with serotype B (subtype B) (70% vs 52%, OR 2.1, 95% CI 1.2-4.2). When we excluded couples in whom the female was also an IDU, the difference in concordance rates was even more pronounced (70% vs 26%, OR 6.8, 95% CI 2.7-17.6). Viral factors or subjects' characteristics may have contributed to the concordance rates. In a multivariate logistic regression analysis, HIV-1 serotype A (subtype E) of male partners (adjusted OR 3.1, 95% CI 1.1-9.0) and history of IDU in female partners (adjusted OR 4.8, 95% CI 1.4-15.9) remained independently associated with HIV seroconcordance. This study suggests that HIV-1 subtype E may be associated with higher risk of heterosexual transmission than subtype B. If so, the predominance of subtype E in Thailand may have contributed to the rapid spread of the HIV epidemic.	UNIV WASHINGTON,SEATTLE,WA 98195; CHULALONGKORN HOSP,BANGKOK,THAILAND; BANGKOK METROPOLITAN ADM,BANGKOK,THAILAND; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; HIV AIDS COLLABORAT,NONTHABURI,THAILAND	University of Washington; University of Washington Seattle; Chulalongkorn University; Centers for Disease Control & Prevention - USA	KUNANUSONT, C (corresponding author), MINIST PUBL HLTH,DEPT COMMUNICABLE DIS CONTROL,DIV AIDS,NONTHABURI 11000,THAILAND.				FOGARTY INTERNATIONAL CENTER [D43TW000007] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW00007] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; AUWANIT W, 1990, Southeast Asian Journal of Tropical Medicine and Public Health, V21, P53; BONGAARTS J, 1989, AIDS, V3, P373, DOI 10.1097/00002030-198906000-00006; CAMERON DW, 1989, LANCET, V2, P403; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHOTPITAYASUNON.T, 1994, 10TH INT C AIDS YOK; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; FIORE JR, 1993, AIDS, V7, P29, DOI 10.1097/00002030-199301000-00004; GOEDERT JJ, 1987, AIDS RES HUM RETROV, V3, P355, DOI 10.1089/aid.1987.3.355; HAMED KA, 1993, J INFECT DIS, V167, P798, DOI 10.1093/infdis/167.4.798; HOLMES KK, 1988, J ACQ IMMUN DEF SYND, V1, P602; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KREISS JK, 1986, NEW ENGL J MED, V314, P414, DOI 10.1056/NEJM198602133140704; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3; MCCUTCHAN FE, 1992, AIDS RES HUM RETROV, V8, P1887, DOI 10.1089/aid.1992.8.1887; MOSS GB, 1991, J INFECT DIS, V164, P588, DOI 10.1093/infdis/164.3.588; MYERS G, 1992, HUMAN RETROVIRUSES A; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PAU CP, 1993, 1ST NAT C HUM RETR R; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; WENIGER B, 1994, 10TH INT C AIDS YOK; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; 1992, BRIT MED J, V304, P809	30	164	168	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1078	1083						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715340				2022-12-28	WOS:A1995QV41100010
J	DRIFE, J; JOHNSTON, I				DRIFE, J; JOHNSTON, I			HANDLING THE CONFLICTING CULTURES IN THE NHS	BRITISH MEDICAL JOURNAL			English	Article									GEN INFIRM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary	DRIFE, J (corresponding author), UNIV LEEDS,DEPT OBSTET & GYNAECOL,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND.							HANDY CB, UNDERSTANDING ORG, P222; Harrison S., 1988, MANAGING NHS SHIFTIN; KINSTON W, 1994, STRENGTHENING MANAGE, P43; KINSTON W, 1994, STRENGTHENING MANAGE; LICKERT R, 1987, ORG THEORY SELECTED, P293; Mintzberg H., 1983, POWER ORG, DOI DOI 10.1177/017084068400500419	6	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1054	1056		10.1136/bmj.310.6986.1054	http://dx.doi.org/10.1136/bmj.310.6986.1054			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728063	Green Published			2022-12-28	WOS:A1995QV31300023
J	SCHROEDER, SA; BEACHLER, MP				SCHROEDER, SA; BEACHLER, MP			PHYSICIAN SHORTAGES IN RURAL AMERICA	LANCET			English	Editorial Material											SCHROEDER, SA (corresponding author), ROBERT WOOD JOHNSON FDN, PRINCETON, NJ 08540 USA.							Knaus William, 1981, INSIDE RUSSIAN MED; PATHMAN DE, 1994, JAMA-J AM MED ASSOC, V272, P1341, DOI 10.1001/jama.272.17.1341; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559; SCHROEDER SA, 1994, JAMA-J AM MED ASSOC, V272, P239, DOI 10.1001/jama.272.3.239; SCHROEDER SA, 1992, HEALTH AFFAIR, V11, P235, DOI 10.1377/hlthaff.11.1.235; Weinber JP, 1994, JAMA-J AM MED ASSOC, V272, P222; 1994, AAMC REPORTER, V4, P1	8	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 22	1995	345	8956					1001	1002		10.1016/S0140-6736(95)90753-X	http://dx.doi.org/10.1016/S0140-6736(95)90753-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QU573	7723495				2022-12-28	WOS:A1995QU57300005
J	KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW				KING, RW; PETERS, JM; TUGENDREICH, S; ROLFE, M; HIETER, P; KIRSCHNER, MW			A 20S COMPLEX CONTAINING CDC27 AND CDC16 CATALYZES THE MITOSIS-SPECIFIC CONJUGATION OF UBIQUITIN TO CYCLIN-B	CELL			English	Article							MATURATION-PROMOTING FACTOR; CELL-CYCLE; ASPERGILLUS-NIDULANS; CLAM EMBRYO; DEGRADATION; PROTEIN; EXTRACTS; ANAPHASE; DESTRUCTION; KINASE	Cyclin B is degraded at the onset of anaphase by a ubiquitin-dependent proteolytic system. We have fractionated mitotic Xenopus egg extracts to identify components required for this process. We find that UBC4 and at least one other ubiquitin-conjugating enzyme can support cyclin B ubiquitination. The mitotic specificity of cyclin ubiquitination is determined by a 20S complex that contains homologs of budding yeast CDC16 and CDC27. Because these proteins are required for anaphase in yeast and mammalian cells, we refer to this complex as the anaphase-promoting complex (APC). CDC27 antibodies deplete APC activity, while immunopurified CDC27 complexes are sufficient to complement either interphase extracts or a mixture of recombinant UBC4 and the ubiquitin-activating enzyme E1. These results suggest that APC functions as a regulated ubiquitin-protein ligase that targets cyclin B far destruction in mitosis.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; MITOTIX INC, CAMBRIDGE, MA 02139 USA	Johns Hopkins University	KING, RW (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.				NIGMS NIH HHS [GM26875-17, GM39023-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875, R01GM039023] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BAILLY E, 1992, J CELL SCI, V101, P529; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; ENGLE DB, 1988, CELL MOTIL CYTOSKEL, V10, P432, DOI 10.1002/cm.970100310; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIROD PA, 1993, J BIOL CHEM, V268, P955; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; IRNIGER S, 1995, CELL, V81; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUANG J, 1993, J CELL BIOL, V123, P859, DOI 10.1083/jcb.123.4.859; KUANG J, 1991, P NATL ACAD SCI USA, V88, P11530, DOI 10.1073/pnas.88.24.11530; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MALDONADOCODINA G, 1992, J CELL BIOL, V116, P967, DOI 10.1083/jcb.116.4.967; MIRABITO PM, 1993, J CELL BIOL, V120, P959, DOI 10.1083/jcb.120.4.959; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; ODONNELL KL, 1991, J CELL SCI, V99, P711; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUAKIN V, 1995, MOL BIOL CELL, V6, P185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TUGENDREICH S, 1995, CELL, V81; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72	45	824	836	0	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					279	288		10.1016/0092-8674(95)90338-0	http://dx.doi.org/10.1016/0092-8674(95)90338-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736580	hybrid			2022-12-28	WOS:A1995QV41000017
J	INGERSOLL, AP; KANAMORI, H				INGERSOLL, AP; KANAMORI, H			WAVES FROM THE COLLISIONS OF COMET SHOEMAKER-LEVY-9 WITH JUPITER	NATURE			English	Article							VOYAGER	OBSERVATIONS Of the collisions of the fragments of comet Shoemaker-levy 9 with Jupiter provided an unprecedented opportunity to probe the depths of the planet's atmosphere, Images taken by the Hubble Space Telescope revealed circular rings surrounding five of the impact sites(1). The rings were observed for up to 2.5 hours after the impacts and spread at a constant velocity of 450 m s(-1). There are three types of disturbance that might explain these observations: acoustic waves trapped at the tropopause temperature minimum(2), gravity waves propagating vertically and horizontally in the stratosphere(3), and gravity waves trapped in a stable layer which acts as a horizontal waveguide and is located within the hypothesized tropospheric water cloud(4). Here we show that only the last of these phenomena fan match the speed and relative amplitude of the observed waves, with the requirement that the impacts were deep and the stability of the trapping layer is large. The origin of the stable layer is still uncertain, but if it is produced by moist convection in the water cloud, then the ratio of oxygen to hydrogen on Jupiter must be surprisingly large-approximately ten times that on the Sun.			INGERSOLL, AP (corresponding author), CALTECH,DIV GEOL & PLANETARY SCI,PASADENA,CA 91125, USA.							ACHTERBERG RK, 1989, J ATMOS SCI, V46, P2448, DOI 10.1175/1520-0469(1989)046<2448:ANMATJ>2.0.CO;2; BJORAKER GL, 1986, ICARUS, V66, P579, DOI 10.1016/0019-1035(86)90093-X; CARLSON BE, 1992, ASTROPHYS J, V388, P648, DOI 10.1086/171182; CARLSON RW, IN P0RESS GEOPHYS RE; GOLDREICH P, 1990, ASTROPHYS J, V363, P694, DOI 10.1086/169376; GUILLOT T, 1994, ICARUS, V112, P354, DOI 10.1006/icar.1994.1189; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; Hubbard WB, 1989, ORIGIN EVOLUTION PLA, P539; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; KANAMORI H, 1993, GEOPHYS RES LETT, V20, P2921, DOI 10.1029/93GL03187; LINDAL GF, 1981, J GEOPHYS RES-SPACE, V86, P8721, DOI 10.1029/JA086iA10p08721; LINDZEN RS, 1968, MON WEATHER REV, V96, P133, DOI 10.1175/1520-0493(1968)096<0133:OIAWT>2.0.CO;2; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; [No title captured]	15	60	62	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					706	708		10.1038/374706a0	http://dx.doi.org/10.1038/374706a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715724				2022-12-28	WOS:A1995QU30400044
J	BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC				BROWN, JS; WELLS, F; DUCKWORTH, G; PAUL, EA; BARNES, NC			IMPROVING NOTIFICATION RATES FOR TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article									LONDON CHEST HOSP,E LONDON TB CTR,LONDON E2 9JX,ENGLAND; ROYAL LONDON HOSP,COMMUNICABLE DIS CONTROL E LONDON & CITY HLTH AUT,LONDON E1 1BB,ENGLAND; ROYAL LONDON HOSP,COLL MED,DEPT EPIDEMIOL & MED STAT,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; Barts Health NHS Trust; Royal London Hospital								[Anonymous], 1978, Tubercle, V59, P245; CAPEWELL S, 1984, BRIT J DIS CHEST, V78, P317; HICKMAN M, 1992, BRIT MED J, V304, P1567, DOI 10.1136/bmj.304.6841.1567-c; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					974	974		10.1136/bmj.310.6985.974	http://dx.doi.org/10.1136/bmj.310.6985.974			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728034	Green Published			2022-12-28	WOS:A1995QT90400021
J	MAGEE, JC; JOHNSTON, D				MAGEE, JC; JOHNSTON, D			SYNAPTIC ACTIVATION OF VOLTAGE-GATED CHANNELS IN THE DENDRITES OF HIPPOCAMPAL PYRAMIDAL NEURONS	SCIENCE			English	Article							LONG-TERM POTENTIATION; CA2+ CHANNELS; CALCIUM CHANNELS; GUINEA-PIG; P-TYPE; CELLS; RAT; SODIUM; CA1; DETERMINES	Activation of dendritic voltage-gated ion channels by local synaptic input was tested by simultaneous dendrite-attached patch-clamp recordings and whole-cell somatic voltage recordings made from CA1 pyramidal neurons in hippocampal slices. Schaffer collateral stimulation elicited subthreshold excitatory postsynaptic potentials (EPSPs) that opened voltage-gated sodium and calcium channels in the apical dendrites. The EPSP-activated sodium channels opened near the peak of the EPSP, whereas low voltage-activated calcium channels opened near the EPSP peak and during the decay phase. Dendritic high voltage-activated channels required somatic action potential generation or suprathreshold synaptic trains for activation. Dendritic voltage-gated channels are, therefore, likely to participate in dendritic integration of synaptic events.			MAGEE, JC (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030, USA.				NIMH NIH HHS [MH44754] Funding Source: Medline; NINDS NIH HHS [NS09482, NS11535] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH044754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS011535, P50NS011535] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALZHEIMER C, 1993, J NEUROSCI, V13, P660; ANDERSEN P, 1990, COLD SH Q B, V55, P81; CHRISTIE BR, IN PRESS J NEUROPHYS; DEISZ RA, 1991, J NEUROPHYSIOL, V65, P371, DOI 10.1152/jn.1991.65.2.371; ELLINOR PT, 1993, NATURE, V32, P455; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P599, DOI 10.1113/jphysiol.1982.sp014394; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; HARRIS KM, 1992, J NEUROSCI, V12, P2685; Hille B., 1992, IONIC CHANNELS EXCIT; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JAFFE DB, 1993, J NEUROPHYSIOL, V71, P1065; JASLOVE SW, 1992, NEUROSCIENCE, V47, P495, DOI 10.1016/0306-4522(92)90161-T; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; MAGEE JC, IN PRESS J PHYSL LON; MARKRAM H, 1994, P NATL ACAD SCI USA, V91, P5207, DOI 10.1073/pnas.91.11.5207; MIYAKAWA H, 1992, NEURON, V9, P1163, DOI 10.1016/0896-6273(92)90074-N; MOGUL DJ, 1991, J PHYSIOL-LONDON, V433, P259, DOI 10.1113/jphysiol.1991.sp018425; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OGATA N, 1990, PFLUG ARCH EUR J PHY, V416, P594, DOI 10.1007/BF00382695; SAH P, 1988, J GEN PHYSIOL, V91, P373, DOI 10.1085/jgp.91.3.373; SCHNEIDER T, 1994, BIOPHYS J, V66, pA423; SPRUSTON N, 1994, TRENDS NEUROSCI, V17, P161, DOI 10.1016/0166-2236(94)90094-9; SPRUSTON N, 1993, J NEUROPHYSIOL, V70, P781, DOI 10.1152/jn.1993.70.2.781; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; THIBAULT O, 1993, P NATL ACAD SCI USA, V90, P11792, DOI 10.1073/pnas.90.24.11792; TRAUB RD, 1979, J NEUROPHYSIOL, V42, P476, DOI 10.1152/jn.1979.42.2.476; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WESTENBROEK RE, 1992, NEURON, V9, P1099, DOI 10.1016/0896-6273(92)90069-P; WHITE G, 1990, J NEUROPHYSIOL, V64, P1186, DOI 10.1152/jn.1990.64.4.1186; ZHANG JF, 1993, NEUROPHARMACOLOGY, V363, P1075	34	358	363	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					301	304		10.1126/science.7716525	http://dx.doi.org/10.1126/science.7716525			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716525				2022-12-28	WOS:A1995QT18500042
J	FULLER, MT				FULLER, MT			RIDING THE POLAR WINDS - CHROMOSOMES MOTOR DOWN EAST	CELL			English	Review							KINESIN-LIKE PROTEIN; NEWT LUNG-CELLS; DISTRIBUTIVE SEGREGATION; DROSOPHILA-MELANOGASTER; EJECTION PROPERTIES; ASTRAL MICROTUBULE; SPINDLE; ANAPHASE; FORCE; NOD		STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University	FULLER, MT (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.			Fuller, Margaret T/0000-0002-3804-4987				AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; AULT JG, 1991, J CELL SCI, V99, P701; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; CARPENTER ATC, 1991, CELL, V64, P885, DOI 10.1016/0092-8674(91)90313-N; CASSIMERIS L, 1994, J CELL SCI, V107, P285; ENDOW SA, 1993, TRENDS GENET, V9, P52, DOI 10.1016/0168-9525(93)90187-M; HAYS TS, 1982, J CELL BIOL, V93, P374, DOI 10.1083/jcb.93.2.374; HOGAN CJ, 1992, J CELL BIOL, V119, P1277, DOI 10.1083/jcb.119.5.1277; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MITCHISON TJ, 1992, J CELL BIOL, V19, P569; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NICKLAS RB, 1983, J CELL BIOL, V97, P542, DOI 10.1083/jcb.97.2.542; OSTERGREN G, 1950, HEREDITAS, V36, P1; RASOOLY RS, 1991, GENETICS, V129, P409; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Rieder CL, 1991, CURR OPIN CELL BIOL, V3, P59, DOI 10.1016/0955-0674(91)90166-V; SKIBBENS RV, 1993, J CELL BIOL, V122, P859, DOI 10.1083/jcb.122.4.859; SULLIVAN DS, 1992, J CELL BIOL, V119, P379, DOI 10.1083/jcb.119.2.379; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WANG SZ, 1995, J CELL BIOL, V128, P761, DOI 10.1083/jcb.128.5.761; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P; ZHANG P, 1990, GENETICS, V125, P115	30	37	37	6	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					5	8		10.1016/0092-8674(95)90364-X	http://dx.doi.org/10.1016/0092-8674(95)90364-X			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720073	Bronze			2022-12-28	WOS:A1995QR97000002
J	CHIASSON, JL; JOSSE, RG; HUNT, JA; PALMASON, C; RODGER, NW; ROSS, SA; RYAN, EA; TAN, MH; WOLEVER, TMS				CHIASSON, JL; JOSSE, RG; HUNT, JA; PALMASON, C; RODGER, NW; ROSS, SA; RYAN, EA; TAN, MH; WOLEVER, TMS			THE EFFICACY OF ACARBOSE IN THE TREATMENT OF PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A MULTICENTER CONTROLLED CLINICAL-TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES MELLITUS, NONINSULIN-DEPENDENT; ACARBOSE; INSULIN; SULFONYLUREA; METFORMIN	DENSITY-LIPOPROTEIN CHOLESTEROL; CARBOHYDRATE-METABOLISM; WEIGHT-LOSS; NIDDM; SECRETION; SULFONYLUREAS; ABSORPTION; DISEASE; BLOOD	Objective: To evaluate the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycemic control in patients with non-insulin-dependent diabetes mellitus. Design: A 1-year, multicenter, randomized, double-blind, placebo-controlled study. Setting: Seven university-affiliated, community-based, tertiary care diabetes clinics. Patients: 354 patients with non-insulin-dependent diabetes mellitus were recruited; 77 were being treated with diet alone, 83 with diet and metformin, 103 with diet and sulfonylurea, and 91 with diet and insulin. Patients in each treatment group were randomly assigned to either acarbose or placebo for 1 year. Eighty-seven percent of patients receiving acarbose and 92% of those receiving placebo were included in the efficacy analysis (n = 316). Measurements: At baseline and at 3-month intervals, levels of hemoglobin A(1c) (HbA(1c)), fasting and postprandial plasma glucose, fasting and postprandial serum C-peptide, and fasting serum lipids were measured. Results: Compared with placebo, acarbose treatment caused a significant decrease in the mean postprandial plasma glucose peak (90 minutes) in all four groups (19.0 +/- 0.4 mmol/L to 15.5 +/- 0.4 mmol/L; P < 0.001). Analysis of the postprandial plasma glucose incremental area under the curve showed that the change from baseline to the end of the treatment period differed for placebo and acarbose recipients by 4.73 mmol . h/L in the diet alone group (P < 0.001), 2.06 mmol . h/L in the metformin group (P = 0.01), 2.65 mmol . h/L in the sulfonylurea group (P < 0.001), and 3.13 mmol . h/L in the insulin group (P = 0.001). Corresponding decreases in HbA(1c) levels occurred; these were 0.9% in the diet alone group (P = 0.005), 0.8% in the metformin group (P = 0.011), 0.9% in the sulfonylurea group (P = 0.002), and 0.4% in the insulin group (P = 0.077). Acarbose did not significantly affect mean serum C-peptide or mean serum lipid levels. Conclusions: Acarbose improved long-term glycemic control in patients with non-insulin-dependent diabetes mellitus regardless of concomitant antidiabetic medication.	UNIV MONTREAL, MONTREAL, PQ, CANADA; ST MICHAELS HOSP, TORONTO, ON M5B 1W8, CANADA; LIONS GATE HOSP, N VANCOUVER, BC, CANADA; UNIV BRITISH COLUMBIA, N VANCOUVER, BC, CANADA; UNIV TORONTO, DEPT NUTR SCI, TORONTO, ON M5S 1A8, CANADA; MILES CANADA INC, TORONTO, ON, CANADA; ST JOSEPHS HLTH CTR, LONDON, ON N6A 4V2, CANADA; UNIV WESTERN ONTARIO, LONDON, ON, CANADA; FOOTHILLS PROV GEN HOSP, CALGARY, AB, CANADA; UNIV CALGARY, CALGARY, AB, CANADA; UNIV ALBERTA, WALTER C MACKENZIE HLTH SCI CTR, EDMONTON, AB T6G 2S2, CANADA; CAMP HILL MED CTR, DEPT MED, HALIFAX, NS B3J 1B6, CANADA; DALHOUSIE UNIV, HALIFAX, NS, CANADA	Universite de Montreal; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of British Columbia; University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Calgary; University of Calgary; University of Alberta; Dalhousie University; Dalhousie University	CHIASSON, JL (corresponding author), HOP HOTEL DIEU, CTR RECH, 3850 RUE ST URBAIN, MONTREAL, PQ H2W 1T8, CANADA.		Wolever, Thomas/AAC-8066-2022					AKAZAWA Y, 1982, THERAPEUTICS, V36, P848; AKAZAWA Y, 1982, THERAPEUTICS, V36, P870; BAILEY CJ, 1992, DIABETES CARE, V15, P755, DOI 10.2337/diacare.15.6.755; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; BRAND JC, 1991, DIABETES CARE, V14, P95, DOI 10.2337/diacare.14.2.95; BUBER V, 1982, 1ST P INT S AC EFF C, P422; BUCHANAN DR, 1988, EUR J CLIN PHARMACOL, V34, P51, DOI 10.1007/BF01061417; CLISSOLD SP, 1988, DRUGS, V35, P214, DOI 10.2165/00003495-198835030-00003; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GENUTH S, 1990, DIABETES CARE, V13, P1240, DOI 10.2337/diacare.13.12.1240; GERARD J, 1986, DIABETES, V35, P1294, DOI 10.2337/diabetes.35.11.1294; GROOP LC, 1992, DIABETES CARE, V15, P737, DOI 10.2337/diacare.15.6.737; HANEFELD M, 1991, DIABETES CARE, V14, P732, DOI 10.2337/diacare.14.8.732; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; HENRY RR, 1988, J CLIN ENDOCR METAB, V66, P979, DOI 10.1210/jcem-66-5-979; HILLEBRAND I, 1987, DIABETIC MED, V4, P147, DOI 10.1111/j.1464-5491.1987.tb00851.x; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUSE DM, 1989, JAMA-J AM MED ASSOC, V262, P2708, DOI 10.1001/jama.262.19.2708; JENKINS DJA, 1981, DIABETES, V30, P951, DOI 10.2337/diabetes.30.11.951; JENKINS DJA, 1987, MOL ASPECTS MED, V9, P97, DOI 10.1016/0098-2997(87)90019-7; KUZUYA T, 1976, DIABETOLOGIA, V12, P511, DOI 10.1007/BF01219516; LARDINOIS CK, 1984, ARCH INTERN MED, V144, P345, DOI 10.1001/archinte.144.2.345; LILJENQUIST JE, 1978, DIABETES, V27, P563, DOI 10.2337/diab.27.5.563; MADAR Z, 1989, J NUTR, V119, P2023, DOI 10.1093/jn/119.12.2023; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; NOYON R, 1986, NETH J MED, V29, P157; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; Puls W, 1979, Adv Exp Med Biol, V119, P341; REAVEN GM, 1990, DIABETES CARE, V13, P32, DOI 10.2337/diacare.13.3.32; RODIER M, 1988, DIABETES METAB, V14, P12; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; SACHSE G, 1979, DIABETOLOGIA, V17, P287, DOI 10.1007/BF01235884; SAILER D, 1981, HORM METAB RES, V13, P57, DOI 10.1055/s-2007-1019168; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SKYLER JS, 1990, DIABETES MELLITUS TH, P856; TAN MH, 1991, DIABETES RES CLIN PR, V14, pS3, DOI 10.1016/0168-8227(91)90002-U; TURNER RC, 1991, DIABETOLOGIA, V34, P877; VANGAAL L, 1991, Z GASTROENTEROL, V29, P642; WARD WK, 1984, DIABETES CARE, V7, P491, DOI 10.2337/diacare.7.5.491; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Winer BJ., 1971, STAT PRINCIPLES EXPT, V2nd ed; 1982, MANUAL LABORATORY OP; 1993, DIABETES CARE S2, V16, P22; 1985, DIABETES MELLITUS RE, P10	46	368	391	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1994	121	12					928	935		10.7326/0003-4819-121-12-199412150-00004	http://dx.doi.org/10.7326/0003-4819-121-12-199412150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW083	7734015				2022-12-28	WOS:A1994PW08300004
J	LINDBERG, DAB; HUMPHREYS, BL				LINDBERG, DAB; HUMPHREYS, BL			COMPUTERS IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIBRARY				LINDBERG, DAB (corresponding author), NATL LIB MED,BETHESDA,MD 20209, USA.							ACKERMAN M, 1992, MEDINFO 92; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; GRIGSBY J, 1993, 1 CTR HLTH POL RES R; KLEIN MS, 1994, ACAD MED, V69, P489, DOI 10.1097/00001888-199406000-00017; LACROIX EM, 1994, B MED LIBR ASSOC, V82, P412; LASKER RD, 1994, JAMA-J AM MED ASSOC, V272, P1297, DOI 10.1001/jama.272.16.1297; LINDBERG DAB, 1992, B MED LIBR ASSOC, V80, P244; LINDBERG DAB, 1993, JAMA-J AM MED ASSOC, V269, P3124, DOI 10.1001/jama.269.24.3124; LINDBERG DAB, 1993, METHOD INFORM MED, V32, P281, DOI 10.1055/s-0038-1634945; LINDBERG DAB, 1994, 1993 BRIT LIBR DAINT; MARSHALL JG, 1992, B MED LIBR ASSOC, V80, P169; RUSSELL JM, 1966, NEW ENGL J MED, V275, P309, DOI 10.1056/NEJM196608112750605; SATAVA RM, 1993, SURG ENDOSC-ULTRAS, V7, P203, DOI 10.1007/BF00594110; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; 1991, COMPUTER BASED PATIE; 1994, OTAH608 US C OFF TEC	16	32	32	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1667	1668		10.1001/jama.273.21.1667	http://dx.doi.org/10.1001/jama.273.21.1667			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752407				2022-12-28	WOS:A1995RB09700015
J	KORF, B				KORF, B			MOLECULAR MEDICINE - MOLECULAR DIAGNOSIS .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											KORF, B (corresponding author), CHILDRENS HOSP,DIV GENET,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							COOPER DN, 1993, HUM GENET, V92, P211	1	20	20	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1499	1502		10.1056/NEJM199506013322208	http://dx.doi.org/10.1056/NEJM199506013322208			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739688				2022-12-28	WOS:A1995RA14000008
J	TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP				TAPLIN, ME; BUBLEY, GJ; SHUSTER, TD; FRANTZ, ME; SPOONER, AE; OGATA, GK; KEER, HN; BALK, SP			MUTATION OF THE ANDROGEN-RECEPTOR GENE IN METASTATIC ANDROGEN-INDEPENDENT PROSTATE-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STEROID BINDING; EXPRESSION; ACID; SEQUENCE; CELLS; IDENTIFICATION; INSENSITIVITY; DEFINITION; TRIALS; DOMAIN	Background. Metastatic prostate cancer is a leading cause of cancer-related death in men. The rate of response to androgen ablation is high, but most patients relapse as a result of the outgrowth of androgen-independent tumor cells. The androgen receptor, which binds testosterone and stimulates the transcription of androgen-responsive genes, regulates the growth of prostate cells. We analyzed the androgen-receptor genes from samples of metastatic androgen-independent prostate cancers to determine whether mutations in the gene have a role in androgen independence. Methods. Complementary DNA was synthesized from metastatic prostate cancers in 10 patients with androgen-independent prostate cancer, and the expression of the androgen-receptor gene was estimated by amplification with the polymerase chain reaction. Exons B through H of the gene were cloned, and mutations were identified by DNA sequencing. The functional effects of the mutations were assessed in cells transfected with mutant genes. Results. All androgen-independent tumors expressed high levels of androgen-receptor gene transcripts, relative to the levels expressed by an androgen-independent prostate-cancer cell line (LNCaP). Point mutations in the androgen-receptor gene were identified in metastatic cells from 5 of the 10 patients examined. One mutation was in the same codon as the mutation found previously in the androgen-independent prostate-cancer cell line. The mutations were not detected in the primary tumors from two of the patients. Functional studies of two of the mutant androgen receptors demonstrated that they could be activated by progesterone and estrogen. Conclusions. Most metastatic androgen-independent prostate cancers express high levels of androgen-receptor gene transcripts. Mutations in androgen-receptor genes are not uncommon and may provide a selective growth advantage after androgen ablation.	BETH ISRAEL HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; UNIV MASSACHUSETTS,MED CTR,DEPT MED,DIV ONCOL,WORCESTER,MA; HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Beth Israel Deaconess Medical Center; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA051438] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007516] Funding Source: NIH RePORTER; NCI NIH HHS [R-29 CA51438] Funding Source: Medline; NHLBI NIH HHS [HL07516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOOKSTEIN R, 1993, CANCER RES, V53, P3369; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BORING CC, 1992, CA-CANCER J CLIN, V42, P127; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRAWFORD ED, 1992, BRIT J UROL, V70, P33, DOI 10.1111/j.1464-410X.1992.tb15865.x; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Dawson N A, 1993, Oncology (Williston Park), V7, P17; DAWSON NA, 1993, ONCOLOGY, V7, P2; Dawson NA, 1993, ONCOLOGY, V7, P17; DEBELLIS A, 1992, MOL ENDOCRINOL, V6, P1909, DOI 10.1210/me.6.11.1909; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUQUA SAW, 1993, J CELL BIOCHEM, V51, P135, DOI 10.1002/jcb.240510204; GADDIPATI JP, 1994, CANCER RES, V54, P2861; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KARNIK PS, 1994, CANCER RES, V54, P349; LUBAHN DB, 1990, P NATL ACAD SCI USA, V87, P4411; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MARCELLI M, 1990, MOL ENDOCRINOL, V4, P1105, DOI 10.1210/mend-4-8-1105; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PORCELLI S, 1993, J EXP MED, V178, P1, DOI 10.1084/jem.178.1.1; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; RISSTALPERS C, 1993, BIOCHEM BIOPH RES CO, V196, P173, DOI 10.1006/bbrc.1993.2231; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VANTINTEREN H, 1993, CANCER-AM CANCER SOC, V72, P3847, DOI 10.1002/1097-0142(19931215)72:12+<3847::AID-CNCR2820721716>3.0.CO;2-J; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1	39	978	1028	2	39	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1393	1398		10.1056/NEJM199505253322101	http://dx.doi.org/10.1056/NEJM199505253322101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723794	Bronze			2022-12-28	WOS:A1995QY94100001
J	WILCOX, AJ; BAIRD, DD; WEINBERG, CR; HORNSBY, PP; HERBST, AL				WILCOX, AJ; BAIRD, DD; WEINBERG, CR; HORNSBY, PP; HERBST, AL			FERTILITY IN MEN EXPOSED PRENATALLY TO DIETHYLSTILBESTROL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENITAL-TRACT; REPRODUCTIVE-TRACT; INUTERO; PREGNANCY; WOMEN; ADENOCARCINOMA; ASSOCIATION; UTERO; MICE	Background. Prenatal exposure to diethylstilbestrol causes infertility in male mice and has been associated with malformations of the genital tract in men, However, little is known about the fertility of men who have been exposed prenatally to diethylstilbestrol. Methods. In 1950 through 1952, 1646 pregnant women were enrolled in a randomized, placebo-controlled clinical trial of diethylstilbestrol at Chicago Lying-in Hospital. We interviewed men who were born to the women during that study about their fertility. Results. Four decades after their birth, we were able to trace 548 of the surviving sons (68 percent), Ninety percent consented to be interviewed (253 who had been exposed to diethylstilbestrol in utero and 241 who had not been exposed). Congenital malformations of the genitalia were reported three times as often by the diethylstilbestrol-exposed men as by the sons of the women in the placebo group. Within the exposed group, malformations were reported twice as often among those exposed to diethylstilbestrol before the 11th week of gestation as among those exposed later (P=0.05). Men with genital malformations were nonetheless as fertile as other men. The diethylstilbestrol-exposed men (with or without genital malformations) had no impairment of fertility by any measure, including whether they had ever impregnated a woman, age at the birth of their first child, average number of children, medical diagnosis of a fertility problem, or length of time to conception in the most recent pregnancy of the female partner. Finally, diethylstilbestrol-exposed men had no impairment of sexual function, as indicated, for example, by the frequency of intercourse or reported episodes of decreased libido, Conclusions. High doses of diethylstilbestrol did not lead to impairment of fertility or sexual function in adult men who had been exposed to the drug in utero.	NIEHS,STAT & BIOMATH BRANCH,RES TRIANGLE PK,NC 27709; UNIV VIRGINIA,HLTH SCI CTR,CHARLOTTESVILLE,VA; UNIV CHICAGO,DEPT OBSTET & GYNECOL,CHICAGO,IL 60637	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Virginia; University of Chicago	WILCOX, AJ (corresponding author), NIEHS,EPIDEMIOL BRANCH,RES TRIANGLE PK,NC 27709, USA.		Baird, Donna D/D-5214-2017; Wilcox, Allen J/C-7723-2019	Baird, Donna D/0000-0002-5544-2653; Wilcox, Allen J/0000-0002-3376-1311; Weinberg, Clarice/0000-0002-7713-8556				ARAI Y, 1983, INT REV CYTOL, V84, P235, DOI 10.1016/S0074-7696(08)61019-0; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P470, DOI 10.1093/oxfordjournals.aje.a114417; BARNES AB, 1980, NEW ENGL J MED, V302, P609, DOI 10.1056/NEJM198003133021105; BERAL V, 1981, J EPIDEMIOL COMMUN H, V35, P155, DOI 10.1136/jech.35.3.155; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GILL WB, 1989, TOXICITY HORMONES PE, P161; HERBST AL, 1972, NEW ENGL J MED, V287, P1259, DOI 10.1056/NEJM197212212872501; HERBST AL, 1989, SEMIN REPROD ENDOCR, V7, P124, DOI 10.1055/s-2007-1021391; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1981, AM J OBSTET GYNECOL, V144, P1019; KAUFMAN RH, 1977, AM J OBSTET GYNECOL, V128, P51, DOI 10.1016/0002-9378(77)90294-0; LEARY FJ, 1984, JAMA-J AM MED ASSOC, V252, P2984, DOI 10.1001/jama.252.21.2984; MCLACHLAN JA, 1977, J TOXICOL ENV HEALTH, V2, P527, DOI 10.1080/15287397709529453; MCLACHLAN JA, 1975, SCIENCE, V190, P991, DOI 10.1126/science.242076; McLachlan JA, 1981, DEV EFFECTS DIETHYLS, P148; MEYERBAHLBURG HFL, 1984, PROG BRAIN RES, V61, P375; Moore KL, 1993, DEV HUMAN CLIN ORIEN, P156; NEWKIRK P, 1993, MCCALLS          FEB, P93; NEWKIRK P, 1993, MCCALLS          FEB, P164; SENEKJIAN EK, 1988, AM J OBSTET GYNECOL, V158, P493, DOI 10.1016/0002-9378(88)90012-9; Shapiro S, 1979, Epidemiol Rev, V1, P110; SHY KK, 1984, FERTIL STERIL, V42, P772; STENCHEVER MA, 1981, AM J OBSTET GYNECOL, V140, P186, DOI 10.1016/0002-9378(81)90107-1; STILLMAN RJ, 1982, AM J OBSTET GYNECOL, V142, P905, DOI 10.1016/S0002-9378(16)32540-6; THOMPSON RS, 1981, J REPROD MED, V26, P309; WEINBERG CR, 1994, STAT MED, V13, P671, DOI 10.1002/sim.4780130528	28	197	201	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1411	1416		10.1056/NEJM199505253322104	http://dx.doi.org/10.1056/NEJM199505253322104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723797				2022-12-28	WOS:A1995QY94100004
J	RICHARDSON, WS; DETSKY, AS				RICHARDSON, WS; DETSKY, AS			USERS GUIDES TO THE MEDICAL LITERATURE .7. HOW TO USE A CLINICAL DECISION-ANALYSIS .B. WHAT ARE THE RESULTS AND WILL THEY HELP ME IN CARING FOR MY PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION; UTILITY; RISK		UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; UNIV TORONTO, DEPT HLTH ADM, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT MED, TORONTO, ON M5S 1A1, CANADA; TORONTO HOSP, DIV GEN INTERNAL MED & CLIN EPIDEMIOL, TORONTO, ON M5T 2S8, CANADA	University of Rochester; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto				Gerstein, Hertzel/0000-0001-8072-2836				BAKER DW, 1994, JAMA-J AM MED ASSOC, V272, P1614, DOI 10.1001/jama.272.20.1614; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; CUMMINGS SR, 1986, AM REV RESPIR DIS, V134, P453; DEBER RB, 1990, MED DECIS MAKING, V10, P181, DOI 10.1177/0272989X9001000305; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; Dunkman WB, 1993, CIRCULATION S6, V87, pVI194; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; KUBO SH, 1994, ADV INTERNAL MED, V39, P485; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; Sox HC, 1988, MED DECISION MAKING; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; TSEVAT J, 1989, MED DECIS MAKING, V9, P162, DOI 10.1177/0272989X8900900303; TSEVAT J, 1991, CIRCULATION, V83, P1194, DOI 10.1161/01.CIR.83.4.1194; Weinstein MC, 1980, CLIN DECISION ANAL	25	125	127	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1610	1613		10.1001/jama.273.20.1610	http://dx.doi.org/10.1001/jama.273.20.1610			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745775				2022-12-28	WOS:A1995QY54100029
J	FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J				FIELD, K; THOROGOOD, M; SILAGY, C; NORMAND, C; ONEILL, C; MUIR, J			STRATEGIES FOR REDUCING CORONARY RISK-FACTORS IN PRIMARY-CARE - WHICH IS MOST COST-EFFECTIVE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the relative cost effectiveness of a range of screening and intervention strategies for preventing coronary heart disease in primary care. Subjects-7840 patients aged 35-64 years who were participants in a trial of modifying coronary heart disease Ask factors in primary care. Design-Effectiveness of interventions assumed and the potential years of life gained estimated from a risk equation calculated from Framingham study data. Main outcome measure-The cost per year of life gained. Results-The most cost effective strategy was minimal screening of blood pressure and personal history of vascular disease, which cost pound 310-pound 930 per year of life gained for men and pound 1100-pound 3460 for women excluding treatment of raised blood pressure. The extra cost per life year gained by adding smoking history to the screening was pound 400-pound 6300 in men. AU strategies were more cost effective in men than in women and more cost effective in older age groups. Lipid lowering drugs accounted for at least 70% of the estimated costs of all strategies. Cost effectiveness was greatest when drug treatment was limited to those with cholesterol concentrations above 9.5 mmol/l. Conclusions-Universal screening and intervention strategies are an inefficient approach to reducing the coronary heart disease burden. A basic strategy for screening and intervention, targeted at older men with raised blood pressure and limiting the use of cholesterol lowering drugs to those with very high cholesterol concentrations would be most cost effective.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; GWENT COLL,NEWPORT BUSINESS SCH,NEWPORT NP9 5XR,GWENT,WALES; FLINDERS UNIV S AUSTRALIA,SCH MED,DEPT GEN PRACTICE,ADELAIDE,SA 5001,AUSTRALIA; UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,GEN PRACTICE RES GRP,OXFORD OX2 6HE,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; University of Wales Newport; Flinders University South Australia; Radcliffe Infirmary; University of Oxford				Normand, Charles/0000-0002-0885-5754				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; LANGHAM SJ, 1994, HLTH CARE NEEDS ASSE, V1, P341; SILAGY C, 1994, J CLIN EPIDEMIOL, V47, P993, DOI 10.1016/0895-4356(94)90114-7; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1994, BRIT MED J, V308, P308; 1991, DH123 OFF POP CENS S	8	60	61	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1109	1112		10.1136/bmj.310.6987.1109	http://dx.doi.org/10.1136/bmj.310.6987.1109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742678	Green Published			2022-12-28	WOS:A1995QW61800018
J	PATRIARCA, PA; BEELER, JA				PATRIARCA, PA; BEELER, JA			MEASLES VACCINATION AND INFLAMMATORY BOWEL-DISEASE	LANCET			English	Editorial Material							CROHNS-DISEASE; VIRUS				PATRIARCA, PA (corresponding author), US FDA, CTR BIOL EVALUAT & RES, BETHESDA, MD 20205 USA.							ALBRECHT P, 1980, INFECT IMMUN, V27, P969, DOI 10.1128/IAI.27.3.969-978.1980; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111, DOI 10.1093/oxfordjournals.aje.a115754; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; GARLAND CF, 1981, GASTROENTEROLOGY, V81, P1115; HALL AJ, 1993, BRIT MED J, V307, P1294, DOI 10.1136/bmj.307.6915.1294; MCCHESNEY MB, 1989, ADV IMMUNOL, V45, P335, DOI 10.1016/S0065-2776(08)60696-3; MCKENNA MJ, 1990, ACTA OTO-LARYNGOL, P130; RAMSAY MEB, 1994, EPIDEMIOL INFECT, V112, P409, DOI 10.1017/S0950268800057824; THOMPSON NP, IN PRESS EUR J GASTR; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WHELAN G, 1990, MED CLIN N AM, V74, P1; 1995, LANCET, V345, P1071	12	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	1995	345	8957					1062	1063		10.1016/S0140-6736(95)90810-2	http://dx.doi.org/10.1016/S0140-6736(95)90810-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715332				2022-12-28	WOS:A1995QV41100002
J	VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K				VARTIAINEN, E; SARTI, C; TUOMILEHTO, J; KUULASMAA, K			DO CHANGES IN CARDIOVASCULAR RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM STROKE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; COMMUNITY; TRENDS	Objectives-To estimate the extent to which the changes in the main cardiovascular risk factors (blood pressure, smoking, and serum cholesterol concentration) can explain the observed changes in mortality from stroke in Finland during the past 20 years. Design-Predicted changes in mortality from cerebrovascular disease mortality were calculated by a proportional hazards model from data obtained in cross sectional population surveys in 1972, 1977, 1982, 1987, and 1992. Predicted changes were compared with the observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-16 741 men and 16 389 women aged 30-59 randomly selected from the national population register, of whom 14 054 men and 14 546 women participated. Main outcome measures-levels of risk factors and predicted and observed changes in mortality from cerebrovascular disease. Results-The observed changes in diastolic blood pressure, total serum cholesterol concentration, and smoking in the population from 1972 to 1992 predicted a 44% fall in mortality from stroke in men and changes in diastolic blood pressure and smoking predicted a 34% fall in women. The observed fall in mortality from stroke was 66% in men and 60% in women. Conclusions-Two thirds of the fall in mortality hom stroke in men and half in women can be explained by changes in the three main cardiovascular risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.			Kuulasmaa, Kari/0000-0003-2165-1411				BEEVERS DG, 1990, J HUM HYPERTENS, V4, P587; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DOBSON AJ, 1988, STAT MED, V7, P613, DOI 10.1002/sim.4780070508; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; KAGAN A, 1980, STROKE, V11, P14, DOI 10.1161/01.STR.11.1.14; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAXWELL MH, 1982, LANCET, V2, P33; MENOTTI A, 1990, INT J EPIDEMIOL, V19, P309, DOI 10.1093/ije/19.2.309; PIETINEN P, 1990, INT CONGR SER, V953, P243; PUSKA P, 1985, PREV MED, V14, P573, DOI 10.1016/0091-7435(85)90078-7; SHINTON R, 1989, BMJ-BRIT MED J, V298, P789, DOI 10.1136/bmj.298.6676.789; STOKES J, 1989, HYPERTENSION, V13, P113; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TUOMILEHTO J, 1992, AM J EPIDEMIOL, V135, P1259, DOI 10.1093/oxfordjournals.aje.a116232; TUOMILEHTO J, 1987, J HUM HYPERTENS, V1, P201; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; 1992, 1992 FAO WHO INT C N, P11; 1971, AUTOANALYZER II 26A	24	80	80	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	1995	310	6984					901	904		10.1136/bmj.310.6984.901	http://dx.doi.org/10.1136/bmj.310.6984.901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719179	Green Published			2022-12-28	WOS:A1995QR97200020
J	BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P				BRAUN, S; CROIZAT, B; LAGRANGE, MC; WARTER, JM; POINDRON, P			CONSTITUTIVE MUSCULAR ABNORMALITIES IN CULTURE IN SPINAL MUSCULAR-ATROPHY	LANCET			English	Note								To explore the cause of spinal muscular atrophy (SMA), we used an in-vitro model of nerve-muscle co-cultures in which motoneurons were normal and satellite cells were obtained from SMA patients. In co-cultures initiated with satellite cells from type I and type II SMA patients only, we observed degeneration of the innervated fibres after 1-3 weeks of nerve-muscle co-culture. This process involved vacuolisation, disorganisation, and death of the innervated muscle fibres. This observation points to a muscular implication in the severe forms of SMAs.	UNIV LOUIS PASTEUR STRASBOURG 1,UFR SCI,DEPT IMMUNOL & IMMUNOPHARMACOL,F-67401 ILLKIRCH GRAFFENS,FRANCE; ASSOC FRANCAISE MYOPATHIES,PARIS,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Braun, Serge/ABC-4313-2021					ASKANAS V, 1987, J NEUROCYTOL, V16, P523, DOI 10.1007/BF01668506; Askanas V, 1992, HDB CLIN NEUROL, P85; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; HENDERSON CE, 1988, REV NEUROL, V144, P730; MELKI J, 1994, SCIENCE, V264, P1474, DOI 10.1126/science.7910982	5	84	84	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					694	695		10.1016/S0140-6736(95)90869-2	http://dx.doi.org/10.1016/S0140-6736(95)90869-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7741893				2022-12-28	WOS:A1995QM73200010
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; HIP		UNIV ARIZONA, HLTH SCI CTR, TUCSON, AZ USA	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS, SCH MED, WORCESTER, MA 01605 USA.							ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; [Anonymous], 1994, Circulation, V90, P1631; [Anonymous], 1994, Circulation, V89, P1545; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; BLACK IW, 1994, CIRCULATION, V89, P2509, DOI 10.1161/01.CIR.89.6.2509; FATKIN D, 1994, J AM COLL CARDIOL, V23, P307, DOI 10.1016/0735-1097(94)90412-X; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JONKER JJC, 1994, LANCET, V343, P499; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MCBRIDE R, 1994, LANCET, V343, P687; NEUHAUS KL, 1994, CIRCULATION, V90, P1638, DOI 10.1161/01.CIR.90.4.1638; PEDERSEN TR, 1994, LANCET, V344, P1383; VANBERGEN PFMM, 1995, JAMA-J AM MED ASSOC, V273, P925, DOI 10.1001/jama.273.12.925	17	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1662	1664		10.1001/jama.273.21.1662	http://dx.doi.org/10.1001/jama.273.21.1662			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752405				2022-12-28	WOS:A1995RB09700013
J	MCKENDRY, RJR				MCKENDRY, RJR			IS RHEUMATOID-ARTHRITIS CAUSED BY AN INFECTION	LANCET			English	Editorial Material							MINOCYCLINE; TETRACYCLINES; INHIBITION				MCKENDRY, RJR (corresponding author), UNIV OTTAWA,FAC MED,RHEUMAT DIS UNIT,OTTAWA,ON,CANADA.							BAGNALL A W, 1957, Can Med Assoc J, V77, P182; BREEDVELD FC, 1990, J RHEUMATOL, V17, P43; ENNIS RS, 1972, ARTHRITIS RHEUM, V15, P108; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; Forestier J, 1935, J LAB CLIN MED, V20, P827; FREEDMAN A, 1952, LANCET, V2, P231; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; KLOPPENBURG M, 1995, J RHEUMATOL, V22, P611; KLOPPENBURG M, 1992, BR J RHEUMATOL, V31, pS41; Lande K, 1927, MUNCH MED WSCHR, V74, P1132; LANGEVITZ P, 1992, J RHEUMATOL, V19, P1502; MATSUURA T, 1992, LANCET, V340, P1553, DOI 10.1016/0140-6736(92)92810-3; NIP LH, 1993, J PERIODONTAL RES, V28, P379, DOI 10.1111/j.1600-0765.1993.tb01082.x; OLSER W, 1920, PRINCIPLES PRACTICE, P1126; PRUZANSKI W, 1992, BIOCHEM PHARMACOL, V44, P1165, DOI 10.1016/0006-2952(92)90381-R; STANDFORD HC, 1990, MANDELL DOUGLAS BENN, P306; TAYLORROBINSON D, 1992, LANCET, V340, P81, DOI 10.1016/0140-6736(92)90399-N; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001	19	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1319	1320		10.1016/S0140-6736(95)92533-3	http://dx.doi.org/10.1016/S0140-6736(95)92533-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752751				2022-12-28	WOS:A1995RA14800004
J	MARK, DB; HLATKY, MA; CALIFF, RM; NAYLOR, CD; LEE, KL; ARMSTRONG, PW; BARBASH, G; WHITE, H; SIMOONS, ML; NELSON, CL; CLAPPCHANNING, N; KNIGHT, JD; HARRELL, FE; SIMES, J; TOPOL, EJ				MARK, DB; HLATKY, MA; CALIFF, RM; NAYLOR, CD; LEE, KL; ARMSTRONG, PW; BARBASH, G; WHITE, H; SIMOONS, ML; NELSON, CL; CLAPPCHANNING, N; KNIGHT, JD; HARRELL, FE; SIMES, J; TOPOL, EJ			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH TISSUE-PLASMINOGEN ACTIVATOR AS COMPARED WITH STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-THE-NETHERLANDS; CORONARY THROMBOLYSIS; SURVIVAL; BENEFIT; FOLLOW; GUIDE	Background. Patients with acute myocardial infarction who were treated with accelerated tissue plasminogen activator (t-PA) (given over a period of 1 1/2 hours rather than the conventional 3 hours, and with two thirds of the dose given in the first 30 minutes) had a 30-day mortality that was 15 percent lower than that of patients treated with streptokinase in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary arteries (GUSTO) study, This was equivalent to an absolute decrease of 1 percent in 30-day mortality, We sought to assess whether the use of t-PA, as compared with streptokinase, is cost effective. Methods. Our primary, or base-case, analysis of cost effectiveness used data from the GUSTO study and life expectancy projected on the basis of the records of survivors of myocardial infarction in the Duke Cardiovascular Disease Database. In the primary analysis, we assumed that there were no additional treatment costs due to the use of t-PA after the first year and that the comparative survival benefit of t-PA was still evident one year after enrollment. Results. One year after enrollment, patients who received t-PA had both higher costs ($2,845) and a higher survival rate (an increase of 1.1 percent, or 11 per 1000 patients treated) than streptokinase-treated patients. On the basis of the projected life expectancy of each treatment group, the incremental cost-effectiveness ratio with both future costs and benefits discounted at 5 percent per year - was $32,678 per year of life saved, The use of t-PA was least cost effective in younger patients and most cost effective in older patients, At all ages, the use of t-PA in patients with anterior infarctions yielded more favorable cost-effectiveness values, In our secondary analyses, the cost-effectiveness values were most sensitive to a lowering of the projected long-term survival benefits of t-PA and to moderate or greater increases in the projected medical costs for patients in the t-PA group after the first year, In contrast, our results were not sensitive to even very unfavorable assumptions about the additional costs associated with the higher rate of disabling stroke that was noted in patients treated with t-PA in the GUSTO study. Conclusions. The cost effectiveness of treatment with accelerated t-PA rather than streptokinase compares favorably with that of other therapies whose added medical benefit for dollars spent is judged by society to be worthwhile.	DUKE UNIV, MED CTR,DEPT MED,DIV CARDIOL, CLIN TRIALS COORDINATING CTR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, PALO ALTO, CA 94304 USA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; INST CLIN EVALUAT SCI, TORONTO, ON, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; TEL AVIV SORASKY UNIV MED CTR, TEL AVIV, ISRAEL; GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; UNIV SYDNEY, NATL HLTH & MED RES COUNCIL CLIN TRIALS CTR, SYDNEY, NSW 2006, AUSTRALIA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH 44106 USA	Duke University; Duke University; Stanford University; University of Toronto; University of Toronto; University of Alberta; Erasmus University Rotterdam; University of Sydney; Cleveland Clinic Foundation	MARK, DB (corresponding author), DUKE UNIV, MED CTR,DEPT MED,DIV CARDIOL, ECON & QUAL LIFE COORDINATING CTR, POB 3485, DURHAM, NC 27710 USA.			Mark, Daniel/0000-0001-6340-8087; Armstrong, Paul/0000-0002-0460-3445; Topol, Eric/0000-0002-1478-4729; Hlatky, Mark/0000-0003-4686-9441	AHRQ HHS [HS-06503, HS-05635] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALGENT C, 1993, CIRCULATION S2, V88, P290; CERQUEIRA MD, 1992, J AM COLL CARDIOL, V20, P1452, DOI 10.1016/0735-1097(92)90436-Q; COX DR, 1972, J R STAT SOC B, V34, P187; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; HLATKY MA, 1984, STAT MED, V3, P375, DOI 10.1002/sim.4780030415; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; LEE ET, 1980, STATISTICAL METHODS; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARK DB, 1994, TXB INTERVENTIONAL C, P1323; MARK DB, 1995, ACUTE CORONARY CARE, P167; NAYLOR CD, 1993, CAN J CARDIOL, V9, P553; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SIFTON DW, 1993, RED BOOK PHARM FUNDA; SIMOONS ML, 1991, EUR HEART J, V12, P694, DOI 10.1093/eurheartj/12.6.694; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; STEINBERG EP, 1988, J AM COLL CARDIOL, V12, pA58, DOI 10.1016/0735-1097(88)92642-3; TAYLOR GJ, 1992, AM J CARDIOL, V70, P26, DOI 10.1016/0002-9149(92)91384-G; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Torrance GW, 1987, METHODS EC EVALUATIO; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; VERMEER F, 1988, BRIT HEART J, V59, P527; Weinstein MC, 1980, CLIN DECISION ANAL	26	451	453	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1418	1424		10.1056/NEJM199505253322106	http://dx.doi.org/10.1056/NEJM199505253322106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723799	Green Published			2022-12-28	WOS:A1995QY94100006
J	ERNST, E				ERNST, E			A LEADING MEDICAL-SCHOOL SERIOUSLY DAMAGED - VIENNA 1938	ANNALS OF INTERNAL MEDICINE			English	Article								Misguided by the notion that the decline of the German race would be prevented by purifying ''Aryan blood'' and eliminating foreign, particularly Jewish, influences, the Nazis evicted all Jews from universities within their growing empire during the Third Reich. The Medical Faculty of Vienna suffered more than any other European faculty from ''race hygiene.'' Within weeks of the Nazi annexation of Austria in 1938, 153 of the Faculty's 197 members were dismissed. By far the most frequent reason for dismissal was Jewish origin. Most victims managed to emigrate, many died in concentration camps, and others committed suicide. The ''cleansing'' process encountered little resistance, and the vacant posts were quickly filled with persons known not for their medical expertise but for their political trustworthiness. It was in this climate that medical atrocities could be committed. After the collapse of the Third Reich, most members of the Faculty were burdened with a Nazi past. Most remained in office, and those who had to leave were reinstituted swiftly. The Jews evicted in 1938 were discouraged from returning. These events have significantly-and with long-lasting effects-damaged the quality of a once-leading medical school. This story needs to be told to honor its victims and to fortify us so that history does not repeat itself.			ERNST, E (corresponding author), UNIV EXETER, POSTGRAD MED SCH, 25 VICTORIA PK RD, EXETER EX2 4NT, DEVON, ENGLAND.							BAUERMERINSKY J, 1988, ARZTEZEITUNG, V5, P30; Binding Karl, 1920, FREIGABE VERNICHTUNG; BREGGIN PR, 1993, J RISK SAFETY MED, V4, P133; DROBNIEWSKI F, 1993, J ROY SOC MED, V86, P541; FLECK C, 1992, STANDARD        0523; FRANKL VE, 1949, WIEN KLIN WOCHENSCHR, V61, P225; FREIHOFNER G, 1991, OSTERREICHISCHE ARZT, V23, P9; FUCHS G, 1950, OSTERREICHISCHE ARZT, V6, P285; HAECKKEL E, 1924, NATURLICHE SCHOPFUNG, P176; HUBENSTORF M, 1988, VERTRIEBENE VERNUNFT, V2, P766; Hubenstorf M., 1989, WILLF HRIGE WISSENSC; Kater MH, 1989, DOCTORS HITLER; KUMMEL WF, 1989, MED DRITTEN REICH, P30; Lehner M., 1990, THESIS U VIENNA; MAYRHOFER F, 1993, ARZTE WOCHE     0315, V31; MITSCHERLICH A, 1949, DOCTORS INFAMY STORY, P11; Stromberger H., 1988, ARZTE SCHWESTERN SS; WERNHART KR, 1990, DOKUMENTATION VERTRI, P5; ZIMMERMAN V, 1992, DIENSTBARER MED ARZT, P61; 1939, NEUES WIENER TA 0312, V12	20	60	60	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					789	792		10.7326/0003-4819-122-10-199505150-00009	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717602				2022-12-28	WOS:A1995QX14700009
J	HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A				HERINGS, RMC; DEBOER, A; STRICKER, BHC; LEUFKENS, HGM; PORSIUS, A			HYPOGLYCEMIA ASSOCIATED WITH USE OF INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME	LANCET			English	Article							CAPTOPRIL; GLUCOSE	The use of angiotensin-converting-enzyme (ACE) inhibitors has been associated with increased insulin sensitivity in diabetic patients. Although such an effect could be beneficial in the treatment of hypertension or congestive heart failure in diabetic patients, it might also precipitate severe hypoglycaemia. To test this hypothesis we carried out a nested case-control study, using data in the Dutch PHARMO system (1986-92), among diabetic patients treated with insulin or with oral antidiabetic drugs, who were admitted to hospital with hypoglycaemia. We identified 94 patients who had been admitted with hypoglycaemia and selected 654 controls from the same cohort. With adjustment for a wide range of potential confounding factors, hypoglycaemia was significantly associated with current use of ACE inhibitors (odds ratio 2.8 [95% CI 1.4-5.7]). Both among users of insulin and among users of oral antidiabetic drugs, use of ACE inhibitors was significantly associated with an increased risk of hospital admission for hypoglycaemia (2.8 [1.2-6.4] and 4.1 [1.4-12.2], respectively). Although ACE inhibitors have several advantages over other antihypertensive drugs in diabetes, the risk of hypoglycaemia should be taken into account. Further investigation of the mechanism is needed since as many as 13.8% of all hospital admissions for hypoglycaemia might be attributable to use of ACE inhibitors.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC	HERINGS, RMC (corresponding author), UNIV UTRECHT,UTRECHT INST PHARMACEUT SCI,DEPT PHARMACOEPIDEMIOL & PHARMACOTHERAPY,POB 80082,3508 TB UTRECHT,NETHERLANDS.		Herings, Ron/AAE-4096-2021	Herings, Ron/0000-0002-2561-8734				ALLAN SG, 1986, LANCET, V1, P1035; ARUAZPANCHECHO C, 1990, AM J MED, V89, P811; BERNE C, 1991, J INTERN MED, V229, P119; DONNELLY R, 1992, J CARDIOVASC PHARM, V20, pS38, DOI 10.1097/00005344-199200111-00007; EVERETT J, 1994, DRUGS, V47, P286, DOI 10.2165/00003495-199447020-00004; FERRIERE M, 1985, ANN INTERN MED, V102, P134, DOI 10.7326/0003-4819-102-1-134_3; HERINGS RMC, 1992, J EPIDEMIOL COMMUN H, V46, P136, DOI 10.1136/jech.46.2.136; HERINGS RMC, 1993, THESIS UTRECHT U UTR; KAHN HA, 1989, STATISTICAL METHODS; OKSA A, 1992, J CARDIOVASC PHARM, V23, P79; PASSA P, 1987, DIABETES CARE, V10, P200, DOI 10.2337/diacare.10.2.200; RETT K, 1988, NEW ENGL J MED, V319, P1609; SEEFELDT T, 1990, DIABETIC MED, V7, P700, DOI 10.1111/j.1464-5491.1990.tb01473.x; SIEGHIERI G, 1992, DIABETIC MED, V9, P732; UEHARA M, 1994, DIABETOLOGIA, V37, P300, DOI 10.1007/BF00398058; WINOCOUR P, 1986, LANCET, V2, P461; 1994, DRUGS THERAPY PERSPE, V4, P10; 1994, PRESCRIRE, V3, P175; 1992, ANATOMICAL THERAPEUT	19	161	165	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1195	1198		10.1016/S0140-6736(95)91988-0	http://dx.doi.org/10.1016/S0140-6736(95)91988-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739305				2022-12-28	WOS:A1995QX86100006
J	REDELMEIER, DA; MOLIN, JP; TIBSHIRANI, RJ				REDELMEIER, DA; MOLIN, JP; TIBSHIRANI, RJ			A RANDOMIZED TRIAL OF COMPASSIONATE CARE FOR THE HOMELESS IN AN EMERGENCY DEPARTMENT	LANCET			English	Article							HEALTH-CARE; MEDICAL-CARE; SATISFACTION; PATIENT; CANADA; MEN	Homeless adults often visit emergency departments and often leave dissatisfied. We tested whether compassionate care, by improving patient satisfaction, can alter subsequent use of emergency services. We identified 133 consecutive homeless adults visiting one inner-city emergency department who were not acutely psychotic, extremely intoxicated, unable to speak English, or medically unstable. Half were randomly assigned to receive compassionate contact from trained volunteers. All patients otherwise had usual care and were followed for repeat visits to emergency departments. We found that rates of use were high, with patients making an average of seven visits a year (0.60 per month). More than a third of all patients made two or more visits within two days of each other. The average number of visits per month after intervention was significantly lower for patients who received compassionate care (0.43 vs 0.65, p=0.018). Analyses adjusting for each patient's previous rate of use confirmed that compassionate care led to a one third reduction in the number of return visits within one month (95% Cl 14 to 40%). Compassionate management of selected homeless adults decreases repeat visits to the emergency department. One explanation is that patients tend to return frequently until they are satisifed with their treatment.	UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA	University of Toronto; University of Toronto	REDELMEIER, DA (corresponding author), WELLESLEY COLL HOSP,RES INST,DIV CLIN EPIDEMIOL,JONES BLDG,160 WELLESLEY ST E,TORONTO,ON M4Y 1J3,CANADA.							AMBROSIO E, 1992, STREET HLTH REPORT S; BAKER DW, 1994, JAMA-J AM MED ASSOC, V271, P1909, DOI 10.1001/jama.271.24.1909; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRICKNER PW, 1986, ANN INTERN MED, V104, P405, DOI 10.7326/0003-4819-104-3-405; COHEN CI, 1988, GERONTOLOGIST, V28, P58, DOI 10.1093/geront/28.1.58; EVANS RG, 1990, SOC SCI MED, V31, P1347, DOI 10.1016/0277-9536(90)90074-3; FERRIS LE, 1992, CAN MED ASSOC J, V146, P1727; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; FUCHS VR, 1993, FUTURE HLTH POLICY, P67; GELBERG L, 1990, ARCH INTERN MED, V150, P2325, DOI 10.1001/archinte.150.11.2325; Hutchison R R, 1993, J Community Health Nurs, V10, P87, DOI 10.1207/s15327655jchn1002_3; INGRAM DR, 1978, SOC SCI MED-MED GEOG, V12, P55, DOI 10.1016/0160-8002(78)90007-2; Judd V, 1989, Can Nurse, V85, P18; Nordberg M, 1992, Emerg Med Serv, V21, P39; OLIN JS, 1966, CAN MED ASSOC J, V95, P205; PURDIE FRJ, 1981, ANN EMERG MED, V10, P298, DOI 10.1016/S0196-0644(81)80119-9; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; REDELMEIER DA, 1993, NEW ENGL J MED, V328, P772, DOI 10.1056/NEJM199303183281107; REDELMEIER DA, 1993, CLIN RES, V41, pA548; ROSS L, 1991, PERSON SITUATION PER, P235; RUBIN HR, 1993, JAMA-J AM MED ASSOC, V270, P835, DOI 10.1001/jama.270.7.835; Shah N, 1992, Healthc Manage Forum, V5, P4; Shiner P, 1991, Health Serv J, V101, P21; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WATSON WC, 1994, CAN MED ASSOC J, V150, P11	25	74	74	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1131	1134		10.1016/S0140-6736(95)90975-3	http://dx.doi.org/10.1016/S0140-6736(95)90975-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723543				2022-12-28	WOS:A1995QW62200007
J	HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA				HEGLUND, NC; WILLEMS, PA; PENTA, M; CAVAGNA, GA			ENERGY-SAVING GAIT MECHANICS WITH HEAD-SUPPORTED LOADS	NATURE			English	Article							WALKING	IN many areas of the world that lack a transportation infrastructure, people routinely carry extraordinary loads supported by their heads, for example the Sherpa of the Himalayas and the women of East Africa, It has previously been shown that African women from the Kikuyu and Luo tribes can carry loads substantially more cheaply than army recruits(1); however, the mechanism for their economy has remained unknown, Here we investigate, using a force platform, the mechanics of carrying head-supported loads by Kikuyu and Luo women, The weight-specific mechanical work, required to maintain the motion of the common centre of mass of the body and load, decreases with load in the African women, whereas it increases in control subjects, The decrease in work by the African women is a result of a greater conservation of mechanical energy resulting from an improved pendulum-like transfer of energy during each step, back and forth between gravitational potential energy and kinetic energy of the centre of mass.	UNIV CATHOLIQUE LOUVAIN,UNITE READAPTAT,B-1348 LOUVAIN,BELGIUM; UNIV MILAN,IST FISIOL UMANA,I-20133 MILAN,ITALY	Universite Catholique Louvain; University of Milan	HEGLUND, NC (corresponding author), PHAROS SYST INC,S CHELMSFORD,MA 01824, USA.		Cavagna, Giovanni A/G-3564-2013	Cavagna, Giovanni/0000-0003-3081-0939				ALEXANDER R, 1988, ELASTIC MECHANISMS A, P95; ALEXANDER RM, 1986, NATURE, V319, P623, DOI 10.1038/319623a0; CAVAGNA GA, 1975, J APPL PHYSIOL, V39, P174, DOI 10.1152/jappl.1975.39.1.174; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; HEGLUND NC, 1981, J EXP BIOL, V93, P333; JONES CDR, 1987, LANCET, V12, P1331; MALOIY GMO, 1986, NATURE, V319, P668, DOI 10.1038/319668a0; PANDOLF KB, 1977, J APPL PHYSIOL, V43, P577, DOI 10.1152/jappl.1977.43.4.577; WILLEMS PA, 1995, J EXP BIOL, V198, P379	9	124	125	0	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					52	54		10.1038/375052a0	http://dx.doi.org/10.1038/375052a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723841				2022-12-28	WOS:A1995QW60400052
J	SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG				SCHUMACHER, MA; DIXON, MM; KLUGER, R; JONES, RT; BRENNAN, RG			ALLOSTERIC TRANSITION INTERMEDIATES MODELED BY CROSS-LINKED HEMOGLOBINS	NATURE			English	Article							LIGANDED T-STATE; HUMAN-HEMOGLOBIN; CARBON-MONOXIDE; OXYGEN-BINDING; RESOLUTION; DEOXYHEMOGLOBIN; STEREOCHEMISTRY; DYNAMICS	THE structural end-points of haemoglobin's transition from its low-oxygen-affinity (T) to high-oxygen-affinity CR) state, have been well established by X-ray crystallography(1-7), but short-lived intermediates have proved less amenable to X-ray studies, Here we use chemical crosslinking to fix these intermediates for structural characterization. We describe the X-ray structures of three haemoglobins, alpha(2) beta(1)S(82)beta, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, which were crosslinked between the amino groups of residues beta Val1 and beta Lys82 by 3,3'-stilbenedicarboxylic acid (S) or trimesic acid (Tm) while in the deoxy state, and saturated with carbon monoxide before crystallization. alpha(2) beta(1)S(82)beta, which has almost normal oxygen affinity, is completely in the R-state conformation; however, alpha(2) beta(1)Tm(82)beta and alpha(2) beta(1,82)Tm(82)beta, both of which have low oxygen affinity, have been prevented from completing their transition into the R state and display many features of a transitional intermediate, These haemoglobins therefore represent a snapshot of the nascent R state.	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV TORONTO,DEPT CHEM,LASH MILLER LABS,TORONTO,ON M5S 1A1,CANADA	University of Michigan System; University of Michigan; University of Toronto	SCHUMACHER, MA (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Kluger, Ronald/0000-0002-1749-2094; Brennan, Richard/0000-0001-7647-485X				ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; [Anonymous], 1968, J CRYST GROWTH, DOI [rg/10.1016/00220248(68)900717, DOI 10.1016/0022-0248(68)90071-7]; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; DELLANO JJM, 1993, J BIOL CHEM, V268, P27004; DEREWENDA Z, 1990, J MOL BIOL, V211, P515, DOI 10.1016/0022-2836(90)90262-K; DICKERSON RE, 1983, HEMOGLOBIN STRUCTURE, P3; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRANKE G, 1894, ARCH LARYNGOL RHINOL, V1, P230; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KLUGER R, 1992, BIOCHEMISTRY-US, V31, P7551, DOI 10.1021/bi00148a016; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; LIM MH, 1993, P NATL ACAD SCI USA, V90, P5801, DOI 10.1073/pnas.90.12.5801; MUKERJI I, 1994, BIOCHEMISTRY-US, V33, P13132, DOI 10.1021/bi00248a024; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; RODGERS KR, 1994, SCIENCE, V265, P1697, DOI 10.1126/science.8085153; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SILVA MM, 1992, J BIOL CHEM, V267, P17248; SMITH FR, 1991, PROTEINS, V10, P81, DOI 10.1002/prot.340100202; SMITH FR, 1994, PROTEINS, V18, P295, DOI 10.1002/prot.340180310; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	25	81	82	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					84	87		10.1038/375084a0	http://dx.doi.org/10.1038/375084a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723849	Green Submitted			2022-12-28	WOS:A1995QW60400061
J	LOWELL, JA; HOWARD, TK; WHITE, HM; SHENOY, S; HUETTNER, PC; BRENNAN, DC; PETERS, MG				LOWELL, JA; HOWARD, TK; WHITE, HM; SHENOY, S; HUETTNER, PC; BRENNAN, DC; PETERS, MG			SEROLOGICAL EVIDENCE OF PAST HEPATITIS-B INFECTION IN LIVER-DONOR AND HEPATITIS-B INFECTION IN LIVER ALLOGRAFT	LANCET			English	Note							SURFACE-ANTIGEN; CORE ANTIGEN	The presence of hepatitis B surface and core antibodies (anti-HBs and anti-HBc) in a liver donor without hepatitis B surface antigen is taken to indicate resolution of hepatitis B and is not considered to contraindicate donation. We report a liver transplant recipient who developed hepatitis B after such a donation. It seems that hepatitis B virus can reside in the liver of a patient who has seemingly recovered from his disease. We recommend avoidance of liver transplants from donors who are positive for anti-HBs and anti-HBc.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	LOWELL, JA (corresponding author), WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110, USA.							BRAINARD JA, 1994, TRANSPLANTATION, V57, P1753, DOI 10.1097/00007890-199457120-00012; DONOVAN JP, 1994, HEPATOLOGY, V20, pA129; HOOFNAGLE JH, 1978, NEW ENGL J MED, V298, P1379, DOI 10.1056/NEJM197806222982502; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; MARCELLIN P, 1991, GASTROENTEROLOGY, V100, P1432; OMATA M, 1978, GASTROENTEROLOGY, V75, P1003; RADOMSKI JS, 1994, HEPATOLOGY, V20, pA129; SCULLY LJ, 1994, J MED VIROL, V44, P293, DOI 10.1002/jmv.1890440314; THIERS V, 1988, LANCET, V2, P1273; TURKASPA R, 1990, J HEPATOL, V11, P34, DOI 10.1016/0168-8278(90)90268-V	10	53	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1084	1085		10.1016/S0140-6736(95)90819-6	http://dx.doi.org/10.1016/S0140-6736(95)90819-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715341				2022-12-28	WOS:A1995QV41100011
J	HSIEH, JJD; HAYWARD, SD				HSIEH, JJD; HAYWARD, SD			MASKING OF THE CBF1/RBPJ(KAPPA) TRANSCRIPTIONAL REPRESSION DOMAIN BY EPSTEIN-BARR-VIRUS EBNA2	SCIENCE			English	Article							BINDING-PROTEIN GENE; DROSOPHILA HOMOLOG; NUCLEAR ANTIGEN-2; INFECTION; PROMOTER; MOTIF	Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) is a transcriptional activator that is essential for EBV-driven B cell immortalization. EBNA2 is targeted to responsive promoters through interaction with a cellular DNA binding protein, C promoter binding factor 1 (CBF1). A transcriptional repression domain has been identified within CBF1. This domain also interacts with EBNA2, and repression is masked by EBNA2 binding. Thus, EBNA2 acts by countering transcriptional repression. Mutation at amino acid 233 of CBF1 abolishes repression and correlates with a loss-of-function mutation in the Drosophila homolog Su(H).	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,MOLEC VIROL LABS,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R37CA042245, R01CA042245] Funding Source: NIH RePORTER; NCI NIH HHS [CA42245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DOU SB, 1994, MOL CELL BIOL, V14, P3310, DOI 10.1128/MCB.14.5.3310; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GROSSMAN SR, 1994, P NATL ACAD SCI USA, V91, P7568, DOI 10.1073/pnas.91.16.7568; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, 1994, SCIENCE, V265, P92, DOI 10.1126/science.8016657; HSIEH JM, UNPUB; Liebowitz David, 1993, P107; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1994, J VIROL, V68, P5375, DOI 10.1128/JVI.68.9.5375-5383.1994; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WOISETSCHLAEGER M, 1991, P NATL ACAD SCI USA, V88, P3942, DOI 10.1073/pnas.88.9.3942; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	25	262	269	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					560	563		10.1126/science.7725102	http://dx.doi.org/10.1126/science.7725102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725102				2022-12-28	WOS:A1995QV40700035
J	KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW				KOH, JY; GWAG, BJ; LOBNER, D; CHOI, DW			POTENTIATED NECROSIS OF CULTURED CORTICAL-NEURONS BY NEUROTROPHINS	SCIENCE			English	Article							NERVE GROWTH-FACTOR; PROGRAMMED CELL-DEATH; CHOLINERGIC NEURONS; GLUTAMATE NEUROTOXICITY; FACTOR DEPRIVATION; PROTEIN-SYNTHESIS; TRK FAMILY; RAT-BRAIN; DEGENERATION; RECEPTOR	The effects of neurotrophins on several forms of neuronal degeneration in murine cortical cell cultures were examined. Consistent with other studies, brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 all attenuated the apoptotic death induced by serum deprivation or exposure lo the calcium channel antagonist nimodipine, Unexpectedly, however, 24-hour pretreatment with these same neurotrophins markedly potentiated the necrotic death induced by exposure to oxygen-glucose deprivation or N-methyl-D-aspartate. Thus, certain neurotrophins may have opposing effects on different types of death in the same neurons.	WASHINGTON UNIV, SCH MED, CTR STUDY NERVOUS SYST INJURY, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 30337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BEHERENS MI, UNPUB; BERINGER B, 1993, NEUROREPORT, V4, P1303; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, NEURODEGENERATIVE D, P233; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; DAVIES SW, 1992, NEUROSCI LETT, V140, P161, DOI 10.1016/0304-3940(92)90092-L; FERNANDEZSANCHEZ MT, 1993, FEBS LETT, V335, P124, DOI 10.1016/0014-5793(93)80453-2; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gwag B. J., 1994, Society for Neuroscience Abstracts, V20, P248; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HEFTI F, 1986, J NEUROSCI, V6, P2155; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLTZMAN DM, 1995, J NEUROSCI, V15, P1567; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNIPPER M, 1993, NEUROREPORT, V4, P483, DOI 10.1097/00001756-199305000-00005; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; KURE S, 1991, BIOCHEM BIOPH RES CO, V179, P39, DOI 10.1016/0006-291X(91)91330-F; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEVINE ES, IN PRESS J NEUROSCI; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MORELLI A, 1986, J NEUROCHEM, V47, P375; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; RINGSTEDT T, 1993, DEV BRAIN RES, V72, P119, DOI 10.1016/0165-3806(93)90165-7; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SHIGENO T, 1990, NEUROSCI LETT, V120, P117, DOI 10.1016/0304-3940(90)90182-9; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604; WIDMER HR, 1993, NEUROREPORT, V4, P363, DOI 10.1097/00001756-199304000-00005; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YIP NY, 1993, NEURON, V10, P137	42	333	343	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					573	575		10.1126/science.7725105	http://dx.doi.org/10.1126/science.7725105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725105				2022-12-28	WOS:A1995QV40700039
J	SHAPIRO, JA				SHAPIRO, JA			ADAPTIVE MUTATION - WHOS REALLY IN THE GARDEN	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; DIRECTED MUTATION; EVOLUTION; REVERSION; SEQUENCE; FUSIONS; OCCUR; MU				SHAPIRO, JA (corresponding author), UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,920 E 58TH ST,CHICAGO,IL 60637, USA.							Berg DE, 1989, MOBILE DNA; Bukhari AI, 1977, DNA INSERTION ELEMEN; BUSHMAN F, 1995, SCIENCE, V267, P1443, DOI 10.1126/science.7878462; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; Dawkins R., 1986, BLIND WATCHMAKER; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1994, SCIENCE, V265, P407, DOI 10.1126/science.8023164; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; FOSTER PL, 1994, EMBO J, V13, P5240, DOI 10.1002/j.1460-2075.1994.tb06855.x; FOSTER PL, IN PRESS P NAT ACAD; GALITSKI T, 1995, SCIENCE, V268, P421, DOI 10.1126/science.7716546; HALL BG, 1988, GENETICS, V120, P887; HALL BG, 1990, GENETICS, V126, P5; HALL BG, 1992, P NATL ACAD SCI USA, V89, P4300, DOI 10.1073/pnas.89.10.4300; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; LAMBERT ME, 1988, BANBURY REPORT, V30; Luria SE, 1943, GENETICS, V28, P491; MAENHAUTMICHEL G, 1994, EMBO J, V13, P5229, DOI 10.1002/j.1460-2075.1994.tb06854.x; McDonald J.F., 1993, TRANSPOSABLE ELEMENT; MITTLER JE, 1990, NATURE, V344, P173, DOI 10.1038/344173a0; Peters James A., COMMUNICATION; PETERS JE, 1995, J BACTERIOL, V177, P847, DOI 10.1128/jb.177.3.847-850.1995; RADICELLA JP, 1995, SCIENCE, V268, P418, DOI 10.1126/science.7716545; REDFIELD RJ, 1988, GENETICS, V119, P213; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHAPIRO JA, 1984, MOL GEN GENET, V194, P79, DOI 10.1007/BF00383501; SHAPIRO JA, 1993, CURR OPIN GENET DEV, V3, P845, DOI 10.1016/0959-437X(93)90003-8; SHAPIRO JA, 1993, J BACTERIOL, V175, P2625, DOI 10.1128/JB.175.9.2625-2631.1993; SHAPIRO JA, 1990, GENETICS, V126, P293; SHAPIRO JA, 1992, GENETICA, V86, P99, DOI 10.1007/BF00133714; Shapiro JA, 1983, MOBILE GENETIC ELEME; SNIEGOWSKI PD, 1995, J BACTERIOL, V177, P1119, DOI 10.1128/jb.177.4.1119-1120.1995; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEELE DF, 1992, GENETICS, V132, P9; TADDEI F, COMMUNICATION; THALER DS, 1994, SCIENCE, V264, P224, DOI 10.1126/science.8146652; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984	40	45	47	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					373	374		10.1126/science.7716540	http://dx.doi.org/10.1126/science.7716540			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716540				2022-12-28	WOS:A1995QU57200026
J	AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H				AONO, S; ADACHI, Y; UYAMA, E; YAMADA, Y; KEINO, H; NANNO, T; KOIWAI, O; SATO, H			ANALYSIS OF GENES FOR BILIRUBIN UDP-GLUCURONOSYLTRANSFERASE IN GILBERTS-SYNDROME	LANCET			English	Note							CRIGLER-NAJJAR SYNDROME; IDENTIFICATION; COMPLEX; MUTATION; PATIENT	Gilbert's and Crigler-Najjar syndromes are characterised by unconjugated hyperbilirubinaemia due to complete and partial absence of bilirubin UDP-glucuronosyltransferase (UGT). Nucleotide sequences of the genes for bilirubin UGT were analysed in six patients with Gilbert's syndrome. All patients had a missense mutation caused by a single nucleotide substitution and the mutations were heterozygous. In addition, relatives of patients with Crigler-Najjar syndrome types I and II, and of those with Gilbert's syndrome were analysed. All ten relatives with mild hyperbilirubinaemia were heterozygotes with respect to each defective allele. These results suggest that Gilbert's syndrome is inherited as a dominant trait.	SHIGA UNIV MED SCI,DEPT BIOL,OTSU,SHIGA 52021,JAPAN; KINKI UNIV,SCH MED,DEPT PERINATOL,OSAKA,JAPAN; KINKI UNIV,SCH MED,INST DEV RES,DEPT GENET,OSAKA,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,KUMAMOTO,JAPAN; AICHI CANC CTR,RES INST,DEPT BIOCHEM,AICHI,JAPAN	Shiga University of Medical Science; Kindai University (Kinki University); Kindai University (Kinki University); Kumamoto University; Aichi Cancer Center								AONO S, 1993, BIOCHEM BIOPH RES CO, V197, P1239, DOI 10.1006/bbrc.1993.2610; AONO S, 1994, PEDIATR RES, V35, P629, DOI 10.1203/00006450-199406000-00002; BOSMA PJ, 1992, HEPATOLOGY, V15, P941, DOI 10.1002/hep.1840150531; HERIWEGH KP, 1972, BIOCHEM J, V129, P605; MOGHRABI N, 1993, GENOMICS, V18, P171, DOI 10.1006/geno.1993.1451; PETERS WHM, 1984, J BIOL CHEM, V259, P1701; RITTER JK, 1992, J CLIN INVEST, V90, P150, DOI 10.1172/JCI115829; RITTER JK, 1991, J BIOL CHEM, V266, P1043; RITTER JK, 1992, J BIOL CHEM, V26, P3257; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89	10	150	159	1	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					958	959		10.1016/S0140-6736(95)90702-5	http://dx.doi.org/10.1016/S0140-6736(95)90702-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715297				2022-12-28	WOS:A1995QT91900012
J	MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D				MAPLE, PA; EFSTRATIOU, A; GEORGE, RC; ANDREWS, NJ; SESARDIC, D			DIPHTHERIA IMMUNITY IN UK BLOOD-DONORS	LANCET			English	Article							TETANUS; ADULTS; POPULATION; ANTITOXIN; TOXIN	Immunity to diphtheria was determined in serum samples from 1000 UK-born blood donors at the North London Blood Transfusion Centre during a three-month period in 1993; 125 women and 125 men were stratified in 10-year age groups, from 20 to 59. A tissue (vero cell)-culture toxin-neutralisation assay was used to measure serum diphtheria antitoxin concentrations. According to internationally accepted definitions (antitoxin <0.01 IU/mL=susceptibility, 0.01-0.09 IU/mL=basic protection, and greater than or equal to 0.1 IU/mL=full protection), 37.6% of donors were susceptible to diphtheria, 31.5% had basic protection, and 30.9% were fully protected. Log-linear modeling of the influence of age and sex on population immunity showed a significant trend (p<0.001) of decreasing immunity with increasing age: 25.2% of donors aged 20-29 were susceptible compared with 52.8% of those aged 50-59. There was a small sex effect (p=0.052); similar proportions of men and women were susceptible, but fewer women had full protection. There was no age-sex interaction on immunity (p=0.454). Our results suggest that booster immunisation of adults is necessary to increase herd immunity of the adult population.	PUBL HLTH LAB SERV,STAT UNIT,LONDON,ENGLAND; NATL INST BIOL STAND & CONTROLS,DIV BACTERIOL,POTTERS BAR,HERTS,ENGLAND	Public Health England; National Institute for Biological Standards & Control	MAPLE, PA (corresponding author), CENT PUBL HLTH LAB,RESP & SYSTEM INFECT LAB,LONDON NW9 5HT,ENGLAND.			Maple, Peter/0000-0002-5534-5191				AJELLO F, 1991, VACCINE, V9, P502, DOI 10.1016/0264-410X(91)90036-6; CELLESI C, 1989, VACCINE, V7, P417, DOI 10.1016/0264-410X(89)90155-2; CROSSLEY K, 1979, JAMA-J AM MED ASSOC, V242, P2298, DOI 10.1001/jama.242.21.2298; GALAZKA A, 1989, EPIDEMIOL INFECT, V103, P587, DOI 10.1017/S0950268800030983; GALAZKA AM, 1993, WHOEPIGEN9312; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KWANTES W, 1984, J HYG-CAMBRIDGE, V93, P433, DOI 10.1017/S0022172400065025; MASTERTON RG, 1987, J INFECTION, V15, P27, DOI 10.1016/S0163-4453(87)91351-X; MELVILLESMITH M, 1988, J MED MICROBIOL, V25, P279, DOI 10.1099/00222615-25-4-279; MILLER E, 1994, BRIT MED J, V308, P598, DOI 10.1136/bmj.308.6928.598b; PALMER SR, 1983, BRIT MED J, V286, P624, DOI 10.1136/bmj.286.6365.624; PARISH HJ, 1955, BRIT MED J, V2, P631, DOI 10.1136/bmj.2.4940.631; SESARDIC D, 1992, LANCET, V340, P737, DOI 10.1016/0140-6736(92)92284-M; SIMONSEN O, 1989, DAN MED BULL, V36, P24; WEISS BP, 1983, AM J PUBLIC HEALTH, V73, P802, DOI 10.2105/AJPH.73.7.802; 1989, 2ND WHO M NAT PROGR; 1956, LANCET, V2, P1223; 1978, LANCET, V1, P428; 1961, BRIT MED J, V2, P763; 1953, STATISTICAL REV ENGL; 1944, NEW ANN SERIES 1, V19; 1945, 19445 UK MIN HLTH CI; 1993, JUL WHO M DIPHTH EP; 1957, BRIT MED J, V2, P167; 1994, COMMUNICAB DIS REP, V4, P47; 1955, 555 UK MIN HLTH CIRC; 1990, APR WHO M CONTR DIPH; 1962, BRIT MED J, V2, P149; 1993, SERIES MB2, V18	29	84	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					963	965		10.1016/S0140-6736(95)90705-X	http://dx.doi.org/10.1016/S0140-6736(95)90705-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715300				2022-12-28	WOS:A1995QT91900015
J	POLOLI, LH				POLOLI, LH			STANDARDIZED PATIENTS - AS WE EVALUATE, SO SHALL WE REAP	LANCET			English	Editorial Material							CLINICAL SKILLS		E CAROLINA UNIV,SCH MED,DEPT MED,GREENVILLE,NC 27858	University of North Carolina; East Carolina University	POLOLI, LH (corresponding author), E CAROLINA UNIV,SCH MED,OFF ACAD AFFAIRS,BRODY SCI BLDG 2N-45,GREENVILLE,NC 27858, USA.							ANDERSON MB, 1994, TEACH LEARN MED, V6, P15, DOI DOI 10.1080/10401339409539637; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BARROWS HS, 1987, J MED EDUC, V62, P805; BARROWS HS, 1993, ACAD MED, V68, P443, DOI 10.1097/00001888-199306000-00002; COLLIVER JA, 1993, ACAD MED, V68, P455; KLASS DJ, 1994, TEACH LEARN MED, V6, P28; LEWIS CE, 1991, ANN INTERN MED, V144, P54; LIPKIN M, 1987, OFFICE PRACTICE MED, P1287; Morrison LJ., 1994, TEACH LEARN MED, V6, P23; NOEL GL, 1992, ANN INTERN MED, V117, P757, DOI 10.7326/0003-4819-117-9-757; PENTONY P, 1981, MODELS INFLUENCE PSY; POLOLI L, 1993, 18TH P ANN SESS INN; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; 1993, ASS AM MED COLLEGES; 1993, FUNCTIONS STRUCTURE, P15	16	13	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					966	968		10.1016/S0140-6736(95)90706-8	http://dx.doi.org/10.1016/S0140-6736(95)90706-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715301				2022-12-28	WOS:A1995QT91900016
J	ENTWISTLE, V				ENTWISTLE, V			REPORTING RESEARCH IN MEDICAL JOURNALS AND NEWSPAPERS	BRITISH MEDICAL JOURNAL			English	Article								Newspapers are important sources of information about medical advances for many lay people and can influence those working in the health service. Medical journalists on newspapers routinely use general medical journals to obtain information on research. The Lancet and BMJ are both examined carefully by broadsheet journalists in Britain each week. These papers published an average of 1.25 stories from these journals every Friday. The stories focused on serious diseases, topical health problems, and new treatments rather than social problems. The newspaper stories were based on the full research article and not the journals' press releases, although the press releases were valued as early information. Journalists relied heavily on the peer review processes of the journals in ensuring accuracy.	CITY UNIV LONDON,DEPT INFORMAT SCI,LONDON EC1V 0HB,ENGLAND	City University London			Entwistle, Vikki Ann/I-9266-2019	Entwistle, Vikki Ann/0000-0002-0856-4025				Entwistle V., 1992, PUBLIC UNDERST SCI, V1, P367, DOI DOI 10.1088/0963-6625/1/4/002; GALTUNG J, 1965, J INT PEACE RES, V1, P64, DOI DOI 10.1177/002234336500200104; GARLAND R, 1984, J ROY COLL GEN PRACT, V34, P316; HODGSON FW, 1992, MODERN NEWSPAPER PRA; KOREN G, 1991, JAMA-J AM MED ASSOC, V266, P1824, DOI 10.1001/jama.266.13.1824; KRISTIANSEN CM, 1984, JOURNALISM QUART, V61, P364, DOI 10.1177/107769908406100218; KUTNER BN, 1988, ARCH OPHTHALMOL-CHIC, V106, P879; PHILLIPS DP, 1991, NEW ENGL J MED, V325, P1180, DOI 10.1056/NEJM199110173251620; RELMAN AS, 1988, NEW ENGL J MED, V318, P918, DOI 10.1056/NEJM198804073181409; RENNIE D, 1994, JAMA-J AM MED ASSOC, V272, P91, DOI 10.1001/jama.1994.03520020017003; SMITH R, 1994, BRIT MED J, V309, P143, DOI 10.1136/bmj.309.6948.143	11	108	109	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					920	923		10.1136/bmj.310.6984.920	http://dx.doi.org/10.1136/bmj.310.6984.920			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QR972	7719187	Green Published			2022-12-28	WOS:A1995QR97200031
J	TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N				TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N			DIFFERENCES IN MORTALITY AFTER FRACTURE OF HIP - THE EAST-ANGLIAN AUDIT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate differences between hospitals in clinical management of patients admitted With fractured hip and to relate these to mortality at 90 days. Design-A prospective audit of process and outcome of care based on interviews with patients, abstraction from records with standard proforma, and follow up at three months. Data were analysed with chi(2) test and forward stepwise regression modelling of mortality. Setting-All eight hospitals in East Anglia with trauma orthopaedic departments. Patients-580 consecutive patients admitted for fracture of neck of femur. Main outcome measure-Mortality at 90 days. Results-Patients admitted to each hospital were similar with respect to age, sex, pre-existing illnesses, and activities of daily living before fracture. In all, 560 (97%) were treated surgically, by a range of grades of surgeon. Two hundred and sixty one patients (45%; range between hospitals 10-91%) received pharmaceutical thromboembolic prophylaxis, 502 (93%; 81-99%) perioperative antibiotic prophylaxis. The incidence of fatal pulmonary emboli differed between patients who received and those who did not receive prophylaxis against deep vein thrombosis (P=0.001). Mortality at 90 days was 18%, differing significantly between hospitals (5-23%). One hospital had significantly better survival than the others (odds ratio 0 .14; 95% confidence interval 0.04-0.48; P=0.0016). Conclusions-No single factor or aspect of practice accounted for this protective effect. Lower mortality may be associated with the cumulative effects of several aspects of the organisation of treatment and the management of fracture of the hip, including thromboembolic pharmaceutical prophylaxis, antibiotic prophylaxis, and early mobilisation.	ANGLIA & OXFORD REG HLTH AUTHOR,DIRECTORATE PUBL HLTH MED,CAMBRIDGE,ENGLAND; PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED,PETERBOROUGH PE3 6DA,ENGLAND; NORFOLK & NORWICH HEALTHCARE NHS TRUST,NORWICH,NORFOLK,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,ORTHOPAED RES UNIT,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	TODD, CJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,CAMBRIDGE CB2 2SR,ENGLAND.		Hyder, Adnan/AAT-9503-2021; Todd, Chris/A-7904-2010; Todd, Chris/AAD-8661-2022	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Freeman, Carol/0000-0001-9751-0784				ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; FREEMAN CJ, 1995, E ANGLIAN AUDIT FRAC; HOLLINGWORTH W, IN PRESS J PUBLIC HL; PARKER MJ, 1993, J BONE JOINT SURG BR, V75, P797, DOI 10.1302/0301-620X.75B5.8376443; Parker MJ., 1993, HIP FRACTURE MANAGEM; Pearse M, 1992, Health Trends, V24, P134; RUSSELL IT, 1992, QUALITY HLTH CARE, V1, P52; SAINSBURY R, 1991, REV CLIN GERONTOL, V1, P67; TODD C, 1993, TIJDSCHRIFT SOCIALE, V71, P72; 1989, FRACTURED NECK FEMUR; 1990, REPORT E ANGLIAN REG; 1994, HOSPITAL EPISODE STA, V1; 1992, BRIT MED J, V305, P567; 1989, CMND555; 1994, HOSPITAL AMBULANCE S	15	246	248	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					904	908		10.1136/bmj.310.6984.904	http://dx.doi.org/10.1136/bmj.310.6984.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719180	Green Published			2022-12-28	WOS:A1995QR97200021
J	HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N				HOU, XS; CHOU, TB; MELNICK, MB; PERRIMON, N			THE TORSO RECEPTOR TYROSINE KINASE CAN ACTIVATE RAF IN A RAS-INDEPENDENT PATHWAY	CELL			English	Article							NUCLEOTIDE EXCHANGE FACTOR; TERMINAL BODY PATTERN; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; DROSOPHILA-MELANOGASTER; EMBRYONIC TERMINI; GENE TAILLESS; SEVENLESS; TRANSFORMATION; EXPRESSION	Activation of the receptor tyrosine kinase (RTK) torso defines the spatial domains of expression of the transcription factors tailless and huckebein. Previous analyses have demonstrated that Ras1 (p21(ras)) operates upstream of the D-Raf (Raf1) serine/threonine kinase in this signaling pathway. By using a recently developed technique of germline mosaics, we find that D-Raf can be activated by torso in the complete absence of Ras1. This result is supported by analysis of D-Raf activation in the absence of either the exchange factor Son of sevenless (Sos) or the adaptor protein drk (Grb2), as well as by the phenotype of a D-Raf mutation that abolishes binding of Ras1 to D-Raf. Our study provides in vivo evidence that Raf can be activated by an RTK in a Ras-independent pathway.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	HOU, XS (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.		Chou, Tze-Bin/S-1188-2017	Chou, Tze-Bin/0000-0003-2453-0164; Perrimon, Norbert/0000-0001-7542-472X				AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAROLL MP, 1994, J BIOL CHEM, V269, P1249; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1993, NATURE, V362, P152, DOI 10.1038/362152a0; CASANOVA J, 1994, MECH DEVELOP, V48, P59, DOI 10.1016/0925-4773(94)90006-X; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEV Z, 1993, RAS SUPERFAMILY GTPA, P187; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; NEUMANSILBERBER, 1984, CELL, V0037; OLIUVIER JP, 1993, SOS CELL, V73, P179; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1994, TRENDS BIOCHEM SCI, V19, P509, DOI 10.1016/0968-0004(94)90140-6; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1994, CURR OPIN CELL BIOL, V6, P260, DOI 10.1016/0955-0674(94)90145-7; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; ROSE MD, 1990, LABORATORY COURSE MA; Sambrook J, 1989, MOL CLONING LABORATO; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SWANSON KD, 1992, GENE, V113, P183, DOI 10.1016/0378-1119(92)90394-5; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	64	110	110	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					63	71		10.1016/0092-8674(95)90371-2	http://dx.doi.org/10.1016/0092-8674(95)90371-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720074	Bronze			2022-12-28	WOS:A1995QR97000008
J	ALARCON, GS; STRAATON, KV				ALARCON, GS; STRAATON, KV			RHEUMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; ARTHRITIS; OSTEOARTHRITIS; KNEE; DISEASE; ACETAMINOPHEN				ALARCON, GS (corresponding author), UNIV ALABAMA,BIRMINGHAM,AL 35294, USA.							Altman Roy D., 1994, Seminars in Arthritis and Rheumatism, V23, P25, DOI 10.1016/S0049-0172(10)80023-X; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CALLAHAM LF, 1989, SCAND J RHEUMATOL S, V79, P67; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; DEODHAR AA, 1994, ANN RHEUM DIS, V53, P685, DOI 10.1136/ard.53.10.685; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; FRIES JF, 1994, ANN INTERN MED, V121, P502, DOI 10.7326/0003-4819-121-7-199410010-00005; GLADMAN D, 1992, J RHEUMATOL, V19, P1820; GOUGH A, 1994, ARTHRITIS RHEUM, V37, P1166, DOI 10.1002/art.1780370809; GRECOMORO G, 1992, CURR MED RES OPIN, V13, P49, DOI 10.1185/03007999209115222; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; KLOPPENBURG M, 1994, ARTHRITIS RHEUM, V37, P629, DOI 10.1002/art.1780370505; LIANG MH, 1991, RHEUMATOL INT, V11, P133, DOI 10.1007/BF00304502; McDaniel Olga, 1994, Arthritis and Rheumatism, V37, pS169; MORELAND LW, 1993, AM J MED SCI S, V30, P40; MOUNTZ JM, IN PRESS ARTHRITIS R; NEPOM GT, 1992, RHEUM DIS CLIN N AM, V18, P785; PUN YL, 1994, ARTHRITIS RHEUM, V37, P264, DOI 10.1002/art.1780370216; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; RUSSELL IJ, 1994, ARTHRITIS RHEUM-US, V37, P1593, DOI 10.1002/art.1780371106; TILLEY BC, 1995, ANN INTERN MED, V122, P81, DOI 10.7326/0003-4819-122-2-199501150-00001; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WILKENS RF, 1991, ARTHRITIS RHEUM, V34, P43; WILLIAMS HJ, 1993, ARTHRITIS RHEUM-US, V36, P1196, DOI 10.1002/art.1780360904; YANAGAWA A, 1993, J RHEUMATOL, V20, P781	26	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1721	1723						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752437				2022-12-28	WOS:A1995RB09700045
J	HARDY, MA; SUNG, RS				HARDY, MA; SUNG, RS			TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HARDY, MA (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.							BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; CANTAROVICH D, 1994, TRANSPLANTATION, V57, P198, DOI 10.1097/00007890-199401001-00007; COLE EH, 1994, TRANSPLANTATION, V57, P60, DOI 10.1097/00007890-199401000-00012; DUNN SP, 1994, TRANSPLANTATION, V57, P544; GRIFFITH BP, 1994, TRANSPLANTATION, V57, P848, DOI 10.1097/00007890-199403270-00013; HRIEIK DE, 1994, TRANSPLANTATION, V57, P979; LASKOW DA, 1994, TRANSPLANTATION, V57, P640, DOI 10.1097/00007890-199402270-00030; LO CM, 1994, TRANSPLANTATION, V58, P543, DOI 10.1097/00007890-199409150-00003; MCDANIEL DO, 1994, TRANSPLANTATION, V57, P852, DOI 10.1097/00007890-199403270-00014; MEISER BM, 1994, TRANSPLANTATION, V57, P563; MONTAGNINO G, 1994, TRANSPLANTATION, V58, P149, DOI 10.1097/00007890-199405820-00005; NIKAEIN A, 1994, TRANSPLANTATION, V58, P786, DOI 10.1097/00007890-199410150-00006; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; OPELZ G, 1994, NEW ENGL J MED, V330, P816, DOI 10.1056/NEJM199403243301203; TAKEMOTO S, 1994, NEW ENGL J MED, V331, P760, DOI 10.1056/NEJM199409223311202; YANDZA T, 1994, TRANSPLANTATION, V58, P46, DOI 10.1097/00007890-199407000-00009; 1994, NEW ENGL J MED, V331, P1110	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1723	1725						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752438				2022-12-28	WOS:A1995RB09700046
J	MARZUK, PM; BARCHAS, JD				MARZUK, PM; BARCHAS, JD			PSYCHIATRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											MARZUK, PM (corresponding author), CORNELL UNIV,COLL MED,NEW YORK,NY 10021, USA.							ANDREASEN NC, 1994, SCIENCE, V266, P294, DOI 10.1126/science.7939669; BERRETTINI WH, 1994, P NATL ACAD SCI USA, V91, P5918, DOI 10.1073/pnas.91.13.5918; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CRABBE JC, 1994, SCIENCE, V264, P1715, DOI 10.1126/science.8209252; HALLMAYER J, 1994, AM J HUM GENET, V55, P951; HOLLISTER LE, 1994, J CLIN PSYCHOPHARM, V14, P50; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; MAJ M, 1994, ARCH GEN PSYCHIAT, V51, P39; MULLEN PE, 1994, BRIT J PSYCHIAT, V165, P35, DOI 10.1192/bjp.165.1.35; NIELSEN DA, 1994, ARCH GEN PSYCHIAT, V51, P34; OLFSON M, 1994, AM J PSYCHIAT, V151, P1281; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; SARAVAY SM, 1994, PSYCHOSOMATICS, V35, P233, DOI 10.1016/S0033-3182(94)71772-2; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; SULLIVAN MD, 1994, AM J PSYCHIAT, V151, P971; 1994, DIAGNOSTIC STATISTIC	17	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1715	1716						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752433				2022-12-28	WOS:A1995RB09700041
J	ELIA, M				ELIA, M			CHANGING CONCEPTS OF NUTRIENT-REQUIREMENTS IN DISEASE - IMPLICATIONS FOR ARTIFICIAL NUTRITIONAL SUPPORT	LANCET			English	Review							PARENTERAL-NUTRITION; ENERGY-EXPENDITURE; ENTERAL NUTRITION; BURNED CHILDREN				ELIA, M (corresponding author), DUNN CLIN NUTR CTR,HILLS RD,CAMBRIDGE CB2 2DH,ENGLAND.							ALLWOOD MC, 1992, CLIN NUTR, V11, P284, DOI 10.1016/0261-5614(92)90005-B; BOUGLE D, 1993, J PEDIATR GASTR NUTR, V17, P72, DOI 10.1097/00005176-199307000-00010; Byrne Theresa A., 1992, Surgical Forum, V43, P151; CARLSSON M, 1984, CLIN NUTR, V3, P103, DOI 10.1016/S0261-5614(84)80008-4; DALY JM, 1992, SURGERY, V112, P56; Elia M., 1992, International Journal of Food Sciences and Nutrition, V43, P47, DOI 10.3109/09637489209027532; Elia M., 1994, MED INT, V22, P411; ELIA M, 1992, CURR MED LIT CLIN NU, V1, P35; ELIA M, 1994, P NUTR SOC, V53, P114; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FURST P, 1994, EUR J CLIN NUTR, V48, P681; GARIZ MB, 1993, J NUTR, V123, P238; GOLDIN BR, 1991, PROBIOTICS SCI BASIS, P355; GORAN MI, 1990, AM J PHYSIOL, V259, pE576, DOI 10.1152/ajpendo.1990.259.4.E576; HALLIWELL B, 1994, NUTR REV, V52, P253; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HANNING RM, 1991, AM J CLIN NUTR, V54, P905; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HOWARD L, 1980, ANN INTERN MED, V93, P567; KLEIN GL, 1991, AM J CLIN NUTR, V53, P399, DOI 10.1093/ajcn/53.2.399; LAFRANCE RJ, 1991, TOTAL PARENTERAL NUT, P57; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; Moukarzel A., 1993, Clinical Nutrition (Edinburgh), V12, P59, DOI 10.1016/0261-5614(93)90154-V; MURRAY MJ, 1979, AM J CLIN NUTR, V32, P593, DOI 10.1093/ajcn/32.3.593; NAYLOR CD, 1987, GASTROENTEROLOGY, V97, P1033; NOVICK WM, 1988, SURGERY, P99; PLAUTH M, 1993, J HEPATOL, V17, P308, DOI 10.1016/S0168-8278(05)80210-7; PULLICINO E, CNAA DX96679 BRIT LE; PULLICINO E, 1992, METABOLISM, V42, P58; RUDMAN D, 1981, GASTROENTEROLOGY, V81, P1025; SAGAR P, 1995, CLIN NUTR, V14, P13, DOI 10.1016/S0261-5614(06)80004-X; SHENKIN A, 1986, CLIN NUTR, V5, P91, DOI 10.1016/0261-5614(86)90014-2; STANSFIELD SK, 1993, LANCET, V342, P578, DOI 10.1016/0140-6736(93)91410-N; STOBBAERTS RFJ, 1992, Z ERNAHRUNGSWISS, V31, P138, DOI 10.1007/BF01623072; THURNHAM DI, 1994, P NUTR SOC, V53, P557, DOI 10.1079/PNS19940065; WEEKES E, 1994, P NUTR SOC, V53, pA43; ZEIGLER TR, 1992, ANN INTERN MED, V116, P821; 1993, LANCET, V341, P1227; 1991, DIETARY REFERENCE VA; 1994, AM J HOSP PHARM, V51, P1427; 1979, J PARENTERAL ENTERAL, V3, P258; 1989, RECOMMENDED DIETARY; 1994, NEW ENGL J MED, V330, P1029	44	53	59	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1279	1284		10.1016/S0140-6736(95)90929-X	http://dx.doi.org/10.1016/S0140-6736(95)90929-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746061				2022-12-28	WOS:A1995QY93300013
J	RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB				RASTINEJAD, F; PERLMANN, T; EVANS, RM; SIGLER, PB			STRUCTURAL DETERMINANTS OF NUCLEAR RECEPTOR ASSEMBLY ON DNA DIRECT REPEATS	NATURE			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; BINDING DOMAIN; RESPONSE ELEMENTS; X-RECEPTOR; VITAMIN-D; GLUCOCORTICOID RECEPTOR; GENE ENCODES; RXR-BETA; IDENTIFICATION	Nuclear receptor heterodimers recognize response elements composed of two direct repeats of the consensus sequence 5'-AGGTCA-3' separated by one to five base pairs. The 1.9 Angstrom crystal structure of the complex formed by the DNA-binding domains of the 9-cis retinoic acid receptor and thyroid hormone receptor bound to a thyroid-response element shows that the subunits interact through a DNA-supported interface involving the carboxy-terminal extension of the DNA-binding domain of the thyroid hormone receptor. The stereochemistry suggests a mechanism by which heterodimers recognize the inter-half-site spacing between direct repeats.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Yale University; Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Salk Institute			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIOCCO MM, 1994, J MOL BIOL, V235, P709; FREEDMAN L, IN PRESS 9TH P WORKS; GEWIRTH DT, IN PRESS NATURE STRU; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUO ZJ, 1994, EUR J BIOCHEM, V223, P381, DOI 10.1111/j.1432-1033.1994.tb19004.x; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OTWINOWSKI Z, 1991, MLPHARE CCP4 P, P80; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRESLEY JP, 1988, J APPL CRYSTALLOGR, V21, P572; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; XU W, 1993, COLD SPRING HARB SYM, V58, P133, DOI 10.1101/SQB.1993.058.01.017; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x	50	453	463	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					203	211		10.1038/375203a0	http://dx.doi.org/10.1038/375203a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746322				2022-12-28	WOS:A1995QY88100053
J	PINSKI, SL; TROHMAN, RG				PINSKI, SL; TROHMAN, RG			IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS - IMPLICATIONS FOR THE NONELECTROPHYSIOLOGIST	ANNALS OF INTERNAL MEDICINE			English	Review							RADIOFREQUENCY CATHETER ABLATION; SHOCK-WAVE LITHOTRIPSY; VENTRICULAR-TACHYCARDIA; CARDIAC-ARREST; DRUG-THERAPY; DEVICE; MANAGEMENT; ARRHYTHMIAS; INFECTIONS; EMERGENCY	Purpose: To review clinical scenarios in which non-electrophysiologist physicians may interact with patients who have implantable defibrillators. Data Sources: Peer-reviewed original articles and reviews addressing aspects of implantable defibrillator therapy that are relevant to the clinician. Data Synthesis: The capacity of implantable defibrillators to recognize and treat tachyarrhythmias can be temporarily disabled by placing a magnet on top of all devices. General surgery, radiotherapy, lithotripsy, and electroconvulsive therapy can usually be safely done under continuous electrocardiographic monitoring in patients with implantable defibrillators. The device should be deactivated before the procedure is done and reactivated and reassessed immediately afterward. Magnetic resonance imaging is usually contraindicated in patients with implantable defibrillators. The presence of an implantable defibrillator should not deter standard resuscitation techniques. Multiple defibrillator discharges in a short period of time represent a serious problem. Causes of multiple discharges include ventricular electric storm, inefficient defibrillation, nonsustained ventricular tachycardia, and inappropriate shocks caused by supraventricular tachyarrhythmias or oversensing of signals. These patients should be initially evaluated in a setting that allows electrocardiographic monitoring and cardiac resuscitation. The defibrillator should be deactivated if inappropriate firing is documented. Infections of implantable defibrillator systems are potentially life-threatening, and empiric oral antibiotic therapy should never be given when this possibility exists. Adjustment disorders specific to the defibrillator, including anxiety with secondary panic reaction; defibrillator dependence, abuse, or withdrawal; and imaginary shocks are not uncommon. Conclusions: Defibrillator therapy has become increasingly popular and complex. A basic understanding of these devices and skills in the short-term management of device-related problems is valuable for most physicians. These management guidelines will facilitate delivery of optimal care when specialized staff and material resources are not available.			PINSKI, SL (corresponding author), CLEVELAND CLIN FDN, F-15, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							AHERN TS, 1994, J AM COLL CARDIOL, V23, P1521; AVITALL B, 1990, CIRCULATION, V81, P1482, DOI 10.1161/01.CIR.81.5.1482; BADGER JM, 1989, HEART LUNG, V18, P238; BAKKER PFA, 1992, PACE, V15, P654, DOI 10.1111/j.1540-8159.1992.tb05158.x; BANAI S, 1993, J CARDIOVASC ELECTR, V4, P206, DOI 10.1111/j.1540-8167.1993.tb01224.x; BARDY GH, 1992, CIRCULATION, V85, P1689, DOI 10.1161/01.CIR.85.5.1689; BARDY GH, 1993, CIRCULATION, V87, P1152, DOI 10.1161/01.CIR.87.4.1152; BAROLD SS, 1991, CARDIAC PACING ELECT, P608; CHAPMAN PD, 1989, ANN EMERG MED, V18, P579, DOI 10.1016/S0196-0644(89)80848-0; COHEN AI, 1988, PACE, V11, P704, DOI 10.1111/j.1540-8159.1988.tb06020.x; CRAIG SA, 1990, ANN EMERG MED, V19, P421, DOI 10.1016/S0196-0644(05)82351-0; DUNBAR SB, 1993, HEART LUNG, V22, P494; ECHT DS, 1989, CIRCULATION, V79, P1106, DOI 10.1161/01.CIR.79.5.1106; Epstein AE, 1992, PACE, V16, P796; EYSMANN SB, 1986, CIRCULATION, V73, P73, DOI 10.1161/01.CIR.73.1.73; FAHY GJ, 1995, PACE, V18, P172, DOI 10.1111/j.1540-8159.1995.tb02499.x; FALK RH, 1992, ATRIAL FIBRILLATION, P255; FOGOROS RN, 1989, PACE, V12, P1465, DOI 10.1111/j.1540-8159.1989.tb06151.x; FRICCHIONE GL, 1989, AM HEART J, V117, P1411, DOI 10.1016/0002-8703(89)90457-2; GERRING JP, 1982, J CLIN PSYCHIAT, V43, P140; GOLDBERG RJ, 1993, PSYCHOSOMATICS, V34, P273, DOI 10.1016/S0033-3182(93)71892-7; GOODMAN LR, 1989, RADIOLOGY, V170, P447, DOI 10.1148/radiology.170.2.2911667; GRIFFIN JC, 1990, ELECTRICAL THERAPY C, P516; GRIMM W, 1993, PACE, V16, P218, DOI 10.1111/j.1540-8159.1993.tb01565.x; GRIMM W, 1992, PACE, V15, P1667, DOI 10.1111/j.1540-8159.1992.tb02953.x; HIGGINS GL, 1990, AM J EMERG MED, V8, P342, DOI 10.1016/0735-6757(90)90093-F; HOOK BG, 1991, J AM COLL CARDIOL, V17, P985; JOHNSON D, 1994, PACE, V17, P772; JOHNSON NJ, 1991, J AM COLL CARDIOL, V18, P1418, DOI 10.1016/0735-1097(91)90566-R; KAWANISHI DT, 1993, PACE, V16, P186, DOI 10.1111/j.1540-8159.1993.tb01559.x; KLEIN LS, 1991, J AM COLL CARDIOL, V18, P1349, DOI 10.1016/0735-1097(91)90559-R; KLEMAN JM, 1994, CIRCULATION, V90, P2833, DOI 10.1161/01.CIR.90.6.2833; KLEMAN JM, 1994, PACING CLIN ELECTROP, V17, P835; KOU WH, 1990, AM HEART J, V120, P208, DOI 10.1016/0002-8703(90)90181-V; KOWEY PR, 1988, AM J CARDIOL, V61, P1106, DOI 10.1016/0002-9149(88)90135-X; Kuiper R, 1991, J Cardiovasc Nurs, V5, P65; LEE JH, 1994, PACE, V17, P780; LEHMANN MH, 1991, PACE, V14, P969, DOI 10.1111/j.1540-8159.1991.tb04143.x; LEITCH JW, 1991, J AM COLL CARDIOL, V18, P145, DOI 10.1016/S0735-1097(10)80232-3; LERMAN BB, 1990, CIRCULATION, V81, P1409, DOI 10.1161/01.CIR.81.4.1409; MAN KC, 1993, PACE, V16, P1756, DOI 10.1111/j.1540-8159.1993.tb01049.x; MIROWSKI M, 1985, J AM COLL CARDIOL, V6, P461, DOI 10.1016/S0735-1097(85)80186-8; MORRIS PL, 1991, PSYCHOSOMATICS, V32, P58, DOI 10.1016/S0033-3182(91)72112-9; MYERBURG RJ, 1992, CIRCULATION, V86, P691, DOI 10.1161/01.CIR.86.2.691; OSSWALD S, 1993, CIRCULATION, V88, P54; PINSKI SL, 1991, PACE, V14, P7, DOI 10.1111/j.1540-8159.1991.tb04041.x; PINSKI SL, 1994, PACE, V17, P2263, DOI 10.1111/j.1540-8159.1994.tb02374.x; PITNEY MR, 1992, PACE, V15, P1657, DOI 10.1111/j.1540-8159.1992.tb02951.x; PLATIA EV, 1989, AM J CARDIOL, V63, P925, DOI 10.1016/0002-9149(89)90141-0; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; PYCHA C, 1990, CLEV CLIN J MED, V57, P441, DOI 10.3949/ccjm.57.5.441; RODRIGUEZ F, 1991, PACE, V14, P2143, DOI 10.1111/j.1540-8159.1991.tb06485.x; SCHOENFELD MH, 1993, PACE, V16, P2044, DOI 10.1111/j.1540-8159.1993.tb00998.x; SHADER RI, 1993, NEW ENGL J MED, V328, P1398; SOULIMAN SK, 1994, PACE, V17, P270, DOI 10.1111/j.1540-8159.1994.tb01387.x; SPRATT KA, 1993, CLIN INFECT DIS, V17, P679; STAMBLER BS, 1994, J AM COLL CARDIOL, V23, P123, DOI 10.1016/0735-1097(94)90510-X; TCHOU PJ, 1989, INT J PSYCHIAT MED, V19, P393; Tedder M, 1993, ASAIO J, V39, pM711; VASSOLAS G, 1993, PACE, V16, P1245, DOI 10.1111/j.1540-8159.1993.tb01710.x; VENDITTI FJ, 1991, PACE, V14, P1323, DOI 10.1111/j.1540-8159.1991.tb02875.x; VLAY SC, 1989, PACE, V12, P366, DOI 10.1111/j.1540-8159.1989.tb02670.x; WALLS JT, 1989, AM J CARDIOL, V64, P1144, DOI 10.1016/0002-9149(89)90867-9; WHITE RD, 1989, ANN EMERG MED, V18, P586, DOI 10.1016/S0196-0644(89)80849-2; WILLEMS S, 1993, PACE, V16, P1684, DOI 10.1111/j.1540-8159.1993.tb01039.x; WINKLE RA, 1989, J AM COLL CARDIOL, V13, P1353, DOI 10.1016/0735-1097(89)90310-0; WUNDERLY D, 1990, PACE, V13, P1360, DOI 10.1111/j.1540-8159.1990.tb04007.x	67	31	31	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					770	777		10.7326/0003-4819-122-10-199505150-00007	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717600				2022-12-28	WOS:A1995QX14700007
J	MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B				MARTOGLIO, B; HOFMANN, MW; BRUNNER, J; DOBBERSTEIN, B			THE PROTEIN-CONDUCTING CHANNEL IN THE MEMBRANE OF THE ENDOPLASMIC-RETICULUM IS OPEN LATERALLY TOWARD THE LIPID BILAYER	CELL			English	Article							SIGNAL-RECOGNITION PARTICLE; MICROSOMAL-MEMBRANES; SECRETORY PROTEIN; BIOSYNTHETIC INCORPORATION; DOCKING PROTEIN; MESSENGER-RNA; TRANSLOCATION; SEQUENCE; ELONGATION; CHAIN	Lipids and proteins were found to contact a nascent type II membrane protein, as well as a nascent secretory protein, during their insertion into the membrane of the endoplasmic reticulum. This suggests that the protein-conducting channel is open laterally toward the lipid bilayer during an early stage of protein insertion. Contact to lipids was confined to the hydrophobic core region of the respective signal or signal anchor sequence. Thus, the nascent polypeptide is positioned in the translocation complex such that the signal or signal anchor sequence faces the lipid bilayer, whereas the hydrophilic, translocating portion is in proteinaceous environment.	ETH ZURICH, BIOCHEM LAB, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich	MARTOGLIO, B (corresponding author), UNIV HEIDELBERG, ZENTRUM MOLEK BIOL, D-69052 HEIDELBERG, GERMANY.			Hofmann, Michael Werner/0000-0002-2729-6062				ALBERTS B, 1988, MOL BIOL CELL; BAIN JD, 1991, J ORG CHEM, V56, P4615, DOI 10.1021/jo00015a011; BALDINI G, 1988, BIOCHEMISTRY-US, V27, P7951, DOI 10.1021/bi00420a054; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRUNNER J, 1989, METHOD ENZYMOL, V172, P628; BRUNNER J, 1993, CHEM SOC REV, V22, P183, DOI 10.1039/cs9932200183; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CLAESSON L, 1983, P NATL ACAD SCI-BIOL, V80, P7395, DOI 10.1073/pnas.80.24.7395; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; ENGELMANN DM, 1991, CELL, V23, P411; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GLASER KB, 1986, BIOCHEM PHARMACOL, V35, P449, DOI 10.1016/0006-2952(86)90218-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HIGH S, 1993, J BIOL CHEM, V268, P26745; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1987, J BIOL CHEM, V262, P1680; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SIEGEL V, 1985, J CELL BIOL, V100, P1913, DOI 10.1083/jcb.100.6.1913; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VONHEIJNE G, 1986, J MOL BIOL, V189, P239, DOI 10.1016/0022-2836(86)90394-3; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1985, CURRENT TOPICS MEMBR, V24; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323	41	239	239	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					207	214		10.1016/0092-8674(95)90330-5	http://dx.doi.org/10.1016/0092-8674(95)90330-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736572	Bronze, Green Published			2022-12-28	WOS:A1995QV41000009
J	GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP				GLANCY, JM; GARRATT, CJ; WOODS, KL; DEBONE, DP			QT DISPERSION AND MORTALITY AFTER MYOCARDIAL-INFARCTION	LANCET			English	Article							2-YEAR FOLLOW-UP; SUDDEN-DEATH; INTERVAL PROLONGATION; DISCHARGE; MAGNESIUM; RISK	QT dispersion may serve as a measure of variability in ventricular recovery time and may be a means of identifying patients at risk of arrhythmias and sudden death after acute myocardial infarction. We investigated this possibility on electrocardiograms (ECGs) recorded 2 or 3 days after infarction (early) and at least 4 weeks later (late). 163 patients who died between 1 day and 5 years after infarct were compared with an equal number of survivors matched for age and sex. 53 of the patients who died and 82 survivors also had late ECGs. There was no difference in early QT dispersion between the patients who died and the survivors (mean QT(c) dispersion 112.1 [SD 44.4] vs 109.9 [42.7] ms(1/2)). QT(c) dispersion fell significantly from early to late ECGs in survivors (110.9 [48.5] to 76.5 [28.8] ms(1/2)), but not in patients who died during follow-up (108.0 [51.0] to 98.9 [43.1] ms(1/2)). The difference between the groups in the mean change was significant (34.4 [55.2] vs 9.1 [60.8] ms(1/2), p=0.016). QT dispersion measured on an ECG recorded 2 or 3 days after acute myocardial infarction does not predict mortality during the next 5 years. Increased QT dispersion on ECGs recorded at least 4 weeks after infarct may be associated with subsequent mortality, but this finding must be confirmed in a prospective trial.	UNIV LEICESTER,DIV CARDIOL,LEICESTER,LEICS,ENGLAND; UNIV LEICESTER,DEPT MED & THERAPEUT,DIV CLIN PHARMACOL,LEICESTER,LEICS,ENGLAND	University of Leicester; University of Leicester								AHNVE S, 1984, AM HEART J, V108, P395, DOI 10.1016/0002-8703(84)90631-8; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BHULLAR HK, 1993, J ELECTROCARDIOL, V26, P321, DOI 10.1016/0022-0736(93)90053-G; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; BUTROUS GS, 1989, CLIN ASPECTS VENTRIC, P379; DAVEY P, 1994, BRIT HEART J, V71, P268; DAY CP, 1990, BRIT HEART J, V63, P342; DOROGHAZI RM, 1977, AM J CARDIOL, V41, P684; ELDAR M, 1990, BRIT HEART J, V63, P273; GLANCY JM, 1994, CLIN SCI S30, V86, P18; HIGHAM P, 1994, BRIT HEART J, V71, P508; HIGHAM PD, 1991, CIRCULATION S2, V13, P61; LAUNBJERG J, 1994, BRIT MED J, V308, P1196, DOI 10.1136/bmj.308.6938.1196; LEPESCHKIN E, 1952, CIRCULATION, V6, P378, DOI 10.1161/01.CIR.6.3.378; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; POHJOLASINTONEN S, 1986, AM J CARDIOL, V57, P1066, DOI 10.1016/0002-9149(86)90675-2; POTRATZ J, 1993, EUR HEART J S, V114, P254; PYE M, 1993, BRIT HEART J, V71, P511; SCHWARTZ PJ, 1978, CIRCULATION, V57, P1074, DOI 10.1161/01.CIR.57.6.1074; SHEN AC, 1972, AM J PATHOL, V67, P417; WARD D E, 1988, European Heart Journal, V9, P139; WHEELAN K, 1986, AM J CARDIOL, V57, P745, DOI 10.1016/0002-9149(86)90606-5; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; ZARDINI P, 1993, AM J CARDIOL, V72, pG98, DOI 10.1016/0002-9149(93)90114-R; 1983, NEW ENGL J MED, V309, P331	25	256	258	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					945	948		10.1016/S0140-6736(95)90697-5	http://dx.doi.org/10.1016/S0140-6736(95)90697-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715292				2022-12-28	WOS:A1995QT91900007
J	DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC				DAMBROSIO, D; HIPPEN, KL; MINSKOFF, SA; MELLMAN, I; PANI, G; SIMINOVITCH, KA; CAMBIER, JC			RECRUITMENT AND ACTIVATION OF PTP1C IN NEGATIVE REGULATION OF ANTIGEN RECEPTOR SIGNALING BY FC-GAMMA-RIIB1	SCIENCE			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASES; FC-GAMMA RECEPTOR; LYMPHOCYTES-B; CROSS-LINKING; MOTH-EATEN; PHOSPHOTYROSINE PHOSPHATASE; IMMUNODEFICIENT MUTANT; MOTHEATEN LOCUS; SH2 DOMAINS	Coligation of the Fc receptor on B cells, Fc gamma RIIB1, with the B cell antigen receptor (BCR) leads to abortive BCR signaling. Here it was shown that the Fc gamma RIIB1 recruits the phosphotyrosine phosphatase PTP1C after BCR coligation. This association is mediated by the binding of a 13-amino acid tyrosine-phosphorylated sequence to the carboxyl terminal Src homology 2 domain of PTP1C and activates PTP1C. Inhibitory signaling and PTP1C recruitment are dependent on the presence of the tyrosine within the 13-amino acid sequence. Inhibitory signaling mediated by Fc gamma RIIB1 is deficient in motheaten mice which do not express functional PTP1C. Thus, PTP1C is an effector of BCR-Fc gamma RIIB1 negative signal cooperativity.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Yale University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute			Pani, Giovambattista/AAB-1446-2019; Siminovitch, Katherine/K-1475-2013; Mellman, Ira/ABG-5896-2020	Pani, Giovambattista/0000-0001-7133-8728; Cambier, John/0000-0002-7803-242X				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN PL, 1971, IMMUNOLOGY, V21, P967; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; DAMBROSIO D, UNPUB; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FRIDMAN WH, 1992, IMMUNOL REV, V125, P49, DOI 10.1111/j.1600-065X.1992.tb00625.x; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GREEN MC, 1975, J HERED, V66, P250, DOI 10.1093/oxfordjournals.jhered.a108625; HIPPEN KL, 1993, BIOCHEMISTRY-US, V32, P12405, DOI 10.1021/bi00097a019; JONES B, 1986, J IMMUNOL, V136, P348; JUSTEMENT LB, 1989, J IMMUNOL, V143, P881; KIM KJ, 1979, J IMMUNOL, V122, P549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHLER H, 1977, J IMMUNOL, V119, P1979; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PHILLIPS NE, 1984, J IMMUNOL, V132, P627; PHILLIPS NE, 1983, J IMMUNOL, V130, P602; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1976, J IMMUNOL, V116, P936; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SHULTZ LD, 1988, CURR TOP MICROBIOL, V137, P216; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; UNKELESS JC, 1988, ANNU REV IMMUNOL, V6, P251, DOI 10.1146/annurev.iy.06.040188.001343; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WILSON HA, 1987, J IMMUNOL, V138, P1712; YAMADA T, 1993, EUR J BIOCHEM, V213, P455, DOI 10.1111/j.1432-1033.1993.tb17781.x; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	42	526	529	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					293	297		10.1126/science.7716523	http://dx.doi.org/10.1126/science.7716523			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716523				2022-12-28	WOS:A1995QT18500040
J	SAIDMAN, LJ				SAIDMAN, LJ			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDURAL ANALGESIA				SAIDMAN, LJ (corresponding author), UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093, USA.							ANTOGNINI JF, 1993, ANESTHESIOLOGY, V79, P1244, DOI 10.1097/00000542-199312000-00015; BOUAZIZ H, 1994, ANESTHESIOLOGY, V81, P930; CHENEY FW, 1994, ANESTHESIOLOGY, V80, P806, DOI 10.1097/00000542-199404000-00012; CHENEY FW, 1994, AM SOC ANESTHESIOLOG, V58, P7; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; FILOS KS, 1994, ANESTHESIOLOGY, V81, P591, DOI 10.1097/00000542-199409000-00011; KROLL DA, 1990, ANESTHESIOLOGY, V73, P202, DOI 10.1097/00000542-199008000-00002; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; THORP JA, 1991, AM J PERINAT, V8, P402, DOI 10.1055/s-2007-999426; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; WARNER MA, 1994, ANESTHESIOLOGY, V81, P6, DOI 10.1097/00000542-199407000-00004; WARNER MA, 1994, ANESTHESIOLOGY, V81, P1332, DOI 10.1097/00000542-199412000-00006; WOOLF SH, 1991, AHCPR910007 US PHS U	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1661	1662						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752404				2022-12-28	WOS:A1995RB09700012
J	HAVEL, RJ; RAPAPORT, E				HAVEL, RJ; RAPAPORT, E			DRUG-THERAPY - MANAGEMENT OF PRIMARY HYPERLIPIDEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY DISEASE; LOW-DENSITY-LIPOPROTEIN; ENDOTHELIUM-DEPENDENT RELAXATION; TRIGLYCERIDE-RICH LIPOPROTEINS; AORTOCORONARY-BYPASS-SURGERY; FACTOR INTERVENTION TRIAL; SERUM-CHOLESTEROL LEVELS; APOLIPOPROTEIN-A-I; MYOCARDIAL-INFARCTION; HEART-DISEASE		UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	HAVEL, RJ (corresponding author), UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA.							ABATE N, 1993, ATHEROSCLEROSIS, V104, P159, DOI 10.1016/0021-9150(93)90187-Y; AMBROSE JA, 1988, J AM COLL CARDIOL, V12, P56, DOI 10.1016/0735-1097(88)90356-7; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1991, JAMA, V265, P3255; ANSTIN MA, 1990, CIRCULATION, V82, P495; ARMSTRONG ML, 1972, CIRC RES, V30, P675, DOI 10.1161/01.RES.30.6.675; ASSMANN G, 1992, AM J CARDIOL, V70, pH10, DOI 10.1016/0002-9149(92)91084-H; AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; AVOGARO P, 1980, ATHEROSCLEROSIS, V37, P69, DOI 10.1016/0021-9150(80)90094-5; BELCHETZ PE, 1994, NEW ENGL J MED, V330, P1062; BIERMAN EL, 1992, ARTERIOSCLER THROMB, V12, P647, DOI 10.1161/01.ATV.12.6.647; BLANKENHORN DH, 1993, WESTERN J MED, V159, P172; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1988, JAMA-J AM MED ASSOC, V259, P2698; BOOKSTEIN L, 1990, ARCH INTERN MED, V150, P1653, DOI 10.1001/archinte.150.8.1653; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; CASTELLI WP, 1992, AM J CARDIOL, V70, pH3, DOI 10.1016/0002-9149(92)91083-G; CONSTANT.P, 1966, J ATHEROSCLER RES, V6, P1, DOI 10.1016/S0368-1319(66)80056-X; DAVIES MJ, 1990, CIRCULATION, V82, P38; DENKE MA, 1993, ARCH INTERN MED, V153, P1093, DOI 10.1001/archinte.153.9.1093; DENKE MA, 1994, ARCH INTERN MED, V154, P317, DOI 10.1001/archinte.154.3.317; FIELDING CJ, 1992, FASEB J, V6, P3162, DOI 10.1096/fasebj.6.13.1327930; FITZGIBBON GM, 1991, J AM COLL CARDIOL, V17, P1075, DOI 10.1016/0735-1097(91)90834-V; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GARG A, 1990, DIABETES CARE, V13, P153, DOI 10.2337/diacare.13.2.153; GENEST J, 1992, J AM COLL CARDIOL, V19, P792, DOI 10.1016/0735-1097(92)90520-W; GOFMAN JW, 1954, PHYSIOL REV, V34, P589, DOI 10.1152/physrev.1954.34.3.589; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HAVEL RJ, 1989, CLIN EXP HYPERTENS A, V11, P887, DOI 10.3109/10641968909035380; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAVEL RJ, 1984, J LIPID RES, V25, P1570; HAVEL RJ, 1990, CIRCULATION, V81, P694, DOI 10.1161/01.CIR.81.2.694; HAVEL RJ, 1982, MED CLIN N AM, V66, P441, DOI 10.1016/S0025-7125(16)31429-8; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; HODIS HN, 1994, CIRCULATION, V90, P42, DOI 10.1161/01.CIR.90.1.42; HOLME I, 1993, BRIT HEART J, V69, pS42; HOSENPUD JD, 1992, J HEART LUNG TRANSPL, V11, P9; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAMEDA K, 1984, ATHEROSCLEROSIS, V51, P241, DOI 10.1016/0021-9150(84)90171-0; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KEYS A, 1984, PREV MED, V13, P141, DOI 10.1016/0091-7435(84)90047-1; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KOBAYASHI S, 1992, NUTR REV, V50, P353, DOI 10.1111/j.1753-4887.1992.tb02478.x; KRAUSS RM, 1987, LANCET, V2, P62; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; LENDON CL, 1991, ATHEROSCLEROSIS, V87, P87, DOI 10.1016/0021-9150(91)90235-U; LEUNG WH, 1993, LANCET, V341, P1496, DOI 10.1016/0140-6736(93)90634-S; LEVINE S, 1985, AM J CARDIOL, V55, P673, DOI 10.1016/0002-9149(85)90134-1; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; LIU MW, 1989, CIRCULATION, V79, P1374, DOI 10.1161/01.CIR.79.6.1374; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MYERS LH, 1976, J LAB CLIN MED, V88, P491; National Cholesterol Education Program, 1994, CIRCULATION, V89, P1333, DOI [10.1161/01.CIR.89.3.1333, DOI 10.1161/01.CIR.89.3.1333]; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PHILLIPS NR, 1993, CIRCULATION, V88, P2762, DOI 10.1161/01.CIR.88.6.2762; RAPP JH, 1994, ARTERIOSCLER THROMB, V14, P1767, DOI 10.1161/01.ATV.14.11.1767; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; REARDON MF, 1985, CIRCULATION, V71, P881, DOI 10.1161/01.CIR.71.5.881; ROUSSOW JE, 1991, DRUG TREATMENT HYPER, P67; RUBIESPRAT J, 1993, DIABETES CARE, V16, P1081, DOI 10.2337/diacare.16.8.1081; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SATA T, 1972, J LIPID RES, V13, P757; SEMPOS C, 1988, AM J PUBLIC HEALTH, V78, P1422, DOI 10.2105/AJPH.78.11.1422; SEMPOS C, 1989, AM J PUBLIC HEALTH, V79, P1677; SENTI M, 1991, CLIN CHEM, V37, P1394; SHAH PK, 1992, CIRCULATION, V85, P1279, DOI 10.1161/01.CIR.85.4.1279; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SMITH GD, 1993, BRIT MED J, V306, P1648; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STEINER G, 1987, CIRCULATION, V75, P124, DOI 10.1161/01.CIR.75.1.124; TATAMI R, 1981, CIRCULATION, V64, P1174, DOI 10.1161/01.CIR.64.6.1174; THOM TJ, 1987, CORONARY HEART DISEA; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; VANDERMEER, 1993, LANCET, V342, P690; VANDERMEER J, 1993, LANCET, V342, P257, DOI 10.1016/0140-6736(93)91815-4; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WEINTRAUB WS, 1994, NEW ENGL J MED, V331, P1331, DOI 10.1056/NEJM199411173312002; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WONG ND, 1991, ANN INTERN MED, V115, P687, DOI 10.7326/0003-4819-115-9-687; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; 1993, PHS DHHS NIH931088 P; 1982, DHEW NIH75628 PUBL; 1992, NATIONAL DISEASE THE, V2; 1980, PHS DHHS NIH801527 P	103	149	154	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1491	1498		10.1056/NEJM199506013322207	http://dx.doi.org/10.1056/NEJM199506013322207			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739687				2022-12-28	WOS:A1995RA14000007
J	IOANNIDIS, JPA; CAPPELLERI, JC; LAU, J; SKOLNIK, PR; MELVILLE, B; CHALMERS, TC; SACKS, HS				IOANNIDIS, JPA; CAPPELLERI, JC; LAU, J; SKOLNIK, PR; MELVILLE, B; CHALMERS, TC; SACKS, HS			EARLY OR DEFERRED ZIDOVUDINE THERAPY IN HIV-INFECTED PATIENTS WITHOUT AN AIDS-DEFINING ILLNESS - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; CUBIC MILLIMETER; COMPLEX; EFFICACY; SAFETY	Purpose: To do a meta-analysis on the efficacy of early or deferred zidovudine monotherapy in patients with human immunodeficiency virus (HIV) infection but not the acquired immunodeficiency syndrome (AIDS). Data Sources: Articles on zidovudine monotherapy published through May 1994. Study Selection: Double-blind, randomized, placebo-controlled trials addressing the efficacy of zidovudine monotherapy in HIV-infected persons without an AIDS-defining illness. Data Extraction: Progression to any primary trial end point; any clinical end point; and AIDS or death. Data were stratified according to disease stage at study entry and duration of follow-up (short-term, <14 months; long-term, >21 months). Data Synthesis: Early initiation of zidovudine therapy was of short-term benefit for all the end points evaluated (for example, the risk ratio for progression to any primary end point was 0.51; 95% Cl, 0.41 to 0.64). Long-term trials showed a marginally significant trend of decreased progression to any primary end point (risk ratio, 0.73; Cl, 0.52 to 1.03). The trend was not significant for other end points. With further stratification according to disease stage, progression to AIDS or death in the short term was significantly decreased for both symptomatic and asymptomatic patients with CD4 cell counts of less than 500 x 10(6)/L (risk ratios, 0.26 [Cl, 0.13 to 0.56] and 0.43 [Cl, 0.30 to 0.64], respectively). A regression analysis indicated a larger relative benefit in short-term trials and symptomatic patients than in long-term trials and asymptomatic patients. Conclusions: Early initiation of zidovudine therapy offers a benefit that decreases over time. Symptomatic patients experience a larger benefit than asymptomatic patients. The implications beyond 3 years of follow-up remain unknown.	TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA USA; MT SINAI SCH MED, NEW YORK, NY USA	Tufts University; Tufts Medical Center; Icahn School of Medicine at Mount Sinai			Ioannidis, John P. A./G-9836-2011		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045686] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS07782] Funding Source: Medline; NIAID NIH HHS [T32 AI07389] Funding Source: Medline; NIMH NIH HHS [R01 MH45686] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; COOPER DA, 1991, AIDS, V5, P933, DOI 10.1097/00002030-199108000-00003; COOPER DA, 1994, NEW ENGL J MED, V330, P1759; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER M, 1994, LANCET, V343, P1355, DOI 10.1016/S0140-6736(94)92490-2; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; LAGAKOS S, 1991, JAMA-J AM MED ASSOC, V266, P2709, DOI 10.1001/jama.266.19.2709; LENDERKING WR, 1994, NEW ENGL J MED, V330, P738, DOI 10.1056/NEJM199403173301102; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MANNUCCI PM, 1994, BRIT J HAEMATOL, V86, P174, DOI 10.1111/j.1365-2141.1994.tb03270.x; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MERIGAN TC, 1991, BLOOD, V78, P900; MULDER JW, 1994, AIDS, V8, P313, DOI 10.1097/00002030-199403000-00004; ODDONE EZ, 1993, BRIT MED J, V307, P1322, DOI 10.1136/bmj.307.6915.1322; PETO R, 1993, LANCET, V341, P1022, DOI 10.1016/0140-6736(93)91109-Y; PHILLIPS AN, 1993, NEW ENGL J MED, V329, P1895, DOI 10.1056/NEJM199312163292516; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REMICK S, 1993, 9TH INT C AIDS BERL; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; Rothman K, 1986, MODERN EPIDEMIOLOGY; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; SELIGMANN M, 1994, LANCET, V343, P871; SIMBERKOFF MS, 1992, 8TH INT C AIDS; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, AM J MED, V89, P335; 1988, SAS GUIDE PERSONAL C	35	74	76	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					856	866		10.7326/0003-4819-122-11-199506010-00009	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741372				2022-12-28	WOS:A1995RA13900009
J	VANPEENEN, HJ				VANPEENEN, HJ			2ND OPINIONS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					876	877		10.7326/0003-4819-122-11-199506010-00012	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741374				2022-12-28	WOS:A1995RA13900012
J	FLORIN, THJ; HILLS, BA				FLORIN, THJ; HILLS, BA			DOES COUNTERPERFUSION SUPERSATURATION CAUSE GAS CYSTS IN PNEUMATOSIS CYSTOIDES COLI, AND CAN BREATHING HELIOX REDUCE THEM	LANCET			English	Article							INTESTINALIS; EXCRETION	The pathogenesis of pneumatosis cystoides coli remains obscure in the absence of an explanation for why pockets of gas should form in the first place and why they should be maintained in the wall and mesentery of the colon. Counterperfusion supersaturation could explain the formation and location of the gas cysts, which occur mostly near brood vessels on the mesenteric border of the colon, and the absence of methane gas in them. The hypothesis can be tested by treating patients with pneumatosis cystoides coli with heliox.	MATER MISERICORDIAE HOSP,MATER RES INST,BRISBANE,QLD 4101,AUSTRALIA	Mater Research	FLORIN, THJ (corresponding author), UNIV QUEENSLAND,DEPT MED,ST LUCIA,QLD 4067,AUSTRALIA.		Florin, Tim HJ/F-1890-2010					BLENKARN GD, 1971, AEROSPACE MED, V42, P141; CHRISTL SU, 1993, GASTROENTEROLOGY, V104, P392, DOI 10.1016/0016-5085(93)90406-3; COLLINS JM, 1978, J APPL PHYSIOL, V44, P914, DOI 10.1152/jappl.1978.44.6.914; ECKER JA, 1971, AM J GASTROENTEROL, V56, P125; ELLIS BW, 1980, BRIT MED J, V280, P763, DOI 10.1136/bmj.280.6216.763-a; FORGACS P, 1973, LANCET, V1, P579; GILLON J, 1979, GUT, V20, P1008, DOI 10.1136/gut.20.11.1008; HABOUBI NY, 1984, HISTOPATHOLOGY, V8, P145, DOI 10.1111/j.1365-2559.1984.tb02329.x; HAYDUK W, 1974, AICHE J, V20, P611, DOI 10.1002/aic.690200329; Hills B.A., 1988, BIOL SURFACTANT; HILLS BA, 1977, J APPL PHYSIOL, V42, P758, DOI 10.1152/jappl.1977.42.5.758; HILLS BA, 1969, CLIN SCI, V36, P185; HILLS BA, 1983, AM J PHYSIOL, V244, P561; HILS BA, 1977, DECOMPRESSION SICKNE; HUGHES DTD, 1966, GUT, V7, P553, DOI 10.1136/gut.7.5.553; KOSS LG, 1952, AMA ARCH PATHOL, V53, P523; LAMBERTSEN CJ, 1975, J APPL PHYSIOL, V39, P434, DOI 10.1152/jappl.1975.39.3.434; LEVITT MD, 1971, NEW ENGL J MED, V284, P1394, DOI 10.1056/NEJM197106242842502; MAHMOOD A, 1993, ARCH BIOCHEM BIOPHYS, V300, P280, DOI 10.1006/abbi.1993.1039; MCKAY LF, 1985, GUT, V26, P69, DOI 10.1136/gut.26.1.69; READ NW, 1984, GUT, V25, P839, DOI 10.1136/gut.25.8.839; REINHOFF WF, 1959, ANN SURG, V149, P593; STIENNON OA, 1951, AMA AM J DIS CHILD, V81, P651, DOI 10.1001/archpedi.1951.02040030664004; VANDERLINDEN W, 1979, SCAND J GASTROENTERO, V14, P173, DOI 10.3109/00365527909179864	24	26	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1220	1222		10.1016/S0140-6736(95)91996-1	http://dx.doi.org/10.1016/S0140-6736(95)91996-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739311				2022-12-28	WOS:A1995QX86100014
J	HEBERT, PC; WELLS, G; MARSHALL, J; MARTIN, C; TWEEDDALE, M; PAGLIARELLO, G; BLAJCHMAN, M				HEBERT, PC; WELLS, G; MARSHALL, J; MARTIN, C; TWEEDDALE, M; PAGLIARELLO, G; BLAJCHMAN, M			TRANSFUSION REQUIREMENTS IN CRITICAL CARE - A PILOT-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY; UNITED-STATES; BLOOD; MORTALITY; SEPSIS; SHOCK; HEMOGLOBIN; STRATEGIES; SEVERITY	Objective.-To evaluate the effects of a restrictive and a liberal red blood cell (RBC) transfusion strategy on mortality and morbidity in critically ill patients. Study Design.-Multicenter, prospective, randomized clinical trial. Patient Population.-Sixty-nine normovolemic critically ill patients admitted to one of five tertiary level intensive care units with hemoglobin values less than 90 g/L within 72 hours of admission. Interventions.-Patients were randomly allocated to one of two RBC transfusion strategies. Hemoglobin values were maintained between 100 and 120 g/L in the liberal transfusion group and between 70 and 90 g/L in the restrictive group. Results.-Primary diagnosis and mean+/-SD age (58.6+/-15 vs 59.0+/-21 years) and Acute Physiology and Chronic Health Evaluation II score (20+/-6.2 vs 21 +/-7.2) were similar in the restrictive and liberal groups, respectively. Daily hemoglobin values averaged 90 g/L in the restrictive group vs 109 g/L in the liberal group (P<.001). The restrictive group received 2.5 U per patient compared with 4.8 U per patient in the liberal group. This represents a 48% relative decrease (P<.001) in RBC units transfused per patient. The 30-day mortality rate was 24% in the restrictive group compared with 25% in the liberal group; the 95% confidence interval around the absolute difference was -19% to 21%. Similar observations were noted for intensive care unit mortality (P=.76) and 120-day mortality (P>.99). In addition, survival analysis comparing time until death in both groups did not reveal any significant difference (P=.93) between groups. Organ dysfunction scores were also similar (P=.44). Conclusion.-In this small randomized trial, neither mortality nor the development of organ dysfunction was affected by the transfusion strategy, which suggests that a more restrictive approach to the transfusion of RBCs may be safe in critically ill patients. However, the study lacked power to detect small but clinically significant differences. Therefore, further investigations of RBC transfusion strategies are warranted.	UNIV WESTERN ONTARIO, CRIT CARE PROGRAM, LONDON, ON, CANADA; UNIV TORONTO, CRIT CARE PROGRAM, TORONTO, ON, CANADA; UNIV OTTAWA, CRIT CARE PROGRAM, OTTAWA, ON, CANADA; UNIV BRITISH COLUMBIA, CRIT CARE PROGRAM, VANCOUVER, BC, CANADA; UNIV OTTAWA, CLIN EPIDEMIOL UNIT, OTTAWA, ON, CANADA; MCMASTER UNIV, DEPT PATHOL, HAMILTON, ON, CANADA	Western University (University of Western Ontario); University of Toronto; University of Ottawa; University of British Columbia; University of Ottawa; McMaster University			Martin, Claudio/G-3327-2011; Wells, George A/M-4549-2017	Wells, George A/0000-0002-2289-9139				ABEL FL, 1989, AM J PHYSIOL, V257, pR1265, DOI 10.1152/ajpregu.1989.257.6.R1265; ALEXIU O, 1975, ANAESTHESIA, V30, P609, DOI 10.1111/j.1365-2044.1975.tb00920.x; BAYER WL, 1980, ANN THORAC SURG, V29, P117, DOI 10.1016/S0003-4975(10)61648-7; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CANE RD, 1990, CRIT CARE MED, V18, P1046, DOI 10.1097/00003246-199009000-00028; CARSON JL, 1988, LANCET, V1, P727; CROSBY ET, 1992, CAN J ANAESTH, V39, P695, DOI 10.1007/BF03008233; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; CZER LSC, 1980, CRIT CARE MED, V8, P710, DOI 10.1097/00003246-198012000-00002; Friedman LM, 1985, FUNDAMENTALS CLIN TR; FULLERTON WT, 1962, LANCET, V1, P75; GOLLUB S, 1966, JAMA-J AM MED ASSOC, V198, P149; GUTIERREZ G, 1986, Journal of Critical Care, V1, P45, DOI 10.1016/S0883-9441(86)80116-2; Hebert P. C., 1994, Clinical and Investigative Medicine, V17, pB22; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; KAWAGUCHI A, 1984, CIRCULATION, V70, P30; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Marshall JC, 1994, SEPSIS CURRENT PERSP, P38; Messmer K, 1972, ADV MICROCIRCULAT, V18, P1; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; SHOEMAKER WC, 1990, CRIT CARE MED, V18, pS19; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; SPENCE RK, 1990, AM J SURG, V159, P320, DOI 10.1016/S0002-9610(05)81227-9; STEHLING L, 1989, ANESTH ANALG, V68, pS1; STEHLING LC, 1982, INT ANESTHESIOL CLIN, V20, P45; STEHLING LC, 1987, VOX SANG, V52, P60, DOI 10.1111/j.1423-0410.1987.tb02990.x; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1988, TRANSFUSION, V28, P513, DOI 10.1046/j.1537-2995.1988.28689059022.x; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WEISEL RD, 1984, J THORAC CARDIOV SUR, V88, P26; WEISEL RD, 1984, J THORAC CARDIOVASC, V104, P308; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393	37	120	124	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1439	1444		10.1001/jama.273.18.1439	http://dx.doi.org/10.1001/jama.273.18.1439			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723158				2022-12-28	WOS:A1995QW27900032
J	WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B				WILLEMSEN, R; MOHKAMSING, S; DEVRIES, B; DEVYS, D; VANDENOUWELAND, A; MANDEL, JL; GALJAARD, H; OOSTRA, B			RAPID ANTIBODY-TEST FOR FRAGILE-X SYNDROME	LANCET			English	Note							CGG REPEAT; FMR-1; CARRIERS	Fragile X syndrome is the most common known cause of inherited mental retardation. Identification of patients and carriers of fragile X syndrome is usually done with a DNA test system but we have developed a rapid antibody to identify fragile X patients. This non-invasive test requires only 1 or 2 drops of blood and can be used for screening large groups of mentally retarded people and neonates for fragile X syndrome.	ERASMUS UNIV ROTTERDAM,DEPT CLIN GENET,3000 DR ROTTERDAM,NETHERLANDS; UNIV STRASBOURG 1,CU,INSERM,CNRS,INST GENET & BIOL MOLEC & CELLULAIRE,STRASBOURG,FRANCE	Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Devys, Didier/0000-0001-9655-3512				DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; OOSTRA BA, 1993, J MED GENET, V30, P410, DOI 10.1136/jmg.30.5.410; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536	9	137	140	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1147	1148		10.1016/S0140-6736(95)90979-6	http://dx.doi.org/10.1016/S0140-6736(95)90979-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723547				2022-12-28	WOS:A1995QW62200011
J	HEBERT, DN; FOELLMER, B; HELENIUS, A				HEBERT, DN; FOELLMER, B; HELENIUS, A			GLUCOSE TRIMMING AND REGLUCOSYLATION DETERMINE GLYCOPROTEIN ASSOCIATION WITH CALNEXIN IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; INFLUENZA-VIRUS HEMAGGLUTININ; BINDING-PROTEINS; DISULFIDE BONDS; MICROSOMES; PURIFICATION; MEMBRANE; GLUCOSYLTRANSFERASE; INHIBITORS; MATURATION	To determine the role of N-linked oligosaccharides in the folding of glycoproteins, we analyzed the processing of in vitro translated influenza hemagglutinin (HA) in dog pancreas microsomes. We found that binding to calnexin, a membrane-bound molecular chaperone, was specific to molecules that possessed monoglucosylated core glycans. In the microsomes, these were generated either by glucose removal from the original triglucosylated core oligosaccharide by glucosidases I and II or by reglucosylation of already unglucosylated high mannose glycans. Release of fully folded HA from calnexin required the removal of the remaining glucose by glucosidase II. The results provided an explanation for trimming and reglucosylation activities in the endoplasmic reticulum and established a direct correlation between glycosylation and folding.			HEBERT, DN (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM38346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; ATKINSON PH, 1984, J CELL BIOL, V98, P2245, DOI 10.1083/jcb.98.6.2245; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRAIZUMI S, 1993, J BIOL CHEM, V268, P9927; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; JACKSON MR, 1994, SCIENCE, V263, P384, DOI 10.1126/science.8278813; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KERN G, 1993, PROTEIN SCI, V2, P1862, DOI 10.1002/pro.5560021108; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LE AQ, 1994, J BIOL CHEM, V269, P7514; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PIND S, 1994, J BIOL CHEM, V289, P12784; RAJOGAPALAN S, 1994, SCIENCE, V263, P387; ROBERTS PC, 1993, J VIROL, V67, P3048, DOI 10.1128/JVI.67.6.3048-3060.1993; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; SUH KS, 1989, J CELL BIOL, V108, P811, DOI 10.1083/jcb.108.3.811; TATU U, 1995, IN PRESS EMBO J; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WADA I, 1994, J BIOL CHEM, V269, P7464; WADA I, 1991, J BIOL CHEM, V266, P19599; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	51	448	453	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					425	433		10.1016/0092-8674(95)90395-X	http://dx.doi.org/10.1016/0092-8674(95)90395-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736594	hybrid			2022-12-28	WOS:A1995QW89400014
J	ALBERTS, B				ALBERTS, B			WEINTRAUB,HAROLD,M. (1945-95) - OBITUARY	NATURE			English	Item About an Individual											ALBERTS, B (corresponding author), NATL ACAD SCI,2101 CONSTITUT AVE NW,WASHINGTON,DC 20148, USA.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					19	19		10.1038/375019a0	http://dx.doi.org/10.1038/375019a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723834	Bronze			2022-12-28	WOS:A1995QW60400034
J	KWAK, LW; TAUB, DD; DUFFEY, PL; BENSINGER, WI; BRYANT, EM; REYNOLDS, CW; LONGO, DL				KWAK, LW; TAUB, DD; DUFFEY, PL; BENSINGER, WI; BRYANT, EM; REYNOLDS, CW; LONGO, DL			TRANSFER OF MYELOMA IDIOTYPE-SPECIFIC IMMUNITY FROM AN ACTIVELY IMMUNIZED MARROW DONOR	LANCET			English	Article							BONE-MARROW; T-CELLS; TRANSPLANTATION; SURFACE	The idiotype of myeloma immunoglobulin can be used as a unique tumour-specific antigen. We tested the hypothesis that tumour antigen-specific immunity can be transferred from bone-marrow-transplant donor to recipient. We immunised a healthy sibling donor with myeloma immunoglobulin from the plasma of the recipient, conjugated to an immunogenic carrier protein and emulsified in an adjuvant, before marrow transplantation. Detection of a lymphoproliferative response, a parallel response in the carrier protein, recovery of a recipient CD4+ T-cell line with unique specificity for myeloma idiotype, and demonstration by in-situ hybridisation that the cell line was of donor origin, proved that a myeloma idiotype-specific T-cell response was successfully transferred to the recipient. Donor immunisation with myeloma idiotype may represent a new strategy for enhancing the specific antitumour effect of allogeneic marrow grafts.	PROGRAM RESOURCES INC DYNCORP,CLIN IMMUNOL SERV,FREDERICK,MD; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Fred Hutchinson Cancer Center	KWAK, LW (corresponding author), NCI,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21702, USA.		Longo, Dan L./F-6022-2011	Kwak, Larry/0000-0002-1884-5349				ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484; BILADEAU D, 1993, J EXP MED, V187, P1023; CAO WX, 1994, J EXP MED, V179, P195, DOI 10.1084/jem.179.1.195; Coligan JKA, 1991, CURRENT PROTOCOLS IM; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; KATO S, 1990, BLOOD, V75, P806; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LAU YF, 1984, LANCET, V1, P14; LAURITZSEN GF, 1993, CELL IMMUNOL, V148, P177, DOI 10.1006/cimm.1993.1100; LUM LG, 1986, J CLIN IMMUNOL, V6, P389, DOI 10.1007/BF00915378; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; RIDDELL SR, 1992, SCIENCE, V257, P238; ROULEAU M, 1993, TRANSPLANTATION, V55, P72, DOI 10.1097/00007890-199301000-00014; STEVENSON GT, 1975, NATURE, V254, P714, DOI 10.1038/254714a0; WIMPERIS JZ, 1986, LANCET, V1, P339	15	222	237	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1016	1020		10.1016/S0140-6736(95)90757-2	http://dx.doi.org/10.1016/S0140-6736(95)90757-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723498				2022-12-28	WOS:A1995QU57300009
J	SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B				SPRUSTON, N; SCHILLER, Y; STUART, G; SAKMANN, B			ACTIVITY-DEPENDENT ACTION-POTENTIAL INVASION AND CALCIUM INFLUX INTO HIPPOCAMPAL CA1 DENDRITES	SCIENCE			English	Article							LONG-TERM POTENTIATION; SOURCE-DENSITY ANALYSIS; PYRAMIDAL CELLS; CA2+ ENTRY; SYNAPTIC TRANSMISSION; NEURONS; RECORDINGS; ACTIVATION; DISCHARGE	The temporal and spatial profile of activity-evoked changes in membrane potential and intracellular calcium concentration in the dendrites of hippocampal CA1 pyramidal neurons was examined with simultaneous somatic and dendritic patch-pipette recording and calcium imaging experiments. Action potentials are initiated close to the soma of these neurons and backpropagate into the dendrites in an activity-dependent manner; those occurring early in a train propagate actively, whereas those occurring later fail to actively invade the distal dendrites. Consistent with this finding, dendritic calcium transients evoked by single action potentials do not significantly attenuate with distance from the soma, whereas those evoked by trains attenuate substantially. Failure of action potential propagation into the distal dendrites often occurs at branch points. Consequently, neighboring regions of the dendritic tree can experience different voltage and calcium signals during repetitive action potential firing. The influence of backpropagating action potentials on synaptic integration and plasticity will therefore depend on both the extent of dendritic branching and the pattern of neuronal activity.			SPRUSTON, N (corresponding author), MAX PLANCK INST MED RES,ZELLPHYSIOL ABT,JAHNSTR 29,D-69120 HEIDELBERG,GERMANY.		Hausser, Michael/AAW-6827-2020; stuart, greg j/F-7328-2011	Hausser, Michael/0000-0002-2673-8957; Spruston, Nelson/0000-0003-3118-1636; stuart, greg/0000-0001-9395-2219				ANDERSEN P, 1966, EXP BRAIN RES, V2, P247; ANDERSEN P, 1966, ACTA PHYSIOL SCAND, V66, P461, DOI 10.1111/j.1748-1716.1966.tb03224.x; ANDERSEN P, 1960, ACTA PHYSIOL SCAND, V48, P178, DOI 10.1111/j.1748-1716.1960.tb01856.x; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COLLING SB, 1994, NEUROSCI LETT, V172, P73, DOI 10.1016/0304-3940(94)90665-3; CRAGG BG, 1955, J PHYSIOL-LONDON, V129, P608, DOI 10.1113/jphysiol.1955.sp005382; Eccles, 2013, PHYSL SYNAPSES; FUJITA Y, 1962, J NEUROPHYSIOL, V25, P209, DOI 10.1152/jn.1962.25.2.209; GOLDSTEIN SS, 1974, BIOPHYS J, V14, P731, DOI 10.1016/S0006-3495(74)85947-3; GROVER LM, 1990, NATURE, V347, P447; GUSTAFSSON B, 1987, J NEUROSCI, V7, P774; HERRERAS O, 1990, J NEUROPHYSIOL, V64, P1429, DOI 10.1152/jn.1990.64.5.1429; JAFFE DB, 1992, NATURE, V357, P244, DOI 10.1038/357244a0; JEFFERYS JGR, 1979, J PHYSIOL-LONDON, V289, P375, DOI 10.1113/jphysiol.1979.sp012742; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KULLMANN DM, 1992, NEURON, V9, P1175, DOI 10.1016/0896-6273(92)90075-O; LUSCHER C, 1994, J NEUROPHYSIOL, V72, P634, DOI 10.1152/jn.1994.72.2.634; LUSCHER G, 1994, J NEUROPHYSIOL, V72, P622; MAGEE JC, IN PRESS J PHYSL LON; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MIYAKAWA H, 1986, BRAIN RES, V399, P303, DOI 10.1016/0006-8993(86)91520-9; PERKEL DJ, 1993, NEURON, V11, P817, DOI 10.1016/0896-6273(93)90111-4; POOLOS NP, 1990, BRAIN RES, V524, P342, DOI 10.1016/0006-8993(90)90714-M; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; REGEHR WG, 1992, J NEUROSCI, V12, P4202; RICHARDSON TL, 1987, J NEUROPHYSIOL, V58, P981, DOI 10.1152/jn.1987.58.5.981; SCHILLER J, IN PRESS J PHYSL LON; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P272, DOI 10.1152/jn.1961.24.3.272; SPRUSTON N, 1995, J PHYSIOL-LONDON, V482, P325, DOI 10.1113/jphysiol.1995.sp020521; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; TURNER RW, 1989, J NEUROPHYSIOL, V62, P1375, DOI 10.1152/jn.1989.62.6.1375; TURNER RW, 1991, J NEUROSCI, V11, P2270; WONG RKS, 1979, P NATL ACAD SCI USA, V76, P986, DOI 10.1073/pnas.76.2.986	36	661	668	0	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					297	300		10.1126/science.7716524	http://dx.doi.org/10.1126/science.7716524			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716524				2022-12-28	WOS:A1995QT18500041
J	KHOO, SH; ROBERTS, JS; MANDAL, BK				KHOO, SH; ROBERTS, JS; MANDAL, BK			SAFETY AND EFFICACY OF COMBINED MENINGOCOCCAL AND TYPHOID VACCINE	BRITISH MEDICAL JOURNAL			English	Article							CAPSULAR POLYSACCHARIDE VACCINE		N MANCHESTER GRP HOSP,MONSALL UNIT,DEPT TROP MED & INFECT DIS,MANCHESTER M8 6RL,LANCS,ENGLAND; MERIEUX UK,MAIDENHEAD SL6 7BU,BERKS,ENGLAND									ARNOLD WSG, 1992, J INFECTION, V25, P63, DOI 10.1016/0163-4453(92)93537-Z; KLUGMAN KP, 1987, LANCET, V2, P1165; ZANGWILL KM, 1994, J INFECT DIS, V169, P847, DOI 10.1093/infdis/169.4.847; 1992, IMMUNISATION INFECTI	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					908	909		10.1136/bmj.310.6984.908	http://dx.doi.org/10.1136/bmj.310.6984.908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719181	Green Published			2022-12-28	WOS:A1995QR97200022
J	REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD				REINKE, P; FIETZE, E; ODEHAKIM, S; PROSCH, S; LIPPERT, J; EWERT, R; VOLK, HD			LATE-ACUTE VENAL ALLOGRAFT-REJECTION AND SYMPTOMLESS CYTOMEGALOVIRUS-INFECTION	LANCET			English	Note							RECIPIENTS	The role of cytomegalovirus infection in allograft injury is controversial. A subgroup of renal graft recipients who bad histologically proven late-acute rejection did not respond to conventional anti-rejection therapy (80% graft loss within 1 year). These patients showed an expansion of memory-type CD8 peripheral-blood T cells that expressed interferon-gamma mRNA and an association with clinically symptomless cytomegalovirus infection (82% PCR positive, 42% antigenaemia). Antiviral therapy with ganciclovir resulted in stable improved graft function in 17 of 21 treated patients with cytomegalovirus-associated late-acute rejection. The results underline the clinical relevance of cytomegalovirus-related graft injury and offer a novel therapeutic approach.	FREE UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM CHARITE,INST VIROL,D-10098 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	REINKE, P (corresponding author), FREE UNIV BERLIN,KLINIKUM CHARITE,MED NEPHROL CLIN 5,D-10098 BERLIN,GERMANY.		volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Reinke, Petra/0000-0003-0771-4375				ALMOND PS, 1994, TRANSPLANTATION, V55, P752; CAPPEL R, 1978, ARCH VIROL, V56, P149, DOI 10.1007/BF01317289; DOCKE WD, 1994, LANCET, V343, P268, DOI 10.1016/S0140-6736(94)91116-9; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; PLATZER C, 1909, TRANSPLANTATION, V58, P264; RAO KV, 1989, TRANSPLANTATION, V47, P290, DOI 10.1097/00007890-198902000-00019; REINKE P, 1994, TRANSPLANTATION, V58, P35, DOI 10.1097/00007890-199407150-00007; REIPERT B, 1992, CLIN EXP IMMUNOL, V89, P143; SIMMONS RL, 1970, TRANSPL P, V2, P419; Tolkoff-Rubin N E, 1992, Curr Opin Nephrol Hypertens, V1, P243, DOI 10.1097/00041552-199212000-00009	10	169	175	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 24	1994	344	8939-4					1737	1738		10.1016/S0140-6736(94)92887-8	http://dx.doi.org/10.1016/S0140-6736(94)92887-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY281	7741857				2022-12-28	WOS:A1994PY28100010
J	HEADRICK, LA; NEUHAUSER, D				HEADRICK, LA; NEUHAUSER, D			QUALITY HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HEADRICK, LA (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH 44106, USA.							Batalden P B, 1993, Jt Comm J Qual Improv, V19, P424; BATALDEN PB, 1993, MANUAL HLTH SERVICE; BERWICK DB, 1994, EYES IMPROVEMENT; BLUTH EI, 1993, AM J ROENTGENOL, V160, P995, DOI 10.2214/ajr.160.5.8470615; Deming W., 1994, NEW EC; HEADRICK LA, 1993, JAMA-J AM MED ASSOC, V271, P1711; LAFFEL G, 1992, QUALITY MANAGEMENT H; McGarvey R N, 1993, QRB Qual Rev Bull, V19, P124; PARENTI CM, 1994, ARCH INTERN MED, V154, P1829, DOI 10.1001/archinte.154.16.1829; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; YOUNG MJ, 1994, JOINT COMM J QUAL IM, V20, P120, DOI 10.1016/S1070-3241(16)30055-4; 1994, QUAL IMPROV TOTAL QU, V6, P77; 1995, JT COMM J QUAL IMPRO, V21, P5	14	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1718	1720						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752435				2022-12-28	WOS:A1995RB09700043
J	PINGLETON, SK				PINGLETON, SK			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASTHMA; DEATH; RISK				PINGLETON, SK (corresponding author), UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103, USA.							[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1994, JAMA-J AM MED ASSOC, V271, P1412; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAHTELA T, 1993, NEW ENGL J MED, V331, P700; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; MALFMO NA, 1991, NEW ENGL J MED, V321, P285; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SLY MS, 1994, ANN ALLERGY, V73, P259; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; 1989, NATIONAL HEART LUNG; 1991, 913042 US DEP HLTH H	19	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1717	1718						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752434				2022-12-28	WOS:A1995RB09700042
J	CASSILETH, BR; VLASSOV, VV; CHAPMAN, CC				CASSILETH, BR; VLASSOV, VV; CHAPMAN, CC			HEALTH-CARE, MEDICAL-PRACTICE, AND MEDICAL-ETHICS IN RUSSIA TODAY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EURASIA; QUALITY		UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC USA; DUKE UNIV, SCH MED, DEPT FAMILY & COMMUNITY MED, DURHAM, NC USA; SARATOV MED UNIV, DEPT AEROSP MED, SARATOV, RUSSIA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; Razumovsky Saratov State Medical University			Vlassov, Vasiliy/B-4036-2014	Vlassov, Vasiliy/0000-0001-5203-549X				Aseev A. V., 1992, Voprosy Onkologii (St. Petersburg), V38, P851; BABAITSEV AV, 1992, KLIN MED MOSCOW+, V70, P93; BARACH I, 1989, OGONYOK, V11, P13; BLINOV NN, 1989, VOP ONKOL+, V35, P643; BLINOV NN, 1990, VOP ONKOL, V8, P966; BOLIUH BA, 1993, VOP ONKOL, V38, P98; CASSILETH BR, 1983, PERSPECT BIOL MED, V26, P362; CHUGUNOVA N, 1991, OGONYOK, V43, P6; CHVIRKOV GY, 1992, ZDRAVOOHR ROSS FEDER, V10, P7; ERLANGER S, 1992, NY TIMES        0509, P1; FESHBACH M, 1993, AM ENTERPRISE, V24, P14; FISHBEIN DJ, 1991, JAMA-J AM MED ASSOC, V266, P1211, DOI 10.1001/jama.266.9.1211; Franz M J, 1991, Diabetes Educ, V17, P466, DOI 10.1177/014572179101700609; Friendly A., 1992, ECOCIDE USSR HLTH NA; GELLERT GA, 1992, NEW ENGL J MED, V326, P1021, DOI 10.1056/NEJM199204093261512; GELLERT GA, 1991, BRIT MED J, V302, P633, DOI 10.1136/bmj.302.6777.633; GLUZMAN SF, 1991, J MED ETHICS, V17, P19, DOI 10.1136/jme.17.Suppl.19; GRIFFIN GC, 1991, POSTGRAD MED, V90, P15; HOFFMAN MS, 1992, WORLD ALMANAC 1993, P940; KAPITZA S, 1991, SCI AM           AUG, P32; KASSOY E, 1992, FELDSHERS MED SOCIOL; KISUNKO G, 1994, 2ND EC HLTH CARE SER; Korotkikh Raisa V., 1993, Kennedy Institute of Ethics Journal, V3, P411; LIGHT DW, 1991, LANCET, V337, P778, DOI 10.1016/0140-6736(91)91385-8; MACKAY J, 1993, STATE HLTH ATLAS, P66; MONTEGUT AJ, 1992, NEW ENGL J MED, V327, P737; PETROV MN, 1989, SOV ZDRAVOOKHR, V10, P30; REVICH BA, 1994, ARCH ENVIRON HEALTH, V49, P59, DOI 10.1080/00039896.1994.9934416; ROBBINS A, 1990, JAMA-J AM MED ASSOC, V264, P1097, DOI 10.1001/jama.264.9.1097; RYAN M, 1993, BRIT MED J, V306, P909, DOI 10.1136/bmj.306.6882.909; Solzhenitsyn Alexander, 1975, GULAG ARCHIPELAGO; SOSHNIKOV EI, 1985, LABOR HLTH MED WORKE, P7; SPECTER M, 1994, NY TIMES        0306; STARINSKIY VV, 1989, SOV ZDRAVOOKHR, V5, P17; ZAKIROVA SA, 1993, ZDRAVOOHR ROS FEDER, V10, P3; 1990, USSR NUMBERS 1990; 1989, POPULATION USSR 1988, P664; 1993, STAT B METROP INSUR, V74, P28; 1990, PROTECTION HLTH USSR, P150; 1994, NY TIMES        0514, P10	40	30	30	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1569	1573		10.1001/jama.273.20.1569	http://dx.doi.org/10.1001/jama.273.20.1569			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QY541	7745761				2022-12-28	WOS:A1995QY54100009
J	HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB				HALL, IP; WHEATLEY, A; WILDING, P; LIGGETT, SB			ASSOCIATION OF GLU-27 BETA(2)-ADRENOCEPTOR POLYMORPHISM WITH LOWER AIRWAY REACTIVITY IN ASTHMATIC SUBJECTS	LANCET			English	Note								Cells expressing the Glu 27 beta(2)-adrenoceptor polymorphism show attenuated down-regulation of the receptor after long-term exposure to agonist. We studied beta(2)-adrenoceptor genotype for the Gln/Glu 27 polymorphism and airway reactivity in 65 patients with mild to moderate asthma. Glu 27 homozygotes had a four-fold higher geometric mean methacholine PD20 (provocative dose) than individuals who were homozygous for the wild-type (Gln 27) form of the receptor; heterozygotes had an intermediate value (3.23, 0.86, 1.96 mu mol, respectively), These data suggest that beta(2)-adrenoceptor genotype is important in the establishment of the asthmatic phenotype.	CITY HOSP,RESP MED UNIT,NOTTINGHAM NG5 1PB,ENGLAND; UNIV CINCINNATI,MED CTR,DEPT PULM & CRIT CARE MED,CINCINNATI,OH 45267	University of Nottingham; University System of Ohio; University of Cincinnati	HALL, IP (corresponding author), UNIV NOTTINGHAM HOSP,DEPT MED,DIV THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND.		liggett, stephen b/E-7453-2012	Hall, Ian/0000-0001-9933-3216; Henry, Amanda/0000-0001-6299-7676; Liggett, Stephen B./0000-0002-0128-3669	NHLBI NIH HHS [HL 45967] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL045967, R37HL045967, R01HL045967] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GREEN SA, IN PRESS AM J RESPIR; GUNNEBERG A, 1993, CLIN CHEM, V39, P2157; Postma D. S., 1994, European Respiratory Journal, V7, p423S; REISHAUS E, 1993, AM J RESPIR CELL MOL, V8, P334; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	6	260	273	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1213	1214		10.1016/S0140-6736(95)91994-5	http://dx.doi.org/10.1016/S0140-6736(95)91994-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739309				2022-12-28	WOS:A1995QX86100012
J	POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P				POWER, JP; LAWLOR, E; DAVIDSON, F; HOLMES, EC; YAP, PL; SIMMONDS, P			MOLECULAR EPIDEMIOLOGY OF AN OUTBREAK OF INFECTION WITH HEPATITIS-C VIRUS IN RECIPIENTS OF ANTI-D IMMUNOGLOBULIN	LANCET			English	Note								In a retrospective investigation of possible transmission of hepatitis C virus (HCV) by anti-rhesus D immunoglobulin (anti-D) in 1977, we compared variants infecting anti-D recipients in Ireland of one of the implicated batches with those of epidemiologically unrelated HCV-infected individuals. All 100 of the recipients of the batch investigated to date were infected with a single genotype (type 1), consistent with a single-source outbreak, whereas a wider range of genotypes (1, 2, and 3) were found in anti-HCV positive individuals from Ireland infected by different routes. Nucleotide sequences from a 222 base fragment from tbe NS-5 region of the genome amplified from stored aliquots of the implicated batch closely matched those detected in anti-D recipients 17 years after the transmission event. This study shows the value of molecular epidemiological techniques for identifying distant sources of infection, and for the epidemiological investigation of the current distribution and transmission of HCV in different populations.	UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; ST FINBARRS HOSP, BLOOD TRANSFUS SERV BOARD, CORK, IRELAND; BLOOD TRANSFUS SERV BOARD, DUBLIN 4, IRELAND; EDINBURGH & SE SCOTLAND BLOOD TRANSFUS SERV, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Edinburgh; University of Oxford			Holmes, Edward/GVR-9499-2022	Simmonds, Peter/0000-0002-7964-4700; Holmes, Edward/0000-0001-9596-3552				DITTMANN S, 1991, J HEPATOL, V13, P323, DOI 10.1016/0168-8278(91)90076-N; HOLMES EC, 1993, NATURE, V364, P766, DOI 10.1038/364766b0; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; POWER JP, 1994, LANCET, V344, P1166, DOI 10.1016/S0140-6736(94)90679-3; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; VIAZOV S, 1994, J VIROL METHODS, V48, P81, DOI 10.1016/0166-0934(94)90091-4	8	112	118	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 13	1995	345	8959					1211	1213		10.1016/S0140-6736(95)91993-7	http://dx.doi.org/10.1016/S0140-6736(95)91993-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739308				2022-12-28	WOS:A1995QX86100011
J	van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM				van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM			CHANGES IN DUTCH OPINIONS ON ACTIVE EUTHANASIA, 1966 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL DECISIONS; LIFE; END		UNIV UTRECHT, CTR BIOETH & HLTH LAW, ROTTERDAM, NETHERLANDS	Utrecht University	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							Adriaansens H. P. M., 1981, VRIJWILLIG INITIATIE; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Ester P., 1993, INDIVIDUALIZING SOC; Inglehart RonaldF., 1977, SILENT REVOLUTION; Mayer William G., 1992, CHANGING AM MIND WHY; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; SCHUYT C, 1991, OP ZOEK NAAR HART VE; Seper F., 1980, DECLARATION EUTHANAS; Stimson J. A., 1991, PUBLIC OPINION AM MO; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; 1994, 1994 SOC CULT PLANN; 1988, EUTHANASIE PASTORAAT; 1987, BIOETHICS, V1, P163	15	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1411	1414		10.1001/jama.273.18.1411	http://dx.doi.org/10.1001/jama.273.18.1411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723147				2022-12-28	WOS:A1995QW27900010
J	GRAY, DT; THORBURN, J; LUNDORFF, P; STRANDELL, A; LINDBLOM, B				GRAY, DT; THORBURN, J; LUNDORFF, P; STRANDELL, A; LINDBLOM, B			A COST-EFFECTIVENESS STUDY OF A RANDOMIZED TRIAL OF LAPAROSCOPY VERSUS LAPAROTOMY FOR ECTOPIC PREGNANCY	LANCET			English	Article							ECONOMIC-ANALYSIS; MANAGEMENT	We compared the cost-effectiveness of therapeutic laparoscopy and open laparotomy for treatment of laparoscopically diagnosed ectopic pregnancy. Clinical outcomes of ectopic pregnancy treatment were based on results of a randomised trial done between 1987 and 1989 at Sahlgrenska University Hospital (Goteborg, Sweden). We estimated costs for inpatient and follow-up care of ectopic pregnancy by the two methods. Observed resource use (eg, procedure duration) was multiplied by 1992 estimates of resource unit cost (eg, cost per minute of laparoscopy time), based on detailed internal cost accounting data from Huddinge University Hospital. By specified criteria, the initial procedure eliminated trophoblastic activity without major complications in 81% (95% Cl: 68-90) of 52 laparoscopy patients, versus 95% (85-99) of 57 laparotomy patients. Residual trophoblast or complications were successfully treated in all remaining patients. Mean simulated costs (standard error) for the overall laparoscopy strategy were 28 058 (1780) Swedish kronor versus 32 699 (1080) kronor for laparotomy (p=0.03). In the baseline simulation and most sensitivity analyses, laparoscopy produced final outcomes equivalent to those of laparotomy at lower costs. As laparoscopic outcomes improve, this newer approach should become increasingly preferable.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT COMMUNITY MED,STOCKHOLM,SWEDEN; GOTHENBURG UNIV,SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN; VIBORG HOSP,DEPT OBSTET & GYNECOL,VIBORG,DENMARK; UNIV UPPSALA,DEPT OBSTET & GYNECOL,UPPSALA,SWEDEN	Karolinska Institutet; Sahlgrenska University Hospital; University of Gothenburg; Aarhus University; Uppsala University	GRAY, DT (corresponding author), MAYO CLIN,CLIN EPIDEMIOL SECT,200 1ST ST SW,ROCHESTER,MN 55905, USA.							ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; BAUMANN R, 1991, BRIT J OBSTET GYNAEC, V98, P765, DOI 10.1111/j.1471-0528.1991.tb13480.x; BENGTSSON G, 1992, OBSTET GYNECOL, V79, P589; BRUMSTED J, 1988, OBSTET GYNECOL, V71, P889; CHALMERS T, 1982, AM J MED, V7, P233; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; DRUMMOND MF, 1984, CONTROL CLIN TRIALS, V5, P115, DOI 10.1016/0197-2456(84)90118-1; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GINSBURG PB, 1984, NEW ENGL J MED, V310, P893, DOI 10.1056/NEJM198404053101406; GOODWIN PJ, 1988, J CLIN ONCOL, V6, P1537, DOI 10.1200/JCO.1988.6.10.1537; GRAY DT, 1993, NEW ENGL J MED, V329, P1517, DOI 10.1056/NEJM199311183292101; GRAY DT, 1989, SOCIOECONOMICS SURGI, P228; GREENLAND S, 1980, INT J EPIDEMIOL, V9, P361, DOI 10.1093/ije/9.4.361; JOHNSON AG, 1994, LANCET, V344, P1140, DOI 10.1016/S0140-6736(94)90637-8; LEVINE RL, 1985, J REPROD MED, V30, P655; Lundorff P, 1991, ACTA OBSTET GYN SCAN, V70, P343, DOI 10.3109/00016349109007885; MAJEED AW, 1994, APR ASS SURG GB IR A; MAKINEN JI, 1987, BRIT MED J, V294, P740, DOI 10.1136/bmj.294.6574.740; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; MURPHY AA, 1992, FERTIL STERIL, V57, P1180; THORBURN J, 1986, EUR J OBSTET GYN R B, V23, P333, DOI 10.1016/0028-2243(86)90168-1; THORBURN JEK, 1983, ACTA OBSTET GYN SCAN, V62, P543, DOI 10.3109/00016348309156246; Torrance GW, 1987, METHODS EC EVALUATIO; VERMESH M, 1989, OBSTET GYNECOL, V73, P400; WEINSTEIN MC, 1981, MED DECIS MAKING, V4, P309; Weinstein MC, 1980, CLIN DECISION ANAL; WOODS JR, 1992, HEALTH SERV RES, V27, P219; 1988, PRODUCT LINE MANAGER; 1992, MMWR-MORBID MORTAL W, V41, P591; 1992, ECONOMIST, V323, P81	30	72	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1139	1143		10.1016/S0140-6736(95)90977-X	http://dx.doi.org/10.1016/S0140-6736(95)90977-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723545				2022-12-28	WOS:A1995QW62200009
J	MCMANUS, IC				MCMANUS, IC			EXAMINING THE EDUCATED AND THE TRAINED	LANCET			English	Article											MCMANUS, IC (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,NORFOLK PL,LONDON W2 1PG,ENGLAND.			McManus, Ian/0000-0003-3510-4814				[Anonymous], 1975, REPORT COMMITTEE INQ; CALMAN KC, 1988, MED EDUC, V22, P488, DOI 10.1111/j.1365-2923.1988.tb00790.x; CASE S, 1994, CERTIFICATION RECERT, P19; DOWNIE RS, 1992, MAKING DOCTOR MED ED; Fleming P.R., 1976, EXAMINATIONS MED; Flexner A, 1925, MED ED COMP STUDY; HARDY G. H., 1926, MATH GAZ, V13, P61; HUXLEY TH, 1911, APHORISMS REFLECTION; Kaufman A, 1985, IMPLEMENTING PROBLEM; MCMANUS IC, 1989, BRIT MED J, V298, P1051, DOI 10.1136/bmj.298.6680.1051; MILLER GH, 1972, MED ED CRITICAL APPR; NEWBLE D, 1994, CERTIFICATION RECERT, P13; NEWBLE D, 1994, CERTIFICATION RECERT; PICKERING G, 1978, QUEST EXCELLENCE MED; SMITH R, 1989, BRIT MED J, V298, P1372, DOI 10.1136/bmj.298.6684.1372; 1993, TOMORROWS DOCTORS RE, P1	16	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1151	1153		10.1016/S0140-6736(95)90981-8	http://dx.doi.org/10.1016/S0140-6736(95)90981-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723549				2022-12-28	WOS:A1995QW62200013
J	PETERSEN, C				PETERSEN, C			CRYPTOSPORIDIUM AND THE FOOD-SUPPLY	LANCET			English	Editorial Material											PETERSEN, C (corresponding author), SAN FRANCISCO GEN HOSP,DIV INFECT DIS,SAN FRANCISCO,CA 94110, USA.							BIER JW, 1991, J TROP MED PUBL 1222, pS144; DUPONT HL, IN PRESS N ENGL J ME; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MCANULTY JM, 1994, JAMA-J AM MED ASSOC, V272, P1597, DOI 10.1001/jama.272.20.1597; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; MILLARD PS, 1994, JAMA-J AM MED ASSOC, V272, P1592, DOI 10.1001/jama.272.20.1592; MOLBAK K, 1993, BRIT MED J, V307, P417, DOI 10.1136/bmj.307.6901.417; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; Ungar B. L. P., 1990, Cryptosporidiosis of man and animals., P59	10	10	10	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1128	1129		10.1016/S0140-6736(95)90972-9	http://dx.doi.org/10.1016/S0140-6736(95)90972-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723540				2022-12-28	WOS:A1995QW62200004
J	BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M				BARBERIS, A; PEARLBERG, J; SIMKOVICH, N; FARRELL, S; REINAGEL, P; BAMDAD, C; SIGAL, G; PTASHNE, M			CONTACT WITH A COMPONENT OF THE POLYMERASE-II HOLOENZYME SUFFICES FOR GENE ACTIVATION	CELL			English	Article							TRANSCRIPTION FACTOR-TFIIB; SACCHAROMYCES-CEREVISIAE; GAL11 PROTEIN; INITIATION; BINDING; COMPLEX; MECHANISM; GALACTOSE; MUTATION; DOMAIN	In yeast strains bearing the point mutation called GAL11P (for potentiator), certain GAL4 derivatives lacking any classical activating region work as strong activators. The P mutation confers upon GAL11, a component of the RNA polymerase II holoenzyme, the ability to interact with a portion of the dimerization region of GAL4, The region of GAL11 affected by the P mutation is evidently functionally inert in ordinary cells, suggesting that this mutation is of no functional significance beyond creating an artificial target for the GAL4 dimerization fragment. From these observations and further analyses of GAL11, we propose that a single activator-holoenzyme contact can trigger gene activation simply by recruiting the latter to DNA.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,PROGRAM BIOPHYS,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Harvard University			Reinagel, Pamela/ABI-7659-2020	Reinagel, Pamela/0000-0002-6338-2611				BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY M, 1994, NATURE, V368, P402, DOI 10.1038/368402a0; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; FASSLER JS, 1989, MOL CELL BIOL, V9, P5602, DOI 10.1128/MCB.9.12.5602; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JOUNG JK, 1994, SCIENCE, V265, P1863, DOI 10.1126/science.8091212; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LONG RM, 1991, MOL CELL BIOL, V11, P2311, DOI 10.1128/MCB.11.4.2311; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; NOGI Y, 1980, CURR GENET, V2, P115, DOI 10.1007/BF00420623; PTASHNE M, 1992, GENETIC SWITCH GENE; PTASHNE M, 1988, NATURE, V335, P983; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REINAGEL P, 1994, THESIS HARVARD U CAM; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Rose MD., 1990, METHODS YEAST GENETI; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; SAKURAI H, 1993, P NATL ACAD SCI USA, V90, P8382, DOI 10.1073/pnas.90.18.8382; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; SUZUKI Y, 1988, MOL CELL BIOL, V12, P4806; THOMPSON CM, 1993, CELL, V73, P1367; THOMPSON CM, 1995, IN PRESS P NATL ACAD; VALLIER LG, 1991, GENETICS, V129, P675; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	53	238	245	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					359	368		10.1016/0092-8674(95)90389-5	http://dx.doi.org/10.1016/0092-8674(95)90389-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736588	Bronze			2022-12-28	WOS:A1995QW89400008
J	LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND				LARSSON, SH; CHARLIEU, JP; MIYAGAWA, K; ENGELKAMP, D; RASSOULZADEGAN, M; ROSS, A; CUZIN, F; VANHEYNINGEN, V; HASTIE, ND			SUBNUCLEAR LOCALIZATION OF WT1 IN SPLICING OR TRANSCRIPTION FACTOR DOMAINS IS REGULATED BY ALTERNATIVE SPLICING	CELL			English	Article							ZINC FINGER PROTEIN; WILMS-TUMOR LOCUS; CELL-NUCLEUS; GENE; RNA; SNRNP; INVIVO; DNA; PURIFICATION; RECOGNITION	WT1 is a tumor suppressor gene with a key role in urogenital development and the pathogenesis of Wilms' tumor. Two alternative splice sites in the WT1 transcript allow the gene to encode four proteins. These carry four Kruppel-type zinc fingers and to date have primarily been implicated in transcriptional control of genes involved in growth regulation. However, here we demonstrate colocalization of WT1 with splicing factors in the fetal kidney and testis and in expressing cell lines. Using immunoprecipitation, we show that two WT1 isoforms directly associate with one or a limited number of components in the spliceosomes and coiled bodies. Moreover, COS cell expression studies suggest that alternative splicing within the WT1 zinc finger region determines whether the protein localizes mainly with splicing factors or with DNA in transcription factor domains in the nucleus. We propose that WT1 plays roles in posttranscriptional processing of RNA as well as in transcription.	UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	LARSSON, SH (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Rassoulzadegan, Minoo/O-7939-2016; van Heyningen, Veronica/B-8039-2008; VAN HEYNINGEN, Veronica/GYE-0531-2022	van Heyningen, Veronica/0000-0003-0359-0141; 	MRC [MC_U127527199] Funding Source: UKRI; Medical Research Council [MC_U127527199] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOSHER J, 1992, J VIROL, V66, P3140, DOI 10.1128/JVI.66.5.3140-3150.1992; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1988, ANNU REV GENET, V28, P523; HOGAN B, 1986, MANIPULATING MOUSE E; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KENT GRL, 1994, THESIS U EDINBURGH M; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; MATTAJ IW, 1994, NATURE, V372, P727, DOI 10.1038/372727a0; Moore M., 1993, RNA WORLD, P303; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NEWMAN A, 1994, CURR OPIN CELL BIOL, V6, P360, DOI 10.1016/0955-0674(94)90027-2; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PAN ZQ, 1988, SCIENCE, V241, P1328, DOI 10.1126/science.2970672; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; Sambrook J, 1989, MOL CLONING LABORATO; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; WIJNHOLDS J, 1988, EMBO J, V7, P2757, DOI 10.1002/j.1460-2075.1988.tb03130.x; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	51	423	434	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					391	401		10.1016/0092-8674(95)90392-5	http://dx.doi.org/10.1016/0092-8674(95)90392-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736591	Bronze			2022-12-28	WOS:A1995QW89400011
J	STASKAWICZ, BJ; AUSUBEL, FM; BAKER, BJ; ELLIS, JG; JONES, JDG				STASKAWICZ, BJ; AUSUBEL, FM; BAKER, BJ; ELLIS, JG; JONES, JDG			MOLECULAR-GENETICS OF PLANT-DISEASE RESISTANCE	SCIENCE			English	Article							NF-KAPPA-B; PROTEIN-KINASE; TRANSMEMBRANE PROTEIN; ELEMENT ACTIVATOR; DROSOPHILA EMBRYO; GENES; TOMATO; MAIZE; ARABIDOPSIS; PHENOTYPE	Plant breeders have used disease resistance genes (R genes) to control plant disease since the turn of the century, Molecular cloning of R genes that enable plants to resist a diverse range of pathogens has revealed that the proteins encoded by these genes have several features in common. These findings suggest that plants may have evolved common signal transduction mechanisms for the expression of resistance to a wide range of unrelated pathogens. Characterization of the molecular signals involved in pathogen recognition and of the molecular events that specify the expression of resistance may lead to novel strategies for plant disease control.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT BIOL MOLEC,BOSTON,MA 02114; USDA ARS,CTR PLANT GENE EXPRESS,ALBANY,CA 94710; CSIRO,DIV PLANT IND,CANBERRA,ACT,AUSTRALIA; CSIRO,COOPERAT RES CTR PLANT SCI,CANBERRA,ACT,AUSTRALIA; JOHN INNES CTR PLANT SCI RES,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; United States Department of Agriculture (USDA); Commonwealth Scientific & Industrial Research Organisation (CSIRO); Commonwealth Scientific & Industrial Research Organisation (CSIRO); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	STASKAWICZ, BJ (corresponding author), UNIV CALIF BERKELEY,DEPT PLANT BIOL,BERKELEY,CA 94720, USA.		Baker, Barbara/L-7198-2016; Jones, Jonathan DG/J-5129-2012; Baker, Barbara/Z-1108-2019; Ellis, Jeffrey G/A-1999-2010	Baker, Barbara/0000-0002-1276-971X; Jones, Jonathan DG/0000-0002-4953-261X; Baker, Barbara/0000-0002-1276-971X; 				Agrios G.N., 2005, PLANT PATHOL, V5th; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAKER B, 1986, P NATL ACAD SCI USA, V83, P4844, DOI 10.1073/pnas.83.13.4844; BENNETZEN JL, 1992, PLANT MOL BIOL, V20, P575, DOI 10.1007/BF00046442; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Biffen RH, 1905, J AGR SCI, V1, P4, DOI 10.1017/S0021859600000137; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; BRIGGS SP, IN PRESS BIOESSAYS; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CULVER JN, 1991, MOL PLANT MICROBE IN, V4, P458, DOI 10.1094/MPMI-4-458; DANGL JL, 1994, BACTERIAL PATHOGENES, V192, P99; Dangl JL, 1993, ADV PLANT PATHOL, V10, P127; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; DELORENZO G, 1994, BIOCHEM SOC T, V22, P394, DOI 10.1042/bst0220394; DEWIT PJG, IN PRESS ADV PLANT P; DEWIT PJGM, 1992, ANNU REV PHYTOPATHOL, V30, P391, DOI 10.1146/annurev.py.30.090192.002135; DIETRICH RA, CELL, V77, P565; ELLIS JG, IN PRESS P NATL ACAD; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GLAZEBROOK J, 1994, P NATL ACAD SCI USA, V91, P8955, DOI 10.1073/pnas.91.19.8955; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, P NATL ACAD SCI USA, V91, P10445, DOI 10.1073/pnas.91.22.10445; HARLAN JR, 1971, SCIENCE, V174, P468, DOI 10.1126/science.174.4008.468; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HONEE G, 1994, ADV MOL GENETICS PLA, V3, P199; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JOHAL GS, 1992, SCIENCE, V258, P985, DOI 10.1126/science.1359642; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JONES JDG, 1989, SCIENCE, V244, P204, DOI 10.1126/science.244.4901.204; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KEARNEY B, 1990, NATURE, V346, P385, DOI 10.1038/346385a0; Keen N. T., 1993, Biotechnology in plant disease control., P65; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; Klement Z., 1982, PHYTOPATHOGENIC PROK, V2, P149; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LAWRENCE GJ, IN PRESS P LANT CELL; LEPPIK EE, 1970, ANNU REV PHYTOPATHOL, V8, P323, DOI 10.1146/annurev.py.08.090170.001543; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MARTIN G, 1994, PLANT CELL, V6, P511; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTINI N, 1993, MOL GEN GENET, V236, P179, DOI 10.1007/BF00277110; MEELEY RB, 1992, PLANT CELL, V4, P71, DOI 10.1105/tpc.4.1.71; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MEYEROWITZ EM, 1989, CELL, V56, P263, DOI 10.1016/0092-8674(89)90900-8; MIDLAND SL, 1993, J ORG CHEM, V58, P2940, DOI 10.1021/jo00063a007; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; PRYOR T, 1987, TRENDS GENET, V3, P157, DOI 10.1016/0168-9525(87)90217-4; PRYOR T, 1993, ADV PLANT PATHOL, V10, P281; RICIGLIANO W, 1993, P NATL ACAD SCI USA, V90, P9533; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; RYALS J, 1994, PLANT PHYSIOL, V104, P1109, DOI 10.1104/pp.104.4.1109; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STJOHNSTON D, 1992, CELL, V68, P201; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; VANDENACKERVEKE.GF, 1992, PLANT J, V2, P359, DOI 10.1111/J.1365-313X.1992.00359.X; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WALKER JC, 1993, PLANT J, V3, P451, DOI 10.1046/j.1365-313X.1993.t01-23-00999.x; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; WOLFE MS, 1985, ANNU REV PHYTOPATHOL, V23, P251, DOI 10.1146/annurev.py.23.090185.001343; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	79	699	774	2	86	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					661	667		10.1126/science.7732374	http://dx.doi.org/10.1126/science.7732374			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732374				2022-12-28	WOS:A1995QW60300034
J	ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M				ALKEMA, MJ; VANDERLUGT, NMT; BOBELDIJK, RC; BERNS, A; VANLOHUIZEN, M			TRANSFORMATION OF AXIAL SKELETON DUE TO OVEREXPRESSION OF BMI-1 IN TRANSGENIC MICE	NATURE			English	Article							POSITION-EFFECT VARIEGATION; POSTERIOR SEX COMBS; NULL MUTATION; RETINOIC ACID; DROSOPHILA; GENE; CHROMATIN; MOUSE; MYC; LYMPHOMAGENESIS	THE oncogene bmi-1, which was originally found to be involved in B- and T-cell lymphoma formation(1-3) encodes a protein with a domain of homology to the Drosophila protein Posterior sex combs (Psc) and its relative Suppressor 2 of Zeste (Su(z)2) (refs 4 and 5), Psc is a member of the Polycomb-group gene family, which is required to maintain the repression of homeotic genes that regulate the identities of Drosophila segments(6). The possibility that bmi-1 may play a similar role in vertebrates was suggested by our previous finding(7) that mice lacking the bmi-1 gene show posterior transformations of the axial skeleton. Here we report that transgenic mice overexpressing Bmi-1 protein show the opposite phenotype, namely a dose-dependent anterior transformation of vertebral identity, The anterior expression boundary of the Hoxc-5 gene is shifted in the posterior direction, indicating that Bmi-1 is involved in the repression of Hox genes. We propose that Bmi-1 is a member of a vertebrate Polycomb complex that regulates segmental identity by repressing Hox genes throughout development.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,DEPT BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; University of Amsterdam								ADLER PN, 1991, DEV GENET, V12, P349, DOI 10.1002/dvg.1020120504; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CONDIE BG, 1993, DEVELOPMENT, V119, P579; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FRANKE A, 1993, EMBO J, V12, P1513; GAUNT SJ, 1990, DEVELOPMENT, V109, P329; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KRESS C, 1990, DEVELOPMENT, V109, P775; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVY LS, 1993, ONCOGENE, V8, P1833; LOCKE J, 1988, GENETICS, V120, P181; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; MARTIN EC, 1993, DEVELOPMENT, V117, P641; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PELLEGRI F, 1994, GENETICS, V136, P1341; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RASTELLI L, 1992, EMBO J, V11, P2941; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; SHARP EJ, 1994, DEV BIOL, V161, P379, DOI 10.1006/dbio.1994.1039; SIMON J, 1992, DEVELOPMENT, V114, P493; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	28	148	152	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					724	727		10.1038/374724a0	http://dx.doi.org/10.1038/374724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715727				2022-12-28	WOS:A1995QU30400050
J	MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC				MANGTANI, P; JOLLEY, DJ; WATSON, JM; RODRIGUES, LC			SOCIOECONOMIC DEPRIVATION AND NOTIFICATION RATES FOR TUBERCULOSIS IN LONDON DURING 1982-91	BRITISH MEDICAL JOURNAL			English	Article							NEW-YORK-CITY; OUTBREAK; HOMELESS; SHELTER	Objectives-To investigate the association between four sociodemographic measures (unemployment, overcrowding, low social class, and the proportion of migrants from areas of high prevalence of tuberculosis) and average level and rate of change of notification rates for tuberculosis. Design-Ecological analysis of both the average and the rate of change of standardised annual notification rates for tuberculosis from 1982-91 and sociodemographic measures from the 1981 and 1991 censuses. Setting-32 London boroughs. Subjects and data-Sociodemographic measures from the 1981 and 1991 censuses and tuberculosis notification rates for 1982-91. Main outcome measures-A measure of the association between average levels and rate of change in tuberculosis notification rates and four sociodemographic measures in 1981 and between the rate of change in tuberculosis notification rates between 1981 and 1991 and changes in sociodemographic measures between 1981 and 1991. Results-The average level of notifications was correlated with overcrowding and the proportion of migrants but not with unemployment or social class. No significant association was found between the rate of change in notification rates and sociodemographic measures in 1981. An association was found between increases in unemployment and the Fate of change in notification rates, but the effect was small. Changes in the levels of unemployment explained 23% of the variation between boroughs in the rate of change in their notification rates. Conclusion-The average tuberculosis notification rates were related to overcrowding and the proportion of migrants in 1981. Only increases in unemployment from 1981 to 1991, however, were significantly associated with the rate of change in notifications over the same period.	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,LONDON WC1E 7HT,ENGLAND; PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; Public Health England	MANGTANI, P (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,KEPPEL ST,LONDON WC1E 7HT,ENGLAND.		RODRIGUES, LAURA CUNHA/AAO-4130-2021	Mangtani, Punam/0000-0001-7074-2999				BRADLEY BL, 1988, BMJ-BRIT MED J, V297, P595, DOI 10.1136/bmj.297.6648.595; BRESLOW NE, 1980, STATISTICAL METHODS, V2; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; GREENLAND S, 1989, INT J EPIDEMIOL, V18, P269, DOI 10.1093/ije/18.1.269; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PATEL KR, 1985, BRIT J DIS CHEST, V79, P60, DOI 10.1016/0007-0971(85)90008-7; RAMSDEN SS, 1988, J ROY COLL PHYS LOND, V22, P16; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SHELDON CD, 1992, THORAX, V47, P1015, DOI 10.1136/thx.47.12.1015; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; TEALE C, 1991, J INFECTION, V23, P327, DOI 10.1016/0163-4453(91)93224-Z; Townsend PP., 1988, HLTH DEPRIVATION INE; WATSON JM, 1993, THORAX, V48, P199, DOI 10.1136/thx.48.3.199; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; WATSON JM, 1991, COMMUN DIS REP CDR R, V1, P13; 1988, MMWR-MORBID MORTAL W, V36, P817; 1979, TUBERCLE, V191, P194; 1982, BRIT MED J, V284, P1454; 1985, BRIT MED J, V291, P658; 1992, THORAX, V47, P770	24	81	85	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					963	966		10.1136/bmj.310.6985.963	http://dx.doi.org/10.1136/bmj.310.6985.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728030	Green Published			2022-12-28	WOS:A1995QT90400017
J	DICKERSIN, K; SCHERER, R; LEFEBVRE, C				DICKERSIN, K; SCHERER, R; LEFEBVRE, C			SYSTEMATIC REVIEWS - IDENTIFYING RELEVANT STUDIES FOR SYSTEMATIC REVIEWS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS; META-ANALYSIS; MEDICAL LITERATURE; PUBLICATION BIAS; MEDLINE; METAANALYSIS; RETRIEVAL; SEARCHES; MEDLARS; CARE	Objective-To examine the sensitivity and precision of Medline searching for randomised clinical trials. Design-Comparison of results of Medline searches to a ''gold standard'' of known randomised clinical trials in ophthalmology published in 1988; systematic review (meta-analysis) of results of similar, but separate, studies from many fields of medicine. Populations-Randomised clinical trials published in 1988 in journals indexed in Medline, and those not indexed in Medline and identified by hand search, comprised the gold standard. Gold standards for the other studies combined in the meta-analysis were based on: randomised clinical trials published in any journal, whether indexed in Medline or not; those published in any journal indexed in Medline; or those published in a selected group of journals indexed in Medline. Main outcome measure-Sensitivity (proportion of the total number of known randomised clinical trials identified by the search) and precision (proportion of publications retrieved by Medline that were actually randomised clinical trials) were calculated for each study and combined to obtain weighted means. Searches producing the ''best'' sensitivity were used for sensitivity and precision estimates when multiple searches were performed. Results-The sensitivity of searching for ophthalmology randomised clinical trials published in 1988 was 82%, when the gold standard was for any journal, 87% for any journal indexed in Medline, and 88% for selected journals indexed in Medline. Weighted means for sensitivity across all studies were 51%, 77%, and 63%, respectively. The weighted mean for precision was 8% (median 32.5%). Most searchers seemed not to use freetext subject terms and truncation of those terms. Conclusion-Although the indexing terms available for searching Medline for randomised clinical trials have improved, sensitivity still remains unsatisfactory. A mechanism is needed to ''register'' known trials, preferably by retrospective tagging of Medline entries, and incorporating trials published before 1966 and in journals not indexed by Medline into the system.	UNITED KINGDOM COCHRANE CTR, OXFORD OX2 7LG, ENGLAND	Cochrane Centre	DICKERSIN, K (corresponding author), UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, BALTIMORE, MD 21201 USA.		Dickersin, Kay/A-4576-2008					ADAMS CE, IN PRESS PSYCHOL MED; BERNSTEIN F, 1988, CONTROL CLIN TRIALS, V9, P23, DOI 10.1016/0197-2456(88)90006-2; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; DAYA S, 1989, BRIT J OBSTET GYNAEC, V96, P275, DOI 10.1111/j.1471-0528.1989.tb02386.x; DICKERSIN K, 1993, ANN NY ACAD SCI, V703, P135, DOI 10.1111/j.1749-6632.1993.tb26343.x; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DICKERSIN K, 1985, CONTROL CLIN TRIALS, V6, P306, DOI 10.1016/0197-2456(85)90106-0; DICKERSIN K, 1992, CONTROL CLIN TRIALS, V13, P170, DOI 10.1016/0197-2456(92)90022-R; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1992, STAT MED, V11, P345, DOI 10.1002/sim.4780110307; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; GOTZSCHE PC, 1991, DAN MED BULL, V38, P476; HOFMANS EA, 1990, HUISARTS WET, V33, P103; JADAD AR, 1993, BMJ-BRIT MED J, V307, P66, DOI 10.1136/bmj.307.6895.66-a; Jadad AR., 1993, ONLINE J CURR CLIN T; KIRPALANI H, 1989, PEDIATRICS, V83, P543; KLEIJNEN J, 1992, PHARM WEEKBLAD, V14, P316, DOI 10.1007/BF01977620; LACY JB, 1993, UNPUB ADM INTRAVENOU; OHLSSON A, 1989, AM J OBSTET GYNECOL, V160, P890, DOI 10.1016/0002-9378(89)90306-2; POYNARD T, 1985, CONTROL CLIN TRIALS, V6, P271, DOI 10.1016/0197-2456(85)90103-5; SCHERER R, 1994, EDITING REFEREED SCI, V24, P120; SCHERER RW, 1994, JAMA-J AM MED ASSOC, V272, P158, DOI 10.1001/jama.272.2.158; SCHERER RW, 1992, INVEST OPHTH VIS SCI, V33, P1323; SILAGY C, 1993, BMJ-BRIT MED J, V306, P897, DOI 10.1136/bmj.306.6882.897; SOLOMON MJ, 1994, SURGERY, V115, P707; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K; 1993, CLIN TRIALS METAANAL, V28, P255; 1993, FACT SHEET TECHNICAL	31	1268	1303	5	60	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1286	1291		10.1136/bmj.309.6964.1286	http://dx.doi.org/10.1136/bmj.309.6964.1286			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7718048	Green Published			2022-12-28	WOS:A1994PT03300033
J	CRUTCHFIELD, CE; BISIG, TJ				CRUTCHFIELD, CE; BISIG, TJ			COINING	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905	Mayo Clinic	CRUTCHFIELD, CE (corresponding author), GUNDERSON CLIN LTD,LA CROSSE,WI 54601, USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 8	1995	332	23					1552	1552		10.1056/NEJM199506083322305	http://dx.doi.org/10.1056/NEJM199506083322305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB196	7739709				2022-12-28	WOS:A1995RB19600005
J	FOEGE, W				FOEGE, W			PREVENTIVE MEDICINE AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FOEGE, W (corresponding author), EMORY UNIV,CARTER CTR,ATLANTA,GA 30322, USA.							ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; Carnegie Task Force on Meeting the Needs of Young Children & Carnegie Corporation of New York, 1994, STARTING POINTS M NE; Foege W H, 1995, Curr Issues Public Health, V1, P2; LIU JC, 1995, COMMUNICATION  0112; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; Preston Richard, 1994, HOT ZONE; SATCHER D, 1995, EMERG INFECT DIS, V1, P1, DOI 10.3201/eid0101.950101; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; 1994, GUINEA WORM WRAPUP, V46; 1995, STATE WORLDS CHILDRE; 1994, NOT EVEN ONE REPORT; 1994, MMWR-MORBID MORTAL W, V43, P857; 1994, MMWR-MORBID MORTAL W, V43, P415; 1994, GLOBAL AIDS NEWS, V3, P1; 1994, MMWR-MORBID MORTAL W, V4330, P548; 1994, MMWR-MORBID MORTAL W, V43, P409; 1994, SEP UN INT C POP DEV, pCH4; [No title captured]	18	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1712	1713						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752432				2022-12-28	WOS:A1995RB09700040
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.							BOHN MJ, 1994, AM J ADDICTION, V3, P91; BROWN SA, 1995, AM J PSYCHIAT, V152, P45; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; HASIN D, 1994, ALCOHOL CLIN EXP RES, V18, P1348, DOI 10.1111/j.1530-0277.1994.tb01435.x; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P898; LEVIN ED, 1994, J CLIN PSYCHOPHARM, V14, P41; MUELLER TI, 1994, AM J PSYCHIAT, V151, P701; SAITZ R, 1994, JAMA-J AM MED ASSOC, V272, P519, DOI 10.1001/jama.272.7.519; SCHUCKIT MA, 1994, AM J PSYCHIAT, V151, P1723; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; TIIHONEN J, 1994, AM J PSYCHIAT, V151, P1505; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; 1987, DIAGNOSTIC STATISTIC; 1994, DIAGNOSTIC STATISTIC	15	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1656	1657		10.1001/jama.273.21.1656	http://dx.doi.org/10.1001/jama.273.21.1656			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752401				2022-12-28	WOS:A1995RB09700009
J	MASSRY, SG				MASSRY, SG			NEPHROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARATHYROID-HORMONE; ALPORT SYNDROME; X-CHROMOSOME; KIDNEY; IDENTIFICATION; RECEPTOR; DISEASE; GENE				MASSRY, SG (corresponding author), UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA.							ATKIN CL, 1988, AM J HUM GENET, V42, P249; BAKER DF, 1990, SCIENCE, V248, P1224; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; MASSRY SG, 1994, SEMIN NEPHROL, V14, P219; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SAKURABA H, 1990, AM J HUM GENET, V47, P784; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SMOGOREZEWSKI M, IN PRESS KIDNEY INT; TIAN J, 1994, AM J NEPHROL, V14, P41, DOI 10.1159/000168684; TIAN J, 1993, AM J NEPHROL, V13, P210, DOI 10.1159/000168620; URENA P, 1994, KIDNEY INT, V45, P605, DOI 10.1038/ki.1994.79	18	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1693	1695						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752421				2022-12-28	WOS:A1995RB09700029
J	ORGAN, CH; GOLDSTEIN, LJ				ORGAN, CH; GOLDSTEIN, LJ			GENERAL-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ORGAN, CH (corresponding author), UNIV CALIF DAVIS,OAKLAND,CA, USA.							BROOKS DC, 1994, ARCH SURG-CHICAGO, V129, P361; COLALRD JM, 1994, ANN SURG, V220, P146; DETMER DE, 1994, ARCH SURG-CHICAGO, V129, P123; EVERS BM, 1994, ANN SURG, V219, P596, DOI 10.1097/00000658-199406000-00002; FALCONER JS, 1994, ANN SURG, V219, P325, DOI 10.1097/00000658-199404000-00001; FOSTER RS, 1994, ARCH SURG-CHICAGO, V129, P571; GREIF F, 1994, ANN SURG, V219, P40, DOI 10.1097/00000658-199401000-00007; HUNT TK, 1994, ARCH SURG-CHICAGO, V129, P825; JAMIESON GG, 1994, ANN SURG, V220, P137, DOI 10.1097/00000658-199408000-00004; JORDAN PH, 1994, ANN SURG, V220, P283, DOI 10.1097/00000658-199409000-00005; LONGAKER MT, 1994, ANN SURG, V219, P65, DOI 10.1097/00000658-199401000-00011; MARIN ML, 1994, AM J SURG, V168, P156, DOI 10.1016/S0002-9610(94)80058-8; MEISNER S, 1994, ANN SURG, V220, P164, DOI 10.1097/00000658-199408000-00007; MOORE WS, 1994, ANN SURG, V220, P331, DOI 10.1097/00000658-199409000-00009; MUELLER CB, 1994, ARCH SURG-CHICAGO, V129, P1001; ORLOFF MS, 1994, ANN SURG, V220, P578; PISTERS PWT, 1994, ANN SURG, V219, P225, DOI 10.1097/00000658-199403000-00002; ROZGA J, 1994, ANN SURG, V219, P538, DOI 10.1097/00000658-199405000-00012; WELLS SA, 1994, ANN SURG, V220, P237, DOI 10.1097/00000658-199409000-00002; 1994, CLIN ALERT NEWS 0928	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1682	1684						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752415				2022-12-28	WOS:A1995RB09700023
J	SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE				SCHROEDER, PL; FILLER, SJ; RAMIREZ, B; LAZARCHIK, DA; VAEZI, MF; RICHTER, JE			DENTAL EROSION AND ACID REFLUX DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						DENTAL ENAMEL; GASTROESOPHAGEAL REFLUX; DENTIN; GASTRIC ACID	GASTROESOPHAGEAL REFLUX; ANOREXIA-NERVOSA; HIATUS-HERNIA; BULIMIA; MANIFESTATIONS; COMPLICATIONS; ASSOCIATION; VOLUNTEERS; POPULATION; ENAMEL	Objective: To determine the relation between gastroesophageal reflux disease and dental erosion using ambulatory 24-hour esophageal pH testing. Design: Cross-sectional observational study. Setting: Tertiary referral center. Patients: The dental group consisted of 12 patients with idiopathic dental erosion who were identified by dentists and screened for gastroesophageal reflux disease using 24-hour pH testing. The gastroenterology group consisted of 30 patients who had 24-hour pH testing in the esophageal laboratory and who were referred for dental evaluation (10 did not have reflux, 10 had distal reflux, and 10 had proximal reflux). Measurements: 24-hour esophageal pH monitoring using a pH probe in the distal and proximal esophagus; Complete dental examination with particular attention to the presence and severity of dental erosion; plaque; gingival damage; and decayed, missing, and filled teeth. Analysis of saliva for pH, flow rates, buffering capacity, and calcium and phosphorus levels. Standardized questionnaire to ascertain possible causes of dental erosion and presence of reflux symptoms. Results: Ten of the 12 patients in the dental group (83% [95% Cl, 52% to 98%]) had gastroesophageal reflux on esophageal pH monitoring. Nine had distal and 7 had proximal reflux. Seven had reflux in the upright position only, 1 had reflux in the supine position only, and 2 had both upright and supine reflux. No saliva abnormalities were found. Ten patients had typical symptoms of gastroesophageal reflux, but dietary or mechanical problems that may have been causing dental erosion were not identified. In the gastroenterology group, upright reflux was seen in 5 of the 10 patients with distal reflux and in all 10 patients with proximal reflux. In addition, 40% of patients in the gastroenterology group (12 of 30) had dental erosion (4 of the 10 with distal reflux [40%], 7 of the 10 with proximal reflux [70%], and only 1 of the 10 without reflux [10%]; P = 0.02 for those with reflux compared with those without reflux). The cumulative dental erosion score correlated with proximal upright reflux when all 24 study patients with erosion were analyzed (r = 0.55 [P < 0.01]); this correlation was even stronger in the subgroup of 12 patients with abnormal amounts of proximal upright reflux (r = 0.84 [P = 0.001]). Conclusion: Dental erosion is a common finding in patients with gastroesophageal reflux disease and should be considered an atypical manifestation of this disease.	UNIV ALABAMA, DIV GASTROENTEROL, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, SCH DENT, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham								Allan D N, 1969, Br Dent J, V126, P311; ASHER C, 1987, BRIT DENT J, V162, P384, DOI 10.1038/sj.bdj.4806141; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; CATE HJT, 1968, BRIT J IND MED, V25, P249; CENTERWALL BS, 1986, AM J EPIDEMIOL, V123, P641, DOI 10.1093/oxfordjournals.aje.a114283; DAWES C, 1970, J DENT RES, V49, P1263, DOI 10.1177/00220345700490061501; DESCHNER WK, 1989, AM J GASTROENTEROL, V84, P1; DREWNOWSKI A, 1988, AM J PSYCHIAT, V145, P753; DUCOLONE A, 1987, AM REV RESPIR DIS, V135, P327; ECCLES JD, 1974, J DENT, V2, P153, DOI 10.1016/0300-5712(74)90044-X; ECCLES JD, 1978, LANCET, V2, P479; FRASER D, 1987, FUNDAMENTALS CLIN CH, P721; FRASER D, 1987, FUNDAMENTALS CLIN CH, P716; HELLSTROM I, 1977, SCAND J DENT RES, V85, P71; HOWDEN GF, 1971, BRIT DENT J, V131, P455, DOI 10.1038/sj.bdj.4802772; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; JACOB P, 1991, GASTROENTEROLOGY, V100, P305, DOI 10.1016/0016-5085(91)90196-R; JARVINEN V, 1988, ORAL SURG ORAL MED O, V65, P298, DOI 10.1016/0030-4220(88)90113-2; JARVINEN V, 1992, CARIES RES, V26, P391; JONES RRH, 1989, J DENT RES, V68, P1275, DOI 10.1177/00220345890680081201; KAHRILAS PJ, 1987, GASTROENTEROLOGY, V92, P466, DOI 10.1016/0016-5085(87)90143-0; KATZMAN MA, 1984, INT J EAT DISORDER, V3, P53; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; KRASSE B, 1985, CARIES RISK, P41; LEVINE RS, 1973, J DENT, V2, P85, DOI 10.1016/S0300-5712(73)80025-9; LOC J, 1963, ACTA ODONTOL SCAND, V21, P532; LUSSI A, 1991, COMMUNITY DENT ORAL, V19, P286, DOI 10.1111/j.1600-0528.1991.tb00169.x; LYNCH JB, 1947, BRIT J IND MED, V4, P84; MALCOLM D, 1961, BRIT J IND MED, V18, P63; Mandel I D, 1977, J Dent Guid Counc Handicap, V16, P3; MILOSEVIC A, 1989, BRIT DENT J, V167, P66, DOI 10.1038/sj.bdj.4806915; MYLLARNIEMI H, 1985, ANN SURG, V202, P159, DOI 10.1097/00000658-198508000-00004; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; PETERSEN PE, 1991, COMMUNITY DENT ORAL, V19, P104, DOI 10.1111/j.1600-0528.1991.tb00121.x; PINDBORG JJ, 1970, PATHOLOGY DENT HARD, P312; RICHTER JE, 1992, DIGEST DIS SCI, V37, P849, DOI 10.1007/BF01300382; RICHTER JE, 1987, DIGEST DIS SCI, V32, P583, DOI 10.1007/BF01296157; ROBERTS MW, 1987, J AM DENT ASSOC, V115, P407, DOI 10.14219/jada.archive.1987.0262; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968; SINCLAIR JW, 1991, AMBULATORY ESOPHAGEA, P23; SOGNNAES RF, 1972, J AM DENT ASSOC, V84, P571, DOI 10.14219/jada.archive.1972.0116; SREEBNY LM, 1988, DIAGNOSIS COMPENDIUM, V9, P569; SUDDICK RP, 1980, BIOL BASIS DENTAL CA, P132; TAYLOR G, 1992, J DENT CHILD, V59, P182; TUOMINEN M, 1989, SCAND J WORK ENV HEA, V15, P335, DOI 10.5271/sjweh.1841; WOLTGENS J H M, 1985, Clinical Preventive Dentistry, V7, P8; ZIPKIN I, 1949, J DENT RES, V28, P613, DOI 10.1177/00220345490280061301	48	115	121	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					809	815		10.7326/0003-4819-122-11-199506010-00001	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741364				2022-12-28	WOS:A1995RA13900001
J	SEMBA, RD; MUNASIR, Z; BEELER, J; AKIB, A; MUHILAL; AUDET, S; SOMMER, A				SEMBA, RD; MUNASIR, Z; BEELER, J; AKIB, A; MUHILAL; AUDET, S; SOMMER, A			REDUCED SEROCONVERSION TO MEASLES IN INFANTS GIVEN VITAMIN-A WITH MEASLES VACCINATION	LANCET			English	Article							IMMUNIZATION; ANTIBODY; CHILDREN	Administration of 100 000 IU vitamin A at the time of measles immunisation is currently recommended for infants in developing countries. However, the safety and value of giving vitamin A, a potent immune enhancer, with live measles virus vaccines are unknown. We conducted a randomised, double-blind, placebo-controlled clinical trial in Indonesia to evaluate the effect of simultaneous vitamin A supplementation on the immune response to measles immunisation at six months of age. 336 infants received either vitamin A (100 000 IU) or placebo when immunised with standard-titre Schwarz measles vaccine. 82% of infants seroconverted to measles. In a multiple logistic regression model adjusting for maternal antibody titres, vitamin A supplementation was associated with a lower likelihood of seroconversion to measles (odds ratio 0.40, 95% CI 0.19-0.88), and girls were less likely to seroconvert than boys (0.34, 0.15-0.76). Immunisation with standard-titre Schwarz vaccine at six months of age in this study population is characterised by high seroconversion rates. However, simultaneous high-dose vitamin A may interfere with seroconversion to live measles vaccine in infants with maternal antibody.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC MICROBIOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT IMMUNOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DIV HUMAN NUTR,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT OPHTHALMOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV HUMAN NUTR,BALTIMORE,MD 21287; UNIV INDONESIA,DEPT CHILD HLTH,JAKARTA,INDONESIA; US FDA,DIV VIRAL PROD,BETHESDA,MD 20014; MINIST HLTH,CTR NUTR RES & DEV,BOGOR,INDONESIA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Indonesia; US Food & Drug Administration (FDA); Ministry of Health - Indonesia	SEMBA, RD (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,BALTIMORE,MD 21287, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030042, R55HD030042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035143] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35143] Funding Source: Medline; NICHD NIH HHS [HD30042] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AABY P, 1989, B WORLD HEALTH ORGAN, V67, P443; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; COUTSOUDIS A, 1992, PEDIATR INFECT DIS J, V11, P203, DOI 10.1097/00006454-199203000-00006; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; LEON ME, 1993, J INFECT DIS, V168, P1097, DOI 10.1093/infdis/168.5.1097; MARKOWITZ LE, 1990, NEW ENGL J MED, V322, P580, DOI 10.1056/NEJM199003013220903; SEMBA RD, 1994, CLIN INFECT DIS, V19, P489, DOI 10.1093/clinids/19.3.489; 1992, VITAMIN A DEFICIENCY; 1993, WORLD SUMMIT CHILDRE, P1; 1987, WHO WKLY EPIDEMIOL R, V62, P5	10	71	72	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1330	1332						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752754				2022-12-28	WOS:A1995RA14800007
J	EVERHART, J; WRIGHT, D				EVERHART, J; WRIGHT, D			DIABETES-MELLITUS AS A RISK FACTOR FOR PANCREATIC-CANCER - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							IMPAIRED GLUCOSE-TOLERANCE; PAST MEDICAL HISTORY; BEVERAGE CONSUMPTION; PLASMA-GLUCOSE; MORTALITY; METABOLISM; CARCINOMA; ALCOHOL; INSULIN; COFFEE	Objective.-To evaluate diabetes mellitus as a risk factor for pancreatic cancer with the consideration that diabetes may also be a consequence of pancreatic cancer. Data Sources.-Pertinent studies of diabetes mellitus and pancreatic cancer published between 1975 and 1994 were identified from a MEDLINE search and from citations in articles and books. Study Selection.-Twenty of a total of 30 case-control and cohort studies met the two inclusion criteria: cases with a duration of diabetes of at feast 1 year prior to either pancreatic cancer diagnosis or death and the ability to calculate an appropriate relative risk (RR) estimate and variance. Data Extraction and Synthesis.-The pooled RR and 95% confidence interval (CI) of pancreatic cancer for diabetics relative to nondiabetics was 2.1 (1.6 to 2.8). There was a tendency for a higher RR for the nine cohort studies (RR, 2.6; 95% CI, 1.6 to 4.1) than for the II case-control studies (RR, 1.8; 95% CI, 1.1 to 2.7). Requiring diabetes duration of at least 5 years resulted in an RR of 2.0 (95% CI, 1.2 to 3.2). Conclusion.-Pancreatic cancer occurs with increased frequency among persons with long-standing diabetes.	WESTAT CORP, ROCKVILLE, MD USA	Westat	EVERHART, J (corresponding author), NIDDKD, DIV DIGEST DIS & NUTR, NATCHER BLDG, ROOM 6AN-12J, 45 CTR DR MSC 6600, BETHESDA, MD 20892 USA.							ADAMI HO, 1991, CANCER CAUSE CONTROL, V2, P307, DOI 10.1007/BF00051670; AHLBOM A, 1993, BIOSTATISTICS EPIDEM, P85; BALKAU B, 1993, DIABETES METAB, V19, P458; BRENNAN MF, 1993, CANCER PRINCIPLES PR, P849; CUZICK J, 1989, INT J CANCER, V43, P415, DOI 10.1002/ijc.2910430312; DEMESQUITA HBB, 1992, INT J CANCER, V52, P17, DOI 10.1002/ijc.2910520105; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EKOE JM, 1992, REV EPIDEMIOL SANTE, V40, P447; FARROW DC, 1990, INT J CANCER, V45, P816, DOI 10.1002/ijc.2910450504; FRIEDMAN GD, 1993, INT J EPIDEMIOL, V22, P30, DOI 10.1093/ije/22.1.30; GOLD EB, 1985, CANCER-AM CANCER SOC, V55, P460, DOI 10.1002/1097-0142(19850115)55:2<460::AID-CNCR2820550229>3.0.CO;2-V; GREEN A, 1985, DIABETOLOGIA, V28, P128; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GULLO L, 1994, NEW ENGL J MED, V331, P81, DOI 10.1056/NEJM199407143310203; HADDOCK G, 1990, BRIT J SURG, V77, P1159, DOI 10.1002/bjs.1800771025; HARRIS MI, 1992, DIABETES CARE, V15, P815, DOI 10.2337/diacare.15.7.815; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HENDERSON JR, 1981, GUT, V22, P158, DOI 10.1136/gut.22.2.158; HIATT RA, 1988, INT J CANCER, V41, P794, DOI 10.1002/ijc.2910410603; JAIN M, 1991, INT J CANCER, V47, P384, DOI 10.1002/ijc.2910470313; KALAPOTHAKI V, 1993, CANCER CAUSE CONTROL, V4, P375, DOI 10.1007/BF00051341; KATZ LA, 1985, BOCKUS GASTROENTEROL, V7, P4647; KESSLER II, 1970, J NATL CANCER I, V44, P673; LAVECCHIA C, 1990, ONCOLOGY-BASEL, V47, P463; LEVINE W, 1990, AM J EPIDEMIOL, V131, P254, DOI 10.1093/oxfordjournals.aje.a115495; LIN R S, 1981, Journal of the American Medical Association, V245, P147, DOI 10.1001/jama.245.2.147; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; Manousos O, 1981, Cancer Detect Prev, V4, P439; MILLS PK, 1988, CANCER-AM CANCER SOC, V61, P2578, DOI 10.1002/1097-0142(19880615)61:12&lt;2578::AID-CNCR2820611232&gt;3.0.CO;2-0; MIZUNO S, 1992, JPN J CLIN ONCOL, V22, P286; Morris D V, 1984, Diabet Med, V1, P119; NORELL S, 1986, BRIT J CANCER, V54, P377, DOI 10.1038/bjc.1986.185; NOY A, 1994, J CLIN ENDOCR METAB, V79, P1223, DOI 10.1210/jc.79.5.1223; OMARA BA, 1985, J CHRON DIS, V38, P435, DOI 10.1016/0021-9681(85)90139-0; PERMERT J, 1993, BRIT J SURG, V80, P1047, DOI 10.1002/bjs.1800800841; PERMERT J, 1993, EUR J SURG, V159, P101; PERMERT J, 1991, INT J PANCREATOL, V9, P113; RAGOZZINO M, 1982, J CHRON DIS, V35, P13, DOI 10.1016/0021-9681(82)90025-X; RYAN JC, 1993, GASTROINTESTINAL DIS, P193; SASAKI A, 1989, DIABETES RES CLIN PR, V7, P33, DOI 10.1016/0168-8227(89)90042-9; SEARLE SR, 1992, VARIANCE COMPONENTS, P40; SHIBATA A, 1994, INT J CANCER, V58, P46, DOI 10.1002/ijc.2910580109; SMITH GD, 1992, AM J EPIDEMIOL, V136, P1110, DOI 10.1093/oxfordjournals.aje.a116576; TAKEDA Y, 1991, J CANCER RES CLIN, V117, P416, DOI 10.1007/BF01612760; TAYLOR WF, 1994, PHS NIH941447 US DEP, P247; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WHITTEMORE AS, 1983, J CHRON DIS, V36, P251, DOI 10.1016/0021-9681(83)90059-0; WILLIAMS JA, 1985, DIABETES, V34, P980, DOI 10.2337/diabetes.34.10.980; WYNDER EL, 1973, JNCI-J NATL CANCER I, V50, P645, DOI 10.1093/jnci/50.3.645; 1992, SAS P229 SAS I INC T, P6	50	537	557	0	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1605	1609		10.1001/jama.273.20.1605	http://dx.doi.org/10.1001/jama.273.20.1605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745774				2022-12-28	WOS:A1995QY54100028
J	POLIS, MA; MASUR, H				POLIS, MA; MASUR, H			PROMISING NEW TREATMENTS FOR CYTOMEGALOVIRUS RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; INTRAVITREAL GANCICLOVIR; AIDS PATIENTS; FOSCARNET; EFFICACY; THERAPY		NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT CRIT CARE MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	POLIS, MA (corresponding author), NIAID,IMMUNOREGULAT LAB,BLDG 10,ROOM 11C103,BETHESDA,MD 20892, USA.			Polis, Michael/0000-0002-9151-2268				CANTRILL HL, 1989, OPHTHALMOLOGY, V96, P367, DOI 10.1016/S0161-6420(89)32900-9; COHEREAUMASSIN I, 1991, OPHTHALMOLOGY, V98, P1348; CRUMPACKER C, 1993, 1ST NAT C HUM RETR W; DIAZLLOPIS M, 1992, AM J OPHTHALMOL, V114, P742, DOI 10.1016/S0002-9394(14)74054-1; DIETERICH DT, 1993, J INFECT DIS, V167, P1184, DOI 10.1093/infdis/167.5.1184; FAULDS D, 1990, DRUGS, V39, P597, DOI 10.2165/00003495-199039040-00008; FREEMAN WR, 1991, AM J OPHTHALMOL, V112, P234; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; HOOVER DR, 1993, NEW ENGL J MED, V323, P1922; JABS DA, 1991, ARCH OPHTHALMOL-CHIC, V109, P794, DOI 10.1001/archopht.1991.01080060058024; JACOBSON MA, 1990, ANTIMICROB AGENTS CH, V34, P176, DOI 10.1128/AAC.34.1.176; JAFFE H, 1995, 2ND NAT C HUM RETR R; KUPPERMANN BD, 1993, J INFECT DIS, V168, P1506, DOI 10.1093/infdis/168.6.1506; LALEZARI J, 1995, 2ND NAT C HUM RETR W; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; PALESTINE AG, 1994, 10TH INT C AIDS YOK, V2; POLIS MA, 1993, AM J MED, V94, P175, DOI 10.1016/0002-9343(93)90180-W; POLIS MA, 1993, 31ST ANN M INF DIS S; SPECTOR SA, 1993, J INFECT DIS, V168, P557, DOI 10.1093/infdis/168.3.557; SPECTOR SA, 1995, 2ND NAT C HUM RETR W; TOLPIN M, 1993, 9 INT C AIDS BERL; 1994, CYTOVENE PRODUCT INF; 1992, NEW ENGL J MED, V326, P213	24	20	20	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1457	1459		10.1001/jama.273.18.1457	http://dx.doi.org/10.1001/jama.273.18.1457			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723160				2022-12-28	WOS:A1995QW27900035
J	NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A				NUDLER, E; KASHLEV, M; NIKIFOROV, V; GOLDFARB, A			COUPLING BETWEEN TRANSCRIPTION TERMINATION AND RNA-POLYMERASE INCHWORMING	CELL			English	Article							ELONGATION FACTOR-SII; ESCHERICHIA-COLI; TERNARY COMPLEXES; GENE-EXPRESSION; INVITRO; PROTEIN; DNA	Advancement of RNA polymerase of E. coli occurs in alternating laps of monotonic and inchworm-like movement. Cycles of inchworming are encoded in DNA and involve straining and relaxation of the ternary complex accompanied by characteristic leaping of DNA and RNA footprints. We demonstrate that the oligo(T) tract that constitutes a normal part of transcription terminators acts as an inchworming signal so that the leap coincides with the termination event. Prevention of leaping with a roadblock of cleavage-defective EcoRI protein results in suppression of RNA chain release at a termination site. The results indicate that straining and relaxation of RNA polymerase are steps in the termination mechanism.	RUSSIAN ACAD SCI, INST MOLEC GENET, MOSCOW 123182, RUSSIA	Russian Academy of Sciences	NUDLER, E (corresponding author), PUBL HLTH RES INST, 455 1ST AVE, NEW YORK, NY 10016 USA.			Nudler, Evgeny/0000-0002-8811-3071	NIGMS NIH HHS [GM49242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, J BIOL CHEM, V268, P23477; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; DAUBE SS, 1995, IN PRESS P NATL ACAD; FRIEDMAN DI, 1987, ANNU REV GENET, V21, P453; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; LEE F, 1977, P NATL ACAD SCI USA, V74, P4365, DOI 10.1073/pnas.74.10.4365; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; REINES D, 1989, J BIOL CHEM, V264, P10799; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG MT, 1989, J BIOL CHEM, V264, P2634; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	31	106	107	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					351	357		10.1016/0092-8674(95)90388-7	http://dx.doi.org/10.1016/0092-8674(95)90388-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736587	Bronze			2022-12-28	WOS:A1995QW89400007
J	FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U				FRANKLIN, KA; NILSSON, JB; SAHLIN, C; NASLUND, U			SLEEP-APNEA AND NOCTURNAL ANGINA	LANCET			English	Note							MECHANISMS; APNEA	Hypoxaemia occurs with sloop apnoea and might induce nocturnal angina. Sleep apnoea was found in 9 of 10 patients with nocturnal angina pectoris. Nocturnal angina diminished during treatment of sleep apnoea by continuous positive airway-pressure, and the number of nocturnal myocardial ischaemic events measured by computerised vector-cardiography was reduced.	UNIV HOSP NO SWEDEN,DEPT INTERNAL MED,S-90185 UMEA,SWEDEN	Umea University	FRANKLIN, KA (corresponding author), UNIV HOSP NO SWEDEN,DEPT PULM MED & ALLERGOL,S-90185 UMEA,SWEDEN.			Franklin, Karl/0000-0002-5306-1697; Naslund, Ulf/0000-0003-4100-8298				BALFORS EM, 1994, AM J RESP CRIT CARE, V150, P1587, DOI 10.1164/ajrccm.150.6.7952619; CHIERCHIA S, 1980, CIRCULATION, V61, P759, DOI 10.1161/01.CIR.61.4.759; GUILLEMINAULT C, 1984, LANCET, V1, P126; JENSEN SM, 1994, CORONARY ARTERY DIS, V5, P507; QUYYUMI AA, 1984, LANCET, V1, P1207; SULLIVAN CE, 1981, LANCET, V1, P862; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	7	189	193	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1085	1087		10.1016/S0140-6736(95)90820-X	http://dx.doi.org/10.1016/S0140-6736(95)90820-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715342				2022-12-28	WOS:A1995QV41100012
J	GRAHAMESMITH, D				GRAHAMESMITH, D			EVIDENCE BASED MEDICINE - SOCRATIC DISSENT	BRITISH MEDICAL JOURNAL			English	Article											GRAHAMESMITH, D (corresponding author), RADCLIFFE INFIRM,DEPT CLIN PATHOL,OXFORD OX2 6HE,ENGLAND.								0	99	105	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1126	1127		10.1136/bmj.310.6987.1126	http://dx.doi.org/10.1136/bmj.310.6987.1126			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742683	Green Published			2022-12-28	WOS:A1995QW61800024
J	KALE, R				KALE, R			IMPRESSIONS OF HEALTH IN THE NEW SOUTH-AFRICA - A PERIOD OF CONVALESCENCE	BRITISH MEDICAL JOURNAL			English	Article							MEDICINE; CARE											BENATAR SR, 1991, NEW ENGL J MED, V325, P30, DOI 10.1056/NEJM199107043250106; BENATAR SR, 1986, NEW ENGL J MED, V315, P527, DOI 10.1056/NEJM198608213150829; BLUMSON D, 1994, BARAGWANAH HOSPITAL, P7; VANDERLINDE I, 1994, S AFR MED J, V84, P15; VANRENSBURG HCJ, 1993, S AFRICAN J SOCIOLOG, V24, P99; 1994, HLTH TRENDS S AFRICA, P19; 1993, 1993 WORLD BANK WORL, P238	7	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1119	1122		10.1136/bmj.310.6987.1119	http://dx.doi.org/10.1136/bmj.310.6987.1119			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742681	Green Published			2022-12-28	WOS:A1995QW61800022
J	WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C				WILKINSON, P; HANSELL, DM; JANSSENS, J; RUBENS, M; RUDD, RM; TAYLOR, AN; MCDONALD, C			IS LUNG-CANCER ASSOCIATED WITH ASBESTOS EXPOSURE WHEN THERE ARE NO SMALL OPACITIES ON THE CHEST RADIOGRAPH	LANCET			English	Article							WORKERS; MORTALITY	This study was designed to test the hypothesis that the risk of lung cancer from asbestos exposure is confined to persons with radiographic evidence of pulmonary fibrosis. Occupational and smoking histories were obtained from 271 patients with a confirmed diagnosis of primary lung cancer and 678 referents (279 with other respiratory disease and 399 with cardiac disease). Histories were reviewed blind to assess the timing, duration, and probability of exposure to asbestos. To allow for a lag between asbestos exposure and the development of lung cancer, subjects were classified by the time they had spent in an occupation entailing definite or probable exposure more than 15 years before diagnosis. The presence and extent of fibrosis was assessed blindly from chest radiographs by three readers and scored for small opacities with the ILO 1989 International Classification of Radiographs of the Pneumoconioses. 93 (34.3%) cases had worked in an occupation with definite or probable asbestos exposure compared with 176 (25. 8%) referents (crude odds ratio for lung cancer 1.49, 95% CI 1.09-2.04). After adjustment for age, sex, smoking history, and area of referral, the odds ratio (95% CI) was 2.03 (1.00-4.13) in the subgroup of 211 with a median ILO score for small parenchymal opacities of 1/0 or more, and 1.56 (1.02-2.39) in the 738 with a score of 0/1 or less (ie, those without radiological evidence of pulmonary fibrosis). These results suggest that asbestos is associated with lung cancer even in the absence of radiologically apparent pulmonary fibrosis.	ROYAL BROMPTON HOSP,LONDON SW3 6LY,ENGLAND; NATL HEART & LUNG INST,LONDON SW3 6LY,ENGLAND; LONDON CHEST HOSP,LONDON E2 9JX,ENGLAND	Royal Brompton Hospital; Imperial College London; University of London; Queen Mary University London				Wilkinson, Paul/0000-0001-7456-259X				DOLL R, 1981, CAUSES CANC, P1238; HUGHES JM, 1991, BRIT J IND MED, V48, P229; IRVINE HD, 1993, BMJ-BRIT MED J, V306, P1503, DOI 10.1136/bmj.306.6891.1503; KIPEN HM, 1987, BRIT J IND MED, V44, P96; LIDDELL FDK, 1980, BRIT J IND MED, V37, P257; LIDDELL FDK, 1977, BRIT J IND MED, V34, P85; MARTISCHNIG M, 1977, BMJ-BRIT MED J, V1, P756; MCDONALD AD, 1980, CANCER, V46, P1650, DOI 10.1002/1097-0142(19801001)46:7<1650::AID-CNCR2820460726>3.0.CO;2-Y; MCDONALD JC, 1981, QUANTIFICATION OCCUP, P73; MCLEOD TC, 1983, RADIOLOGY, V149, P353; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; RECKLAKE MR, 1991, MINERAL FIBERS HLTH, P105; SLUISCREMER GK, 1989, BRIT J IND MED, V46, P537; STAPLES CA, 1989, AM REV RESPIR DIS, V139, P1502, DOI 10.1164/ajrccm/139.6.1502; 1980, OCCUPATIONAL SAFETY, V22; CANCER STATISTIC MB1, V20	16	72	73	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 29	1995	345	8957					1074	1078		10.1016/S0140-6736(95)90817-X	http://dx.doi.org/10.1016/S0140-6736(95)90817-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715339				2022-12-28	WOS:A1995QV41100009
J	PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL				PHILLIPS, JH; GUMPERZ, JE; PARHAM, P; LANIER, LL			SUPERANTIGEN-DEPENDENT, CELL-MEDIATED CYTOTOXICITY INHIBITED BY MHC CLASS-I RECEPTORS ON T-LYMPHOCYTES	SCIENCE			English	Article							NATURAL-KILLER-CELLS; ENTEROTOXIN-B; NK CLONES; SPECIFICITY; EXPRESSION; SUSCEPTIBILITY; STIMULATION; PROTECTION; COMPLEX; ALLELES	Bacterial superantigens bind with high affinity to major histocompatibility complex (MHC) class II antigens on antigen-presenting cells and with T cell antigen receptor (TCR) beta chains on T lymphocytes,which results in the T cell activation responsible for toxic shock syndrome and food poisoning, Many cytotoxic T lymphocyte (CTL) clones were shown to have receptors for human leukocyte antigen (HLA) class I molecules that inhibited superantigen-induced cytotoxicity against appropriate class I-bearing target cells. One type of inhibitory receptor, NKB1, was present on CD4(+) and CD8(+)TCR alpha beta(+) CTL clones and blocked the killing of staphylococcal enterotoxin B (SEB)-coated targets bearing certain polymorphic HLA-B molecules. Expression of HLA-A, -B, and -C molecules on the SEE-coated targets also protected against cytolysis mediated by many NKB1-negative T cell clones, suggesting the presence of additional inhibitory MHC class I receptors. These HLA class I receptors may limit tissue destruction and possibly autoimmunity caused by activated T lymphocytes.	STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; STANFORD UNIV,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University; Stanford University	PHILLIPS, JH (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT HUMAN IMMUNOL,901 CALIF AVE,PALO ALTO,CA 94304, USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952	NIAID NIH HHS [AI22039] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022039] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; FRASER JD, 1989, NATURE, V339, P221, DOI 10.1038/339221a0; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; HEWITT CRA, 1992, J EXP MED, V175, P1493, DOI 10.1084/jem.175.6.1493; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KIM JS, 1994, SCIENCE, V266, P1870, DOI 10.1126/science.7997880; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; LANIER LL, 1983, J IMMUNOL, V131, P1789; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOLLICK JA, 1989, SCIENCE, V244, P817, DOI 10.1126/science.2658055; PALIARD X, 1991, SCIENCE, V253, P325, DOI 10.1126/science.1857971; Phillips J. A., UNPUB; PULLEN AM, 1990, CELL, V61, P1365, DOI 10.1016/0092-8674(90)90700-O; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; SETH A, 1994, NATURE, V369, P324, DOI 10.1038/369324a0; SHIMIZU Y, 1989, EUR J IMMUNOL, V19, P447, DOI 10.1002/eji.1830190306; STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361; SUNDSTEDT A, 1994, IMMUNOLOGY, V82, P117; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2	27	310	314	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					403	405		10.1126/science.7716542	http://dx.doi.org/10.1126/science.7716542			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716542				2022-12-28	WOS:A1995QU57200035
J	THOMAS, SA; MATSUMOTO, AM; PALMITER, RD				THOMAS, SA; MATSUMOTO, AM; PALMITER, RD			NORADRENALINE IS ESSENTIAL FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article								CATECHOLAMINES such as noradrenaline and adrenaline have been implicated in numerous physiological processes(1-4) but, although catecholamine synthesis begins at mid-gestation(5), previous studies have provided little evidence for any role in early development(6,7). Furthermore, there are several case reports of humans with noradrenaline deficiency(8). To investigate this, we used gene targeting(9) to produce mice lacking dopamine beta-hydroxylase and therefore unable to synthesize noradrenaline or adrenaline. We report here that in heterozygous mothers, most homozygous embryos died in utero, and only about 5% reached adulthood. Survival probably depends on catecholamine transfer across the placenta because, in homozygous mothers, all embryos die in utero. Mortality was due to lack of noradrenaline in utero because it could be prevented by treatment with dihydroxyphenylserine, a precursor that can be converted to noradrenaline in the absence of dopamine beta-hydroxylase. Mutant embryos had a histological phenotype similar to that of embryos deficient in tyrosine hydroxylase(10), suggesting that death might be due to cardiovascular failure.	UNIV WASHINGTON,SCH MED,VET ADM MED CTR,CTR GERENTOL RES EDUC & CLIN,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	THOMAS, SA (corresponding author), UNIV WASHINGTON,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM,SL-15,SEATTLE,WA 98195, USA.		Matsumoto, Alvin/AAH-6096-2020					ANGELETTI PU, 1970, P NATL ACAD SCI USA, V65, P114, DOI 10.1073/pnas.65.1.114; [Anonymous], 1989, SCIENCE; BERTI F, 1965, MED PHARMACOL EXP, V13, P227; KUDLACZ EM, 1990, J DEV PHYSIOL, V13, P243; LEVIMONT.R, 1966, PHARMACOL REV, V18, P619; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; ROSEN TS, 1979, J PHARMACOL EXP THER, V208, P118; Rosenblueth A, 1937, AUTONOMIC NEUROEFFEC; Schlumpf M., 1980, BIOGENIC AMINES DEV, P567	9	443	450	2	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					643	646		10.1038/374643a0	http://dx.doi.org/10.1038/374643a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715704				2022-12-28	WOS:A1995QT18900060
J	KANE, RL; KANE, RA				KANE, RL; KANE, RA			LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; NURSING-HOME; SERVICES				KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455, USA.							ARRAS J, 1995, BRINGING HOSPITAL HO; EUSTIS NN, 1992, GENERATIONS, V16, P17; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Kane RA, 1993, ASSISTED LIVING US N; KANE RL, 1992, GERONTOLOGIST, V32, P771, DOI 10.1093/geront/32.6.771; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1990, GERONTOLOGIST, V30, P291, DOI 10.1093/geront/30.3.291; KANE RL, 1994, GERONTOLOGIST, V34, P598, DOI 10.1093/geront/34.5.598; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; MANTON KG, 1994, MED CARE, V32, P277, DOI 10.1097/00005650-199403000-00007; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; NEWCOMER R, 1990, GERONTOLOGIST, V30, P86, DOI 10.1093/geront/30.1.86; NEWCOMER R, 1990, HEALTH SERV RES, V25, P425; SIMONRUSINOWITZ L, 1993, GERONTOLOGIST, V33, P159, DOI 10.1093/geront/33.2.159; 1994, GAOHEHE94167 US GEN; 1994, GAOHEHS9526 US GEN A	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1690	1691		10.1001/jama.273.21.1690	http://dx.doi.org/10.1001/jama.273.21.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752419				2022-12-28	WOS:A1995RB09700027
J	PELLEGRINO, ED				PELLEGRINO, ED			ETHICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007, USA.							ANNAS GJ, 1994, KENNEDY I ETHICS, V4, P234; Ashley Benedict, 1994, FETAL TISSUE ISSUE M, P33; DYM M, 1994, P NATL ACAD SCI USA, V91, P1; HUMPHRY D, 1994, EUTHANASIA RES GUIDA, V1, P1; Macklin Ruth, 1994, Kennedy Institute of Ethics Journal, V4, P209; MARWICK C, 1994, JAMA-J AM MED ASSOC, V272, P1311, DOI 10.1001/jama.272.17.1311; MCCORMICK RA, 1994, HASTINGS CENT REP, V24, P14, DOI 10.2307/3562177; PELLEGRINO ED, 1991, JAMA-J AM MED ASSOC, V265, P3051; PELLEGRINO ED, 1990, GIFT LIFE CATHOLIC S, P1; PELLEGRINO ED, 1991, JAMA-J AM MED ASSOC, V265, P3202; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P875; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P874; 1994, REPORT HUMAN EMBRYO; 1994, OFFICIAL 1994 GENERA, P121; 1995, ORIGINS, V24, P667; 1995, 1 THINGS, V49, P17	17	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1674	1676		10.1001/jama.273.21.1674	http://dx.doi.org/10.1001/jama.273.21.1674			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752411				2022-12-28	WOS:A1995RB09700019
J	FLEGEL, KM				FLEGEL, KM			FROM DELIRIUM CORDIS TO ATRIAL-FIBRILLATION - HISTORICAL DEVELOPMENT OF A DISEASE CONCEPT	ANNALS OF INTERNAL MEDICINE			English	Article							CONSCIOUS DOGS; TACHYCARDIA; ARRHYTHMIAS; EXCITATION	In 1874, the electrical stimulation of animal hearts made known the existence of atrial fibrillation, but atrial fibrillation was not associated with its clinical counterpart, arrhythmia perpetua, until 1909, by which time simultaneous recordings of the human heartbeat, the venous and arterial pulses, and electrocardiographic activity had revealed the common origin of these events. After the electrical basis of atrial fibrillation was found and after atrial fibrillation was clearly distinguished from Ventricular fibrillation, investigation into its mechanism ensued. Two contrasting theories, that of circus movement and that of tachysystole from a single focus, led to 30 years of research and debate. Pivotal to the argument was the notion of blocked conduction. Although the theory of circus movement prevailed for a long time, it appeared to be demolished by electrophysiologic experiments done between 1948 and 1950. The realization that blocked conduction could later reenter led to more recent research in animals and humans that revived the notion of circular conduction, although in a much more sophisticated form.	MCGILL UNIV, MONTREAL, PQ, CANADA	McGill University	FLEGEL, KM (corresponding author), ROYAL VICTORIA HOSP, DIV GEN INTERNAL MED, ROOM A421, 687 PINE AVE W, MONTREAL, PQ H3A 1A1, CANADA.							ALLESSIE M, 1991, CIRCULATION, V84, P1689, DOI 10.1161/01.CIR.84.4.1689; ALLESSIE M, 1982, ATRIAL FIBRILLATION, P44; Allessie M, 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; ALLESSIE MA, 1977, CIRC RES, V41, P9, DOI 10.1161/01.RES.41.1.9; AUBERT H, 1874, PFLUGERS ARCH, V9, P115; BAMBERGER H, 1963, WURZBURGERMED Z, V4, P232; BHARATI S, 1992, ATRIAL FIBRILLATION, P15; BOUILLAND J, 1835, TRAITE CLIN MALADIES, P141; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; Cushny A E, 1899, J Exp Med, V4, P327, DOI 10.1084/jem.4.3-4.327; Cushny AR, 1907, AM J MED SCI, V133, P66, DOI 10.1097/00000441-190701000-00006; Einthoven W, 1915, HEART-J STUD CIRC, V6, P107; Einthoven W., 1906, ARCH INT PHYSIOL, V4, P132; Engelman TW, 1896, ARCH GES PHYSL, V62, P543; ERICHSEN JE, 1842, LONDON MED GAZ, V30, P561; FREDERICQ L, 1904, ARCH INT PHYSL, V2, P281; FYE WB, 1985, CIRCULATION, V71, P858, DOI 10.1161/01.CIR.71.5.858; Garrey WE, 1924, PHYSIOL REV, V4, P215, DOI 10.1152/physrev.1924.4.2.215; Garrey WE, 1914, AM J PHYSIOL, V33, P397, DOI 10.1152/ajplegacy.1914.33.3.397; GERSTENFELD EP, 1992, CIRCULATION, V86, P375, DOI 10.1161/01.CIR.86.2.375; HARVEY W, 1990, CIRCLATION BLOOD OTH, P25; Hering HE, 1906, DEUT MED WOCHENSCHR, V32, P0213, DOI 10.1055/s-0028-1141852; HERING HE, 1903, PRAGER MED WOCHENSCH, V28, P377; Hering HE, 1908, DTSCH ARCH KLIN MED, Vxciv, P205; Hewlett AW, 1908, J AMER MED ASSOC, V51, P655; HOLFA M, 1850, Z RATION MED, V9, P107; HUNTER J, 1794, TREATISE BLOOD INFLA, P187; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; KREHL L, 1892, ARCH EXP PATHOL PH, V30, P49; KRONECKER H, 1884, BERLINER KLINISCHE W, V21, P738; Lewis T, 1912, HEART-J STUD CIRC, V3, P173; Lewis T, 1920, HEART-J STUD CIRC, V7, P191; Lewis T, 1921, HEART-J STUD CIRC, V8, P141; Lewis T, 1909, Br Med J, V2, P1528; Lewis T, 1910, HEART-J STUD CIRC, V1, P306; Lewis T, 1921, HEART-J STUD CIRC, V8, P341; Lewis T, 1921, HEART-J STUD CIRC, V8, P361; Mackenzie J, 1907, Q J MED, V1, P39; MacKenzie J, 1907, AM J MED SCI, V134, P12, DOI 10.1097/00000441-190707000-00002; Mackenzie J, 1904, BRIT MED J, V1904, P529; Mackenzie J, 1905, BRIT MED J, V1905, P812; MACKENZIE J, 1894, J PATHOL BACTERIOL, V2, P84; MACKENZIE J, 1902, STUDY PULSE ARTERIAL, P188; MACKENZIE J, 1908, DISEASES HEART, P298; MAREY EJ, 1863, PHYSL MED CIRCULATIO, P531; Mayer A, 1906, RHYTHMICAL PULSATION, V47, P1; McMichael J, 1981, J R Coll Gen Pract, V31, P402; MCMICHAEL J, 1982, HIST ATRIAL FIBRILLA, V48, P193; McWilliam J A, 1887, J Physiol, V8, P296; Mines GR, 1913, J PHYSIOL-LONDON, V46, P349; Mines GR, 1914, T R SOC CAN, V8, P43; MOE GK, 1959, AM HEART J, V58, P59, DOI 10.1016/0002-8703(59)90274-1; MURGATROYD FD, 1993, LANCET, V341, P1317; NOTHNAGEL H, 1876, ARCH KLINISCHE MED, V17, P190; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PORTER WT, 1894, J PHYSIOL-LONDON, V15, P121; PRINZMETAL M, 1950, CIRCULATION, V1, P241, DOI 10.1161/01.CIR.1.2.241; RENSMA PL, 1988, CIRC RES, V62, P395, DOI 10.1161/01.RES.62.2.395; RIEGEL F, 1882, DTSCH ARCH KLIN MED, V31, P1; ROSE G, 1978, BRIT HEART J, V40, P636; Rothberger C, 1909, WIEN KLIN WOCHENSCHR, V22, P839; Rothberger C.J., 1931, ERGEBN PHYSL, V32, P472; Rothberger CJ, 1914, PFLUG ARCH GES PHYS, V160, P42, DOI 10.1007/BF01680717; ROTHBERGER CJ, 1923, KLIN WCHNSCHR, V2, P1407; ROTHBERGER CJ, 1922, KLIN WOCHENSCHR, V1, P82; SCHERF D, 1948, AM HEART J, V36, P241, DOI 10.1016/0002-8703(48)90403-7; SCHERF D, 1953, ARCH INTERN MED, V91, P333, DOI 10.1001/archinte.1953.00240150052007; Schmitt FO, 1928, AM J PHYSIOL, V87, P326, DOI 10.1152/ajplegacy.1928.87.2.326; VULPIAN A, 1874, PFLUGERS ARCH PHYSL, V6, P975; WALDO AL, 1987, CIRCULATION, V75, P37; WENCKEBACH KF, 1907, ARCH ANAT PHYSIOL, V1, P1; WINTERBERG H, 1906, Z EXPT PATHOLOGIE TH, V3, P182; WOOD PH, 1968, DISESES HEART CIRCUL, P275	74	21	22	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					867	873		10.7326/0003-4819-122-11-199506010-00010	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741373				2022-12-28	WOS:A1995RA13900010
J	CRAWSHAW, R; ROGERS, DE; PELLEGRINO, ED; BULGER, RJ; LUNDBERG, GD; BRISTOW, LR; CASSEL, CK; BARONDESS, JA				CRAWSHAW, R; ROGERS, DE; PELLEGRINO, ED; BULGER, RJ; LUNDBERG, GD; BRISTOW, LR; CASSEL, CK; BARONDESS, JA			PATIENT-PHYSICIAN COVENANT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									GEORGETOWN UNIV,MED CTR,CTR CLIN BIOETH,WASHINGTON,DC 20007; ASSOC ACAD HLTH CTR,WASHINGTON,DC; AMER MED ASSOC,CHICAGO,IL 60610; UNIV CHICAGO,DEPT INTERNAL MED,CHICAGO,IL 60637; NEW YORK ACAD MED,NEW YORK,NY	Georgetown University; American Medical Association; University of Chicago; New York Academy of Medicine									0	96	96	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1553	1553		10.1001/jama.273.19.1553	http://dx.doi.org/10.1001/jama.273.19.1553			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739086				2022-12-28	WOS:A1995QX41800042
J	DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA				DAUTERMAN, K; PAK, PH; MAUGHAN, WL; NUSSBACHER, A; ARIE, S; LIU, CP; KASS, DA			CONTRIBUTION OF EXTERNAL FORCES TO LEFT-VENTRICULAR DIASTOLIC PRESSURE - IMPLICATIONS FOR THE CLINICAL USE OF THE STARLING LAW	ANNALS OF INTERNAL MEDICINE			English	Article						VENTRICULAR FUNCTION, LEFT; VENTRICULAR DYSFUNCTION, LEFT; HEART CATHETERIZATION; CARDIAC OUTPUT; DIASTOLIC	VOLUME RELATIONS; PERICARDIUM; DOGS; CURVE; NITROGLYCERIN; RELAXATION; MECHANISM; AFTERLOAD; REDUCTION; OCCLUSION	Objective: To test whether a substantial proportion of measured resting left ventricular diastolic pressure stems from forces external to the left ventricle (such as right-heart filling) in normal and chronically diseased hearts. Design: Nonrandomized study with single intervention. Setting: University hospital. Patients: 29 patients referred for cardiac catheterization who had normal left ventricles and ejection fractions (n = 12); chronic heart disease due to idiopathic dilated cardiomyopathy (n = 6); ischemic heart disease(n = 6); or left ventricular hypertrophy (n = 5). Intervention: Acute reduction of external forces imposed on the left ventricle using balloon obstruction of inferior vena caval inflow to the right heart. Measurements: Continuous catheter-derived left ventricular pressure-volume data before and after abrupt obstruction of inferior vena caval inflow. Diastolic pressures were measured at the same volume just before atrial systole before and after sudden decrease of external (right-heart and pericardial) forces. The resulting decline in pressure was a measure of the contribution of these external forces to resting left ventricular diastolic pressure. Results: The decline in pressure when external forces were released averaged -19% +/- 13% with minimal change in left ventricular end-diastolic volume (-3.66% +/- 6.7%) and cardiac output (-5% +/- 8%). In all patients combined, the decline in pressure when external forces (Delta P-d) were released correlated with resting left ventricular diastolic pressure (LVP(d)) given by: Delta P-d = 0.38 x (LVP(d) 6) [r = 0.86, P < 0.0001]. This indicates that when resting diastolic pressure was more than 6 mm Hg, almost 38% of the pressure was due to external factors. This percentage was similar among all subgroups. Furthermore, the left ventricular diastolic pressure could be reduced by this percentage with only minimal compromise to ventricular filling and cardiac output. Conclusions: A substantial proportion of measured resting left ventricular diastolic pressure stems from forces extrinsic to the left ventricle rather than from diastolic stiffness in the left ventricle itself. This markedly influences the dependence of cardiac output on filling pressure and has important implications for clinical application of the Starling law.	JOHNS HOPKINS MED INST, BALTIMORE, MD 21205 USA; INST CORACAO, SAO PAULO, BRAZIL; VET GEN HOSP, TAIPEI, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine; Universidade de Sao Paulo					NHLBI NIH HHS [HL-47511] Funding Source: Medline; NIA NIH HHS [AG-12249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN EL, 1976, CIRCULATION, V54, P662, DOI 10.1161/01.CIR.54.4.662; APPLEGATE RJ, 1990, AM J PHYSIOL, V258, pH1079, DOI 10.1152/ajpheart.1990.258.4.H1079; APPLEGATE RJ, 1992, AM J PHYSIOL, V262, pH1725, DOI 10.1152/ajpheart.1992.262.6.H1725; BHARGAVA V, 1983, AM HEART J, V105, P995, DOI 10.1016/0002-8703(83)90402-7; BLANCHARD DG, 1992, CIRCULATION, V85, P1414, DOI 10.1161/01.CIR.85.4.1414; BRAUNWALD E, 1963, AM J MED, V34, P147, DOI 10.1016/0002-9343(63)90049-4; BRODIE BR, 1977, J CLIN INVEST, V59, P59, DOI 10.1172/JCI108622; CARROLL JD, 1986, CIRCULATION, V74, P815, DOI 10.1161/01.CIR.74.4.815; FREEMAN GL, 1984, CIRC RES, V54, P294, DOI 10.1161/01.RES.54.3.294; GILBERT JC, 1989, CIRC RES, V64, P827, DOI 10.1161/01.RES.64.5.827; JANICKI JS, 1980, AM J PHYSIOL, V238, pH494, DOI 10.1152/ajpheart.1980.238.4.H494; JANICKI JS, 1990, CIRCULATION, V81, P15; KASS DA, 1988, CATHETER CARDIO DIAG, V15, P192, DOI 10.1002/ccd.1810150314; KASS DA, 1993, ANN INTERN MED, V119, P466, DOI 10.7326/0003-4819-119-6-199309150-00004; KASS DA, 1990, CIRCULATION, V81, P447, DOI 10.1161/01.CIR.81.2.447; KINGMA I, 1986, AM J CARDIOL, V57, P673, DOI 10.1016/0002-9149(86)90857-X; LANKFORD EB, 1990, AM J PHYSIOL, V258, pH1933, DOI 10.1152/ajpheart.1990.258.6.H1933; LEWINTER MM, 1982, CIRC RES, V50, P501, DOI 10.1161/01.RES.50.4.501; LUDBROOK PA, 1979, CIRCULATION, V59, P21, DOI 10.1161/01.CIR.59.1.21; LUDBROOK PA, 1977, CIRCULATION, V56, P937, DOI 10.1161/01.CIR.56.6.937; RAFF GL, 1981, CIRC RES, V48, P813, DOI 10.1161/01.RES.48.6.813; ROSS J, 1979, CIRCULATION, V59, P32, DOI 10.1161/01.CIR.59.1.32; SHIRATO K, 1978, CIRCULATION, V57, P1191, DOI 10.1161/01.CIR.57.6.1191; SLINKER BK, 1989, AM J PHYSIOL, V256, pH567, DOI 10.1152/ajpheart.1989.256.2.H567; STARLING EH, 1978, CIRC RES, V42, P433; TYBERG JV, 1978, EUR J CARDIOL, V7, P163; TYSON GS, 1984, CIRC RES, V54, P173, DOI 10.1161/01.RES.54.2.173	27	80	80	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					737	742		10.7326/0003-4819-122-10-199505150-00001	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717595				2022-12-28	WOS:A1995QX14700001
J	PROVINCE, MA; HADLEY, EC; HORNBROOK, MC; LIPSITZ, LA; MULROW, CD; ORY, MG; SATTIN, RW; TINETTI, ME; WOLF, SL				PROVINCE, MA; HADLEY, EC; HORNBROOK, MC; LIPSITZ, LA; MULROW, CD; ORY, MG; SATTIN, RW; TINETTI, ME; WOLF, SL			THE EFFECTS OF EXERCISE ON FALLS IN ELDERLY PATIENTS - A PREPLANNED METAANALYSIS OF THE FICSIT TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL STATUS; OLDER PERSONS; RISK-FACTORS; POPULATION; FRAILTY; PREDICTORS; COMMUNITY; INJURIES; BALANCE; PEOPLE	Objective.-To determine if short-term exercise reduces falls and fall-related injuries in the elderly. Design.-A preplanned meta-analysis of the seven Frailty and Injuries: Cooperative Studies of Intervention Techniques (FICSIT)-independent, randomized, controlled clinical trials that assessed intervention efficacy in reducing falls and frailty in elderly patients. All included an exercise component for 10 to 36 weeks. Fall and injury follow-up was obtained for up to 2 to 4 years. Setting.-Two nursing home and five community-dwelling (three health maintenance organizations) sites. Six were group and center based; one was conducted at home. Participants.-Numbers of participants ranged from 100 to 1323 per study. Subjects were mostly ambulatory and cognitively intact, with minimum ages of 60 to 75 years, although some studies required additional deficits, such as functionally dependent in two or more activities of daily living, balance deficits or lower extremity weakness, or high risk of falling. Interventions.-Exercise components varied across studies in character, duration, frequency, and intensity. Training was performed in one area or more of endurance, flexibility, balance platform, Tai Chi (dynamic balance), and resistance. Several treatment arms included additional nonexercise components, such as behavioral components, medication changes, education, functional activity, or nutritional supplements. Main Outcome Measures.-Time to each fall (fall-related injury) by self-report and/or medical records. Results.-Using the Andersen-Gill extension of the Cox model that allows multiple fall outcomes per patient, the adjusted fall incidence ratio for treatment arms including general exercise was 0.90 (95% confidence limits [CL], 0.81, 0.99) and for those including balance was 0.83 (95% CL, 0.70, 0.98). No exercise component was significant for injurious falls, but power was low to detect this outcome. Conclusions.-Treatments including exercise for elderly adults reduce the risk of falls.	NIA,BETHESDA,MD 20892; KAISER PERMANENTE CTR HLTH RES,PORTLAND,OR; HARVARD UNIV,BETH ISRAEL HOSP,HEBREW REHABIL CTR AGED,BOSTON,MA 02215; AUDIE L MURPHY MEM VET ADM MED CTR,DEPT MED,SAN ANTONIO,TX; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341; YALE UNIV,SCH MED,PROGRAM AGING,NEW HAVEN,CT; EMORY UNIV,SCH MED,DEPT REHABIL MED,ATLANTA,GA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Kaiser Permanente; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Centers for Disease Control & Prevention - USA; Yale University; Emory University	PROVINCE, MA (corresponding author), WASHINGTON UNIV,SCH MED,DIV BIOSTAT,BOX 8067,600 S EUCLID ST,ST LOUIS,MO 63110, USA.		Ory, Marcia/L-4025-2019; Wolf, Steve/F-6588-2010	Wolf, Steve/0000-0002-9446-8995; Miller, J Philip/0000-0003-4568-6846				ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; [Anonymous], 1989, SAS STAT USERS GUIDE, V2; BERSTEIN AB, 1990, J AGING HEALTH, V2, P157; BLAKE AJ, 1988, AGE AGEING, V17, P365, DOI 10.1093/ageing/17.6.365; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112; CWIKEL J, 1992, ISRAEL J MED SCI, V37, P137; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNCAN PW, 1992, J GERONTOL, V47, pM93, DOI 10.1093/geronj/47.3.M93; DUNN JE, 1992, AM J PUBLIC HEALTH, V82, P395, DOI 10.2105/AJPH.82.3.395; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P27; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; GRISSO JA, 1992, J AM GERIATR SOC, V40, P673; HORNBROOK MC, 1993, J AM GERIATR SOC, V41, P309, DOI 10.1111/j.1532-5415.1993.tb06709.x; Kelsey JL, 1992, AM J EPIDEMIOL, V135, P447; KIEL DP, 1991, MED CARE, V29, P221; LIPSITZ LA, 1991, J GERONTOL, V46, pM112; LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69; MILLER JP, 1991, CONTROL CLIN TRIALS, V12, P612; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; MULROW CD, 1993, J AM GERIATR SOC, V41, P326, DOI 10.1111/j.1532-5415.1993.tb06712.x; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V2261, P2663; NEVITT MC, 1991, REDUCING FRAILTY FAL, P476; ORY MG, 1993, J AM GERIATR SOC, V41, P283, DOI 10.1111/j.1532-5415.1993.tb06707.x; ROBBINS AS, 1989, ARCH INTERN MED, V149, P1628, DOI 10.1001/archinte.1989.00390070138022; SATTIN RW, 1992, ANNU REV PUBL HEALTH, V13, P489, DOI 10.1146/annurev.pu.13.050192.002421; Sjorgen H, 1991, J AGING HEALTH, V3, P107, DOI DOI 10.1177/089826439100300106; SOROCK GS, 1988, J GERONTOL, V43, pM134, DOI 10.1093/geronj/43.5.M134; SPEECHLEY M, 1991, J AM GERIATR SOC, V39, P46, DOI 10.1111/j.1532-5415.1991.tb05905.x; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1993, J AM GERIATR SOC, V41, P315, DOI 10.1111/j.1532-5415.1993.tb06710.x; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tinetti ME, 1986, J AM GERIATR SOC, V34, P119; TINETTI ME, 1992, FALLS BALANCE GAIT D, P6; WALLACE RB, 1993, J AM GERIATR SOC, V41, P338, DOI 10.1111/j.1532-5415.1993.tb06715.x; WOLF SL, 1993, J AM GERIATR SOC, V41, P329, DOI 10.1111/j.1532-5415.1993.tb06713.x; WOLFSON L, 1993, J AM GERIATR SOC, V41, P341, DOI 10.1111/j.1532-5415.1993.tb06716.x; [No title captured]; 1989, SAS STAT USERS GUIDE, V1; 1991, S PLUS USERS MANUAL, V2	44	742	756	3	123	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1341	1347		10.1001/jama.273.17.1341	http://dx.doi.org/10.1001/jama.273.17.1341			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715058				2022-12-28	WOS:A1995QV30700018
J	CHATTERJEE, S; STRUHL, K				CHATTERJEE, S; STRUHL, K			CONNECTING A PROMOTER-BOUND PROTEIN TO TBP BYPASSES THE NEED FOR A TRANSCRIPTIONAL ACTIVATION DOMAIN	NATURE			English	Article							CRYSTAL-STRUCTURE; TATA ELEMENTS; YEAST; BINDING; INVITRO; SPECIFICITY; MECHANISM; MUTANTS; COMPLEX; CLONING	BIOCHEMICAL analyses have suggested potential targets for transcriptional activation domains, which include several components of the RNA polymerase II machinery(1-7), as well as the chromatin template(8-12). Here we examine the mechanism of transcriptional activation in yeast cells by connecting a heterologous DNA-binding domain (LexA) to the TATA-binding protein (TBP), LexA-TBP efficiently activates transcription from a promoter containing a LexA operator upstream of a TATA element, Activation is promoter-specific and is sensitive to mutations on the DNA-binding surface of TBP; hence it is not due to a fortuitous activation domain on TBP, Thus a promoter-bound protein lacking an activation domain can stimulate transcription if it is directly connected to TBP. This suggests that recruitment of TBP to the promoter can be a rate-limiting step for transcription in vivo, and that interactions between activation domains and factors that function after TBP recruitment can be bypassed for activation.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								ARNDT KM, 1992, MOL CELL BIOL, V12, P2372, DOI 10.1128/MCB.12.5.2372; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; CORMACK BP, 1994, GENE DEV, V8, P1335, DOI 10.1101/gad.8.11.1335; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HARBURY PAB, 1989, MOL CELL BIOL, V9, P5298, DOI 10.1128/MCB.9.12.5298; HILL DE, 1986, SCIENCE, V234, P451, DOI 10.1126/science.3532321; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x	31	174	176	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					820	822		10.1038/374820a0	http://dx.doi.org/10.1038/374820a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723828				2022-12-28	WOS:A1995QV31500050
J	MURAKAMI, H; OKAYAMA, H				MURAKAMI, H; OKAYAMA, H			A KINASE FROM FISSION YEAST RESPONSIBLE FOR BLOCKING MITOSIS IN S-PHASE	NATURE			English	Article							DNA-POLYMERASE-ALPHA; SCHIZOSACCHAROMYCES-POMBE; GENE; REPAIR; REPLICATION; DIVISION; MUTANTS; CLONING; RAD1	IN virtually all eukaryotes, mitosis starts after the completion of DNA synthesis, This orderly process is ensured by the checkpoint mechanism that blocks:the onset of mitosis while DNA is being Synthesized or is damaged, In the fission yeast Schizosaccharomyces pombe, this mechanism involves some rad(+) and hus(+) genes(1-4). However, it is not known how the checkpoint system monitors these events, Recently a multicopy suppressor of a temperature-sensitive DNA polymerase-alpha mutant was isolated, This gene, named cds1(+) (checking DNA synthesis), encodes a typical protein kinase, Here we report that this protein kinase is a key component of the DNA replication-monitoring S/G2 checkpoint system, Our data suggest that its primary role is to monitor DNA synthesis by interacting: with DNA polymerase alpha and send a signal to block the onset of mitosis while DNA synthesis is in progress.	JRDC,ERATO,OKAYAMA CELL SWITCHING PROJECT,SAKYO KU,KYOTO,JAPAN		MURAKAMI, H (corresponding author), UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN.							ALKHODAIRY, 1994, MOL BIOL CELL, V5, P147; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; Allen JB, 1994, GENE DEV, V8, P2416; DAMAGNEZ V, 1991, MOL GEN GENET, V226, P182, DOI 10.1007/BF00273602; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FANTES P, 1979, NATURE, V279, P428, DOI 10.1038/279428a0; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; MURRAY JM, 1991, NUCLEIC ACIDS RES, V19, P3525, DOI 10.1093/nar/19.13.3525; NASMYTH KA, 1977, CELL, V12, P101; PECK VM, 1993, BIOCHEM BIOPH RES CO, V190, P325, DOI 10.1006/bbrc.1993.1051; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHENG P, 1993, MOL CELL BIOL, V9, P5829	22	254	260	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					817	819		10.1038/374817a0	http://dx.doi.org/10.1038/374817a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723827				2022-12-28	WOS:A1995QV31500049
J	WATSON, NJ; HUTCHINSON, CH; ATTA, HR				WATSON, NJ; HUTCHINSON, CH; ATTA, HR			VITAMIN-A-DEFICIENCY AND XEROPHTHALMIA IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article							A-DEFICIENCY; RAT-LIVER; RETINOL; PLASMA				WATSON, NJ (corresponding author), ABERDEEN ROYAL INFIRM,DEPT OPHTHALMOL,FORESTERHILL SITE,ABERDEEN AB9 2ZB,SCOTLAND.							AMEDEEMANESME O, 1987, AM J CLIN NUTR, V46, P286, DOI 10.1093/ajcn/46.2.286; ARROYAVE G, 1982, BIOCH METHODOLOGY AS; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; BROWN M, 1990, PRESENT KNOWLEDGE NU, V6; BUCHANAN NM, 1987, SCOT MED J, V32, P52, DOI 10.1177/003693308703200211; HUMPHREY JH, 1992, B WORLD HEALTH ORGAN, V70, P225; ISHIHARA S, 1991, NUTRITION, V7, P81; JACKSON AA, 1987, OXFORD TXB MED, V1; KATO M, 1984, J CELL BIOL, V98, P1696, DOI 10.1083/jcb.98.5.1696; OLSON JA, 1983, J NUTR, V113, P2184, DOI 10.1093/jn/113.11.2184; PERIMAN I, 1983, BR J OPHTHALMOL, V67, P37; RESNIKOFF S, 1992, EUR J CLIN NUTR, V46, P25; ROULAND JF, 1989, J FR OPHTALMOL, V12, P273; SOMMER A, 1978, ARCH OPHTHALMOL-CHIC, V96, P1630, DOI 10.1001/archopht.1978.03910060264016; TENG KH, 1965, OPHTHALMOLOGICA, V150, P219; WITTPENN JR, 1986, ARCH OPHTHALMOL-CHIC, V104, P237	16	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1050	1051		10.1136/bmj.310.6986.1050	http://dx.doi.org/10.1136/bmj.310.6986.1050			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728061	Green Published			2022-12-28	WOS:A1995QV31300021
J	MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T				MIYAZAKI, T; LIU, ZJ; KAWAHARA, A; MINAMI, Y; YAMADA, K; TSUJIMOTO, Y; BARSOUMIAN, EL; PERLMUTTER, RM; TANIGUCHI, T			3 DISTINCT IL-2 SIGNALING PATHWAYS MEDIATED BY BCL-2, C-MYC, AND LCK COOPERATE IN HEMATOPOIETIC-CELL PROLIFERATION	CELL			English	Article							RECEPTOR-BETA-CHAIN; PROTEIN-TYROSINE KINASE; INTERLEUKIN-2 RECEPTOR; FOLLICULAR LYMPHOMA; LIGAND-BINDING; TRANSDUCTION; APOPTOSIS; DEATH; ACTIVATION; LINE	Two interleukin-2 receptor-dependent signaling pathways have thus far been identified: the c-fos/c-jun induction pathway mediated by src family protein-tyrosine kinases and the c-myo induction pathway. Here, we provide evidence for the existence of a third, rapamycin-sensitive pathway, which results in the induction of another proto-oncogene, bcl-2. In the hematopoietic cell line BAF-B03, the expression of any two of lckF505 (an active form of p56(lck)), Bcl-2, or c-Myc is sufficient to promote transit of the cell cycle, regardless of the activation state of the third pathway. We also provide evidence that epidermal growth factor receptor signaling may act through the same pathway that involves p56(lck). These studies demonstrate a novel approach to dissecting signaling pathways regulating cellular proliferation.	NIPPON BOEHRINGER INGELHEIM CO LTD,INST MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,SUITA,OSAKA 565,JAPAN; UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,HOWARD HUGHES MED INST,SEATTLE,WA 98195; UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	Boehringer Ingelheim; Osaka University; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Tokyo	MIYAZAKI, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,1-3 YAMADAOKA,SUITA,OSAKA 565,JAPAN.		Miyazaki, Tadaaki/D-9368-2012					ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COLLINS MKL, 1993, TRENDS BIOCHEM SCI, V18, P307, DOI 10.1016/0968-0004(93)90042-L; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTANI H, 1993, J BIOL CHEM, V268, P22733; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SATOH T, 1992, J BIOL CHEM, V267, P25423; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	46	349	361	2	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					223	231		10.1016/0092-8674(95)90332-1	http://dx.doi.org/10.1016/0092-8674(95)90332-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736574	Bronze			2022-12-28	WOS:A1995QV41000011
J	WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID				WATT, PM; LOUIS, EJ; BORTS, RH; HICKSON, ID			SGS1 - A EUKARYOTIC HOMOLOG OF ESCHERICHIA-COLI RECQ THAT INTERACTS WITH TOPOISOMERASE-II IN-VIVO AND IS REQUIRED FOR FAITHFUL CHROMOSOME SEGREGATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; PROTEIN; MITOSIS; MEIOSIS; YEAST; MUTANTS; NONDISJUNCTION; RECOMBINATION; TRANSMISSION	Topoisomerase II (topo II) catalyzes the decatenation of interlinked DNA molecules and is essential for chromosome segregation. To test the hypothesis that the noncatalytic C-terminal domain of topo II is necessary for mediating interactions with other proteins required for chromosome segregation, we used a two-hybrid cloning strategy to identify proteins that interact with S. cerevisiae topo II in vivo. One protein identified (Sgs1p) is structurally related to E. coli RecQ protein and contains helicase signature! motifs. Strains lacking Sgs1p exhibit elevated levels of chromosome missegregation during both mitotic and meiotic division. We propose a model to account for the interaction of a topoisomerase and a helicase in the faithful segregation of newly replicated eukaryotic chromosomes.	UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, YEAST GENET GRP, OXFORD OX3 9DU, ENGLAND	University of Oxford	WATT, PM (corresponding author), UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND.		Hickson, Ian/AAJ-7548-2020; Louis, Edward/B-7920-2008	Louis, Edward/0000-0003-1157-3608; Hickson, Ian/0000-0002-0583-566X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARTWELL LH, 1985, GENETICS, V110, P381; HOLM C, 1994, CELL, V77, P955, DOI 10.1016/0092-8674(94)90433-2; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HOYT MA, 1992, J CELL BIOL, V118, P109, DOI 10.1083/jcb.118.1.109; KAMIGUCHI Y, 1993, HUM GENET, V90, P533; KOONIN EV, 1991, NATURE, V352, P290, DOI 10.1038/352290c0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LOUIS EJ, 1989, GENETICS, V123, P81; LUISIDELUCA C, 1989, GENETICS, V122, P269; Luria SE, 1943, GENETICS, V28, P491; MCCUSKER JH, 1988, GENETICS, V119, P303; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; MURRAY AW, 1985, ANNU REV CELL BIOL, V1, P289, DOI 10.1146/annurev.cellbio.1.1.289; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROSE D, 1990, CELL, V60, P1009, DOI 10.1016/0092-8674(90)90349-J; ROSE D, 1993, MOL CELL BIOL, V13, P3445, DOI 10.1128/MCB.13.6.3445; SAMEJIMA I, 1993, J CELL SCI, V105, P135; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPENCER F, 1990, GENETICS, V124, P237; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	38	375	379	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					253	260		10.1016/0092-8674(95)90335-6	http://dx.doi.org/10.1016/0092-8674(95)90335-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736577	Bronze			2022-12-28	WOS:A1995QV41000014
J	DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T				DARCANGELO, G; MIAO, GG; CHEN, SC; SOARES, HD; MORGAN, JI; CURRAN, T			A PROTEIN RELATED TO EXTRACELLULAR-MATRIX PROTEINS DELETED IN THE MOUSE MUTANT REELER	NATURE			English	Article							NEURAL CELL-ADHESION; GENE; MICE; CEREBELLUM; MUTATIONS; MOLECULES; ENCODES; BRAIN	THE autosomal recessive mouse mutation reeler(1-3) leads to impaired motor coordination, tremors and ataxia(4). Neurons in affected mice fail to reach their correct locations in the developing brain, disrupting the organization of the cerebellar and cerebral cortices and other laminated regions(5-8). Here we use a previously characterized reeler allele (rl(tg))(9) to clone a gene, reelin, deleted in two reeler alleles. Normal but not mutant mice express reelin in embryonic and postnatal neurons during periods of neuronal migration. The encoded protein resembles extracellular matrix proteins involved in cell adhesion. The reeler phenotype thus seems to reflect a failure of early events associated with brain lamination which are normally controlled by reelin.	HOFFMANN LA ROCHE INC, NEUROGENET PROGRAM, NUTLEY, NJ 07110 USA	Roche Holding	DARCANGELO, G (corresponding author), HOFFMANN LA ROCHE INC, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Curran, Tom/D-7515-2011; Morgan, James/GRO-2905-2022; Curran, Tom/C-1164-2008; Morgan, James/N-8104-2018; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019	Morgan, James/0000-0002-8920-1065; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; D'Arcangelo, Gabriella/0000-0003-1575-1010				BAR I, IN P0RESS GENOMICS; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501; DERER P, 1983, J HIRNFORSCH, V24, P209; DERNONCOURT C, 1991, GENOMICS, V11, P1167, DOI 10.1016/0888-7543(91)90049-K; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FLAHERTY L, 1992, P NATL ACAD SCI USA, V89, P2859, DOI 10.1073/pnas.89.7.2859; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GODFRAIND C, 1988, DEV BRAIN RES, V42, P99, DOI 10.1016/0165-3806(88)90205-2; GOFFINET AM, 1984, BRAIN RES REV, V7, P261, DOI 10.1016/0165-0173(84)90013-4; GOFFINET AM, 1992, INT J DEV BIOL, V36, P101; GUENET JL, 1981, MOUSE NEWS LETT, V41; HAMBURGH M, 1963, DEV BIOL, V8, P165, DOI 10.1016/0012-1606(63)90040-X; HEIJNE GV, 1984, J MOL BIOL, V173, P243; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MARIANI J, 1977, PHILOS T R SOC B, V281, P1, DOI 10.1098/rstb.1977.0121; MIAO GG, 1994, P NATL ACAD SCI USA, V91, P11050, DOI 10.1073/pnas.91.23.11050; MISCHEL PS, 1995, J NEUROPATH EXP NEUR, V54, P137, DOI 10.1097/00005072-199503000-00001; MONTGOMERY JC, IN PRESS MAMM GENOME; OGAWA, IN PRESS NEURONS; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STANFIELD BB, 1979, J COMP NEUROL, V185, P461, DOI 10.1002/cne.901850304; TERASHIMA T, 1986, J COMP NEUROL, V252, P264, DOI 10.1002/cne.902520209; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	30	1412	1437	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 20	1995	374	6524					719	723		10.1038/374719a0	http://dx.doi.org/10.1038/374719a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715726				2022-12-28	WOS:A1995QU30400049
J	HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB				HE, X; SAINTJEANNET, JP; WOODGETT, JR; VARMUS, HE; DAWID, IB			GLYCOGEN-SYNTHASE KINASE-3 AND DORSOVENTRAL PATTERNING IN XENOPUS EMBRYOS	NATURE			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; AXIAL MESODERM; BODY AXIS; EXPRESSION; DROSOPHILA; WINGLESS; XWNT-8	Glycogen synthase kinase 3 (GSK-3) is homologous to the product of the Drosophila gene shaggy (zeste-white 3), which is required for signalling by wingless during Drosophila development. To test whether GSK-3 is also involved in vertebrate pattern formation, its role was investigated during early Xenopus development. It was found that dominant-negative GSK-3 mutants induced dorsal differentiation, whereas wild-type GSK-3 induced ventralization. These results indicate that GSK-3 is required for ventral differentiation, and suggest that dorsal differentiation may involve the suppression of GSK-3 activity by a wingless/wnt-related signal.	NICHHD,GENET MOLEC LAB,BETHESDA,MD 20892; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University Toronto Affiliates; University Health Network Toronto	HE, X (corresponding author), NCI,VARMUS LAB,BLDG 49,ROOM 4A56,BETHESDA,MD 20892, USA.		Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797				AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BOHN H, 1992, J EMBRYOL EXP MORPH, V28, P185; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V289, P6259; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P1661; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; GERHART J, 1989, DEVELOPMENT, V107, P37; GRAFF JM, 1994, CELL, V79, P169, DOI 10.1016/0092-8674(94)90409-X; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SATO SM, 1991, DEVELOPMENT, V112, P747; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STANBOLIC V, 1994, BIOCHEM J, V303, P701; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269	50	440	449	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					617	622		10.1038/374617a0	http://dx.doi.org/10.1038/374617a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715701				2022-12-28	WOS:A1995QT18900051
J	MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM				MILLS, JL; MCPARTLIN, JM; KIRKE, PN; LEE, YJ; CONLEY, MR; WEIR, DG; SCOTT, JM			HOMOCYSTEINE METABOLISM IN PREGNANCIES COMPLICATED BY NEURAL-TUBE DEFECTS	LANCET			English	Article							VITAMIN SUPPLEMENTATION; PLASMA; PREVENTION; METHIONINE; FOLATE; SERUM; ACID	Folic acid taken around the time of conception can prevent many neural-tube defects, Women with low-normal vitamin B-12 values may also be at increased risk. We considered whether homocysteine metabolism via the enzyme methionine synthase, which requires both folate and B-12, could be the critical defect in folate-related neural tube defects. Blood was obtained during pregnancies that produced 81 infants with neural-tube defects and 323 normal children, Samples were assayed for homocysteine, methylmalonic acid, plasma folate, red-cell folate, and B-12. Mothers of children with neural-tube defects had significantly higher homocysteine values (8.62 [SD 2.8] mu mol/L) than did B-12-matched controls (7.96 [2.5] mu mol/L, p=0.03). The difference was significant (p=0.004) in the lower half of the B-12 distribution after adjusting for plasma folate. Our study shows that an abnormality in homocysteine metabolism, apparently related to methionine synthase, is present in many women who give birth to children with neural-tube defects. Overcoming this abnormality is likely to be the mechanism by which folic acid prevents neural-tube defects. These findings suggest that the most effective periconceptional prophylaxis to prevent neural-tube defects may require B-12 as well as fotic acid.	HLTH RES BOARD,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT CLIN MED,DUBLIN,IRELAND; UNIV DUBLIN TRINITY COLL,DEPT BIOCHEM,DUBLIN,IRELAND	Health Research Board - Ireland; Trinity College Dublin; Trinity College Dublin	MILLS, JL (corresponding author), NICHHD,DESPR,PEDIAT EPIDEMIOL SECT,EPIDEMIOL BRANCH,6100 EXECUT BLVD,ROOM 7B03,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				ADAMS MJ, 1993 SOC EP RES ANN; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; COELHO CND, 1989, J NUTR, V119, P1716, DOI 10.1093/jn/119.11.1716; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; ESSIEN FB, 1993, J NUTR, V123, P27, DOI 10.1093/jn/123.1.27; KANG SS, 1991, AM J HUM GENET, V48, P546; KIRKE PN, 1993, Q J MED, V86, P703; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MCMURRAY CH, 1986, J CHROMATOGR, V378, P201, DOI 10.1016/S0378-4347(00)80713-6; SMITHELLS RW, 1983, LANCET, V1, P1027; STEEGERSTHEUNIS.RP, 1991, NEW ENGL J MED, V324, P199; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; 1991, LANCET, V338, P131	13	560	576	0	30	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 21	1995	345	8943					149	151		10.1016/S0140-6736(95)90165-5	http://dx.doi.org/10.1016/S0140-6736(95)90165-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7741859				2022-12-28	WOS:A1995QC55000008
J	CORONADO, BE; OPAL, SM; YOBURN, DC				CORONADO, BE; OPAL, SM; YOBURN, DC			ANTIBIOTIC-INDUCED D-LACTIC ACIDOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							SHORT-BOWEL SYNDROME; D-LACTATE; BYPASS; ENCEPHALOPATHY	Objective: To describe a case of oral antibiotic-induced D-lactic acidosis in a patient with enteric overgrowth of Lactobacillus acidophilus. Design: Single case study. Setting: University-affiliated community hospital. Intervention: Oral carbohydrate challenge test with 4000 kcal/d. Main Results: A patient had several episodes of D-lactic acidosis after receiving oral antibiotics. Stool cultures yielded Lactobacillus acidophilus resistant to the implicated agents. Provocative challenge with dietary carbohydrate alone, in the absence of antibiotics, failed to reproduce the syndrome. Conclusions: Oral antibiotics may induce D-lactic acidosis in patients with the short-bowel syndrome by promoting the overgrowth of resistant D-lactate-producing organisms. Interactions between carbohydrate intake and antibiotic use are likely determinants in the development of this syndrome. Periodic use of stool cultures with antimicrobial susceptibility testing may assist in the management of these patients by optimizing the selection of antimicrobial agents.	BROWN UNIV, PROVIDENCE, RI 02912 USA; MEM HOSP RHODE ISL, DIV INFECT DIS, PAWTUCKET, RI 02860 USA	Brown University								AYUB A, 1981, JAMA-J AM MED ASSOC, V246, P970, DOI 10.1001/jama.246.9.970; CARR DB, 1982, ANN NEUROL, V11, P195, DOI 10.1002/ana.410110216; DAHLQUIST NR, 1984, MAYO CLIN PROC, V59, P141, DOI 10.1016/S0025-6196(12)60764-2; DEWIND LT, 1976, JAMA-J AM MED ASSOC, V236, P2298, DOI 10.1001/jama.236.20.2298; DOUGHERTY RW, 1975, AM J VET RES, V36, P833; DUNLOP RH, 1965, ANN NY ACAD SCI, V119, P1109, DOI 10.1111/j.1749-6632.1965.tb47466.x; EYS JV, 1962, J NUTR, V76, P375; HUDSON M, 1990, Q J MED, V74, P157; KARTON M, 1987, JPEN-PARENTER ENTER, V11, P586, DOI 10.1177/0148607187011006586; MASON PD, 1986, BRIT MED J, V292, P1105, DOI 10.1136/bmj.292.6528.1105; OH MS, 1979, NEW ENGL J MED, V301, P249, DOI 10.1056/NEJM197908023010505; OH MS, 1985, METABOLISM, V34, P621, DOI 10.1016/0026-0495(85)90088-5; PERLMUTTER DH, 1983, J PEDIATR-US, V102, P234, DOI 10.1016/S0022-3476(83)80527-7; RAMAKRISHNAN T, 1985, JPEN-PARENTER ENTER, V9, P361, DOI 10.1177/0148607185009003361; Sahm D.H., 1991, MANUAL CLIN MICROBIO; Sneath PHA, 1986, BERGEYS MANUAL SYSTE, V2, P1105; STOLBERG L, 1982, NEW ENGL J MED, V306, P1344, DOI 10.1056/NEJM198206033062207; SUBER RL, 1979, AM J VET RES, V40, P1005; THURN JR, 1985, AM J MED, V79, P717, DOI 10.1016/0002-9343(85)90522-4; TRAUBE M, 1983, ANN INTERN MED, V98, P171, DOI 10.7326/0003-4819-98-2-171	20	40	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					839	842		10.7326/0003-4819-122-11-199506010-00005	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741368				2022-12-28	WOS:A1995RA13900005
J	TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL				TONG, MJ; ELFARRA, NS; REIKES, AR; CO, RL			CLINICAL OUTCOMES AFTER TRANSFUSION-ASSOCIATED HEPATITIS-C	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC ACTIVE HEPATITIS; NON-B-HEPATITIS; POSTTRANSFUSION HEPATITIS; NON-A; FOLLOW-UP; VIRUS	Background. The extent of serious complications in people who have acquired chronic hepatitis C after a blood transfusion is unclear. Methods. We studied 131 patients with chronic posttransfusion hepatitis C who were referred to our center between February 1980 and June 1994. Eighty-two other patients were excluded because they had multiple transfusions, hemophilia, intravenous drug use, human immunodeficiency virus infection, hepatitis B infection, hemochromatosis, or alcoholic liver disease. Liver biopsies were performed in 101 patients; biopsies were not performed in the other 30 patients, all with signs of cirrhosis, because the results of coagulation tests were abnormal. Results. The mean age of the patients was 57 years (range, 21 to 81) at the time of our initial evaluation. The mean age at the time of the blood transfusion was 35 years (range, 1 to 76). The mean duration of follow-up after presentation to us was 3.9 years (range, 1 to 15). Eighty-eight of the patients (67.2 percent) initially had fatigue, and 89 (67.9 percent) had hepatomegaly. Twenty-seven patients (20.6 percent) initially had chronic hepatitis, 30 (22.9 percent) had chronic active hepatitis, 67 (51.1 percent) had cirrhosis, and 7 (5.3 percent) had hepatocellular carcinoma. Hepatocellular carcinoma developed in an additional seven patients an average of 36 months (range, 7 to 121) after the initial visit. During follow-up, 20 patients (15.3 percent) died: 8 from complications of cirrhosis (1 after a liver transplantation); 11 from hepatocellular carcinoma; and 1, with chronic active hepatitis, from pneumonia. Conclusions. in a group of patients seen at a referral center, chronic post-transfusion hepatitis C was a progressive disease and, in some patients, led to death from either liver failure or hepatocellular carcinoma.			TONG, MJ (corresponding author), HUNTINGTON MEM HOSP, CTR LIVER, 744 FAIRMOUNT AVE, PASADENA, CA 91105 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; BOYER JL, 1976, GASTROENTEROLOGY, V70, P1161; CHIEN DY, 1993, J GASTROEN HEPATOL, V8, pS33; DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; KORETZ RL, 1993, ANN INTERN MED, V119, P110, DOI 10.7326/0003-4819-119-2-199307150-00003; LUDWIG J, 1993, GASTROENTEROLOGY, V105, P274, DOI 10.1016/0016-5085(93)90037-D; MATTSSON L, 1988, LIVER, V8, P184; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; TONG MJ, 1994, WESTERN J MED, V160, P133; TONG MJ, 1987, HEPATOLOGY, V7, P713, DOI 10.1002/hep.1840070416; TREMOLADA F, 1992, J HEPATOL, V16, P273, DOI 10.1016/S0168-8278(05)80657-9	13	1024	1056	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1463	1466		10.1056/NEJM199506013322202	http://dx.doi.org/10.1056/NEJM199506013322202			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739682				2022-12-28	WOS:A1995RA14000002
J	ELIA, M				ELIA, M			AN INTERNATIONAL PERSPECTIVE ON ARTIFICIAL NUTRITIONAL SUPPORT IN THE COMMUNITY	LANCET			English	Review							HOME PARENTERAL-NUTRITION; SMALL-BOWEL TRANSPLANTATION; GASTROSTOMY; MANAGEMENT				ELIA, M (corresponding author), DUNN CLIN NUTR CTR,HILLS RD,CAMBRIDGE CB2 2DH,ENGLAND.							ABUELMAGD, 1994, J AM COLL SURGEONS, V179, P385; ALLISON S, IN PRESS CLIN NUTR S, V1; AUGUST DA, 1991, JPEN-PARENTER ENTER, V15, P323, DOI 10.1177/0148607191015003323; BROVIAC JW, 1974, SURG GYNECOL OBSTET, V139, P24; CARTER DM, 1993, CLIN NUTR, V12, P208, DOI 10.1016/0261-5614(93)90016-W; CLARK CLI, 1992, BRIT J SURG, V79, P676, DOI 10.1002/bjs.1800790728; DEFRANCESCO A, IN PRESS CLIN NUTR S, V1; ELIA M, 1993, J ROY COLL PHYS LOND, V27, P8; ELIA M, 1994, NUTRITION, V10, P1; ELIA M, 1994, ENTERAL PARENTERAL N; Fallowfield L., 1991, QUALITY LIFE MISSING; GAGGIOTTI G, IN PRESS CLIN NUTR S, V1; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; HERMANNZAIDINS M, 1989, NUTRITION SUPPORT HO, P25; HOLDEN CE, 1991, ARCH DIS CHILD, V66, P148, DOI 10.1136/adc.66.1.148; HOWARD L, 1993, CANCER, V72, P3531, DOI 10.1002/1097-0142(19931201)72:11+<3531::AID-CNCR2820721621>3.0.CO;2-6; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; KELLY G, 1950, THEOL STUD, V12, P550; KING D, 1989, NUTRITION SUPPORT HO, P229; MESSING B, 1989, CLIN NUTR, V8, P3, DOI 10.1016/0261-5614(89)90018-6; MESSING B, 1988, PRESSE MED, V17, P845; MUGHAL M, 1986, LANCET, V2, P383; OHANRAHAN T, 1992, CLIN NUTR, V11, P331, DOI 10.1016/0261-5614(92)90083-3; PARIS JJ, 1993, CLIN NUTR S1, P12; PARKER T, IN PRESS J R COLL PH; PAYNEJAMES J, 1990, BRIT MED J, V301, P1, DOI 10.1136/bmj.301.6742.1; PERL M, 1980, JPEN-PARENTER ENTER, V4, P554, DOI 10.1177/0148607180004006554; ROBINOVITCH AE, 1981, JPEN-PARENTER ENTER, V5, P522, DOI 10.1177/0148607181005006522; SCHRAUT WH, 1988, GASTROENTEROLOGY, V94, P525, DOI 10.1016/0016-5085(88)90449-0; SCRIBNER BH, 1970, J AMER MED ASSOC, V212, P457, DOI 10.1001/jama.212.3.457; SHILS ME, 1970, NEW ENGL J MED, V283, P341, DOI 10.1056/NEJM197008132830705; SMITH CE, 1993, JPEN-PARENTER ENTER, V17, P501, DOI 10.1177/0148607193017006501; TAYLOR CA, 1992, MAYO CLIN PROC, V67, P1042, DOI 10.1016/S0025-6196(12)61118-5; TILSON MD, 1980, SURG CLIN N AM, V60, P1273; TODO S, 1995, 15TH WORLD C TRANSPL, V27, P1355; WEEKES E, 1992, J HUM NUTR DIET, V5, P41; WHEATLEY C, 1994, MED INT, V22, P407; Wilcock H, 1991, Health Trends, V23, P93; WOOD S, 1994, MED INT, V22, P406; 1994, STATISTICAL YB 1994, P216; IN PRESS CLIN NUTR S, V1; 1993, 1985 1991 OL F ANN R; 1988, NUTR CLIN PRACTICE, V5, P202; 1992, POSITIVE APPROACH TR; 1992, 1985 1990 OL F ANN R	45	57	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1345	1349		10.1016/S0140-6736(95)92541-4	http://dx.doi.org/10.1016/S0140-6736(95)92541-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752759				2022-12-28	WOS:A1995RA14800012
J	POST, JC; PRESTON, RA; AUL, JJ; LARKINSPETTIGREW, M; RYDQUISTWHITE, J; ANDERSON, KW; WADOWSKY, RM; REAGAN, DR; WALKER, ES; KINGSLEY, LA; MAGIT, AE; EHRLICH, GD				POST, JC; PRESTON, RA; AUL, JJ; LARKINSPETTIGREW, M; RYDQUISTWHITE, J; ANDERSON, KW; WADOWSKY, RM; REAGAN, DR; WALKER, ES; KINGSLEY, LA; MAGIT, AE; EHRLICH, GD			MOLECULAR ANALYSIS OF BACTERIAL PATHOGENS IN OTITIS-MEDIA WITH EFFUSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ENZYMATIC AMPLIFICATION; HAEMOPHILUS-INFLUENZAE; WHIPPLES-DISEASE; RIBOSOMAL DNA; IDENTIFICATION; ANTIBIOTICS; SEQUENCES; INVITRO	Objective.-To determine if the polymerase chain reaction (PCR) can detect bacterial DNA in pediatric middle ear effusions that are sterile by standard cultural methods. Design.-Single-center, blinded, comparative study of diagnostic assays. The PCR-based detection systems for Moraxella catarrhalis, Haemophilus influenzae, and Streptococcus pneumoniae were designed and validated using a battery of DNAs obtained from cultured bacteria. Chronic middle ear effusion specimens were collected and comparatively analyzed by culture and the PCR. Setting.-Tertiary care pediatric hospital. Patients.-A total of 97 middle ear effusions were collected from pediatric outpatients at Children's Hospital of Pittsburgh (Pal during myringotomy and tube placement for chronic otitis media with effusion (duration >3 months). All patients had failed multiple courses of antimicrobial therapy and were diagnosed by a combination of validated otoscopy and tympanograms. Main Outcome Measure.-Differences in the percentage of positive test results between PCR-based assays and culture for M catarrhalis, H influenzae, and S pneumoniae. Results.-Of the 97 specimens of otitis media with effusion, 28 (28.9%) tested positive by both culture and PCR for M catarrhalis, H influenzae, or S pneumoniae, An additional 47 specimens (48%) were PCR positive/culture negative for these three bacterial species. Thus, 75 (77.3%) of the 97 specimens tested PCR positive for one or more of the three test organisms. The minimum number of bacterial genomic equivalents present in the average culture-negative ear was estimated to be greater than 10(4) based on dilutional experiments. Conclusions.-The PCR-based assay systems can detect the presence of bacterial DNA in a significant percentage of culturally sterile middle ear effusions. While this finding is not proof of an active bacterial infectious process, the large number of bacterial genomic equivalents present in the ears is suggestive of an active process.	UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT OTOLARYNGOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT MICROBIOL & INFECT DIS, PITTSBURGH, PA 15261 USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT OTOLARYNGOL, PITTSBURGH, PA 15213 USA; CHILDRENS HOSP PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15213 USA; E TENNESSEE STATE UNIV, JAMES H QUILLEN COLL MED, DEPT INTERNAL MED, JOHNSON CITY, TN 37614 USA; MT HOME VET ADM MED CTR, JOHNSON CITY, TN USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; East Tennessee State University				Kingsley, Lawrence/0000-0002-7000-8556; Ehrlich, Garth/0000-0003-1140-6594	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002148] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00084] Funding Source: Medline; NIDCD NIH HHS [DC02148] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; BHAGAVATI S, 1988, NEW ENGL J MED, V318, P1141, DOI 10.1056/NEJM198805053181801; BLUESTONE CD, 1992, OTOLARYNG HEAD NECK, V106, P2, DOI 10.1177/019459989210600103; Bluestone CD., 2007, OTITIS MEDIA INFANTS, V4th; DAVIS BD, 1990, MICROBIOLOGY, P65; DEMARIA TF, 1984, RECENT ADV OTITIS ME, P123; DOWSON CG, 1990, P NATL ACAD SCI USA, V87, P5858, DOI 10.1073/pnas.87.15.5858; EHRLICH G D, 1991, Clinical Microbiology Newsletter, V13, P149, DOI 10.1016/0196-4399(91)90060-9; EHRLICH GD, 1989, BLOOD, V74, P1658; EHRLICH GD, 1990, PCR PROTOCOLS GUIDE, P325; EHRLICH GD, 1993, PCR BASED DIAGNOSTIC, P415; FRY NK, 1991, FEMS MICROBIOL LETT, V83, P165; GIEBINK GS, 1982, PEDIATR INFECT DIS J, V1, P98, DOI 10.1097/00006454-198203000-00007; GIEBINK GS, 1989, PEDIATR INFECT DIS J, V8, pS18; HOTOMI M, 1993, INT J PEDIATR OTORHI, V27, P119, DOI 10.1016/0165-5876(93)90127-O; HYKIN PG, 1994, J MED MICROBIOL, V40, P408, DOI 10.1099/00222615-40-6-408; KLEINMAN LC, 1994, JAMA-J AM MED ASSOC, V271, P1250, DOI 10.1001/jama.271.16.1250; KWOK S, 1987, J VIROL, V61, P1690, DOI 10.1128/JVI.61.5.1690-1694.1987; LEMARCO KL, 1984, ANN OTO RHINOL LARYN, V93, P76; LIEBLING MR, 1994, ARTHRITIS RHEUM, V37, P702, DOI 10.1002/art.1780370514; LOOS BG, 1989, INFECT IMMUN, V57, P2751, DOI 10.1128/IAI.57.9.2751-2757.1989; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; Maniatis T., 1982, MOL CLONING; MURPHY TF, 1989, PEDIATR INFECT DIS J, V8, pS75; POST JC, 1993, FEB ASS RES OT ANN M; POST JC, 1992, FEB ASS RES OT ANN M; REAGAN DR, 1992, JUN AM SOC MICR ANN; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; ROBERTS GD, 1991, MANUAL CLIN MICROBIO, P307; ROSENFELD RM, 1992, OTOLARYNG HEAD NECK, V106, P378, DOI 10.1177/019459989210600411; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHAPPERT SM, 1992, OFFICE VISITS OTITIS; SIRKO DA, 1993, PCR BASED DIAGNOSTIC, P19; STEPHENSON JS, 1993, RECENT ADV OTITIS ME, P389; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; STOOL SE, 1994, PHS AHCPR940622 US D; VANKETEL RJ, 1990, J MED MICROBIOL, V33, P271, DOI 10.1099/00222615-33-4-271; VIROLAINEN A, 1994, J CLIN MICROBIOL, V32, P2667, DOI 10.1128/JCM.32.11.2667-2670.1994; WADOWSKY RM, 1994, J CLIN MICROBIOL, V32, P1054, DOI 10.1128/JCM.32.4.1054-1057.1994; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; WILSON KH, 1990, J CLIN MICROBIOL, V28, P1942, DOI 10.1128/JCM.28.9.1942-1946.1990; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z	43	223	232	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1598	1604		10.1001/jama.273.20.1598	http://dx.doi.org/10.1001/jama.273.20.1598			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745773				2022-12-28	WOS:A1995QY54100027
J	SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C				SAINSBURY, R; HAWARD, B; RIDER, L; JOHNSTON, C; ROUND, C			INFLUENCE OF CLINICIAN WORKLOAD AND PATTERNS OF TREATMENT ON SURVIVAL FROM BREAST-CANCER	LANCET			English	Article								Chemotherapy and hormone therapy prolong disease-free and overall survival for patients with breast cancer in the clinical-trial setting, but it is not clear if this translates into a benefit on a population basis. It is also not clear if surgical caseload has any influence on survival. We used cancer-registry data from 12 861 patients with breast cancer treated in Yorkshire, UK, between 1979 and 1988, and found that patients of surgeons with higher rates of usage of chemotherapy and hormone therapy (regional mean usage 9.3%, range 0-46%) had prolonged survival. There was considerable variation in survival of breast cancer patients between surgeons, but their rate of use of chemotherapy and hormone therapy explained about 26% of this survival variation. Had the practice of the surgeons with the better outcomes been used by all treating clinicians, 5-year survival would have increased by about 4-5%, Examination of differences in survival as a function of consultant caseload demonstrated poorer results amongst those surgeons treating less than 30 new cases of breast cancer per year (risk ratio [95% CI] for treating >30 compared with <10=0.85 [0.77-0.93]). We recommend that patients with breast cancer be dealt with only by clinicians who see more than 30 new cases per year and who have a full range of treatment options available within a multidisciplinary setting.	COOKRIDGE HOSP,YORKSHIRE CANC ORG,DEPT CANC STUDIES,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,CLIN TRIALS & RES UNIT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND; COOKRIDGE HOSP,YORKSHIRE CANC ORG,YORKSHIRE CANC REGISTRY,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND	Cookridge Hospital; Cookridge Hospital; University of Leeds; Cookridge Hospital	SAINSBURY, R (corresponding author), ROYAL INFIRM,DEPT SURG,HUDDERSFIELD HD3 3EA,W YORKSHIRE,ENGLAND.							BERINO F, IN PRESS IARC SCI PU, V132; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS S, 1987, JNCI-J NATL CANCER I, V78, P471; GILLIS CR, 1991, LANCET, V337, P611, DOI 10.1016/0140-6736(91)91673-I; HENDERSON R, 1955, STAT MED, V14, P161; KRAMER S, 1984, J CLIN ONCOL, V2, P917, DOI 10.1200/JCO.1984.2.8.917; LUFT HS, 1987, HEALTH SERV RES, V22, P157; LUFT HS, 1990, HOSPITAL VOLUME PHYS; MATTHEWS HR, 1986, BRIT J SURG, V73, P621; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; MORPHET C, 1992, INTERPRETATION SMALL, P62; SAINSBURY JRC, 1995, BRIT J CANCER, V71, P1275; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT J CANCER, V70, P352, DOI 10.1038/bjc.1994.306; 1994, CONSULTATIVE DOCUMEN; 1995, MACMILLAN DIRECTORY; 1995, PROVISION BREAST SER	17	309	310	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1265	1270		10.1016/S0140-6736(95)90924-9	http://dx.doi.org/10.1016/S0140-6736(95)90924-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746056				2022-12-28	WOS:A1995QY93300008
J	ELSTON, TN; DUDLEY, JM; SHEARER, MJ; SCHEY, SA				ELSTON, TN; DUDLEY, JM; SHEARER, MJ; SCHEY, SA			VITAMIN-K PROPHYLAXIS IN HIGH-DOSE CHEMOTHERAPY	LANCET			English	Letter							PLASMA				ELSTON, TN (corresponding author), GUYS HOSP,ST THOMAS ST,LONDON SE1 9RT,ENGLAND.		Dudley, John/D-3222-2011; Shearer, Martin/GWZ-2085-2022	Dudley, John/0000-0001-9520-9699; 				ROGERS JS, 1988, J CLIN ONCOL, V6, P276, DOI 10.1200/JCO.1988.6.2.276; RUIZ MA, 1989, CANCER, V63, P643, DOI 10.1002/1097-0142(19890215)63:4<643::AID-CNCR2820630407>3.0.CO;2-J; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1245	1245		10.1016/S0140-6736(95)92031-5	http://dx.doi.org/10.1016/S0140-6736(95)92031-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739334				2022-12-28	WOS:A1995QX86100055
J	WILLIAMS, AC				WILLIAMS, AC			DOPAMINE, DYSTONIA, AND THE DEFICIENT COFACTOR	LANCET			English	Editorial Material							TETRAHYDROBIOPTERIN				WILLIAMS, AC (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM,W MIDLANDS,ENGLAND.							FINK JK, 1988, NEUROLOGY, V38, P707, DOI 10.1212/WNL.38.5.707; FURUKAWA Y, 1993, ADV NEUROL, V60, P562; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; LEWITT PA, 1986, NEUROLOGY, V36, P760, DOI 10.1212/WNL.36.6.760; LOVENBERG W, 1979, SCIENCE, V204, P624, DOI 10.1126/science.432666; NYGAARD TG, 1993, NAT GENET, V5, P386, DOI 10.1038/ng1293-386; RAJPUT AH, 1994, ANN NEUROL, V35, P396, DOI 10.1002/ana.410350405; Segawa M., 1971, SHINRYO TOKYO, V24, P667; TAKAHASHI H, 1994, ANN NEUROL, V35, P354, DOI 10.1002/ana.410350317; WILLIAMS A, 1979, LANCET, V2, P410; WILLIAMS AC, 1980, J NEUROL NEUROSUR PS, V43, P735, DOI 10.1136/jnnp.43.8.735	11	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1130	1130		10.1016/S0140-6736(95)90974-5	http://dx.doi.org/10.1016/S0140-6736(95)90974-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723542				2022-12-28	WOS:A1995QW62200006
J	FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J				FULOP, V; MOIR, JWB; FERGUSON, SJ; HAJDU, J			THE ANATOMY OF A BIFUNCTIONAL ENZYME - STRUCTURAL BASIS FOR REDUCTION OF OXYGEN TO WATER AND SYNTHESIS OF NITRIC-OXIDE BY CYTOCHROME CD(1)	CELL			English	Article							PSEUDOMONAS-AERUGINOSA; PARACOCCUS-DENITRIFICANS; THIOSPHAERA-PANTOTROPHA; PROTEIN; GENE; DEHYDROGENASE; REFINEMENT; RESOLUTION; LOCATION; SEQUENCE	Cytochrome cd(1)-nitrite reductase is a bifunctional enzyme that catalyzes the one-electron reduction of nitrite to nitric oxide and the four-electron reduction of oxygen to water. The 1.55 Angstrom crystal structure of the dimeric enzyme from Thiosphaera pantotropha is reported here. The protein was sequenced from the X-ray structure. Each subunit contains a covalent c heme with two axial His ligands (His-17, His-69) and a unique noncovalent d(1) heme ligated by Tyr-25 and His-200. The d(1) heme is the mononuclear iron center where both oxygen and nitrite reduction take place. The two types of heme are located in separate domains whose arrangement suggests a mechanism requiring domain movement during catalysis.	UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND	University of Oxford; University of Oxford	FULOP, V (corresponding author), UNIV OXFORD, MOLEC BIOPHYS LAB, REX RICHARDS BLDG, OXFORD OX1 3QU, ENGLAND.		Fulop, Vilmos/AAZ-7720-2021	Moir, James/0000-0003-2972-5235				AKEY CW, 1980, J MOL BIOL, V136, P19, DOI 10.1016/0022-2836(80)90364-2; ALEFOUNDER PR, 1980, BIOCHEM J, V192, P231, DOI 10.1042/bj1920231; ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BERGER H, 1980, BIOCHIM BIOPHYS ACTA, V622, P355, DOI 10.1016/0005-2795(80)90047-1; BLATT Y, 1979, BIOCHEMISTRY-US, V18, P2917, DOI 10.1021/bi00580a037; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRITTAIN T, 1992, EUR J BIOCHEM, V209, P793, DOI 10.1111/j.1432-1033.1992.tb17350.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHOTHIA C, 1993, STRUCTURE, V1, P217, DOI 10.1016/0969-2126(93)90010-E; DEBOER APN, 1994, ANTON LEEUW INT J G, V66, P111, DOI 10.1007/BF00871635; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HOROWITZ PM, 1982, J BIOL CHEM, V257, P9258; HUYNH BH, 1982, J BIOL CHEM, V257, P9576; JOHNSON MK, 1980, BIOCHEM J, V189, P285, DOI 10.1042/bj1890285; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; JUNGST A, 1991, MOL GEN GENET, V225, P241, DOI 10.1007/BF00269855; KUKIMOTO M, 1994, BIOCHEMISTRY-US, V33, P5246, DOI 10.1021/bi00183a030; LAM Y, 1969, BIOCHIM BIOPHYS ACTA, V180, P459, DOI 10.1016/0005-2728(69)90025-5; LUDWIG W, 1993, INT J SYST BACTERIOL, V43, P363, DOI 10.1099/00207713-43-2-363; MAKINEN MW, 1983, SCIENCE, V222, P929, DOI 10.1126/science.6415814; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; MOIR JWB, 1993, THESIS OXFORD U OXFO; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MURZIN AG, 1992, PROTEINS, V14, P191, DOI 10.1002/prot.340140206; OHSHIMA T, 1993, J FERMENT BIOENG, V76, P82, DOI 10.1016/0922-338X(93)90061-C; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; PARR SR, 1977, BIOCHEM J, V167, P447, DOI 10.1042/bj1670447; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1994, FEBS LETT, V341, P1, DOI 10.1016/0014-5793(94)80228-9; SILVESTRINI MC, 1989, FEBS LETT, V254, P33, DOI 10.1016/0014-5793(89)81004-X; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SMITH GB, 1992, APPL ENVIRON MICROB, V58, P376, DOI 10.1128/AEM.58.1.376-384.1992; SUTHERLAND J, 1986, BIOCHEM J, V233, P893, DOI 10.1042/bj2330893; TAKANO T, 1981, J MOL BIOL, V153, P95, DOI 10.1016/0022-2836(81)90529-5; TAKANO T, 1979, J MOL BIOL, V133, P185, DOI 10.1016/0022-2836(79)90257-2; TIMKOVICH R, 1985, ARCH BIOCHEM BIOPHYS, V240, P689, DOI 10.1016/0003-9861(85)90077-3; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VELLIEUX FMD, 1989, EMBO J, V8, P2171, DOI 10.1002/j.1460-2075.1989.tb08339.x; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P113; WALSH TA, 1979, BIOCHEM J, V177, P29, DOI 10.1042/bj1770029; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; XIA ZX, 1992, J BIOL CHEM, V267, P22289; YAMANAKA T, 1963, BIOCHIM BIOPHYS ACTA, V67, P379	50	255	265	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 5	1995	81	3					369	377		10.1016/0092-8674(95)90390-9	http://dx.doi.org/10.1016/0092-8674(95)90390-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736589	Bronze			2022-12-28	WOS:A1995QW89400009
J	WILSON, C; SZOSTAK, JW				WILSON, C; SZOSTAK, JW			IN-VITRO EVOLUTION OF A SELF-ALKYLATING RIBOZYME	NATURE			English	Article							RNA	RNA enzymes are postulated to have catalysed all chemical reactions in the earliest living cells. This idea is now investigated in a search for alkyl transferases from a pool of random sequence RNAs. Selection for self-biotinylation yields a transfer RNA-like ribozyme that efficiently catalyses carbon-nitrogen bond formation. Ribozymes can thus promote reactions other than those involving the RNA sugar-phosphate backbone, suggesting that RNA may be capable of a broad range of catalytic activities.	MASSACHUSETTS GEN HOSP,DEPT BIOL MOLEC,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital								ALHAKIM AH, 1988, BIOCHEM J, V251, P935, DOI 10.1042/bj2510935; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; FERSHT A, 1985, ENZYME STRUCTURE MEC, P57; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; JANDA KD, 1990, J AM CHEM SOC, V112, P1274, DOI 10.1021/ja00159a074; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; PEATTIE DA, 1979, P NATL ACAD SCI USA, V76, P1760, DOI 10.1073/pnas.76.4.1760; PRUDENTJR, 1994, SCIENCE, V264, P1924; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; WILSON C, 1992, CURR OPIN STRUC BIOL, V2, P749	19	194	208	0	18	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 27	1995	374	6525					777	782		10.1038/374777a0	http://dx.doi.org/10.1038/374777a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV315	7723823				2022-12-28	WOS:A1995QV31500035
J	INGAMELLS, S; SAUNDERS, NJ; BURGE, D				INGAMELLS, S; SAUNDERS, NJ; BURGE, D			GASTROSCHISIS AND REDUCED FETAL HEART-RATE-VARIABILITY	LANCET			English	Note								Most liveborn babies with gastroschisis do well after surgical repair, although about one-eighth of affected cases die late in utero. Our practice is to use weekly computerised cardiotocograph (CTG) analysis after week 34 of gestation in cases of gastroschisis. In a look-back at the records in 18 such singleton pregnancies, CTG showed 7 to be highly abnormal or preterminal. All but 1 of these 7 had a normal fetal heart rate. In all 7 cases, delivery was expedited. Only 1 infant had neurological sequelae, and in all the abdominal defect was successfully repaired. Monitoring of these high-risk pregnancies with serial computerised CTG may be helpful in timing delivery.	PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND									COHEN WR, 1986, CLIN OBSTET GYNECOL, V29, P73, DOI 10.1097/00003081-198603000-00011; CRAWFORD RAF, 1992, BRIT J OBSTET GYNAEC, V99, P899, DOI 10.1111/j.1471-0528.1992.tb14438.x; DAWES GS, 1991, J PERINAT MED, V19, P39, DOI 10.1515/jpme.1991.19.1-2.39; DEVRIES PA, 1980, J PEDIATR SURG, V15, P245, DOI 10.1016/S0022-3468(80)80130-8; FRIES MH, 1993, J ULTRAS MED, V12, P583; LINDHAM S, 1981, ACTA PAEDIATR SCAND, V70, P55, DOI 10.1111/j.1651-2227.1981.tb07173.x; SMITH JH, 1988, BRIT J OBSTET GYNAEC, V95, P980, DOI 10.1111/j.1471-0528.1988.tb06501.x; STREET P, 1991, AM J OBSTET GYNECOL, V165, P515, DOI 10.1016/0002-9378(91)90277-X; TORFS C, 1990, J PEDIATR-US, V116, P1, DOI 10.1016/S0022-3476(05)81637-3; VISSER GHA, 1990, AM J OBSTET GYNECOL, V162, P698, DOI 10.1016/0002-9378(90)90989-K	10	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 22	1995	345	8956					1024	1025		10.1016/S0140-6736(95)90760-2	http://dx.doi.org/10.1016/S0140-6736(95)90760-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7723500				2022-12-28	WOS:A1995QU57300012
J	LARUE, F; COLLEAU, SM; BRASSEUR, L; CLEELAND, CS				LARUE, F; COLLEAU, SM; BRASSEUR, L; CLEELAND, CS			MULTICENTER STUDY OF CANCER PAIN AND ITS TREATMENT IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objective-To describe the treatment of cancer pain in France and to evaluate the predictive factors for inadequate management. Design-Multicentre, representative cross sectional survey. Setting-20 treatment centres, including cancer centres, university hospitals, state hospitals, private clinics, and one homecare setting (in which patients are supported at home). Subjects-605 patients with cancer. Main measures-Patients rated prevalence and severity of pain and functional impairment related to pain. Doctors reported patients' cancer characteristic, performance status, pain severity, and analgesic drugs ordered. Results-57% (340/601) of patients with cancer reported pain due to their disease, and, of those with pain, 69% (224/325) rated their worst pain at a level that impaired their ability to function. 30% (84/279) were reported as receiving no drugs for their pain. Of the 270 patients in pain for whom information on treatment was available 51% (137/270) were not receiving adequate pain relief, according to an index based on the World Health Organisation's guidelines. French doctors were found to underestimate the severity of their patients' pain. Younger patients, patients without metastatic disease, patients with a better performance status, and patients who rated their pain as more severe than their doctors did were at greater risk for undertreatment of their pain. Conclusions-In the light of the high prevalence and the severity of pain among patients with cancer, the assessment and treatment of cancer pain in France remain inadequate, emphasising the need for changes in patient care.	UNIV WISCONSIN,SCH MED,PAIN RES GRP,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,WHO,COLLABORATING CTR SYMPTOM EVALUAT CANC CARE,MADISON,WI 53706; HOP AMBROISE PARE,F-92104 BOULOGNE,FRANCE	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; World Health Organization; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	LARUE, F (corresponding author), HOP INT UNIV PARIS,PAIN CONSULTAT,F-75674 PARIS,FRANCE.							Boureau F, 1988, PRATIQUE TRAITEMENT; BRASSEUR L, 1993, J PAIN SYMPTOM MANAG, V8, P412, DOI 10.1016/0885-3924(93)90066-5; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; Cleeland CS, 1991, EFFECT CANC QUALITY, P294; Cleeland CS, 1989, ISSUES PAIN MEASUREM, P391; CLELLAND CS, 1994, NEW ENGL J MED, V330, P592; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; PICHARDLEANDRI E, 1989, DOULEUR CHEZ ENFANT; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, 8632B B OFF MIN AFF; 1990, CANCER PAIN RELIEF P; 1986, SOIGNER ACCOMPAGNER; 1986, CANCER PAIN RELIEF	15	250	257	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1034	1037		10.1136/bmj.310.6986.1034	http://dx.doi.org/10.1136/bmj.310.6986.1034			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728056	Green Published			2022-12-28	WOS:A1995QV31300015
J	AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA				AGUILARBRYAN, L; NICHOLS, CG; WECHSLER, SW; CLEMENT, JP; BOYD, AE; GONZALEZ, G; HERRERASOSA, H; NGUY, K; BRYAN, J; NELSON, DA			CLONING OF THE BETA-CELL HIGH-AFFINITY SULFONYLUREA RECEPTOR - A REGULATOR OF INSULIN-SECRETION	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC B-CELLS; PROTEIN-PHOSPHORYLATION; POTASSIUM CHANNELS; GLYBURIDE ANALOG; STRUCTURAL MODEL; BINDING-SITES; HIT CELLS; ATP; MEMBRANE	Sulfonylureas are a class of drugs widely used to promote insulin secretion in the treatment of non-insulin-dependent diabetes mellitus. These drugs interact with the sulfonylurea receptor of pancreatic beta cells and inhibit the conductance of adenosine triphosphate (ATP)-dependent potassium (K-ATP) channels. Cloning of complementary DNAs for the high-affinity sulfonylurea receptor indicates that it is a member of the ATP-binding cassette or traffic ATPase superfamily with multiple membrane-spanning domains and two nucleotide binding folds. The results suggest that the sulfonylurea receptor may sense changes in ATP and ADP concentration, affect K-ATP channel activity, and thereby modulate insulin release.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Baylor College of Medicine; Washington University (WUSTL); Washington University (WUSTL)	AGUILARBRYAN, L (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Nichols, Colin/D-6336-2012		NHLBI NIH HHS [HL45742] Funding Source: Medline; NIDDK NIH HHS [DK44311, DK41898] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041898, R01DK044311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1992, J BIOL CHEM, V267, P14934; AGUILARBRYAN L, 1990, J BIOL CHEM, V265, P8218; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Ashford M. L. J, 1990, POTASSIUM CHANNELS S, P300; BERNARDI H, 1992, BIOCHEMISTRY-US, V31, P6328, DOI 10.1021/bi00142a023; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COOK DL, 1991, TRENDS NEUROSCI, V14, P411, DOI 10.1016/0166-2236(91)90033-Q; DEWEILLE JR, 1992, J BIOL CHEM, V267, P4557; DUNNE MJ, 1989, FEBS LETT, V250, P262, DOI 10.1016/0014-5793(89)80734-3; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GILON P, 1993, J BIOL CHEM, V268, P22265; HENQUIN JC, 1984, EXPERIENTIA, V40, P1043, DOI 10.1007/BF01971450; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KHAN RN, 1993, P ROY SOC B-BIOL SCI, V253, P225, DOI 10.1098/rspb.1993.0107; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAMER W, 1988, FEBS LETT, V229, P355, DOI 10.1016/0014-5793(88)81155-4; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; NELSON DA, 1992, J BIOL CHEM, V267, P14928; NICHOLS CG, 1991, BIOPHYS J, V60, P1164, DOI 10.1016/S0006-3495(91)82152-X; NIKI I, 1991, BIOCHIM BIOPHYS ACTA, V1133, P95, DOI 10.1016/0167-4889(91)90246-T; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PANTEN U, 1992, HORM METAB RES, V24, P549, DOI 10.1055/s-2007-1003387; QSHFORD ML, 1994, NATURE, V370, P456; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RONNER P, 1993, DIABETES, V42, P1760, DOI 10.2337/diabetes.42.12.1760; SCHWANSTECHER C, 1992, MOL PHARMACOL, V41, P480; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; SKEER JM, 1994, FEBS LETT, V338, P98, DOI 10.1016/0014-5793(94)80124-X; STURGESS NC, 1985, LANCET, V31, P474; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; 1991, PROGRAM MANUAL GCG P	42	1182	1218	2	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					423	426		10.1126/science.7716547	http://dx.doi.org/10.1126/science.7716547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716547				2022-12-28	WOS:A1995QU57200042
J	COLONNA, M; SAMARIDIS, J				COLONNA, M; SAMARIDIS, J			CLONING OF IMMUNOGLOBULIN-SUPERFAMILY MEMBERS ASSOCIATED WITH HLA-C AND HLA-B RECOGNITION BY HUMAN NATURAL-KILLER-CELLS	SCIENCE			English	Article							NK CLONES; ALLOANTIGEN RECOGNITION; ANTIGEN RECOGNITION; EXPRESSION; MOLECULES; SPECIFICITY; RECEPTORS; LYSIS; GENE; HETEROGENEITY	Cytotoxicity by natural killer (NK) cells is inhibited by major histocompatibility complex (MHC) class I molecules on target cells. This inhibition may be mediated by NK receptors with different MHC specificities. A family of four NK-specific complementary DNAs (cDNAs), designated NKATs (NK-associated transcripts), was identified that encoded related transmembrane proteins, characterized by an extracellular region with two or three immunoglobulin-superfamily domains and by a cytoplasmic domain with an unusual antigen receptor activation motif (ARAM). The distribution of these cDNAs was clonotypic and correlated with NK cell inhibition by particular class I alleles. Thus, NKAT cDNAs may encode receptors for class I molecules on NK cells.			COLONNA, M (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.			Colonna, Marco/0000-0001-5222-4987				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARM JP, 1991, J BIOL CHEM, V266, P15966; BARCLAY AN, 1993, LEUKOCYTE ANTIGEN FA, P64; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P7983, DOI 10.1073/pnas.89.17.7983; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; COMPTON T, 1990, PCR PROTOCOLS GUIDE, P39; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIORDA R, 1990, SCIENCE, V249, P1298, DOI 10.1126/science.2399464; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; KORNBLUTH J, 1982, J IMMUNOL, V129, P2831; LANIER LL, 1983, J IMMUNOL, V131, P1789; LARSEN CJ, 1988, LEUKEMIA, V2, P247; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LITWIN V, 1994, J EXP MED, V180, P537, DOI 10.1084/jem.180.2.537; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MALISZEWSKI CR, 1990, J EXP MED, V172, P1665, DOI 10.1084/jem.172.6.1665; MALNATI MS, 1995, SCIENCE, V267, P1016, DOI 10.1126/science.7863326; MELERO I, 1994, J IMMUNOL, V152, P1662; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; STORKUS WJ, 1991, CRIT REV IMMUNOL, V10, P393; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	33	689	725	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					405	408		10.1126/science.7716543	http://dx.doi.org/10.1126/science.7716543			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716543				2022-12-28	WOS:A1995QU57200036
J	NAVARATNAM, N; BHATTACHARYA, S; FUJINO, T; PATEL, D; JARMUZ, AL; SCOTT, J				NAVARATNAM, N; BHATTACHARYA, S; FUJINO, T; PATEL, D; JARMUZ, AL; SCOTT, J			EVOLUTIONARY ORIGINS OF APO-B MESSENGER-RNA EDITING - CATALYSIS BY A CYTIDINE DEAMINASE THAT HAS ACQUIRED A NOVEL RNA-BINDING MOTIF AT ITS ACTIVE-SITE	CELL			English	Article							B MESSENGER-RNA; SEQUENCE REQUIREMENTS; DIRECTED MUTAGENESIS; APOLIPOPROTEIN; PROTEINS; MITOCHONDRIA; SUBUNIT	The site-specific C to U editing of apolipoprotein B100 (apoB100) mRNA requires a 27 kDa protein (p27) with homology to cytidine deaminase, Here, we show that p27 is a zinc-containing deaminase, which operates catalytically like the E. coli enzyme that acts on monomeric substrate, In contrast with the bacterial enzyme that does not bind RNA, p27 interacts with its polymeric apoB mRNA substrate at AU sequences adjacent to the editing site. This interaction is necessary for editing. RNA binding is mediated through amino acid residues involved in zinc coordination, in proton shuttling, and in forming the alpha beta alpha structure that encompasses the active site. However, certain mutations that inactivate the enzyme do not affect RNA binding. Thus, RNA binding does not require a catalytically active site. The acquisition of polymeric substrate binding provides a route for the evolution of this editing enzyme from one that acts on monomeric substrates.			NAVARATNAM, N (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOLEC MED GRP,DU CANE RD,LONDON W12 0NN,ENGLAND.		Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478				BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BARNES C, 1994, BIOCHEM BIOPH RES CO, V197, P1410; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BHATTACHARYA S, 1994, TRENDS BIOCHEM SCI, V3, P105; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1991, NUCLEIC ACIDS RES, V13, P3569; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HENTZE MW, 1994, TRENDS BIOCHEM SCI, V19, P101, DOI 10.1016/0968-0004(94)90198-8; HIESEL R, 1994, P NATL ACAD SCI USA, V91, P629, DOI 10.1073/pnas.91.2.629; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; HUGHES SD, 1994, SCI SESS AM HEART AS, V67, P14; Ipata P L, 1978, Methods Enzymol, V51, P394; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maley G F, 1978, Methods Enzymol, V51, P412; MALEY GF, 1990, J BIOL CHEM, V285, P47; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOORE JT, 1993, J BIOL CHEM, V268, P2288; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; Neuhard J, 1978, Methods Enzymol, V51, P418; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; ROTHMAN K, 1978, METHOD ENZYMOL, V51, P408; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH AA, 1994, BIOCHEMISTRY-US, V33, P6468, DOI 10.1021/bi00187a012; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; WENTWORTH DF, 1978, METHOD ENZYMOL, V51, P408; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	39	155	160	1	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 21	1995	81	2					187	195		10.1016/0092-8674(95)90328-3	http://dx.doi.org/10.1016/0092-8674(95)90328-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736571	Bronze			2022-12-28	WOS:A1995QV41000007
J	PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC				PAPAVASILIOU, F; MISULOVIN, Z; SUH, HK; NUSSENZWEIG, MC			THE ROLE OF IG-BETA IN PRECURSOR B-CELL TRANSITION AND ALLELIC EXCLUSION	SCIENCE			English	Article							ANTIGEN RECEPTOR COMPLEX; T-CELL; TRANSGENIC MICE; LYMPHOCYTE-B; LIGHT-CHAIN; PRE-B; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; GENE REARRANGEMENT; IMMUNOGLOBULIN-MU	Lymphocytes express multicomponent receptor complexes that mediate diverse antigen-dependent and antigen-independent responses. Despite the central role of antigen-independent events in B cell development, little is known about the mechanisms by which they are initiated. The association between the membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta heterodimer is now shown to be essential in inducing both the transition from progenitor to precursor B cells and subsequent allelic exclusion in transgenic mice. The cytoplasmic domain of Ig beta is sufficient to induce these early antigen-independent events by a mechanism that requires conserved tyrosine residues in this protein.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI037526, R29AI033890, R01AI033890, R01AI037526] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37526, AI33890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON SJ, 1993, NATURE, V365, P552, DOI 10.1038/365552a0; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRUPP SA, 1993, J BIOL CHEM, V268, P25776; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; IGLESIAS A, 1993, EUR J IMMUNOL, V23, P2622, DOI 10.1002/eji.1830231036; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; LOVE PJ, 1994, J EXP MED, V180, P1485; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MATSUO T, 1993, J IMMUNOL, V150, P3766; METZGER H, 1992, J IMMUNOL, V149, P1477; MINAMI Y, 1987, P NATL ACAD SCI USA, V84, P2688, DOI 10.1073/pnas.84.9.2688; MITCHELL RN, 1991, J BIOL CHEM, V266, P8856; MOMBAERTS P, 1992, CELL, V66, P869; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PATEL KJ, 1993, CELL, V74, P939, DOI 10.1016/0092-8674(93)90473-4; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PFEFFER K, 1994, ANNU REV IMMUNOL, V12, P367, DOI 10.1146/annurev.immunol.12.1.367; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RETH M, 1994, CURR OPIN IMMUNOL, V12, P196; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SHINKAI Y, 1992, CELL, V66, P855; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WEGNER AMK, 1992, CELL, V68, P83; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	52	123	124	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 21	1995	268	5209					408	411		10.1126/science.7716544	http://dx.doi.org/10.1126/science.7716544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU572	7716544				2022-12-28	WOS:A1995QU57200037
J	MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A				MAIGNAN, S; GUILLOTEAU, JP; FROMAGE, N; ARNOUX, B; BECQUART, J; DUCRUIX, A			CRYSTAL-STRUCTURE OF THE MAMMALIAN GRB2 ADAPTER	SCIENCE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; SH3 DOMAINS; TYROSINE KINASES; PROTEIN; RAS	The mammalian growth factor receptor- binding protein Grb2 is an adaptor that mediates activation of guanine nucleotide exchange on Ras. Grb2 binds to the receptor through its SH2 domain and to the carboxyl-terminal domain of Son of sevenless through its two SH3 domains. It is thus a key element in the signal transduction pathway. The crystal structure of Grb2 was determined to 3.1 angstrom resolution. The asymmetric unit is composed of an embedded dimer. The interlaced junctions between the SH2 and SH3 domains bring the two adjacent faces of the SH3 domains in van der Waals contact but leave room for the binding of proline-rich peptides.	UNIV PARIS SUD, STRUCT BIOL LAB, CNRS, UNITE MIXTE RECH, F-91198 GIF SUR YVETTE, FRANCE; RHONE POULENC RORER, SERV BIOCHIM, F-94403 Vitry Sur Seine, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis								BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WITTEKIND M, 1994, BIOCHEMISTRY-US, V33, P13531, DOI 10.1021/bi00250a004; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	181	194	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 14	1995	268	5208					291	293		10.1126/science.7716522	http://dx.doi.org/10.1126/science.7716522			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716522				2022-12-28	WOS:A1995QT18500039
J	MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F				MEDA, L; CASSATELLA, MA; SZENDREI, GI; OTVOS, L; BARON, P; VILLALBA, M; FERRARI, D; ROSSI, F			ACTIVATION OF MICROGLIAL CELLS BY BETA-AMYLOID PROTEIN AND INTERFERON-GAMMA	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; NITRIC-OXIDE; NEURODEGENERATION; MACROPHAGES; CYTOKINES; INVITRO; RELEASE	ALZHEIMER'S disease is the most common cause of progressive intellectual failure(1). The lesions that develop, called senile plaques, are extracellular deposits principally composed of insoluble aggregates of beta-amyloid protein (A beta), infiltrated by reactive microglia and astrocytes(2,3). Although A beta, and a portion of it, the fragment 25-35 (A beta(25-35)), have been shown to exert a direct toxic effect on neurons(4-6), the role of microglia in such neuronal injury remains unclear(7). Here we report a synergistic effect between A beta and interferon-gamma (IFN-gamma) in triggering the production of reactive nitrogen intermediates and tumour-necrosis factor-alpha (TNF-alpha) from microglia. Furthermore, using co-culture experiments, we show that activation of microglia with IFN-gamma and A beta leads to neuronal cell injury in vitro. These findings suggest that A beta and IFN-gamma activate microglia to produce reactive nitrogen intermediates and TNF-alpha, and this may have a role in the pathogenesis of neuronal degeneration observed in ageing and Alzheimer's disease.	UNIV VERONA,INST GEN PATHOL,I-37134 VERONA,ITALY; UNIV MILAN,INST NEUROL,I-20122 MILAN,ITALY; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV FERRARA,INST GEN PATHOL,I-44100 FERRARA,ITALY	University of Verona; University of Milan; The Wistar Institute; University of Ferrara			Cassatella, M A/B-8037-2013; Ferrari, Davide/F-5644-2015; villalba, martin/N-7123-2017; villalba, martin/AAG-2604-2020	Cassatella, M A/0000-0001-7824-1806; Ferrari, Davide/0000-0002-5727-9204; villalba, martin/0000-0002-4385-4888; villalba, martin/0000-0002-4385-4888				AGRESTI C, 1991, DEV BIOL, V144, P16, DOI 10.1016/0012-1606(91)90474-H; ARANJO DM, 1992, BRAIN RES, V569, P141; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DICKSON D, 1990, Society for Neuroscience Abstracts, V16, P1267; DING AH, 1988, J IMMUNOL, V141, P2407; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HERNANDEZCASELL.T, 1993, J IMMUNOL, V151, P3999; KOWALL NW, 1991, P NATL ACAD SCI USA, V88, P7247, DOI 10.1073/pnas.88.16.7247; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; OTVOS L, 1993, EUR J BIOCHEM, V211, P249, DOI 10.1111/j.1432-1033.1993.tb19893.x; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SELKOE DJ, 1987, SCIENCE, V235, P873, DOI 10.1126/science.3544219; SHER PK, 1990, BRAIN RES BULL, V25, P697, DOI 10.1016/0361-9230(90)90045-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; VILLALBA M, 1994, J BIOL CHEM, V269, P2468; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849	27	1193	1242	1	101	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					647	650		10.1038/374647a0	http://dx.doi.org/10.1038/374647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715705				2022-12-28	WOS:A1995QT18900061
J	TANZI, RE				TANZI, RE			CLINICAL IMPLICATIONS OF BASIC RESEARCH - A PROMISING ANIMAL-MODEL OF ALZHEIMERS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TANZI, RE (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290	3	10	15	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 1	1995	332	22					1512	1513		10.1056/NEJM199506013322212	http://dx.doi.org/10.1056/NEJM199506013322212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA140	7739692				2022-12-28	WOS:A1995RA14000012
J	GRINYO, J; GROTH, C; PICHLMAYR, R; SADEK, SA; VANRENTERGHEM, Y; BEHREND, M; LUCK, R; MORESO, F; PEETERS, J; RODICIO, J; MORALES, J; ALBRECHTSEN, D; FAUCHALD, P; SADEK, S; LODGE, J; SOULILLOU, JP; CANTAROVICH, D; VANSON, W; TEGZESS, A; WAGNER, K; ERHARD, J; BRATTSTROM, C; MJORNSTEDT, L; WIESEL, M; CARL, S; NEUMAYER, HH; HAUSER, I; LANG, P; BOURGEON, B; TUFVESON, G; GANNEDAHL, G; EKBERG, H; PERSSON, N; TARANTINO, A; CAMPISE, M; THIEL, G; ZEILER, M; HENE, R; LIGTENBERG, G; MORGAN, A; RIGG, K; HOOFTMAN, L; HUTCHINSON, K				GRINYO, J; GROTH, C; PICHLMAYR, R; SADEK, SA; VANRENTERGHEM, Y; BEHREND, M; LUCK, R; MORESO, F; PEETERS, J; RODICIO, J; MORALES, J; ALBRECHTSEN, D; FAUCHALD, P; SADEK, S; LODGE, J; SOULILLOU, JP; CANTAROVICH, D; VANSON, W; TEGZESS, A; WAGNER, K; ERHARD, J; BRATTSTROM, C; MJORNSTEDT, L; WIESEL, M; CARL, S; NEUMAYER, HH; HAUSER, I; LANG, P; BOURGEON, B; TUFVESON, G; GANNEDAHL, G; EKBERG, H; PERSSON, N; TARANTINO, A; CAMPISE, M; THIEL, G; ZEILER, M; HENE, R; LIGTENBERG, G; MORGAN, A; RIGG, K; HOOFTMAN, L; HUTCHINSON, K			PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION	LANCET			English	Article							CADAVERIC RENAL-TRANSPLANTATION; ALLOGRAFT-REJECTION; TOLERANCE INDUCTION; ADULT MICE; RS-61443; TRIAL; RECIPIENTS; EPISODES; RS61443; IMPACT	Preliminary studies suggested that mycophenolate mofetil (MMF), which inhibits proliferation of T and B cells, may reduce the frequency of acute rejection after renal transplantation. Our randomised, double-blind, multicentre, placebo-controlled study compared the efficacy and safety of MMF with placebo for prevention of acute rejection episodes after first or second cadaveric renal allograft transplantation. 491 patients were enrolled; 166 were assigned placebo, 165 MMF 2 g, and 160 MMF 3 g. Patients also received cyclosporin and corticosteroids. Significantly fewer (p less than or equal to 0.001) patients had biopsy-proven rejection or withdrew early from the trial (for any reason) during the first 6 months after transplantation with MMF 2 g (30.3%) or 3 g (38.8%) than with placebo (56.0%). The corresponding percentages for biopsy-proven rejection were 17.0%, 13.8%, and 46.4%. 28.5% of MMF 2 g and 24.4% of MMF 3 g patients needed full courses of corticosteroids or antilymphocyte agents for treatment of rejection episodes in the first 6 months, compared with 51.8% of placebo recipients. By 6 months, 10.2%, 6.7%, and 8.8% of the patients in the placebo, MMF 2 g, and MMF 3 g groups, respectively, had died or lost the graft. Overall, the frequency of adverse events was similar in all treatment groups, although gastrointestinal problems, leucopenia, and opportunistic infections were more common in the MMF groups and there was a trend for more events in the 3 g than the 2 g group. MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, The 3 g dose was somewhat less well tolerated.	HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30625 HANNOVER,GERMANY; BELLVITGE HOSP,BARCELONA,SPAIN; UZ GASTHUISBERG,LOUVAIN,BELGIUM; HOSP 12 OCTUBRE,E-28041 MADRID,SPAIN; NATL HOSP,RIKSHOSP,OSLO,NORWAY; ST JAMES UNIV HOSP,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND; UNIV HOSP NANTES,NANTES,FRANCE; UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; UNIV ESSEN GESAMTHSCH,ESSEN,GERMANY; HUDDINGE HOSP,STOCKHOLM,SWEDEN; SAHLGRENS UNIV HOSP,GOTHENBURG,SWEDEN; UNIV HEIDELBERG,HEIDELBERG,GERMANY; UNIV ERLANGEN NURNBERG,NURNBERG,GERMANY; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; UNIV UPPSALA HOSP,UPPSALA,SWEDEN; UNIV HOSP MALMO,MALMO,SWEDEN; OSPED MAGGIORE,MILAN,ITALY; KANTONSSPITAL BASEL,BASEL,SWITZERLAND; UNIV UTRECHT HOSP,UTRECHT,NETHERLANDS; SYNTEX RES EUROPE,MAIDENHEAD,BERKS,ENGLAND	Hannover Medical School; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; KU Leuven; University Hospital Leuven; Hospital Universitario 12 de Octubre; University of Oslo; National Hospital Norway; Saint James's University Hospital; Nantes Universite; CHU de Nantes; University of Groningen; University of Duisburg Essen; Sahlgrenska University Hospital; Ruprecht Karls University Heidelberg; University of Erlangen Nuremberg; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Uppsala University; Uppsala University Hospital; Lund University; Skane University Hospital; Utrecht University; Utrecht University Medical Center			Zeiler, Matthias/AAC-6195-2022; Mateos, Francesc Moreso/O-6451-2016; Campise, Mariarosaria/ABF-9706-2020	Zeiler, Matthias/0000-0001-6066-6144; 				ALMOND PS, 1993, TRANSPLANTATION, V55, P752, DOI 10.1097/00007890-199304000-00013; DEIERHOI MH, 1993, TRANSPLANT P, V25, P693; DEIERHOI MH, 1993, ANN SURG, V217, P476, DOI 10.1097/00000658-199305010-00007; Fleiss JL, 1981, STAT METHODS RATES P; Gjertson D W, 1991, Clin Transpl, P225; GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013; HAO L, 1991, TRANSPLANT P, V23, P733; HAO L, 1990, TRANSPLANT P, V22, P876; Koyama H, 1992, Clin Transpl, P391; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; LINDHOLM A, 1992, TRANSPLANTATION, V54, P624, DOI 10.1097/00007890-199210000-00011; MORRIS RE, 1990, TRANSPLANT P, V22, P1659; PLATZ KP, 1991, TRANSPLANTATION, V51, P27, DOI 10.1097/00007890-199101000-00003; PLATZ KP, 1991, SURGERY, V110, P736; SALAMAN JR, 1993, TRANSPLANT P, V25, P695; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259; SOLLINGER HW, 1992, ANN SURG, V216, P513, DOI 10.1097/00000658-199210000-00014; TESI RJ, 1993, CLIN TRANSPLANT, V7, P345	18	930	953	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1321	1325						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752752				2022-12-28	WOS:A1995RA14800005
J	TONKIN, SL; DAVIS, SL; GUNN, TR				TONKIN, SL; DAVIS, SL; GUNN, TR			NASAL ROUTE FOR INFANT RESUSCITATION BY MOTHERS	LANCET			English	Article							AIRWAY	In infants under 6 months of age air normally enters the trachea by the nose because the tongue fills the oral cavity, and the oral route is open only when the infant is making muscular efforts such as crying or gasping. The present recommendation for infant resuscitation is for the resuscitator's mouth to cover the mouth and nose of the baby. We set out to test whether this recommendation is feasible. We measured the dimensions of the faces of 28 babies aged between 2 and 4 months (the age when resuscitation is most often needed) and of the mouths of 25 of their mothers. Only 2 mothers would have been able to cover with their mouths the nose and closed mouth of 2 babies (not their own). The mannequins often used to teach adults to resuscitate infants are misleading because they present a wide open mouth, thus implying that that is the preferred route. We recommend that the nasal route of air entry be taught to parents for resuscitation of babies who have stopped breathing.	UNIV AUCKLAND,AUCKLAND,NEW ZEALAND	University of Auckland	TONKIN, SL (corresponding author), NEW ZEALAND COT DEATH ASSOC,POB 28-177,AUCKLAND,NEW ZEALAND.							GUNN TR, 1989, PEDIATRICS, V84, P73; SIEBERT J R, 1991, Pediatric Pathology, V11, P813; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1988, NEW ZEAL MED J, V101, P261; WILSON SL, 1980, J APPL PHYSIOL, V48, P500, DOI 10.1152/jappl.1980.48.3.500; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1994, PUBLIC HLTH COMMISSI	7	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1353	1354		10.1016/S0140-6736(95)92543-0	http://dx.doi.org/10.1016/S0140-6736(95)92543-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752760				2022-12-28	WOS:A1995RA14800014
J	CHARACHE, S; TERRIN, ML; MOORE, RD; DOVER, GJ; BARTON, FB; ECKERT, SV; MCMAHON, RP; BONDS, DR; ORRINGER, E; JONES, S; STRAYHORN, D; ROSSE, W; PHILLIPS, G; PEACE, D; JOHNSONTELFAIR, A; MILNER, P; KUTLAR, A; TRACY, A; BALLAS, SK; ALLEN, GE; MOSHANG, J; SCOTT, B; STEINBERG, M; ANDERSON, A; SABAHI, V; PEGELOW, C; TEMPLE, D; CASE, E; HARRELL, R; CHILDERIE, S; EMBURY, S; SCHMIDT, B; DAVIES, D; KOSHY, M; TALISCHYZAHED, N; DORN, L; PENDARVIS, G; MCGEE, M; TELFER, M; DAVIS, A; CASTRO, O; FINKE, H; PERLIN, E; SITEMAN, J; GASCON, P; DIPAOLO, P; GARGIULO, S; ECKMAN, J; BAILEY, JH; PLATT, A; WALLER, L; RAMIREZ, G; KNORS, V; HERNANDEZ, S; RODRIGUEZ, EM; WILKES, E; VICHINSKY, E; CLASTER, S; EARLES, A; KLEMAN, K; MCLAUGHLIN, K; SWERDLOW, P; SMITH, W; MADDOX, B; USRY, L; BRENNER, A; WILLIAMS, K; OBRIEN, R; GENTHER, K; SHURIN, S; BERMAN, B; CHIARUCCI, K; KEVERLINE, L; OLIVIERI, N; SHAW, D; LEWIS, N; BRIDGES, K; TYNAN, B; WINOGRAD, C; BELLEVUE, R; DOSIK, H; SHEIKHAI, M; RYANS, P; SOUFFRANT, H; PRCHAL, J; BRADDOCK, J; MCARDLE, T; CARLOS, T; SCHMOTZER, A; GARDNER, D; MOORE, R; DOVER, G; BERGNER, M; EWART, C; ECKERT, S; LENT, C; ULRICH, J; FISHPAW, L; TIRADO, G; GIBSON, J; MOELLER, T; NAGEL, T; TERRIN, M; HANDY, C; HARRIS, D; CANNER, M; DEPKIN, J; MEINERT, N; CARROLL, M; GIRO, R; KARABELAS, S; KELLY, C; HEYMAN, M; BEILINSON, P; DRUSKIN, M; ELLIS, P; FLOOD, WA; KRAVITZ, S; LANZKRON, S; LORICA, V; MOLITERNO, A; NAHUM, A; NESBITT, JA; ROSENTHAL, L; SHARFMAN, W; STREIFF, M; WACHSMAN, M; BRAY, P; VANDANG, C; CASELLA, J; MCGUIRE, M; PATRICK, L; SCHAAD, H; STEINER, C; JOHNSON, C; BANK, A; CUTTER, G; DAVIS, CE; HUNTLEY, O; LESSIN, L; PLATT, O; GRAYSECUNDY, M; BONDS, D; REID, C; GELLER, H; WACLAWIW, M				CHARACHE, S; TERRIN, ML; MOORE, RD; DOVER, GJ; BARTON, FB; ECKERT, SV; MCMAHON, RP; BONDS, DR; ORRINGER, E; JONES, S; STRAYHORN, D; ROSSE, W; PHILLIPS, G; PEACE, D; JOHNSONTELFAIR, A; MILNER, P; KUTLAR, A; TRACY, A; BALLAS, SK; ALLEN, GE; MOSHANG, J; SCOTT, B; STEINBERG, M; ANDERSON, A; SABAHI, V; PEGELOW, C; TEMPLE, D; CASE, E; HARRELL, R; CHILDERIE, S; EMBURY, S; SCHMIDT, B; DAVIES, D; KOSHY, M; TALISCHYZAHED, N; DORN, L; PENDARVIS, G; MCGEE, M; TELFER, M; DAVIS, A; CASTRO, O; FINKE, H; PERLIN, E; SITEMAN, J; GASCON, P; DIPAOLO, P; GARGIULO, S; ECKMAN, J; BAILEY, JH; PLATT, A; WALLER, L; RAMIREZ, G; KNORS, V; HERNANDEZ, S; RODRIGUEZ, EM; WILKES, E; VICHINSKY, E; CLASTER, S; EARLES, A; KLEMAN, K; MCLAUGHLIN, K; SWERDLOW, P; SMITH, W; MADDOX, B; USRY, L; BRENNER, A; WILLIAMS, K; OBRIEN, R; GENTHER, K; SHURIN, S; BERMAN, B; CHIARUCCI, K; KEVERLINE, L; OLIVIERI, N; SHAW, D; LEWIS, N; BRIDGES, K; TYNAN, B; WINOGRAD, C; BELLEVUE, R; DOSIK, H; SHEIKHAI, M; RYANS, P; SOUFFRANT, H; PRCHAL, J; BRADDOCK, J; MCARDLE, T; CARLOS, T; SCHMOTZER, A; GARDNER, D; MOORE, R; DOVER, G; BERGNER, M; EWART, C; ECKERT, S; LENT, C; ULRICH, J; FISHPAW, L; TIRADO, G; GIBSON, J; MOELLER, T; NAGEL, T; TERRIN, M; HANDY, C; HARRIS, D; CANNER, M; DEPKIN, J; MEINERT, N; CARROLL, M; GIRO, R; KARABELAS, S; KELLY, C; HEYMAN, M; BEILINSON, P; DRUSKIN, M; ELLIS, P; FLOOD, WA; KRAVITZ, S; LANZKRON, S; LORICA, V; MOLITERNO, A; NAHUM, A; NESBITT, JA; ROSENTHAL, L; SHARFMAN, W; STREIFF, M; WACHSMAN, M; BRAY, P; VANDANG, C; CASELLA, J; MCGUIRE, M; PATRICK, L; SCHAAD, H; STEINER, C; JOHNSON, C; BANK, A; CUTTER, G; DAVIS, CE; HUNTLEY, O; LESSIN, L; PLATT, O; GRAYSECUNDY, M; BONDS, D; REID, C; GELLER, H; WACLAWIW, M			EFFECT OF HYDROXYUREA ON THE FREQUENCY OF PAINFUL CRISES IN SICKLE-CELL-ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL HEMOGLOBIN; KINETICS; BABOONS; DISEASE	Background. In a previous open-label study of hydroxyurea therapy, the synthesis of fetal hemoglobin increased in most patients with sickle cell anemia, with only mild myelotoxicity. By inhibiting sickling, increased levels of fetal hemoglobin might decrease the frequency of painful crises. Methods. In a double-blind, randomized clinical trial, we tested the efficacy of hydroxyurea in reducing the frequency of painful crises in adults with a history of three or more such crises per year. The trial was stopped after a mean follow-up of 21 months. Results. Among 148 men and 151 women studied at 21 clinics, the 152 patients assigned to hydroxyurea treatment had lower annual rates of crises than the 147 patients given placebo (median, 2.5 vs. 4.5 crises per year, P<0.001). The median times to the first crisis (3.0 vs. 1.5 months, P=0.01) and the second crisis (8.8 vs. 4.6 months, P<0.001) were longer with hydroxyurea treatment. Fewer patients assigned to hydroxyurea had chest syndrome (25 vs, 51, P<0.001), and fewer underwent transfusions (48 vs. 73, P=0.001). At the end of the study, the doses of hydroxyurea ranged from 0 to 35 mg per kilogram of body weight per day. Treatment with hydroxyurea did not cause any important adverse effects. Conclusions. Hydroxyurea therapy can ameliorate the clinical course of sickle cell anemia in some adults with three or more painful crises per year, Maximal tolerated doses of hydroxyurea may not be necessary to achieve a therapeutic effect. The beneficial effects of hydroxyurea do not become manifest for several months, and its use must be carefully monitored, The long-term safety of hydroxyurea in patients with sickle cell anemia is uncertain.	JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD USA; MARYLAND MED RES INST, BALTIMORE, MD 21287 USA; NHLBI, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; DUKE UNIV, DURHAM, NC USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; UNIV MISSISSIPPI, JACKSON, MS 39216 USA; UNIV MIAMI, MIAMI, FL 33152 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; UNIV ILLINOIS, CHICAGO, IL USA; MICHAEL REESE HOSP & MED CTR, CHICAGO, IL 60616 USA; HOWARD UNIV, WASHINGTON, DC 20059 USA; UNIV MED & DENT NEW JERSEY, NEWARK, NJ 07103 USA; EMORY UNIV, ATLANTA, GA 30322 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; CHILDRENS HOSP OAKLAND, OAKLAND, CA USA; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, RICHMOND, VA USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; INTERFAITH MED CTR, BROOKLYN, NY USA; UNIV ALABAMA, BIRMINGHAM, AL USA; UNIV PITTSBURGH, PITTSBURGH, PA USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; Duke University; University System of Georgia; Augusta University; Jefferson University; University of Mississippi; University of Miami; San Francisco General Hospital Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Michael Reese Hospital & Medical Center; Howard University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Emory University; Mount Sinai St. Luke's; Mount Sinai West; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Virginia Commonwealth University; Case Western Reserve University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Brigham & Women's Hospital; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Lanzkron, Sophie/AFU-9516-2022; Cutter, Gary/AAY-5392-2021; McMahon, Robert P/C-5462-2009; Vichinsky, Elliott P/F-8541-2011; Lanzkron, Sophie/AAD-7584-2022; Olivieri, Nancy/AAI-2250-2020	Lanzkron, Sophie/0000-0002-2878-0251; Cutter, Gary/0000-0002-8455-980X; Vichinsky, Elliott P/0000-0002-0500-9579; Lanzkron, Sophie/0000-0002-2878-0251; Barton, Franca/0000-0002-6628-5745	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL045692, U01HL045696] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00046] Funding Source: Medline; NHLBI NIH HHS [UO1-HL45692, UO1-HL45696] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLARD BPF, 1975, PEDIATR RES, V9, P139, DOI 10.1203/00006450-197503000-00006; ADRAGNA NC, 1994, BLOOD, V83, P553; BALLAS SK, 1989, AM J HEMATOL, V32, P104, DOI 10.1002/ajh.2830320206; Berk PD., 1995, POLYCYTHEMIA VERA MY, P166; BLOSSFELD HP, 1989, EVENT HIST ANAL STAT, P141; BOIVIN P, 1993, NOUV REV FR HEMATOL, V35, P491; CHARACHE S, 1992, BLOOD, V79, P2555; Charache S, 1990, Adv Pediatr, V37, P1; CHARACHE S, IN PRESS CONTROL CLI; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P213; DESESSO JM, 1990, REPROD TOXICOL, V4, P145, DOI 10.1016/0890-6238(90)90009-K; DESIMONE J, 1982, P NATL ACAD SCI-BIOL, V79, P4428, DOI 10.1073/pnas.79.14.4428; DOVER GJ, 1994, BLOOD, V84, P339; Draper L., 1965, MAR OBS, V35, P193, DOI 10.1002/j.1477-8696.1966.tb05176.x; DRAPER LR, 1982, J TOXICOL ENV HLTH, V10, P297; EVENSON DP, 1993, CELL PROLIFERAT, V26, P147, DOI 10.1111/j.1365-2184.1993.tb00015.x; FELLER W, 1957, INTRO PROBABILITY TH, V1, P88; FERM VH, 1966, ARCH PATHOL, V81, P174; FIENBERG SE, 1980, ANAL CROSS CLASSIFIE, P8; FRUCHTMAN SM, 1994, BLOOD, V84, pA518; GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602; HOLLAND JF, 1993, CANCER MED, V1, P698; JACKSON N, 1993, BRIT J HAEMATOL, V85, P203, DOI 10.1111/j.1365-2141.1993.tb08672.x; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI, P1; LIU DP, 1990, AM J HEMATOL, V33, P50; LORI F, 1994, SCIENCE, V266, P801, DOI 10.1126/science.7973634; LU ZH, 1994, BLOOD, V84, pA404; NOGUCHI CT, 1988, NEW ENGL J MED, V318, P96, DOI 10.1056/NEJM198801143180207; ORRINGER EP, 1991, BLOOD, V78, P212; PAPAYANNOPOULOU T, 1984, SCIENCE, V224, P617, DOI 10.1126/science.6200940; PLATT OS, 1984, J CLIN INVEST, V74, P652, DOI 10.1172/JCI111464; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; TRIADOU P, 1994, NOUV REV FR HEMATOL, V36, P367; VEITH R, 1985, BLOOD, V66, P456; VICHINSKY EP, 1994, BLOOD, V83, P124; WEICHSELBAUM RR, 1993, CANCER MED, V1, P539; WEINFELD A, 1994, EUR J HAEMATOL, V52, P134	37	1641	1682	2	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 18	1995	332	20					1317	1322		10.1056/NEJM199505183322001	http://dx.doi.org/10.1056/NEJM199505183322001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX857	7715639	Bronze			2022-12-28	WOS:A1995QX85700001
J	GIUSTI, RM; IWAMOTO, K; HATCH, EE				GIUSTI, RM; IWAMOTO, K; HATCH, EE			DIETHYLSTILBESTROL REVISITED - A REVIEW OF THE LONG-TERM HEALTH-EFFECTS	ANNALS OF INTERNAL MEDICINE			English	Review							CLEAR-CELL ADENOCARCINOMA; WOMEN EXPOSED INUTERO; GENITAL-TRACT CHANGES; FOLLOW-UP; TESTICULAR CANCER; RISK-FACTORS; YOUNG-WOMEN; BREAST-CANCER; STILBESTROL THERAPY; VAGINAL ADENOSIS	Purpose: To review the literature on the long-term health effects of exposure to diethylstilbestrol (DES) among women prescribed DES during pregnancy (DES mothers), among their children exposed in utero to the drug (DES sons and daughters) and among the progeny of these exposed sons and daughters (DES grandchildren). Data Sources: English-language articles were identified through MEDLINE and CANCERLIT searches and through review of the bibliographies of identified articles. Study Selection: All human studies relevant to longterm health effects of exposure to DES were reviewed. Data Extraction: Descriptive data on existing DES cohorts were extracted from early publications. Risk estimates for health effects were extracted from published reports. Data Synthesis: An estimated 5 to 10 million Americans received DES during pregnancy or were exposed to the drug in utero. Exposure to DES has been associated with an increased risk for breast cancer in DES mothers (relative risk, <2.0) and with a lifetime risk of clear-cell cervicovaginal cancer in DES daughters of 1/1000 to 1/10 000. The association between DES exposure and testicular cancer in DES sons remains controversial. Exposure to DES has also been linked to reproductive tract abnormalities in DES sons and daughters that consist of immune system disorders and psychosexual effects. No evidence for transgenerational effects currently exists. Recommendations for screening persons exposed to DES are reviewed. Conclusions: Further research is needed to define long-term health effects related to DES exposure. Such research would provide a basis for counseling persons exposed to DES and would further understanding of environmental and pharmacologic compounds similar to DES.			GIUSTI, RM (corresponding author), NCI, DIV CANC TREATMENT, OFF DIRECTOR, BLDG 31, ROOM 3A44, BETHESDA, MD 20892 USA.			Hatch, Elizabeth/0000-0001-7901-3928				[Anonymous], 1991, IARC MONOGR EVAL CAR, V53, P179; ASSIES J, 1991, LANCET, V337, P983, DOI 10.1016/0140-6736(91)91623-3; BARNES AB, 1980, NEW ENGL J MED, V302, P609, DOI 10.1056/NEJM198003133021105; BERAL V, 1980, BRIT MED J, V281, P1098, DOI 10.1136/bmj.281.6248.1098; BERAL V, 1981, J EPIDEMIOL COMMUN H, V35, P155, DOI 10.1136/jech.35.3.155; BERENDES HW, 1993, CONTROL CLIN TRIALS, V14, P179, DOI 10.1016/0197-2456(93)90001-T; BIBBO M, 1977, OBSTET GYNECOL, V49, P1; BIBBO M, 1975, J REPROD MED, V15, P29; BIBBO M, 1978, NEW ENGL J MED, V298, P763, DOI 10.1056/NEJM197804062981403; BLAIR PB, 1992, NIH WORKSHOP LONG TE, P30; BLAIR PB, 1981, DEV EFFECTS DIETHYLS, P167; BRACKBILL Y, 1978, LANCET, V2, P520; BROWN LM, 1986, CANCER RES, V46, P4812; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; CONLEY GR, 1983, JAMA-J AM MED ASSOC, V249, P1325, DOI 10.1001/jama.249.10.1325; COSGROVE MD, 1977, J UROLOGY, V117, P220, DOI 10.1016/S0022-5347(17)58407-4; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889; DEPUE RH, 1983, J NATL CANCER I, V71, P1151; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; DRISCOLL SG, 1980, OBSTET GYNECOL, V56, P537; ENDO S, 1994, CANCER GENET CYTOGEN, V74, P99, DOI 10.1016/0165-4608(94)90005-1; FABER K, 1990, GYNECOL ONCOL, V37, P125, DOI 10.1016/0090-8258(90)90320-K; FERGUSON JH, 1953, AM J OBSTET GYNECOL, V65, P592, DOI 10.1016/0002-9378(83)90615-4; FORD CD, 1983, GYNECOL ONCOL, V16, P400, DOI 10.1016/0090-8258(83)90168-3; FRANK AR, 1985, J REPROD MED, V30, P400; FULLER GB, 1981, J STEROID BIOCHEM, V15, P497, DOI 10.1016/0022-4731(81)90321-6; GERSHMAN ST, 1988, INT J EPIDEMIOL, V17, P738, DOI 10.1093/ije/17.4.738; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GOODMAN A, 1991, GYNECOL ONCOL, V43, P173, DOI 10.1016/0090-8258(91)90067-F; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; GREENWALD P, 1971, NEW ENGL J MED, V285, P390, DOI 10.1056/NEJM197108122850707; GUSTAVSON CR, 1991, BEHAV NEURAL BIOL, V55, P307, DOI 10.1016/0163-1047(91)90645-7; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; HANEY AF, 1992, NIH WORKSHOP LONG TE, P46; HELMERHORST TJM, 1989, AM J OBSTET GYNECOL, V161, P1191, DOI 10.1016/0002-9378(89)90662-5; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HENDERSON BE, 1973, NEW ENGL J MED, V288, P354, DOI 10.1056/NEJM197302152880708; HERBST AL, 1972, NEW ENGL J MED, V287, P1259, DOI 10.1056/NEJM197212212872501; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2; HERBST AL, 1979, AM J OBSTET GYNECOL, V135, P876, DOI 10.1016/0002-9378(79)90814-7; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERBST AL, 1990, SEMIN SURG ONCOL, V6, P343, DOI 10.1002/ssu.2980060609; HERBST AL, 1986, AM J OBSTET GYNECOL, V154, P814, DOI 10.1016/0002-9378(86)90464-3; HILL EC, 1973, AM J OBSTET GYNECOL, V116, P470, DOI 10.1016/0002-9378(73)90903-4; HINES M, 1985, HORM BEHAV, V19, P331, DOI 10.1016/0018-506X(85)90031-5; HINES M, 1982, SOC NEUR ABSTR, V8, P196; HORNSBY PP, 1994, AM J OBSTET GYNECOL, V170, P709, DOI 10.1016/S0002-9378(94)70268-3; HORWITZ RI, 1988, J CLIN EPIDEMIOL, V41, P593, DOI 10.1016/0895-4356(88)90064-9; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; KARANDE VC, 1990, FERTIL STERIL, V54, P287; KAUFMAN RH, 1980, AM J OBSTET GYNECOL, V137, P299, DOI 10.1016/0002-9378(80)90913-8; KAUFMAN RH, 1986, AM J OBSTET GYNECOL, V154, P1312, DOI 10.1016/0002-9378(86)90718-0; KAUFMAN RH, 1978, ISRAEL J MED SCI, V14, P353; LABARTHE D, 1978, OBSTET GYNECOL, V51, P453, DOI 10.1097/00006250-197804000-00014; LEARY FJ, 1984, JAMA-J AM MED ASSOC, V252, P2984, DOI 10.1001/jama.252.21.2984; LEVINE RU, 1993, AM J OBSTET GYNECOL, V169, P1125, DOI 10.1016/0002-9378(93)90267-M; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MASCARO ML, 1991, AM J LAW MED, V17, P435; MAYDL R, 1983, ENDOCRINOLOGY, V113, P146, DOI 10.1210/endo-113-1-146; MCLACHLAN JA, 1993, ENVIRON HEALTH PERSP, V101, P386, DOI 10.2307/3431891; MELNICK S, 1987, NEW ENGL J MED, V316, P514, DOI 10.1056/NEJM198702263160905; METZLER M, 1981, CRC CR REV BIOCH MOL, V10, P171, DOI 10.3109/10409238109113599; METZLER M, 1981, DEV EFFECTS DIETHYLS, P158; Morrell JA, 1941, J CLIN ENDOCRINOL, V1, P419, DOI 10.1210/jcem-1-5-419; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; NEWBOLD RR, 1985, CANCER RES, V45, P5145; NEWBOLD RR, 1987, J UROLOGY, V138, P1446, DOI 10.1016/S0022-5347(17)43672-X; NEWBOLD RR, 1993, ENVIRON HEALTH PERSP, V101, P208, DOI 10.2307/3431541; NOLLER KL, 1974, MED CLIN N AM, V58, P793, DOI 10.1016/S0025-7125(16)32122-8; NOLLER KL, 1983, AM J OBSTET GYNECOL, V146, P279, DOI 10.1016/0002-9378(83)90749-4; NOLLER KL, 1988, FERTIL STERIL, V49, P1080; NOLLER KL, 1993, OBSTET GYNECOL C MAR, P165; OBRIEN PC, 1979, OBSTET GYNECOL, V53, P300; PERESS MR, 1982, AM J OBSTET GYNECOL, V144, P135, DOI 10.1016/0002-9378(82)90613-5; ROBBOY SJ, 1982, OBSTET GYNECOL, V60, P546; ROBBOY SJ, 1981, AM J OBSTET GYNECOL, V140, P579, DOI 10.1016/0002-9378(81)90236-2; ROBBOY SJ, 1984, JAMA-J AM MED ASSOC, V252, P2979, DOI 10.1001/jama.252.21.2979; ROBBOY SJ, 1979, OBSTET GYNECOL, V53, P309; SCHOTTENFELD D, 1980, AM J EPIDEMIOL, V112, P232, DOI 10.1093/oxfordjournals.aje.a112989; SENEKJIAN EK, 1988, AM J OBSTET GYNECOL, V158, P493, DOI 10.1016/0002-9378(88)90012-9; SEOUD MAF, 1993, GYNECOL ONCOL, V50, P371, DOI 10.1006/gyno.1993.1228; SHAH HC, 1976, J PHARMACOL EXP THER, V197, P687; SHARP GB, 1990, AM J OBSTET GYNECOL, V162, P994, DOI 10.1016/0002-9378(90)91303-T; SHARP GB, 1991, AM J EPIDEMIOL, V134, P1316, DOI 10.1093/oxfordjournals.aje.a116034; SHARP GB, 1990, CANCER, V66, P2215, DOI 10.1002/1097-0142(19901115)66:10<2215::AID-CNCR2820661029>3.0.CO;2-Q; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SMITH OW, 1949, AM J OBSTET GYNECOL, V58, P994; SMITH OW, 1949, NEW ENGL J MED, V241, P562, DOI 10.1056/NEJM194910132411503; STENCHEVER MA, 1981, AM J OBSTET GYNECOL, V140, P186, DOI 10.1016/0002-9378(81)90107-1; STONE R, 1993, SCIENCE, V259, P1815; SWAN SH, 1992, NIH WORKSH LONG TERM, P42; SWYER GIM, 1953, P SOC ENDOCRINOLOGY, V10, pR6; TARTTELIN MF, 1988, BRAIN RES, V456, P271, DOI 10.1016/0006-8993(88)90227-2; TOMATIS L, 1994, JPN J CANCER RES, V85, P443, DOI 10.1111/j.1349-7006.1994.tb02378.x; TURUSOV VS, 1992, INT J CANCER, V50, P131, DOI 10.1002/ijc.2910500126; VERIDIANO NP, 1981, OBSTET GYNECOL, V58, P58; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x; WAGGONER SE, 1994, OBSTET GYNECOL, V84, P404; WALKER AH, 1988, BRIT J CANCER, V57, P418, DOI 10.1038/bjc.1988.95; WALKER BE, 1989, IARC SCI PUBL, P349; WALKER BE, 1984, J NATL CANCER I, V73, P133; WALTERS LM, 1993, REPROD TOXICOL, V7, P599, DOI 10.1016/0890-6238(93)90036-7; WAYS SC, 1987, FERTIL STERIL, V48, P193; WHITEHEAD ED, 1981, J UROLOGY, V125, P47, DOI 10.1016/S0022-5347(17)54895-8; WU CH, 1980, OBSTET GYNECOL, V55, P157; 1994, INT J GYNECOL OBSTET, V44, P184; 1971, FDA DRUG EXPERIENCE; 1955, LANCET, V269, P833	112	316	331	2	30	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					778	788		10.7326/0003-4819-122-10-199505150-00008	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717601				2022-12-28	WOS:A1995QX14700008
J	PODZAMCZER, D; SALAZAR, A; JIMENEZ, J; CONSIGLIO, E; SANTIN, M; CASANOVA, A; RUFI, G; GUDIOL, F				PODZAMCZER, D; SALAZAR, A; JIMENEZ, J; CONSIGLIO, E; SANTIN, M; CASANOVA, A; RUFI, G; GUDIOL, F			INTERMITTENT TRIMETHOPRIM-SULFAMETHOXAZOLE COMPARED WITH DAPSONE-PYRIMETHAMINE FOR THE SIMULTANEOUS PRIMARY PROPHYLAXIS OF PNEUMOCYSTIS PNEUMONIA AND TOXOPLASMOSIS IN PATIENTS INFECTED WITH HIV	ANNALS OF INTERNAL MEDICINE			English	Article						PNEUMONIA, PNEUMOCYSTIS CARINII; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOX-AZOLE COMBINATION; DAPSONE; PYRIMETHAMINE	IMMUNODEFICIENCY-VIRUS INFECTION; CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; CEREBRAL TOXOPLASMOSIS; CONTROLLED TRIAL; PREVENTION; AIDS; COTRIMOXAZOLE; ENCEPHALITIS; EFFICACY	Objective: To evaluate the efficacy and safety of two oral, intermittent drug regimens for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV infection. Design: Nonblinded randomized study: Patients received either 1) trimethoprim-sulfamethoxazole (160 mg-800 mg orally twice a day on a thrice weekly regimen) or 2) 100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly. Setting: University teaching hospital in Barcelona. Patients: 230 patients infected with HIV who had CD4 cell counts of less than 200 x 10(6)/L and who had not previously had P. carinii pneumonia or toxoplasmosis. Measurements: Clinical and biological evaluations; adverse reactions; and end points of P. carinii pneumonia, toxoplasmosis, and death. Results: After a median follow-up of 430 days, 6 (6.3%) of 96 evaluable patients receiving dapsone-pyrimethamine and 0 of 104 evaluable patients receiving trimethoprim-sulfamethoxazole developed P. carinii pneumonia (P < 0.0001). The cumulative rates of P carinii pneumonia at 12 and 24 months were 0% and 0% for patients receiving trimethoprim-sulfamethoxazole and 4% and 11% for patients receiving dapsone-pyrimethamine (Mantel-Cox, P = 0.014). However, only one episode of P. carinii pneumonia developed while patients were taking these drugs. No differences were observed for toxoplasmosis (one episode in the trimethopri m-sulfamethoxazole arm and two in the dapsone-pyrimethamine arm), with cumulative rates at 12 and 24 months of 0% and 4% for the trimethoprim-sulfamethoxazole arm and 2% and 7% for the dapsone-pyrimethamine arm (P = 0.65). Similar mortality rates were observed during follow-up (P = 0.85). Nineteen patients (9.5%) discontinued therapy with the drugs because of adverse effects: Ten were in the trimethoprim-sulfamethoxazole arm and 9 were in the dapsone-pyrimethamine arm (P = 0.95). Conclusions: Thrice-weekly trimethoprim-sulfamethoxazole is an effective and well-tolerated regimen for the simultaneous primary prophylaxis of P. carinii pneumonia and toxoplasmosis in patients infected with HIV. Twice-weekly dapsone-pyrimethamine appears to be a safe and effective alternative.			PODZAMCZER, D (corresponding author), UNIV BARCELONA, CIUTAT SANITARIA BELLVITGE, INFECT DIS SERV, C FEIXA LLARGA S-N, E-08907 BARCELONA, SPAIN.							ALLEGRA CJ, 1990, J CLIN INVEST, V85, P371, DOI 10.1172/JCI114448; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTINORI A, 1992, LANCET, V340, P788, DOI 10.1016/0140-6736(92)92326-B; BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOLAO F, 1991, 7 INT C AIDS, P252; BROUGHTON MC, 1991, ANTIMICROB AGENTS CH, V35, P1348, DOI 10.1128/AAC.35.7.1348; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CLOTET B, 1991, AIDS, V5, P601, DOI 10.1097/00002030-199105000-00024; COKER RJ, 1992, LANCET, V340, P1099, DOI 10.1016/0140-6736(92)93120-C; CUSHION MT, 1985, ANTIMICROB AGENTS CH, V28, P796, DOI 10.1128/AAC.28.6.796; DEROUIN F, 1991, ANTIMICROB AGENTS CH, V35, P252, DOI 10.1128/AAC.35.2.252; ELIASZEWICZ M, 1992, 6TH INT C AIDS, P242; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GONZALEZ AH, 1989, J ANTIMICROB CHEMOTH, V24, P19, DOI 10.1093/jac/24.1.19; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; Hardy W. D., 1994, AIDS (Philadelphia), V8, pS15, DOI 10.1097/00002030-199411004-00059; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOROWITZ HW, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90649-N; HUGHES WT, 1990, LANCET, V336, P1066, DOI 10.1016/0140-6736(90)92533-N; HUGHES WT, 1988, ANTIMICROB AGENTS CH, V32, P623, DOI 10.1128/AAC.32.5.623; JORDE UP, 1993, AIDS, V7, P355, DOI 10.1097/00002030-199303000-00008; MACGREGOR RR, 1992, AM J MED, V92, P227, DOI 10.1016/0002-9343(92)90122-R; MAY T, 1994, J ACQ IMMUN DEF SYND, V7, P457; METROKA CE, 1991, NEW ENGL J MED, V325, P737; MIRO JM, 1994, MED CLIN-BARCELONA, V102, P566; OFARRELL N, 1991, LANCET, V337, P986, DOI 10.1016/0140-6736(91)91629-9; OPRAVIL M, 1994, ANTIMICROB AGENTS CH, V38, P1197, DOI 10.1128/AAC.38.5.1197; OPRAVIL M, 1993, 33RD INT C ANT AG CH, P316; OPRAVIL M, 1993, 9TH INT C AIDS, P373; PERTEL P, 1994, CLIN INFECT DIS, V18, P630, DOI 10.1093/clinids/18.4.630; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; TORRES RA, 1993, AM J MED, V95, P573, DOI 10.1016/0002-9343(93)90352-P; WORMSER GP, 1991, ARCH INTERN MED, V151, P688, DOI 10.1001/archinte.151.4.688; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T	40	98	100	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					755	761		10.7326/0003-4819-122-10-199505150-00004	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717598				2022-12-28	WOS:A1995QX14700004
J	MUGFORD, M				MUGFORD, M			PUBLISHING ECONOMICALLY	LANCET			English	Editorial Material											MUGFORD, M (corresponding author), RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.							GERARD K, 1992, HEALTH POLICY, V21, P249, DOI 10.1016/0168-8510(92)90022-4; JEFFERSON T, 1994, HEALTH ECON, V3, P25, DOI 10.1002/hec.4730030105; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; Lundorff P, 1991, ACTA OBSTET GYN SCAN, V70, P343, DOI 10.3109/00016349109007885; Torrance GW, 1987, METHODS EC EVALUATIO; WILLIAMS A, 1974, BRIT MED BULL, V30, P252, DOI 10.1093/oxfordjournals.bmb.a071211; 1994, GUIDELINES EC EVALUA; 1994, B BOTTOMLEY WELCOMES	8	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1127	1128		10.1016/S0140-6736(95)90971-0	http://dx.doi.org/10.1016/S0140-6736(95)90971-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QW622	7723539				2022-12-28	WOS:A1995QW62200003
J	FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST				FENG, Y; ZHANG, FP; LOKEY, LK; CHASTAIN, JL; LAKKIS, L; EBERHART, D; WARREN, ST			TRANSLATIONAL SUPPRESSION BY TRINUCLEOTIDE REPEAT EXPANSION AT FMR1	SCIENCE			English	Article							FRAGILE-X-SYNDROME; EUKARYOTIC MESSENGER-RNAS; CGG-REPEAT; SECONDARY STRUCTURE; I LOCUS; INITIATION; INSTABILITY; METHYLATION; PROTEIN; GENE	Fragile X syndrome is the result of the unstable expansion of a trinucleotide repeat in the 5'-untranslated region of the FMR1 gene. Fibroblast subclones from a mildly affected patient, each containing stable FMR1 alleles with 57 to 285 CGG repeats, were shown to exhibit normal steady-state levels of FMR1 messenger RNA. However, FMR protein was markedly diminished from transcript with more than 200 repeats. Such transcripts were associated with stalled 40S ribosomal subunits. These results suggest that a structural RNA transition beyond 200 repeats impedes the linear 40S migration along the 5'-untranslated region. This results in translational inhibition by trinucleotide repeat expansion.	EMORY UNIV,SCH MED,HOWARD HUGHES MED INST,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT PEDIAT,ATLANTA,GA 30322	Emory University; Howard Hughes Medical Institute; Emory University; Emory University			Warren, Stephen T/A-2498-2012	Feng, Yue/0000-0002-7905-2182	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD020521, R01HD020521] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAIRN SB, 1988, MOL CELL BIOL, V8, P1591; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DANOFF A, 1988, J BIOL CHEM, V263, P16461; DEVRIES BBA, 1993, EUR J HUM GENET, V1, P72; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FENG Y, 1995, AM J HUM GENET, V56, P106; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HAGERMAN R, UNPUB; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST MC, 1994, HUM MOL GENET, V3, P1553, DOI 10.1093/hmg/3.9.1553; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JOLLY DJ, 1983, P NATL ACAD SCI-BIOL, V80, P477, DOI 10.1073/pnas.80.2.477; KNIGHT SJL, 1992, AM J MED GENET, V43, P217, DOI 10.1002/ajmg.1320430135; KOZAK M, 1991, GENE EXPRESSION, V1, P117; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KRUYER H, 1994, AM J HUM GENET, V54, P437; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MACDONALD ME, 1993, GENOME REARRANGEMENT, V7, pCH2; MCCONKIEROSELL A, 1993, AM J HUM GENET, V53, P800; MERENSTEIN SA, 1994, J AM ACAD CHILD PSY, V33, P1316, DOI 10.1097/00004583-199411000-00014; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; ROUSSEAU F, 1994, AM J HUM GENET, V55, P225; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STALEY L, 1993, AM J DIS CHILD, V147, P724; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; Taylor A. K., 1994, American Journal of Human Genetics, V55, pA18; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; WARREN ST, 1995, ANNU REV NEUROSCI, V18, P77, DOI 10.1146/annurev.neuro.18.1.77; WARREN ST, 1994, JAMA-J AM MED ASSOC, V271, P536, DOI 10.1001/jama.271.7.536; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	43	258	262	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					731	734		10.1126/science.7732383	http://dx.doi.org/10.1126/science.7732383			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732383				2022-12-28	WOS:A1995QW60300052
J	PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL				PARSONS, LM; FOX, PT; DOWNS, JH; GLASS, T; HIRSCH, TB; MARTIN, CC; JERABEK, PA; LANCASTER, JL			USE OF IMPLICIT MOTOR IMAGERY FOR VISUAL SHAPE-DISCRIMINATION AS REVEALED BY PET	NATURE			English	Article							CEREBRAL BLOOD-FLOW; VOLUNTARY MOVEMENTS; CORTEX; BRAIN	POSITRON emission tomography (PET) can be used to map brain regions that are active when a visual object (for example, a hand) is discriminated from its mirror form. Chronometric studies(1-3) suggest that viewers 'solve' this visual shape task by mentally modelling it as a reaching task, implicitly moving their left hand into the orientation of any left-hand stimulus (and conversely for a right-hand stimulus). Here we describe an experiment in which visual and somatic processing are dissociated by presenting right hands to the left visual field and vice versa, Frontal (motor), parietal (somatosensory) and cerebellar (sensorimotor) regions similar to those activated by actual(4,5) and imagined(6-8) movement are strongly activated, whereas primary somatosensory and motor cortices are not, We conclude that mental imagery is realized at intermediate-to-high order, modality-specific cortical systems, but does not require primary cortex and is not constrained to the perceptual systems of the presented stimuli.	UNIV TEXAS, DEPT PSYCHOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin	PARSONS, LM (corresponding author), UNIV TEXAS, HLTH SCI CTR, CTR RES IMAGING, 7703 FLOYD CURL DR, SAN ANTONIO, TX 78284 USA.		Fox, Peter/B-4725-2010; Lancaster, Jack L/F-2994-2010; Galantucci, Bruno/E-5770-2010	Fox, Peter/0000-0002-0465-2028; Parsons, Lawrence/0000-0001-7498-8742				Andersen RA, 1987, HDB PHYSL 1, VV, P483; BIEDERMAN I, 1990, INVITATION COGNITIVE, V2, P41; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; DUM RP, 1991, LIFE SCI R, V50, P383; FOX P T, 1987, Society for Neuroscience Abstracts, V13, P1433; FOX PT, 1989, J NUCL MED, V30, P141; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; GOLDBERG ME, 1990, J NEUROPHYSIOL, V64, P489, DOI 10.1152/jn.1990.64.2.489; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; Heilman KM., 1993, CLIN NEUROPSYCHOLOGY, P279; Heilman KM., 1993, INT J CLIN NEUROPSYC, V3dr edn, P141; HINTON GE, 1988, COGNITION, V30, P1, DOI 10.1016/0010-0277(88)90002-9; Johnson-Laird PN., 1989, FDN COGNITIVE SCI, P469; KOSSLYN SM, 1993, J COGNITIVE NEUROSCI, V5, P263, DOI 10.1162/jocn.1993.5.3.263; Marr D., 1982, VISION; PARSONS LM, 1994, J EXP PSYCHOL HUMAN, V20, P709, DOI 10.1037/0096-1523.20.4.709; PARSONS LM, 1987, J EXP PSYCHOL GEN, V116, P172, DOI 10.1037/0096-3445.116.2.172; PARSONS LM, 1987, COGNITIVE PSYCHOL, V19, P178, DOI 10.1016/0010-0285(87)90011-9; PERRETT DI, 1994, CARN S COGN, P33; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MJ, 1994, IMAGES MIND, V30, P90; ROLAND PE, 1982, J NEUROPHYSIOL, V48, P467, DOI 10.1152/jn.1982.48.2.467; ROLAND PE, 1980, J NEUROPHYSIOL, V43, P118, DOI 10.1152/jn.1980.43.1.118; Shepard RN., 1982, J HIST BEHAV SCI, V19, P301, DOI 10.2307/1422825; STEIN JF, 1991, BRAIN SPACE, P185; Talairach J., 1988, COPLANAR STEREOTAXIC; TANJI J, 1994, NEUROSCI RES, V19, P251, DOI 10.1016/0168-0102(94)90038-8; TARR MJ, 1995, PSYCHON B REV, V2, P55, DOI 10.3758/BF03214412; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	30	522	530	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 4	1995	375	6526					54	58		10.1038/375054a0	http://dx.doi.org/10.1038/375054a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723842				2022-12-28	WOS:A1995QW60400053
J	STURROCK, NDC; PAGE, SR; CLARKE, P; TATTERSALL, RB				STURROCK, NDC; PAGE, SR; CLARKE, P; TATTERSALL, RB			INSULIN-DEPENDENT DIABETES IN NONAGENARIANS	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIABET UNIT,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								GALE EAM, 1981, DIABETOLOGIA, V21, P25, DOI 10.1007/BF03216218; GREGORY R, 1991, DIABETIC MED, V8, P72, DOI 10.1111/j.1464-5491.1991.tb01519.x; KILVERT A, 1986, Q J MED, V60, P865; LAWRENCE RD, 1951, BRIT MED J, V1, P373, DOI 10.1136/bmj.1.4703.373; MOLBAK AG, 1994, DIABETIC MED, V11, P650, DOI 10.1111/j.1464-5491.1994.tb00327.x; TINDALL H, 1988, DIABETIC MED, V5, P533, DOI 10.1111/j.1464-5491.1988.tb01046.x; Wilson R M, 1985, Diabet Med, V2, P167	7	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 29	1995	310	6987					1117	1118		10.1136/bmj.310.6987.1117	http://dx.doi.org/10.1136/bmj.310.6987.1117			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW618	7742680	Green Published			2022-12-28	WOS:A1995QW61800020
J	WHITTLE, HC; MAINE, N; PILKINGTON, J; MENDY, M; FORTUIN, M; BUNN, J; ALLISON, L; HOWARD, C; HALL, A				WHITTLE, HC; MAINE, N; PILKINGTON, J; MENDY, M; FORTUIN, M; BUNN, J; ALLISON, L; HOWARD, C; HALL, A			LONG-TERM EFFICACY OF CONTINUING HEPATITIS-B VACCINATION IN INFANCY IN 2 GAMBIAN VILLAGES	LANCET			English	Article							TRANSMISSION; CHILDREN; VIRUS	In 1984, all non-immune children under the age of 5 years in the Gambian villages of Keneba and Manduar were vaccinated against hepatitis B virus (HBV). All children born in these villages since 1984 have been vaccinated in infancy. Despite a rapid fall in antibody concentrations, vaccine efficacy against HBV infection and chronic carriage of HBsAg has increased with time. Overall, vaccine efficacies in 1993 against HBV infection and chronic HBsAg carriage were 94.7% (95% CI 93.0-96.0) and 95.3% (91.0-97.5), respectively. Breakthrough infections in vaccinated children largely originate from chronic HBsAg carriers. Thus, we tested 261 chronic carriers for HBV DNA and e antigen. The prevalence of these markers of infectivity, and the amount of HBV DNA, decreased greatly with age. Detailed studies of breakthrough infections over two 4-year periods revealed that in the second period there were fewer than half the expected numbers of infections. Our findings suggest that in Keneba acid Manduar longterm vaccination is progressively decreasing HBV transmission by chronic carriers, since their infectivity diminishes with time.	DUNN NUTR UNIT, KENEBA, GAMBIA; GAMBIA HEPATITIS INTERVENT STUDY, BANJUL, GAMBIA; UNIV LONDON ROYAL VET COLL, DEPT PATHOL, LONDON SW1, ENGLAND	University of London; University of London Royal Veterinary College	WHITTLE, HC (corresponding author), MRC LABS, POB 273, BANJUL, GAMBIA.		Mendy, Maimuna/ABD-5038-2021					BAH E, 1990, BRIT J CANCER, V62, P647, DOI 10.1038/bjc.1990.347; Barin F, 1981, Prog Med Virol, V27, P148; COURSAGET P, 1990, COLLOQ INSE, V194, P287; COURSAGET P, 1986, LANCET, V2, P1143; EDMUNDS WJ, 1993, P ROY SOC B-BIOL SCI, V253, P197, DOI 10.1098/rspb.1993.0102; FORTUIN M, 1994, J INFECT DIS, V169, P1374, DOI 10.1093/infdis/169.6.1374; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; HALL AJ, 1989, LANCET, V1, P1057; KARTHIGESU VD, 1994, J GEN VIROL, V75, P443, DOI 10.1099/0022-1317-75-2-443; MAYANS MV, 1990, LANCET, V336, P1107, DOI 10.1016/0140-6736(90)92580-B; MCGREGOR IA, 1976, OIKOS, V27, P180, DOI 10.2307/3543897; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; WELLER IVD, 1982, J MED VIROL, V9, P273, DOI 10.1002/jmv.1890090405; WHITTLE H, 1990, J INFECT DIS, V161, P1112, DOI 10.1093/infdis/161.6.1112; WHITTLE HC, 1987, ANN TROP PAEDIATR, V7, P6, DOI 10.1080/02724936.1987.11748464; WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4; WHITTLE HC, 1983, LANCET, V1, P1203	17	112	112	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 29	1995	345	8957					1089	1092		10.1016/S0140-6736(95)90822-6	http://dx.doi.org/10.1016/S0140-6736(95)90822-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV411	7715343				2022-12-28	WOS:A1995QV41100014
J	WEISSMAN, JS; SIGLER, PB; HORWICH, AL				WEISSMAN, JS; SIGLER, PB; HORWICH, AL			FROM THE CRADLE TO THE GRAVE - RING COMPLEXES IN THE LIFE OF A PROTEIN	SCIENCE			English	Editorial Material									YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510	Yale University; Yale University	WEISSMAN, JS (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510, USA.							BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; KNOWLES JR, 1965, J THEOR BIOL, V9, P213, DOI 10.1016/0022-5193(65)90108-6; LORIMER GH, 1994, STRUCTURE, V2, P1125, DOI 10.1016/S0969-2126(94)00114-6; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RECHSTEINER M, 1993, J BIOL CHEM, V268, P60; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2	19	30	31	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					523	524		10.1126/science.7725096	http://dx.doi.org/10.1126/science.7725096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725096				2022-12-28	WOS:A1995QV40700026
J	HORTON, R				HORTON, R			THE RHETORIC OF RESEARCH	BRITISH MEDICAL JOURNAL			English	Article											HORTON, R (corresponding author), LANCET,655 AVE AMER,NEW YORK,NY 10010, USA.		Biggs, Michael A. R./B-9009-2013; Greenhalgh, Trisha/B-1825-2015	Biggs, Michael A. R./0000-0002-4411-5737; Greenhalgh, Trisha/0000-0003-2369-8088				Altman L. K., 1990, ETHICS POLICY SCI PU, P257; GOODMAN SN, 1993, 2ND P INT C PEER REV; Gross Alan G., 1990, RHETORIC SCI; Hopkins A., 1988, ENGL SPECIF PURP, V7, P113, DOI [10.1016/0889-4906(88)90029-4, DOI 10.1016/0889-4906(88)90029-4]; HORTON RC, 1995, DIFFICLT HYPERTENSIO, P265; Lawson-Tancred H.C., 1991, ART RHETORIC; Locke David Millard, 1992, SCI WRITING; Simpson P., 1993, LANGUAGE IDEOLOGY PO; 1993, LANCET, V341, P1359	9	80	89	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					985	987		10.1136/bmj.310.6985.985	http://dx.doi.org/10.1136/bmj.310.6985.985			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	QT904	7728037	Green Published			2022-12-28	WOS:A1995QT90400025
J	DEFRANCO, AL; LAW, DA				DEFRANCO, AL; LAW, DA			TYROSINE PHOSPHATASES AND THE ANTIBODY-RESPONSE	SCIENCE			English	Editorial Material							HEMATOPOIETIC-CELL PHOSPHATASE; IMMUNOGLOBULIN; RECEPTOR; LYMPHOCYTES; STIMULATION		UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	DEFRANCO, AL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BIJSTERBOSCH MK, 1985, J EXP MED, V162, P1825, DOI 10.1084/jem.162.6.1825; CHOQUET D, 1993, J CELL BIOL, V121, P355, DOI 10.1083/jcb.121.2.355; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; GOLD MR, 1994, ADV IMMUNOL, V55, P221; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; SCHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367; Schultz Leonard D., 1993, Cell, V73, P1445; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; WILSON HA, 1987, J IMMUNOL, V138, P1712; XIAO S, 1994, J BIOL CHEM, V269, P21244; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350	20	21	21	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					263	264		10.1126/science.7716518	http://dx.doi.org/10.1126/science.7716518			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716518				2022-12-28	WOS:A1995QT18500027
J	ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF				ZHAO, JH; HOGAN, EM; BEVENSEE, MO; BORON, WF			OUT-OF-EQUILIBRIUM CO2/HCO3- SOLUTIONS AND THEIR USE IN CHARACTERIZING A NEW K/HCO3 COTRANSPORTER	NATURE			English	Article							SQUID GIANT-AXONS; INTRACELLULAR-PH; MECHANISM; CELL	IN typical physiological solutions, CO2 is in equilibrium with HCO3- and H+ (CO2 + H2O reversible arrow HCO3- + H+). Because one cannot independently alter CO2 and HCO3- concentrations and pH, it is impossible to distinguish between the effects of CO2 and HCO3- on physiological processes. Here we describe a continuous-flow, rapid-mixing approach for generating out-of-equilibrium CO2/HCO3- solutions with a physiological pH and CO2 (but little HCO3-), or pH and HCO3- (but little CO2). We have exploited these out-of-equilibrium solutions to introduce HCO3- exclusively to either the outside or inside of a squid giant axon, and verify the presence of a new K/HCO3 cotransporter. The out-of-equilibrium approach could be useful in a variety of applications for independently controlling CO2 and HCO3- concentrations and pH.			ZHAO, JH (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510, USA.		Boron, Walter/ABI-1564-2020	Boron, Walter/0000-0003-4741-7287				AICKIN CC, 1994, J PHYSIOL-LONDON, V479, P301, DOI 10.1113/jphysiol.1994.sp020297; BARO I, 1989, J PHYSIOL-LONDON, V417, pP161; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1983, J GEN PHYSIOL, V81, P53, DOI 10.1085/jgp.81.1.53; BORON WF, 1983, J GEN PHYSIOL, V81, P373, DOI 10.1085/jgp.81.3.373; BRAZEAU P, 1953, AM J PHYSIOL, V175, P33, DOI 10.1152/ajplegacy.1953.175.1.33; BRINLEY FJ, 1967, J GEN PHYSIOL, V50, P2303, DOI 10.1085/jgp.50.10.2303; CABANTCHIK ZI, 1978, BIOCHIM BIOPHYS ACTA, V515, P239; DALZIEL K, 1953, BIOCHEM J, V55, P79, DOI 10.1042/bj0550079; DORMAN PJ, 1954, J CLIN INVEST, V33, P82, DOI 10.1172/JCI102874; Eigen M., 1961, Z PHYS CHEM FRANKFUR, V30, P130; FRANKENHAEUSER B, 1956, J PHYSIOL-LONDON, V131, P341, DOI 10.1113/jphysiol.1956.sp005467; GIBBONS BH, 1963, J BIOL CHEM, V238, P3502; HINKE JAM, 1967, GLASS ELECTRODES HYD, P464; HO C, 1963, J BIOL CHEM, V238, P3499; HOGAN EM, IN PRESS J GEN PHYSL; NATTIE EE, 1995, LUNG BIOL HLTH DIS, V79, P473; POCOCK G, 1992, EUR J NEUROSCI, V4, P136, DOI 10.1111/j.1460-9568.1992.tb00860.x; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSSIBERNARDI L, 1968, J BIOL CHEM, V243, P1297; ROUGHTON FJW, 1941, J AM CHEM SOC, V63, P29; THOMAS RC, 1976, NATURE, V262, P54, DOI 10.1038/262054a0	22	56	56	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					636	639		10.1038/374636a0	http://dx.doi.org/10.1038/374636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715702				2022-12-28	WOS:A1995QT18900058
J	VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C				VERNOS, I; RAATS, J; HIRANO, T; HEASMAN, J; KARSENTI, E; WYLIE, C			XKLP1, A CHROMOSOMAL XENOPUS KINESIN-LIKE PROTEIN ESSENTIAL FOR SPINDLE ORGANIZATION AND CHROMOSOME POSITIONING	CELL			English	Article							OOCYTES; SEQUENCE; INVITRO; MICROTUBULES; CYTOKERATIN; DROSOPHILA; INDUCTION; EXTRACTS; EMBRYOS; CYCLE	Xklp1 is a novel Xenopus kinesin-like protein with a motor domain at the amino terminus, nuclear localisation sequences in the stalk, and a putative zinc fingerlike sequence in the tail. It is nuclear during interphase and chromosomal during mitosis. During late anaphase, a fraction of the protein relocalizes to the spindle interzone and accumulates in the midbody during telophase. Depletion of Xklp1 protein by antisense oligo knockout in oocytes leads to defective mitosis during the first cell cycles following fertilization. The bipolarity of spindles assembled in vitro in the presence of anti-Xklp1 antibodies is unstable, and the chromosomes fail to congress on the metaphase plate.	EUROPEAN MOLEC BIOL LAB,CELL BIOPHYS PROGRAMME,D-69117 HEIDELBERG,GERMANY; UNIV MINNESOTA,SCH MED,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND	European Molecular Biology Laboratory (EMBL); University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California San Francisco	VERNOS, I (corresponding author), EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Hirano, Tatsuya/F-6008-2011; Vernos, Isabelle/C-1687-2015	Hirano, Tatsuya/0000-0002-4219-6473; Vernos, Isabelle/0000-0003-1469-9214	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; BLOOM GS, 1995, PROTEIN PROFILE, V1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FRANZ JK, 1986, P NATL ACAD SCI USA, V83, P6475, DOI 10.1073/pnas.83.17.6475; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; GORBSKY GJ, 1992, BIOESSAYS, V14, P73, DOI 10.1002/bies.950140202; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HARLOW E, 1988, ANTIBODIES LABORATOR; HEASMAN J, 1994, DEVELOPMENT, V120, P49; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1992, DEV S, V116, P119; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAZIA D, 1987, INT REV CYTOL, V100, P49; MILLER L, 1977, IN VITRO CELL DEV B, V13, P557; MURRAY AW, 1991, METHOD CELL BIOL, V36, P573; NICKLAS RB, 1985, J CELL BIOL, V100, P1, DOI 10.1083/jcb.100.1.1; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pereira Andrea, 1994, V13, P269; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; ROSENFELD R, 1993, J BIOMOL STRUCT DYN, V11, P557, DOI 10.1080/07391102.1993.10508015; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SEKINE Y, 1994, J CELL BIOL, V127, P187, DOI 10.1083/jcb.127.1.187; STELZER EHK, 1989, P SOC PHOTOOPT INSTR, V1028, P146; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; TORPEY N, 1992, NATURE, V357, P413, DOI 10.1038/357413a0; TORPEY NP, 1990, DEVELOPMENT, V110, P1185; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERNOS I, 1993, DEV BIOL, V157, P232, DOI 10.1006/dbio.1993.1127; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	42	209	212	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					117	127		10.1016/0092-8674(95)90376-3	http://dx.doi.org/10.1016/0092-8674(95)90376-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720067	Bronze			2022-12-28	WOS:A1995QR97000013
J	REDDICK, RL; MCLENDON, WW				REDDICK, RL; MCLENDON, WW			PATHOLOGY AND LABORATORY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											REDDICK, RL (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.							DATTA YH, 1994, J CLIN ONCOL, V12, P475, DOI 10.1200/JCO.1994.12.3.475; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HAMLIN WB, 1994, CLIN LAB MED, V14, P605, DOI 10.1016/S0272-2712(18)30370-6; HANDORF CR, 1994, CLIN LAB MED, V14, P539, DOI 10.1016/S0272-2712(18)30367-6; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KATZ AE, 1994, UROLOGY, V43, P765, DOI 10.1016/0090-4295(94)90132-5; MARKIN RS, 1994, AM PATHOL REV, V95, P4; NOGUCHI S, 1994, CANCER, V74, P1595, DOI 10.1002/1097-0142(19940901)74:5<1595::AID-CNCR2820740516>3.0.CO;2-L; SARKAR FH, 1993, DIAGN MOL PATHOL, V2, P210, DOI 10.1097/00019606-199303000-00029; TOMPKINS LS, 1994, J INFECT DIS, V170, P1068, DOI 10.1093/infdis/170.5.1068; WINKER MA, 1995, JAMA-J AM MED ASSOC, V273, P241, DOI 10.1001/jama.273.3.241; WOO J, 1994, CLIN LAB MED, V14, P459, DOI 10.1016/S0272-2712(18)30363-9; 1992, EMERGING INFECTIONS	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1707	1708						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752429				2022-12-28	WOS:A1995RB09700037
J	LEINUNG, MC; LIPORACE, R; MILLER, CH				LEINUNG, MC; LIPORACE, R; MILLER, CH			INDUCTION OF ADRENAL SUPPRESSION BY MEGESTROL-ACETATE IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Note							EXOGENOUS ADRENOCORTICOTROPIC HORMONE; BREAST-CANCER; MEDROXYPROGESTERONE ACETATE; CORTISOL RESPONSES; CATS; PROGESTERONE; CACHEXIA; THERAPY	Objective: To investigate the development of secondary adrenal suppression in a patient with the acquired immunodeficiency syndrome (AIDS) who was receiving megestrol acetate. Design and Patients: Case report of one patient abruptly withdrawn from long-term therapy with megestrol acetate; prospective study of four patients with AIDS who were starting therapy with megestrol acetate for cachexia. Setting: Outpatient clinic of a university hospital. Interventions: Study patients received megestrol acetate, 80 mg three times daily. Measurements: Study patients had cosyntropin-stimulation testing and oral glucose tolerance testing before and after starting therapy with megestrol acetate. Results: The patient described in the case report developed symptoms of adrenal insufficiency after withdrawal of megestrol acetate after 4 years of treatment. His basal cortisol and adrenocorticotropic hormone (ACTH) levels were low. He showed an abnormally diminished response to a short cosyntropin-stimulation test but did respond to a 3-day cosyntropin-stimulation test. The morning cortisol levels of the study patients decreased significantly (from 11.0 +/- 1.8 mu g/dL to 1.5 +/- 0.9 mu g/dL; P < 0.01), and the ACTH revels of these patients decreased to below normal (from 16.6 +/- 5.5 pg/mL to 6.3 +/- 3.3 pg/mL; P = 0.02) during treatment with megestrol acetate. Cortisol levels after administration of cosyntropin decreased significantly (from 27.3 +/- 3.3 pg/mL to 9.3 +/- 6.3 pg/mL; P = 0.01) during treatment with megestrol acetate. The results of oral glucose tolerance testing in two patients were consistent with the development of insulin resistance, and daily insulin requirements increased 10-fold in a patient who had preexisting diabetes. Conclusions: Prolonged administration of megestrol acetate can induce clinically significant secondary adrenal suppression, and abrupt withdrawal of megestrol acetate after prolonged administration can cause adrenal insufficiency.	ALBANY MED COLL, DIV HIV MED A158, ALBANY, NY 12208 USA	Albany Medical College	LEINUNG, MC (corresponding author), ALBANY MED COLL, DIV ENDOCRINOL & METAB A44, NEW SCOTLAND AVE, ALBANY, NY 12208 USA.							ALEXIEVAFIGUSCH J, 1984, EUR J CANCER CLIN ON, V20, P33, DOI 10.1016/0277-5379(84)90031-2; BRIGGS MH, 1973, STEROIDS, V22, P555, DOI 10.1016/0039-128X(73)90011-1; CHASTAIN CB, 1981, AM J VET RES, V42, P2029; HENRY K, 1992, ANN INTERN MED, V116, P53, DOI 10.7326/0003-4819-116-1-53; HUG V, 1991, BRIT J CANCER, V63, P454, DOI 10.1038/bjc.1991.105; LOPRINZI CL, 1992, MAYO CLIN PROC, V67, P1160, DOI 10.1016/S0025-6196(12)61145-8; MATHEWS JH, 1970, J CLIN ENDOCR METAB, V30, P653, DOI 10.1210/jcem-30-5-653; MCEVOY GK, 1990, AM HOSPITAL FORMULAR, P526; MIDDLETON DJ, 1987, CAN J VET RES, V51, P60; OSTER MH, 1994, ANN INTERN MED, V121, P400, DOI 10.7326/0003-4819-121-6-199409150-00002; PETERSON ME, 1987, RES VET SCI, V42, P354, DOI 10.1016/S0034-5288(18)30718-5; ROUSSEAU GG, 1973, J MOL BIOL, V79, P539, DOI 10.1016/0022-2836(73)90405-1; SCHACTER LP, 1990, SEMIN ONCOL, V17, P38; SIMINOSKI K, 1989, ANN INTERN MED, V111, P758, DOI 10.7326/0003-4819-111-9-758; SVEC F, 1980, ENDOCRINOLOGY, V107, P566, DOI 10.1210/endo-107-2-566; VANVEELEN H, 1985, CANCER TREAT REP, V69, P977; VONROENN JH, 1994, ANN INTERN MED, V121, P393, DOI 10.7326/0003-4819-121-6-199409150-00001; VONROENN JH, 1988, ANN INTERN MED, V109, P840, DOI 10.7326/0003-4819-109-10-840; WATSON ADJ, 1989, RES VET SCI, V47, P374, DOI 10.1016/S0034-5288(18)31264-5	19	83	84	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					843	845		10.7326/0003-4819-122-11-199506010-00006	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741369				2022-12-28	WOS:A1995RA13900006
J	LIU, X; ERNFORS, P; WU, H; JAENISCH, R				LIU, X; ERNFORS, P; WU, H; JAENISCH, R			SENSORY BUT NOT MOTOR-NEURON DEFICITS IN MICE LACKING NT4 AND BDNF	NATURE			English	Article							TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; RECEPTOR; TRKB; SURVIVAL	NEUROTROPHINS play important roles in neuronal survival during vertebrate development(1-3). Neurotrophin-4 (NT4), alone or in combination with brain-derived neurotrophic factor (BDNF), has been suggested to be necessary for the survival of peripheral sensory neurons and central nervous system (CNS) neurons, including motor neurons(4-16). To define the role of NT4 in vivo, we generated mice lacking NT4 by gene targeting. NT4-deficient mice were viable but exhibited a loss of sensory neurons in the nodose-petrosal and geniculate ganglia. In contrast, motor neurons of the facial nucleus and sympathetic neurons of the superior cervical ganglion were unaffected, and there was no obvious loss of dopaminergic neurons in the substantia nigra. In mice lacking both NT4 and BDNF14,15, facial motor neurons remained unaffected, whereas the loss of sensory neurons was more severe than with either mutation alone. Thus NT4 is required during development for the survival of some peripheral sensory neurons but not sympathetic or motor neurons.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT)	LIU, X (corresponding author), MIT,WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Ernfors, Patrik/0000-0002-1140-3986				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; DAVIES AM, 1993, J NEUROSCI, V13, P4961; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; FISCHER W, 1994, P NATL ACAD SCI USA, V91, P8607, DOI 10.1073/pnas.91.18.8607; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HYMAN C, 1994, J NEUROSCI, V14, P335; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1994, ANN NEUROL, V35, pS13, DOI 10.1002/ana.410350706; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KLEIN R, 1993, CELL, V75, P113, DOI 10.1016/0092-8674(93)90683-H; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	29	317	320	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 18	1995	375	6528					238	241		10.1038/375238a0	http://dx.doi.org/10.1038/375238a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY881	7746325				2022-12-28	WOS:A1995QY88100064
J	SRIDHAR, MK				SRIDHAR, MK			WHY DO PATIENTS WITH EMPHYSEMA LOSE WEIGHT	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; TUMOR-NECROSIS-FACTOR; MALNOURISHED PATIENTS		UNIV GLASGOW,DEPT HUMAN NUTR,GLASGOW G61 1BD,LANARK,SCOTLAND	University of Glasgow	SRIDHAR, MK (corresponding author), UNIV GLASGOW,DEPT RESP MED,GLASGOW G61 1BD,LANARK,SCOTLAND.							BAIN M, 1994, EUR RESPIR J, V7, P248; DEGODY I, 1994, AM J RESP CRIT CARE, V149, P1017; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; DONAHOE M, 1989, AM REV RESPIR DIS, V140, P385, DOI 10.1164/ajrccm/140.2.385; ELBORN JS, 1993, CLIN SCI, V85, P563, DOI 10.1042/cs0850563; ENGELEN MPKJ, 1994, EUR RESPIR J, V7, P1793, DOI 10.1183/09031936.94.07101793; FILLEY GF, 1968, AM J MED, V44, P26, DOI 10.1016/0002-9343(68)90234-9; FOWLER J, 1898, DISEASES LUNGS, P171; GREEN JH, 1992, CLIN SCI, V83, P109, DOI 10.1042/cs0830109; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P467; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; ROGERS RM, 1992, AM REV RESPIR DIS, V146, P1511, DOI 10.1164/ajrccm/146.6.1511; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435	13	29	31	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 13	1995	345	8959					1190	1191		10.1016/S0140-6736(95)91984-8	http://dx.doi.org/10.1016/S0140-6736(95)91984-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX861	7739302				2022-12-28	WOS:A1995QX86100002
J	LOEB, JM; OLEARY, DS				LOEB, JM; OLEARY, DS			A CALL FOR COLLABORATION IN PERFORMANCE-MEASUREMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LOEB, JM (corresponding author), JOINT COMMISS ACCREDITAT HEALTHCARE ORG,DEPT RES & EVALUAT,OAKBROOK TERRACE,IL, USA.							1995, JAMA-J AM MED ASSOC, V273, P691	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1405	1405		10.1001/jama.273.18.1405	http://dx.doi.org/10.1001/jama.273.18.1405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723143				2022-12-28	WOS:A1995QW27900005
J	COSTER, TS; KILLEEN, KP; WALDOR, MK; BEATTIE, DT; SPRIGGS, DR; KENNER, JR; TROFA, A; SADOFF, JC; MEKALANOS, JJ; TAYLOR, DN				COSTER, TS; KILLEEN, KP; WALDOR, MK; BEATTIE, DT; SPRIGGS, DR; KENNER, JR; TROFA, A; SADOFF, JC; MEKALANOS, JJ; TAYLOR, DN			SAFETY, IMMUNOGENICITY, AND EFFICACY OF LIVE ATTENUATED VIBRIO-CHOLERAE O139 VACCINE PROTOTYPE	LANCET			English	Article							BANGLADESH; RESPONSES; NON-01; SYSTEM	New vaccines are needed to prevent cholera caused by Vibrio cholerae O139. Attenuated V cholerae O139 vaccines were made by deleting multiple copies of the cholera-toxin genetic element from two virulent strains of the organism, MO10 and Al4456. The deletion mutants were further modified by insertion of a construct that encoded the B subunit of cholera toxin, thus generating strains Bengal-3 and VRI-16, A stable spontaneous nonmotile derivative of Bengal-3 was isolated end designated Bengal-15; VRI-16 is naturally non-motile. Bengal-3, Bengal-15, and VRI-16 were evaluated as oral single-dose cholera vaccine candidates in 4 volunteers each, and MO10 was given to 3 volunteers, 1 of 4 volunteers who received Bengal-3 and all 3 who received MO10 had diarrhoea, VRI-16 caused no significant symptoms but was not immunogenic. Bengal-15 produced few symptoms and was nearly as immunogenic as MO10. Subsequently, Bengal-15 was given to 10 volunteers at a dose of 10(6) colony-forming units. No volunteers had diarrhoea, and other subjective symptoms were as common in vaccinees as in 3 buffer recipients. 1 month after vaccination, 7 vaccinees, the 3 buffer recipients, and 3 unimmunised subjects were challenged with 5x10(6) colony-forming units of V cholerae O139. 5 of 6 controls had cholera-like diarrhoea, By contrast, 1 of 7 vaccinees had diarrhoea, which was mild and had a long incubation period. Vaccine protective efficacy was 83%. Our results indicate the Bengal-15 is a safe live attenuated vaccine candidate for cholera caused by the O139 serogroup.	INST VIRUS RES,CAMBRIDGE,MA; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA; WALTER REED ARMY INST RES,DEPT CLIN TRIALS,DIV COMMUN DIS & IMMUNOL,WASHINGTON,DC	Harvard University; Harvard Medical School; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	COSTER, TS (corresponding author), USA,MED RES INST INFECT DIS,DIV MED,CLIN STUDIES BRANCH,FREDERICK,MD 21702, USA.							ALBERT MJ, 1993, LANCET, V341, P704; Barua Dhiman, 1992, P1; Blake Paul A., 1994, P293; CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235; CLEMENTS ML, 1982, J INFECT DIS, V145, P465, DOI 10.1093/infdis/145.4.465; HALL RH, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92839-L; HISTATSUNE K, 1994, BIOCHEM BIOPH RES CO, V196, P1309; JOHNSON JA, 1994, INFECT IMMUN, V62, P2108, DOI 10.1128/IAI.62.5.2108-2110.1994; Levine Myron M., 1992, P285; MEKALANOS JJ, 1994, SCIENCE, V265, P1387, DOI 10.1126/science.8073279; Mekalanos John J., 1994, Current Opinion in Biotechnology, V5, P312, DOI 10.1016/0958-1669(94)90035-3; MORRIS JG, 1994, VIBRIO CHOLERAE CHOL, P95; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5; SVENNERHOLM AM, 1983, J INFECT DIS, V147, P514, DOI 10.1093/infdis/147.3.514; TAYLOR DN, 1994, J INFECT DIS, V170, P1518, DOI 10.1093/infdis/170.6.1518; WALDOR MK, 1994, P NATL ACAD SCI USA, V91, P11388, DOI 10.1073/pnas.91.24.11388; WALDOR MK, 1994, INFECT IMMUN, V62, P72, DOI 10.1128/IAI.62.1.72-78.1994; WALDOR MK, 1994, J INFECT DIS, V170, P278, DOI 10.1093/infdis/170.2.278; WALDOR MK, 1994, LANCET, V343, P1366, DOI 10.1016/S0140-6736(94)92504-6; WASHINGTON JA, 1971, APPL MICROBIOL, V22, P267, DOI 10.1128/AEM.22.3.267-269.1971	21	113	118	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					949	952						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715293				2022-12-28	WOS:A1995QT91900008
J	GREENHALGH, T; HORTON, R				GREENHALGH, T; HORTON, R			SCIENTIFIC HEADS ARE NOT TURNED BY RHETORIC - COMMENTARY	BRITISH MEDICAL JOURNAL			English	Article													Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				BUTLER D, 1995, NATURE, V373, P553; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; GORE SM, 1992, LANCET, V340, P100, DOI 10.1016/0140-6736(92)90409-V; HORTON RC, 1995, EUROPEAN SCI EDITING, V54, P3; OLSON CM, 1995, JAMA-J AM MED ASSOC, V273, P72, DOI 10.1001/jama.1995.03520250088040; SCHULZ DK, 1995, JAMA-J AM MED ASSOC, V273, P408; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, ANN INTERN MED, V121, P894	9	12	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					987	988		10.1136/bmj.310.6985.987	http://dx.doi.org/10.1136/bmj.310.6985.987			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	QT904	7728038	Green Published			2022-12-28	WOS:A1995QT90400026
J	TOWNEND, JN; LITTLER, WA				TOWNEND, JN; LITTLER, WA			CARDIAC VAGAL ACTIVITY - A TARGET FOR INTERVENTION IN HEART-DISEASE	LANCET			English	Editorial Material							CONVERTING ENZYME-INHIBITION; ACUTE MYOCARDIAL-INFARCTION; FAILURE; HYDRALAZINE; MORTALITY; TRIAL; TONE				TOWNEND, JN (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT CARDIOVASC MED,BIRMINGHAM,W MIDLANDS,ENGLAND.			Townend, Jonathan/0000-0002-5881-5806				ABLAD B, 1991, J AM COLL CARDIOL, V17, pA1545; BINKLEY PF, 1993, J AM COLL CARDIOL, V21, P655, DOI 10.1016/0735-1097(93)90098-L; BONADUCE D, 1994, CIRCULATION, V90, P108, DOI 10.1161/01.CIR.90.1.108; CASADEI B, 1993, CIRCULATION, V88, P353, DOI 10.1161/01.CIR.88.2.353; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; FARRELL TG, 1992, BRIT HEART J, V67, P129; FONAROW GC, 1992, J AM COLL CARDIOL, V19, P842, DOI 10.1016/0735-1097(92)90529-V; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LAROVERE MT, 1994, CIRCULATION, V90, P838, DOI 10.1161/01.CIR.90.2.838; LUMBERS ER, 1979, J PHYSIOL-LONDON, V294, P69, DOI 10.1113/jphysiol.1979.sp012915; MALLIANI A, 1994, BRIT HEART J, V71, P1; TOWNEND JN, IN PRESS HYPERTENSIO; WILKSTRAND J, 1992, EUR HEART J SD, V113, P111; ZUANETTI G, 1987, CIRC RES, V61, P429, DOI 10.1161/01.RES.61.3.429	16	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					937	938		10.1016/S0140-6736(95)90694-0	http://dx.doi.org/10.1016/S0140-6736(95)90694-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715289				2022-12-28	WOS:A1995QT91900004
J	GENUIS, SJ; GENUIS, SK				GENUIS, SJ; GENUIS, SK			ADOLESCENT SEXUAL INVOLVEMENT - TIME FOR PRIMARY PREVENTION	LANCET			English	Editorial Material							EDUCATION; SWEDEN; SCHOOL											BOWIE WR, 1993, CAN J OBSTET GYNECOL, V5, P399; GENUIS SJ, 1993, J SOC OBSTET GYNECOL, V15, P552; GRIFFIN GC, 1993, POSTGRAD MED, V93, P21; GULLY PR, 1992, CAN MED ASSOC J, V147, P893; HAUSSER D, 1994, PEDIATRICS, V93, P580; HERLITZ C, 1992, SCAND J SOC MED, V20, P102, DOI 10.1177/140349489202000207; HOWARD M, 1990, FAM PLANN PERSPECT, V22, P21, DOI 10.2307/2135434; KLEIN J, 1994, NEWSWEEK, V123, P29; MCKEOWN DJ, 1993, SEXUAL HLTH DATA REP; PERSSON E, 1992, GENITOURIN MED, V68, P26; POWELL MG, 1993, CAN J OBSTET GYNECOL, V5, P383; POWELL MG, 1993, TREAT FEMALE PATIENT, V7, P10; ROSENFELD WD, 1991, PEDIATR ANN, V20, P303, DOI 10.3928/0090-4481-19910601-07; STOUT JW, 1989, PEDIATRICS, V83, P375; VINCENT ML, 1987, JAMA-J AM MED ASSOC, V257, P3382, DOI 10.1001/jama.257.24.3382; 1993, PROG HUM REPROD RES, V27, P6; 1991, MMWR-MORBID MORTAL W, V39, P929	17	14	14	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					240	241		10.1016/S0140-6736(95)90229-5	http://dx.doi.org/10.1016/S0140-6736(95)90229-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QD532	7741863				2022-12-28	WOS:A1995QD53200015
J	HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T				HAKAMA, M; HOLLI, K; ISOLA, J; KALLIONIEMI, OP; KARKKAINEN, A; VISAKORPI, T; PUKKALA, E; SAARENMAA, I; GEIGER, U; IKKALA, J; NIEMINEN, T; GODENHJELM, K; KOIVULA, T			AGGRESSIVENESS OF SCREEN-DETECTED BREAST CANCERS	LANCET			English	Article							DNA FLOW-CYTOMETRY; PROGNOSTIC VALUE; MAMMOGRAPHY; EXPRESSION; FEATURES; SURVIVAL	It is not clear whether screening for breast cancer works as public hearth policy and whether early indicators of effect predict an ultimate reduction in mortality. The malignant potentials of 248 breast cancers detected by the screening service in Finland were compared with those of 490 control cancers diagnosed before the screening service was established. Aggressiveness was assessed by DNA flow cytometry and clinical status by cancer size and node involvement. After the first screening round, the results of DNA flow cytometry were the same in cancers diagnosed by screening and in controls; these findings are consistent with the hypothesis that the biological aggressiveness of breast cancer remains constant as the cancer progresses. The proportion of patients with node-negative and small T1 cancers after the first screening was higher among the screened population than among controls, indicating earliness of diagnosis among those screened. Cancers diagnosed in the first round had a low malignant potential, as indicated by the DNA flow-cytometry and by clinical stage. Lower aggressiveness of cancers found by screening than of control cancers would indicate overdiagnosis or length-biased sampling, but not earliness of diagnosis. Screening with mammography is practised as a public health policy in Finland. The results predict that the mortality reduction found in randomised trials can be repeated with a screening service.	FINNISH CANC REGISTRY, SF-00170 HELSINKI, FINLAND; TAMPERE UNIV HOSP, TAMPERE, FINLAND; UNIV TAMPERE, DEPT BIOMED SCI, SF-33101 TAMPERE, FINLAND; PIRKANMAA CANC SOC, TAMPERE, FINLAND; HATANPAA HOSP, TAMPERE, FINLAND; SATAKUNTA CANC SOC, PORI, FINLAND; KYMENLAAKSO CANC SOC, KOTKA, FINLAND	Finnish Cancer Registry; Tampere University; Tampere University Hospital; Tampere University	HAKAMA, M (corresponding author), UNIV TAMPERE, DEPT PUBL HLTH, BOX 607, SF-33101 TAMPERE, FINLAND.		Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332				CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COLE P, 1978, SCREENING CANCER REP; DAY NE, 1991, CANCER SCREENING, P391; DAY NE, 1988, SCREENING BREAST CAN; DONN AS, 1985, B CANCER, V72, P381; HAKAMA M, 1991, BRIT J CANCER, V64, P962, DOI 10.1038/bjc.1991.436; ISOLA J, 1993, J CLIN ONCOL, V11, P36, DOI 10.1200/JCO.1993.11.1.36; ISOLA J, 1992, J NATL CANCER I, V84, P874; KALLIONIEMI OP, 1991, INT J CANCER, V49, P650, DOI 10.1002/ijc.2910490504; KALLIONIEMI OP, 1991, CYTOMETRY, V12, P413, DOI 10.1002/cyto.990120506; KALLIONIEMI OP, 1988, INT J CANCER, V42, P697, DOI 10.1002/ijc.2910420511; KALLIONIEMI OP, 1988, CANCER, V62, P88; MILLER AB, 1991, CANCER SCREENING, P1; PEETERS PHM, 1989, INT J EPIDEMIOL, V18, P295, DOI 10.1093/ije/18.2.295; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; SAXEN E, 1964, ANN MED EXP BIOL FEN, V42, P1; TABAR L, 1992, LANCET, V339, P412, DOI 10.1016/0140-6736(92)90090-P; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; UYTERLINDE AM, 1991, INT J CANCER, V48, P173, DOI 10.1002/ijc.2910480204; Zelen M., 1976, BREAST CANCER TRENDS, P287	20	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					221	224						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7741862				2022-12-28	WOS:A1995QD53200009
J	ALAZRAKI, NP				ALAZRAKI, NP			NUCLEAR-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCINTIGRAPHY				ALAZRAKI, NP (corresponding author), EMORY UNIV,SCH MED,ATLANTA,GA 30322, USA.							ALEX JC, 1993, SURG ONCOL, V2, P303, DOI 10.1016/S0960-7404(06)80006-X; BAX JJ, 1993, EUR HEART J, V14, P1675, DOI 10.1093/eurheartj/14.12.1675; BERMAN DS, 1993, J AM COLL CARDIOL, V22, P1455, DOI 10.1016/0735-1097(93)90557-H; CHUA T, 1994, J AM COLL CARDIOL, V23, P1107, DOI 10.1016/0735-1097(94)90598-3; DREYFUS GD, 1994, ANN THORAC SURG, V57, P1402, DOI 10.1016/0003-4975(94)90091-4; HE ZX, 1993, J NUCL MED, V34, P1472; KHALKHALI I, 1994, J AM COLL SURGEONS, V178, P491; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; KNUUTI MJ, 1994, AM HEART J, V127, P785, DOI 10.1016/0002-8703(94)90545-2; KRAG DN, 1993, SURG ONCOL, V2, P335, DOI 10.1016/0960-7404(93)90064-6; KWEKKEBOOM DJ, 1993, EUR J NUCL MED, V20, P283; KWEKKEBOOM DJ, 1993, J NUCL MED, V34, P873; STEINBERG EH, 1993, AM J CARDIOL, V71, P1270, DOI 10.1016/0002-9149(93)90538-N; STRATMANN HG, 1993, AM J CARDIOL, V73, P647; TAYLOR A, 1995, AM J ROENTGENOL, V164, P31, DOI 10.2214/ajr.164.1.7998566; UREN RF, 1993, J NUCL MED, V34, P1435; WAHL RL, 1994, RADIOLOGY, V193, P604, DOI 10.1148/radiology.193.3.7972793	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1697	1698						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752423				2022-12-28	WOS:A1995RB09700031
J	JOYNT, RJ				JOYNT, RJ			NEUROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											JOYNT, RJ (corresponding author), UNIV ROCHESTER,601 ELMWOOD AVE,ROCHESTER,NY 14627, USA.							BIKKINA M, 1994, JAMA-J AM MED ASSOC, V272, P33, DOI 10.1001/jama.272.1.33; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; GORELICK PB, 1994, STROKE, V25, P220, DOI 10.1161/01.STR.25.1.220; GRAFFAGNINO C, 1994, ARCH NEUROL-CHICAGO, V51, P981, DOI 10.1001/archneur.1994.00540220027011; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; MOREAU T, 1994, LANCET, V344, P298, DOI 10.1016/S0140-6736(94)91339-0; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; SADOVNICK D, 1994, ARCH NEUROL-CHICAGO, V51, P1120; SCINTO LFM, 1994, SCIENCE, V266, P1051, DOI 10.1126/science.7973660; TAKAHASHI H, 1993, LANCET, V342, P1016, DOI 10.1016/0140-6736(93)92878-W; VANNIEKERK ABW, 1994, LANCET, V344, P661, DOI 10.1016/S0140-6736(94)92090-7; 1994, CAROTID ENDARTERECTO, P1; 1994, NEUROLOGY, V44, P1537	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1695	1697						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752422				2022-12-28	WOS:A1995RB09700030
J	LITWIN, MS				LITWIN, MS			UROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											LITWIN, MS (corresponding author), UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024, USA.			Litwin, Mark/0000-0002-2318-344X				BARRY MJ, 1992, J UROLOGY, V148, P1549, DOI 10.1016/S0022-5347(17)36966-5; BELLDEGRUN A, 1993, J UROLOGY, V150, P1384, DOI 10.1016/S0022-5347(17)35785-3; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLINTON JJ, 1994, JAMA-J AM MED ASSOC, V271, P1151, DOI 10.1001/jama.271.15.1151; EPSTEIN JI, 1994, JAMA-J AM MED ASSOC, V271, P368, DOI 10.1001/jama.271.5.368; GARNICK MB, 1994, SCI AM, V270, P72, DOI 10.1038/scientificamerican0494-72; HANDLEY MR, 1994, J UROLOGY, V152, P1689, DOI 10.1016/S0022-5347(17)32362-5; HERR HW, 1994, J UROLOGY, V151, P652, DOI 10.1016/S0022-5347(17)35038-3; KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P773, DOI 10.1001/jama.272.10.773; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; LITWIN MS, 1994, J UROLOGY, V152, P1680, DOI 10.1016/S0022-5347(17)32359-5; RITTMASTER RS, 1994, NEW ENGL J MED, V330, P120; ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907; WOOLF SH, 1994, J UROLOGY, V152, P1685, DOI 10.1016/S0022-5347(17)32361-3; 1994, AHCPR940582 AG HLTH	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1725	1726						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752439				2022-12-28	WOS:A1995RB09700047
J	LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK				LOTAN, R; XU, XC; LIPPMAN, SM; RO, JY; LEE, JS; LEE, JJ; HONG, WK			SUPPRESSION OF RETINOIC ACID RECEPTOR-BETA IN PREMALIGNANT ORAL LESIONS AND ITS UP-REGULATION BY ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SQUAMOUS-CELL CARCINOMA; MESSENGER-RNA LEVELS; HUMAN LUNG-CANCER; NUCLEAR RECEPTORS; VITAMIN-A; EXPRESSION; LINES; KERATINOCYTES; KERATIN-19; TISSUES	Background. Retinoids are effective in the treatment and prevention of certain human cancers. Most of their actions are thought to result from changes in gene expression mediated by nuclear retinoic acid receptors and retinoid X receptors. We conducted a study to determine whether the expression of these receptors was altered in premalignant oral lesions and, if so, whether their expression could be restored by treatment with isotretinoin. Methods. We performed in situ hybridization of retinoic acid receptors and retinoid X receptors using antisense riboprobes in specimens of oral mucosa from 7 normal subjects and specimens of premalignant oral lesions from 52 patients before treatment with isotretinoin and from 39 of the 52 patients after three months of treatment. Results. All the normal specimens expressed retinoic acid receptor-beta messenger RNA (mRNA). In contrast, retinoic acid receptor-beta mRNA was detected in only 21 of the 52 premalignant oral lesions (P = 0.003). Thirty-five of the 39 specimens available for evaluation after treatment expressed retinoic acid receptor-beta mRNA (P<0.001). All normal and premalignant specimens expressed similar levels of mRNA for retinoic acid receptor-alpha and retinoic acid receptor-gamma and the three types of retinoid X receptors, alpha, beta, and gamma. The levels of retinoic acid receptor-beta mRNA increased in the specimens from 18 of the 22 patients who had responses to isotretinoin and in 8 of the 17 specimens from the patients without responses (P = 0.04). Conclusions. The expression of retinoic acid receptor-beta mRNA is selectively lost in premalignant oral lesions and can be restored by treatment with isotretinoin. Restoration of the expression of retinoic acid receptor-beta mRNA is associated with a clinical response. Retinoic acid receptor-beta may have a role in mediating the response to retinoids and may be a useful intermediate biologic marker in trials of these agents for the prevention of oral carcinogenesis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT PATHOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT BIOMATH, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	LOTAN, R (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL 108, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.		Center, Univ of Texas-M D Anderson Cancer/AAE-8182-2019; Lee, Jack/P-7331-2019	Center, Univ of Texas-M D Anderson Cancer/0000-0001-5469-9214; Lee, Jack/0000-0002-4584-929X	NATIONAL CANCER INSTITUTE [U01CA046303, P01CA052051] Funding Source: NIH RePORTER; NCI NIH HHS [CA46303, P01 CA 52051] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTSCH D, 1992, EMBO J, V11, P2283, DOI 10.1002/j.1460-2075.1992.tb05287.x; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHIESA F, 1992, ORAL ONCOL, V28B, P97; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; CROWE DL, 1991, DIFFERENTIATION, V48, P199, DOI 10.1111/j.1432-0436.1991.tb00258.x; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FRANGIONI JV, 1994, J CELL SCI, V107, P827; GEBERT, 1992, ONCOGENE, V7, P821; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Gudas Lorraine J., 1994, P443; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Haq R, 1991, Biochem Biophys Res Commun, V180, P1137; HARNISH DC, 1990, DIFFERENTIATION, V45, P103, DOI 10.1111/j.1432-0436.1990.tb00463.x; Hong Waun Ki, 1994, P597; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KRUYT FAE, 1993, MOL ENDOCRINOL, V7, P604, DOI 10.1210/me.7.4.604; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; LIPPMAN SM, 1994, J CLIN ONCOL, V12, P851, DOI 10.1200/JCO.1994.12.4.851; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; Mangelsdorf David J., 1994, P319; MEYSKENS FL, 1994, J NATL CANCER I, V86, P539, DOI 10.1093/jnci/86.7.539; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MORRISSKAY G, 1992, CANCER SURV, V14, P181; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; VERMA AK, 1992, J NUTR, V122, P2144, DOI 10.1093/jn/122.11.2144; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Woolson R. F, 1987, STATISTICAL METHODS; XU XC, 1994, DIAGN MOL PATHOL, V3, P122, DOI 10.1097/00019606-199406000-00009; XU XC, 1994, CANCER RES, V54, P3580	43	369	372	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1405	1410		10.1056/NEJM199505253322103	http://dx.doi.org/10.1056/NEJM199505253322103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723796	Bronze			2022-12-28	WOS:A1995QY94100003
J	WARLOW, C				WARLOW, C			ENDARTERECTOMY FOR ASYMPTOMATIC CAROTID STENOSIS	LANCET			English	Editorial Material							POPULATION; PREVALENCE; BRUIT				WARLOW, C (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP NHS TRUST,DEPT CLIN NEUROSCI,EDINBURGH,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1992, Mayo Clin Proc, V67, P513; CLAGETT GP, 1984, SURGERY, V96, P823; HALLIDAY AW, 1994, EUR J VASCULAR SURG, V8, P703; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; LAGNEAU P, 1993, J MAL VASCUL, V18, P209; MEISSNER I, 1987, JAMA-J AM MED ASSOC, V258, P2704; MITCHELL J R, 1962, Br Med J, V1, P1293; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; PRATI P, 1992, STROKE, V23, P1705, DOI 10.1161/01.STR.23.12.1705; RICCI S, 1991, CEREBROVASC DIS, V1, P16, DOI 10.1159/000108810; ROTHWELL PM, 1994, STROKE, V25, P2435, DOI 10.1161/01.STR.25.12.2435; WIEBERS DO, 1990, STROKE, V21, P984, DOI 10.1161/01.STR.21.7.984; 1991, LANCET, V337, P1235; 1995, JAMA-J AM MED ASSOC, V273, P1421; 1995, LANCET, V345, P209; 1991, STROKE, V22, P1229; 1993, MANAGEMENT PATIENTS; 1991, NEW ENGL J MED, V325, P445	19	68	69	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1254	1255		10.1016/S0140-6736(95)90920-6	http://dx.doi.org/10.1016/S0140-6736(95)90920-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746052				2022-12-28	WOS:A1995QY93300004
J	DESTAFANO, F				DESTAFANO, F			EFFECTS OF AGENT-ORANGE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VIETNAM VETERANS; ADIPOSE-TISSUE; DIBENZOFURANS; DIOXINS				DESTAFANO, F (corresponding author), MARSHFIELD MED RES & EDUC FDN,MARSHFIELD,WI 54449, USA.							ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; KAHN PC, 1988, JAMA-J AM MED ASSOC, V259, P1661, DOI 10.1001/jama.259.11.1661; KANG HK, 1991, AM J PUBLIC HEALTH, V81, P344, DOI 10.2105/AJPH.81.3.344; SCHECTER A, 1987, 7TH INT S CHLOR DIOX; WOLFE WH, 1990, JAMA-J AM MED ASSOC, V264, P1824, DOI 10.1001/jama.264.14.1824; 1988, JAMA-J AM MED ASSOC, V259, P2715; 1989, HLTH STATUS VIETNAM, V2; 1990, ARCH INTERN MED, V150, P2495; 1988, JAMA-J AM MED ASSOC, V259, P2708; 1990, ARCH INTERN MED, V150, P2485; 1990, ARCH INTERN MED, V150, P2473; 1988, JAMA-J AM MED ASSOC, V260, P1249; 1987, JAMA-J AM MED ASSOC, V257, P790; 1988, JAMA-J AM MED ASSOC, V259, P2701	15	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1494	1494		10.1001/jama.273.19.1494	http://dx.doi.org/10.1001/jama.273.19.1494			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739073				2022-12-28	WOS:A1995QX41800029
J	NASH, IS; PASTERNAK, RC				NASH, IS; PASTERNAK, RC			PHYSICIAN, EDUCATE THYSELF	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL-EDUCATION; COMMISSION; REFORM		MASSACHUSETTS GEN HOSP, DEPT MED, CARDIAC UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School								EBERT RH, 1981, NEW ENGL J MED, V305, P1343, DOI 10.1056/NEJM198111263052211; ENARSON C, 1992, JAMA-J AM MED ASSOC, V268, P1141, DOI 10.1001/jama.268.9.1141; IGLEHART JK, 1994, NEW ENGL J MED, V330, P1167, DOI 10.1056/NEJM199404213301628; IGLEHART JK, 1993, NEW ENGL J MED, V329, P1593, DOI 10.1056/NEJM199311183292129; MARINO BS, 1994, HLTH CARE POLICY HAR; MARSTON RQ, 1992, JAMA-J AM MED ASSOC, V268, P1144; NORTON EC, 1994, JAMA-J AM MED ASSOC, V271, P1520, DOI 10.1001/jama.271.19.1520; ONEIL EH, 1992, JAMA-J AM MED ASSOC, V268, P1146, DOI 10.1001/jama.268.9.1146; THIER SO, 1994, ACAD MED, V69, P185, DOI 10.1097/00001888-199403000-00003; WEINER J, 1994, JAMA-J AM MED ASSOC, V271, P1525, DOI 10.1001/jama.271.19.1525	10	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1533	1534		10.1001/jama.273.19.1533	http://dx.doi.org/10.1001/jama.273.19.1533			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739081				2022-12-28	WOS:A1995QX41800037
J	VLADECK, BC				VLADECK, BC			MANAGED CARE AND QUALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.							1994, JAMA-J AM MED ASSOC, V271, P1896	1	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1483	1483		10.1001/jama.273.19.1483	http://dx.doi.org/10.1001/jama.273.19.1483			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX418	7739057				2022-12-28	WOS:A1995QX41800003
J	BLACKSTONE, M				BLACKSTONE, M			COLORECTAL ADENOMAS ON FOLLOW-UP COLONOSCOPY - IS THE CANCER RISK UNCHANGED	LANCET			English	Editorial Material							POLYPS				BLACKSTONE, M (corresponding author), UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; HOFF G, 1986, SCAND J GASTROENTERO, V21, P853, DOI 10.3109/00365528609011130; NEUGUT AI, 1995, GASTROENTEROLOGY, V108, P402, DOI 10.1016/0016-5085(95)90066-7; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701	7	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1126	1127		10.1016/S0140-6736(95)90970-2	http://dx.doi.org/10.1016/S0140-6736(95)90970-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723538				2022-12-28	WOS:A1995QW62200002
J	EVERED, D; LAZAR, P				EVERED, D; LAZAR, P			MISCONDUCT IN MEDICAL-RESEARCH	LANCET			English	Editorial Material									INSERM,F-75654 PARIS 13,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)								1988, GUIDELINES INVESTIGA; 1991, 111397688EN FINAL CO; 1991, BRIT MED J, V302, P388	3	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1161	1162		10.1016/S0140-6736(95)90984-2	http://dx.doi.org/10.1016/S0140-6736(95)90984-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723552				2022-12-28	WOS:A1995QW62200016
J	MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T				MA, JKC; HIATT, A; HEIN, M; VINE, ND; WANG, F; STABILA, P; VANDOLLEWEERD, C; MOSTOV, K; LEHNER, T			GENERATION AND ASSEMBLY OF SECRETORY ANTIBODIES IN PLANTS	SCIENCE			English	Article							LOCAL PASSIVE-IMMUNIZATION; IMMUNOGLOBULIN-A; MONOCLONAL-ANTIBODIES; STREPTOCOCCUS-MUTANS; EPITHELIAL TRANSPORT; MUCOSAL IMMUNITY; J-CHAIN; IGA; EXPRESSION; COMPONENT	Four transgenic Nicotiana tabacum plants were generated that expressed a murine monoclonal antibody kappa chain, a hybrid immunoglobulin A-G heavy chain, a murine joining chain, and a rabbit secretory component, respectively. Successive sexual crosses between these plants and filial recombinants resulted in plants that expressed all four protein chains simultaneously. These chains were assembled into a functional, high molecular weight secretory immunoglobulin that recognized the native streptococcal antigen I/II cell surface adhesion molecule. In plants, single cells are able to assemble secretory antibodies, whereas two different cell types are required in mammals. Transgenic plants may be suitable for large-scale production of recombinant secretory immunoglobulin A for passive mucosal immunotherapy. Plant cells also possess the requisite mechanisms for assembly and expression of other complex recombinant protein molecules.	PLANET BIOTECHNOL, SAN DIEGO, CA 92121 USA; Scripps Res Inst, DEPT CELL BIOL, DIV PLANT BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	MA, JKC (corresponding author), UNITED MED & DENT SCH, GUYS HOSP, DEPT IMMUNOL, 28TH FLOOR, GUYS TOWER, LONDON SE1 9RT, ENGLAND.			mostov, keith/0000-0002-8123-6247; van Dolleweerd, Craig/0000-0002-1380-6930; Ma, Julian/0000-0003-0767-0042	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHNEN DJ, 1986, J CLIN INVEST, V77, P1841, DOI 10.1172/JCI112510; APODACA G, 1993, J BIOL CHEM, V268, P20380; BARNES WM, 1990, P NATL ACAD SCI USA, V87, P9183, DOI 10.1073/pnas.87.23.9183; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; HEIN MB, 1991, BIOTECHNOL PROGR, V7, P455, DOI 10.1021/bp00011a011; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; KILIAN M, 1988, MICROBIOL REV, V52, P296, DOI 10.1128/MMBR.52.2.296-303.1988; KNIGHT KL, 1975, J IMMUNOL, V115, P595; LEHNER T, 1985, INFECT IMMUN, V50, P796, DOI 10.1128/IAI.50.3.796-799.1985; MA JKC, 1994, EUR J IMMUNOL, V24, P131, DOI 10.1002/eji.1830240120; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MATSUUCHI L, 1986, P NATL ACAD SCI USA, V83, P456, DOI 10.1073/pnas.83.2.456; MESTECKY J, 1987, ADV IMMUNOL, V40, P153, DOI 10.1016/S0065-2776(08)60240-0; MOSTOV KE, 1994, ANNU REV IMMUNOL, V12, P63, DOI 10.1146/annurev.immunol.12.1.63; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; SCHNEIDERMAN RD, 1989, P NATL ACAD SCI USA, V86, P7561, DOI 10.1073/pnas.86.19.7561; SMITH R, 1989, ORAL MICROBIOL IMMUN, V4, P153, DOI 10.1111/j.1399-302X.1989.tb00243.x; UNDERDOWN BJ, 1974, J IMMUNOL, V112, P949; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	24	407	498	1	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 5	1995	268	5211					716	719		10.1126/science.7732380	http://dx.doi.org/10.1126/science.7732380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732380				2022-12-28	WOS:A1995QW60300048
J	GOLDBERG, AL				GOLDBERG, AL			FUNCTIONS OF THE PROTEASOME - THE LYSIS AT THE END OF THE TUNNEL	SCIENCE			English	Editorial Material							COMPLEX; UBIQUITIN; PROTEINS				GOLDBERG, AL (corresponding author), HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA.							AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; BARACOS VE, IN PRESS AM J PHYSL; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, IN PRESS SCIENCE; GACZYNSKA M, 1993, ENZYME PROTEIN, V47, P354, DOI 10.1159/000468693; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KING RW, 1995, IN PRESS CELL; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PALOMBELLA VJ, UNPUB; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEEMULLER E, 1995, FEBS LETT, V359, P173, DOI 10.1016/0014-5793(95)00036-9; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; TANAKA K, 1992, NEW BIOL, V4, P173; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WILK S, 1993, ENZYME PROTEIN, V47, P306, DOI 10.1159/000468688; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; YOSHIMURA T, 1993, J STRUCT BIOL, V111, P200, DOI 10.1006/jsbi.1993.1050; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	43	295	309	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 28	1995	268	5210					522	523		10.1126/science.7725095	http://dx.doi.org/10.1126/science.7725095			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725095				2022-12-28	WOS:A1995QV40700025
J	KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ				KIEFER, MC; BRAUER, MJ; POWERS, VC; WU, JJ; UMANSKY, SR; TOMEI, LD; BARR, PJ			MODULATION OF APOPTOSIS BY THE WIDELY DISTRIBUTED BCL-2 HOMOLOG BAK	NATURE			English	Article							PROGRAMMED CELL-DEATH; MOLECULAR-CLONING; GENE; PROTEIN; RNA	MEMBERS Of the Bcl-2 family of proteins are characterized by their ability to modulate cell death, Bcl-2 and some of its homologues inhibit apoptosis(1-4), whereas other family members, such as Bax, will accelerate apoptosis under certain conditions(5). Here we describe the identification and characterization of a complementary DNA that encodes a previously unknown Bcl-2 homologue designated Bak. Like Bax, the bak gene product primarily enhances apoptotic cell death following an appropriate stimulus. Unlike Bax, however, Bak can inhibit cell death in an Epstein-Barr-virus-transformed cell line. The widespread tissue distribution of Bak messenger RNA, including those containing long-lived, terminally differentiated cell types, suggests that cell-death-inducing activity is broadly distributed, and that tissue-specific modulation of apoptosis is controlled primarily by regulation of molecules that inhibit apoptosis.			KIEFER, MC (corresponding author), LXR BIOTECHNOL INC, 1401 MARINA WAY S, RICHMOND, CA 94804 USA.							BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J, 1989, MOL CLONING LABORATO; STRIKE LE, 1984, J IMMUNOL, V132, P1798; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAPF J, 1990, J BIOL CHEM, V265, P14892	19	483	507	2	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 20	1995	374	6524					736	739		10.1038/374736a0	http://dx.doi.org/10.1038/374736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QU304	7715731				2022-12-28	WOS:A1995QU30400054
J	LOWN, B				LOWN, B			TIME TO LEAVE BEHIND GENOCIDAL WEAPONS	BRITISH MEDICAL JOURNAL			English	Article											LOWN, B (corresponding author), INT PHYSICIANS PREVENT NUCL WAR,126 ROGERS ST,CAMBRIDGE,MA 02142, USA.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					993	994		10.1136/bmj.310.6985.993	http://dx.doi.org/10.1136/bmj.310.6985.993			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT904	7728040	Green Published			2022-12-28	WOS:A1995QT90400029
J	HIDALGO, P; MACKINNON, R				HIDALGO, P; MACKINNON, R			REVEALING THE ARCHITECTURE OF A K+ CHANNEL PORE THROUGH MUTANT CYCLES WITH A PEPTIDE INHIBITOR	SCIENCE			English	Article							POTASSIUM CHANNEL; TEA BLOCKADE; BINDING-SITE; CHARYBDOTOXIN; ION; TETRAETHYLAMMONIUM; SELECTIVITY; REGION	Thermodynamic mutant cycles provide a formalism for studying energetic coupling between amino acids on the interaction surface in a protein-protein complex. This approach was applied to the Shaker potassium channel and to a high-affinity peptide inhibitor (scorpion toxin) that binds to its pore entryway. The assignment of pairwise interactions defined the spatial arrangement of channel amino acids with respect to the known inhibitor structure. A strong constraint was placed on the Shaker channel pore-forming region by requiring its amino-terminal border to be 12 to 15 angstroms from the central axis. This method is directly applicable to sodium, calcium, and other ion channels where inhibitor or modulatory proteins bind with high affinity.			HIDALGO, P (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115, USA.		Hidalgo, Patricia/I-7506-2013	Hidalgo, Patricia/0000-0002-4162-6590	NIGMS NIH HHS [GM43949] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DEBIASI M, 1993, BIOPHYS J, V64, pA341; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GROSS AF, UNPUB; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HILLE B, 1975, IONIC SELECTIVITY NA, P255; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; KREZEL AM, UNPUB; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PARK CS, 1991, P NATL ACAD SCI USA, V88, P2046, DOI 10.1073/pnas.88.6.2046; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	23	417	424	1	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					307	310		10.1126/science.7716527	http://dx.doi.org/10.1126/science.7716527			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716527				2022-12-28	WOS:A1995QT18500044
J	SMITH, AB; ESKO, JD; HAJDUK, SL				SMITH, AB; ESKO, JD; HAJDUK, SL			KILLING OF TRYPANOSOMES BY THE HUMAN HAPTOGLOBIN-RELATED PROTEIN	SCIENCE			English	Article							GENE; IDENTIFICATION; BRUCEI; LIVER	African trypanosomes cause disease in humans and animals. Trypanosoma brucei brucei affects cattle but not humans because of its sensitivity to a subclass of human high density lipoproteins (HDLs) called trypanosome lytic factor (TLF). TLF contains two apolipoproteins that are sufficient to cause lysis of T. b. brucei in vitro. These proteins were identified as the human haptoglobin-related protein and paraoxonase-arylesterase. An antibody to haptoglobin inhibited TLF activity. TLF was shown to exhibit peroxidase activity and to be inhibited by catalase. These results suggest that TLF kills trypanosomes by oxidative damage initiated by its peroxidase activity.	UNIV ALABAMA,SCH MED & DENT,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NIAID NIH HHS [AI273316] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAERNSTEIN HD, 1963, J PARASITOL, V49, P12, DOI 10.2307/3275663; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BONKOVSKY HL, 1991, AM J MED SCI, V301, P32, DOI 10.1097/00000441-199101000-00006; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONNELL GE, 1959, BIOCHEM J, V72, P115, DOI 10.1042/bj0720115; FAWCETT HAC, 1990, BIOCHIM BIOPHYS ACTA, V1048, P187, DOI 10.1016/0167-4781(90)90055-7; HAGER KM, 1994, J CELL BIOL, V126, P155, DOI 10.1083/jcb.126.1.155; HAJDUK SL, 1989, J BIOL CHEM, V264, P5210; KINO K, 1980, J BIOL CHEM, V255, P9616; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MCEVOY SM, 1988, J BIOL CHEM, V263, P15740; MESHNICK SR, 1977, BIOCHEM PHARMACOL, V26, P1923, DOI 10.1016/0006-2952(77)90167-8; MESHNICK SR, 1978, J EXP MED, V148, P569, DOI 10.1084/jem.148.2.569; MOLINA HA, 1989, IMMUNOLOGY, V66, P289; OSHIRO S, 1988, J BIOL CHEM, V263, P16032; RIFKIN MR, 1978, EXP PARASITOL, V46, P189, DOI 10.1016/0014-4894(78)90131-5; SEED JR, 1990, J PROTOZOOL, V37, P393, DOI 10.1111/j.1550-7408.1990.tb01163.x; TYTLER EM, 1995, MOL BIOCHEM PARASIT, V69, P9, DOI 10.1016/0166-6851(94)00172-J; YANG FM, 1983, P NATL ACAD SCI-BIOL, V80, P5875, DOI 10.1073/pnas.80.19.5875; ZECH R, 1993, CHEM-BIOL INTERACT, V87, P85, DOI 10.1016/0009-2797(93)90028-W; [No title captured]	21	147	152	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 14	1995	268	5208					284	286		10.1126/science.7716520	http://dx.doi.org/10.1126/science.7716520			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT185	7716520				2022-12-28	WOS:A1995QT18500037
J	CULLEN, C				CULLEN, C			NEEDHAM,JOSEPH (1900-95)	NATURE			English	Item About an Individual											CULLEN, C (corresponding author), UNIV LONDON SCH ORIENTAL & AFRICAN STUDIES,DEPT HIST,THORNHAUGH ST,RUSSELL SQ,LONDON WC1H 0XG,ENGLAND.							NEEDHAM J, PUBLICATION LIST	1	0	0	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 13	1995	374	6523					597	597		10.1038/374597b0	http://dx.doi.org/10.1038/374597b0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715697				2022-12-28	WOS:A1995QT18900038
J	ANDREWS, JS; DEANGELIS, CD				ANDREWS, JS; DEANGELIS, CD			PEDIATRICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; RANDOMIZED DOUBLE-BLIND; CROUP; DEXAMETHASONE				ANDREWS, JS (corresponding author), JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205, USA.			Andrews, John/0000-0002-2008-2686				DENNY FW, 1983, PEDIATRICS, V71, P871; GIDDING SS, 1994, PEDIATRICS, V94, P750; HUSBY S, 1993, ARCH DIS CHILD, V68, P352, DOI 10.1136/adc.68.3.352; KLASSEN TP, 1994, NEW ENGL J MED, V331, P285, DOI 10.1056/NEJM199408043310501; KUUSELA AL, 1988, ACTA PAEDIATR SCAND, V77, P99, DOI 10.1111/j.1651-2227.1988.tb10606.x; OLDS DL, 1994, PEDIATRICS, V93, P228; OLDS DL, 1994, PEDIATRICS, V93, P221; SUPER DM, 1989, J PEDIATR-US, V115, P323, DOI 10.1016/S0022-3476(89)80095-2; TIBBALLS J, 1992, LANCET, V340, P745, DOI 10.1016/0140-6736(92)92293-O; 1994, MMWR-MORBID MORTAL W, V43, P789; 1994, MMWR-MORBID MORTAL W, V43, P1; 1994, PEDIATRICS, V93, P866; 1993, MMWR-MORBID MORTAL W, V42, P18; 1994, MMWR-MORBID MORTAL W, V43, P409	14	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1708	1710		10.1001/jama.273.21.1708	http://dx.doi.org/10.1001/jama.273.21.1708			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752430				2022-12-28	WOS:A1995RB09700038
J	QUILLIGAN, EJ				QUILLIGAN, EJ			OBSTETRICS AND GYNECOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESTROGEN-PROGESTIN; TRIAL; WOMEN				QUILLIGAN, EJ (corresponding author), UNIV CALIF IRVINE,COLL MED,ORANGE,CA 92668, USA.							CARR BR, 1993, J CLIN ENDOCR METAB, V76, P1217, DOI 10.1210/jc.76.5.1217; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DEVINCENZI IA, 1994, NEW ENGL J MED, V331, P342; FINDLAY I, 1994, BRIT HEART J, V71, P213; FRIEDMAN AJ, 1993, J CLIN ENDOCR METAB, V76, P1439, DOI 10.1210/jc.76.6.1439; GABAY M, 1994, CESAREAN SECTIONS CU; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; Mofenson LM, 1994, SEMIN PEDIAT INFECT, V5, P252; NACHTIGALL MJ, 1992, OBSTET GYNECOL, V80, P827; NWANYANWU OC, 1993, AM J DRUG ALCOHOL AB, V19, P399, DOI 10.3109/00952999309001630; PATRIZIO P, 1994, FERTIL STERIL, V61, P265; PATRIZIO P, 1993, HUM REPROD, V8, P1259, DOI 10.1093/oxfordjournals.humrep.a138237; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; 1995, JAMA-J AM MED ASSOC, V273, P199	14	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1700	1702						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752425				2022-12-28	WOS:A1995RB09700033
J	HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T				HERTZMAN, PA; CLAUW, DJ; KAUFMAN, LD; VARGA, J; SILVER, RM; THACKER, HL; MEASE, P; ESPINOZA, LR; PINCUS, T			THE EOSINOPHILIA-MYALGIA-SYNDROME - STATUS OF 205 PATIENTS AND RESULTS OF TREATMENT 2 YEARS AFTER ONSET	ANNALS OF INTERNAL MEDICINE			English	Review							TOXIC OIL SYNDROME; RHEUMATOID-ARTHRITIS; FOLLOW-UP; TRYPTOPHAN; INGESTION; FASCIITIS	Objective: To describe the course of the eosinophilia-myalgia syndrome during a 2-year period. Design: 15 physicians completed a structured review;form to describe symptoms, physical findings, laboratory data, and responses to treatments in 205 patients with the eosinophilia-myalgia syndrome at the onset of illness and after 18 to 24 months of follow-up. Setting: 15 university and private clinical practice settings. Patients: 205 patients for whom follow-up data were available and who met four criteria at diagnosis: eosinophil count of 1000 cells/mm(3) or greater; presence of fasciitis, peripheral neuropathy, polyradiculopathy, interstitial pulmonary disease, pulmonary hypertension, or myocardial involvement; history of L-tryptophan consumption; and absence of other conditions that could account for these findings. Intervention: Empirical interventions by the physicians. Measurements: Symptoms, physical findings, laboratory test results, biopsy findings, radiographic reports, therapeutic interventions, and responses to these interventions. Results: After 18 to 24 months, all symptoms except cognitive changes were reported to have improved in most patients. Nearly all physical findings were also reported to have improved or resolved in most patients; only peripheral neuropathy was unchanged. No evidence of ongoing inflammatory disease was reported. Prednisone was reported to be helpful in 79% of patients who received it during the acute phase of the syndrome. No other treatment was reported to be consistently beneficial. Conclusions: 18 to 24 months after the onset of illness, most symptoms and physical findings in most patients with the eosinophilia-myalgia syndrome resolved or improved. Cognitive changes were reported to be worse in 32% of patients. Prednisone was helpful in the acute phase of illness. No treatment was clearly valuable in management of the later phase of the syndrome.	VANDERBILT UNIV, SCH MED, DEPT MED, DIV RHEUMATOL & IMMUNOL, NASHVILLE, TN 37232 USA; LOS ALAMOS MED CTR, LOS ALAMOS, NM 87544 USA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; SUNY STONY BROOK, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, STONY BROOK, NY 11794 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA; MINOR & JAMES MED CTR, SEATTLE, WA 98104 USA; LOUISIANA STATE UNIV, MED CTR, NEW ORLEANS, LA USA	Vanderbilt University; Georgetown University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Jefferson University; Medical University of South Carolina; Cleveland Clinic Foundation; Louisiana State University System					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R18AR021393] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 21393] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; ALONSORUIZ A, 1993, MEDICINE, V72, P285, DOI 10.1097/00005792-199309000-00001; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; CULPEPPER RC, 1991, ANN INTERN MED, V115, P437, DOI 10.7326/0003-4819-115-6-437; DUFFY J, 1992, HOSP PRACT, V27, P65; FREUNDLICH B, 1990, ANN INTERN MED, V112, P758, DOI 10.7326/0003-4819-112-10-758; GUADINO EA, 1995, IN PRESS NEUROPSYCHI; HERTZMAN P A, 1991, Arthritis and Rheumatism, V34, pS131; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; HERTZMAN PA, 1993, ARTHRITIS RHEUM, V36, pS115; HERTZMAN PA, 1991, J RHEUMATOL, V18, P867; HERTZMAN PA, 1995, J RHEUMATOL, V22, P161; HERTZMAN PA, 1993, J RHEUMATOL, V20, P1707; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KAUFMAN LD, 1994, RHEUM DIS CLIN N AM, V20, P973; KAUFMAN LD, 1994, ARTHRITIS RHEUM-US, V37, P84, DOI 10.1002/art.1780370112; KAUFMAN LD, 1995, J RHEUMATOL, V22, P282; KILBOURNE EM, 1991, J AM COLL CARDIOL, V18, P711, DOI 10.1016/0735-1097(91)90794-A; KILBOURNE EM, 1992, EPIDEMIOL REV, V14, P16, DOI 10.1093/oxfordjournals.epirev.a036085; KRUPP LB, 1993, NEUROLOGY, V43, P931, DOI 10.1212/WNL.43.5.931; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; PHILEN RM, 1993, SEMIN ARTHRITIS RHEU, V23, P104, DOI 10.1016/S0049-0172(05)80017-4; PINCUS T, 1992, J RHEUMATOL, V19, P1874; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; PINCUS T, 1989, ANN INTERN MED, V110, P259, DOI 10.7326/0003-4819-110-4-259; SACK KE, 1992, SOUTHERN MED J, V85, P878, DOI 10.1097/00007611-199209000-00005; SILVER RM, 1991, ARCH DERMATOL, V127, P1214, DOI 10.1001/archderm.127.8.1214; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; THACKER HL, 1991, CLEV CLIN J MED, V58, P400, DOI 10.3949/ccjm.58.5.400; VARGA J, 1991, J RHEUMATOL, V18, P259; WOLFE F, 1991, J RHEUMATOL, V18, P643; 1989, MMWR MORBMORTAL WKLY, V38, P765; 1990, JAMA-J AM MED ASSOC, V263, P633	33	30	33	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1995	122	11					851	855		10.7326/0003-4819-122-11-199506010-00008	http://dx.doi.org/10.7326/0003-4819-122-11-199506010-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA139	7741371				2022-12-28	WOS:A1995RA13900008
J	COOPER, JR				COOPER, JR			INCLUDING NARCOTIC ADDICTION TREATMENT IN AN OFFICE-BASED PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METHADONE-MAINTENANCE				COOPER, JR (corresponding author), NIDA,DIV CLIN SERV & RES,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							Ball J.C., 2012, EFFECTIVENESS METHAD; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; DOLE VP, 1992, JAMA-J AM MED ASSOC, V267, P2234, DOI 10.1001/jama.267.16.2234; GRAHAM LA, 1994, NOV NAT I DRUG AB ME; MOLINARI SP, 1994, J LAW MED ETHICS, V22, P231, DOI 10.1111/j.1748-720X.1994.tb01300.x; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; PAYTE JT, 1994, 25TH AM SOC ADD MED; 1970, L91513 PUB; 1974, L93281 PUB; 1994, DEV ANTIADDICTION ME; 1984, L98473 PUB; 1995, FEDERAL REGULATION M	12	27	28	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1619	1620		10.1001/jama.273.20.1619	http://dx.doi.org/10.1001/jama.273.20.1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745777				2022-12-28	WOS:A1995QY54100031
J	BLAISE, D; OLIVE, D; MICHALLET, M; MARIT, G; LEBLOND, V; MARANINCHI, D				BLAISE, D; OLIVE, D; MICHALLET, M; MARIT, G; LEBLOND, V; MARANINCHI, D			IMPAIRMENT OF LEUKEMIA-FREE SURVIVAL BY ADDITION OF INTERLEUKIN-2-RECEPTOR ANTIBODY TO STANDARD GRAFT-VERSUS-HOST PROPHYLAXIS	LANCET			English	Article							RECEPTOR MONOCLONAL-ANTIBODY; BONE-MARROW TRANSPLANTATION; T-CELL DEPLETION; DISEASE; TRIAL; PREVENTION; LEUKEMIA; GROWTH; 33B3.1; GVHD	Graft-versus-host disease (GVHD) is the most important adverse effect of HLA-matched allogeneic bone-marrow transplantation. T-cell depletion of the graft eliminates GVHD but also causes an unacceptable increase in rejections and leukaemic relapses. We have attempted to block the activation of resting T cells with a monoclonal antibody against the interleukin-2 receptor (33B3.1). 101 patients with leukaemia (acute lymphocytic 22, acute myelogenous 34, chronic myeloid 45) in first complete remission or first chronic phase were randomly assigned to groups receiving standard post-transplantation immunosuppression (methotrexate plus cyclosporin; n=50) or the standard treatment plus antibody 33B3.1 (n=51). There were 2 graft failures in the 33B3.1 group. The antibody did not significantly affect the cumulative frequency of acute GVHD of grade 2 or worse (19 [38%] vs 23 [46%]) but merely delayed its onset (median 36 [IQR 21-70] vs 25 [11-44] days; p<0.01). At median follow-up of 58 (range 41-71) months, the antibody-treated group had significantly lower leukaemia-free survival (p<0.05) mainly because of a progressive increase in the rate of late relapses (p=0.08). Our findings confirm the importance of T cells in transplantation for leukaemia. The fine balance between the early modulation of transplant immunity and leukaemic control suggests that further anti-leukaemic measures may be needed when attempts are made to improve tolerance between the graft acid the leukaemic host.	INSERM,U119,F-13273 MARSEILLE,FRANCE; HOP EDOUARD HERRIOT,LYON,FRANCE; HOP HAUT LEVEQUE,BORDEAUX,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	BLAISE, D (corresponding author), INST J PAOLI I CALMETTES,232 BLVD ST MARGUERITE,F-13273 MARSEILLE,FRANCE.		Blaise, Didier/R-2483-2016	Blaise, Didier/0000-0002-5684-9447				ANASETTI C, 1994, BLOOD, V84, P1320; ANASETTI C, 1991, BONE MARROW TRANSPL, V7, P375; BELANGER C, 1993, BONE MARROW TRANSPL, V11, P293; BLAISE D, 1992, BLOOD, V79, P2578; BLAISE D, 1991, BONE MARROW TRANSPL, V8, P105; BLAISE D, 1989, LANCET, V1, P1333; BLAISE D, 1993, LANCET, V341, P51, DOI 10.1016/0140-6736(93)92526-Y; BURAKOFF SJ, 1990, GRAFT VS HOST DISEAS, V12, P311; DEVERGIE A, 1994, 1ST M EUR HAEM ASS B; DEVERGIE A, 1990, BONE MARROW TRANSPL, V5, P239; FERRARA JLM, 1986, J IMMUNOL, V137, P1874; HEEG K, 1988, J IMMUNOL, V141, P2330; JUNGHANS RP, 1990, CANCER RES, V50, P1495; KIRKMAN RL, 1985, J EXP MED, V162, P358, DOI 10.1084/jem.162.1.358; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; MARANINCHI D, 1987, LANCET, V25, P175; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; OLIVE D, 1986, EUR J IMMUNOL, V16, P611, DOI 10.1002/eji.1830160605; SHAPIRO ME, 1987, TRANSPLANT P, V19, P594; SOULILLOU JP, 1990, NEW ENGL J MED, V322, P1175, DOI 10.1056/NEJM199004263221702; STROM TB, 1986, TRANSPLANTATION APPR, P227	21	62	63	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1144	1146		10.1016/S0140-6736(95)90978-8	http://dx.doi.org/10.1016/S0140-6736(95)90978-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723546				2022-12-28	WOS:A1995QW62200010
J	HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ				HAQ, TA; MASON, HS; CLEMENTS, JD; ARNTZEN, CJ			ORAL IMMUNIZATION WITH A RECOMBINANT BACTERIAL-ANTIGEN PRODUCED IN TRANSGENIC PLANTS	SCIENCE			English	Article							ESCHERICHIA-COLI; IMMUNE-RESPONSE; VIBRIO-CHOLERAE; B-SUBUNIT; PROTEINS; ENTEROTOXIN; VACCINE; TOXIN; IDENTIFICATION; TRANSLOCATION	The binding subunit of Escherichia coli heat-labile enterotoxin (LT-B) is a highly active oral immunogen. Transgenic tobacco and potato plants were made with the use of genes encoding LT-B or an LT-B fusion protein with a microsomal retention sequence. The plants expressed the foreign peptides, both of which formed oligomers that bound the natural ligand. Mice immunized by gavage produced serum and gut mucosal anti-LT-B immunoglobulins that neutralized the enterotoxin in cell protection assays. Feeding mice fresh transgenic potato tubers also caused oral immunization.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, PLANT BIOTECHNOL PROGRAM, HOUSTON, TX 77030 USA; TULANE UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NEW ORLEANS, LA 70112 USA	Texas A&M University System; Tulane University					PHS HHS [1 R01 A136519-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNTZEN CJ, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P339; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CARDENAS L, 1993, INFECT IMMUN, V61, P4629; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENTS JD, 1978, INFECT IMMUN, V21, P1036, DOI 10.1128/IAI.21.3.1036-1039.1978; CLEMENTS JD, 1984, INFECT IMMUN, V46, P564, DOI 10.1128/IAI.46.2.564-569.1984; DEAIZPURUA HJ, 1988, J EXP MED, V167, P440, DOI 10.1084/jem.167.2.440; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HOLMGREN J, 1983, PROG ALLERGY, V33, P106; HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; HORSCH RB, 1991, PLANT MOL BIOL MANUA; JEFFERSON RA, 1987, EMBO J, V6, P3901; JONES JDG, 1985, EMBO J, V4, P2411, DOI 10.1002/j.1460-2075.1985.tb03949.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON HS, 1988, PLANT MOL BIOL, V11, P845, DOI 10.1007/BF00019524; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; MESTECKY J, 1989, CURR TOP MICROBIOL, V146, P3; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; PELTOLA H, 1991, LANCET, V338, P1285, DOI 10.1016/0140-6736(91)92590-X; PERL A, 1991, PLANT SCI, V73, P87, DOI 10.1016/0168-9452(91)90129-V; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; SACK RB, 1980, J INFECT DIS, V142, P279, DOI 10.1093/infdis/142.2.279; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; WANDELT CI, 1992, PLANT J, V2, P181; WENZLER H, 1989, PLANT SCI, V63, P79, DOI 10.1016/0168-9452(89)90103-9	28	474	553	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 5	1995	268	5211					714	716		10.1126/science.7732379	http://dx.doi.org/10.1126/science.7732379			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW603	7732379				2022-12-28	WOS:A1995QW60300047
J	KIMHA, J; KERR, K; MACDONALD, PM				KIMHA, J; KERR, K; MACDONALD, PM			TRANSLATIONAL REGULATION OF OSKAR MESSENGER-RNA BY BRUNO, AN OVARIAN RNA-BINDING PROTEIN, IS ESSENTIAL	CELL			English	Article							BICOID MESSENGER-RNA; EARLY DROSOPHILA EMBRYO; GERM-CELL FORMATION; ANTEROPOSTERIOR POLARITY; EXUPERANTIA GENE; POSTERIOR POLE; LOCALIZATION; PATTERN; NANOS; ELEMENTS	Oskar (osk) protein directs the deployment of nanos (nos), the posterior body-patterning morphogen in Drosophila. To avoid inappropriate activation of nos, osk activity must appear only at the posterior pole of the oocyte, where the osk mRNA becomes localized during oogenesis. Here, we show that translation of osk mRNA is, and must be, repressed prior to its localization; absence of repression allows osk protein to accumulate throughout the oocyte, specifying posterior body patterning throughout the embryo. Translational repression is mediated by an ovarian protein, bruno, that binds specifically to bruno response elements (BREs), present in multiple copies in the osk mRNA 3'UTR. Addition of BREs to a heterologous mRNA renders it sensitive to translational repression in the ovary.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University								BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; Davidson E. H., 1986, GENE ACTIVITY EARLY; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EPHRUSSI A, 1991, CELL, V68, P37; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; HAY B, 1990, DEVELOPMENT, V109, P425; HAZELRIGG T, 1990, GENETICS, V126, P607; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LEHMANN R, 1991, DEVELOPMENT, V112, P679; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WEBSTER PJ, 1994, DEVELOPMENT, V120, P2027; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1992, SEM DEV BIOL, V3, P399	40	364	368	0	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 5	1995	81	3					403	412		10.1016/0092-8674(95)90393-3	http://dx.doi.org/10.1016/0092-8674(95)90393-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QW894	7736592	Bronze			2022-12-28	WOS:A1995QW89400012
J	LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC				LUNARDIISKANDAR, Y; BRYANT, JL; ZEMAN, RA; LAM, VH; SAMANIEGO, F; BESNIER, JM; HERMANS, P; THIERRY, AR; GILL, P; GALLO, RC			TUMORIGENESIS AND METASTASIS OF NEOPLASTIC KAPOSIS-SARCOMA CELL-LINE IN IMMUNODEFICIENT MICE BLOCKED BY A HUMAN-PREGNANCY HORMONE	NATURE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; LONG-TERM CULTURE; GROWTH-FACTOR; EXPRESSION; MECHANISMS; AUTOCRINE; PARACRINE; INVITRO; DEATH; HTLV	KAPOSI's sarcoma (KS) occurs more often in men than in women and HIV-1-associated KS has a high occurrence in homosexual men (over 30%). Most cultures of KS tumours yield cells with properties of hyperplastic (not malignant) endothelial cells under the control of several cytokines(1-7). The role of HIV-1 may be in promoting high levels of some cytokines and providing stimulation to angiogenesis by the HIV-1 Tat protein(8), which synergizes with basic fibroblast growth factor in promoting these effects(9), Here,ve describe an immortalized AIDS-KS cell line (KS Y-1) and show that these cells produce malignant metastatic tumours in nude mice and are killed in vitro and in vivo (apparently by apoptosis) by a pregnancy hormone, the beta-chain of human chorionic gonadotropin. Similarly, chorionic gonadotropin kills KS SLK, cells from another neoplastic cell line (established from a non-HIV-associated KS)(10), as well as the hyperplastic KS cells from clinical specimens grown in short-term culture, but does not kill normal endothelial cells, These results provide evidence that KS can evolve into a malignancy and have implications for the hormonal treatment of this tumour.	NCI, TUMOR CELL BIOL LAB, BETHESDA, MD 20892 USA; NIDR, ANIM CARE UNIT, BETHESDA, MD 20892 USA; GYNECOL & OBSTET MED CTR, F-75017 PARIS, FRANCE; FREE UNIV BRUSSELS, HOP ST PIERRE, DEPT MALAD INFECT, B-1000 BRUSSELS, BELGIUM; UNIV SO CALIF, SCH MED, LOS ANGELES, CA 90033 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Southern California			thierry, alain/F-9492-2014					ASHITAKA Y, 1980, CHORIONIC GONADOTROP, P147; CAI J, 1994, AM J PATHOL, V145, P74; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; ELMAZAR MMA, 1989, REPROD TOXICOL, V3, P135, DOI 10.1016/0890-6238(89)90047-6; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FAN C, 1987, J CLIN ENDOCR METAB, V64, P313, DOI 10.1210/jcem-64-2-313; HORNE CHW, 1979, INVEST CELL PATHOL, V2, P217; JOHNSON MR, 1993, ACTA ENDOCRINOL-COP, V129, P121, DOI 10.1530/acta.0.1290121; KORNYEI JL, 1993, BIOL REPROD, V49, P1149, DOI 10.1095/biolreprod49.6.1149; LUNARDIISKANDAR Y, 1993, J EXP MED, V177, P741, DOI 10.1084/jem.177.3.741; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARTIN MC, 1991, BASIC CLIN ENDOCRINO, P543; MASOOD R, 1994, AIDS RES HUM RETROV, V10, P969, DOI 10.1089/aid.1994.10.969; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAHRAOUI Y, 1992, CELL IMMUNOL, V139, P318, DOI 10.1016/0008-8749(92)90074-Y; SALAHUDDIN SZ, 1988, SCIENCE, V242, P430, DOI 10.1126/science.2459779; SLEGAL B, 1990, CANCER, V65, P492; STIMSON WH, 1983, IMMUNOLOGY REPRODUCT, P281; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TORRY RJ, 1992, AM J REPROD IMMUNOL, V27, P171, DOI 10.1111/j.1600-0897.1992.tb00746.x; WIDE L, 1980, CHORIONIC GONADOTROP, P37	26	206	229	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 4	1995	375	6526					64	68		10.1038/375064a0	http://dx.doi.org/10.1038/375064a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QW604	7723844	Green Submitted			2022-12-28	WOS:A1995QW60400056
J	HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA				HEBERT, LE; SCHERR, PA; BECKETT, LA; ALBERT, MS; PILGRIM, DM; CHOWN, MJ; FUNKENSTEIN, HH; EVANS, DA			AGE-SPECIFIC INCIDENCE OF ALZHEIMERS-DISEASE IN A COMMUNITY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEMENTING ILLNESSES; SENILE DEMENTIA; UNITED-STATES; PREVALENCE; PERIODS; LUNDBY; RATES	Objective.-To determine age-specific incidence rates of clinically diagnosed Alzheimer's disease. Design.-Cohort, followed a mean of 4.3 years. Setting.-East Boston, Mass. Participants.-Of 2313 persons aged 65 years and older who were initially free of Alzheimer's disease, 1601 participated in the ascertainment of incident disease (80% of survivors), 409 declined participation, and 303 died before the end of the follow-up period. A stratified sample of 642 persons received detailed clinical evaluation. Outcome Measure.-Diagnosis of new probable Alzheimer's disease through structured clinical evaluation including neurologic, neuropsychological, and psychiatric examination. Community incidence rates were computed by 5-year age groups, adjusted for gender, single year of age, length of follow-up interval, and sampling design. Results.-The estimated annual incidence of Alzheimer's disease in the population was 0.6% (95% confidence interval [CI], 0.3% to 0.9%) for persons aged 65 to 69 years, 1.0% (95% CI, 0.6% to 1.4%) for persons aged 70 to 74 years, 2.0% (95% CI, 1.3% to 2.7%) for persons aged 75 to 79 years, 3.3% (95% CI, 2.2% to 4.4%) for persons aged 80 to 84 years, and 8.4% (95% CI, 3.7% to 13.1%) for persons aged 85 years and older. Conclusions.-The incidence of Alzheimer's disease is substantial and is approximately 14 times higher among persons older than 85 years compared with those between 65 and 69 years of age.	RUSH UNIV,RUSH ALZHEIMERS DIS CTR,CHICAGO,IL 60612; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; CTR DIS CONTROL & PREVENT,NATL CTR CHRON DIS PREVENT & HLTH PROMOT,AGING STUDIES BRANCH,ATLANTA,GA 30341; MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115	Rush University; Rush University; Centers for Disease Control & Prevention - USA; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	HEBERT, LE (corresponding author), RUSH INST AGING,1645 W JACKSON BLVD,SUITE 675,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE ON AGING [P30AG010161, R01AG005362, U01AG006789] Funding Source: NIH RePORTER; NIA NIH HHS [AG06789, AG10161, AG05362] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AKESSON HO, 1969, HUM HERED, V19, P546, DOI 10.1159/000152266; ALBERT M, 1991, INT J NEUROSCI, V57, P167, DOI 10.3109/00207459109150691; ARONSON MK, 1991, ARCH INTERN MED, V151, P989, DOI 10.1001/archinte.1991.00400050129024; BACHMAN DL, 1993, NEUROLOGY, V43, P515, DOI 10.1212/WNL.43.3_Part_1.515; BECKETT LA, 1992, J CLIN EPIDEMIOL, V45, P393, DOI 10.1016/0895-4356(92)90040-T; Benton A.L., 1974, REVISED VISUAL RETEN; COPELAND JRM, 1992, BRIT J PSYCHIAT, V161, P230, DOI 10.1192/bjp.161.2.230; Cornoni-Huntley J., 1986, ESTABLISHED POPULATI; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; EVANS DA, 1990, AM J EPIDEMIOL, V134, P403; EVANS RA, 1993, OSTEOPOROSIS INT, V3, P71, DOI 10.1007/BF01623376; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; GRUENBERG EM, 1987, SOC STRESS DISEASE; HAGNELL O, 1981, NEUROPSYCHOBIOLOGY, V7, P201, DOI 10.1159/000117852; JARVIK LF, 1980, ARCH GEN PSYCHIAT, V37, P280; KAPLAN E, 1976, BOSTON NAMING TEST; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; KAY DWK, 1966, J PSYCHOSOM RES, V10, P3, DOI 10.1016/0022-3999(66)90128-0; KOKMEN E, 1988, NEUROLOGY, V38, P975, DOI 10.1212/WNL.38.6.975; LARSSON T, 1963, ACTA PSYCHIATR SCA S, V167, P1; LAUNER LJ, 1992, NEUROEPIDEMIOLOGY, V11, P127, DOI 10.1159/000110922; MATTIS S, 1976, GERIATRIC PSYCHIATRY; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MIRSKY A, 1978, ED BRAIN 77 YB 2; MOLSA PK, 1982, ACTA NEUROL SCAND, V65, P541; MORGAN K, 1992, NEUROEPIDEMIOLOGY, V11, P80, DOI 10.1159/000110995; MOSS MB, 1986, ARCH NEUROL-CHICAGO, V43, P239, DOI 10.1001/archneur.1986.00520030031008; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; RORSMAN B, 1986, NEUROPSYCHOBIOLOGY, V15, P122, DOI 10.1159/000118254; RUBIN EH, 1989, ARCH NEUROL-CHICAGO, V46, P379, DOI 10.1001/archneur.1989.00520400033016; SAYETTA RB, 1986, J CHRON DIS, V39, P271, DOI 10.1016/0021-9681(86)90049-4; SCHOENBERG BS, 1987, ANN NEUROL, V22, P724, DOI 10.1002/ana.410220608; SPENCER G, 1984, US BUREAU CENSUS P25, V952; TAEUBER CM, 1983, US BUREAU CENSUS P23, V128; TORREY BB, 1987, US BUREAU CENSUS P95, V78	36	326	336	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1354	1359		10.1001/jama.273.17.1354	http://dx.doi.org/10.1001/jama.273.17.1354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV307	7715060				2022-12-28	WOS:A1995QV30700020
J	ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T				ENDRIZZI, JA; CRONK, JD; WANG, WD; CRABTREE, GR; ALBER, T			CRYSTAL-STRUCTURE OF DCOH, A BIFUNCTIONAL, PROTEIN-BINDING TRANSCRIPTIONAL COACTIVATOR	SCIENCE			English	Article							NUCLEAR FACTOR-I; DIMERIZATION DOMAIN; 4A-CARBINOLAMINE DEHYDRATASE; DNA-BINDING; ACTIVATION DOMAINS; RAT-LIVER; HOMEODOMAIN; HYDROXYLASE; PROMOTERS; RECOGNITION	DCoH, the dimerization cofactor of hepatocyte nuclear factor-1, stimulates gene expression by associating with specific DNA binding proteins and also catalyzes the dehydration of the biopterin cofactor of phenylalanine hydroxylase. The x-ray crystal structure determined at 3 angstrom resolution reveals that DCoH forms a tetramer containing two saddle-shaped grooves that comprise likely macromolecule binding sites. Two equivalent enzyme active sites flank each saddle, suggesting that there is a spatial connection between the catalytic and binding activities. Structural similarities between the DCoH fold and nucleic acid-binding proteins argue that the saddle motif has evolved to bind diverse ligands or that DCoH unexpectedly may bind nucleic acids.	STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305	Stanford University; Howard Hughes Medical Institute; Stanford University	ENDRIZZI, JA (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.		Wang, Weidong/AAV-2446-2021	Wang, Weidong/0000-0002-0658-7928				BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; CITRON BA, 1992, P NATL ACAD SCI USA, V89, P11891, DOI 10.1073/pnas.89.24.11891; CITRON BA, 1993, AM J HUM GENET, V53, P768; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CRONK JD, UNPUB; DAVIS MD, 1992, FEBS LETT, V302, P73, DOI 10.1016/0014-5793(92)80288-R; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; HANSEN LP, 1994, THESIS STANFORD U ST; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HUANG CY, 1973, J BIOL CHEM, V248, P4235; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAUFMAN S, 1970, J BIOL CHEM, V245, P4751; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V360, P520; KIM Y, 1993, NATURE, V360, P512; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P921; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; LAZARUS RA, 1983, J BIOL CHEM, V258, P960; LEE AL, 1994, BIOCHEMISTRY-US, V33, P13775, DOI 10.1021/bi00250a031; LUNDQVIST T, 1994, STRUCTURE, V2, P937, DOI 10.1016/S0969-2126(94)00095-6; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; NAGAI K, 1991, NATURE, V348, P515; NICOSIA A, 1990, CELL, V61, P1225, DOI 10.1016/0092-8674(90)90687-A; NIKOLOV DB, 1994, NAT STRUCT BIOL, V1, P621, DOI 10.1038/nsb0994-621; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PASTORE A, 1992, PROTEIN ENG, V5, P749, DOI 10.1093/protein/5.8.749; PASTORE A, 1991, BIOCHEMISTRY-US, V30, P148, DOI 10.1021/bi00215a022; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEIGEMANN W, 1991, PROTEIN VERSION 3 1; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VONSTRANDMANN EP, IN PRESS DEVELOPMENT; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZENG WL, 1993, DEVELOPMENT, V118, P339; ZHAO GS, 1994, P NATL ACAD SCI USA, V91, P1366, DOI 10.1073/pnas.91.4.1366; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	53	56	56	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 28	1995	268	5210					556	559		10.1126/science.7725101	http://dx.doi.org/10.1126/science.7725101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QV407	7725101				2022-12-28	WOS:A1995QV40700034
J	JONES, L				JONES, L			ON A FRONT-LINE	BRITISH MEDICAL JOURNAL			English	Article								Like the patients, doctors in Sarajevo depend largely on humanitarian aid; everyone in the public sector has worked without pay for almost three years. The hospital is on a front line; yet the psychiatric department continues to function, even conducting large scale studies of psychosocial aspects of war in Bosnia-Hercegovina. The type of inpatient morbidity and treatment patterns have changed. A plethora of psychosocial rehabilitation programmes has emerged, including counselling, drop in centres, and attending to special needs of elderly people, schoolchildren, and women. The most prominent psychological symptoms were exhaustion at the prospect of a third winter of war and bewilderment at the Western stereotype of Bosnians as Muslim fundamentalists.			JONES, L (corresponding author), INST FAMILY PSYCHIAT,IPSWICH IP1 3TF,SUFFOLK,ENGLAND.							SUMMERFIELD D, IN PRESS PSYCHOL TRA	1	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1052	1054		10.1136/bmj.310.6986.1052	http://dx.doi.org/10.1136/bmj.310.6986.1052			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728062	Green Published			2022-12-28	WOS:A1995QV31300022
J	STJOHNSTON, D				STJOHNSTON, D			THE INTRACELLULAR-LOCALIZATION OF MESSENGER-RNAS	CELL			English	Review							XENOPUS-OOCYTES; DROSOPHILA OOGENESIS; BICOID RNA; POSTERIOR DETERMINANT; INSITU HYBRIDIZATION; BINDING PROTEIN; VEGETAL CORTEX; ANTERIOR POLE; GERM PLASM; TGF-BETA		UNIV CAMBRIDGE, DEPT GENET, CAMBRIDGE CB2 1QR, ENGLAND	University of Cambridge	STJOHNSTON, D (corresponding author), UNIV CAMBRIDGE, INST CANC RES CAMPAIGN, WELLCOME TRUST, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.		St Johnston, Daniel/C-9568-2009	St Johnston, Daniel/0000-0001-5582-3301	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; Ainger K., 1993, Molecular Biology of the Cell, V4, p421A; BASSELL GJ, 1994, J CELL BIOL, V126, P863, DOI 10.1083/jcb.126.4.863; BASSELL GJ, 1994, NEURON, V12, P571, DOI 10.1016/0896-6273(94)90213-5; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BRUCKENSTEIN DA, 1990, NEURON, V5, P809, DOI 10.1016/0896-6273(90)90340-L; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CLARK I, 1994, CURR BIOL, V4, P289, DOI 10.1016/S0960-9822(00)00068-3; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; DING D, 1993, MOL CELL BIOL, V13, P3773, DOI 10.1128/MCB.13.6.3773; DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; Driever Wolfgang, 1993, P301; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; ELINSON RP, 1993, DEV BIOL, V160, P554, DOI 10.1006/dbio.1993.1329; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GUTZEIT H, 1986, ROUX ARCH DEV BIOL, V195, P173, DOI 10.1007/BF02439435; HILL MA, 1993, J CELL BIOL, V122, P825, DOI 10.1083/jcb.122.4.825; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JEFFERY WR, 1983, DEV BIOL, V99, P408, DOI 10.1016/0012-1606(83)90290-7; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; JONGENS TA, 1994, GENE DEV, V8, P2123, DOI 10.1101/gad.8.18.2123; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; KLOC M, 1995, DEVELOPMENT, V121, P287; KLOC M, 1994, SCIENCE, V265, P1101, DOI 10.1126/science.7520603; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KU M, 1993, DEVELOPMENT, V119, P1161; LANE ME, 1994, GENE DEV, V8, P2986, DOI 10.1101/gad.8.24.2986; LAWRENCE JB, 1986, CELL, V45, P407, DOI 10.1016/0092-8674(86)90326-0; LI MG, 1994, J CELL BIOL, V126, P1475, DOI 10.1083/jcb.126.6.1475; LITMAN P, 1994, NEURON, V13, P1463, DOI 10.1016/0896-6273(94)90432-4; MACDONALD PM, 1991, GENE DEV, V5, P2455, DOI 10.1101/gad.5.12b.2455; MACDONALD PM, 1993, DEVELOPMENT, V118, P1233; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARCEY D, 1991, EMBO J, V10, P4259, DOI 10.1002/j.1460-2075.1991.tb05004.x; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MORRIS EJ, 1994, J CELL SCI, V107, P377; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEWMARK PA, 1994, DEVELOPMENT, V120, P1303; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; RAFF JW, 1990, DEVELOPMENT, V110, P1249; RAN B, 1994, DEVELOPMENT, V120, P1233; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHWARTZ SP, 1992, P NATL ACAD SCI USA, V89, P11895, DOI 10.1073/pnas.89.24.11895; STEPHENSON EC, 1988, GENE DEV, V2, P1655, DOI 10.1101/gad.2.12a.1655; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; TORRE ER, 1992, J NEUROSCI, V12, P762; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIESCHAUS E, 1978, ROUX ARCH DEV BIOL, V184, P75, DOI 10.1007/BF00848670; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269; WILSON IA, 1995, IN PRESS BIOCH J; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	88	467	473	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 21	1995	81	2					161	170		10.1016/0092-8674(95)90324-0	http://dx.doi.org/10.1016/0092-8674(95)90324-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QV410	7736568	Bronze			2022-12-28	WOS:A1995QV41000003
J	MOSS, F; GARSIDE, P				MOSS, F; GARSIDE, P			THE IMPORTANCE OF QUALITY - SHARING RESPONSIBILITY FOR IMPROVING PATIENT-CARE	BRITISH MEDICAL JOURNAL			English	Article							DOCTORS ROLE; MANAGEMENT; NHS		UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LONDON SW7,ENGLAND	Imperial College London	MOSS, F (corresponding author), CENT MIDDLESEX HOSP NHS TRUST,LONDON NW10 7NS,ENGLAND.							BELBIN RM, 1976, J GEN MANAGE, V3, P23, DOI 10.1177/030630707600300303; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BERWICK DM, 1992, BRIT MED J, V304, P304, DOI 10.1136/bmj.304.6822.304; BERWICK DM, 1990, CURING HLTH CARE; MCNICOL M, 1993, QUALITY HLTH CARE, V2, P217; NEE PA, 1994, QUAL HEALTH CARE, V2, P29; 1994, VFM UPDATE PLUS, V1	7	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 15	1995	310	6985					996	999		10.1136/bmj.310.6985.996	http://dx.doi.org/10.1136/bmj.310.6985.996			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT904	7728042	Green Published			2022-12-28	WOS:A1995QT90400031
J	ZHOU, QY; QUAIFE, CJ; PALMITER, RD				ZHOU, QY; QUAIFE, CJ; PALMITER, RD			TARGETED DISRUPTION OF THE TYROSINE-HYDROXYLASE GENE REVEALS THAT CATECHOLAMINES ARE REQUIRED FOR MOUSE FETAL DEVELOPMENT	NATURE			English	Article							SUPERIOR CERVICAL-GANGLION; MICE; RAT; CELLS; PHENOTYPE; PROTOONCOGENE; NEURONS; BRAIN	TYROSINE hydroxylase catalyses the initial, rate-limiting step in the catecholamine biosynthetic pathway. Catecholamines, which include dopamine, noradrenaline, and adrenaline, are important neurotransmitters and hormones that regulate visceral functions, motor coordination and arousal in adults(1). The gene encoding tyrosine hydroxylase becomes transcriptionally active in developing neuroblasts during mid-gestation of rodent embryos, before the onset of neurotransmission(2-6). Here we show that inactivation of both tyrosine hydroxylase alleles results in mid-gestational lethality: about 90% of mutant embryos die between embryonic days 11.5 and 15.5, apparently of cardiovascular failure. Administration of L-DOPA (dihydroxyphenylalanine), the product of the tyrosine hydroxylase reaction, to pregnant females results in complete rescue of mutant mice in utero. Without further treatment, however, they die before weaning. We conclude that catecholamines are essential for mouse fetal development and postnatal survival.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	ZHOU, QY (corresponding author), UNIV WASHINGTON, HOWARD HUGHES MED INST, SL-15, SEATTLE, WA 98195 USA.							BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; COCHARD P, 1978, P NATL ACAD SCI USA, V75, P2986, DOI 10.1073/pnas.75.6.2986; COOPER JR, 1991, BIOCH BASIS NEUROPHA, P221; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DELATORRE JC, 1980, J NEUROSCI METH, V3, P1, DOI 10.1016/0165-0270(80)90029-1; GERSHON MD, 1984, J NEUROSCI, V4, P2269; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HALL AK, 1991, J NEUROSCI, V11, P472; IWATA N, 1992, BIOCHEM BIOPH RES CO, V182, P348, DOI 10.1016/S0006-291X(05)80151-2; JONAKAIT GM, 1989, J HISTOCHEM CYTOCHEM, V37, P1; KATO T, 1987, BIOCHEM PHARMACOL, V36, P3051, DOI 10.1016/0006-2952(87)90223-1; Kaufman M.H., 1992, ATLAS MOUSE DEV; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; OMALLEY KL, 1988, NUCLEIC ACIDS RES, V16, P4437; RUBIN E, 1985, J NEUROSCI, V5, P673; Sambrook J, 1989, MOL CLONING LABORATO; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPECHT LA, 1981, J COMP NEUROL, V199, P233, DOI 10.1002/cne.901990207; TEITELMAN G, 1979, P NATL ACAD SCI USA, V76, P509, DOI 10.1073/pnas.76.1.509; TEITELMAN G, 1981, DEV BIOL, V86, P348, DOI 10.1016/0012-1606(81)90192-5; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	22	375	384	0	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 13	1995	374	6523					640	643		10.1038/374640a0	http://dx.doi.org/10.1038/374640a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QT189	7715703				2022-12-28	WOS:A1995QT18900059
J	LEMAIRE, P; GARRETT, N; GURDON, JB				LEMAIRE, P; GARRETT, N; GURDON, JB			EXPRESSION CLONING OF SIAMOIS, A XENOPUS HOMEOBOX GENE EXPRESSED IN DORSAL VEGETAL CELLS OF BLASTULAS AND ABLE TO INDUCE A COMPLETE SECONDARY AXIS	CELL			English	Article							BONE MORPHOGENETIC PROTEIN-4; MESODERM INDUCTION; SPEMANN ORGANIZER; VENTRALIZING FACTOR; INJECTED XWNT-8; LAEVIS EMBRYOS; MESSENGER-RNAS; EARLY RESPONSE; GASTRULA; HOMOLOG	Using an expression cloning strategy that relies on a functional assay, we have cloned a novel Xenopus homeobox-containing gene, Siamois. Embryos injected in a ventral-vegetal blastomere with as little as 5 pg of Siamois mRNA develop a complete secondary axis, but the progeny of the injected cells do not participate in the secondary axis formation. In normal development, Siamois mRNA is first detected shortly after the midblastula transition, which is earlier than mRNAs for goosecoid or Xbrachyury, and is present most abundantly in the dorsal endoderm of early gastrulae. The activation of this gene can be obtained cell autonomously in dispersed embryo cells. These results indicate that Siamois may play an important role in the formation of the Nieuwkoop center.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge			Lemaire, Patrick/D-4237-2009; Lemaire, Patrick/P-8228-2019; Lemaire, Patrick/B-5560-2012	Lemaire, Patrick/0000-0003-4925-2009; Lemaire, Patrick/0000-0003-4925-2009; GURDON, JOHN/0000-0002-5621-3799	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DALE L, 1987, DEVELOPMENT, V99, P527; DALE L, 1992, DEVELOPMENT, V115, P573; DAWID IB, 1994, J BIOL CHEM, V269, P6259; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1986, DEV BIOL, V115, P340, DOI 10.1016/0012-1606(86)90254-X; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HEWITT JE, 1994, HUM MOL GENET, V3, P1287, DOI 10.1093/hmg/3.8.1287; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KATO K, 1992, P NATL ACAD SCI USA, V90, P1310; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KU M, 1993, DEVELOPMENT, V119, P1161; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; Vize P. D., 1991, METHOD CELL BIOL, V36, P368	30	469	477	1	15	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 7	1995	81	1					85	94		10.1016/0092-8674(95)90373-9	http://dx.doi.org/10.1016/0092-8674(95)90373-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QR970	7720076	Bronze			2022-12-28	WOS:A1995QR97000010
J	INSUA, JT; SACKS, HS; LAU, TS; LAU, J; REITMAN, D; PAGANO, D; CHALMERS, TC				INSUA, JT; SACKS, HS; LAU, TS; LAU, J; REITMAN, D; PAGANO, D; CHALMERS, TC			DRUG-TREATMENT OF HYPERTENSION IN THE ELDERLY - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							ISOLATED SYSTOLIC HYPERTENSION; HIGH BLOOD-PRESSURE; FOLLOW-UP PROGRAM; MILD HYPERTENSION; CLINICAL-TRIALS; MYOCARDIAL-INFARCTION; PARADOXICAL SURVIVAL; PRIMARY PREVENTION; MORTALITY; STROKE	Purpose: A meta-analysis of the effect of antihypertensive drug treatment on mortality and morbidity in elderly patients. Data sources: A literature search of published articles from January 1980 to February 1992. Study selection: Randomized controlled trials of drug treatment of hypertension with end points for elderly patients reported separately. Data extraction: Mortality or morbidity end points or both in patients older than 59 years were pooled by determination of typical odds ratio. A meta-regression was used to study heterogeneity. Results: Nine major trials with 15 559 patients older than 59 years were identified. Death rates in the control group varied between 2.7% and 77.2%; stroke and coronary mortality increased with the severity-of-illness rank (P < 0.001). Overall, treated patients had an approximately 12% reduction in all-cause mortality (odds ratio, 0.88; 95% CI, 0.80 to 0.97; 953 events compared with 1069 events, P = 0.009). There was a 36% reduction in stroke mortality (odds ratio, 0.64; CI, 0.49 to 0.82; 94 events compared with 149 events, P < 0.001) and a 25% reduction in coronary heart disease mortality (odds ratio, 0.75; CI, 0.64 to 0.88; 263 events compared with 350 events, P < 0.001). Coronary morbidity was reduced 15% (odds ratio, 0.85; CI, 0.73 to 0.99; 325 events compared with 379 events, P = 0.036), and stroke morbidity was reduced 35% (odds ratio, 0.65; CI, 0.55 to 0.76; 247 events compared with 382 events, P < 0.001). Conclusion: Overall, treatment of hypertension in elderly patients produces a significant benefit in total mortality and cardiovascular morbidity and mortality. However, this benefit may be reduced in the oldest age groups.	CUNY MT SINAI SCH MED, CLIN TRIALS UNIT, NEW YORK, NY 10029 USA; TUFTS UNIV NEW ENGLAND MED CTR, CTR HLTH SERV RES & STUDY DESIGN, BOSTON, MA 02111 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Tufts Medical Center; Harvard University; Harvard T.H. Chan School of Public Health					AHRQ HHS [HS 077A2-01, HS 05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AGRESTI E, 1984, ANAL ORDINAL CATEGOR, P247; AMERY A, 1985, LANCET, V1, P1349; AMERY A, 1986, LANCET, V2, P589; ANASTOS K, 1991, ANN INTERN MED, V115, P287, DOI 10.7326/0003-4819-115-4-287; [Anonymous], 1985, J Hypertens, V3, P379; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1973, BMJ-BRIT MED J, V3, P434; [Anonymous], 1982, NEW ENGL J MED, V307, P976; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1972, CIRCULATION, V45, P991; [Anonymous], 1970, JAMA, V213, P1143; [Anonymous], 1984, HYPERTENSION, V6, pI198; APPLEGATE WB, 1990, J AM GERIATR SOC, V38, P943, DOI 10.1111/j.1532-5415.1990.tb05713.x; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; APPLEGATE WB, 1990, PRINCIPLES GERIATRIC, P484; BLACK HR, 1991, HYPERTENSION, V17, P1; BONITA R, 1988, STROKE, V19, P669, DOI 10.1161/01.STR.19.6.669; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BORHANI NO, 1991, HYPERTENSION, V17, P2, DOI 10.1161/01.HYP.17.3_Suppl.II2; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; CARTER AB, 1970, LANCET, V1, P485; CELIS H, 1993, NETH J MED, V43, pS66; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; COOPE J, 1987, J HYPERTENS, V5, pS69; CRUICKSHANK JM, 1987, LANCET, V1, P581; CURB JD, 1985, AM J EPIDEMIOL, V121, P371, DOI 10.1093/oxfordjournals.aje.a114008; CURB JD, 1985, JAMA-J AM MED ASSOC, V253, P3263, DOI 10.1001/jama.253.22.3263; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; DAHLOF B, 1986, J HYPERTENS, V4, P511, DOI 10.1097/00004872-198608000-00019; DALHOF B, 1987, J HYPERTENS        S, V5, pS607; DAVIS BR, 1987, CIRCULATION, V75, P340, DOI 10.1161/01.CIR.75.2.340; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Draper N.R., 1981, APPL REGRESSION ANAL, Vsecond, DOI DOI 10.1002/9781118625590; DRIZID T, 1986, DHHS PHS861684 US DE; EKBOM T, 1988, J HYPERTENS, V6, pS626, DOI 10.1097/00004872-198812040-00196; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLEISS JL, 1981, STATISTICAL METHODS, P67; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FORD CE, 1988, JAMA-J AM MED ASSOC, V259, P2113; FORETTE F, 1991, AM J MED, V90, pS14, DOI 10.1016/0002-9343(91)90430-6; GARLAND C, 1983, AM J EPIDEMIOL, V118, P365, DOI 10.1093/oxfordjournals.aje.a113644; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GREENLAND S, 1990, STAT MED, V9, P247, DOI 10.1002/sim.4780090307; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALVORSEN KT, 1992, MED USES STAT, P413; HAMILTON M, 1964, LANCET, V1, P235; HEIGELAND A, 1980, AM J MED, V69, P725; HULLEY SB, 1985, AM J CARDIOL, V56, P913, DOI 10.1016/0002-9149(85)90404-7; Hypertension Detection Follow-up Program Cooperative Group, 1979, JAMA-J AM MED ASSOC, V242, P2562, DOI DOI 10.1001/JAMA.1979.03300230018021; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KANNEL WB, 1985, AM HEART J, V109, P581, DOI 10.1016/0002-8703(85)90566-6; KANNEL WB, 1989, J CARDIOVASC PHARM, V13, pS4, DOI 10.1097/00005344-198900131-00003; KANNRY JL, 1989, CONTROLLED CLIN TRIA, V10, P348; Kaplan N, 1990, CLIN HYPERTENSION, V5; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KURAMOTO K, 1981, JPN HEART J, V22, P75; LANGER RD, 1989, BRIT MED J, V298, P1356, DOI 10.1136/bmj.298.6684.1356; LANGER RD, 1991, AM J EPIDEMIOL, V134, P29, DOI 10.1093/oxfordjournals.aje.a115990; LANGFORD HG, 1986, PROG CARDIOVASC DIS, V29, P29, DOI 10.1016/0033-0620(86)90033-2; LEONETTI G, 1992, J HYPERTENS, V10, pS3; LEW EA, 1990, HYPERTENSION PATHOPH, P175; MANTEL N, 1959, J NATL CANCER I, V22, P719; MANTON KG, 1989, MILBANK Q, V67, P13, DOI 10.2307/3350235; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; MAXWELL MH, 1985, J CARDIOVASC PHARM, V7, pS5, DOI 10.1097/00005344-198507002-00002; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MORGAN TO, 1980, MED J AUSTRALIA, V2, P27, DOI 10.5694/j.1326-5377.1980.tb131808.x; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OKELLY BF, 1989, ANN INTERN MED, V110, P1017, DOI 10.7326/0003-4819-110-12-1017; OMALLEY K, 1988, J HYPERTENS        S, V6, pS33; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PERRY HM, 1989, STROKE, V20, P4, DOI 10.1161/01.STR.20.1.4; PERRY HM, 1978, ANN NY ACAD SCI, V304, P267; PETROVITCH H, 1991, HYPERTENSION, V17, P16; PRIDDLE WW, 1968, J AM GERIATR SOC, V16, P887, DOI 10.1111/j.1532-5415.1968.tb02683.x; PROBSTFIELD JL, 1988, J CLIN EPIDEMIOL, V41, P1197; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROCCELLA EJ, 1986, JAMA-J AM MED ASSOC, V256, P70; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P176; SACKS HS, 1985, MT SINAI J MED, V52, P265; SMITH WM, 1970, CIRC RES, V40, P198; Sorensen K H, 1988, Scand J Prim Health Care, V6, P105, DOI 10.3109/02813438809009299; SPRACKLING ME, 1981, BRIT MED J, V283, P1151, DOI 10.1136/bmj.283.6300.1151; STAESSEN J, 1990, J HYPERTENS, V8, P393, DOI 10.1097/00004872-199005000-00001; STAESSEN J, 1988, EUR HEART J, V9, P215, DOI 10.1093/oxfordjournals.eurheartj.a062486; STAESSEN J, 1992, J CARDIOVASC PHARM, V19, P120, DOI 10.1097/00005344-199201000-00017; STAESSEN J, 1989, HYPERTENSION ELDERLY, P320; VERBRUGGE LM, 1989, MILBANK Q, V67, P450, DOI 10.2307/3350223; VISCOLI CM, 1990, HYPERTENSION PATHOPH, P191; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; WINKER MA, 1991, JAMA-J AM MED ASSOC, V265, P3301, DOI 10.1001/jama.265.24.3301; WITTES J, 1991, HYPERTENSION, V17, P162; WOLFF FW, 1966, J CHRON DIS, V19, P227, DOI 10.1016/0021-9681(66)90128-7; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1987, STAT MED, V6, P217, DOI 10.1002/sim.4780060302; 1978, JAMA-J AM MED ASSOC, V239, P1507; 1962, ARCH INTERN MED, V110, P222; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1961, ARCH INTERN MED, V106, P133; 1981, MED J AUSTRALIA, V2, P398; 1974, JAMA-J AM MED ASSOC, V229, P409; 1982, JAMA-J AM MED ASSOC, V247, P633; 1962, ARCH INTERN MED, V110, P230	108	173	173	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					355	362		10.7326/0003-4819-121-5-199409010-00008	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	7726892				2022-12-28	WOS:A1994PD70100008
J	ROTHWELL, PM				ROTHWELL, PM			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											ROTHWELL, PM (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				REILLY D, 1994, LANCET, V344, P1601, DOI 10.1016/S0140-6736(94)90407-3	1	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200030
J	KAHN, MF				KAHN, MF			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											KAHN, MF (corresponding author), HOP BICHAT, SERV RHUMATOL, 46 RUE HENRI HUCHARD, F-75018 PARIS, FRANCE.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				MAYAUX MJ, 1988, LANCET, V1, P528; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157	2	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200032
J	AULAS, JJ				AULAS, JJ			IS THE EVIDENCE FOR HOMEOPATHT REPRODUCIBLE	LANCET			English	Letter											AULAS, JJ (corresponding author), REVUE PRESCRIRE, F-75527 PARIS 11, FRANCE.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211					0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 28	1995	345	8944					251	251		10.1016/S0140-6736(95)90246-5	http://dx.doi.org/10.1016/S0140-6736(95)90246-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7734017				2022-12-28	WOS:A1995QD53200031
